// Reference=MNI
// Kumari V, 2010: Self Undistorted, All Subjects, Increases
// Kumari V, 2010: Self Distorted, All Subjects, Increases
// Kumari V, 2010: Other Undistorted, All Subjects, Increases
// Kumari V, 2010: Other Distorted, All Subjects, Increases
// Kumari V, 2010: Self Undistorted, All Subjects, Decreases
// Kumari V, 2010: Self Distorted, All Subjects, Decreases
// Kumari V, 2010: Other Undistorted, All Subjects, Decreases
// Kumari V, 2010: Other Distorted, All Subjects, Decreases
// Kumari V, 2010: Self > Other, All Subjects
// Kumari V, 2010: Other > Self, All Subjects
// Kumari V, 2010: Undistorted > Distorted, All Subjects
// Kumari V, 2010: Good Performers > Poor Performers, Self Undistorted
// Kumari V, 2010: Good Performers > Poor Performers, Self Distorted
// Kumari V, 2010: Good Performers > Poor Performers, Other Undistorted
// Kumari V, 2010: Good Performers > Poor Performers, Other Distorted
// Kumari V, 2010: Poor Performers > Good Performers, Self Undistorted
// Kumari V, 2010: Poor Performers > Good Performers, Other Undistorted
// Kumari V, 2010: Poor Performers > Good Performers, Other Distorted
// Kumari V, 2010: Self > Other, Good and Poor Performers
// Kumari V, 2010: Healthy Controls > Schizophrenia, Self Undistorted
// Kumari V, 2010: Schizophrenia > Healthy Controls, Self Undistorted
// Kumari V, 2010: Schizophrenia > Healthy Controls, Other Distorted
// Kumari V, 2010: Other > Self, Healthy Controls and Schizophrenia
// Kumari V, 2010: Undistorted > Distorted, Healthy Controls and Schizophrenia
// Subjects=20
56	-24	4
-50	-36	16
56	-34	16
18	-66	6
-14	-76	12
-18	-78	22
58	-26	4
58	-36	14
60	-22	20
-54	-36	14
-58	-24	4
10	-16	4
-20	-80	34
-14	-76	12
30	-78	26
16	-78	26
44	-70	2
56	-26	0
62	-36	8
46	-30	14
-54	-38	14
-34	22	8
-58	2	-2
-2	-30	-8
12	-16	8
-6	-20	4
-52	-32	10
10	-18	4
-56	-12	12
62	-16	4
64	-36	14
60	-4	12
-22	-36	16
22	-40	12
32	-46	2
6	32	-4
6	24	0
4	14	6
-32	-50	0
-26	-46	10
32	-44	6
-2	18	4
-16	28	2
10	26	2
-30	-48	4
-46	-66	28
32	-44	16
-2	34	2
20	32	-4
10	38	-2
22	-52	18
16	-50	26
34	-50	16
-8	26	10
-12	46	-8
-22	42	0
44	-42	22
-34	-48	20
16	-52	24
-2	10	8
0	0	-8
38	-22	22
32	30	0
20	-4	-2
54	-24	0
34	6	-2
-52	-36	10
-14	-82	14
-10	-96	22
-24	-90	28
16	-70	10
24	-60	4
16	-78	14
56	-26	2
46	-30	12
56	-6	18
-44	-38	14
-54	-26	18
-54	-34	16
-52	-40	14
-52	-36	26
56	-28	0
62	-34	6
52	-36	16
-58	-6	10
-38	14	-2
-58	-24	6
60	-26	0
62	-12	0
54	-22	6
2	32	4
-22	-28	-14
-14	40	6
-24	42	6
-4	28	6
30	-52	16
36	-52	8
28	-52	24
-12	-52	22
-44	-66	28
20	32	6
-6	26	6
-18	32	4
28	34	4
-28	-30	-8
-38	-34	-8
8	-30	14
-4	-30	14
-14	-36	12
-48	-36	18
-56	-28	0
50	-32	20
58	-28	8
64	-38	8
-54	-32	10
-56	-42	16
-50	-40	-2
-16	-38	0
4	-6	4
-6	10	6
40	-24	18
36	-22	-10
42	30	12

// Righi G, 2010: Competitor > No Competitor
// Righi G, 2010: No Competitor > Competitor
// Righi G, 2010: First Run > Second Run
// Righi G, 2010: Second Run > First Run
// Subjects=18
63.7	53.75	30.28
54.14	-1.77	14.98
2.98	9.23	38.06
51.04	-43.55	11.82
-51.57	51.17	48.55
34.71	-13.72	-13.91
5.74	100.22	17.01
21.48	103.83	-20.27
-10.52	87.78	-18.56
2.29	77.83	-24.56
-35.46	55.47	61.39
-55.27	65.82	-9.51
34.99	64.9	53.1
28.07	95.9	0.39
63.78	31.55	32.14
2.63	55.02	10.8
41.31	73.94	45.57

// Sergerie K, 2010: Happy Faces, Conjunction Analysis, Patients + Controls
// Sergerie K, 2010: Sad Faces, Conjunction Analysis, Patients + Controls
// Sergerie K, 2010: Happy Faces, Controls > Patients
// Sergerie K, 2010: Correlation, Happy Faces, Controls
// Sergerie K, 2010: Correlation, Happy Faces, Patients
// Sergerie K, 2010: Happy Faces, Patients > Controls
// Sergerie K, 2010: Correlation, Happy Faces, Controls
// Sergerie K, 2010: Correlation, Happy Faces, Patients
// Sergerie K, 2010: Sad Faces, Patients > Controls
// Sergerie K, 2010: Correlation, Sad Faces, Controls
// Sergerie K, 2010: Correlation, Sad Faces, Patients
// Subjects=20
-12	-26	24
24	-30	20
-34	-26	-18
28	-58	20
46	-66	20
22	-36	-6
-32	-36	-12
24	-6	-26
-26	62	16
-4	26	60
-36	0	46
-20	36	-8
-44	28	-8
-32	22	-16
-32	4	32
-28	-22	24
-30	-60	54
-54	-4	-18
-64	-36	-2
-54	-70	8
-48	-54	-16
-40	-60	-18
-30	-16	-34
-54	-70	-8
-38	-84	-10
-28	-14	-24
-28	0	-26
36	36	-12
54	32	20
46	28	-10
56	22	20
48	-40	36
52	0	-20
42	-70	18
48	-8	-22
62	-14	-22
10	-54	26
22	-36	-6
24	-2	-26
32	-4	-14
-26	62	16
-4	26	60
54	32	20
-36	0	46
56	22	20
-32	22	-16
-32	4	32
-28	-22	24
-30	-60	54
48	-40	36
52	0	-20
-54	-4	-18
-64	-36	-2
-54	-70	8
48	-8	-22
62	-14	-22
-48	-54	-16
-40	-60	-18
-30	-16	-34
10	-54	26
-54	-70	-8
-38	-84	-10
-28	-14	-24
-28	0	-26
-26	62	16
-4	26	60
54	32	20
-36	0	46
56	22	20
-32	22	-16
-32	4	32
-28	-22	24
-30	-60	54
48	-40	36
52	0	-20
-54	-4	-18
-64	-36	-2
-54	-70	8
48	-8	-22
62	-14	-22
-48	-54	-16
-40	-60	-18
-30	-16	-34
10	-54	26
-54	-70	-8
-38	-84	-10
-28	-14	-24
-28	0	-26
-30	-50	8
-30	-50	8
-30	-50	8
26	26	-22
40	-22	26
-36	-26	34
-50	-34	42
10	-30	22
26	26	-22
40	-22	26
-36	-26	34
-50	-34	42
10	-30	22
26	26	-22
40	-22	26
-36	-26	34
-50	-34	42
10	-30	22

// Mobascher A, 2010: Activation in Response to Laser Stimulation
// Subjects=20
52	-24	22
60	-44	34
38	22	-2
30	-38	62
26	0	-22
32	-12	62
36	48	18
-64	-20	20
-36	22	0
-64	-24	22
6	12	36
14	-70	38
-14	-46	-34
10	-4	0
-10	-10	4
-6	-14	-20
-6	-20	-28

// Benoit M M, 2010: Incongruent Non-McGurk - Congruent Pa
// Benoit M M, 2010: Incongruent McGurk Fusion - Congruent Pa
// Benoit M M, 2010: Incongruent Non-McGurk - Incongruent McGurk Fusion
// Subjects=16
-65.95	-21.44	-1.51
-28.75	-2.68	47.9
-29.43	19.94	-17.45
-50.45	-38.54	47.14
-3.15	22.86	38.66
-8.7	-81.51	-3.04
-13.14	-101.1	-4.14
55.07	-33.7	-1.54
38.3	25.92	-4
10.9	21.25	30.27
44.49	9.18	29.56
47.96	-43.58	43.31
13.25	-91.69	-1.77
16.01	-95.82	7.8
-27.16	-2.31	46.96
-41	-78.28	-5.17
-61.31	-36.03	-2.01
-29.18	25.84	-10.03
-67.88	-17.18	-1.29
-44.79	-42.03	45.58
-41.06	9.04	36.69
39.28	22.14	-3.36
58.59	-42.22	7.61
10.29	15.79	46.46
44.09	20.48	-3.28
72.38	-39.38	23.94
27.46	-92.28	-2.44
34.61	-63.23	35.41
-32.13	55.81	-6.15
-33.48	4.44	-22.12
-65.64	-30.35	34.69
-18.9	-52.57	3.23
51.98	-55.21	-8.4
23.66	-69.13	55.1
4.29	-69.84	8.99
26.7	-57	10.67
38.21	7.82	46.92
9.79	-88.96	8.97
36.76	23.68	3
14.61	-105.97	17.14

// Davey C G, 2010: Positive Feedback Faces > Control Feedback Faces
// Subjects=19
0	60	-4
-4	68	10
8	36	4
2	-10	22
0	-32	28
-6	-46	14
2	-66	20
-24	42	40
-24	28	48
-22	44	26
-62	-10	-22
-42	-60	44
-22	-78	-20
-18	-100	0
22	60	26
38	14	-18
64	-12	-24
16	-96	-2
4	6	-4
-24	-10	-24
30	-8	-22
0	-20	-18
26	-48	-24

// Domes G, 2010: Negative Pictures > Neutral Pictures, Males and Females
// Domes G, 2010: Neutral Pictures > Negative Pictures, Males and Females
// Domes G, 2010: Females > Males, Negative Pictures > Neutral Pictures
// Domes G, 2010: Decrease Emotions > Maintain Emotions, Females and Males
// Domes G, 2010: Increase Emotions > Maintain Emotions, Females and Males
// Domes G, 2010: Males > Females, Decrease Emotions > Maintain Emotions
// Domes G, 2010: Males > Females, Increase Emotions > Maintain Emotions
// Subjects=16
51	-63	0
48	-39	-21
45	-51	-12
-54	-69	6
-45	-39	-21
-66	-27	33
-33	-45	48
-45	-33	39
6	60	27
6	54	39
54	-27	36
3	15	27
-6	18	27
-9	27	30
-21	-3	-12
21	15	3
12	-9	6
51	15	21
36	-45	57
54	0	48
-24	-9	48
-3	-66	36
54	36	6
42	36	9
30	-42	-6
-30	-45	-6
21	-57	15
27	3	30
24	3	48
15	21	48
-51	-69	6
-3	12	60
12	3	66
-45	0	51
-54	21	-3
-60	15	24
-36	15	3
54	27	-6
60	24	6
60	15	-3
57	-42	27
33	42	27
33	30	33
-63	-51	21
-63	-33	0
-66	-48	6
-30	48	27
51	3	48
0	6	63
-3	18	39
-6	12	24
-51	12	0
-60	15	24
-12	-33	3
6	-45	3
-18	-12	-12
45	12	6
48	-54	-36
36	-51	-33
-57	-42	24
-6	-66	63
-6	-75	57
57	0	48
-3	-63	-15
9	0	-6
-12	57	36
-33	48	30
21	-24	-9
-60	-21	3
-57	6	0
36	21	-21
6	42	12
18	-15	57
-18	-33	72
9	-36	75
-6	-9	72
-57	-6	24
-63	12	9
-39	15	-6
-18	-6	-15
-24	-69	51
-12	-75	51
-27	36	24
-33	45	18
15	-48	0
6	-60	6
30	18	21
30	-36	-36
63	-51	-3
27	-21	-9
27	30	39
36	36	36
57	-39	18
60	27	6
-45	-54	-9
-54	-18	-3
-12	-15	9
-18	-12	15
-30	-33	-27
-57	-60	0
63	-9	-6
-45	3	39
-36	0	45
12	-81	48
24	-72	45

// Linke J, 2010: Correct Responses - Incorrect Responses
// Linke J, 2010: Incorrect Responses - Correct Responses
// Linke J, 2010: Behavioural Switching
// Linke J, 2010: Positve Correlation with Extrinsic Motivation
// Linke J, 2010: Negataive Correlation with Intrinsic Motivation
// Subjects=33
-15	36	51
-9	33	-9
6	33	-15
6	45	-6
-33	33	-15
-6	-54	15
6	-48	18
-6	-42	33
-51	-3	-6
-54	-54	-9
-45	-78	33
30	-9	-24
24	-3	-18
30	-9	-6
9	-9	-9
-15	6	-12
21	6	63
-30	48	18
-30	-3	60
-3	12	54
6	18	45
-33	24	3
30	24	0
-27	0	63
-24	-3	51
6	21	45
36	39	33
36	51	18
33	60	0
3	30	36
-12	27	30
51	21	0
48	-45	45
30	-48	45
-24	-45	42
-48	-36	48
12	-60	54
-12	-60	54
30	21	-9
-39	15	-6
-33	21	3
45	-30	-9
-36	-60	-33
-27	-69	-30
-15	-75	-30
-18	36	42
30	45	39
18	-9	54
-15	-6	54
12	-30	33
-12	-57	24
-6	-36	78
42	-66	45
-39	-60	27
57	-24	3
51	-30	-24
24	0	21
-15	-3	27
-24	12	9
27	0	-15
-15	36	42
33	39	45
18	-9	54
-39	-60	27
57	-24	3
48	-27	-24
21	30	6
-24	12	12
24	-27	-15

// Markov V, 2010: At Risk Patients > Healthy Controls, 2-Back > 0-Back
// Subjects=22
29.49	27.22	28.08
-33.23	40.82	27.8

// Notebaert K, 2010: Number Identification Trials - Null Events
// Subjects=13
34	-50	46
28	-62	50
-28	-60	46
-32	-62	56
42	-58	-6
34	-92	-8
36	-46	-18
-36	-58	-14
-34	-74	-10
-36	-84	0
-2	10	46
6	14	46
2	20	34
32	40	20
50	10	34
16	-22	12
10	-12	14
36	26	0
48	12	4
30	20	4
-30	26	4
-40	18	-8

// Simoes-Franklin C, 2010: Punishment Go-NoGo > Neutral Go-NoGo
// Simoes-Franklin C, 2010: Neutral Go-NoGo vs. Punishment Go-NoGo, Errors
// Simoes-Franklin C, 2010: Nuetral Go-NoGo vs. Punishment Go-NoGo, Successful 
// Inhibitions
// Subjects=16
25.07	4.08	58.87
-19.8	-5.88	57.99
37.64	7.04	27.25
-37.18	8.62	26.86
4.67	4.07	46.84
3.47	17.04	35.73
28.39	-60.63	47.53
-28.29	-47.05	49.27
-14.8	-1.79	14.1
16.09	1.77	2.29
-22.43	4.29	-3.05
34.12	24.63	-6.53
-28.92	23.28	-4.57
-48.75	-12.62	42.16
34.51	17.74	42
46.39	-.71	50.1
-29.73	29.19	30.63
37.5	41.85	23.22
43.75	44.66	3.95
-31	50.19	13.27
23.41	57.32	4.24
-6.34	31.47	16.78
3.49	19.41	38.87
11.25	-68.82	39.49
53.96	-33.79	48.33
-35.79	-42.96	47.9
-56.14	-47.99	39.63
-53.17	-17.45	21.43
50.33	-41.52	-10.09
-45.57	-58.99	20.36
59.06	-56.04	7.76
53.66	-34.67	9.38
-10.21	-76.49	24.77
15.33	-69.71	13.87
-17.07	13.38	3.93
17.08	13.07	-3.13
42.77	16.99	4.05
-41.62	12.34	6.53
-16.07	8.21	-7.92
6.59	-31.15	4.05
-4.11	-14.84	9.49
4.79	-3.45	59.73
47.2	10.9	21.24
33.2	38.22	17.99
42.67	48.89	3.61
26.58	60.25	0.61
-1.94	20.64	27.68
8.7	29.08	25.73
4.63	12.44	45.02
-47.83	-8.62	25.08
-47.75	-64.97	11.97
24.54	3	-10.18
-19.2	7.91	2.18
57.06	-38.14	33.05
36.29	17.33	-4.82
-30	26.45	-4.83
14.96	12.08	-1.91
8.69	-4.02	10.67

// Thimm M, 2010: At Risk Patients > Healthy Controls, Face Encoding
// Thimm M, 2010: At Risk Patients > Healthy Controls, Face Retrieval
// Subjects=29
-26	37	-4
-8	-95	7
24	-83	10
2	-72	33
14	29	32
59	5	22
50	-43	39

// Tseng M T, 2010: Innocuous Heat vs. Reference Temperature
// Tseng M T, 2010: Noxious Heat vs. Reference Temperature
// Tseng M T, 2010: Innocuous Heat > Noxious Heat
// Tseng M T, 2010: Noxious Heat > Innocuous Heat
// Subjects=12
-52	-40	40
58	-34	40
-64	-26	18
58	-24	22
-36	-20	6
38	-2	6
-14	-44	64
48	2	48
10	-18	-12
-34	46	10
-38	26	26
40	36	18
-46	16	-6
-44	10	20
32	20	-4
42	36	8
48	12	18
-32	18	-2
34	16	0
-32	-56	-50
40	-54	-38
-2	26	48
4	14	52
-6	-20	70
-14	-18	18
6	-18	12
-6	20	28
-10	28	22
2	18	32
-14	-2	10
14	4	-4
-6	-20	-22
-30	34	10
40	54	14
48	18	30
-40	14	-8
-52	8	22
26	10	-20
50	12	22
54	18	18
-34	16	6
36	16	2
-18	-62	-26
36	-52	-38
-14	-6	72
10	16	56
-4	-30	70
-14	-8	6
10	-6	8
-6	2	40
-4	4	42
2	2	44
2	20	32
-30	-18	8
20	10	-10
-6	-18	-14

// Ziv M, 2010: Pain (Cued + Uncued) >  Warm (Cued + Uncued)
// Ziv M, 2010: Pain (Cued + Uncued) >  Warm (Cued + Uncued), Pain Expectancy 
// Sensitivity as Covariate
// Ziv M, 2010: Pain (Cued + Uncued) >  Warm (Cued + Uncued), Harm Avoidance 
// as Covariate
// Subjects=10
58.15	-33.48	38.22
-59.5	-25.43	28.86
57	6.33	43.82
-37.03	-4.09	41.31
-3.88	8.42	48.8
6.83	8.74	52
4.57	6.39	35.49
-3.91	10.28	45.3
41.72	16.1	6.37
-37.33	20.28	12.5
25.7	8.35	3.86
-23.5	13.08	0.68
15.1	-8.38	8.73
-10.58	-9.93	4.69
-67.2	-10.19	6.48
36.38	51.19	20.22
9.01	-8.34	51.17
55.05	-14.86	59
2.39	-79.79	-5.21
28.63	3.34	-33.67
-30.13	2.01	-31.77
27.77	-16.53	-15.27
-27.72	-30.27	-9.02
0.93	-27.84	-35.2
36.34	-65.61	-31.32
3.51	18.53	41.18
-.77	20.61	41.05
-8.31	18.91	33.47
3.79	0.58	70.56
-.48	0.55	70.61
42.29	-22	64.2
11.15	-53.39	32.62
-4.92	-40.71	32.86
-44.45	-71.67	21.41
-37.66	-1.8	-39.17
7.61	-5.25	8.55
25.74	-18.69	-1.68
29.83	-8.49	-21.54
-24.66	-7.67	-19.87

// Grabenhorst F, 2010: Negative Correlation with Pleasantness of Texture
// Grabenhorst F, 2010: Positive Correlation with Pleasantness of Flavor
// Grabenhorst F, 2010: Correlation with Fattiness
// Subjects=14
-16	0	4
-2	-8	12
32	46	22
24	6	42
-36	50	-4
46	42	24
40	56	10
56	-8	18
14	-14	-4
42	10	46
-6	52	46
38	56	26
28	-14	0
28	6	22
-34	-20	-10

// Alexander W H, 2010: Main Effects of Error Likelihood in the Anterior 
// Cingulate Cortex (High - Low Error Likelihood)
// Alexander W H, 2010: Main Effects of Error Likelihood for Low Reward 
// Magnitude (High RM/High EL - High RM/Low EL)
// Alexander W H, 2010: Main Effects of Error Likelihood for High Reward 
// Magnitude (High RM/High EL - High RM/Low EL)
// Alexander W H, 2010: Main Effects of Reward Magnitude (High - Low Reward 
// Magnitude)
// Subjects=24
4	-4	52
6	-4	46
6	-4	46
-26	-18	-20
8	2	-6
-54	30	6

// Burke C J, 2010: Value-Preference Contrast
// Burke C J, 2010: High Variance > Low Variance
// Burke C J, 2010: Effect of Chimpanzee Social Information
// Subjects=17
-9	-51	0
-12	33	-12
-63	-12	6
33	-12	-21
3	-66	-3
-42	6	6
36	0	12
24	-24	-21
-18	36	27
6	63	24
-51	21	0
45	33	-9
-30	24	0
12	42	18
-45	39	3

// Daniel R, 2010: Effect of Entropy
// Daniel R, 2010: Effect of Training
// Daniel R, 2010: Negative > Positive Feedback
// Daniel R, 2010: Positive > Negative Feedback
// Subjects=27
18	55	-13
45	49	-10
6	25	37
-6	25	37
-30	23	-4
30	23	-9
33	8	38
-42	4	27
-24	-1	44
15	-5	20
-9	-9	3
24	-27	-6
-30	-42	41
30	-42	41
54	-53	-5
-45	-53	-7
-12	-71	-17
12	-71	-17
24	46	-7
-36	27	13
33	23	-4
54	10	24
-6	23	43
6	23	43
-59	10	27
-9	9	13
12	-8	9
33	9	60
33	-87	7
33	59	16
36	58	0
39	33	18
48	25	32
45	14	44
-33	53	17
30	46	-10
3	29	54
-3	29	54
42	20	-16
-33	14	-11
-59	-24	-6
62	-33	-11
36	-42	41
-36	-45	35
-3	-25	29
3	-25	29
12	-62	42
-12	-80	-16
21	-52	69
15	-7	-22
12	11	-13
54	-6	50
27	-33	-14
24	-83	26
30	-16	-19
-24	-16	-22
42	-72	9

// Fleming S M, 2010: Cost > Neutral, Activations
// Fleming S M, 2010: Greater Criterion Shifts in the House Value Condition > 
// Lesser Criterion Shifts in the HV Condition
// Fleming S M, 2010: Effects Of Categorical Uncertainty: Positive Correlation 
// with Uncertainty
// Fleming S M, 2010: Negative Correlation with Categorical Uncertainty 
// (Greater Activation in Easy Certain Decisions)
// Fleming S M, 2010: Activity Under Conditions of Asymmetric Cost, 
// Independent of Changes in Categorical Uncertainty
// Fleming S M, 2010: Activity Under Conditions of Categorical Uncertainty, 
// Independent of Changes in Category Value
// Fleming S M, 2010: Activations Correlated with Increasing Wins
// Subjects=15
-36	3	24
-27	-3	54
-15	-18	0
26	-9	54
-36	-39	45
-45	21	0
36	15	-6
-36	-72	21
6	36	30
6	12	51
42	24	-3
9	33	-6
6	36	30
-27	-3	54
15	-18	0
27	-9	54
-36	-72	21
36	15	-6
9	12	48
-9	12	48
-3	42	30
-9	9	-3
30	-81	-30

// Grabenhorst F, 2010: Healthy Controls - Thermal Stimulus Only
// Subjects=12
-28	52	-2
2	44	-2
-6	8	-16
-32	56	-6
4	38	-2
-2	20	-4

// Grabenhorst F, 2010: Healthy Controls - Taste Stimulus Only
// Subjects=12
-28	52	-2
2	44	-2
-6	8	-16
-28	52	-2
4	44	-2
-6	10	-16

// Grabenhorst F, 2010: Healthy Controls - Thermal and Taste Stimuli
// Subjects=14
-28	52	-2
2	44	-2
-6	8	-16
-32	56	-6
4	38	-2
-2	20	-4
-28	52	-2
4	44	-2
-6	10	-16
52	-20	-28
44	-12	58
-26	48	2
-10	-2	0
64	-14	22
4	4	48
-30	46	4
-28	52	2
46	42	24
12	50	-8
8	30	16
56	-8	18
22	36	-10
14	-14	-5
42	10	46
50	28	30
40	16	18
10	6	20
18	16	-6
-18	4	14
32	48	-8
-40	44	28
50	26	30
44	18	34
-8	6	48
36	56	28
-12	10	-6
-34	56	20
-46	18	40
12	14	-2
-16	4	14

// Guitart-Masip M, 2010: (Sure/CSwin + Gamble/CSlose) - (Gamble/CSwin + 
// SureCSlose)
// Subjects=21
-6	-6	52
8	-10	54
-16	-34	42
-12	-34	50
38	-16	-8
12	22	0
-22	6	-18
-6	-40	-18
36	8	-30
-32	-74	8
-10	-22	56
16	-8	-2
24	-6	-28
-8	32	28
-6	-64	-28
-8	-60	-20
14	36	30
8	32	22
16	34	20
50	12	-8
4	4	46
10	-22	12
34	-50	-38
-26	-52	-38
2	-72	4
50	2	0
-2	-50	-50

// Han S, 2010: HITs > CRs No-Incentive Condition, Activations
// Han S, 2010: HITs > CRs F-Map All Conditions, Activations
// Subjects=20
-6	26	46
-42	50	4
-4	-44	40
10	-44	40
-18	-78	-6
-6	-72	32
-44	-60	50
-34	-80	46
-8	-2	22
-6	4	14
-6	8	4
8	-2	20
8	12	22
-56	-38	-20
-20	-82	-14
16	-70	-6
-8	4	6
-10	6	18
8	4	8
8	12	22
12	8	16
14	-6	22
-8	-26	20
6	-6	2
-2	-28	2
-34	18	2
-6	26	44
-42	44	4
-44	32	20
-28	22	-6
32	26	-8
-30	-68	48
-50	-58	50
-6	-72	36
14	-62	20
-44	-76	40
52	-22	12
-64	-42	-10
-4	-34	30
-6	12	24

// Hartstra E, 2010: First Phase > Third Phase Contrast
// Hartstra E, 2010: Third Phase > First Phase Contrast
// Hartstra E, 2010: First Phase > Third Phase (Reward Trials Only)
// Hartstra E, 2010: Third Phase > First Phase (Reward Trials Only)
// Hartstra E, 2010: Third Phase > First Phase (Punishment Trials Only)
// Subjects=20
-6	12	54
-42	3	36
30	6	57
-27	0	54
30	54	0
39	36	39
45	42	21
48	-42	54
33	-69	36
3	-75	54
-42	-42	45
-24	-60	42
-45	-39	57
-18	-81	3
-24	-78	-9
30	24	0
30	24	12
-6	51	9
9	54	-3
0	57	-9
-57	-12	12
-48	-72	30
-60	-30	18
-9	-63	21
-12	-45	30
3	39	6
-3	-24	45
-36	3	-12
-12	-66	-6
-6	12	54
-9	18	48
24	6	54
33	6	54
21	15	66
42	36	36
39	33	45
-42	3	30
-27	0	54
30	54	0
45	-39	45
48	-42	54
42	-60	51
-27	-60	42
-45	-42	48
-24	-72	33
6	-72	57
-9	-78	3
-24	-69	-3
-21	-81	0
-6	57	6
-3	60	-9
-9	63	-3
-57	-6	12
-45	-9	6
-57	-6	3
-51	24	-3
-39	33	-12
-45	21	-12
-12	-39	45
-9	-48	36
-9	-60	24
12	-69	-6
-48	-72	30
-39	-78	33
3	3	45
-24	36	48
-21	42	42
6	54	18
-3	57	9
3	42	3
-6	-63	27
-9	-54	9
-42	-75	30

// Kahnt T, 2010: Regions Where the Variability of Reward Predictions of 
// Individual Attributes is Encoded
// Kahnt T, 2010: Regions Where the Combind Value of Multi-Attribute Objects 
// is Encoded
// Subjects=16
-33	24	24
3	-36	69
-39	-57	-36
36	-63	-27
-6	51	-6

// Kahnt T, 2010: Value of Anticipated Outcomes Independent of the Sensory 
// Properties of the Cues
// Kahnt T, 2010: Value During Both Anticipation and Receipt of Reward
// Subjects=16
3	33	-6
6	6	-6
3	54	-15

// Norbury R, 2010: Group x Emotion Interaction in Regions of Increased 
// Activation to Fear in Recovered Depression Group
// Subjects=16
-36	14	36
26	16	52
16	8	8

// Peters J, 2010: Activity for Presentation of Delayed Reward: Episodic > 
// Control
// Peters J, 2010: Correlation between Subjective Value and BOLD Responses in 
// Control and Episodic Conditions
// Peters J, 2010: Correlation between Subjective Value and BOLD Responses: 
// Episodic > Control
// Peters J, 2010: Correlation b/t Sub. Value and BOLD Responses in both 
// Episodic and Control and Episodic > Control
// Peters J, 2010: Positive Correlation between Neural Tag-Effect and 
// Behavioral Tag-Effect
// Peters J, 2010: Negative Correlation between the Neural Tag-Effect and the 
// Behavioral Tag-Effect
// Subjects=30
-6	-54	14
-6	-60	24
6	-52	16
-44	22	22
-38	-54	-16
-30	-76	-10
-8	34	-12
-56	-44	6
-44	-66	32
-52	-68	24
-30	18	-20
-42	16	-24
-52	-10	-16
-36	50	-10
10	8	0
-2	-28	24
-4	-42	28
-18	12	-14
-10	8	-6
-50	-38	-2
-46	-36	34
-46	-44	30
-36	30	0
6	26	16
6	34	14
56	-38	-6
-44	2	56
-48	10	50
-66	-42	32
-58	-46	42
-56	-36	32
-38	36	36
-30	32	40
-42	50	20
-2	16	36
-4	6	46
0	0	54
42	48	26
38	42	36
50	4	8
-16	12	56
-12	0	64
18	-40	-16
-30	-8	20
-24	-2	20
-60	-22	-6
-12	58	34
-14	64	24
-26	10	-28
-34	14	-24
-50	8	-8
-66	-24	22
40	-18	-24
24	2	-24
-10	-52	40
-18	-54	58
-24	-60	50
-18	-50	66
52	10	46
54	0	46
58	-8	46
-20	-60	-8
2	-8	38
16	-20	60
10	-26	62
-36	-72	30
-44	-76	22
-14	-34	40
-54	2	38
38	14	-20
-18	-42	52
-32	-40	-8
62	6	34
36	-82	34
26	-86	36
-22	-8	58
10	-44	54
-66	-46	-2
64	-34	28
66	-28	34
-30	-44	48
8	-78	-12
16	8	54
-22	-34	58
-66	-42	30
18	34	18
16	32	26
-30	2	30
-20	34	22
-32	32	24
-34	40	20
-66	-20	-8
-58	-28	-8

// Smith D V, 2010: Monetary Rewards (Regardless of Value) > Photographs of 
// Faces
// Smith D V, 2010: Photographs of Faces (Regardless of Attractiveness) > 
// Monetary Rewards
// Smith D V, 2010: Sensitivity to Monetary Value:  Large Gains (+$5 & +$2) > 
// Large Losses (-$5 & -$2)
// Smith D V, 2010: Increasing Activation with Increasing Monetary Reward Size
// Smith D V, 2010: Sensitivity to Social Value:  Attractive Faces (4-Star) > 
// Unattractive Faces (1-Star)
// Smith D V, 2010: Increasing Activation with Increasing Social Reward Size
// Subjects=23
4	-72	34
40	-40	44
32	4	64
62	-46	-8
-24	6	62
-52	-56	-14
48	-62	6
-42	-78	0
6	40	-22
12	58	2
-2	68	-2
10	64	0
0	44	-10
-2	62	-2
-18	32	34
-14	40	6
-26	20	44
-24	24	52
-18	46	10
0	68	-2
12	60	0
8	68	0
-6	72	-4
4	52	-10
0	48	-8
-8	18	-6
0	38	-12
0	42	-6
-18	18	0
50	-76	-2
34	-92	-6
40	-82	8
54	-72	10
48	-74	6
40	-84	-2
50	-76	-2
36	-84	16
40	-82	6
4	-80	16
12	-86	10
34	28	-6
0	48	-8
-8	16	-6
14	-16	-2
-16	16	2
-18	-62	48
-26	-50	48
-10	-64	60
-20	-54	34
-20	-90	24
-26	-82	36
-26	-68	24
-28	-70	20
-34	-86	24

// Zheng H, 2010: Large Group Context:  Positive Frame Activations > Negative 
// Frame Activations
// Zheng H, 2010: Small Group Context:  Positive Frame Activations > Negative 
// Frame Activations
// Zheng H, 2010: Activations Across Both Positive and Negative Frames:  Large 
// Group > Small Group
// Subjects=22
33	29	-8
33	-13	13
33	-31	52
24	32	-8

// Kasahara M, 2011: Healthy Controls
// Subjects=9
-54	-36	-26
-44	-52	54
-20	-10	46
10	-56	-30
-10	-54	-32
-20	-56	-38
44	30	30
52	30	34
44	44	28
-54	-36	-26
-44	-52	54
28	6	56
10	-56	-30
-10	-54	-32
-20	-56	-38
42	30	28
52	30	34
44	44	28
-54	-36	-26
-66	-34	-12
-8	0	28
6	10	24
-10	-30	26
-34	-26	38
-56	-24	32
-54	-30	38
-32	-68	46
-10	-68	58
-22	-70	60
6	-44	-36
8	-60	-20
12	-58	-30
40	-32	36
44	-48	40
44	-42	52
26	-12	50
28	6	54
24	0	50
-26	12	-30
-28	22	-26
-46	-6	-36
52	44	2
46	48	-6
58	28	14
-28	-92	-10
-12	-90	-18
-6	-98	-12

// Kasahara M, 2011: Traumatic Brain Injury (TBI) Patients
// Subjects=9
-52	-42	44
-36	-26	48
-34	-34	66
44	-40	34
52	-42	42
32	-42	34
18	-46	8
32	-62	-6
26	-56	-4
38	2	56
34	2	48
24	8	60
-52	-42	44
-36	-26	48
-34	-34	66
44	-40	34
52	-42	42
32	-42	34
42	34	38
38	2	56
12	14	58
34	2	48
-58	6	20
-62	6	22
-40	-4	26
-54	-36	-26
-66	-34	-12
-8	0	28
6	10	24
-10	-30	26
-34	-26	38
-56	-24	32
-54	-30	38
-32	-68	46
-10	-68	58
-22	-70	60
6	-44	-36
8	-60	-20
12	-58	-30
40	-32	36
44	-48	40
44	-42	52
26	-12	50
28	6	54
24	0	50
-26	12	-30
-28	22	-26
-46	-6	-36
52	44	2
46	48	-6
58	28	14
-28	-92	-10
-12	-90	-18
-6	-98	-12

// Medaglia J D, 2011: Main Effect of Group
// Medaglia J D, 2011: Main Effect of Practice
// Medaglia J D, 2011: TBI Patients > Healthy Controls, 2-Back
// Medaglia J D, 2011: Healthy Controls > TBI Patients, 1-Back
// Medaglia J D, 2011: Healthy Controls > TBI Patients, 2-Back
// Medaglia J D, 2011: Main Effect of Load
// Medaglia J D, 2011: TBI Patients > Healthy Controls, 1-Back
// Subjects=12
60	-4	22
40	4	50
0	-18	66
2	-76	40
32	-78	32
8	-8	44
2	-34	48
-18	-30	70
-22	-84	28
-48	-32	34
62	-20	30
42	0	50
20	14	58
54	10	34
38	58	2
20	64	8
44	4	-8
50	-36	-8
2	-2	36
8	-40	36
10	42	10
50	14	-8
42	-52	46
54	10	16
40	26	6
44	24	22
36	34	-2
18	22	2
-54	-26	38
-18	0	58
-30	-4	54
-42	-8	48
-20	-80	38
-34	-64	50
-36	36	28
-52	-38	22
-34	-74	-14
-8	20	40
-46	-52	-22
-42	-50	42
-44	-28	14
-44	24	22
-48	18	-2
-22	18	14
-24	-20	18
-28	-20	4
-4	0	0
56	-2	24
-40	-40	16
-34	0	-32
-10	20	20
24	-14	34
-10	20	20
34	8	30
26	4	56
10	-54	44
0	-80	0
20	-58	30
20	12	-10
12	10	-2
10	-4	-8
8	-18	2
-30	6	56
-44	-6	44
-12	-62	46
-42	24	32
-8	10	52
-10	16	46
-48	-54	-12
-36	-76	26
-44	20	22
-12	2	2
-16	16	2
-22	8	-8
-6	-18	0
60	-4	22
52	-10	36
18	20	60
44	2	54
2	-76	42
40	14	50
4	52	46
50	8	36
12	72	14
26	66	12
30	-80	32
52	-44	0
8	-8	42
4	-38	6
4	-64	10
18	-40	42
30	-62	26
40	-40	50
54	-14	12
46	22	8
46	36	20
40	20	-16
-50	-28	38
-18	-30	70
-4	2	66
-28	14	48
-4	-22	56
-38	28	34
-38	44	26
-40	-26	14
-4	-80	16
-20	-82	36
-38	-82	28
-20	-68	-2
-22	-58	-6
-40	4	-32
-2	-44	14
-6	-40	6
-18	-74	28
-12	8	38
-42	-56	-16
-42	22	-22
-38	-62	38
-48	-74	24
-40	-52	50
-58	-12	14
-42	40	24

// Venkatraman V, 2011: Rested Wakeful Session, Decision Phase
// Venkatraman V, 2011: Sleep Deprived Session, Decision Phase
// Venkatraman V, 2011: Rested Wakeful > Sleep Deprivation, Decision Phase
// Venkatraman V, 2011: Sleep Deprived > Rested Wakeful, Decision Phase
// Venkatraman V, 2011: Rested Wakeful > Sleep Deprived, Loss Focus
// Subjects=29
8	-70	43
-26	61	43
24	-94	-10
-30	-90	-10
-42	-63	-20
32	2	49
-31	1	49
-48	9	29
48	14	29
1	18	46
32	24	-2
-30	21	-2
45	31	18
30	-65	44
-28	59	42
23	-92	-12
-30	-90	-9
-41	-67	-17
34	-1	49
-26	-4	48
-50	12	29
46	12	25
-6	19	44
31	20	0
-30	22	-4
45	31	19
20	-74	50
-14	-73	50
14	-8	-3
45	-70	-15
-45	-50	-18
-1	18	-14
-3	33	-24
-36	40	-10
37	37	-16
39	19	2
-34	19	2
1	33	48

// Cowdrey F A, 2011: Chocolate in the Mouth: Recovered Anorexia Nervosa 
// Subjects > Healthy Controls
// Cowdrey F A, 2011: Sight of Chocolate: Recovered Anorexia Nervosa Subjects 
// > Healthy Controls
// Cowdrey F A, 2011: Chocolate in Mouth with Sight of Chocolate: Recovered 
// Anorexia Nervosa > Healthy Controls
// Cowdrey F A, 2011: Strawberry in Mouth - Rinse, Recovered Anorexia Nervosa 
// Subjects > Healthy Controls
// Cowdrey F A, 2011: Strawberry in Mouth with Sight of Strawberry: Recovered 
// Anorexia Nervosa > Healthy Controls
// Cowdrey F A, 2011: Main Effect of Chocolate in the Mouth
// Cowdrey F A, 2011: Main Effect of Sight of Chocolate
// Cowdrey F A, 2011: Main Effect of Strawberry in the Mouth
// Cowdrey F A, 2011: Main Effect of Sight of Moldy Strawberries
// Subjects=15
12	8	0
-20	2	8
0	-36	20
38	-80	-10
12	66	12
-1	28	-12
14	10	-4
42	-14	4
24	4	14
10	6	34
42	-14	20
14	12	12
8	46	22
-32	20	2
36	18	2
10	8	-4
-2	34	20
18	20	-14
14	-96	-4
-26	-92	-6
10	6	-4
8	18	38
40	44	34
32	48	18
30	24	-2
-32	20	8
16	12	-2
10	-96	-2
-18	-90	-8
-30	20	8
38	-4	10
38	22	-16

// Ihssen N, 2011: Alcohol - Neutral, Group Interaction between Heavy and 
// Light Nonalcoholic Drinkers
// Ihssen N, 2011: Concern - Neutral, Group Interaction between Heavy and 
// Light Nonalcoholic Drinkers
// Ihssen N, 2011: Alcohol - Concern, Group Interaction between Heavy and 
// Light Nonalcoholic Drinkers
// Ihssen N, 2011: Positive - Neutral, Group Interaction between Heavy and 
// Light Nonalcoholic Drinkers
// Ihssen N, 2011: Negative - Neutral, Group Interaction between Heavy and 
// Light Nonalcoholic Drinkers
// Subjects=11
-18.21	8.2	-7.89
-40.58	3.29	-.53
49.21	-4.72	-2.01
49.27	19.03	16.07
34.5	1.11	33.36
-40.51	-4.74	5.72
48.27	9.85	21.32
55.97	-28.46	34.48
10.01	-13.5	39.33
10.75	-55.3	-19.63
-7.49	-33.12	-20.16
13.09	-35.63	14.38
28.91	31.51	14.15

// Lang S, 2012: Borderline Personality Disorder (BPD) Patients, 
// Trauma-Exposed
// Subjects=14
3	56	1
-3	53	-2
-3	44	-2
-3	35	10
-3	-52	22
3	47	10
-3	56	-5
-9	38	-14
-3	44	-8
0	38	7
-9	44	-2
3	-73	34
-60	-16	-5
-51	-19	-11
-21	-1	1
48	-43	13
48	-46	16
-66	-37	7

// Lang S, 2012: Healthy Controls, Non-Traumatized
// Subjects=15
3	56	1
-3	53	-2
-3	44	-2
-3	35	10
-3	-52	22
-6	44	46
-39	14	31
-45	41	7
-36	50	13
-36	14	34
3	47	10
-51	-61	34
-27	-55	37
-15	41	31
-21	41	31
-27	-7	-17
9	38	-2
-48	-28	-2
-24	41	31
-18	44	28
36	-4	46
-54	-31	-2
-24	-58	43
-63	-49	28
39	-37	46
21	-22	1
-24	-7	-2
-9	-49	37
-9	62	25
-54	-16	-14
18	-4	-23

// Lang S, 2012: Healthy Controls, Non-PTSD
// Subjects=14
-6	44	46
-39	14	31
-45	41	7
-36	50	13
-36	14	34
-51	-61	34
-27	-55	37
-42	41	7
36	50	7
-42	20	43
-33	-58	46
-3	-73	37
-3	-31	28
60	-28	22
-63	-31	22
24	-49	58
-51	-64	4
-63	-31	22
24	-76	22
-54	-55	13
-21	-82	43

// Niedtfeld I, 2010: (Early, Negative vs Rest), BPD Patients > Healthy 
// Controls
// Niedtfeld I, 2010: (Early, Neutral vs Rest), BPD Patients > Healthy 
// Controls
// Niedtfeld I, 2010: (Late, Neutral, Hot vs Rest), BPD Patients > Healthy 
// Controls
// Niedtfeld I, 2010: (Late, Neutral, Hot vs Rest), Healthy Controls > BPD 
// Patients
// Niedtfeld I, 2010: (Late, Neutral, Warm vs Rest), BPD Patients > Healthy 
// Controls
// Niedtfeld I, 2010: (Late, Negative, Hot vs Rest), BPD Patients > Healthy 
// Controls
// Niedtfeld I, 2010: (Early, Negative > Early, Neutral), Whole Group
// Niedtfeld I, 2010: (Late, Neutral, Hot > Late, Neutral, Warm), Whole Group
// Niedtfeld I, 2010: (Late, Negative, Hot > Late, Negative, Warm), Whole 
// Group
// Subjects=20
21	48	12
-18	63	15
0	42	6
-33	30	48
-45	15	-18
36	-78	-18
9	-12	48
27	-45	42
42	-9	0
36	36	42
24	-69	42
45	0	33
-12	-60	24
-12	-27	30
24	-6	-21
-15	-87	36
-24	-3	-21
-39	3	-12
21	-3	-21
-24	-6	-21
-36	27	48
9	-15	48
-12	-6	30
36	36	42
-15	-27	33
-3	-30	18
42	42	-3
21	-63	36
42	-9	60
39	-33	48
-12	66	12
15	30	60
9	-12	51
-42	6	-12
-15	-18	-12
-42	6	-12
-12	-90	12
48	27	27
-39	0	-12
-42	-9	-3
18	-6	-12
-42	-9	-3
42	0	-9
-45	12	-18
24	-6	-21
-24	36	48
-9	66	12
6	-15	48
42	-3	0
-42	0	-8
-27	-3	-21
-48	-72	9
-60	-6	-15
0	3	30
0	-3	72
3	18	18
-21	-6	-15
21	-6	-15
39	15	21
-42	6	21
6	36	3
-9	-63	24
-3	-27	24
-45	-72	45
39	-21	21
-39	3	-12
48	-72	0
24	-30	3
30	0	51

// Schulze L, 2011: Borderline Personality Disorder (BPD) Patients
// Subjects=15
52	-64	-2
42	-52	-14
44	-44	-18
-52	-66	8
-44	-46	-20
28	-54	54
38	-48	62
10	-20	-12
-62	-26	34
66	-20	30
52	-20	32
16	-70	-26
-42	-42	52
30	-36	40
-2	-48	28
6	56	30
8	56	38
26	-80	38
-42	-32	40
44	20	26
-22	-2	-14
8	2	-2
38	-10	-8
44	-8	-2
22	-2	30
30	2	28
26	-16	68
-50	-24	0
4	-64	-40
2	0	30
56	-14	-8
-54	-42	6
-42	-58	34
-50	-52	36
48	-6	-26
24	16	50
-6	-20	44
46	4	-26
-24	-42	66
36	-40	52
58	-46	22
-50	-56	22
-52	20	-6
-2	14	56
-8	20	64
-2	22	44
-44	8	48
-34	8	42
-34	4	54
-34	-56	-30
-52	20	26
-58	-46	26
36	-56	-30
36	-68	-28
-14	22	46
50	30	-10
-2	36	32
56	20	-4
-52	16	-4
-40	6	2
-38	26	0
0	10	62
2	16	40
-6	22	66
-54	-44	26
46	14	-2
56	12	0
34	-54	-30
30	-76	-24
40	-62	-28
0	4	20
10	-8	-12
4	2	-6
-44	8	48
-60	14	18
-4	-30	6
0	-38	0
-10	-36	10
0	20	10
30	-42	4
-32	-56	-28
62	-44	-14
40	-48	56
44	-34	58
24	0	-2
-48	28	-6
50	-54	22
-36	16	52
-2	-74	38
-50	-46	-2
-28	-12	16
-18	-38	-40
30	-16	68
34	-24	20
-4	-78	-28
-28	-22	72
16	10	42
38	12	10
2	-76	46
-8	-10	32
18	-32	2
-10	-28	-2
-50	-28	50
-52	-36	56
-28	-74	2
-44	-6	-30
48	-66	0
42	-52	-14
44	-64	12
-46	-48	-20
-48	-72	14
-48	-70	0
-52	-66	6
-22	-4	-14
22	-4	-12
30	0	-28
-28	-42	-10
-16	-62	20
30	-44	-8
20	-54	16
-36	-48	-42
-32	-54	-30
56	22	-4
-44	22	-12
-50	18	-4
-54	20	-4
30	-76	-26
-52	14	-2
6	14	36
2	14	48
-30	16	8
-44	22	-14
-50	18	-4
-54	20	-4
48	6	4
-44	6	2
56	20	-4

// Schulze L, 2011: Healthy Controls
// Subjects=15
52	-64	-2
42	-52	-14
44	-44	-18
-52	-66	8
-44	-46	-20
28	-54	54
38	-48	62
10	-20	-12
-62	-26	34
66	-20	30
52	-20	32
16	-70	-26
-42	-42	52
30	-36	40
-2	-48	28
6	56	30
8	56	38
26	-80	38
-42	-32	40
44	20	26
-22	-2	-14
8	2	-2
38	-10	-8
44	-8	-2
22	-2	30
30	2	28
26	-16	68
-50	-24	0
4	-64	-40
2	0	30
56	-14	-8
-54	-42	6
-42	-58	34
-50	-52	36
48	-6	-26
24	16	50
-6	-20	44
46	4	-26
-24	-42	66
36	-40	52
58	-46	22
-50	-56	22
-52	20	-6
-2	14	56
-8	20	64
-2	22	44
-44	8	48
-34	8	42
-34	4	54
-34	-56	-30
-52	20	26
-58	-46	26
36	-56	-30
36	-68	-28
-14	22	46
50	30	-10
-2	36	32
56	20	-4
-52	16	-4
-40	6	2
-38	26	0
0	10	62
2	16	40
-6	22	66
-54	-44	26
46	14	-2
56	12	0
34	-54	-30
30	-76	-24
40	-62	-28
0	4	20
10	-8	-12
4	2	-6
-44	8	48
-60	14	18
-4	-30	6
0	-38	0
-10	-36	10
0	20	10
30	-42	4
-32	-56	-28
62	-44	-14
40	-48	56
44	-34	58
24	0	-2
-48	28	-6
50	-54	22
-36	16	52
-2	-74	38
-50	-46	-2
-28	-12	16
-18	-38	-40
30	-16	68
34	-24	20
-4	-78	-28
-28	-22	72
16	10	42
38	12	10
2	-76	46
-8	-10	32
18	-32	2
-10	-28	-2
-50	-28	50
-52	-36	56
-28	-74	2
-44	-6	-30
-54	-66	8
-44	-74	-6
50	-64	-2
48	-66	-12
42	-48	-14
-44	-58	-18
-42	-46	-20
36	-42	54
30	-48	52
26	-56	56
52	-20	32
-2	-48	28
6	58	28
-28	18	-20
-32	22	-2
-26	16	-22
-34	24	-16
-36	30	-2
40	-10	-10
38	30	4
44	22	-8
34	10	-16
46	22	-8
-28	2	-22
-20	-2	-12
-22	2	-16
18	-4	-12
30	-42	-8
20	-54	16
-18	-58	16
-26	-44	-8
-48	24	-4
-56	28	4
-34	48	-14
-2	14	56
-44	8	46
-34	8	42
-54	-44	2
-14	18	50
-32	50	22
50	30	-10
50	18	-6
34	-26	18
-2	14	58
-52	16	-4
-44	22	-2
-40	6	2
-48	16	-4
-34	30	-2
-40	22	-16
46	16	-4
-54	-42	26
40	-62	-28
0	18	40
-2	22	30
-8	-34	8
48	18	-6
-4	6	18
-44	4	48
-20	18	-16
46	-30	60

// Victor T A, 2010: Masked Sad Faces vs. Masked Happy Faces, MDD Patients > 
// Healthy Controls
// Victor T A, 2010: Masked Sad Faces vs. Masked Happy Faces, Healthy Controls 
// > MDD Patients
// Victor T A, 2010: Unmasked Sad Faces vs. Unmasked Happy Faces, MDD Patients 
// > Healthy Controls
// Victor T A, 2010: Unmasked Sad Faces vs. Unmasked Happy Faces, Healthy 
// Controls > MDD Patients
// Subjects=22
-28	-18	-14
-8	-29	5
-38	13	-21
4	-17	49
38	-13	47
50	-15	49
26	-23	53
-44	-5	48
-51	-4	41
61	-9	10
58	-10	-15
50	-21	16

// Vollstadt-Klein S, 2011: Alcohol Cues > Neutral Cues, Abstinent 
// Alcohol-Dependent Patients
// Vollstadt-Klein S, 2011: Positive Correlation between BOLD Response and 
// Attentional Bias Score
// Subjects=38
-20	-100	-6
32	-94	-8
-12	-6	10
0	-40	28
-6	8	60
-58	-16	-26
0	-20	10
-36	-4	44
-12	60	2
32	-64	46
-30	-66	40
-14	52	-8
-16	2	-14
34	22	-14
-52	14	-16
-6	54	8
42	18	12
-16	-34	4
-42	2	10
-38	-62	28
36	-2	0
-26	22	-18
-32	16	8

// Grabski K, 2011: Tongue - Rest
// Grabski K, 2011: Vowel Vocalization - Rest
// Grabski K, 2011: Jaw - Rest
// Grabski K, 2011: Lips - Rest
// Grabski K, 2011: Conjunction
// Grabski K, 2011: Main Effect
// Subjects=13
-20	-28	58
56	-4	30
-52	-8	32
0	-6	58
-62	0	26
-58	8	30
58	8	28
-38	-44	54
-62	-6	18
-20	-52	64
14	-64	56
36	16	8
-26	-2	-4
24	8	6
18	-8	-4
18	4	20
16	-20	-2
-16	-62	-20
18	-60	-20
10	-58	-14
-60	-4	18
52	-6	32
-52	-8	32
44	-8	30
-4	-4	62
8	-4	60
-60	-4	36
54	-6	38
-42	-24	8
50	-16	6
52	-20	0
58	-26	24
-58	-6	10
60	-4	6
46	8	2
10	14	34
26	-2	-8
-26	-8	-6
24	-4	-2
22	-10	-4
32	-8	12
-14	-20	0
14	-18	4
-12	-64	-16
20	-60	-20
18	-62	10
-48	-12	34
54	-6	32
-52	-8	32
60	-10	34
-18	-4	68
2	-6	58
-44	-12	60
54	-6	38
58	8	28
-40	-26	12
-62	-30	34
64	-26	22
-46	-28	20
52	-28	20
-62	-6	18
-38	-12	18
-6	8	38
26	6	-6
16	-20	-2
-16	-62	-18
20	-60	-20
-48	-12	36
-54	-16	42
-22	-2	66
-10	-2	70
2	-6	58
-44	-12	60
54	-6	40
-58	8	30
58	8	30
-48	-26	38
-48	-28	20
60	-16	22
-20	-52	64
-38	-14	20
-6	8	38
-26	-2	-4
-24	0	-4
-14	-20	2
-16	-62	-18
18	-58	-20
-48	-12	36
40	-12	46
-50	-16	40
-4	-4	62
-56	-4	40
54	-6	40
58	6	30
-48	-28	20
-26	-2	-4
-16	-62	-18
18	-58	-20
-60	-4	18
-52	-8	32
-52	-16	4
44	-22	4

// Ogura E, 2012: Lip-Pursing/Lip-Stretching - Rest
// Ogura E, 2012: Tongue Protrusion - Rest
// Ogura E, 2012: Lateral Tongue - Rest
// Ogura E, 2012: Oral Ball-Rolling - Rest
// Subjects=8
11	-58	-15
22	-58	-21
-18	-58	-24
43	-11	36
54	-14	45
58	-14	36
29	-11	-3
54	-7	30
65	-4	15
-50	-11	30
-58	-7	27
14	-61	-15
47	-14	36
54	-11	33
54	-11	48
-54	-14	36
-61	-14	30
-43	-14	36
14	-61	-18
-11	-54	-21
-11	-65	-18
25	0	-3
29	-14	6
-4	0	54
-4	-4	63
14	-61	-18
-58	-11	24
-61	-22	21
-58	-18	42
-14	-58	-18
-29	-54	-24
50	-14	39
54	-7	27
43	-7	57
14	-18	0
4	0	60
-4	-7	54
-14	-22	3
-25	-7	0
-29	-14	-3

// Wong D, 2011: Tooth Grinding Patients
// Subjects=10
-54	-6	44
-48	-10	50
-48	-14	32
56	-2	36
54	0	48
52	-8	32
-24	8	2
-26	-4	12
26	2	2
26	0	-12
-56	-16	32
-58	-10	38
-64	-16	26
52	-8	30
58	-2	38
62	-20	36
8	-2	62
-6	-2	58
-46	-44	56
-46	-42	46
24	10	0
26	0	8
24	2	-2
-20	-50	44
-32	-42	42
-46	-52	46
-50	-62	-2
-32	-60	-14
-40	-70	-10
0	12	46
-4	0	54
24	-62	-8
-16	-66	-4
-22	-74	6

// Wong D, 2011: Healthy Controls
// Subjects=9
-46	-12	34
-56	-8	44
-60	-2	32
54	-2	38
46	-8	36
54	-4	46
-2	-2	58
-8	-8	66
6	0	64
-56	-46	40
-48	-54	46
-20	-46	40
-50	-60	-4
-58	-52	0
-52	-66	-12
-36	-84	-8
-38	-72	-10
-32	-60	-14
-30	-32	14
-26	-14	4
-32	-24	6
26	0	2
20	0	12
26	-12	6
16	-56	-20
16	-46	-22
6	-54	-14
-56	-12	40
50	-6	34
58	-6	48
68	-14	24
-4	0	54
6	-2	64
-22	-74	6
-18	-86	8
-28	-84	8
-24	-10	4
-26	-6	-14
28	-2	-10
26	10	2
26	-2	2
-8	-20	4
10	-18	4
-20	-50	44
-32	-42	42
-46	-52	46
-50	-62	-2
-32	-60	-14
-40	-70	-10
0	12	46
-4	0	54
24	-62	-8
-16	-66	-4
-22	-74	6

// Duka T, 2011: A+ or B+ vs. C- or D-, Reward vs. Non Reward
// Duka T, 2011: (AB-) - (CD-), Incentive Conflict
// Duka T, 2011: (A-) - (A+), Reversal
// Duka T, 2011: (A+) - (A-), Reversal
// Subjects=8
-16	-42	-48
-6	-52	10
-22	-14	-18
-4	52	-12
-16	32	52
14	-6	44
-8	-10	48
-48	-14	54
32	-14	16
32	14	-40
-48	-64	22
-34	-8	0
-16	52	-4
-6	38	-24
8	10	68
42	-16	-26
-12	48	36
-26	56	-2
-6	66	18
-22	-66	28

// Goudriaan A E, 2010: Problem Gamblers
// Subjects=17
-42	9	33
42	15	30
-30	33	-9
36	36	-6
-33	-18	-21
33	-15	-15
-27	-33	-21
27	-48	-15
-27	-84	-9
-39	-78	9
36	-45	-15
27	-84	-9
24	-81	12
-18	-30	-3
18	-30	-3
-42	12	33
54	24	30
-33	33	12
36	33	-6
-30	-21	-21
30	-21	-21
-33	-48	-18
33	-48	-18
-21	-6	-18
24	-6	-18
-24	-84	-6
-33	-72	21
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
42	15	33
36	33	-6
-30	-15	-15
33	-15	-15
-24	-33	-18
36	-48	-24
-21	-6	-15
21	-6	-15
-30	-84	-9
-36	-81	12
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
-9	27	57
-27	-45	-15
33	-45	-12
-36	-66	27
45	-63	30
60	-54	12
-3	54	36
-33	48	6
3	54	0
-39	6	-15
-45	-63	33
45	-63	39
60	-36	-3
39	7	30
-18	-24	-21
21	-27	-21
15	0	-15
-33	-78	12
-39	-72	12
-48	9	33
45	0	42
-42	24	3
-27	-45	-15
27	-36	-21
30	-60	-15
-21	9	-18
15	5	-10
57	-60	3
-33	-78	12
27	-72	33
-6	66	15
9	60	15
15	51	3
-6	48	3
6	45	6
-3	-48	33
-39	45	-3
-6	27	39
-48	21	-3
-15	15	6

// Goudriaan A E, 2010: FTND-High Heavy Smokers
// Subjects=10
-42	9	33
42	15	30
-30	33	-9
36	36	-6
-33	-18	-21
33	-15	-15
-27	-33	-21
27	-48	-15
-27	-84	-9
-39	-78	9
36	-45	-15
27	-84	-9
24	-81	12
-18	-30	-3
18	-30	-3
-42	12	33
54	24	30
-33	33	12
36	33	-6
-30	-21	-21
30	-21	-21
-33	-48	-18
33	-48	-18
-21	-6	-18
24	-6	-18
-24	-84	-6
-33	-72	21
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
42	15	33
36	33	-6
-30	-15	-15
33	-15	-15
-24	-33	-18
36	-48	-24
-21	-6	-15
21	-6	-15
-30	-84	-9
-36	-81	12
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
-9	27	57
-27	-45	-15
33	-45	-12
-36	-66	27
45	-63	30
60	-54	12
-3	54	36
-33	48	6
3	54	0
-39	6	-15
-45	-63	33
45	-63	39
60	-36	-3
-48	9	33
45	0	42
-42	24	3
-27	-45	-15
27	-36	-21
30	-60	-15
-21	9	-18
15	5	-10
57	-60	3
-33	-78	12
27	-72	33
-12	54	-3
12	51	0
-33	51	6
-6	42	9
-3	48	6
6	42	9
-9	-60	36
-12	51	-3
9	51	6
33	42	42
-6	42	9
9	42	6
-51	6	-21
-45	9	-15
36	9	-9
-6	-54	36
-6	66	15
9	60	15
15	51	3
-6	48	3
6	45	6
-3	-48	33
-36	6	60
-18	3	-21

// Goudriaan A E, 2010: FTND-Low Heavy Smokers
// Subjects=8
-42	9	33
42	15	30
-30	33	-9
36	36	-6
-33	-18	-21
33	-15	-15
-27	-33	-21
27	-48	-15
-27	-84	-9
-39	-78	9
36	-45	-15
27	-84	-9
24	-81	12
-18	-30	-3
18	-30	-3
-42	12	33
54	24	30
-33	33	12
36	33	-6
-30	-21	-21
30	-21	-21
-33	-48	-18
33	-48	-18
-21	-6	-18
24	-6	-18
-24	-84	-6
-33	-72	21
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
42	15	33
36	33	-6
-30	-15	-15
33	-15	-15
-24	-33	-18
36	-48	-24
-21	-6	-15
21	-6	-15
-30	-84	-9
-36	-81	12
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
-9	27	57
-27	-45	-15
33	-45	-12
-36	-66	27
45	-63	30
60	-54	12
-3	54	36
-33	48	6
3	54	0
-39	6	-15
-45	-63	33
45	-63	39
60	-36	-3
-48	9	33
45	0	42
-42	24	3
-27	-45	-15
27	-36	-21
30	-60	-15
-21	9	-18
15	5	-10
57	-60	3
-33	-78	12
27	-72	33
-12	51	-3
9	51	6
33	42	42
-6	42	9
9	42	6
-51	6	-21
-45	9	-15
36	9	-9
-6	-54	36
-36	6	60
-18	3	-21

// Goudriaan A E, 2010: Healthy Controls
// Subjects=17
-42	9	33
42	15	30
-30	33	-9
36	36	-6
-33	-18	-21
33	-15	-15
-27	-33	-21
27	-48	-15
-27	-84	-9
-39	-78	9
36	-45	-15
27	-84	-9
24	-81	12
-18	-30	-3
18	-30	-3
-42	12	33
54	24	30
-33	33	12
36	33	-6
-30	-21	-21
30	-21	-21
-33	-48	-18
33	-48	-18
-21	-6	-18
24	-6	-18
-24	-84	-6
-33	-72	21
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
42	15	33
36	33	-6
-30	-15	-15
33	-15	-15
-24	-33	-18
36	-48	-24
-21	-6	-15
21	-6	-15
-30	-84	-9
-36	-81	12
39	-63	-15
24	-84	-15
24	-90	12
-21	-30	-3
21	-30	-3
-9	27	57
-27	-45	-15
33	-45	-12
-36	-66	27
45	-63	30
60	-54	12
-3	54	36
-33	48	6
3	54	0
-39	6	-15
-45	-63	33
45	-63	39
60	-36	-3
39	7	30
-18	-24	-21
21	-27	-21
15	0	-15
-33	-78	12
-39	-72	12
-12	54	-3
12	51	0
-33	51	6
-6	42	9
-3	48	6
6	42	9
-9	-60	36

// Versace F, 2011: Cigarette > Neutral Cues
// Subjects=35
-48.86	-66.46	6.53
55.83	-60.72	2.61
-41.14	-41.93	47.87
36.94	-41.83	55.89
-25.08	-83.3	34.43
25.17	-77.2	40.03
-2.68	-60.53	37.84
-46.98	34.14	13.68
-50.03	8.29	23.69
-38.35	-6.76	6.98
0.94	41.52	-5.33
-.7	-24.74	32.59
10.72	4.74	-.13

// Addicott M A, 2012: Selection Phase, Money > Control, Abstinent > Satiated
// Addicott M A, 2012: Anticipation Phase, Money > Control, Abstinent > 
// Satiated
// Addicott M A, 2012: Anticipation Phase, Money > Control, Satiated > 
// Abstinent
// Addicott M A, 2012: Outcome Phase, Win > No Win, Satiated > Abstinent
// Subjects=13
-26	-32	60
44	-8	-12
-16	-56	-4
52	-26	22
34	-30	54
-2	-54	-16
-60	4	4
36	-8	-8
-34	52	8
34	-8	46
-40	-70	6
14	-2	68
22	-66	16
-30	22	58
52	36	-14
-2	-60	12
-12	16	36
12	-14	48
4	54	-24
26	46	20
-38	6	-2
14	40	-6
-2	-28	56
28	-14	-2
-2	48	-6

// Burger K S, 2012: Reduced Responsivity to Milkshake Receipt as a Function 
// of the Frequency of Ice Cream Consumption
// Burger K S, 2012: Milkshake Receipt > Tasteless Solution Receipt
// Subjects=151
33	35	37
-6	38	16
9	29	31
33	5	13
39	11	13
18	5	22
-33	14	-14
-24	11	1
-21	8	-14
24	8	-8
-33	32	37
-21	32	40
45	-13	37
-51	-13	28
-48	-16	31
39	41	31
42	44	22
30	53	25
-12	-16	40
-18	-31	-40

// Park S Q, 2010: Correlation between BOLD Activity and Prediction-Errors in 
// All Subjects
// Subjects=16
-38	28	42
44	20	38
-28	24	-10
36	22	-8
-8	-10	-16
14	-2	-14
14	6	-12
-8	8	-4
8	6	-4
2	32	56
-6	34	30
-48	-48	36
48	-50	36
-30	54	0
22	52	20

// Bragulat V, 2010: Preferred Food-Related Odors > Nonappetitive Odors, All 
// Participants (Pleasantness Rating Covariate)
// Bragulat V, 2010: Preferred Food-Related Odors > Nonappetitive Odors, Obese 
// > Lean (Pleasantness Rating Covariate)
// Bragulat V, 2010: Preferred Food-Related Odors > Nonappetitive Odors, Lean 
// > Obese (Pleasantness Rating Covariate)
// Subjects=5
-4	-88	2
22	28	46
-32	0	62
60	-6	6
-34	14	38
50	10	42
22	-16	20
-56	-8	6
2	40	-8
-60	-56	16
-56	-16	20
-6	-6	60
44	-12	-2
46	-68	34
-42	26	-4
-8	-64	42
16	-28	-8
4	22	30
-10	-78	50
40	-12	40
-48	-64	-12
-36	44	6
66	-40	2
54	-4	26
62	-10	-10
32	-82	28
-12	-34	-2
36	32	36
-14	-16	-20
-26	-62	-4
26	-14	-12
-24	-48	52
22	-48	-4
20	-16	-8
58	32	8
-30	34	28
-32	-12	12
-56	-58	6
6	8	40
-22	28	38
-8	30	52
34	42	22
42	42	4

// Brooks S J, 2011: Healthy Controls
// Subjects=24
-3.11	-67.19	-20.7
55.56	-10.74	-11.61
55.78	-37.03	6.2
-3.03	2.86	18.03
58.83	-26.58	-10.32
-53.36	-15.02	-2.2
48.58	-67.17	30

// Brooks S J, 2011: Restricting Type Anorexia Nervosa Patients
// Subjects=11
-18.05	-79.17	-22.87
51.52	11.44	27.84
44.34	-62.37	37.45
-25.56	-71.81	-23.4
-13.65	-89.91	-10.87
44.02	7.88	23.76
1.3	48.46	43.15
58.6	-28.98	-41.34
-10.09	-49.95	51.54
47.4	0.9	43.27
43.95	-1.69	10.07
16.18	10.46	18.29
-44.53	8.81	43.66
-60.97	-4.29	-14.16
-3.01	-70.56	-9.27
1.35	-41.07	13.86
51.75	-34.57	38.38
-2.61	-49.9	51.45

// Brooks S J, 2011: Binge Purging Type Anorexia Nervosa Patients
// Subjects=7
-18.05	-79.17	-22.87
51.52	11.44	27.84
44.34	-62.37	37.45
-3.27	-61.16	-39.05
27.88	-67	-21.07
25.04	1.62	54.61
58.6	-28.98	-41.34
-10.09	-49.95	51.54
-37.31	-59.73	-17.59
43.95	-1.69	10.07
16.18	10.46	18.29
-44.53	8.81	43.66
-18.24	-68.99	-42.68
-22.66	3.03	-33.06
-2.72	-67.48	30.62
28.2	13.27	53.6

// Brooks S J, 2011: Bulimia Nervosa Patients
// Subjects=8
13.12	-84.75	-1.57
-33.84	-28.37	29.93
-48.15	11.11	-8.91
-56.34	-12.64	28.87
58.6	-28.98	-41.34
-10.09	-49.95	51.54
47.4	0.9	43.27
-37.31	-59.73	-17.59
43.95	-1.69	10.07
16.18	10.46	18.29
-44.53	8.81	43.66
-60.97	-4.29	-14.16
-3.01	-70.56	-9.27
1.35	-41.07	13.86
51.75	-34.57	38.38
-2.61	-49.9	51.45
-18.24	-68.99	-42.68
-22.66	3.03	-33.06
-2.72	-67.48	30.62
28.2	13.27	53.6
58.83	-26.58	-10.32
-53.36	-15.02	-2.2
48.58	-67.17	30

// Frank S, 2010: Healthy Control Males
// Subjects=6
21	36	-12
-15	-87	-12
-30	15	-21
-3	-42	12
-24	-39	45
0	-15	9
21	60	12
-9	33	33
15	39	15
-39	-39	48
-54	3	45
24	-15	63
15	-63	60
24	-48	-24
-15	-18	6
9	51	9
0	-48	33
-45	-69	33
51	-75	36
63	-12	-12
-6	33	63
-54	33	3
48	21	-30
-15	-87	-3
0	-48	33
-45	-75	45
-15	54	6
-9	27	-9
51	-75	36
-30	18	-18
60	-63	36
-63	-36	3
-30	21	-18
15	30	-15
27	18	-18
54	39	-3
-51	-72	36
6	54	6
0	-51	33
-6	42	-3
-6	-69	27
48	21	-24
60	-63	36
-21	30	45
-66	-15	-9

// Frank S, 2010: Healthy Control Females
// Subjects=6
21	36	-12
-15	-87	-12
-30	15	-21
-3	-42	12
-24	-39	45
0	-15	9
21	60	12
-9	33	33
15	39	15
-3	45	54
24	-72	-6
-15	48	-6
-24	18	60
9	21	-12
-24	-72	-3
-39	-39	48
-54	3	45
24	-15	63
15	-63	60
24	-48	-24
-15	-18	6
9	51	9
0	-48	33
-45	-69	33
51	-75	36
63	-12	-12
-6	33	63
-54	33	3
48	21	-30
-15	-87	-3
0	-48	33
-45	-75	45
-15	54	6
-9	27	-9
51	-75	36
-30	18	-18
60	-63	36
-63	-36	3
-30	21	-18
15	30	-15
27	18	-18
54	39	-3
-51	-72	36
6	54	6
0	-51	33
-6	42	-3
-6	-69	27
48	21	-24
60	-63	36
-21	30	45
-66	-15	-9

// Schacht J P, 2011: Alcohol > Neutral Beverages, Scan 1
// Schacht J P, 2011: Alcohol > Neutral Beverages, Scan 2
// Schacht J P, 2011: Alcohol > Neutral Beverages, Scan 2 > Scan 1
// Subjects=9
-18	15	12
12	9	-3
18	12	12
27	-9	0

// Demos K E, 2011: Main Effect of Dietary Status, Dieters > Non-Dieters
// Demos K E, 2011: Main Effect of Dietary Status, Non-Dieters > Dieters
// Demos K E, 2011: Main Effect of Preload, Milkshake > Water
// Demos K E, 2011: Main Effect of Preload, Water > Milkshake
// Demos K E, 2011: Restraint x Preload Interaction
// Subjects=25
-54	-72	23
-48	41	-2
36	-50	49
-15	18	60
-54	19	7
36	4	14
29	-86	-7
36	19	27
15	60	21
9	-96	2
15	26	-9
-42	-18	45
74	-41	-6
42	58	-5
-24	-15	48
6	34	34
12	9	-3
-18	6	8
-15	3	-8
-12	15	16
-27	-4	-20

// Dimitropoulos A, 2012: Food > Object, Obesity Patients > Healthy Controls, 
// Pre-Meal
// Dimitropoulos A, 2012: High-Calorie Food > Object, Obesity Patients > 
// Healthy Controls, Pre-Meal
// Dimitropoulos A, 2012: Low-Calorie Food > Object, Obesity Patients > 
// Healthy Controls, Pre-Meal
// Dimitropoulos A, 2012: Food > Object, Healthy Controls > Obesity Patients, 
// Pre-Meal
// Dimitropoulos A, 2012: High-Calorie > Low-Calorie Food, Healthy Controls > 
// Obesity Patients, Pre-Meal
// Dimitropoulos A, 2012: High-Calorie Food > Object, Healthy Controls > 
// Obesity Patients, Pre-Meal
// Dimitropoulos A, 2012: Food > Object, Obesity Patients > Healthy Controls, 
// Post-Meal
// Dimitropoulos A, 2012: High-Calorie Food > Object, Obesity Patients > 
// Healthy Controls, Post-Meal
// Dimitropoulos A, 2012: Low-Calorie Food > Object, Obesity Patients > 
// Healthy Controls, Post-Meal
// Subjects=16
25.43	62.65	-9.61
-35.49	67.74	-7.11
-34.44	67.57	-9.34
45.82	64.85	3.35
-37.59	64.81	-3.5
-1.68	17.92	61.36
51.24	-56.34	-36.73
-29.73	33.59	32.49
-48.02	1.47	4.17
-23.03	-22.7	47.17
-57.52	-10.59	14.21
-41.53	0.08	13.13
-23.58	-12.95	-19.44
49.08	-54.33	-37.99
-15.92	-69.29	-19.26
-31.85	36.03	36.77
-41.58	0.71	7.5
-13.5	-4.84	43.33
-35.48	-2.51	-34.68
-44.61	-29.37	17.87
-56.41	-16.75	16.94
1.04	59.01	14.39
31.89	27.02	-16.74
19.58	21.25	47.45
20.5	-47.36	-.33
31.97	6.93	-15.05
47.97	8.97	-17.64
-9.52	-46.28	-11.23
5.68	29.88	50.24
3.33	54.05	32.62
35.13	31.78	-10.48
-3.38	16.78	-22.16
9.71	9.82	10.61
30.05	-35.84	-3.64
-16.23	63.71	-5.88
22.78	21.18	46.31
1.07	58.21	17.8
23.73	-49.2	3.13
-1.12	24.68	-2.78
49.04	4.57	-19.51
-52.53	18.77	-19.54
-59.47	-50.35	23.14
58.16	-63.05	27.32

// Khader P H, 2010: Noun Generation > Rhyme Generation
// Khader P H, 2010: Verb Generation > Rhyme Generation
// Khader P H, 2010: Noun Generation > Letter-Search
// Khader P H, 2010: Verb Generation > Letter-Search
// Khader P H, 2010: Nouns > Verbs
// Khader P H, 2010: Verbs > Nouns
// Subjects=17
-65.39	50.13	-11.98
-41.79	61.15	4.67
-52.5	71.84	6.12
-6.52	62.51	5.26
46.86	65.57	-1.18
55.33	59.4	-13.03
57.52	52.18	-10.22
63.2	30.46	24.99
-41.31	-66.79	15.39
-53.05	-67.83	16.73
-3.23	56.78	13.51
-47.06	26.69	-.19
0.16	23.57	24.06
7.81	-58.12	12.98
-3.25	57.67	11.21
-47.04	23.6	1.18
0.15	22.42	23.05
-64.92	-51.5	8.8
-50.83	-77.88	24.24
62.23	-44.31	7.85
-64.83	-43.96	23.78
25.14	-84.14	32.81
-56.49	11	17.96

// Leidy H J, 2011: Food > Non-Food, Breakfast Skipping > Normal Protein
// Leidy H J, 2011: Food > Non-Food, Normal Protein > High Protein
// Subjects=10
-19.27	-21.39	-18.78
22.4	-4.76	-13.96
-3.37	26.81	-16.31
-3.38	43.18	-11
28.82	-14.5	-16.57
-16.15	0.84	-20.68
-28.8	-37.05	-14.01
-29.03	3.42	-27.44
35.31	19.32	7.29
-31.99	12.57	8.63
32.11	45.71	18.5
-38.26	37.05	36.76

// Miedl S F, 2010: Problem Gamblers (PG)
// Subjects=12
50.49	45.78	-15.58
73.54	-24.77	-2.27
12.02	-33.29	1.86
73.62	-19.79	5.08
58.43	-11.54	2.28
65	-30.56	5.17
48.78	-26.36	5.04
-.89	-24.2	7.91
-14.3	5.27	-20.55
18.11	5.38	-21.12
-28.33	6.83	65.82
-17.39	-55.55	63.96
-22.41	-100.18	0.11
-9.48	-83.98	0.52
-7.17	-81.76	12.59
-18	-103.9	6
-11.55	-61.47	11.78
-7.74	10.27	-13.31
11.68	10.13	-15.87
3.7	-21.05	29.93
-9.56	-13.5	8.12
-15.96	-15.02	15.1
-3.26	-78.28	-19.2
3.2	-82.82	-22.22
11.91	-82.27	-16.82
3.39	-78.07	-5.88
27.68	23.32	55.39
-32.7	-52.59	50.48
-28.24	-46.12	62.09
-9.1	39.25	55.56
52.63	47.81	-16.94
73.5	-25.08	-5.6
-46.85	24.95	-26.43
49.53	-45.94	59.63
61.13	-53.51	35.53
53.74	-51.12	49.98
-18.74	-15.35	-34.12
9.84	-33.4	0.79
-30.52	0.03	62.05
38.52	10.49	55.35
34.3	6.84	62.51
47.08	6.6	47.75
-55.77	6.81	32.67
51.3	-11.65	36.03
20.26	7.52	-21.36
27.71	23.53	57.61
-44.16	-24.77	4.22
53.02	-18.26	-.32
63.32	-18.22	45.44
49.49	-33.08	59.48
51.41	-25.06	41.84
-30.45	-44.31	58.59
30.07	-65.78	55.2
-15.94	-59.77	7.2
-9.47	-86.1	0.73
3.39	-78.07	-5.88
-20.16	-103.91	6.04
-7.17	-81.76	12.59
19.04	-98.2	30.58
29.25	-55.54	-7.43
-31.3	-11.21	-.7
29.26	9.08	6.34
35.69	-15.33	-2.56
29.1	12.3	-5.18
-37.75	-25.27	-1.44
18.81	-65.95	19.55
-7.74	10.27	-13.31
11.69	8.01	-15.66
-.55	-24.9	34.87
-7.52	-16.55	-1.7
-11.65	-19.47	13.23
-20.45	-25.1	-.63
11.94	-20.74	-1.62
18.48	-15.94	3.4
3.2	-82.82	-22.22
11.91	-82.27	-16.82

// Miedl S F, 2010: Occasional Gamblers (OG)
// Subjects=12
50.49	45.78	-15.58
73.54	-24.77	-2.27
12.02	-33.29	1.86
73.62	-19.79	5.08
58.43	-11.54	2.28
65	-30.56	5.17
48.78	-26.36	5.04
-.89	-24.2	7.91
-14.3	5.27	-20.55
18.11	5.38	-21.12
-28.33	6.83	65.82
-17.39	-55.55	63.96
-22.41	-100.18	0.11
-9.48	-83.98	0.52
-7.17	-81.76	12.59
-18	-103.9	6
-11.55	-61.47	11.78
-7.74	10.27	-13.31
11.68	10.13	-15.87
3.7	-21.05	29.93
-9.56	-13.5	8.12
-15.96	-15.02	15.1
-3.26	-78.28	-19.2
3.2	-82.82	-22.22
11.91	-82.27	-16.82
3.39	-78.07	-5.88
27.68	23.32	55.39
-32.7	-52.59	50.48
-28.24	-46.12	62.09
-.36	14.82	57.83
23.59	-8.94	66.49
46.83	-14.93	24.11
73.62	-19.79	5.08
58.43	-11.54	2.28
65.03	-30.35	7.39
48.82	-28.28	7.47
31.43	-46.61	-3.87
-5.21	-21.99	8.88
7.75	-21.94	8.66
46.78	-26.29	17.39
49.05	-10.15	29.2
-14.3	5.27	-20.55
18.11	5.38	-21.12
-28.33	6.83	65.82
-17.39	-55.55	63.96
-22.41	-100.18	0.11
-9.52	-79.93	-2.12
-7.17	-81.76	12.59
-2.73	-89.63	20.02
-11.55	-61.47	11.78
14.45	-92.53	11.05
14.74	-95.88	32.66
18.84	-72.33	20.18
8.06	-94.06	18.03
25.16	-63.67	9.13
20.94	-64.02	17.08
-7.74	10.27	-13.31
11.68	10.13	-15.87
3.7	-21.05	29.93
-9.56	-13.5	8.12
-15.98	-13	13.78
20.75	-26.05	9.96
-3.12	-78.3	-7.99
27.06	-66.7	-11.89

// Murdaugh D L, 2012: Healthy Controls (n=13)
// Subjects=13
20	-32	14
-46	-64	-14
40	-88	10
-46	30	10
48	34	-2
34	-56	56
-36	10	-18
-26	-70	32
-54	-24	26
48	14	8
-8	-28	0

// Murdaugh D L, 2012: Healthy Controls (n=11)
// Subjects=11
58	-58	32
10	-60	20

// Murdaugh D L, 2012: Obesity Patients (n=25)
// Subjects=25
-36	-2	-2
38	4	-18
-20	-2	-22
2	36	14
-6	-6	28
-52	-32	42
-26	-86	14
-50	-70	-8
-36	4	-20
-26	12	18
-50	36	4
26	-22	24
52	-28	42
66	-20	34
62	-18	42
4	22	42
-6	30	40
54	-38	40
18	-72	46
22	-50	48
-2	-32	28
6	-34	40
44	4	42
40	-74	30
44	12	-16
46	18	6
-2	10	42
4	4	42
-8	18	28
-20	-56	56
18	-58	54
-46	-36	42
44	10	52
2	-68	16
-12	-64	-4
-24	-76	26
-6	-28	-30
60	-44	-2

// Murdaugh D L, 2012: Obesity Patients (n=22)
// Subjects=22
34	-18	-2
32	-20	18
32	-24	-8
30	-80	-4
36	-86	26
28	-86	26
-44	-36	36
6	-80	-22
28	-80	-20
-8	-10	-10
-48	26	14
38	-74	22
12	-24	-6
-30	-12	-6
-18	18	-6
-42	26	14

// Nummenmaa L, 2012: Appetizing > Bland Foods, All Subjects
// Nummenmaa L, 2012: Appetizing and Bland Foods, Obesity Patients > Healthy 
// Controls
// Nummenmaa L, 2012: Appetizing and Bland Foods, Healthy Controls > Obesity 
// Patients
// Nummenmaa L, 2012: Appetizing > Bland Foods, Obesity Patients > Healthy 
// Controls
// Nummenmaa L, 2012: Appetizing > Bland Foods, Healthy Controls > Obesity 
// Patients
// Subjects=15
26	-48	-20
-16	-100	-6
6	-50	24
50	-6	4
28	-96	-12
-10	60	18
44	-40	2
-48	-28	14
-52	-14	12
14	-48	62
-44	-26	54
-34	-20	2
10	22	6
8	-10	66
-24	-42	56
2	-28	34
-24	26	40
-46	-68	20
-26	-52	-16
2	-14	38
-30	-10	-26
8	-38	18
56	-16	30
-40	-58	-10
-42	4	10
18	30	4
-42	4	10
20	34	-8
38	32	-8
46	12	-26
52	-38	18
20	40	38
38	-38	38
-38	34	10
30	6	54
36	-76	30
-22	-38	46
60	-24	-10
48	-32	40
26	28	54
8	-14	36
-30	-74	22
-20	-64	44
-62	-28	0
-8	-80	0

// Rubinstein M L, 2011: Smoking-Related > Neutral
// Subjects=12
-10	38	-10
46	-68	-2
38	-68	-10
46	-66	-10

// Willms J L, 2011: Verbs > Nouns
// Subjects=16
-50	-42	4
-2	14	64
-2	20	56
-46	6	42
-48	20	26
-34	6	58
34	-86	0

// Yu X, 2011: (Nouns - Fixation) > (Verbs - Fixation)
// Yu X, 2011: (Verbs - Fixation) > (Nouns - Fixation)
// Yu X, 2011: High-Imageability Nouns > High-Imageability Verbs
// Yu X, 2011: High-Imageability Verbs > High-Imageability Nouns
// Yu X, 2011: Low-Imageability Verbs > Low-Imageability Nouns
// Subjects=20
-42	33	-18
-12	42	42
-3	36	-24
-54	3	-33
-30	-33	-21
33	-30	-21
-33	-72	39
45	-75	45
-51	9	6
-45	-51	9
51	-39	9
21	-63	9
24	-69	-48
-30	24	60
-45	39	-18
-33	15	-21
36	39	-18
-54	3	-36
-33	-36	-18
36	-33	-18
-33	-72	39
-6	-57	12
-51	9	6
39	18	12
12	-33	63
60	0	45
-57	-39	21
-36	-96	9
18	-90	18
24	-69	-48
-30	-54	-48
-60	3	36
36	0	30
-12	15	51
18	36	27
-66	-48	9
54	-36	9
30	-57	3
-9	-75	-39

// DeWall C N, 2012: Exclusion > Inclusion
// Subjects=25
-36	24	-3
33	15	-12
42	30	-3
48	27	6
-48	36	-9
-6	-15	-15
3	42	48
-9	-93	3
3	-51	-36
-15	-75	-33
24	-69	-3
-36	-69	-15
48	-15	-18
54	-45	15
-12	-63	33

// Han S, 2010: Death-Related > Neutral-Valence Words
// Han S, 2010: Negative-Valence > Neutral-Valence Words
// Han S, 2010: Neutral-Valence > Death-Related Words
// Han S, 2010: Negative-Valence > Death-Related Words
// Subjects=20
-4	48	36
-6	-58	38
-32	-66	40
40	-64	28
44	16	38
-48	24	20
-6	42	22
-8	60	18
-12	-74	14
-8	-58	46
30	24	46
24	48	30
42	-30	12
-40	-4	2
48	-8	10
0	14	28
-40	-14	12
42	-8	8

// Herwig U, 2011: High Risk > Low Risk, Whole Evaluation Period
// Herwig U, 2011: High Risk > Low Risk, First Volume
// Herwig U, 2011: High Risk > Low Risk, First Two Volumes
// Subjects=18
39.44	18.95	-11.69
4.3	-6.39	-5.81
-4.97	-32.42	29.93
-5.29	13.62	6
-4.79	-73.41	36.71
13.91	-6.33	-5.93
-8.49	-9.38	-2.07
49.56	-68.02	18.91
-43.37	-71.49	23.61
-7.98	-70	39.81
-56.57	-42.5	-13.24
39.43	15.52	-14.74
-5.3	-6.19	-2.37
-11.68	13.84	9.4
7.5	36.41	10.64
-8.4	27.83	24.92
-33.78	4.1	50.62
49.54	0.91	43.24
-4.86	8.21	59.98
1.47	-38.73	30.39
-40.14	-71.22	26.9
49.65	-70.42	29.15
-7.98	-70	39.81
-53.4	-39.57	-16.86

// Pereira M G, 2010: Detection Only vs. Baseline
// Pereira M G, 2010: Unpleasent Viewing vs. Neutral Viewing
// Pereira M G, 2010: Detection after Unpleasant vs Detection after Neutral
// Subjects=11
24	-88	-10
-34	-84	2
30	-80	10
-54	-2	46
-24	8	40
30	20	40
-24	2	4
24	-4	4
-38	-84	8
-32	-14	16
-40	-40	52
-26	-20	68
-58	-4	42
-18	-2	56
-4	8	46
-18	4	12

// Yoshino A, 2010: Pain > No Pain
// Subjects=15
-2	8	32
40	-12	8
-38	-12	6
10	-16	10
-8	-20	0
30	-4	-14
60	-20	20
-60	-20	12
34	52	24

// Toyomura A, 2011: Healthy Controls
// Subjects=12
-62	-10	6
68	-30	8
14	-60	40
-52	-24	4
64	-32	8
8	-58	38
-64	-10	4
66	-30	8
-46	-26	16
64	-20	0
14	10	2
40	20	24
40	-42	42
-62	-34	22
66	-22	2
48	-16	16
-10	20	36
40	18	38
-50	-38	16
64	-20	2
42	22	18

// Toyomura A, 2011: Stuttering Patients
// Subjects=12
-50	-34	18
66	-20	2
-12	2	4
-50	6	26
46	22	20
-10	-44	8
-30	-2	50
36	-42	44
-62	-28	12
66	-24	2
-58	-48	22
48	-54	24
-10	-54	38
8	-48	42
-26	26	42
40	20	38
-18	-48	-2
-58	-32	12
66	-20	2
40	-38	20
-46	-26	16
64	-20	0
14	10	2
40	20	24
40	-42	42
-62	-34	22
66	-22	2
48	-16	16
-10	20	36
40	18	38
-50	-38	16
64	-20	2
42	22	18

// Pavuluri M N, 2010: Adolescent Bipolar Disorder Patients
// Subjects=13
16.35	-14.15	30.39
-11.47	-7	28.99
54.72	-14.95	16.63
-17	4.2	9.16
19.12	74.64	8.41
-10.8	74.54	9.88
9.57	58.8	10.96
-55.56	29.35	7.49
-5.88	-30.8	51
28.96	-21.84	-1.45
-23.45	-20.47	-6.54
29.03	-22.21	7.5
-.94	-16.31	4
-9.75	71.03	5.7
-32.14	2.23	-15.04
-44.99	51.28	1.07
6.36	55.53	10.16
-45.16	19.9	-33.1
51.79	-70.32	30.23
22.48	7.1	1.77
25.82	-17.83	9.4
-19.15	-22.3	-3.09
-5.56	52.6	-12.88
12.6	53.77	-13.18
-7.64	44.39	-8.82
3	54.94	-10.94
7.38	11.01	-15.11
6.72	-50.64	13.48
-3.88	-59.71	21.06
-60.65	-27.35	17.88
12.72	8.84	-16.11
-16.13	6.55	-15.58

// Pavuluri M N, 2010: Healthy Controls
// Subjects=13
16.35	-14.15	30.39
-11.47	-7	28.99
54.72	-14.95	16.63
-17	4.2	9.16
19.12	74.64	8.41
-10.8	74.54	9.88
9.57	58.8	10.96
-55.56	29.35	7.49
-5.88	-30.8	51
28.96	-21.84	-1.45
-23.45	-20.47	-6.54
29.03	-22.21	7.5
-.94	-16.31	4
-9.75	71.03	5.7
-32.14	2.23	-15.04
-44.99	51.28	1.07
6.36	55.53	10.16
-45.16	19.9	-33.1
51.79	-70.32	30.23
22.48	7.1	1.77
25.82	-17.83	9.4
-19.15	-22.3	-3.09
-46.08	51.1	-1.13
25.44	67.13	-6.64
-.75	36.19	49.78
16.42	3	45.68
-10.27	-3.51	46.53
29.02	-19.04	7.23
-23.36	-9.58	10.39
12.85	16.81	4.41
-12.82	16.4	1.4

// Pompei F, 2011: Bipolar Disorder Patients
// Subjects=39
36.45	-55.64	48.48
-19.66	-70.63	52.04
38.54	-45.21	45.17
-43.51	-27.54	54.91
-1.15	12.19	-4.65
37.55	28.41	-17
-28.89	48.59	30.32
-2.44	48.89	-13.86
-48.15	7.25	36.98
-62.03	-36.4	41.53
-17.38	-68.62	61.89
-4.45	21.54	-7.76

// Pompei F, 2011: Healthy Controls
// Subjects=48
36.45	-55.64	48.48
-19.66	-70.63	52.04
38.54	-45.21	45.17
-43.51	-27.54	54.91
-1.15	12.19	-4.65
37.55	28.41	-17
-53.64	18.62	32.58
37.56	27.35	-16.9
-18.26	33.14	13.74
-33.01	3.05	37.14
-17.95	-36.74	24.01
38.63	-53.3	50.46
40.68	-47.53	43.13
-30.6	-65.11	42.72
-.12	17.3	-7.42

// Pompei F, 2011: Healthy Controls, Relatives of Bipolar Disorder Patients
// Subjects=25
36.45	-55.64	48.48
-19.66	-70.63	52.04
38.54	-45.21	45.17
-43.51	-27.54	54.91
-1.15	12.19	-4.65
37.55	28.41	-17
-39.34	23.83	53.12
-44.01	24.52	26.23
35.45	25.52	-13.32
-16.42	46.07	-8.86
-43.94	5.37	28.13
-22.18	-37.2	30.85
-36.93	-59.64	55.73
-45.67	-47.21	51.29
-12.01	20.45	-7.53

// Pompei F, 2011: Major Depressive Disorder Patients, Relatives of Bipolar 
// Disorder Patients
// Subjects=14
36.45	-55.64	48.48
-19.66	-70.63	52.04
38.54	-45.21	45.17
-43.51	-27.54	54.91
-1.15	12.19	-4.65
37.55	28.41	-17
-43.95	34.82	33.06
30.91	46.91	-25.44
-14.24	46.18	-7.79
-45.85	19.25	50.32
25.36	-37.03	30.02
-24.12	-56.37	43.98
-45.61	-40.21	57.32
-9.83	21.73	-5.45

// Singh M K, 2010: Pediatric Bipolar Disorder Patients
// Subjects=26
4	16	-8
-14	-102	-10
8	18	42
34	24	34

// Singh M K, 2010: Healthy Controls
// Subjects=22
52	6	30
10	10	46
34	24	34

// Townsend J D, 2012: Bipolar Disorder Patients
// Subjects=32
-34	36	30
24	44	16
-36	46	20
34	58	14
-44	16	-10
-32	24	-6
40	20	0
-34	16	4
14	12	34
52	-32	-6
44	-50	40
26	-70	50
60	-48	28
-30	-94	-6
-38	-78	-8
38	-62	-10
24	-94	0
8	-88	4
16	-4	20
16	6	8

// Townsend J D, 2012: Healthy Controls
// Subjects=30
-36	38	36
-36	48	20
32	58	16
-28	-4	48
-34	20	2
36	20	2
-42	14	2
2	16	38
-58	-46	20
-58	-40	42
-36	-46	44
46	-44	38
-58	-48	28
62	-44	30
-36	-90	-6
30	-60	36
-16	10	8
24	10	14
-22	10	8
20	10	0
-14	-10	8
16	-10	8
-8	-16	-8
10	-14	-10

// Zandbelt B B, 2011: Schizophrenia Patients
// Subjects=22
32	-76	20
12	16	-12
16	8	-12
28	0	-4
-20	12	-12
-16	8	-16
-12	12	-12
-12	12	0
-20	8	8
-24	4	-4
-56	-20	44
-44	-28	48
-36	-28	64
-28	-24	68
-40	-20	40
-40	-40	60
-36	-44	64
-28	-44	68
-52	-44	0
-52	-52	4
40	0	36
44	16	32
-12	-4	64
32	28	-4
40	8	28
56	16	16
16	0	64
48	4	36
4	12	48
-4	8	52
44	0	44
32	40	24
40	0	52
36	28	28
48	36	24
4	16	56
40	24	32
20	8	0
12	32	24
44	16	-8
-8	12	44
40	8	-4
4	24	44
-32	-8	52
32	56	12
24	-4	48
4	32	36
-36	16	0
64	-36	12
32	-60	40
28	-68	36
56	-40	24
52	-44	36
52	-48	4
44	-56	0
48	-40	48
28	56	-4
32	64	0
-32	-60	44
-48	-40	36
-56	-32	28
-40	-56	44
-24	-60	32
-60	-24	20
-36	-48	32
52	-28	-8
-36	36	32
-28	36	20
-36	-32	56
-36	-28	64
-36	-20	40
-48	-16	48
-16	-32	72
-16	-32	56
36	-24	12
44	12	-32
20	20	20
24	-16	28
60	-4	-4
56	4	-28
40	-8	12
48	-24	4
60	0	-16
52	-8	-24
32	-12	28
24	8	32
0	-64	24
-4	-52	8
-8	-48	-4
16	-48	-4
-56	-12	-20
-12	-68	16
8	-52	12
0	-52	24
-8	-56	-12
-48	-8	-20
-8	-60	0
-16	-64	12
-40	-72	24
-20	-16	-24
-20	-56	12
28	-60	4
-60	-8	-8
16	-52	-16
-52	-68	20
-44	-4	-28
-52	-12	0
-48	4	-28
-36	-8	-24
20	-68	12
-32	-16	16
-24	-24	-20
32	-48	8
-32	-32	16
-24	-36	-20
-28	-28	16
12	-44	-12
-56	-8	12
28	-52	12
-36	-52	12
-28	-36	-12
-4	-36	40
36	-40	24
32	-48	20
-12	-80	20
-44	20	-28
-20	-84	36
36	-32	-12
-52	-24	4
-40	12	-36
32	-40	0
-40	-16	8
-40	-40	4
-36	-36	12
-36	-48	0
-16	-44	-24
-12	36	44
-8	60	20
4	56	-12
0	68	0
-24	28	48
-28	24	52
-8	52	40
-8	48	48
4	68	8
-36	12	48
8	56	28
8	56	44
44	-16	36
4	-28	68
64	-4	28
40	-28	60
16	-32	68
24	-28	64
4	-20	56
48	-12	52
44	-24	56
60	-4	16
-48	28	12
-36	36	-12
-52	40	4
24	-16	-24
32	-4	-24
0	28	-4
0	20	-8
-12	36	-4

// Zandbelt B B, 2011: Healthy Control Siblings of Schizophrenia Patients
// Subjects=22
52	4	48
48	0	44
40	-4	44
40	20	-4
48	12	0
-16	-72	28
-24	-68	28
-16	-76	40
-40	-80	8
-44	-36	40
-52	-28	36
0	16	32
0	24	36
28	-68	32
32	-68	24
4	20	52
4	8	48
0	4	56
20	12	-12
-24	12	-12
-20	8	-8
-12	16	-12
-20	8	48
-48	-20	52
-52	-20	44
-44	-24	40
48	16	-4
40	20	0
32	24	8
4	8	44
24	12	-8
8	16	36
36	36	36
28	-4	64
40	8	32
32	36	28
0	28	32
32	48	32
4	24	36
0	32	24
48	8	24
36	-4	56
48	4	48
12	0	68
8	-4	64
16	8	4
36	20	24
48	32	32
28	-8	44
32	4	44
28	0	48
12	-8	4
-12	-4	60
12	-8	56
28	-64	32
64	-44	24
60	-40	16
24	-64	40
60	-44	8
32	-52	40
60	-40	40
16	-72	40
28	-68	20
32	-60	40
48	-76	4
28	-48	36
52	-48	32
52	-36	24
52	-24	-16
36	-72	16
52	-48	0
56	-32	36
48	-52	40
48	-32	-4
52	-64	-4
52	-48	-12
8	-68	56
40	-52	56
32	-80	4
36	-84	8
-28	-24	4
-36	20	-4
-36	40	32
-40	32	40
-28	48	20
-32	52	24
-32	-8	44
-40	0	32
-56	-48	4
-56	-48	32
-44	-40	40
-56	-44	44
-56	-36	24
-64	-28	24
-24	-72	20
-28	-76	16
-40	-80	0
-36	-84	4
-52	-60	-8
-48	-68	-4
-40	-72	0
-28	-52	36
-12	-72	36
-20	-72	40
-24	-64	36
36	60	-4
28	64	0
-4	60	0
0	24	-8
-20	24	44
-8	56	36
-4	68	16
-16	68	20
-4	48	44
-16	36	44
0	12	-12
-12	40	52
-8	24	4
8	40	-12
12	-56	4
-12	-60	8
-8	-48	28
-4	-64	20
32	-52	4
20	-44	16
-24	-16	-24
-20	-8	-20
-28	-28	-20
-40	-16	-24
-44	-72	24
-40	-80	28
24	-12	-24
12	-4	-24
64	-4	24
64	-12	36
-36	-32	64
-20	-36	68
-56	-20	44
-40	-24	48
-40	12	-36
-44	0	-36
40	-16	12
-52	28	12

// Zandbelt B B, 2011: Healthy Controls
// Subjects=22
-56	-44	28
-56	-44	36
-52	-28	40
-56	-32	32
-36	-24	32
-48	-36	32
-44	-60	36
-12	-20	4
-12	0	4
12	0	4
12	-20	8
8	-8	8
16	8	0
-12	-32	4
16	-32	8
20	-12	8
24	-20	8
32	-64	44
60	-36	28
16	-80	44
40	-36	36
-8	-80	40
-16	-84	40
-4	-64	56
-24	-52	60
-20	-76	36
64	-44	12
32	-44	44
52	-32	32
-20	-72	44
12	-88	32
56	-32	-12
48	-32	-8
-24	-64	56
52	-32	44
64	-48	32
52	-44	0
68	-20	-12
60	-24	28
-40	-8	48
-24	-4	52
-24	0	64
-24	-12	64
-20	-4	68
-16	-20	68
52	16	-4
36	24	-4
52	8	12
4	16	44
4	8	52
4	32	40
44	24	36
20	44	32
52	4	44
40	0	48
32	32	36
16	4	64
-8	36	36
52	4	36
52	8	28
16	-20	64
4	16	60
4	0	68
4	-12	64
40	20	48
16	-20	72
36	-4	60
32	48	24
4	16	28
8	-16	68
36	20	4
44	-76	4
36	-80	24
28	-76	16
52	-60	0
52	-56	-16
48	-48	-12
-28	40	36
-32	28	40
-40	40	24
-48	12	-8
12	-44	36
12	-28	36
16	-44	24
-24	-76	16
-36	-52	48
28	-4	8
24	0	4
28	8	0
16	8	12
28	-8	-8
32	-12	-4
44	16	48
24	24	56
24	32	52
32	32	44
28	12	64
24	12	52
-28	-4	4
-24	-8	12
48	28	24
56	24	28
40	56	8
16	-28	-12
-4	-32	-4
-44	-16	56
-52	-16	48
32	20	0
40	52	20
48	16	8
36	44	28
36	-4	48
40	0	44
24	-4	60
40	0	32
52	16	28
48	8	28
28	52	24
40	-4	60
52	20	20
20	0	8
16	8	8
44	0	56
20	4	68
12	12	4
40	16	48
48	28	28
40	32	32
36	24	36
-28	24	-8
-40	16	4
36	-52	36
56	-40	28
20	-72	36
48	-40	4
44	-52	36
56	-48	28
48	-60	0
56	-44	36
64	-44	16
52	-56	40
60	-4	8
52	-44	48
32	-72	20
44	-72	8
28	-68	56
4	28	36
-40	0	32
4	12	48
-4	8	48
-20	-8	60
8	16	40
-8	28	20
4	28	52
-44	-4	44
-44	4	20
8	32	24
-28	-64	36
-20	-68	40
-12	-72	36
8	-16	8
48	-24	-12
56	-28	-16
60	-24	-12
-56	-44	20
-60	-52	32
-56	-44	36
-64	-52	20
-56	-48	8
0	-20	-12
-32	52	28
-36	36	36
-40	48	16
-8	-56	8
12	-56	8
-4	-60	24
20	-48	8
-16	-52	0
36	-16	-20
8	-48	-4
16	-48	-4
28	-24	-16
-20	-28	-20
-24	-20	-24
20	-36	-16
-20	-4	-16
20	-16	-24
36	-40	-4
-24	-36	-16
32	-52	4
36	-32	-16
-20	-44	-8
20	-24	-24
-4	64	-8
-12	56	32
-16	32	44
0	48	-16
-12	68	8
-20	16	48
-4	64	24
0	44	-8
-4	52	44
0	68	8
12	40	-12
0	40	4
12	36	0
0	48	0
-40	-72	24
-48	-72	20
-40	-80	28
-28	-84	36
60	-8	-20
48	-4	4
52	-8	8
48	-12	12
68	-12	-4
-56	-8	-20
-44	0	-32
-48	12	28
-44	8	-36
64	-4	32
52	-12	36
-36	-12	12
48	-72	24
48	-64	20
-8	-36	64
8	-36	60
-52	-16	44
-40	-20	48
-44	-16	56

// Diaz M T, 2011: All Valid Sentences > Nonword Sentences
// Diaz M T, 2011: Metaphor > Literal
// Diaz M T, 2011: Congruent > Incongruent
// Diaz M T, 2011: Incongruent > Congruent
// Subjects=16
-54	28	2
34	26	-6
-38	20	14
28	20	-4
-10	58	24
-60	-32	2
50	-18	-8
-34	16	-18
-8	56	32
-58	-18	-14
-58	-42	4
-8	-12	42
30	-98	12
-46	34	-8
52	26	10
36	2	46
-6	34	46
6	52	-24
44	22	-22
-60	-40	-8
-40	-52	28
30	-92	8
0	-28	-10
-60	-4	-4
-46	-22	24
-38	-26	68

// Strother L, 2012: Finger vs. Rest
// Strother L, 2012: Wrist vs. Rest
// Strother L, 2012: Elbow vs. Rest
// Subjects=13
-48.6	-28.6	55.76
-41.15	-14.64	56.74
-39.96	-25.41	68.78
-45.43	-32.27	49.34
-50.74	-26.5	55.61
-40.09	-20.18	53.84
-35.79	-16.64	57.96
-34.69	-19.54	61.54
-47.59	-18.28	51.54
-42.23	-15.79	55.73
-39.98	-26.72	65.54
-50.78	-15.92	54.73
-42.22	-23.45	53.03
-37.92	-26.42	55.46
-35.74	-38.04	56.41
-38.97	-24.06	58.62
-33.57	-27.83	64.45
-38.96	-37.09	55.25
-47.49	-38.11	56.55
-29.38	-26.46	54.25
-32.56	-18.47	61.42
-29.34	-28.23	58.86
-34.67	-38.03	56.4
-39.03	-27.91	50.02
-36.79	-34.62	59.48
-44.34	-32	52.66
-37.93	-31.97	52.58
-35.75	-34.87	56.14
-29.27	-40.75	62.14
-32.55	-27.19	58.81
-29.28	-38.63	61.96
-25.08	-33.83	54.82
-28.3	-32.97	52.55
-26.13	-24.87	60.77
-25.1	-19.74	58.1
-22.92	-22.65	61.66
-30.37	-37.75	59.67
-29.34	-28.23	58.86
-31.48	-34.84	56.09
-34.69	-31.69	55.86
-25.11	-28.72	52.16
-28.25	-32.45	59.2

// Chevrier A, 2010: Post-Error Slowing Activations
// Chevrier A, 2010: Post-Error Slowing Deactivations
// Subjects=14
-8.64	31.95	-4.42
21.49	46.33	27.49
32.28	39.76	37.95
20.07	41.58	-20.05
12.41	-12.95	73.82
57.78	2.19	4.01
-59.75	3.86	8.56
-47.52	-53.77	46.71
67.52	-16.27	12.13
58.77	-5.26	-9.88
-58.79	-1.65	-7.72
48.98	1.77	-28.2
-47.21	4.28	-28.42
46.97	-76	-42.84
8.55	-15.33	-11.8
-7.47	-16.49	-11.52
-17.98	44.58	35.89
28.66	20.14	-22.81
-18.34	17.83	-20.97
7.05	-35.16	62.37
-10.03	-38.34	63.94
-44.38	-67.55	33.33
17.55	-100.7	11.98
-18.15	6.6	-1.07
23.43	1.5	-15.61
-27.84	3.57	-11.85
-12.79	-.86	-1.62
17.08	-13.25	-13.19
-19.26	-12.5	-13.95

// Georgiadis J R, 2010: Stimulation > Non-Stimulation Without Erection 
// (Activations)
// Georgiadis J R, 2010: Stimulation < Non-Stimulation Without Erection 
// (Deactivations)
// Georgiadis J R, 2010: Stimulation > Non-Stimulation With Erection 
// (Activations)
// Georgiadis J R, 2010: Stimulation < Non-Stimulation With Erection 
// (Deactivations)
// Georgiadis J R, 2010: Correlation between Regional Cerebral Blood Flow 
// (rCBF) and Penile Circumference (Activations)
// Georgiadis J R, 2010: Correlation between rCBF and Penile Circumference 
// (Deactivations)
// Georgiadis J R, 2010: Correlation between rCBF and Rate of Circumferential 
// Change (Activations)
// Georgiadis J R, 2010: Correlation between rCBF and Rate of Circumferential 
// Change (Deactivations)
// Georgiadis J R, 2010: Correlation between rCBF and Subjective Sexual 
// Arousal (Activations)
// Georgiadis J R, 2010: Correlation between rCBF and Subjective Sexual 
// Arousal (Deactivations)
// Subjects=16
20	-42	64
-6	-16	62
34	-20	44
-24	-4	58
50	-32	16
-48	-38	26
-8	2	36
-18	-52	6
48	24	-2
-48	2	2
-44	-62	8
32	24	8
30	14	0
-30	-20	10
-30	6	-4
32	0	-6
12	-4	12
-56	30	18
38	64	0
-44	52	-14
8	64	10
6	48	-16
-48	0	58
-2	-58	42
42	-86	26
26	-92	28
70	-22	10
-60	-2	-20
20	-38	64
-16	-34	60
-6	-16	60
22	-8	58
18	32	38
-32	32	-8
48	-38	16
-50	-22	22
2	0	44
54	0	4
-48	-4	10
46	-70	8
-44	-64	6
16	-80	6
-26	-68	4
34	18	8
32	-4	6
-22	4	6
16	-2	-6
-20	8	-12
-2	4	68
-42	30	-20
4	44	-14
2	40	4
-2	22	-18
-18	-20	-16
-2	0	-12
8	-38	72
4	-10	60
40	-6	54
16	12	60
42	-34	22
-4	16	24
50	0	8
-50	-2	-2
-22	-44	4
-36	6	0
34	-14	18
34	-26	20
-34	-14	-2
-30	0	2
32	0	-6
12	-4	-6
56	36	20
-54	32	20
40	62	6
-44	56	-10
14	72	0
42	-86	26
-30	-98	12
66	-8	-8
-62	-8	-16
-28	-40	-6
20	-42	68
-18	-40	58
36	26	26
52	-26	-2
-52	-22	14
2	2	44
4	-34	24
56	0	4
58	-58	8
-54	-62	10
32	28	-2
-34	30	-4
-18	10	-8
16	-2	-6
-4	24	54
-2	28	-12
-30	-2	-16
-4	2	-10
6	-42	64
-20	-42	60
8	-10	60
-4	-12	64
26	-26	54
-24	-28	54
-10	16	46
-34	48	16
-44	-22	24
16	-48	64
-10	2	38
48	-2	8
-50	-4	6
32	22	2
32	16	-6
-38	2	-10
30	0	-8
10	34	-22

// Johnstone T, 2012: 49 > 44 C; Modulated by Fit to Pain-Experience Function
// Subjects=14
45.94	13.33	-2.37
-4.26	-14.18	-9.52
6.82	11.91	51.73
4.61	-27.25	27.16
-32.08	16.03	-1.7
60.25	-39.35	30.88
4.58	0.93	33.72
18.16	5.5	-4.74
19.39	-10.38	9.96
27.87	-27.56	-6.54
47.24	-16.13	15.7
-15.91	-12.08	4.93
58.85	-32.92	-9.79

// Dichter G S, 2012: Anticipation, Controls > ASD (Money Trials)
// Dichter G S, 2012: Anticipation, ASD > Controls (Money Trials)
// Dichter G S, 2012: Outcome, ASD > Controls (Money Trials)
// Dichter G S, 2012: Anticipation, ASD > Control (Face Trials)
// Dichter G S, 2012: Outcome, ASD > Controls (Face Trials)
// Subjects=16
-4	6	-4
24	4	-20
0	-2	24
-30	38	-2
30	58	16
-26	38	-14
20	50	-16
40	-68	24
54	-30	16
38	2	40
10	12	-14
-4	22	-8
64	-28	40
58	-42	32
-62	-44	40
46	-22	-14
-48	-36	-6
24	-12	-30
-8	-20	54
46	6	-28
54	12	4
-48	14	6
-24	2	52
14	-10	72
-40	46	18
44	10	-6
26	-62	4
-10	-76	4
8	-62	4
50	-76	30
26	-64	34
18	-80	42
46	-8	12
-46	16	-4
40	22	2
56	2	44
24	10	-6
22	-4	-32
-26	-4	-30
4	-36	4
-20	54	28
-14	-40	4
32	-66	8
-36	-66	8
36	-58	-6
-34	-2	18
-36	-32	28
-34	-38	10
24	-52	24
-28	-62	14
-56	-54	-14
42	-58	16
44	6	52
0	18	60
-26	4	60
38	14	-6
-30	12	-12
-42	14	-4
-8	-76	4
10	-56	-2
18	-82	42
-20	2	-4
-10	-34	-16
-18	-62	16
32	-2	4
-28	-4	8
-46	-58	8
52	6	-20

// Fernandez-Corcuera P, 2013: Depressive Bipolar Patients
// Subjects=41
-44	4	28
-42	-44	42
36	-54	44
32	-62	-32
-22	-4	8
-6	-50	10
2	54	-8
44	-12	8
-30	-56	-34
-34	-2	50
10	-64	64
-4	38	-10

// Fernandez-Corcuera P, 2013: Healthy Controls
// Subjects=41
-42	14	28
46	-44	44
-6	52	-8
0	-46	30
46	-8	-6
-44	-78	34
38	-26	70
-30	-56	-34
-34	-2	50
10	-64	64
-4	38	-10

// Garrett A, 2011: Healthy Controls
// Subjects=19
62.67	37.06	5.25
60.54	37.26	7.5
40.58	15.19	48.13
-43.58	-42.3	46.29
-43.65	-40.59	41.64
57.01	-31.24	55.8
47.33	-54.98	54.96
55.9	-27.09	54.29
-30.67	21.95	55.4
-60.2	22.44	27.84
-32.88	21.52	50.99
-60.21	22.33	26.73
-45.75	-40.19	46.11
-43.65	-38.47	41.42
40.55	12.75	45.01
-53.67	18.41	30.36
3.83	25.91	49.93
-.45	23.97	52.44
16.64	-81.37	15.51
29.49	-65.78	9.26
-60.53	-54.46	-13.85
-56.23	-54.65	-16.15
-58.25	-68.92	-7.98

// Garrett A, 2011: Psychotic Major Depression Group
// Subjects=16
61.02	12.41	40.21
61	16.67	39.79
58.54	13.31	15.51
-43.65	-40.59	41.64
-43.62	-40.39	43.86
36.4	-62.54	43.56
38.55	-60.41	43.32
49.38	-40.5	49.01
-50.57	21.74	19.9
-55.84	18.3	29.29
-53.51	20.72	43.58
10.13	36.59	37.56
10.13	36.59	37.56
62.78	20.35	10.26
62.84	17.58	15.02
31.81	20.82	39.88
34.01	18.9	42.27
33.32	19.24	-11.54
38.52	-58.49	40.89
40.71	-60.4	43.28
40.71	-60.4	43.28
-43.57	-35.61	48.98
-28.34	-73.09	49.07
36.36	-58.5	40.92
8	36.79	39.82
7.89	42.55	32.53
7.99	38.92	39.61
-52.65	15.77	25.01

// Garrett A, 2011: Nonpsychotic Major Depression Group
// Subjects=15
56.13	44.27	2.4
62.8	35.87	15.45
38.44	6.57	47.9
45.08	-46.89	49.71
-37.2	12.79	49.69
-46.32	33.25	16.44
12.28	38.72	37.32
10.15	38.92	39.57
-48.47	31.12	16.69
-52.25	-35.95	45.8
-45.82	-38.47	41.46
-20.27	-102.51	-1.94
-20.23	-104.43	0.49
-22.43	-102.52	-1.9
-60.54	-52.33	-14.07
-52.86	-73.37	-9.87
-58.39	-54.66	-16.11
-52.84	-71.03	-7.86
64.78	-49.76	-16.45
60.44	-52.11	-18.39
64.86	-51.37	-10.69
53.67	-40.69	46.71
49.27	-42.39	40.23
-11.73	10.52	12.5
14.17	10.4	9.83
16.18	14.79	-.72

// Kleinhans N, 2010: Autism Spectrum Disorder (ASD) Patients
// Subjects=29
-28	-92	-6
34	-70	-16
-36	-62	-18
24	0	-16
-20	-6	-16
44	20	22
-38	6	28
40	-62	18
-16	-64	12
-44	20	20
48	-48	-18
22	-2	-16
-58	-32	-2

// Kleinhans N, 2010: Healthy Controls
// Subjects=25
22	-92	-10
-40	-60	-14
38	-52	-22
18	-10	-12
-18	-8	-14
52	24	26
-44	20	24
52	-44	10
-16	-64	12
-44	20	20

// Lee T W, 2013: Healthy Controls
// Subjects=14
16.46	6.77	53.17
-23.05	4.59	56.03
37.8	-2.25	44.76
36.46	46.59	29.52
-42.32	4.13	51.83
-32.66	13.42	60.98
-38.58	49.11	0.06
63.29	13.8	29.73
-39.71	50.71	-6.75
50.42	11.09	23.42
-45.81	13.26	18.77
49.52	1.88	42.04
-48.94	4.15	25.14
-34.8	-5.34	52.54
14.34	6.93	55.41
-6.09	21.9	44.35
8.82	24.82	39.47
5.73	5.13	46.74
-1.81	9.95	40.84
9.91	21.74	40.83
-7.14	13.35	43.96
29.41	-55.6	43.75
-22.93	-67.8	42.03
38.99	-63.63	35.39
-36.79	-54.34	52.21
35.52	-56.53	3.61
-35.82	-49.9	40.68
8.13	-70.19	49.68
-7.88	-67.82	54.13
52.45	-36.13	-9.45
-44.68	-55.32	-1.15
-68.33	-21.8	-5.92
52.46	-51.45	-14.85
-48.88	-68.84	3.38
25.92	-60.73	5.19
-14.64	-69.26	8.6
46.02	-46.29	-16.33
-43.64	-62.17	-7.27
-28.39	-72.29	25.74
54.69	-65.81	-8.1
3.72	-95.7	22.87
-34.95	-77.21	3.92
2.45	-96.71	-3.79
1.34	-92.74	-7.46
34.13	21.46	-6.26
27.78	20.96	1.66
24.68	-8.67	4.18
-17.04	-8.37	-2.05
17.26	0.69	15.75
-14.82	-.82	12.9
19.39	-13.64	9.12
-14.85	-8.82	5.76
9.56	-30.19	-25.07
-13.92	-22.41	-18.76
10.71	-18.41	-10.45
-8.51	-20.55	-8.94
7.46	-60.58	-32.53
-38.49	-58.74	-32.16
10.72	66.27	24.82
-15.79	49.59	45.48
1.94	47.36	-12.52
-0.03	56.8	13.47
22.74	-46.23	14.05
69.7	-41.09	7.5
-52.39	-6.18	-11.87
51.19	-6.33	-23.08
-51.42	-7.12	-24.07
44.63	2.03	-38.21
-31.24	-5.02	-40.09
21.25	-11.08	-26.8
-36.62	9.92	-39.05
8.46	13.39	-11.98
-15.06	23.02	-9.17
27.52	3.96	-39.29
-33.39	-2.92	-40.24
39.77	-18.29	15.97
-37.88	-86.46	35.96
-14.68	-94.95	-7.09
9.61	21.91	1.79
-5.3	16.88	6.85
-25.79	-7.14	-26.59
-31.39	-63.65	55.16
-33.6	-53.43	49.87
-58.51	14.47	35.54
71.85	-43.11	8.76
28.57	7.14	-39.57
-30.26	8.3	-46.79
-22.6	-4.03	-28
42.68	61.12	10.39
23.29	60.43	-10.52
29.9	69.13	18.79
-49.07	41.16	22.04
-56.53	-48.67	-10.49
48.46	-85.97	7.05

// Lee T W, 2013: Depressive Patients
// Subjects=14
-31.39	-63.65	55.16
-33.6	-53.43	49.87
-58.51	14.47	35.54
71.85	-43.11	8.76
28.57	7.14	-39.57
-30.26	8.3	-46.79
-22.6	-4.03	-28
42.68	61.12	10.39
23.29	60.43	-10.52
29.9	69.13	18.79
-49.07	41.16	22.04
-56.53	-48.67	-10.49
48.46	-85.97	7.05

// Newman S D, 2011: Number Easy vs. Fixation
// Newman S D, 2011: Number Hard vs. Fixation
// Newman S D, 2011: Word Easy vs. Fixation
// Newman S D, 2011: Word Hard vs. Fixation
// Newman S D, 2011: Word > Number
// Newman S D, 2011: Number > Word
// Newman S D, 2011: Hard > Easy
// Newman S D, 2011: Interaction
// Newman S D, 2011: Number Easy Correlation With Reading Span
// Newman S D, 2011: Number Hard Correlation With Reading Span
// Newman S D, 2011: Word Easy Correlation With Reading Span
// Newman S D, 2011: Word Hard Correlation With Reading Span
// Subjects=15
32	-50	44
-38	-46	48
-28	-64	46
-4	16	46
-8	4	14
26	-62	-30
12	8	12
-32	2	54
-48	2	36
-38	-46	48
-30	-60	42
-14	-2	0
-4	18	48
32	-50	42
-4	-24	-10
10	6	12
-48	2	36
-30	4	54
28	-2	58
-2	10	46
-18	-10	2
24	-28	-2
12	-76	-14
-12	-90	-4
34	-50	46
34	-54	-28
-44	-44	50
-28	-64	50
2	-70	52
-34	-52	-28
-24	-30	8
-46	2	32
-32	2	56
-4	10	48
-32	2	54
-46	-42	46
-32	-58	42
-36	-56	-16
34	-54	50
32	-56	-28
12	-74	-16
-54	12	26
-14	-90	-4
30	18	0
-16	2	2
4	-72	52
-28	18	0
12	-8	-2
8	-48	-12
26	-2	58
-4	6	58
-30	30	2
-36	10	32
24	-68	-6
-14	-76	-10
6	-86	2
2	-52	-28
8	-8	-6
46	-32	2
22	10	8
-24	-42	6
-54	-30	40
-42	-4	20
22	-42	12
-12	36	8
36	-40	50
-20	6	64
-30	2	66
-4	12	52
-32	-52	36
-46	-50	44
-52	-46	50
30	10	62
20	6	60
24	4	68
-10	-64	48
-30	50	8
-36	58	12
-2	-30	-22
38	32	46
46	38	30
30	-54	-30
10	-70	-26
-40	-68	50
18	-94	4
-24	-52	36
-22	-96	2
8	8	52
-34	-68	6
16	-92	0
8	8	52
-12	-16	8
-12	-10	18
44	10	20
-24	-98	0
-34	-70	6
34	-76	-4
-52	14	40
-42	26	-6
-48	10	12
24	-76	6
8	52	52
-24	-98	0
0	0	72
-48	8	30
26	-100	2
24	-78	4
40	8	24
44	-30	46

// Preusse F, 2011: Task Difficulty (Diagonal > Horizontal > Vertical > 
// Identity)
// Preusse F, 2011: HI-FluIQ > AVE-FluIQ
// Preusse F, 2011: AVE-FluIQ > HI-FluIQ
// Preusse F, 2011: Task Difficulty * Fluid Intelligence
// Subjects=18
-36	-44	40
38	-78	36
-28	-4	62
28	12	52
-52	8	26
-52	-68	0
-28	-58	56
22	-66	46
6	50	6
52	-70	28
-10	-80	48
-48	-70	2
54	-64	0

// Vizueta N, 2012: Healthy Controls > Depressed Bipolar II Patients, Match 
// Emotions vs. Match Forms
// Subjects=21
-32	40	-8
26	16	-20
-2	42	-16
-26	48	-12
-42	0	40
38	-12	6
-36	-14	16
-2	44	-8
2	44	-8
-2	30	18
26	-2	-16
-36	-14	-16
34	-20	-12
26	8	-8
-56	-22	-12
60	-10	-10
60	-40	20
64	-38	14
52	-58	22
-52	-52	40
-50	-54	32
60	-52	24
-4	-82	-8

// Contreras J M, 2012: Categorical Knowledge (Non-Social > Social)
// Contreras J M, 2012: Feature Verification (Object > Person)
// Contreras J M, 2012: Categorical Knowledge (Social > Non-Social)
// Contreras J M, 2012: Feature Verification (Person > Object)
// Subjects=19
-46	-36	44
-58	-60	-4
6	12	22
-48	6	18
14	-18	68
42	-10	24
-44	38	12
-24	10	56
-48	-52	-12
-40	32	14
-4	-58	28
-8	56	34
-4	48	-8
-50	-10	-22
60	-2	-22
-56	-60	24
56	-56	18
-12	-96	-4
-26	-74	-16
-10	38	50
-2	58	22
-56	-4	-24
38	22	-22
-56	-64	26
54	-12	-32
-40	20	-16
-4	0	6
44	30	-8
62	18	16

// Ebisch S J, 2012: High-GF > Low-GF
// Ebisch S J, 2012: Induction Conjunction Analysis
// Ebisch S J, 2012: Visualization Conjunction Analysis
// Subjects=10
24.98	8.68	49.56
47.02	20.02	1.52
-43.71	30.45	20.65
-26.2	-64.02	36.17
-27.34	-76.94	20.54
-29.79	-56	-11.3
31.08	-46.12	-12.82
-49.71	-42.24	44.65
48.55	-42.16	36.83
4.49	24.19	31.77

// Greimel E, 2010: Other > Control, Correlations with Age
// Greimel E, 2010: Self > Control, Correlation with Age
// Greimel E, 2010: Self vs. Other, Correlations with Age
// Greimel E, 2010: Other > Control
// Greimel E, 2010: Self > Control
// Greimel E, 2010: Self > Other
// Greimel E, 2010: Other > Self
// Subjects=15
28	-68	48
42	-48	54
8	-38	14
-6	64	-4
4	54	-14
-32	-4	66
-36	8	60
-12	22	64
-34	2	64
-46	-20	60
-2	-48	34
12	-50	32
-62	-40	32
-48	-68	24
64	-58	18
-52	-56	8
68	-46	2
-52	-24	-28
48	-20	-32
50	12	-36
22	-12	-24
-6	-60	34
10	-52	34
40	-78	-36
-2	62	10
-14	48	36
54	30	-6
0	-18	38
-48	-66	28
64	-46	20
-56	-64	22
54	-36	-4
52	8	-36
44	18	-34
-2	-50	30
-2	-58	34
12	-50	28
-4	-68	20
-6	-62	2
10	-62	0
34	-78	-38
-30	-84	-36
-4	54	10
-14	48	38
-42	12	46
-48	22	12
-52	-50	48
-56	-64	30
-60	-40	-8
28	-80	-38
-38	-24	-28
-26	-52	-10
-30	-30	-24
-28	-86	-16
-28	-94	-4

// Hampshire A, 2011: Normals (Experiment 1)
// Subjects=16
-30	24	-2
30	28	0
-28	-2	60
-44	48	16
26	4	54
48	44	22
-4	16	48
-28	-48	48
30	-68	36
-10	4	2
12	4	0
-30	52	-2
36	60	16
-32	54	20
-44	28	38
44	46	20
50	24	32
8	-56	58
-26	-56	56
22	-60	46
-46	40	0
-46	30	16
-40	40	-16
-44	-50	-8
-28	-66	32
-22	18	60
-32	60	16
16	64	-2
-26	44	36
36	58	-2
42	22	38
44	46	20
14	-68	44
-16	-54	44
44	-48	48
-46	40	0
-40	40	-10
-62	-52	-8

// Hampshire A, 2011: Normals (Experiment 2)
// Subjects=21
26	-54	50
-28	-54	48
-16	48	4
30	30	42
26	60	2
-28	-46	-18
-40	36	-12
-48	36	8
-48	46	4
-10	50	22

// Hasenkamp W, 2012: Aware > MW
// Hasenkamp W, 2012: Shift > MW
// Hasenkamp W, 2012: Focus > MW
// Hasenkamp W, 2012: MW > Shift
// Hasenkamp W, 2012: Positive correlation between practice time and aware 
// phase
// Hasenkamp W, 2012: Negative correlation between practice time and shift 
// phase
// Hasenkamp W, 2012: Positive correlation between practice time and focus 
// phase
// Subjects=14
-44.44	-27.57	41.13
41.68	1.33	-5.77
-8.3	9.05	29.84
-33.2	22.03	-6.65
-5.4	-20.42	-21.25
-29.21	-50.01	66.26
-28.83	53.8	18.52
45.86	59.74	6.01
-12.56	-6.2	25.59
26.84	-11.74	5.53
60.38	-38.06	47.5
-46.32	-53.45	64.51
45.07	41.78	35.4
46.11	38.19	30.12
52.67	-28.36	22.24
-17.79	-58.91	18.92
-51.86	-13.82	54.56
27.2	-95.9	18.16
16.4	13.83	48.11
-36.91	-83.08	24.51
53.88	-77.42	20.76
1.94	34.16	-18.11
28.87	-29.39	-16.43
-52.35	-10.07	-7.08
-26.89	-9.68	-31.94
-46.21	-8.46	-41.86
4.7	-5.45	47.63
17.96	57.23	-10.19
-61.92	-14.08	-3.03
-20.34	-.53	-10.48
36.29	-45.26	-29.68
46.17	-42.55	4.55
-48.89	-20.68	20.53
32.99	14.08	-19.01
-11.69	-59.84	-21.22
-61.9	24.62	15.77
-9.04	-5.04	67.83
36.42	-0.05	4.44
8.56	-61.37	-29.13

// Jack A I, 2013: Social > Rest, Mechanical < Rest
// Jack A I, 2013: Mechanical > Rest, Social < Rest
// Jack A I, 2013: Social > Mechanical
// Jack A I, 2013: Mechanical > Social
// Subjects=45
-.58	-55.4	35.16
-0.02	51.34	11.7
-53.99	-36.81	46.48
-37.96	-44.37	43.58
-40.57	36.38	14.54
14.43	-98.72	24.12
28.89	-82.91	-34.25
-22.41	-78.99	-33.99
-53.99	-65.41	34.38
-60.51	-59.96	22.84
56.02	-56.55	29.03
3.46	-57.78	4.08
2.61	-54.41	33.92
4.17	-54.94	-41.89
-5.07	-46.65	11.06
65.45	-44.12	10.03
7.67	-38.63	3.54
-54.34	-39.35	-.14
-36.04	-31.27	20.16
-8.46	-32.1	-6.85
19.29	-27.87	-9.76
56.71	-27.48	-7.99
-60.85	-27.21	-7.78
2.56	-18.66	42.08
-20.31	-18.85	-13.41
57.69	-16.27	-14.52
3.37	-14.8	9.4
72.63	-13.09	-16.07
23.5	-12.07	-12.25
-54.58	-6.71	-18.49
52.18	1.71	-29.34
-50.43	3.03	-30.51
35.12	14.09	-19.04
-37.57	13.4	-21.49
40.3	13.47	-41.35
4.76	24.82	67.4
3.12	18.81	-10.14
57.76	23.94	9.99
53.39	25.09	-2.32
-46.06	26.01	-9.07
19.48	36.68	40.59
15.29	41.91	53.58
2.97	42.54	-19.94
-1.06	53.88	17.08
20.46	55.55	36.76
5.53	55.72	40.26
-14.88	58.88	27.97
43.28	-78.83	31.04
-23.96	-68.43	47.67
36.96	-67.98	48.05
19.91	-65.46	54.72
-11.05	-64.16	60.55
38.42	-68.39	-40.04
-54.31	-62.07	-4.93
62.12	-57.48	-11.11
-18.64	-46.74	52.48
40.37	-51.69	-58.19
-30.86	-46.15	-7.65
-46.46	-41.79	50.15
44.37	-40.1	50.09
33.24	-43.65	-8.6
59.28	-33.93	46.05
16.53	-33.21	45.37
-62.6	-32	40.6
-12.36	-30.47	42.12
-23.02	-10.47	53.95
-38.39	-9.3	1.61
43.88	-5.63	0.36
-.78	0.72	31.57
-23.05	5.73	57.05
26.1	5.94	55.36
-50	4.23	26.26
52.54	5.39	18.3
-29.9	15.33	2.8
-3.95	26.4	47.29
-43.74	35.65	19.09
45.99	40.25	15.45
-47.05	42.18	7.43
44.76	51.73	-1.11

// Luo J, 2013: Experiment 1 Normals
// Subjects=19
1.38	-75.94	3.4
55.83	-49.72	7.27
-2.28	57.79	-1.08
1.41	-29.47	26.27
4.47	-17.79	11.87
-56.32	-43.28	18.05

// Mannie Z N, 2010: Load Response Activity, FH Participants > Healthy 
// Controls
// Mannie Z N, 2010: Quadratic Load Response Activity, FH Participants > 
// Healthy Controls
// Subjects=15
-50	-78	4
52	0	0
-6	-68	54

// Oei N Y L, 2012: Emotional > Neutral Distractors
// Oei N Y L, 2012: Neutral > Emotional Distractors
// Subjects=40
42	-62	-12
-52	-70	12
-36	30	-2
52	30	4
22	-4	-18
-30	-10	-36
54	8	-32
38	0	-16
62	-4	-4
-66	-28	8
24	-26	70
-24	-30	66
42	52	-10
0	-70	22
30	-94	-10
-30	22	54
24	38	46
50	28	32
-36	-60	38
46	44	16
54	-38	52
52	-22	56
36	-24	48
-24	34	34
46	-42	38

// Perlman S B, 2011: Controls > Autistic Subjects, Free Viewing
// Subjects=7
30.06	-57.76	-11.84
20.27	-6.8	-12.65
-24.68	-1.24	-19.29

// Sebastian C L, 2012: Affective ToM > PC
// Sebastian C L, 2012: Cognitive ToM > PC
// Sebastian C L, 2012: Affective ToM > Cognitive ToM
// Sebastian C L, 2012: Cognitive ToM > Affective ToM
// Subjects=15
8	-54	26
-6	-46	26
-54	-50	18
10	50	22
-8	54	0
50	8	-24
52	-48	20
-62	-10	-14
8	-60	26
-40	-80	22
50	-48	20
56	-6	-16
-62	-12	-12
-6	-52	26
4	-54	28
50	10	-24
-46	-54	-6
30	-44	-10
-20	-76	50
-22	8	52
24	8	52
-40	-8	30
-46	4	36

// Soto D, 2012: Cue-type effects - Verbal > Visual
// Soto D, 2012: Cue-type effects - Visual > Verbal
// Soto D, 2012: Cue repetition effects: (Valid + Invalid)/2 vs Neutral - 
// Conjunction Visual and Vebal
// Soto D, 2012: Cue repetition effects: (Valid + Invalid)/2 vs Neutral - 
// Verbal
// Soto D, 2012: Cue repetition effects: (Valid + Invalid)/2 vs Neutral - 
// Visual
// Soto D, 2012: Cue-validity effects: Valid > Neutral > Invalid - Conjuction 
// Visual and Verbal
// Soto D, 2012: Cue-validity effects: Valid > Neutral > Invalid - Verbal
// Soto D, 2012: Cue-validity effects: Valid > Neutral > Invalid - Visual
// Subjects=10
24	-96	2
-16	-98	4
-38	-44	-24
38	-78	6
-42	-72	6
30	-66	-14
-12	-40	-16
10	46	32
22	6	36
-8	-44	22
6	56	34
-40	-16	18
-14	32	56
-22	54	32
14	34	56
-50	22	2
-54	-8	-34
50	10	-20
-58	-30	-10
66	-32	-2
-28	-20	-24
30	-26	-24
-14	-56	32
-12	-20	-18
-12	-62	-32
-34	-40	18
22	22	24
28	-54	62
-36	-22	32
38	-22	14
-32	-80	-6
-50	-56	-8
34	-20	-12
-40	-74	2
-48	-76	18
48	-26	40
8	16	28
-14	50	-2
32	58	6
46	-4	-4
-32	8	14
-26	-34	-2
28	-24	4
-26	-16	-14
-28	-8	8
-10	20	-6
22	22	-2
16	-18	-22
-16	-26	-24
-16	-8	54
12	28	56
50	-34	14
34	-16	-12

// Tamm L, 2012: Fluid Reasoning, Controls > ADHD
// Subjects=10
33	-73	14
-8	-78	-31

// Tian F, 2011: Successful > Unsuccessful Preparation
// Subjects=16
-21.21	42.18	32.79
-52.98	-60.55	28.38
14.06	-76.17	-14.57
36.49	-10.28	9.76
-34.09	-11.22	3.96
-36.92	-20.59	48.27
1.58	-16.67	54.19

// Zarnhofer S, 2013: Story, Visualization
// Zarnhofer S, 2013: Formulation, Visualization
// Zarnhofer S, 2013: Story, Verbalization
// Zarnhofer S, 2013: Formulation, Verbalization
// Subjects=36
-12	-85	19
51	-73	1
-6	-67	7
36	-58	-5
-27	-37	4
36	-58	-5
-9	-55	67
27	-31	13
9	2	-14

// Osumi T, 2012: Negative Correlation: Psychopathy vs. [UG (unfair-fair)+DG 
// (unfair-fair)]
// Osumi T, 2012: Negative Correlation: Psychopathy vs. [UG (unfair-fair)-DG 
// (unfair-fair)]
// Subjects=20
-30	-58	54
-8	-8	0
28	2	-16
-36	-36	12
26	-16	-6
54	-12	-12

// Veit R, 2010: Anticipation of pain (High + Low Punishment)
// Veit R, 2010: Anticipation of pain, High > Low Punishment
// Veit R, 2010: Observation of opponent pain (High + Low Punishment)
// Veit R, 2010: Observation of opponent pain, High > Low Punishment
// Veit R, 2010: Retaliation of pain (High + Low Punishment)
// Veit R, 2010: Retaliation of pain, High > Low Punishment
// Subjects=10
69	-42	21
60	-18	30
-48	-63	0
51	27	9
12	-84	-12
-48	-87	-6
60	21	-6
-33	24	-21
-57	12	45
-9	-9	6
-45	0	54
51	-6	48
0	15	60
66	-24	30
-60	12	6
-39	24	9
15	3	3
-12	3	3
45	-63	-15
15	-99	18
-66	-12	-24
69	-18	-18
45	-45	-15
21	-33	-18
66	-42	12
12	-57	27
45	-45	27
60	27	-9
39	0	39
51	30	21
42	18	-6
9	42	51
-33	15	-12
63	-9	-15
-54	-69	15
-42	21	-9
66	-48	12
-63	-51	12
51	-48	-18
-3	69	-6
30	-6	-15
42	-75	6
66	-36	18
51	-51	-21
57	-36	45
-45	-54	42
27	-42	12
-30	-36	-18
66	-33	30
-21	-21	-18
45	-60	45
9	-12	-18
-42	24	9
-57	21	18
0	-21	39
-21	-6	-12

// Terasawa Y, 2013: Body Now > Possession Now
// Terasawa Y, 2013: Emotion Now > Possession Now
// Terasawa Y, 2013: Body Usual > Possession Usual
// Terasawa Y, 2013: Emotion Usual > Possession Usual
// Terasawa Y, 2013: Common Activations, Emotion Now and Body Now
// Terasawa Y, 2013: Coactivated Areas for Body Now and Emotion Now 
// (Conjunction Analysis)
// Terasawa Y, 2013: Coactivated Areas for Body Usual and Emotion Usual 
// (Conjunction Analysis)
// Terasawa Y, 2013: Emotion Now > Body Now
// Terasawa Y, 2013: Body Now > Emotion Now
// Subjects=18
-12	-72	-12
39	21	6
3	-48	-9
15	-72	-39
-24	12	24
-3	-18	33
51	45	-3
-9	-84	-18
-57	12	-12
-51	33	-3
51	18	-15
21	-84	-15
-60	-48	9
2	-60	-18
-9	75	-9
-18	-84	15
42	-75	12
39	-18	54
-36	-15	51
-18	-54	60
15	-51	54
-9	-72	-6
9	-84	-6
60	-27	36
-63	-9	27
27	-60	-15
-42	-63	-15
-18	-84	12
-39	-3	21
36	-39	69
54	15	-9
-51	-15	45
-54	-27	45
-60	-39	24
-20	36	-12
36	18	6
-3	-75	-3
-48	6	36
-33	-3	63
-6	9	57
-51	18	-12
-57	-42	6
54	18	-6
-51	-21	30
54	18	-6
-51	-27	3
36	18	6
-33	18	6
-9	-81	0
9	-87	3
-42	-27	57
-3	-3	57
-48	6	42
-24	-66	51
42	-87	3
-48	21	-9
-48	-57	26
-51	33	-3
-54	18	-14
-42	18	54
-1	-49	28
-1	58	21
-1	39	-1
57	30	10
-35	-14	52

// Fan L Y, 2014: Healthy Controls
// Subjects=23
24	45	-12
33	18	12
-9	21	24
12	30	18

// Fan L Y, 2014: Attention Deficit Hyperactivity Disorder (ADHD) Patients
// Subjects=25
30	15	12
-3	30	0
3	30	0
33	18	12
-9	21	24
12	30	18

// Rahm C, 2014: Affective Stroop (aStroop), Control
// Rahm C, 2014: aStroop, SSRI
// Rahm C, 2014: Counting Stroop (cStroop), Control
// Rahm C, 2014: cStroop, SSRI
// Subjects=11
-56	-70	22
-2	-60	10
-62	-54	-2
-24	-54	36
-44	24	40
-2	-60	10
-6	-50	28
-20	-12	-16
-26	-72	-16
-54	-16	56
-42	32	-2
0	6	46
36	14	38
-32	18	-2
42	-46	36
4	40	36
48	20	42
36	32	2
-32	18	-8
-48	14	6
-54	16	28
62	-54	-4
44	20	-12
-58	-46	-8
-14	-74	-46

// Adank P, 2012: Noise > Clear
// Adank P, 2012: Clear > Noise
// Adank P, 2012: Accent > Clear
// Adank P, 2012: Clear > Accent
// Adank P, 2012: Noise > Accent
// Adank P, 2012: Accent > Noise
// Adank P, 2012: Clear < [Noise + Accent]
// Adank P, 2012: [Noise + Accent] < Clear
// Subjects=26
32	28	10
-32	24	8
6	-14	28
-24	-40	-2
-12	10	-2
12	20	36
30	40	24
8	22	18
-40	-22	12
-40	-20	54
34	-22	10
-36	22	-26
34	42	-14
-54	-44	-6
14	-50	-20
-8	50	40
66	-42	-8
-54	-44	-6
-60	-12	-6
-14	56	40
14	46	16
-52	-56	46
32	28	8
30	42	28
-34	18	0
10	22	40
-8	34	24
-40	-20	8
46	-14	4
12	-72	6
32	36	10
-12	10	-2
-42	-24	16
-40	-20	54
-36	22	-24
-10	52	42
-62	-50	-6
-34	-68	36
62	-42	-8
-44	16	46
16	50	50

// Gillath O, 2012: Normals
// Subjects=39
10	12	0
-4	14	26
4	-16	42
-42	20	10
-34	18	-16
-38	28	-4
40	22	10
28	28	-10
-30	18	52
-56	-62	6
-54	-64	20
-58	-54	38
64	-48	32
-6	20	24
-32	18	-14
42	20	14
-36	20	12
50	-66	-6
-62	-40	-8
-54	-66	8
-8	-72	38
6	-58	48
12	-72	38
66	-46	30
-28	20	-10
-40	-40	42
6	66	12
60	12	36
58	6	42
34	4	52
38	-86	2
38	-60	28
20	-34	-6
52	-26	50
4	-44	18
12	-74	42
30	-68	40
26	44	36
-30	-66	52
34	-54	48
-10	-6	4
-8	22	32
14	-40	-4
-22	-98	12
50	10	32
36	32	-8
42	-78	-2
-36	16	12
4	18	46
-30	-8	58
-32	38	-10
-26	-90	8
-54	-68	8
30	-92	6
-18	-36	-6
6	-38	24
-44	-2	36
54	-2	52
48	16	8
-2	-66	46
-32	48	34
24	48	22

// Gillath O, 2012: Subgroup of Normals, Healthy heterosexual males
// Subjects=19
-56	-14	-6
-6	44	-8
34	-80	10
-40	-56	16
-6	-66	18
-22	14	-4
-2	34	16
4	10	2
10	12	-6
-4	20	26
2	-26	30
2	-18	34
2	-48	0
20	-2	-4
42	18	14
28	30	-10
36	16	0
42	48	28
46	12	34
32	44	24
-14	12	-6
66	-44	26
26	48	18
6	50	30
2	-18	10

// Gillath O, 2012: Subgroup of Normals, Healthy heterosexual females
// Subjects=20
-56	-14	-6
-6	44	-8
34	-80	10
-40	-56	16
-6	-66	18
-22	14	-4
0	20	22
8	8	8
12	2	16
-14	-4	20
4	-4	30
10	0	-2
-42	24	6
-48	14	16
-32	18	-14
58	20	16
44	-76	-4
-48	-58	46
-44	2	52
-34	-6	46
50	12	48
54	-64	4
-24	42	46
-28	52	32
6	16	52
10	48	40
12	58	28
-54	-52	10
-52	-56	34
64	-48	30
-8	-28	38
10	18	38
-10	-72	32
-18	-44	-10
-50	6	30
38	-84	-2
-42	-30	36
-30	22	4
-4	60	12
10	10	-18
-20	2	-14
18	2	-16
54	-26	52
-4	-58	18
6	-48	14
-34	-8	50
-46	-4	58
-24	-56	44
-10	-80	40
14	-48	48
10	-60	62
-18	14	-6
-20	48	34
-26	-68	52
30	12	-24

// Herrmann B, 2012: Univariate Analysis, grammaticality and perceptual 
// markedness contrast
// Subjects=25
-54	8	10
-60	-22	-2
-54	5	-14
57	-28	1
60	-4	-8
-45	-22	1
48	-22	7

// Huang C M, 2012: Incongruent vs. Congruent - Physical Size Task
// Huang C M, 2012: Incongruent vs. Congruent - Numerical Magnitude Task
// Huang C M, 2012: Older > Young - Physical Size Task
// Huang C M, 2012: Older > Young - Numerical Magnitude Task
// Huang C M, 2012: Older > Young - Physical Size Task and Numerical Magnitude 
// Task
// Subjects=15
44	24	2
-54	12	18
32	44	10
-38	8	34
10	20	42
14	8	42
-30	10	12
-48	6	44
-32	-50	48
38	-48	46
60	-32	50
12	-66	64
34	-56	60
-8	-46	-18
16	-48	-44
46	-28	6
-52	-50	14
-6	-22	6
52	20	14
-36	28	8
28	58	32
8	22	20
-32	50	36
40	56	8
16	-68	48
16	-68	50
-48	-38	44
-12	-70	42
62	-36	34
-30	-58	-36
36	-50	-32
-24	-72	32
-14	-24	10
-28	-18	72
32	-32	74
38	-6	66
6	-2	70
-4	30	-10
-24	12	-26
34	62	8
36	-44	54
-22	-44	-24
20	-68	-20
46	-28	14
-30	-62	42
38	-50	44
-32	-54	34
-12	-72	40
58	-32	0
-52	-6	52
-36	52	22
34	60	22
-10	-10	62
-60	-36	12
-20	-34	-26
12	-54	-22

// Isenberg A L, 2012: Sensory motor integration contrast
// Isenberg A L, 2012: Spatial hearing contrast
// Subjects=17
-58	6	20
-7	8	37
-41	-44	57
-31	30	0
-53	32	17
-52	22	12
-33	-19	35
-21	-13	7
-31	28	10
-50	-34	12
-37	-9	67
-25	11	-25
-35	20	-25
47	-12	45
49	5	2
22	12	2
62	11	7
26	-5	7
65	2	20
11	1	10
14	-18	10
34	-7	0
28	-3	-10
65	3	30
6	-5	12
55	-34	25
2	42	20
28	-21	7
61	-27	12
-45	-1	-5
-29	-27	15
-54	-1	-3
-52	-29	5
-17	-25	7
-58	3	32
-9	-17	2
-47	-11	12
-43	12	32
-17	-15	67
45	-33	72
22	3	56
51	-9	32
12	-60	20
38	-15	20

// Masten C L, 2012: Social Exclusion vs Control
// Subjects=21
42	27	-9
-45	18	-15
0	15	27
54	-69	3
63	-42	24
39	-51	-15
9	-54	60
-48	-72	12
-57	-48	27
42	3	54
0	54	15
45	24	24
3	54	39
6	6	9
-3	-30	-3
-15	-78	-30
-30	9	-24
-24	0	69
-39	-60	-12
6	-42	-36
-24	-72	36
-42	15	24
15	-3	-15
27	54	9
12	27	21

// Minamoto T, 2012: Distractors Forgotten - Remembered
// Minamoto T, 2012: Distractors Remembered - Forgotten
// Minamoto T, 2012: Memorandum Remembered - Forgotten
// Minamoto T, 2012: Functional Connectivity Contrast: Distractors Forgotten - 
// Remembered
// Minamoto T, 2012: Functional Connectivity Contrast: Distractors Remembered 
// - Forgotten
// Subjects=29
16.76	27.87	47.28
-17.8	29.98	48.78
-22.73	61.53	7.64
26.97	63.94	7.68
-6.55	-8.22	75.9
56.85	-59.8	37.34
3.97	-45.33	45.77
1.92	-70.76	49.45
10.75	-41.96	69.98
-66.56	-30.32	26.44
65.32	-52.3	25.25
-48.13	-61.52	24.73
-64.46	-50.5	17.2
-17.73	-67.92	34.93
3.85	-7.9	44.31
-2.72	-41.38	30.93
-20.55	-29.13	-9.2
22.67	-89.13	-21.93
-29.21	-85.06	-21.45
-39.79	-69.19	-.42
-29.36	62.6	-3.56
34.12	15.38	50.46
58.54	24.26	17.79
51.09	5.4	23.14
-4.65	6.29	58.74
30.07	-54.83	57.48
38.74	-50.24	60.24
-26.19	-44.71	54.07
50.75	-54.06	-15.79
-46.28	-58.37	0.86
42.74	-71.21	30.87
-41.56	-80.54	27.62
38.21	-90.32	10.42
20.94	-94.64	11.14
-22.64	-40.62	-5.78
-22.78	3.19	-7.88
13.86	-36.73	-23.6
14.01	-71.73	-19.02
31.36	-62.43	-12.39
-44.49	47.24	-6.26
-40.06	34.91	-.63
14.93	11.76	70.2
17.12	-6.63	68.62
-35.1	3.56	42.72
-10.94	-6.52	71.32
-10.88	-17.05	73.49
-15.21	-34.6	69.69
6.04	-16.4	45.12
42.28	-28.72	3.14
7.77	-38.21	6.91
-11.8	13.29	7.75
-22.65	17.3	5.29
29.22	-33.85	-5.1
50.35	16.26	-32.83
-7.65	-36.08	-15.45

// Bzdok D, 2012: (TR--AG) and (AT--AG) and (TR--HA) and (AT--HA)
// Bzdok D, 2012: (TR--AG) and (AT--AG)
// Bzdok D, 2012: (TR--HA) and (AT--HA)
// Bzdok D, 2012: (TR--AG) and (AT--AG) and (HA--AG)
// Bzdok D, 2012: (TR--HA) and (AT--HA) and (AG--HA)
// Bzdok D, 2012: AT--TR
// Bzdok D, 2012: TR--AT
// Bzdok D, 2012: TR and AT and HA and AG
// Bzdok D, 2012: Male AT- female AT
// Subjects=44
-2	57	17
-17	58	23
-54	24	6
35	-81	-38
-3	60	15
-3	39	-17
-50	27	0
-45	12	-41
-3	38	11
-2	-20	38
-3	-48	29
-24	-23	-18
-33	-12	-23
-29	-6	-21
-33	-6	-29
-27	-81	-39
-35	-80	-35
33	-81	-36
-2	57	17
-48	20	6
45	26	-8
-38	24	-20
29	18	-20
-5	-2	3
2	-17	5
-45	12	44
42	23	23
-45	12	-39
50	-62	38
33	-75	50
-44	-69	-42
-29	-81	-36
35	-81	-38
-11	51	-11
-41	24	-11
33	24	-6
41	21	-6
-53	32	15
42	23	23
33	47	11
33	-75	50
-41	-65	-41
33	-39	-12
-24	-44	-11
-12	-78	-9
-41	-78	15
-66	-39	-5
57	-51	15
57	-8	-17
-33	-8	50
29	-6	48
45	6	29
-5	8	48
5	9	48
-41	5	29
56	17	32
-32	-47	45
29	-57	42
-30	-50	48
29	-63	50
-20	12	-5
18	12	-3
-24	-92	-14
27	-86	-12
-8	-26	-6
8	-26	-8
-23	-26	-6
24	-27	-5
0	-23	11
5	-6	8
5	-20	12

// Gutchess A H, 2012: False Alarms: Positive Modulations (Lrg>Med>Small)
// Gutchess A H, 2012: False Alarms: Negative Modulations (Small>Med>Lrg)
// Gutchess A H, 2012: Hits: Positive Modulations (Lrg>Med>Small)
// Gutchess A H, 2012: Hits: Negative Modulations (Small>Med>Lrg)
// Gutchess A H, 2012: False alarms > hits
// Gutchess A H, 2012: Hits > false alarms
// Gutchess A H, 2012: Hits-Novel and False alarms-Novel
// Gutchess A H, 2012: All Hits - All False Alarms
// Gutchess A H, 2012: All False Alarms - All Hits
// Subjects=16
36	-38	-26
38	-10	-18
2	-64	10
16	-70	12
34	-24	58
14	24	0
-26	-48	58
58	-56	30
-60	-54	30
-54	-76	12
-48	-58	50
38	-90	-2
32	-76	32
-30	-92	10
38	-60	-14
-16	12	0
-28	-12	12
-24	14	12
36	-52	-24
-18	40	14
0	-42	-16
-14	-32	52
28	38	4
34	-38	-26
44	-74	-12
34	-52	-24
38	-16	-24
42	-18	-16
-34	-70	-16
-28	-92	8
-28	-86	2
10	-10	32
-4	-20	-8
-14	-34	26
-24	-28	24
-44	20	-12
-34	22	-12
-16	60	20
34	-24	56
64	-58	24
64	-54	34
-44	-66	6
-54	-72	14
46	-66	20
52	-68	14
-26	10	44
-20	18	48
28	-50	48
36	-60	44
12	-72	52
26	-52	-24
32	-44	-22
44	-52	-16
-22	-32	-32
-20	-48	-24
-30	-40	-30
24	-38	-20
26	-26	-10
-20	-92	10
54	10	44
58	2	34
42	4	22
8	26	48
14	0	54
-8	14	42
-42	24	30
-54	22	32
42	30	20
42	48	28
34	32	26
38	-6	50
30	-10	48
42	6	52
-14	-12	34
-4	0	6
4	-2	6
-12	4	6
64	-22	38
64	-20	28
64	-30	42
-50	-26	36
-56	-20	46
-28	-46	48
-44	-42	38
-26	-56	32
-42	12	40
-42	0	40
-50	10	36
10	-56	-22
2	-62	-20
12	-70	-18
42	24	40
38	24	48
46	18	50
-24	-58	-10
-24	-52	4
-14	-62	-20
-14	-64	-12
-18	-76	36
28	-8	-4
24	-8	-14
30	-62	-20
50	-18	32
48	-30	28
-14	-76	60
-8	-68	58
-14	-60	60
-28	-90	24
-20	-92	32
-16	-42	-26
4	-20	46
-10	-18	50
-16	-20	40
-26	-40	16
-26	-48	24
-22	-38	24
-26	-40	-6
32	-80	26
-50	-10	-8
-36	-16	-8
-44	-16	-6
30	40	-4
16	20	34
10	18	24
36	52	18
34	48	10
28	42	6
40	-16	30
28	-12	34
46	-10	26

// Hargreaves I S, 2012: Animal SCT > Concrete SCT
// Hargreaves I S, 2012: Concrete SCT > Animal SCT
// Subjects=15
-2.18	20.84	-21.6
-5.47	56.73	-20.71
-47.32	-34.44	12.42
-66.46	-23.89	-19.27
-48.22	-76.61	13.09
-59.96	-61.11	-7.88
-31.55	-36.34	-20.84
-2.85	-58.17	14.89
7.22	52.64	-20.5
24.66	-19.28	77.55
19.99	22.65	-29.62
71.04	-28.44	24.63
27.39	10.28	-43.25
67.85	-34.67	9.53
67.7	-10.81	-14.3
32.93	-39.6	-14.34
-1.01	37.31	40.53
-66.39	-6.07	30.56
59.3	4.3	26.89

// Kalm K, 2012: Encoding > Unmodelled Rest
// Kalm K, 2012: Load: Supraspan > Subspan
// Kalm K, 2012: Load: Subspan > Supraspan
// Kalm K, 2012: Ungrouped > Grouped
// Kalm K, 2012: Supraspan: Grouped > Ungrouped
// Kalm K, 2012: Subspan: Ungrouped > Grouped
// Subjects=23
-62	-26	2
-36	20	-2
-32	36	-8
-46	38	28
-54	4	32
-52	-38	36
52	14	-26
34	20	10
32	-40	-38
28	16	14
44	44	28
22	44	40
54	-20	38
-44	-20	6
50	-12	8
18	-104	2
-56	-6	-4
-42	22	-30
-42	-8	38
-34	38	-14
-34	44	20
58	12	-30
40	20	8
54	10	28
46	36	-6
-54	2	-2
62	-2	-6
52	8	-24
-56	-22	36
-48	2	26
-56	-30	16
-36	20	-2
-28	-2	-58
-38	54	14
60	-22	20

// Kalpouzos G, 2012: Encoding vs. Control, Young > Older, ANOVA
// Kalpouzos G, 2012: Encoding vs. Control, Young > Older, ANCOVA
// Kalpouzos G, 2012: Encoding vs. Control, Older > Young, ANOVA
// Kalpouzos G, 2012: Encoding vs. Control, Older > Young, ANCOVA
// Kalpouzos G, 2012: Retrieval vs. Control, Young > Older, ANOVA
// Kalpouzos G, 2012: Retrieval vs. Control, Young > Older, ANCOVA
// Kalpouzos G, 2012: Retrieval vs. Control, Older > Young, ANOVA
// Kalpouzos G, 2012: Retrieval vs. Control, Older > Young, ANCOVA
// Subjects=16
-10	58	14
36	32	-22
-10	-32	70
36	-26	68
16	-62	52
44	-26	58
64	0	20
-42	6	-26
-62	-52	12
52	14	-16
-18	-2	-26
22	6	-26
-12	-44	-6
-14	-94	14
-42	-74	12
34	-78	0
28	-50	-14
-16	-64	-48
-32	-60	-24
6	-62	-46
-10	12	-12
36	-12	12
-10	58	12
-10	-30	68
32	-26	68
44	-26	60
-42	6	-24
-52	-4	-10
48	12	-16
24	12	-26
-16	-90	14
14	-68	14
6	-92	0
22	-56	14
-12	-70	8
6	-78	6
-46	-74	12
34	-80	0
30	-46	-16
-16	-64	-48
6	-62	-46
-10	10	-10
34	-12	12
-18	-84	-34
-18	-82	-32
-32	-82	-4
34	-80	-4
16	-94	2
-32	-82	-4
34	-80	-2
-14	28	56
-28	30	40
-42	-12	56
38	-20	68
-62	4	16
-44	-64	52
-52	-30	36
-56	-36	52
52	-72	30
62	-28	40
60	-52	-8
62	2	-6
28	-76	42
38	-80	-26
8	-86	-28
-36	-70	-30
20	-74	-32
-16	28	58
-44	-66	50
-50	-28	36
52	-72	30
58	-50	-10
30	-86	-28
34	-82	-26
8	-86	-30

// Marvel C L, 2012: Manipulation (2 target -1 target) vs Storage (2 target -1 
// target) during delay
// Marvel C L, 2012: Manipulation (2 target -1 target) vs Storage (2 target -1 
// target) during delay, Deactivations
// Marvel C L, 2012: Manipulation (2 target - 1 target) vs Storage (2 target - 
// 1 target) during encoding
// Marvel C L, 2012: Manipulation (2 target - 1 target) vs Storage (2 target - 
// 1 target) during encoding, Deactivations
// Marvel C L, 2012: Negative correlation between BOLD and accuracy scores 
// during 2 target manipulation
// Subjects=16
-4	22	12
-42	10	30
-40	40	38
-30	26	-2
-36	18	2
-46	4	40
-4	8	66
-8	20	52
-10	18	42
10	18	52
-14	0	26
-14	-12	14
-44	-44	44
-38	-60	-32
-28	-72	38
-10	-70	52
38	42	26
48	34	38
14	26	26
6	24	10
52	24	28
26	18	26
64	14	-38
18	6	27
12	8	18
0	-2	8
0	-28	14
20	-30	2
36	-54	54
36	-46	46
28	-66	38
32	-60	-30
32	-70	-54
0	-76	4
-30	-46	76
-52	-72	42
44	-24	16
30	-32	66
58	-64	24
-18	46	-6
0	58	-8
-16	54	12
-12	38	2
-32	42	-34
-24	6	-4
-8	-48	36
-12	-60	10
-8	-62	28
-16	-88	14
20	46	-6
22	60	-14
20	44	-18
14	38	4
16	36	-12
32	40	-32
30	32	-18
24	16	0
36	12	-36
46	-54	12
8	-54	26
-46	4	-2
46	64	-18
-34	16	6
-40	6	28
-48	-46	-42
-26	-52	-34
-6	-56	-34
-42	-66	-40
-14	-74	-28
22	-62	-32

// Aue T, 2012: Favorite team vs. baseline, whole brain analyses
// Aue T, 2012: Least favorite team vs. baseline, whole brain analyses
// Aue T, 2012: Favorite team vs. least favorite team
// Subjects=13
0.38	-30.11	31.91
2.12	47.04	10.92
61.31	-49.37	25.02
-44.97	6.47	-14.13
-54.11	-57.89	21.48
-10.32	-89.67	5.8
-1.69	-50.38	31.4
52.32	-8.9	-15.07
46.1	33.61	26.04
57.93	6.99	24.79
50.1	30.81	-10.57
21.71	-93.08	0.14
-25.29	-29.46	28.8
-24.27	-67.29	7.43
29.78	11.86	-19.9
-4.89	-28.31	41.86
2.17	46.41	16.55
-7.42	-12.63	-2.92
54.69	-25.15	8.57
-53.11	-46.51	17.17
-10.34	-88.78	3.5
-1.69	-50.38	31.4
32.11	16.04	6.49
-39.67	29.13	-10.52
3.6	-16.8	38.56
57.93	6.99	24.79
3.2	-53.92	-28.58
44	-71.42	-10.85
34.16	-52.93	-32.36
41.85	34.99	30.43
-23.44	-37.9	-11.77
20.6	-90.25	-4.54
-34.38	52.77	-8.1
1.13	-70.76	-26.03
-40.42	23.58	27.88
-23.2	-67.28	7.42
29.45	-58.43	48.45
-35.06	-65.12	-4.89
-1.09	60.14	15.44

// Moseley R, 2012: All emotion words > Baseline
// Moseley R, 2012: Abstract emotion words > Baseline
// Moseley R, 2012: Experimental words
// Moseley R, 2012: Face words
// Moseley R, 2012: Arm words
// Subjects=18
-56	4	24
-50	-10	44
-44	26	-2
60	2	38
8	22	52
-8	22	38
6	40	10
-10	54	12
-28	34	-5
-56	-34	2
-38	-44	-14
-40	-62	-12
-48	-34	38
-52	-38	30
8	-62	2
-2	-70	2
-56	4	24
-48	-12	40
-56	-8	44
56	0	40
60	2	24
-10	56	12
8	52	8
-60	-34	2
-40	-40	-14
-44	-74	-8
-48	16	-26
50	-32	24
36	-64	2
16	-50	64
28	24	6
34	-16	22
-54	-8	42
-56	4	20
-34	0	32
-30	26	10
-42	28	-4
-42	28	6
-6	18	40
-4	-2	60
60	2	38
12	18	44
-56	-34	2
-40	-40	-18
-60	-36	24
-62	-18	20
-56	-22	32
66	-36	30
-50	-2	42
-56	4	12
-54	6	34
-30	28	0
-28	22	8
-6	14	40
6	12	34
62	10	12
30	30	4
30	22	6
-64	-20	-18
-52	-56	2
-40	-42	-18
-44	-50	-28
-56	-38	26
62	-36	30
-44	-80	-8
-54	-8	42
-62	-36	22
-46	24	16
-8	20	38
-8	0	62
-28	-6	52
58	2	38
64	2	12
40	22	-4
-52	6	-8
-46	14	0
-34	-18	12
-46	-38	2
-40	-42	-20
-44	-60	-12
-48	-32	40
68	-40	28
4	-44	-34

// Greck M D, 2012: Intentional empathy for familiar angry > baseline - 
// transcultural constants
// Greck M D, 2012: Intentional empathy for familiar angry > baseline, Chinese 
// > Germans
// Greck M D, 2012: Intentional empathy for familiar angry > baseline, Chinese 
// > Germans
// Greck M D, 2012: Intentional empathy for familiar neutral > baseline - 
// transcultural constants
// Greck M D, 2012: Intentional empathy for familiar neutral > baseline, 
// Chinese > Germans
// Greck M D, 2012: Intentional empathy for familiar neutral > baseline, 
// Germans > Chinese
// Subjects=16
-43.59	-.22	23.22
-40.35	-22.92	18.39
30.34	15.48	54.51
-4.89	2.41	53.78
11.09	-1.26	46.09
-28.75	-26.59	-2.62
-18.16	-12.15	-9.53
35.86	88.66	-31.99
39.53	-61.44	-32.82
-15.46	94.7	-31.91
-41.07	52.02	-44.76
-30.93	57.47	24.92
-24.66	79.2	16.34
-5.36	83.26	25.81
42.98	-2.87	22.44
33.23	-24.02	-2.44
23.57	-11.39	-3.38
26.64	66.31	10.14
33.22	74.75	36.12
-2.41	34.5	-27.01
8.29	34.65	-26.03
26.49	35.19	-20.71
-50.44	47.93	-14.2
-21.62	34.64	-23.45
-5.33	34.14	9.86
-45.64	-4.83	32.55
59.93	51.76	25.47
61.78	16.91	-26.27
57.7	-11.78	-11.55
-42.8	-.92	-13.54
-43.59	-.22	23.22
-40.35	-22.92	18.39
49.4	-6	22.63
26.89	-43.09	-.76
-4.88	2.58	55.99
11.1	-1.18	47.2
-27.67	-27.55	-1.44
33.21	-24.27	-5.76
-21.35	-8.74	-6.44
35.86	88.66	-31.99
39.07	59.1	-42.93
-18.64	94.93	-28.54
-41.06	55.45	-41.7
-37.95	80.85	-43.87
-30.95	60.65	24.66
-8.5	80.58	32.76
26.61	72.65	9.61
17.16	77.57	32.72
-2.38	34.76	-23.68
8.25	36.51	-29.53
-24.53	37.71	16.47
26.51	32.02	-20.44
-21.62	34.64	-23.45
-46.7	-5.81	33.76
-40.63	-2.77	-10.06
58.56	19.01	-26.41

// Uchiyama H, 2012: Metaphor effect [(Mc-Cm)+(Mi-Im)]
// Uchiyama H, 2012: Metaphor-specific effect 
// [(Mc-Cm)+(Mi-Im)]-[(Sc-Cs)-(Si-Is)]
// Uchiyama H, 2012: Sarcasm effect [(Sc-Cs)+(Si-Is)]
// Uchiyama H, 2012: Coherence effect [(Mc-Cm)-(Mi-Im)]+[(Sc-Cs)-(Si-Is)]
// Uchiyama H, 2012: Sarcasm and metaphor effects by the conjunction analysis
// Subjects=20
-12	34	46
-14	56	30
-8	46	12
-4	28	12
10	-4	12
-8	-4	2
10	16	10
-8	12	8
-16	6	-12
-18	-2	-12
-2	-18	-20
18	28	8
-6	22	8
2	56	24
-10	52	16
-6	46	-6
-18	2	-10
-26	0	-20
-28	14	-24
-8	48	-4
-2	52	-14
-14	56	28
-10	48	12
-6	40	-4

// Almeida J R C, 2010: Happy, main effect of group
// Almeida J R C, 2010: Sad, main effect of group
// Almeida J R C, 2010: Fear, main effect of group
// Subjects=15
33	-36	3
27	-51	6
3	33	9
36	-33	12
-18	-33	39
12	-90	18
36	-72	45
-9	-84	6
-39	-54	45
-12	-3	-15
6	-42	-6
12	-90	21
-27	-51	-12
39	33	-18
21	-3	9

// Dowd E C, 2010: Valence Contrast, Total Sample
// Dowd E C, 2010: Arousal Contrast, Total Sample
// Dowd E C, 2010: Valence x Arousal Contrast, Total Sample
// Subjects=32
2.23	-27.63	-5.12
42.84	-52.57	-14.65
49.02	30.72	-11.67
49.35	19.8	26.05
-48.98	16.84	24.08
-56.34	-22.59	24.12
55.69	-2.85	7.8
64.49	-26.55	30.87
49.74	-39.81	53.34
18.93	-56.78	70.73
-17.41	-51.62	71.83
-0.06	34.46	-.27
58.03	-65.57	8.57
4.47	-81.43	-12.9
6.86	-93.11	14.81
-.87	-44.14	1.87
-56.32	-68.45	9.01
50.33	36.56	22.4
-0.03	60.06	14.31
-.58	-24.6	48.19
0.63	-52.8	55
-40.48	-65.93	-14.8

// Foland-Ross L C, 2012: Label emotion vs Match forms (activation, between 
// group differences)
// Subjects=24
42	40	-8
34	30	-5
30	28	-4
6	-75	6
36	14	44
32	15	2
21	3	5
9	-7	5
7	8	-3

// Groen W B, 2010: High functioning Autism adolescents
// Subjects=16
-42	18	-10
50	22	2
-48	22	14
-60	-12	2
62	0	-6
-58	12	26
-36	-74	6

// Groen W B, 2010: Control group
// Subjects=26
-6	-82	24
52	-34	42
52	-14	-12
18	50	10
32	-18	42
12	22	-14
32	-70	-40
-56	-42	-2
-52	26	-6
-54	-2	-14
-42	24	-4
16	-82	-32
-62	-6	-6
-36	-40	-22
-8	8	42
62	2	-10
26	-4	-42
-16	-96	4
26	-82	-36

// Habel U, 2010: Discrimination of Happy faces, Patients<Controls
// Habel U, 2010: Discrimination of Happy faces, Patients>Controls
// Habel U, 2010: Discrimination of Sad faces, Patients<Controls
// Habel U, 2010: Discrimination of Sad faces, Patients>Controls
// Habel U, 2010: Discrimination of Fearful faces, Patients<Controls
// Habel U, 2010: Discrimination of Fearful faces, Patients>Controls
// Habel U, 2010: Discrimination of Angry faces, Patients<Controls
// Habel U, 2010: Discrimination of Angry faces, Patients>Controls
// Habel U, 2010: Discrimination of Neutral faces, Patients<Controls
// Habel U, 2010: Discrimination of Neutral faces, Patients>Controls
// Subjects=17
-6	-102	-2
12	34	18
-30	-38	-4
32	-78	-4
58	-52	6
0	30	48
50	-64	-8
-12	32	18
0	-46	0
44	-16	-2
-34	-94	2
-36	14	-6
-46	44	10
-8	56	16
40	-52	-14
14	-10	16
-6	-44	14
-6	-94	26
12	-90	28
10	34	20
0	30	10
-4	-102	-4
44	6	18
12	-6	16
46	-18	-2
42	-52	-14
66	-54	10
14	-98	0
-44	40	8
-8	50	16
10	34	20
0	30	10
-4	-102	-4
44	6	18
12	-6	16
46	-18	-2
42	-52	-14
66	-54	10
14	-98	0
-44	40	8
-8	50	16
-4	-94	24
28	-66	38
48	0	36
12	-90	26
24	0	6
-4	-102	-2
12	36	22
46	8	18
24	2	4
-30	-90	26
-4	-94	26
50	0	38
48	8	18
-24	-44	-2
0	-100	-6
16	42	8
66	-52	4
68	-40	8
26	-64	38
-30	-90	26
54	4	34
-6	-94	26
-6	28	-14
4	-96	-6
42	-50	-16
34	-64	-14
46	-16	0
26	-66	38
48	0	36
-6	-94	28
28	-4	4
-28	-92	28
-50	-20	40
-36	-38	40
-24	-2	4
0	36	-14

// Hesling I, 2010: High Functioning Autism (HFA) participants
// Subjects=8
-48	-24	4
-24	-70	-34
42	-32	2
0	-6	14
-56	-26	0
56	-6	-14
46	14	-22
-44	-52	22

// Hesling I, 2010: Healthy controls
// Subjects=8
-48	-30	-4
-10	-82	-34
52	-18	-22
-56	-26	0
56	-6	-14
46	14	-22
-44	-52	22
-10	-60	24
-32	30	44
4	26	18

// Hulvershorn L A, 2012: Healthy Controls (HC)
// Subjects=30
-30	24	-2
12	-16	10
-22	-28	-4
34	24	-2
24	-24	-6
6	18	44
-28	-4	-16
44	38	34
-10	-18	8
-24	22	-24

// Hulvershorn L A, 2012: Unmedicated Bipolar depressed (BPD)
// Subjects=30
20	-6	-16
34	24	-2
-32	24	-2
-22	-4	-16
-18	-30	-4
10	-16	10
-10	-18	8
6	18	44
50	46	14

// Hulvershorn L A, 2012: Bipolar hypomania or mania (BPM)
// Subjects=30
34	22	-2
-32	24	-2
22	-28	-4
10	20	44
-10	-18	8
10	-16	8
-18	-30	-4
-42	34	38
14	10	8
-4	8	26
26	46	-16

// Hulvershorn L A, 2012: Bipolar euthymic (BPE)
// Subjects=30
18	-6	-14
-32	24	-4
-18	-30	-4
12	-16	10
-12	-22	14
6	20	36
-42	34	40
14	8	10
-28	-18	8
4	2	28
6	60	-12
8	22	4

// Kaiser M D, 2010: State activity, Coherent biological motion vs. Scrambled 
// biological motion
// Kaiser M D, 2010: Trait activity, Coherent biological motion vs. Scrambled 
// biological motion
// Kaiser M D, 2010: Compensatory activity, Coherent biological motion vs. 
// Scrambled biological motion
// Subjects=17
-43.95	44.42	-5.06
-3.42	35.09	-19.24
49.32	-30.98	2.42
26.66	-11.42	-17.91
47.09	-55.08	-20.06
-43.71	-51.94	-12.59
29.67	0.8	-39.05
-44.76	28.41	21.94
51.29	-38.23	-22.64
-49.1	-44.83	-16.47
51.6	-52.57	12.02
-1.34	43.31	-23.3

// Keehn B, 2014: Autism (ASD) Patients
// Subjects=9
60.81	28.93	-8.31
38.31	79.78	4.41
-26.89	83.62	4.84
38.52	17.22	7.43
10.09	8.22	58.69
-23.36	-29.39	2.01
22.68	-5.11	22.86
-20.03	-28.08	18.59
38.94	-5.87	52.85
6.6	-68.39	-9.56
-38.96	-28.29	58.97
39.02	-67.68	37.96
10.25	-40.68	59.45
-10.19	-19.11	51.18
38.49	19.08	3.93
-32.46	-63.66	55.17
54.7	5.66	21.59
-6.93	-5.37	63.37
-48.85	-1.59	33.43
54.6	24.44	16.68
48.55	-78.43	22.03
22.89	0.38	52.51
-29.68	-71.26	-2.21
-3.91	10.28	45.3
51.34	40.28	15.38
-22.86	-60.43	54.79
-10.15	-8.82	60.36
-16.87	5.49	25.78
35.7	-2.97	49.3
48.28	8.79	21.41
-35.83	-48.84	40.59
-45.44	-35.7	46.29
39.02	-67.68	37.96
26.08	-9.63	46.62
-6.94	-8.8	60.32
6.84	14.29	54.88
25.48	18.18	-20.38
-42.2	-45.19	47.05
-10.3	2.84	46
-.45	-44.17	56.52
54.54	40.3	15.35
-38.85	-56.84	61.37
26.14	8.57	61.83
26.3	-66.73	51.41
35.64	-89.31	6.36
22.9	-2.79	52.78
48.21	4.85	11.7
51.48	-48.31	-1.72
35.82	-67.7	38

// Keehn B, 2014: Typically Developing (TD) Controls
// Subjects=13
32.01	85.34	21.86
28.84	-50.5	-28.04
60.81	28.93	-8.31
29.23	-82.74	9.23
19.35	-29.47	-2.93
39.02	-67.68	37.96
10.25	-40.68	59.45
-10.19	-19.11	51.18
38.49	19.08	3.93
-32.46	-63.66	55.17
54.7	5.66	21.59
-6.93	-5.37	63.37
-48.85	-1.59	33.43
54.6	24.44	16.68
48.55	-78.43	22.03
22.89	0.38	52.51
29.23	-82.74	9.23
-29.53	-79.67	12.99
39.02	-67.68	37.96
26.08	-9.63	46.62
-6.94	-8.8	60.32
6.84	14.29	54.88
25.48	18.18	-20.38
-42.2	-45.19	47.05
-10.3	2.84	46
-.45	-44.17	56.52
54.54	40.3	15.35
-38.85	-56.84	61.37
26.14	8.57	61.83
-29.74	-75.21	-11.92
32.6	-71.15	34.98
37.39	26.48	3.32
22.9	-2.79	52.78
48.21	4.85	11.7
51.48	-48.31	-1.72
35.82	-67.7	38
60.94	3.9	-1.75
-17.14	-1.66	-11.54
38.48	-14.01	-11.14
-58.46	-24.63	25.43
3.59	17.18	51.33
22.66	-77.81	-8.95
-13.53	-73.23	12.27

// Lepage M, 2011: Schizophrenia-Control (Conjunction, Activation)
// Lepage M, 2011: Control > Schizophrenia (Group Comparison, Activation)
// Lepage M, 2011: Schizophrenia>Control (Positive Correlation with flat 
// affect, Activation)
// Lepage M, 2011: Schizophrenia>Control (Negative Correlation with flat 
// affect, Activation)
// Subjects=26
-.66	-89.19	13.21
-55.11	23.36	3.01
63.96	29.9	20.5
24.6	-4.37	-22.5
-33.58	29.4	-2.44
16.65	-5.8	31.56
-37.59	29.55	22.27
-59.19	27.34	22.85
-41.86	23.36	25.19
17.02	23.26	66.78
-5.36	30.54	8.17
-5.28	-19.21	4.13
18.71	-98.46	4.84
15.78	-40.72	-43.41
52.74	11.45	-15.58
5.57	-7.92	9.55
16.35	-38.7	1.21
-4.69	-82.66	37.29
-9.43	-92.38	2.47
-44.47	35.33	-7.32
-35.11	12.28	44.1
-31.1	20.85	20.77
-22.97	-9.21	-25.69
-27.3	-.51	-24.24
37.46	-20.46	-34.58
30.93	-9.85	-35.51
28.74	-1.35	-36.32
43.82	18.05	-36.25
53.6	-39.08	40.95
-15.76	-49.7	23.01
44.93	-17.43	43.44

// Li H, 2012: Schizophrenia patients
// Subjects=12
27	36	30
-36	9	42
3	-6	66
-54	-27	-9
-45	12	-6
6	9	66
-36	42	18
-39	12	39
57	12	24
54	21	9
-39	15	30
6	3	54
-3	21	54
-54	3	-3
-54	-3	12
39	3	18
-45	-18	21
24	-48	66
-15	-45	63
15	-33	63
-39	42	18
39	54	9
42	54	-3
-57	-63	15

// Li H, 2012: Nonpsychotic siblings
// Subjects=12
15	12	51
33	-3	42
-39	12	39
57	12	24
54	21	9
-39	15	30
6	3	54
-3	21	54
-54	3	-3
-54	-3	12
39	3	18
-45	-18	21
24	-48	66
-15	-45	63
15	-33	63
-39	42	18
39	54	9
42	54	-3
-57	-63	15

// Li H, 2012: Healthy controls
// Subjects=12
27	36	30
-36	9	42
3	-6	66
-54	-27	-9
-45	12	-6
6	9	66
-36	42	18
15	12	51
33	-3	42

// Lombardo M V, 2010: Healthy Controls
// Subjects=33
-6	50	-6
-4	62	2
22	-82	-24

// Mickleborough M J, 2011: Post-Traumatic Stress Disorder (PTSD) Patients
// Subjects=17
4	16	0
-8	22	0
-6	18	2
-34	-20	12
-34	18	18
38	-2	20
-4	14	4
-14	24	-2
-18	-16	4
-26	-20	8
-18	-24	10
-14	-24	8
28	38	22
24	-4	-22
-26	12	0
-26	10	-6
20	46	6
-20	56	2
-10	58	28

// Mickleborough M J, 2011: Healthy Controls
// Subjects=26
4	16	0

// Rauch A V, 2013: Sad > Neutral, Schizophrenia > Control
// Rauch A V, 2013: Happy > Neutral, Schizophrenia>Control
// Rauch A V, 2013: Sad > Erased, Schizophrenia > Control
// Rauch A V, 2013: Happy > Erased, Schizophrenia > Control
// Rauch A V, 2013: Neutral > Erased, Control > Schizophrenia
// Subjects=12
-28	-5	-13
34	-3	-23
-18	-3	-15
-26	-5	-15
34	-3	-23
34	-3	-23
-16	-7	-15

// Spengler S, 2010: Correlation: Performance in Imitation-Inhibition Control 
// vs. Neural Activity During ToM
// Subjects=18
15	54	-3
-51	-63	24
60	39	6

// Strigo I A, 2010: PTSD-IPV > Healthy Controls, Warm-Non-Painful Temperature 
// (Run 2 - Run 1)
// Strigo I A, 2010: Healthy Controls > PTSD-IPV, Warm-Non-Painful Temperature 
// (Run 2 - Run 1)
// Strigo I A, 2010: PTSD-IPV > Healthy Controls, Moderately Painful 
// Temperature (Run 2 - Run 1)
// Strigo I A, 2010: PTSD-IPV > Healthy Controls, All Temperatures (Run 2 - 
// Run 1)
// Strigo I A, 2010: Healthy Controls > PTSD-IPV, All Temperatures (Run 2 - 
// Run 1)
// Strigo I A, 2010: PTSD-IPV > Healthy Controls, Run 1: All Temperatures
// Strigo I A, 2010: Healthy Controls > PTSD-IPV, Run 1: All Temperatures
// Strigo I A, 2010: PTSD-IPV > Healthy Controls, Run 2: All Temperatures
// Strigo I A, 2010: Healthy Controls > PTSD-IPV, Run 2: All Temperatures
// Subjects=15
29.33	-49.85	35.46
35.78	-69.19	32.55
-43.57	-40.63	9.88
37.67	13.99	34.47
-51.16	15.34	18.65
-31.96	43.64	24.98
-42.39	15.42	46.43
12.13	-8.2	38.86
35.45	-23.15	8.62
-34.05	-20.73	4.75
51.26	-2.3	-12.27
17.79	-37.84	68.04
46.44	-11.2	52.1
-23.91	-38.26	66.33
-47.68	-19.13	40.46
11.36	-79.77	49.33
62.11	-12.59	5.2
-32.59	-81.49	31.02
-58.55	-44.23	5.89
-4.81	-81.32	30.69
-47.88	-65.2	-4.74
-3.01	9.63	23.04
-24.17	-63	21.57
-31.89	-15.01	9.82
-49.91	-64.1	9.69
44.1	-72.59	1.51
4.72	-81.06	19.4
-14.42	-57.09	42.15
38.64	-46.36	-2.85
-42.56	-46.68	0.34
8.69	-83.15	-21.73
36.3	18.47	-3.8
45.1	21.18	30.44
45.89	-.39	-14.6
2.83	-79.65	51.65
32.65	-84.9	36.13
-43.77	-64.69	-26.02
-54.38	-39.77	-5.68
6.82	-82.54	13.93
7.62	-85.27	-21.54
-31.92	-15.26	6.5
8.92	-67.55	14.88
31.61	-49.44	54.36
-23.99	-55.57	48.82
-14.46	-77.32	28.23
36.8	-79.56	22.26
-42.5	-66.94	-.2
-27.61	-75.28	-13.05
-11.57	-69.55	-9.25
5.22	-46.3	-40.39

// Vaidya C J, 2011: Neutral > Fixation contrast, Gaze task > Arrow task
// Vaidya C J, 2011: Neutral > Fixation contrast, Arrow task > Gaze task
// Vaidya C J, 2011: Congruent > Neutral, Facilitation
// Vaidya C J, 2011: Incongruent > Congruent, Interference
// Subjects=15
12	-97	3
-39	-45	-15
-51	-6	7
53	-18	18
-33	-42	58
30	-39	53
-6	-25	46
18	-7	57
0	29	12
-33	34	4
30	21	33
-15	24	32
48	-12	4
-42	-15	9
24	-45	-12
27	-65	-6
0	32	14
-39	35	29
12	14	8

// Scott-Van Zeeland A A, 2010: Autism Group (ASD)
// Subjects=16
14	12	6
-40	36	8
48	32	16
-40	12	40
50	8	40
-44	4	32
48	6	32
-28	58	-6
28	54	-2
22	-30	-4
4	24	44
-32	16	4
36	16	-4
-30	-68	-16
40	-60	-14
10	-98	16
-48	-52	50
48	-44	54
52	26	34
52	0	48
-40	-70	-18
30	-80	-20
12	-100	16
34	-60	54
40	-52	42
14	52	-14
14	50	-14
-6	38	-16
-2	26	-18
-10	22	0
-26	24	-18
-30	8	42
-38	0	30
28	54	-12
2	42	-4
-2	-34	34
-8	36	-12
30	-72	38
52	26	14
-42	16	36
-44	8	34
48	2	30
44	50	2
30	-20	-14
-38	-68	-18
26	-70	-16
34	-66	46
-46	-52	50
-44	-52	50
50	-46	50
32	-16	2
-8	10	-8
-24	10	-18
38	24	-18
34	-24	42
24	-6	-26
6	44	24
2	-22	46
-20	-74	-10
34	-68	-14
2	-92	6
-18	18	6
16	4	12
-26	14	0
20	10	-2
30	50	-6
-4	36	12
-26	18	-10

// Scott-Van Zeeland A A, 2010: Typically-Developing Controls (TD)
// Subjects=16
12	10	6
-40	38	-10
24	42	-14
28	18	-18
42	38	18
-44	4	32
42	50	4
-16	-36	-4
18	-32	-8
8	30	20
-28	18	-8
34	20	2
-32	-76	-20
37	-72	-16
7	-60	52
40	-52	48
16	4	14
18	4	6
20	4	-2
-46	24	20
-26	14	-20
-48	24	34
44	26	32
-40	2	34
46	4	34
-42	52	-6
-18	-32	-6
-30	16	-8
-28	-70	-18
32	-60	-20
32	-90	-6
-16	10	-2
-12	4	-10
12	6	-8
14	52	-14
14	50	-14
-6	38	-16
-2	26	-18
-12	14	3.18
16	14	2.46
-20	4	2.55
26	6	2.36
-10	14	3.44
6	14	3.37
0	60	3.02
32	32	2.72
-28	26	3.01
-40	-8	3.08
30	64	2.99
0	-48	3.26
24	-56	3.4
36	60	3.26
58	20	3.1
32	-16	2
-8	10	-8
-24	10	-18
38	24	-18
34	-24	42
24	-6	-26
6	44	24
2	-22	46
-20	-74	-10
34	-68	-14
2	-92	6
-8	16	0
8	18	0
-16	66	20
-2	38	6
-2	24	-12
-42	-50	-20
42	-52	-18
-18	18	6
16	4	12
-26	14	0
20	10	-2
30	50	-6
-4	36	12
-26	18	-10

// Scott-Van Zeeland A A, 2010: Autism (ASD) Group
// Subjects=18
-62	-22	6
-50	-30	14
-42	-32	10
52	-20	6
54	-6	0
-50	-32	8
-50	-18	14
-40	-34	10
-66	-30	0
58	-32	8
46	-12	4
46	-26	12
-52	-40	14
-52	-18	0
-50	-28	16
-66	-28	-2
-64	-22	28
46	-10	2
58	-12	12
44	-24	12
52	-8	10
42	8	10
58	-10	26
-14	64	2
-22	60	6
32	50	8
-62	-10	8
-42	-20	46
-50	-22	46
-36	44	12
-14	64	2
30	48	12
44	10	10
34	14	8
-50	-38	18
-52	-42	32
-54	-50	38
24	-52	54
12	0	12
-36	-32	42
-48	-38	40
-22	12	8

// Scott-Van Zeeland A A, 2010: Typically-Developing (TD) Group
// Subjects=18
-58	-22	6
-54	-14	4
-44	-34	10
-20	54	24
-24	50	26
-26	-4	62
-58	12	6
-34	26	32
-48	2	40
-28	52	20
-4	40	22
-52	0	28
-52	-8	44
-56	-38	30
-2	54	6
-8	46	28
58	-20	6
54	-22	8
48	-14	6
-22	24	36
26	6	52
10	38	34
34	32	32
28	12	52
4	42	38
-8	60	12
8	46	26
58	-6	16
10	44	12
-60	-16	10
-56	-10	6
-18	62	8
-26	-6	64
-36	52	4
-42	38	2
-44	34	8
-40	22	12
-62	-26	28
-32	-34	62
-42	-44	56
-18	-26	66
-54	-18	16
-38	-28	54
-34	-28	62
-44	-22	58
-50	-28	52
54	-22	8
60	-18	6
34	-22	14
52	-20	0
52	6	10
32	36	-8
42	40	8
18	56	4
30	52	14
52	-20	34
26	-26	50
32	-44	58
36	-32	56
-56	-24	-24
-52	-22	-22
-64	-16	-16
-56	-4	-4
-50	-20	-20
-58	-2	-2
56	-24	-24
46	-18	-18
40	-22	-22
58	-34	-34
-26	50	26
-8	38	24
26	44	0
-40	40	14
-62	-10	8
-42	-20	46
-50	-22	46
-36	44	12
-14	64	2
30	48	12
44	10	10
34	14	8
-52	-44	30
-54	-50	38
-8	4	4
14	2	6
-50	-38	18
-52	-42	32
-54	-50	38
24	-52	54
12	0	12

// Lockwood P L, 2013: Pain>No Pain
// Lockwood P L, 2013: No Pain>Pain
// Lockwood P L, 2013: Control>CP (for Pain>No Pain)
// Lockwood P L, 2013: CP>Control (for Pain>No Pain)
// Subjects=18
-48	-62	0
-34	-86	-2
-46	-48	-16
-60	-30	34
-52	-26	36
-60	-30	24
46	-56	-8
52	-62	-6
36	-80	8
-52	6	34
-36	-4	14
62	-22	30
36	-34	38
52	40	4
52	8	26
-50	38	10
-30	-6	48
-32	-2	-38
-58	-34	-10
14	24	4
-42	-66	-38
12	-74	-4
-44	-16	-6
0	-48	-20
44	6	-36
10	10	10
-10	12	52
-22	10	-20
-32	12	-16
-36	34	20
-4	-14	20
28	-58	-30
-28	-30	14
14	-72	-32
22	48	22
-16	-8	-4
10	-20	-16
54	38	0
-30	16	2
0	20	24
-4	-62	28
-18	-20	-16
-2	-48	-4

// Schiffer B, 2014: Conflict-related activity (Incongruent-Congruent)
// Schiffer B, 2014: Error-related activity (All error trials- accurate 
// Congruent trials)
// Schiffer B, 2014: Conflict-related activity (Non-Offenders>Offenders)
// Schiffer B, 2014: Conflict-related activity (Offenders>Non-Offenders)
// Schiffer B, 2014: Error-related activity (Non-Offenders>Offenders)
// Subjects=21
-36	-52	40
54	18	-12
48	-50	56
-34	-2	64
32	-68	-30
-34	-68	-30
-14	-6	10
20	-12	22
-44	50	-12
16	10	52
-4	20	48
-40	20	-10
8	20	62
-4	26	42
46	-52	32
38	20	48
64	-32	-12
6	-24	-24
-64	-48	30
-8	4	34
-10	16	38
-52	-2	22
-44	-10	42
-50	-26	2
52	-8	16
46	6	50
-16	0	-26
-12	-6	-8
40	-2	50
52	-12	22
-28	-38	62
24	0	64
30	-6	-12
-22	12	8
-10	12	34
-46	42	14

// Guo X, 2013: (Painful for Violent + Nonviolent) - (Nonpainful for Violent + 
// Nonviolent)
// Guo X, 2013: Correlation of self-rating score and painful-nonpainful 
// activation
// Guo X, 2013: (Painful - Nonpainful for Nonviolent) - (Painful - Nonpainful 
// for Violent)
// Guo X, 2013: (Painful - Nonpainful for Violent) - (Painful and Nonpainful 
// for Nonviolent)
// Subjects=20
-54	8	18
34	20	6
-6	10	40
-34	20	6
4	20	24
-58	-26	40
-36	-40	66
68	-22	32
30	-92	-4
-30	-96	-8
24	2	14
-8	8	48
6	22	24
8	20	30
54	2	12
-22	10	8
-42	10	-12
52	26	-4
6	2	66
-6	10	38
-8	30	24
-44	-2	-16
-34	6	2
-54	-34	22
16	-10	0
24	4	12
36	20	14
54	4	14
20	0	-14
-6	-66	52
-18	6	54
-54	-8	-32
56	-54	16

// Harenski C L, 2010: Psychopaths
// Subjects=16
57	-9	-18
12	39	-9
-48	-72	15
57	-6	-18
9	54	-12
48	-63	27
-60	-9	-21
-27	-77	43
-24	-27	-9
-21	26	46
18	-33	-16
45	-54	-28
-36	49	-5
36	36	26
21	12	5
30	14	55
-59	-7	-17
-45	-69	18
57	-6	-21
56	-63	39
-60	-12	-18
-15	-6	-21
33	-9	-21
12	51	-6
-18	-72	57
-36	-48	-6
27	-30	-9
-3	54	33
-33	18	-21
48	30	-6
-6	-54	-21
-15	-33	-24
3	-3	-12
-15	-87	-3
51	-57	-3
-42	42	-12
-45	18	-24
36	-72	18
33	0	-21
57	-51	27
51	-60	27
45	9	42
-3	18	60

// Harenski C L, 2010: Non-Psychopaths
// Subjects=16
57	-9	-18
12	39	-9
-48	-72	15
57	-6	-18
9	54	-12
48	-63	27
-60	-9	-21
-27	-77	43
-24	-27	-9
-21	26	46
18	-33	-16
45	-54	-28
-36	49	-5
36	36	26
21	12	5
30	14	55
-59	-7	-17
-45	-69	18
57	-6	-21
56	-63	39
-60	-12	-18
-15	-6	-21
33	-9	-21
12	51	-6
-18	-72	57
-36	-48	-6
27	-30	-9
-3	54	33
-33	18	-21
48	30	-6
-6	-54	-21
-15	-33	-24
3	-3	-12
-15	-87	-3
51	-57	-3
-42	42	-12
-45	18	-24
36	-72	18
33	0	-21
57	-51	27
33	0	-21

// Cappelletti M, 2010: Common Conceptual - Fixation
// Cappelletti M, 2010: Conceptual Quantity - Fixation
// Cappelletti M, 2010: Nonquantity Conceptual - Fixation
// Cappelletti M, 2010: Number Conceptual - Fixation
// Cappelletti M, 2010: Object Conceptual - Fixation
// Cappelletti M, 2010: Conceptual Only: Number vs. Object (RT Effects)
// Cappelletti M, 2010: Conceptual vs. Perceptual  (RT Effects)
// Cappelletti M, 2010: Quantity Only (RT Effects)
// Cappelletti M, 2010: Nonquantity Only (RT Effects)
// Cappelletti M, 2010: Conceptual Only (RT Effects)
// Cappelletti M, 2010: Numbers and Object Names (RT Effects)
// Cappelletti M, 2010: Numbers > Words (RT Effects)
// Cappelletti M, 2010: Numbers and Object Names (RT Effects)
// Subjects=22
24	-104	2
28	-92	-4
14	-106	6
14	-106	16
-18	-102	0
-32	-96	-2
-24	-88	-10
30	-58	56
-26	-64	54
46	26	22
38	-76	-20
22	-78	-20
24	-104	2
28	-92	-4
14	-106	6
14	-106	16
-18	-102	0
-32	-96	-2
-24	-88	-10
30	-58	56
-26	-64	54
46	26	22
38	-76	-20
22	-78	-20
24	-104	2
28	-92	-4
14	-106	6
14	-106	16
-18	-102	0
-32	-96	-2
-24	-88	-10
30	-58	56
-26	-64	54
46	26	22
38	-76	-20
22	-78	-20
24	-104	2
28	-92	-4
14	-106	6
14	-106	16
-18	-102	0
-32	-96	-2
-24	-88	-10
30	-58	56
-26	-64	54
46	26	22
38	-76	-20
22	-78	-20
24	-104	2
28	-92	-4
14	-106	6
14	-106	16
-18	-102	0
-32	-96	-2
-24	-88	-10
30	-58	56
-26	-64	54
46	26	22
38	-76	-20
22	-78	-20
28	-70	32
32	-66	32
32	-80	34
42	-78	34
38	-78	30
32	-76	42
30	-62	46
32	-56	42
22	-68	56
18	-70	56
32	-64	54
48	-48	40
44	-44	48
-40	-44	40
-52	-44	46
28	-70	32
32	-66	32
32	-80	34
42	-78	34
38	-78	30
32	-76	42
30	-62	46
32	-56	42
22	-68	56
18	-70	56
32	-64	54
48	-48	40
44	-44	48
-40	-44	40
-52	-44	46
28	-70	32
32	-66	32
32	-80	34
42	-78	34
38	-78	30
32	-76	42
30	-62	46
32	-56	42
22	-68	56
18	-70	56
32	-64	54
48	-48	40
44	-44	48
-40	-44	40
-52	-44	46
28	-70	32
32	-66	32
32	-80	34
42	-78	34
38	-78	30
32	-76	42
30	-62	46
32	-56	42
22	-68	56
18	-70	56
32	-64	54
48	-48	40
44	-44	48
-40	-44	40
-52	-44	46
28	-70	32
32	-66	32
32	-80	34
42	-78	34
38	-78	30
32	-76	42
30	-62	46
32	-56	42
22	-68	56
18	-70	56
32	-64	54
48	-48	40
44	-44	48
-40	-44	40
-52	-44	46
26	-70	60
28	-72	50
34	-63	60
16	-80	54
34	-70	50
40	-64	52
36	-62	52
40	-56	54
50	-44	54
30	-70	32
-24	-60	64
-34	-56	50
-30	-52	46
-40	-52	56
-34	-60	46
-48	-36	56
44	-8	28
-48	-28	20
26	-70	60
28	-72	50
34	-63	60
16	-80	54
34	-70	50
40	-64	52
36	-62	52
40	-56	54
50	-44	54
30	-70	32
-24	-60	64
-34	-56	50
-30	-52	46
-40	-52	56
-34	-60	46
-48	-36	56
44	-8	28
-48	-28	20
26	-70	60
28	-72	50
34	-63	60
16	-80	54
34	-70	50
40	-64	52
36	-62	52
40	-56	54
50	-44	54
30	-70	32
-24	-60	64
-34	-56	50
-30	-52	46
-40	-52	56
-34	-60	46
-48	-36	56
44	-8	28
-48	-28	20

// Kasahara M, 2010: Traumatic Brain Injury Patients
// Subjects=12
-32	-16	56
-44	-6	58
-30	-16	66
-42	-18	30
-46	-12	24
-4	62	0
-32	0	18
-2	-68	-18
-38	-28	38
0	-54	-22
18	-12	24
-52	-20	38
-48	-8	36
-54	-12	44

// Kasahara M, 2010: Healthy Controls
// Subjects=9
-40	-14	64
-46	-12	50
-38	-16	50
20	-54	-30
2	-60	-14
2	-62	-30
-2	-14	52
0	-6	62
8	-12	62
-10	-20	2
-40	-54	36
-28	-4	-8

// Cohn M D, 2013: Persistent Disruptive Behavior Disorders (DBD-p)
// Subjects=25
36	-10	4
40	-6	2
34	-16	10
-30	-6	-12
-24	-6	-10
-16	18	38
-16	10	38
-14	6	38
36	-18	14
34	-14	10
50	-2	8
34	-8	12
38	-8	4
-8	0	42
-6	0	46
8	6	36
12	32	18
20	0	-10
-36	4	-12
-34	8	-12
32	-12	12
32	-16	14
34	-8	12
-30	4	-16
6	6	36

// Cohn M D, 2013: Desistent Disruptive Behavior Disorder (DBD-d)
// Subjects=25
-38	-20	24
42	-4	6
36	-18	14
-14	10	40
-12	16	40
36	-18	14
34	-14	10
50	-2	8
34	-8	12
38	-8	4
-8	0	42
-6	0	46
8	6	36
12	32	18
20	0	-10
-36	4	-12
-34	8	-12
32	-12	12
32	-16	14
34	-8	12
-30	4	-16
6	6	36

// Cohn M D, 2013: Healthy Controls
// Subjects=26
-38	-20	24
42	-4	6
36	-18	14
-14	10	40
-12	16	40
36	-10	4
40	-6	2
34	-16	10
-30	-6	-12
-24	-6	-10
-16	18	38
-16	10	38
-14	6	38
36	-18	14
34	-14	10
50	-2	8
34	-8	12
38	-8	4
-8	0	42
-6	0	46
8	6	36
12	32	18
20	0	-10
-36	4	-12
-34	8	-12
32	-12	12
32	-16	14
34	-8	12
-30	4	-16
6	6	36

// Pawliczek C, 2013: Group by condition interaction p<.001 uncorr., k=20
// Pawliczek C, 2013: Main effect of condition, p<.001 uncorr., k=20
// Pawliczek C, 2013: Main effect of group, p<.001 uncorr., k=20
// Subjects=19
-8	10	26
0	-68	-24
4	-6	0
-22	-6	-12
-34	-44	28
-24	-18	-2
10	-6	-18
34	36	10
-26	-12	22
-12	-10	32
2	30	10
0	12	-6
4	-4	36
16	-34	28
-2	2	64
10	32	64
-22	16	34
-54	-2	48
-62	0	30
36	-24	56
-46	-70	38
50	-74	34
-26	-56	46
32	-44	46
22	-68	40
-28	-34	-14
26	-6	-20
28	-84	-34
6	-50	-46
-26	-82	-30
0	-10	8
-52	26	32
44	52	18
48	20	28
-40	2	58
-6	22	44
10	30	30
24	24	4
38	22	-4
-54	-42	4
-16	16	8
-20	0	18
12	4	0
16	-82	-18
-28	-68	-12
20	-92	30
14	-88	12
34	-86	-8
-24	-92	6

// Pujol J F, 2012: Psychopathic Individuals
// Subjects=22
-12	46	42
-4	-58	36
56	-64	34
-48	-64	32
-60	-10	-8
42	-84	-8
-28	-96	-8
-40	26	-22
4	20	50
8	-32	40
26	-30	-12
-28	-22	-16
10	-26	-18
-8	-24	46
48	-46	12
-60	-34	20
12	-20	2
36	-6	10
-40	0	8
52	-34	56
-38	-34	64
22	-38	-20
-2	54	12

// Pujol J F, 2012: Nonoffender Control Subjects
// Subjects=22
-16	46	44
-2	-60	36
46	-58	30
-50	-66	30
28	-28	-14
-28	-24	-16
0	-32	-12
-12	6	4
54	-20	0
-54	-16	-4
34	-90	0
-12	-104	0
42	32	-20
-46	40	-16
4	20	50
8	-32	40
26	-30	-12
-28	-22	-16
10	-26	-18
0	52	-12
-8	-26	48
62	-50	16
-48	-40	18
12	-18	-4
52	-18	8
-52	-10	2
50	-34	56
-38	-36	60
24	-44	-16
-2	54	12

// Chassy P, 2012: Disk vs. Rest Activation
// Chassy P, 2012: Disk vs. Rest Deactivation
// Chassy P, 2012: Dots vs. Rest Activation
// Chassy P, 2012: Dots vs. Rest Deactivation
// Chassy P, 2012: Positive Integers vs. Rest Activation
// Chassy P, 2012: Positive Integers vs. Rest Deactivation
// Chassy P, 2012: Negative Integers vs. Rest Activation
// Chassy P, 2012: Negative Integers vs. Rest Deactivation
// Chassy P, 2012: Disk (Positive contrast of the time derivative)
// Chassy P, 2012: Disk (Negative contrast of the time derivative)
// Chassy P, 2012: Dots (Positive contrast of the time derivative)
// Chassy P, 2012: Dots (Negative contrast of the time derivative)
// Chassy P, 2012: Positive Integers (Positive contrast of the time 
// derivative)
// Chassy P, 2012: Positive Integers (Negative contrast of the time 
// derivative)
// Chassy P, 2012: Negative Integers (Positive contrast of the time 
// derivative)
// Chassy P, 2012: Negative Integers (Negative contrast of the time 
// derivative)
// Chassy P, 2012: Conjunction Disk^Dots^PI^NI
// Chassy P, 2012: Disk > Dots
// Chassy P, 2012: PI < NI
// Chassy P, 2012: Analogue Routes (Disk and Dots Common Activation)
// Subjects=16
39	-75	3
30	-60	54
-39	-72	0
54	9	33
-36	-15	60
-24	-60	54
42	-21	63
39	-15	21
-45	-78	30
-3	-39	39
-9	-72	30
27	-60	51
51	9	33
33	21	3
-18	-63	48
45	-21	60
51	-69	36
39	-15	21
9	-15	51
-45	-78	33
-9	-60	27
-36	-15	60
-27	-57	57
33	-63	57
42	-24	63
39	-15	21
54	6	-12
51	-72	27
60	0	6
-42	-78	30
-57	0	-15
27	-63	54
39	-75	-3
-27	-60	57
-39	-72	3
54	-6	-15
12	-63	24
51	-72	30
0	33	-12
-39	-78	39
-60	-3	-15
-30	-27	-18
-63	-36	6
18	-90	-3
51	9	33
-15	-93	-3
-9	0	54
-54	6	33
-6	-93	12
-42	-78	36
33	-21	48
36	-78	-6
51	6	30
36	-3	48
30	27	6
-6	0	54
-45	0	33
36	-21	48
51	-69	36
39	-21	9
-6	-93	15
-48	-66	27
18	-93	3
30	-60	39
48	6	33
-36	-69	-15
-39	-21	54
33	-24	54
36	-15	18
54	-69	24
-42	-24	0
54	-3	-9
-6	-93	15
-42	-78	33
-27	-33	-15
-51	-9	27
-6	33	-3
15	-90	-3
48	6	33
30	27	6
3	-24	27
15	-90	24
-6	-93	15
30	-51	48
45	-39	45
30	-60	54
24	-63	51
-24	-60	51
45	-39	45
30	-51	48

// Dormal V, 2012: Numerosity vs. Ref for Numerosity
// Dormal V, 2012: Duration vs. Ref for Duration
// Dormal V, 2012: N vs RefN compared to D vs RefD
// Dormal V, 2012: N vs RefN and D vs RefD
// Subjects=15
50	38	34
10	22	52
44	-46	50
40	24	4
-40	-52	68
50	38	34
10	26	48
44	-46	52
-38	-64	-32
-46	-42	54
36	-62	52
50	38	34
8	26	48
44	-46	52
-40	-48	48

// Clapp W C, 2010: IS interruptor > DS distractor
// Clapp W C, 2010: DS distractor > IS interruptor
// Subjects=22
-41	-13	-30
37	42	20
28	-55	13
-26	-56	-8
43	-47	-11
-23	-91	2
-11	12	6
31	28	3
18	-100	10
6	6	11
25	56	9
-35	-73	9
-12	-8	8
4	46	15
-12	-79	9
40	-63	10
26	5	16
-1	26	19
47	34	27
-42	24	26
6	34	27
40	10	38
13	-69	36
38	-55	34
-39	4	38
1	32	45
36	-51	46
6	51	51
44	-59	53
-2	17	57
4	34	58
-27	-2	71
-41	-66	23
-33	-81	42

// Gazzaley A, 2014: Remember Scenes and Remember Faces > Passive View, 
// Univariate activity contrast
// Subjects=18
-29	-2	59
-32	43	51
-46	-60	-11
-22	-30	-23
-2	13	54
-38	32	31
-30	20	14
-58	10	-6
2	-51	67
22	-66	61
29	-5	52
-20	-32	-23
14	22	8
32	2	66

// Han T, 2012: Fear (eyes-removed>eyes-only)
// Han T, 2012: Happy (eyes-only>eyes-removed)
// Subjects=16
7.63	60.05	-4.4
-40.2	-28.88	50
-43.35	41.6	29.97
51.47	-22.81	48.78
-27.02	36.55	38.9
26.97	37.01	41.36
2.9	-15.05	46.12
24.2	50.43	34.92
-24.68	-.87	-18.65
-32.66	-50.26	-20.78
-51.08	-79.19	18.33
21.07	-1.09	-32.43
-27.42	4.33	-25.42

// Redcay E, 2014: ASD Patients
// Subjects=12
-5.43	34.17	-3.53
15.9	37.12	-8.48
-10.79	50.42	0.75
3.26	41.22	18.09
32.15	43.93	23.1
-28.8	48.68	21.18
20.78	2.82	56.79
20.18	68.04	5.61
3.44	11.24	29.52
-19.45	24	-23.7
24.33	28.32	-26.8
41.63	52.48	8.9
54.46	38.38	4.36
45.12	2.69	25.3
-44.69	-3.82	17.96
-34.17	3.33	-.61
36.33	-25.11	-16.88
-22.27	-43.47	-1.28
-48.11	-35.73	-22.82
-8.02	-39.62	47.3
11.21	-38.44	46.98
-35.72	-72.99	44.84
-6.94	-61.44	40.2
17.71	-89.13	37.77
20.88	-90.6	32.29
-3.88	-70.63	17.51
-14.65	-90.29	-1.9
-38.35	-74.8	-19.66
37.37	-55.03	-32.22
14.89	21.26	-7.14
42.26	-24.46	59.95
-38.97	-28.46	56.76
-9.77	30.2	-13.18
-30.04	42.48	-3.94
-31.03	13.67	-4.86
-44.74	-30.66	1.25
-52.11	-57.05	4.66
-43.76	-40.4	-14.67
-28.64	-46.34	3.49
47.06	-34.48	-15.1
-47.37	59.78	-26.38
28.4	-72.52	45.18
-28.27	-55.69	47.77
-22.08	-66.76	14.05
36.88	-44.64	47.21
-10.2	-25.8	47.28
19.45	-55.91	-.72
-9.15	-84.23	20.94
-9	-81.55	41.91
36.38	-57.52	-23.08
-34.06	-69.15	-15.72
3.19	50.39	12.86
53.64	20	28.21
40.78	-6.83	12.76
45.19	-15.2	27.91
-39.58	-6.19	-13.13
-51.83	-22.28	55.27
-32.08	-57.56	-31.21
-26.72	48.1	13.39
-9.25	2.59	42.66
-32.26	27.35	-20.49
-46.87	-13.07	8.72
-34	-7.02	16.99
-44.73	-33.92	0.41
-44.7	-47.83	-.66
-48.14	-31.68	-25.39
-40.65	-27.06	-21.41
-43.49	-77.09	6.24
-35.85	-53.5	35.4
-17.57	-29.13	59.91
-5.27	15.02	10.35
-56.62	-4.64	-5.26
69.61	-20.03	4.62
54.58	-4.34	2.36
33.53	-41.8	29.16
33.28	13.82	18.93
62.15	8.7	19.02
54.63	-1.63	9.94
55.78	-27.17	9.84
-52.28	-4.98	3.64
-29.86	48.76	22.3
33.02	-52.56	-41.3
-39.26	-70.98	2.34
41.91	20.27	32.78
12.6	60.37	-10.39
-22	17.63	59.39
58.84	-24.29	-8.28
-57.67	-27.45	-11.14
-64.03	-15.97	0.24
56.13	-42.23	49.01
11.74	52.56	12.58
55.69	24.61	18.88
51.43	-24.71	0.76
6.85	-50.41	30.19
7.01	-60.76	47.79
-10.35	-44.94	19.89
-19.9	-88.24	11.37

// Redcay E, 2014: Mental age-matched controls
// Subjects=11
-5.43	34.17	-3.53
15.9	37.12	-8.48
-10.79	50.42	0.75
3.26	41.22	18.09
32.15	43.93	23.1
-28.8	48.68	21.18
20.78	2.82	56.79
20.18	68.04	5.61
3.44	11.24	29.52
-19.45	24	-23.7
24.33	28.32	-26.8
41.63	52.48	8.9
54.46	38.38	4.36
45.12	2.69	25.3
-44.69	-3.82	17.96
-34.17	3.33	-.61
36.33	-25.11	-16.88
-22.27	-43.47	-1.28
-48.11	-35.73	-22.82
-8.02	-39.62	47.3
11.21	-38.44	46.98
-35.72	-72.99	44.84
-6.94	-61.44	40.2
17.71	-89.13	37.77
20.88	-90.6	32.29
-3.88	-70.63	17.51
-14.65	-90.29	-1.9
-38.35	-74.8	-19.66
37.37	-55.03	-32.22
14.89	21.26	-7.14
42.26	-24.46	59.95
-38.97	-28.46	56.76
-9.74	50.26	-1.48
-32.24	58.33	-5.24
-45.35	-60.02	48.32
-13.45	-104.32	9.3
21.94	-90.68	31.16
21.76	-80.42	12.46
-30.3	-36.98	69.64
33.28	13.82	18.93
62.15	8.7	19.02
-16.5	-15.92	65.48
24.14	-28.54	63.85
3.79	-29.09	58.55
-35.2	0.41	2.99
-22.72	46.35	-23.31
-5.59	50.06	-18.24
11.48	47.7	-22.7
-2.11	38.73	13.9
2.4	10.43	32.95
-49.06	-16.94	0.15
23.46	-13.56	-17.7
-13.86	-26.13	-11.75
-1.61	-38.52	47.13
-43.21	-59.92	49.41
-17.59	-89.69	33.77
-17.75	-101.26	7.97
12.32	-95.14	29.42
20.28	-.2	-9.86
-18.11	12.48	6.25
66.41	-3.5	12.19
-39.53	-9.02	-8.43

// Redcay E, 2014: Chronological age-matched controls
// Subjects=12
-9.77	30.2	-13.18
-30.04	42.48	-3.94
-31.03	13.67	-4.86
-44.74	-30.66	1.25
-52.11	-57.05	4.66
-43.76	-40.4	-14.67
-28.64	-46.34	3.49
47.06	-34.48	-15.1
-47.37	59.78	-26.38
28.4	-72.52	45.18
-28.27	-55.69	47.77
-22.08	-66.76	14.05
36.88	-44.64	47.21
-10.2	-25.8	47.28
19.45	-55.91	-.72
-9.15	-84.23	20.94
-9	-81.55	41.91
36.38	-57.52	-23.08
-34.06	-69.15	-15.72
3.19	50.39	12.86
53.64	20	28.21
40.78	-6.83	12.76
45.19	-15.2	27.91
-42.71	18.77	7.12
-58.43	2.04	39.93
-31.16	47.42	-8.8
-3.24	43.58	7.93
-3.33	23.89	-12.72
-.93	49.71	31.92
-39.37	-24.91	6.28
-46.77	-37.3	11.86
-25.39	-57.95	4.43
-61.55	-19.05	42.84
-17.82	-18.5	32.26
-38.36	30.48	20.58
-57.8	-9.1	-21.6
-40.03	-64.56	44.18
-13.8	-70.59	-22.52
-66.15	-18.01	1.55
-47.98	-21.16	0.49
-65.17	-14.55	-8.79
53.58	-20.12	4.81
70.65	-14.82	3.05
-26.42	-58.67	8.96
15.29	12.25	41.57
-9.4	-20.87	14.52
10.91	-20.67	15.38
-27.81	24.77	0.87
-43.55	5.67	30.53
62.08	-17.33	-1.1
64.14	-3.83	-5.6
-60.8	-21.24	0.64
-44.76	-13.31	5.37
-60.74	-52.5	-4.54
54.68	-18.72	9.14
72.78	-17.09	0.99
66.16	-10.47	-22.91
48.96	-1.74	-32.36
-27.49	-58.68	8.98
-21.93	-61.88	35.94
15.52	-65.54	40.28
-3.76	-28.76	49.69
0.62	-55.17	51.85
54.79	7.66	33.69
-14.24	-43.23	69.98
-6.32	-4.62	4.2

// Redcay E, 2014: Subgroup of Participants, males only
// Subjects=26
-5.43	34.17	-3.53
15.84	42.07	-13.35
-8.71	50.98	-6.01
24.62	52.18	20.27
-28.8	48.68	21.18
20.77	4.94	56.62
22.35	65.05	8.06
2.39	5.95	29.98
-19.45	24	-23.7
-18.21	60.92	13.34
33.23	46.23	25.13
-47.67	4.01	50.79
45.12	2.69	25.3
-35.25	13.1	1.93
23.5	-29.68	-19.69
-22.27	-43.47	-1.28
-48.11	-35.73	-22.82
-8.01	-41.73	47.48
13.02	49.33	39.6
-35.72	-72.99	44.84
-12.27	-64.65	40.53
20.88	-90.6	32.29
-3.88	-70.63	17.51
-38.35	-74.8	-19.66
24.61	-45.7	-20.59
13.82	21.25	-7.12
-35.38	-4.74	-22.22
37.99	-27.74	59.16
-35.75	-25.01	59.78
-39.55	-4.79	-8.79
48.05	-.12	-11.3
-43.77	14.44	6.38
-9.32	7.36	35.57
-31.03	13.67	-4.86
-48.05	-9.79	-3.81
-52.11	-57.05	4.66
-34.1	-51.97	-13.82
-28.64	-46.34	3.49
29.47	-71.46	45.08
-26.13	-55.67	47.74
-22.08	-66.76	14.05
-10.27	-18.82	41.12
19.45	-55.91	-.72
-9.15	-84.23	20.94
-9	-81.55	41.91
36.38	-57.52	-23.08
-34.05	-74.52	-16.39
7.55	30.41	15.6
7.48	47.25	13.07
53.64	20	28.21
11.98	1.26	23.57
-19.95	16.7	47.18

// Attout L, 2014: Order STM retrieval
// Attout L, 2014: Alphabetical Order Judgment
// Attout L, 2014: Numerical order judgment
// Attout L, 2014: Conjunction Alphabetical order and Order STM
// Attout L, 2014: Conjunction Order STM and Numerical order judgment
// Attout L, 2014: Distance effect of order STM
// Attout L, 2014: Distance effect of Alphabetical order judgment
// Attout L, 2014: Distance effect of numerical order judgment
// Attout L, 2014: Conjunction of distance effect for alphabeticala andorder 
// STM and numerical vs. luminance
// Attout L, 2014: Conjunction of distance effect for alphabetical order 
// judgment and order STM vs. luminance
// Attout L, 2014: Conjunction of distance effect for order stm and numerical 
// order judgment vs. luminance
// Attout L, 2014: Conjunction of distance effect for alphabetical order 
// judgment and numerical order judgment vs. lum.
// Attout L, 2014: Order STM: Encoding-maintenance phase
// Attout L, 2014: E-M phase inclusive mask over neural substrates associated 
// with 3 distance effects
// Attout L, 2014: E-M phase inclusive mask over neural substrates associated 
// w/ distance effect in STM and num. condit
// Subjects=26
-50	0	46
-28	6	70
-36	18	26
-24	-70	42
-34	-46	38
14	-88	2
-14	-92	-10
30	-68	-28
14	-88	2
-14	-84	-22
16	0	26
-52	-20	16
-50	-34	52
36	-56	-36
-40	-6	10
-22	-4	10
14	-88	2
12	-80	-18
-14	-92	-10
32	-68	-30
-34	-48	40
44	-34	38
38	-40	42
40	-48	48
-28	-54	42
-26	-60	42
24	-62	44
34	-52	44
-2	14	44
4	18	52
-38	-50	36
46	-40	36
30	22	-6
-34	-52	40
40	-48	42
-34	-58	44
-30	-66	54
22	-66	44
34	-62	46
-36	-50	40
-36	-50	40
-34	-48	40
44	-36	38
38	-48	44
-30	-54	42
24	-62	42
34	-52	42
-38	-50	38
46	-40	36
-2	-2	74
-56	-2	20
-4	-48	-22
42	36	30
-36	-42	32
-24	-70	44
32	-70	50
-66	-28	2
-50	-64	-14
-24	-18	-12
24	-94	-10
28	-70	-30
-42	8	26
-44	20	24
-36	-46	34
-42	8	26
-44	20	24
-36	-44	34
-24	-68	44
22	-66	48

// Damarla S R, 2013: Stable Parietal lobe voxels in Pictoral Mode
// Damarla S R, 2013: Stable Parietal lobe voxels in Digit-object mode
// Subjects=10
-11	-53	16
-25	-77	37
27	-77	37
40	-42	53
-29	-45	53
22	-61	57
-37	-52	46
43	-40	51

// Hayashi M J, 2013: Main Effect of Duration Task
// Hayashi M J, 2013: Main Effect of Numerosity Task
// Hayashi M J, 2013: Duration AND Numerosity
// Hayashi M J, 2013: Congruent - Incongruent Contrast (Masked by Duration AND 
// Numerosity)
// Subjects=26
34	20	2
-6	18	48
-34	18	0
48	10	26
48	34	18
-12	6	0
28	-88	18
28	-72	-8
48	-74	10
24	68	-4
-22	-90	10
-26	-76	-8
-22	-93	24
-16	-80	-8
-10	-96	20
40	-80	12
-28	-90	22
22	-90	20
48	6	26
30	-58	-8
-4	36	18
10	28	38
26	-28	60
24	-26	64
50	-32	50
24	-46	54
12	-42	64
-42	-24	8
48	6	26
38	-22	22
28	-88	18
28	-72	-8
48	-74	10
24	-68	-4
28	-74	26
46	34	16
36	12	-8
26	12	-8
0	-52	-34
-4	-58	-16
-22	-90	10
-26	-76	-8
-22	-92	24
-16	-80	-8
-8	30	22
28	-28	62
24	-26	64
50	-32	50
4	-12	4
-4	-12	4
18	-40	4
54	12	28
52	8	30

// He L, 2013: Large > Small
// He L, 2013: Small > Large
// He L, 2013: Nonsymbolic > Symbolic
// He L, 2013: Symbolic > Nonsymbolic
// He L, 2013: Dot-dot > cross-notation trials
// He L, 2013: Digit-digit > cross notation trials
// He L, 2013: Cross-notation > digit-digit trials
// He L, 2013: Overlap between (nonsymbolic>symbolic) and (large>small)
// He L, 2013: Overlap between (Symbolic>nonsymbolic) and (small>large)
// Subjects=20
-23	-62	51
-30	-49	45
-26	-67	35
27	-60	51
28	-67	38
51	-34	49
49	-63	28
26	-60	51
31	-70	28
35	-81	19
-22	-62	51
-33	-41	41
-25	-69	31
-35	-87	14
51	-34	52
55	-56	26
48	-63	30
31	-69	30
-22	-62	44
31	-57	52
-30	-41	40
51	-53	27
30	-55	44
-23	-62	51
-33	-41	41
-26	-67	35
27	-60	51
28	-67	38
51	-34	51
48	-63	30
49	-57	29

// Holloway I D, 2010: Greater Conjunction related activation for Symbolic and 
// Non-symbolic in Adults compared to Children
// Holloway I D, 2010: Greater Conjunction related activation for symbolic and 
// nonsymbolic in children compared to adults
// Subjects=19
44.41	-40.82	54.61
35.76	-46.3	39.55
33.8	-62.03	56.51
39.54	19.97	1.61
-34.68	-11.8	65.35
-24.74	16.82	-19.69
51.5	-15.14	14.45
-46.1	2.52	-23.82
-45.15	12.24	-35.8
5.7	-54.54	18.28
3.08	14.07	-16.44

// Jacob S N, 2014: Line Proportion full brain analysis
// Jacob S N, 2014: Dot Proportion full brain analysis
// Jacob S N, 2014: Line Control (Colour) full brain analysis
// Jacob S N, 2014: Dot Control (Shape) full brain analysis
// Jacob S N, 2014: Adaptation to Line Proportion
// Jacob S N, 2014: Adaptation to Dot Proportion
// Jacob S N, 2014: Numerosity full brain analysis
// Jacob S N, 2014: Overlap of distance effect for proportions and 
// numerosities
// Subjects=15
46	31	46
44	41	52
35	-61	-14
-51	-65	-14
24	-93	6
-18	-96	-3
30	-87	-3
-48	-72	-9
-27	-87	-9
21	-90	-9
-30	-51	48
-30	-54	63
-18	-72	57
24	-63	48
30	-54	48
39	-39	45
-36	-6	57
-45	0	39
48	6	36
-24	-6	51
33	-3	54
42	0	54
-9	6	57
-6	15	45
3	15	42
-33	24	6
-30	27	-6
36	21	0
-21	6	12
27	-75	-15
-21	-93	6
-33	-75	-3
42	-72	9
24	-63	42
27	-51	51
-21	-63	42
-30	-54	54
42	3	30
-48	0	33
6	12	45
12	-27	36
3	-30	42
-6	12	48
3	6	54
36	36	24
-39	39	3
33	27	6
-36	-6	12
-33	18	-9
15	-9	12
9	-21	0
-9	-27	6
-6	-9	15
-24	6	9
-15	6	0
21	0	0
-37	28	50
48	36	45

// Lyons I M, 2013: Whole Brain Conjunction of [NumCard>LumCardNum and 
// DotCard>LumCardDot]
// Lyons I M, 2013: Whole Brain Conjunction of [NumOrd>LumOrdNum and 
// DotOrd>LumOrdDot]
// Lyons I M, 2013: Symbolic: NumOrd>LumSymbolicOrd
// Lyons I M, 2013: Nonsymbolic: Numord>LumNonsymbolicORD
// Lyons I M, 2013: DotOrd>LumOrd(dot) and DotCard>LumCard(Dot)
// Lyons I M, 2013: SymOrd>LumOrd(sym) and SymCard>LumCard(Sym)
// Subjects=33
41.04	-32.61	37.23
1.42	-84.31	5.22
0.31	18.59	42.32
0.37	14.79	48.22
-48.84	7.38	39.37
-56.53	7.31	11.58
43.25	-36.31	44.2
2.41	24.78	39.55
48.24	23.85	23.49
43.67	43.81	-7.13
-45.01	41.25	-4.78
34.15	21.71	-2.94
-33.17	21.31	-2.13
44.31	-34.19	44.01
30.43	-72.56	30.66
3.49	24.87	40.65
42.82	35.02	17.04
49.37	8	24.8
42.6	48.12	-6.36
34.17	20.74	-1.74
-33.16	20.34	-.93
-44.64	-71.44	-3.14
-8.18	-76.45	11.36
44.31	-34.19	44.01
30.43	-72.56	30.66
3.49	24.87	40.65
42.82	35.02	17.04
49.37	8	24.8
42.6	48.12	-6.36
34.17	20.74	-1.74
-33.16	20.34	-.93
-44.64	-71.44	-3.14
-8.18	-76.45	11.36

// Vogel S E, 2013: Number > Control
// Vogel S E, 2013: Brightness > Control
// Vogel S E, 2013: Conjunction of [Number>Control and Brightness>control]
// Vogel S E, 2013: Number Specific Activation
// Subjects=14
10.33	-76.09	55.72
32.61	-61.12	40.83
38.96	-78.23	25.46
35.69	6.8	51.83
9.98	15.91	48.01
44.97	42.87	21.93
-15.57	-98.62	14.42
-12.1	-79.4	56.26
-31.43	-67.34	48.78
51.52	18.04	30.63
35.82	-54.5	43.58
32.51	7.04	55.19
10.34	-79.26	55.99
-34.72	-58.35	41.37
-2.9	25.09	44.05
16.39	-92.85	3.53
52.5	36.83	25.7
35.82	-54.5	43.58
32.51	7.04	55.19
10.34	-79.26	55.99
51.4	36.56	22.39
6.72	25.15	43.93
42.13	-35.69	38.59
-49.72	-42.32	43.55
38.88	-72.4	18.29
26.07	0.14	49.15
-8.87	-80.18	59.63

// Decety J, 2013: Imagine-self perspective
// Decety J, 2013: Imagine-other perspective
// Decety J, 2013: Imagine-self (Controls>psychopaths)
// Decety J, 2013: Imagine-self (Psychopaths > Controls)
// Decety J, 2013: Imagine-other (Controls>psychopaths)
// Decety J, 2013: Imagine-other (Psychopaths>controls)
// Subjects=37
-34	20	2
44	14	0
-58	-28	32
58	-24	34
-4	12	60
6	10	60
-6	20	38
4	18	40
-8	54	14
4	56	18
44	30	-4
-38	28	4
54	12	8
-44	-54	38
46	-66	-12
20	-4	-14
-46	6	-6
34	28	8
-56	-36	36
58	-28	28
-4	12	58
6	10	58
-4	24	26
-6	14	38
0	-10	34
-42	40	10
48	30	0
-8	56	26
8	54	2
-52	8	6
50	12	4
-48	-44	10
50	-36	2
-44	-34	34
-12	0	4
14	58	-2
-12	52	8
0	-28	-14
50	26	8
-4	8	34
4	10	32
-10	2	50
38	20	12
44	-48	14
44	26	2
6	18	34
16	32	12
-44	14	4
34	30	4
-6	16	54
8	24	46
50	-52	22
44	-32	22
-48	-36	22
30	8	2
-14	10	-2
28	48	14
-50	-38	-18
10	16	-6

// Biagi L, 2010: observation of object-related hand actions vs static control 
// conditions
// Subjects=12
-42.49	-69.05	-0.02
45.13	-67.47	-1.16
-52.07	-39.11	16.54
59.07	-38.35	16.31
-58.39	-28.26	33.54
55.98	-31.63	34.74
-35.67	-50.47	60.8
34.87	-44.51	62.83
-28.19	-60.37	55.96
28.41	-61.52	49.83
-30.47	-10.26	57.36
36.84	-6.68	56.29
-47.78	2.9	36.39
51.6	5.61	35.02
56.77	11.59	15.5
57.06	-14.02	42.18
-38.44	-52.68	-22.63
-15.69	-89.96	2.54
21.73	-86.3	5.15
-.37	-47.72	65.74
-39.51	-58.23	-25.5
40.67	-58.47	-21.94

// Bodden M E, 2013: aff-phy
// Bodden M E, 2013: cog-phy
// Bodden M E, 2013: aff-cog
// Subjects=30
46	-54	-16
-38	-4	34
42	4	-24
36	4	52
14	16	-8
38	-40	50
8	-72	46
-4	-28	32
58	-32	38
30	30	-16
-10	-70	-24
36	4	52
40	2	-26
24	-64	50
-48	-50	8
62	-34	38
-16	0	66
2	-14	34
2	22	28
-34	-30	64

// Pardini J E, 2010: Positive Associations between Concussion Symptom 
// Severity and 2-Back vs. 0-Back Contrast
// Pardini J E, 2010: Negative Associations between Concussion Symptom 
// Severity and 2-Back vs. 0-Back Contrast
// Subjects=14
-45.55	8.26	50.41
-20.74	-70.53	47.81
-28.44	1.84	48.52
-33.06	-22.64	-6.25
-29.47	-61.46	28.19
-4.85	-40.03	41.72
21.73	10.35	43.88
39.9	7.2	42.82
37.96	-74.21	36.29
-45.8	-3.12	13.45
-54.43	-9.57	-.41
-50.39	30.93	-13.89
-40.56	-8.6	-2.88
-23.09	-95.75	10.92
-31.71	-75.71	9.34
-34.73	-16.63	57.95
-28.56	-78.49	0.61
-17.51	-48.25	60.4
-20.32	43.65	10.35
-20.41	43.76	-1.93
-12.77	52.04	21.83
-10.4	-55.32	9.61
-11.7	24.67	11.84
2.6	-7.32	51.16
3.52	-84.64	0.76
2.15	19.84	3.17
9.14	-39.97	54.94
9.82	-41.79	3.79
15.61	-44.79	60.85
23.95	-97.49	11.64
17.22	-26.14	-.96
15.21	12.54	31.51
19.43	-42.96	1.54
18.7	-75.64	33.29
25.03	-76.45	22.13
31.6	-29.81	60.52
49.34	-6.6	14.88
43.85	-2.63	-2.12
40.08	-17.24	57.14
42.84	-14.19	-0.02
41.91	-6.13	21.61
48.44	-27.96	27.83
59.28	-15.27	53.41
66.58	-10.5	31.73

// Toepper M, 2010: CBT related activity
// Toepper M, 2010: BST related activity
// Subjects=20
21	-63	66
-39	-45	60
24	-3	57
-27	-3	57
6	-54	54

// Thompson J C, 2014: Intact > Apart
// Thompson J C, 2014: Apart > Intact
// Thompson J C, 2014: Unoccluded > Occluded
// Thompson J C, 2014: Occluded > Unoccluded
// Thompson J C, 2014: Intactness x Occlusion
// Thompson J C, 2014: Upright > Inverted
// Thompson J C, 2014: Unoccluded > Occluded
// Subjects=10
-64	-52	14
-40	-52	22
-40	-40	32
46	-50	-6
44	-40	16
34	-34	34
42	-38	36
-54	-58	6
-26	-80	22
-22	-74	36
30	-66	56
34	-52	64
-38	-52	-22
-30	-48	62
38	-64	-6
-36	-48	22
-20	-62	34
-38	-66	10
64	40	10
-48	-48	-14
-46	-70	6
40	-30	-8
36	-62	6
20	-60	64
-40	-76	-6
-44	-70	4
-46	-46	50
38	-38	-24

// Castelli I, 2010: Healthy Controls Young
// Subjects=12
48	2	54
-42	-4	54
52	24	26
-4	32	56
-26	-50	45
-34	-50	43
-42	22	-20
40	10	-38
50	-36	-6
30	-88	28
12	-80	-6
-4	-84	-12
-4	26	24
-14	4	0
-26	-6	-22
6	-20	-2
2	-38	-8
-18	-46	-26
26	18	32
14	-80	-6
-4	-84	-12
-2	28	12
-48	-8	52
40	-16	66
-46	16	16
-64	-32	18
-24	-20	16
26	-24	18
40	-52	45
55	-1	24
18	38	35
46	30	13
46	-14	-3
-40	-74	41

// Castelli I, 2010: Healthy Controls Old
// Subjects=12
26	18	32
14	-80	-6
-4	-84	-12
-2	28	12
38	-8	50
-40	-4	54
8	10	50
58	24	6
-16	50	30
-50	34	0
-24	-58	52
-32	-50	43
-62	-32	14
58	4	-14
-50	-46	-20
32	-74	22
-26	-98	-4
10	-6	4
26	-24	20
-24	-20	16
-10	-10	12
20	-72	-34
-2	-52	-42
-48	-8	52
40	-16	66
-46	16	16
-64	-32	18
-24	-20	16
26	-24	18
4	62	-3
-47	9	-9
30	13	-17
-32	19	-14
42	30	15

// Corradi-Dell'Acqua C, 2014: Attribution of Beliefs
// Corradi-Dell'Acqua C, 2014: Attribution of Emotions
// Corradi-Dell'Acqua C, 2014: Attribution of Pain
// Corradi-Dell'Acqua C, 2014: Beliefs > Photos
// Corradi-Dell'Acqua C, 2014: Emotions > Photos
// Corradi-Dell'Acqua C, 2014: Pain > Photos
// Corradi-Dell'Acqua C, 2014: Belief > Emotions
// Corradi-Dell'Acqua C, 2014: Emotions > Belief
// Corradi-Dell'Acqua C, 2014: Belief > Pain
// Corradi-Dell'Acqua C, 2014: Pain > Belief
// Corradi-Dell'Acqua C, 2014: Emotion > Pain
// Corradi-Dell'Acqua C, 2014: Pain > Emotion
// Subjects=46
8	58	12
6	54	-6
4	-52	28
60	-58	28
54	8	-26
48	30	-8
24	-10	-16
-52	-58	26
-64	-16	-14
-48	30	-8
-22	-10	-14
-4	44	-10
-2	-18	36
8	-82	28
66	-22	30
-58	-32	32
-4	-28	26
-10	-70	34
64	-32	36
46	42	6
-58	-36	34
-42	42	10
-28	34	-14
-40	-4	-6
8	56	12
-4	44	-14
6	-54	30
58	-46	22
66	-24	-4
26	-22	-16
-48	-58	24
-64	-20	-12
-20	-28	-12
8	56	10
-4	44	-14
0	-14	38
8	-52	28
16	10	-8
62	-8	-12
-12	12	-8
-30	10	-22
66	-40	22
18	-72	2
16	-72	46
12	4	-8
-14	8	-12
-56	-34	36
-38	-8	-6
-6	-60	44
-38	-74	34
-14	-56	16
-6	-60	18
12	2	0
-14	8	4
-2	-56	36
62	-54	26
52	2	-28
24	32	50
-52	-56	30
-64	-14	-12
-28	30	48
-26	-34	-16
6	60	16
2	54	-16
-53	-36	36
-50	8	18
-6	-62	18
-2	48	-18
-4	-52	30
60	-56	28
58	-2	-26
40	-28	64
-54	-60	32
-60	-10	-14
-48	28	8
-58	-34	36
-46	6	16
-40	-12	4

// Das P, 2012: Schizophrenia
// Subjects=20
42	8	30
28	-98	0
40	-80	-8
32	-90	-6
58	-38	14
54	-56	2
44	-60	-6
32	-56	-12
-30	-94	-8
-48	-68	-4
-52	-56	4
-60	-60	-2
-48	-62	-12
60	-26	48
64	-16	36
-18	-78	-40
-32	42	24
-30	56	16
38	32	36
-8	30	28
-8	-100	4
16	-90	24
-10	-90	24
0	-22	32
54	16	2
-52	24	4
46	16	20
68	-34	10

// Das P, 2012: Healthy Control
// Subjects=19
50	18	20
40	12	32
42	8	44
-44	12	24
-38	2	46
-40	-2	34
16	8	66
62	-42	18
44	-78	28
50	-62	-6
38	-64	-10
32	-90	-4
40	-82	18
32	-70	32
32	-58	48
56	-20	24
58	-18	50
14	-74	-38
-30	-92	-8
-36	-88	18
-36	-84	34
-58	-46	14
-60	-58	10
-42	-58	-8
-28	-44	-16
-16	-72	-40
4	-26	-4
-20	36	6
-22	16	54
-14	-102	14
16	-84	24
16	-70	-6
-18	-58	64
20	-52	62
52	-62	46
54	16	2
-52	24	4
46	16	20
68	-34	10

// Dohnel K, 2012: FB > Control FB
// Dohnel K, 2012: TB > Control TB
// Dohnel K, 2012: (FB > Control FB) + (TB > Control TB)
// Dohnel K, 2012: FB > TB
// Dohnel K, 2012: TB > FB
// Dohnel K, 2012: B (FB, TB) > Control (Control FB, Control TB)
// Subjects=18
-31	16	1
51	-43	14
-60	-29	-4
52	31	14
57	-38	4
-52	-66	22
41	-47	-10
55	-47	15
-3	27	52
47	31	30
-49	11	43
34	16	0
-33	28	0
-45	-33	-2
-42	-52	55
12	-60	48
-13	-3	18
-10	54	9
1	37	-14
65	-23	26
0	27	51
47	11	34
-56	17	27
49	-65	10
-52	-66	22
-3	-54	50
41	-49	-7
-39	-49	-9

// Martineau J, 2010: Autism Group (ASD)
// Subjects=7
-32	-34	66
-58	-22	48
20	-42	-32
60	-18	42
30	-42	54
-50	-30	36
44	-26	22
-38	-74	-8
26	-90	14
-26	-84	24
38	-62	2
-56	20	20
52	12	12
22	-44	-32
-32	-26	52

// Martineau J, 2010: Healthy Controls (TD)
// Subjects=8
-36	-28	70
-34	-50	54
-48	-70	-8
46	-68	2
-56	20	20
52	12	12
42	-80	-4
36	-68	8
54	-60	0
4	-72	48
28	-82	38

// Kim J W, 2010: Attitude attribution > Control
// Subjects=24
-52	26	2
-52	26	8
-54	18	4
-50	30	2
-60	-42	4
-52	-48	48

// Spreng R N, 2010: Past, Future, Other > Control
// Spreng R N, 2010: Control > Past, Future, Other
// Spreng R N, 2010: Other > Past, Future
// Spreng R N, 2010: Past, Future > Other
// Subjects=16
-68	-36	-4
-4	20	52
-12	32	20
-8	-44	4
-12	56	44
-44	16	52
-44	36	-12
20	-88	-36
32	-60	4
20	8	12
-20	4	8
-48	28	4
-4	-48	24
-52	24	36
-64	-12	-16
-60	-12	-28
-40	-76	40
-12	64	24
28	-60	-16
-48	-80	8
-48	0	-4
20	-28	0
-16	-40	48
-8	-72	-44
52	0	28
-32	-32	72
48	-36	-4
48	-48	20
-52	-48	12
-4	-36	40
-8	-60	24
-8	-44	8
-24	-40	-20
-32	-80	44
8	-40	4
-20	-20	-24
-4	40	4
-16	64	12
16	-44	-52
-24	16	52
4	-8	12
44	-72	-44
-32	24	-8
28	-40	-12
-12	12	-4
-4	-20	-28

// van der Meer L, 2011: High-inhibition (HI) > Low-inhibition (LI)
// van der Meer L, 2011: HI > Fixation
// van der Meer L, 2011: LI > Fixation
// van der Meer L, 2011: Baseline > Fixation
// van der Meer L, 2011: NoGo > Go
// Subjects=19
-24	-76	-8
10	-84	-2
18	-76	-12
-38	0	42
-40	10	28
-52	16	18
-56	-38	0
-56	-10	-12
-56	-54	16
-18	-94	20
-32	-84	14
-6	16	46
-4	6	60
-2	16	56
-2	-28	-4
-28	-56	44
-10	-86	44
-6	-52	46
-4	-80	44
32	22	6
34	26	-2
30	-86	20
36	-88	14
-26	24	4
-35	22	12
-52	18	18
-30	-2	54
-42	2	44
-8	18	36
-44	-52	42
-56	-42	-2
14	-68	46
-8	-82	-10
24	-78	-10
-56	-54	18
8	-68	-22
34	-58	42
38	-8	54
32	-54	-30
-8	-20	-2
-30	-58	42
36	-58	46
-54	-48	-2
-6	-4	54
10	-16	-4
-32	20	2
-52	4	14
-34	-12	62
44	-24	44
44	-16	58
-28	-52	-34
32	-52	-30
-6	-70	-26
8	-66	-26
-42	-44	40
-58	-36	0
-30	-2	50
-4	-70	42
14	-70	46
-8	12	36
-26	26	2
38	10	0
44	2	8
34	28	-2
-8	-78	-10
16	-76	-10
-36	-10	60
54	-16	42
-30	-52	-32
40	-58	-34
-4	-16	-12
-48	20	-8
58	6	0
16	60	26
38	58	2
16	34	42
-6	42	12
-48	-30	54
-60	-56	2
-44	-76	-12
44	-34	16
56	-54	34
32	-42	66
-60	-52	38

// Abraham A, 2010: (Belief question > Control) + (Desire question > Control)
// Abraham A, 2010: Belief scenario > Desire scenario
// Abraham A, 2010: Belief Question > Desire Question
// Abraham A, 2010: Desire scenario > Belief scenario
// Abraham A, 2010: Desire Question > Belief Question
// Abraham A, 2010: Incongruent > Congruent
// Abraham A, 2010: False beliefs > True beliefs
// Subjects=22
-4	11.62	35.15
8.52	38.19	6.01
-23.46	45.37	19.16
24.63	45.66	18.58
9.03	-29.03	45.1
63.38	-36.84	21.71
60.26	-26.06	37.57
46.99	31.82	2.76
47.11	0.1	5.42
-49.05	-3.65	6.84
-36.2	3.29	12.8
-52.03	-30.93	25.89
-17.15	11.38	-8.17
14.91	18.17	-5.76
-45.89	35.47	16.9
-26.76	64.13	14.28
24.57	61.52	17.26
24.68	52.78	28.02
40.52	47.64	1.51
27.76	58.11	14.16
37.52	46.51	28.4
-45.86	35.72	20.23
-29.78	49.53	32.27
53.8	-72.82	11.46
53.67	-67.51	-2.37
47.31	-80.23	-1.23
44.24	-82.14	15.7
-35.96	-53.56	20.91
-32.65	-68.88	28.85
-45.96	-14.69	-12.34
-1.19	37.11	-7.17
43.77	-11.24	-17.01
47.37	-49.88	19.65
-45.9	-17.35	-5.43
53.47	-6.98	-4.1
-48.76	-46.77	27.18
-58.55	-28.83	12.4
53.82	-72.57	14.78
-33.26	10.51	-17.95
27.69	-5.24	-20.67
27.77	-20.85	-16.02
40.41	-19.4	-39.71
37.96	-21.48	57.52
28.4	-30.8	61.76
12.36	-96.91	34.03
-4.8	-100.95	24.53
-52.1	-31.7	15.92
-4.25	-10.75	-6.46
-10.75	54.2	8.24
8.41	53.54	-1.96
-7.49	67.93	20.43
-.63	-65.78	24.87
-16.69	-62.96	21.48
-1.12	64.28	13.97
-4.42	50.03	-4.87
-.63	-65.78	24.87
-16.78	-47.35	16.82
21.68	-50.55	13.31
-16.83	-47.87	10.18
31.02	-23.74	-12.47
21.32	-1.6	-14.22
31.02	-23.74	-12.47
-29.89	-17.51	-8.95
-48.93	-8.97	20.67
-52.32	-7.61	-2.83
-20.36	11.36	-8.13
-22.8	-26.91	75.4
-29.36	-15.28	61.12
-48.51	-31	66
47.03	28.91	6.35

// Dodell-Feder D, 2010: (Subject-wise) BELIEF > PHOTO
// Dodell-Feder D, 2010: (Item-wise) BELIEF > PHOTO
// Subjects=62
-2	-54	38
52	-52	22
58	-20	-14
-50	-58	20
-60	-24	-8
50	6	-34
2	60	18
10	34	62
0	56	26
-52	4	-28
-20	60	30
46	8	48
2	-92	0
2	-22	42
52	30	-6
2	48	-18
62	-32	0
56	-48	24
58	-22	-10
-50	-50	24
8	-58	40
0	60	18
-18	60	28
12	34	62
2	58	30
62	-24	-10
52	2	-36

// Lee J, 2011: Healthy Controls
// Subjects=14
42	-54	24
-40	-54	24
14	26	42
40	10	42
60	-26	-8
-52	-60	14
-64	-18	-8
38	22	34
-8	-54	40
4	-56	34
10	40	42
-44	-54	24
50	-56	26
-52	-58	34
-58	-58	16
-56	-48	18
52	-50	30
56	-54	26
-56	-56	26
44	-66	38
-50	-70	40
-48	-70	44
4	-64	38
22	28	36
-44	-68	26
62	-8	-14
18	-42	32
12	-52	34
14	38	40
54	-62	28
42	-52	22
-38	-54	26
46	12	-30
56	-54	24
-60	-58	26

// Prochnow D, 2014: Face Affect (Emotional Facial Expessions) > Control, 
// Stimulus Presentation
// Prochnow D, 2014: Face Affect (Emotional Facial Expessions) > Control, 
// Empathic Reasoning Decision
// Subjects=26
48.37	5.33	31.73
-48.03	-63.4	-22.73
-57.22	-16.22	51.48
-47.44	-37.6	63.2
45.25	-53.07	19.94
-47.86	-71.54	-4.21
35.65	-72.67	15
48.34	-77.31	-4.83
-41.14	-15.61	57.93
-50.67	-37.87	59.91
38.64	-68.37	-12.16
51.57	5.35	31.69
-60.44	-13.07	51.25
-51.05	-68.13	-1.11
44.95	-56.15	-19.95
48.35	-80.48	-4.56
-51.18	-76.11	-21.63
-48.27	59.29	-5.14
-47.89	26.96	31.02
-6.08	25.33	47.41
75.12	0.46	35.18
-60.55	2.28	43.27
-32.13	30.83	-2.94
-47.5	-15.13	64.66
-31.49	-51.47	47.45
-12.45	-76.39	12.52
-22.3	-55.79	-9.17
9.83	-81.23	-10.75
-6.17	-81.07	-7.24
-45.07	46.1	-10.76
65.33	33.73	25.81
-47.9	23.53	27.96
-6.09	28.5	47.14
-9.18	23.16	61.01
-47.57	3.9	63.06
-51.25	28.66	11.96
-6.27	-75.49	-17.74
-57.45	30.85	40.84
-48.05	35.2	13.61
-6.15	37.76	43.02
-54.66	33.1	-12.91

// Rothmayr C, 2010: False belief > True belief
// Rothmayr C, 2010: No go > Go
// Rothmayr C, 2010: Conjunction for False belief > True belief and No go > Go
// Rothmayr C, 2010: Masking False belief > True belief with No go > Go
// Subjects=12
-42	22	42
32	4	52
52	-50	38
6	66	22
66	-36	-2
-52	-50	32
-40	52	-4
-64	-38	-10
-18	4	14
-2	-62	44
10	34	46
52	28	30
30	58	10
48	20	-4
-62	-56	36
64	-46	30
6	24	62
-44	20	48
56	-50	36
66	-36	-2
54	26	30
-60	-58	32
10	36	44
-50	-50	30
-4	24	62
-46	26	26
-18	4	14
0	-64	50
-36	56	-6
-32	4	54
-2	50	20
-64	-38	-8
-28	50	28

// Saft C, 2013: pre-HD
// Subjects=30
-8	14	62
-2	6	72
-10	30	54
-10	46	44
-16	52	46
-38	14	48
-42	32	-6
-50	34	-8
-54	26	8
-4	54	-14
-6	52	48
-12	-48	38
2	-50	28
8	-54	40
-44	-60	24
44	-60	24
44	-66	14
52	-50	14
-50	-50	14

// Saft C, 2013: Healthy controls
// Subjects=26
-14	54	34
0	48	-20
6	50	30
6	42	-16
-2	-56	36
18	-66	14
22	-62	6
-60	-6	-12
58	-12	-16
52	-64	2
-54	-54	6
-44	-52	16

// Schlaffke L, 2014: Affective ToM > Control
// Schlaffke L, 2014: Cognitive ToM > Control
// Schlaffke L, 2014: Affective ToM > Cognitive ToM
// Schlaffke L, 2014: Cognitive ToM > Affective ToM
// Subjects=39
-4	12	55
-4	16	49
-8	56	34
-44	18	49
-52	22	10
-58	-60	19
-52	-36	-5
60	-8	-20
52	-76	1
30	-98	4
14	-106	10
42	-76	-8
-4	-54	37
-4	14	58
-46	12	52
-52	-64	19
52	-48	16
-60	-38	-2
50	-64	13
52	-14	20
-56	-6	-23
-48	-80	1
-2	-58	40
-2	30	40
-2	42	49
-52	18	4
-46	32	-5
32	12	-14
8	-68	7
18	-4	16
-12	-6	16
38	-60	25
-36	-82	28
-18	-90	19
-4	-94	16
2	-52	49

// Schnell K, 2010: Affective > Visuospatial
// Schnell K, 2010: 3pp > 1pp
// Schnell K, 2010: (3 pp visuospatial > 1 pp visuospatial) > (3 pp affective 
// > 1 pp affective)
// Schnell K, 2010: (3 pp affective > 1 pp affective) > (3 pp visuospatial > 1 
// pp visuospatial)
// Schnell K, 2010: 3 pp affective > 3 pp visuospatial
// Schnell K, 2010: 3 pp visuospatial > 1 pp visuospatial
// Schnell K, 2010: 1 pp affective > 1 pp visuospatial
// Schnell K, 2010: Conjunction Affective > Visuospatial
// Subjects=21
-6	54	30
6	54	24
-3	45	-15
6	6	9
-3	0	-3
-48	27	-9
-39	21	-15
-45	12	-39
-45	-57	21
-54	-21	-12
-27	0	-24
-18	-9	-24
45	9	-42
66	-51	21
57	30	3
-6	-48	30
-15	-30	27
21	-30	24
-21	15	3
27	-84	-39
-30	-81	-36
30	9	57
27	21	45
-27	9	54
-54	-51	21
-51	-39	6
63	-48	18
57	-54	15
57	-54	24
9	-54	54
-9	-45	48
-33	-36	51
42	-78	33
-39	-75	36
66	-45	30
66	-45	18
51	-18	45
39	-21	42
39	-27	57
-15	-3	42
-12	6	36
42	-48	-6
36	-63	39
-15	-12	24
30	-15	0
36	-9	0
27	-3	21
21	-12	24
30	-33	3
-6	54	36
-6	51	12
9	51	27
-3	45	-15
42	-18	48
42	-9	39
39	-12	69
-42	-12	42
57	30	3
48	33	-3
-45	27	-6
-39	27	-15
-48	3	-30
51	-30	-3
48	-36	3
48	9	-42
48	0	-27
57	3	-24
-57	-66	24
-45	-57	27
-18	-12	-21
-30	-15	-21
-27	0	-24
-54	-51	27
12	-18	48
0	-12	42
21	-30	24
12	-18	24
-12	-27	24
-12	-15	24
-15	-45	27
30	-84	-39
-27	-81	-36
-48	-51	18
-63	-45	18
-54	-54	36
66	-45	18
60	-57	24
66	-42	33
-3	-54	57
6	-48	51
-6	-42	48
-9	51	30
6	54	24
-15	48	39
-48	27	-9
-45	12	-39
-42	21	-12
45	9	-42
57	30	0
45	18	-36
66	-48	21
63	-57	24
27	-84	-39
-30	-81	-36
-6	51	33
9	51	27
57	30	3
51	30	-3
0	45	-15
-9	15	69
-9	21	63
3	9	66
-57	18	15
-45	27	-6
-39	24	-15
-45	9	-36
-60	-21	-18
-54	-24	-3
48	9	-42
45	15	-36
45	-30	-3
45	-42	6
30	-84	-39
-30	-81	-36

// Spunt R P, 2014: (Study 1) Healthy controls
// Subjects=29
-6	58	18
-6	56	40
-6	24	64
8	52	40
-2	44	-18
-46	24	-12
-48	-66	28
-2	-48	30
46	14	-34
-54	-8	-18
60	-8	-22
54	-2	-22
-58	-36	0
34	-80	-34
-30	-82	-32
-42	-42	40
-46	-42	58
40	-42	48
56	-32	50
50	-42	40
60	-24	24
-56	-36	40
-8	-62	58
10	-68	52
-26	-62	58
-24	-70	32

// Spunt R P, 2014: (Study 2) Healthy controls
// Subjects=10
-48	-66	26
-6	-56	28
-42	36	-18
-8	38	-16
-6	54	16
2	-58	22
-8	-62	46
46	-50	24
-44	-50	34
20	10	56
-8	62	22
-20	34	44
-6	48	0
8	58	28
14	50	40
-2	46	-18
-42	30	-14
-48	22	-2
-46	-62	32
56	-62	24
-4	-50	32
-46	6	-34
-60	-12	-16
54	0	-28

// Li X, 2010: Consonant (random) > consonant (fixed)
// Li X, 2010: Rhyme (random) > rhyme (fixed)
// Li X, 2010: Tone (random) > tone (fixed)
// Subjects=12
-36	8	24
-32	-56	34
4	20	44
34	30	6
32	-2	44
30	-56	40
-36	22	26
-26	-66	44
-4	22	42
32	26	-4
10	-78	-28
36	-54	40
28	-4	38
-44	8	30
-28	-64	38
-2	-78	-30
30	30	-4
40	-60	48
36	-4	48
0	18	50

// Nan Y, 2013: Language phrase pitch processing > music phrase pitch 
// processing
// Subjects=18
63	-6	-5
57	-30	5
63	-24	0
-54	-12	-5
-60	-18	5
-54	27	0

// Chang H C, 2014: Tone sandhi sequence > baseline
// Chang H C, 2014: Mixed tone sequence > baseline
// Subjects=15
-31.48	56.31	-1.78
-46.39	48.04	13.86
-44.51	49.26	-7.58
-55.92	15.55	22.84
-37.96	25.68	-7.6
1.94	11.5	68.2
-52.38	7.96	44.82
-66.84	-16.03	7.1
-26.14	-64.06	53.74
-45.62	-40.31	56.21
-.23	-75.02	49.9
-24.54	-97.75	3.26
-44.21	-75.46	-9.81
-5.09	-97.68	2.93
1.17	-3.03	4.66
46.52	54.95	13.84
62.75	20.15	8.04
62.54	18.59	-8.61
46.29	21.51	-10.87
51.59	-6.17	60.14
69.15	-2.35	-3.29
32.3	-57.6	62.19
40.71	-40.74	46.94
3.63	-79.6	12.19
18.63	-55.29	7.29
29.35	-88.72	-6.39
11.83	14.57	-2.87
-48.53	39.42	13.63
-33.64	25.69	-7.68
-.42	15.46	53.28
-32.75	8.32	59.02
-53.66	11.93	29.89
-64.42	-12.99	28.05
-66.87	-16.24	4.88
-30.4	-54.84	60.75
1.99	-64.71	56.69
-11.45	-74.88	17.59
-44.21	-75.46	-9.81
-31.03	-95.65	3.17
-7.24	-99.82	3.17
1.21	-7.08	7.3
-20.57	7.97	-2.78
-11.78	3.62	7.58
1.05	-49.88	-14.24
38.55	10.7	57.57
35.52	21.68	-8.46
6.4	-12.63	73.87
51.57	-6.38	57.92
36.59	-10.81	68.7
53.26	14.22	25.6
53.62	-22.51	46.03
32.3	-57.6	62.19
5.76	-88.51	8.56
12.05	-84.52	-6.51
14.34	-55.1	9.59
20.76	4.67	17.01
11.87	6.06	-2.03

// Alluri V, 2011: Fullness, Positive correlation
// Alluri V, 2011: Fullness, Negative correlation
// Alluri V, 2011: Brightness, Positive correlation
// Alluri V, 2011: Brightness, Negative correlation
// Alluri V, 2011: Activity, Positive correlation
// Alluri V, 2011: Activity, Negative correlation
// Alluri V, 2011: Timbral Complexity, Positive correlation
// Alluri V, 2011: Key Clarity, Negative correlation
// Alluri V, 2011: Pulse Clarity, Negative correlation
// Subjects=11
56.21	-13.13	-3.12
56.21	-13.13	-3.12
55.17	-13.89	0.33
55.07	-2.61	-5.27
69.36	-12.8	11.19
44.59	-26.51	15.21
55.53	-32.02	24.53
58.22	3.27	-11.5
33.28	-85.02	-35.96
28.95	-85.14	-37
33.28	-85.02	-35.96
35.63	-67.19	-17.59
35.63	-67.19	-17.59
7.18	-50.33	-42.31
17.96	-52.62	-44.51
-52.85	-20.76	1.73
-52.85	-20.76	1.73
-56.05	-13.87	6.71
-52.89	-18.84	-.7
-46.19	-27.04	14.56
-53.76	-23.87	14.38
-13.97	-77.59	-11.24
-13.97	-77.59	-11.24
-29.29	-68.15	-24.24
-29.29	-66.02	-24.45
-29.29	-68.15	-24.24
-7.73	-77.2	-30.43
-7.74	-75.07	-30.64
-29.4	-74.5	-34.81
-29.4	-74.5	-34.81
-27.25	-72.37	-35.06
-31.56	-76.64	-34.57
-20.66	-90.11	-30.06
-20.66	-90.11	-30.06
49.35	-17.75	51.24
49.35	-17.75	51.24
45.17	-33.09	59.55
45.13	-33.4	56.22
45.14	-33.3	57.33
45.17	-33.09	59.55
-37.06	-26.66	52.47
-37.06	-26.66	52.47
-32.77	-37.8	47.9
-27.47	39.8	-29.35
-31.78	44.25	-27.47
-17.38	-57.67	64.17
-17.38	-57.67	64.17
-23.94	-37.49	62.28
-15.19	-57.46	66.35
55.18	-18.25	-.36
55.18	-18.25	-.36
53.01	-13.9	0.37
55.07	-2.61	-5.27
69.36	-12.8	11.19
44.59	-26.51	15.21
53.37	-32.03	24.57
50.91	-33.15	1.19
56.03	3.05	-13.69
61.03	5.93	39.73
61.03	5.93	39.73
56.84	5.78	49.9
26.84	12.63	-13.02
26.84	12.63	-13.02
16.14	12.25	-4.95
16.08	7.48	-10.08
24.83	14.82	-.87
-33.58	-67.95	-21.94
-29.28	-63.68	-22.44
-33.58	-67.95	-21.94
-58.28	-14.39	1.19
-58.28	-14.39	1.19
-56.05	-13.87	6.71
-48.64	-7.33	-4.15
-66.72	-19.46	16.4
-48.35	-27.04	14.6
-66.74	-21.79	14.39
-62.7	-11.84	-5.71
-60.69	5.62	-14.19
-57.8	5.61	42.91
-57.8	5.61	42.91
-57.81	5.51	41.8
-20.53	47.61	7.86
-20.55	48.57	6.65
-20.49	47.92	11.19
-5.12	-44.32	11.09
-5.15	-44.53	8.87
56.21	-13.13	-3.12
56.21	-13.13	-3.12
55.17	-13.89	0.33
44.59	-26.51	15.21
55.53	-32.02	24.53
56.06	3.26	-11.47
55.07	-2.61	-5.27
69.36	-12.8	11.19
9.22	64.81	-27.96
9.22	64.81	-27.96
33.29	-86.08	-35.86
28.95	-85.14	-37
33.29	-86.08	-35.86
35.66	-66.98	-15.37
35.66	-66.98	-15.37
-5.17	-40.28	8.45
-5.12	-44.32	11.09
-52.85	-20.76	1.73
-52.85	-20.76	1.73
-56.05	-13.87	6.71
-46.19	-27.04	14.56
-55.92	-23.88	14.42
-60.7	7.75	-14.4
-52.89	-18.84	-.7
-31.45	-68.15	-24.2
-29.29	-66.02	-24.45
-31.45	-68.15	-24.2
-33.69	-76.44	-32.31
-29.4	-74.5	-34.81
-27.25	-72.37	-35.06
-33.69	-76.44	-32.31
-16.13	-77.59	-11.2
-16.12	-78.66	-11.1
47.2	-19.88	51.49
47.2	-19.88	51.49
-37.06	-26.66	52.47
-37.06	-26.66	52.47
-39.26	-31.34	48.49
-17.39	-48.96	65.55
-17.39	-48.96	65.55
-23.94	-37.49	62.28
-15.22	-48.95	65.51
-32.93	14.62	46.07
-32.93	14.62	46.07
-32.95	12.29	44.06
-20.43	59.28	17.91
-20.43	59.28	17.91
-22.57	59.48	20.17
58.32	-6.95	-6.01
58.32	-6.95	-6.01
56.25	-11.76	0.1
71.39	-2.78	3.44
75.69	-24.87	-3.41
55.07	-2.61	-5.27
71.49	-8.64	9.62
58.19	3.06	-13.72
-58.35	-11.62	-3.56
-58.35	-11.62	-3.56
-52.8	-15.98	6.86
-44.03	-27.03	14.53
-60.5	-13.75	-3.32
-27.11	-65.8	-22.27
-27.11	-65.8	-22.27
-31.42	-67.95	-21.98
65.19	0.34	25.65
65.19	0.34	25.65
69.39	7.17	18.17
67.13	-.15	8.85
60.87	-8.4	24.34
53.76	-8.29	60.31
55.9	-8.49	58.05
53.76	-8.29	60.31
55.41	-11.06	19.1
38.08	-14.73	15.27
55.41	-11.06	19.1
14.98	-4.3	70.66
17.14	-4.29	70.63
10.71	-10.49	73.59
17.15	-6.42	70.84
14.98	-4.3	70.66
-45.62	-11.83	62.35
-45.62	-11.83	62.35
-43.46	-10.76	62.21
-48.39	-6.52	15.93
-48.47	-9.38	8.37
-55.88	-10.39	20.93
-48.39	-6.52	15.93
-7.39	59.95	24.35
-9.55	59.94	24.38
-7.39	59.95	24.35
-35.59	-9.96	1.49
-37.75	-12.09	1.74
16.8	-.3	44.46
16.8	-.3	44.46
16.79	1.83	44.25
-33.43	-9.95	1.45
3.73	12	38.99
3.73	12	38.99
5.92	12.22	41.17
15.02	-43.42	65.57
15.02	-43.42	65.57
17.18	-43.41	65.53
42.18	13.17	3.48
42.18	13.17	3.48
44.36	13.39	5.66
52.84	-51.28	-20.58
48.55	-50.02	-18.39
52.84	-51.28	-20.58
-33.61	-8	-12.19
-29.32	-8.2	-14.48
-31.47	-10.33	-14.23
-37.93	-8.02	-12.11
-31.41	-9.92	-9.79
-.59	11.99	39.06
-.59	11.99	39.06
-.6	14.11	38.85
-39.99	14.6	0.25
-39.99	14.6	0.25

// Atzil S, 2011: Own Infant > Unfamiliar Infant
// Subjects=23
64.5	-36.32	28.35
45.14	-70.73	-2
42.22	-5.08	62.79
32.07	22.22	3.74
26.32	-53.27	60.32
7.15	-75.85	59.09
16	18.43	-2.45
15.97	-1.63	-14.15
3.69	-15.86	50.75
6.85	16.66	58.02
6.59	23.86	27.31
-3.08	46.27	28.89
0.79	-48.97	76.98
-9.5	6.62	12.21
-41.41	-74.42	-.7
-19.02	-12.22	17.25
-38.49	14.93	-1.53
-54.07	-49.72	30.83
-66.94	-37.11	29.92
-9.69	-5.21	-16.9
31.91	0.87	-24.58

// Bulthe J, 2014: Subtraction - Fixation
// Subjects=16
-8	8	60
-50	5	28
-22	-55	40
-44	-86	-8
24	-55	50
-22	66	44
42	-84	-8
32	-52	46
44	-76	-18
-44	-44	42
-46	-62	-20
32	4	64
48	10	28
-26	24	2
44	0	54
-20	8	70
-32	28	-4
-42	38	28
42	2	40

// Demeyere N, 2014: Adaptation to categories (repeated categories pairs vs. 
// different categories pairs)
// Demeyere N, 2014: Repetition of small category versus large category (large 
// < small)
// Demeyere N, 2014: Repetition of small cateogry versus large category (small 
// < large)
// Demeyere N, 2014: Numerosity specific repetition [Rep-Cat > (Rep-num + 
// Rep-Exact)]
// Demeyere N, 2014: Interaction S/L with Cat/Num/Ex
// Demeyere N, 2014: Small num < Small cat
// Demeyere N, 2014: Small exact < Small cat
// Subjects=12
-16	4	54
-10	6	60
-28	12	48
-26	-54	32
-14	4	30
12	38	4
-12	42	20
-14	-40	26
-8	-50	32
-44	-62	24
-36	-52	24
54	-56	20
54	-64	36
-16	32	50
-18	2	44
-8	10	46
44	26	6
16	-40	54
-16	-42	60
-34	-38	44
-36	-60	-2
30	-62	0
24	-50	28
-42	-30	18
26	-14	16
-10	32	24
12	42	18
-12	-42	24
-54	-18	30
-36	-62	4
24	18	2
-38	-60	0
16	16	48
-54	-18	30
26	20	0
-36	-60	-2
-12	10	46
10	4	48
-60	-14	24
24	-46	32
38	24	24

// Garbin G, 2012: Object Noun, Event Noun, and Verb > Object Pseudonoun, 
// Event Pseudonoun, and Pseudoverb
// Garbin G, 2012: Object Noun > Object Pseudonoun
// Garbin G, 2012: Event Noun > Event Pseudonoun
// Garbin G, 2012: Verb > Pseudoverb
// Garbin G, 2012: Object Noun > Event Noun
// Garbin G, 2012: Event Noun > Object Noun
// Garbin G, 2012: Object Noun > Verb
// Garbin G, 2012: Verb > Object Noun
// Garbin G, 2012: Event Noun > Verb
// Garbin G, 2012: Verb > Event Noun
// Garbin G, 2012: Object Noun and Event Noun > Verb
// Garbin G, 2012: Verb > Object Noun and Event Noun
// Garbin G, 2012: Object Noun > Event Noun and Verb
// Garbin G, 2012: Event Noun and Verb > Object Noun
// Garbin G, 2012: Object Pseudonoun > Object Noun
// Garbin G, 2012: Event Pseudonoun > Event Noun
// Garbin G, 2012: Pseudoverb > Verb
// Subjects=12
-46	12	10
-48	-54	14
-54	-36	12
-56	-14	18
48	-2	54
52	14	-12
56	-56	12
62	-44	42
66	-20	22
-60	-32	32
-28	32	22
-44	14	16
-26	10	48
-62	-20	12
46	-34	10
56	-58	14
60	-28	16
-42	18	6
-18	44	12
-58	-4	4
-48	-32	22
-56	-6	16
66	-52	10
50	-40	10
40	-54	6
-46	2	8
-36	-6	14
-34	-4	52
-46	-60	46
-16	-56	66
-24	-16	16
48	0	34
68	-36	-6
68	-32	34
6	-78	42
4	-6	42
-38	14	12
-28	30	14
-32	-36	18
-48	34	34
-30	-4	68
-56	6	-4
-34	-32	4
-56	-18	12
-32	-38	66
-10	-38	0
40	10	10
54	42	2
64	14	22
16	20	56
28	-16	66
44	-14	-8
64	-32	12
48	-66	10
48	-30	28
40	-34	60
10	-10	-4
-36	-8	16
-46	2	8
-34	-4	52
-42	-32	48
-16	-56	66
48	0	34
8	-12	54
68	-32	34
6	-78	42
-32	26	-6
-52	10	2
-42	42	6
-20	48	8
-8	66	8
-38	16	14
-48	26	14
-22	8	64
-60	-2	6
-58	-46	8
-46	-50	22
-46	-34	24
-58	-16	18
-18	80	28
-10	28	20
-8	-10	-4
38	20	-10
28	56	-4
4	0	64
48	-26	-8
64	-28	-2
48	-50	6
52	-62	36
20	-46	32
-38	12	10
-28	30	14
-32	-36	18
-34	2	28
-48	34	34
-34	-32	4
-56	-24	10
-12	-62	48
-10	-38	0
40	10	10
54	42	2
64	14	22
12	36	48
26	-12	62
44	-14	-8
64	-32	12
50	-64	10
40	-34	60
10	-10	-4
-32	26	-6
-42	18	2
-42	42	6
-20	48	8
-8	66	8
-22	8	64
-58	-46	8
-52	-58	30
-58	-16	20
-18	-80	28
-28	-50	50
-10	28	20
38	20	-10
28	56	-4
10	-6	66
48	-26	-10
64	-28	-2
50	-50	8
52	-60	36
6	-72	22
-34	-8	6
-48	4	14
-36	4	26
-34	-2	46
-42	-32	46
-20	18	32
46	0	26
40	-82	8
-32	26	-6
-44	18	0
-42	42	6
-20	48	8
-8	66	88
-38	16	16
-48	26	14
-22	8	64
-60	-2	6
-50	-58	30
-66	-42	10
-58	-16	18
-46	-34	24
-48	-52	22
-12	-56	38
-8	-10	-4
-6	-32	6
38	20	-10
28	56	-4
10	-4	66
50	-28	-10
64	-28	-2
52	-62	36
2	-74	30
-36	-6	14
-34	-4	52
-10	-26	54
-46	-26	38
-48	-58	48
-24	-16	16
48	0	34
4	-6	44
8	-12	52
68	-32	34
6	-78	42
60	-38	50
-38	14	10
-46	8	30
-2	20	40
-54	16	4
-42	42	6
-38	24	18
-58	-46	8
-26	-26	2
-12	-64	50
-34	-50	48
-6	-10	-2
40	4	16
62	6	22
18	22	42
62	10	22
58	6	-12
56	-12	-10
64	-28	18
48	-64	8
32	-86	10
54	-62	30
34	-60	50
32	-30	-6
-36	4	16
-22	-12	50
-28	-28	58
-2	-36	42
-18	-18	6
10	16	34
52	-6	48
42	-32	12
52	-62	38
30	-66	50
6	-52	24
6	-10	4
-26	10	64
-8	-4	-4
32	22	14
46	-74	22
-44	8	32
-48	-4	52
-2	4	58
-26	-58	50
-28	-60	60
16	20	40
30	-72	24
44	-66	42

// Haist F, 2014: Adult Healthy Controls
// Subjects=16
-35	-68	39
-46	-68	39
-48	-46	34
-20	-80	30
-14	-73	22
-3	-46	11
32	-67	24
49	-67	28
44	-52	23
10	-84	23
5	-44	11
-40	40	9
-40	31	19
43	-3	35
3	-59	-35
49	15	-4
62	4	22
31	-2	-19
48	-3	-12
16	-61	-15
-39	-43	48
-30	-66	51
-49	-36	47
-13	-69	45
-25	29	35
-32	9	50
-12	71	2
-60	-43	-28
-12	-73	2
-17	-70	15
-43	-75	25
-44	13	-40
-42	1	-37
22	-65	2
14	-72	12
-44	-62	-40
-12	-75	-18
-25	64	18
-16	66	18
-10	-43	-18
13	-49	50
59	-33	22
53	8	18
10	36	-6
33	6	4
-19	-71	-5
-62	-53	-12
-51	-34	0
-55	-34	7
-12	-70	29
-12	-70	11
2	-73	-1
-55	-28	-1
-64	-32	0
40	-21	7
16	-76	12
14	18	10
20	-8	6
-6	-33	61
-6	-46	63
-5	34	-19
-29	-17	-17
23	-11	-21
3	-62	-16

// Haist F, 2014: Adolescents
// Subjects=14
-35	-68	39
-46	-68	39
-48	-46	34
-20	-80	30
-14	-73	22
-3	-46	11
32	-67	24
49	-67	28
44	-52	23
10	-84	23
5	-44	11
-40	40	9
-40	31	19
43	-3	35
3	-59	-35
49	15	-4
62	4	22
31	-2	-19
48	-3	-12
16	-61	-15
-39	-43	48
-30	-66	51
-49	-36	47
-13	-69	45
-25	29	35
-32	9	50
-12	71	2
-60	-43	-28
-12	-73	2
-17	-70	15
-43	-75	25
-44	13	-40
-42	1	-37
22	-65	2
14	-72	12
-44	-62	-40
-12	-75	-18
-25	64	18
-16	66	18
-10	-43	-18
-5	22	-14
-11	-16	64
29	15	28
23	60	24
26	10	42
14	66	18
3	18	-13
7	-20	65
62	-21	-15
53	-64	12
-10	-15	-1
-25	-75	-24
21	-81	-16

// Haist F, 2014: Children
// Subjects=14
-35	-68	39
-46	-68	39
-48	-46	34
-20	-80	30
-14	-73	22
-3	-46	11
32	-67	24
49	-67	28
44	-52	23
10	-84	23
5	-44	11
-40	40	9
-40	31	19
43	-3	35
3	-59	-35
49	15	-4
62	4	22
31	-2	-19
48	-3	-12
16	-61	-15
-39	-43	48
-30	-66	51
-49	-36	47
-13	-69	45
-25	29	35
-32	9	50
-12	71	2
-60	-43	-28
-12	-73	2
-17	-70	15
-43	-75	25
-44	13	-40
-42	1	-37
22	-65	2
14	-72	12
-44	-62	-40
-12	-75	-18
-25	64	18
-16	66	18
-10	-43	-18
-30	-56	50
-26	-66	51
-56	-28	33
-6	-62	31
-58	-21	44
26	-56	48
33	-55	57
45	-59	54
48	-41	54
7	-42	62
-25	28	48
-26	-8	58
-43	-27	60
-10	-9	45
-29	60	-24
29	62	3
22	-15	53
7	-5	39
-12	-86	-1
-32	-84	-4
-36	-89	17
-17	-65	15
-17	-88	26
-44	-43	-21
-55	-63	14
7	-86	-3
14	-70	12
55	-39	20
40	-38	16
-38	-63	-30
36	55	-9
47	-9	-21
-12	-39	19
10	-43	-18

// Hernandez M, 2014: Verbs > Pseudoverbs
// Subjects=14
-48	-70	34
-42	-58	31
-15	38	46
-6	62	7
-6	56	25

// Holloway I D, 2013: Healthy Controls Bilingual (English + Chinese)
// Subjects=13
-31.49	-64.68	41.87
-47.99	-49.85	-12.72
29.41	-54.54	43.66
29.41	-54.54	43.66
32.59	-54.78	40.3
38.61	47.83	31.62
22.37	-67.6	-42.15
-21.91	-48.5	43.74
6.75	15.63	44.73
35.27	22.23	3.7
45.1	7.97	24.86

// Holloway I D, 2013: Healthy Controls Bilingual (English + non-East-Asian)
// Subjects=13
-31.49	-64.68	41.87
-47.99	-49.85	-12.72
32.59	-54.78	40.3
38.61	47.83	31.62
22.37	-67.6	-42.15
-21.91	-48.5	43.74
6.75	15.63	44.73
35.27	22.23	3.7
45.1	7.97	24.86

// Kadosh R C, 2011: Magnitude Change Dots
// Kadosh R C, 2011: Magnitude Change Digits
// Kadosh R C, 2011: Magnitude Change Dots>Digits
// Kadosh R C, 2011: Magnitude Change Digits>Dots
// Kadosh R C, 2011: Magnitude Change Digits&Dots
// Kadosh R C, 2011: Notation Change Dots
// Kadosh R C, 2011: Notation Change Digits
// Kadosh R C, 2011: Notation Change Dots>Digits
// Kadosh R C, 2011: Notation Change Digits>Dots
// Kadosh R C, 2011: Notation change Digits&Dots
// Kadosh R C, 2011: Visuomotor Change Dots
// Kadosh R C, 2011: Visuomotor Change Digits
// Kadosh R C, 2011: Visuomotor Change Digits&Dots
// Subjects=19
-27	-75	27
-30	-90	18
24	-78	39
27	-51	51
-27	-72	-9
21	-78	-9
-42	-69	-9
-27	-90	-3
-39	-87	-6
33	-87	-3
-27	-75	27
-30	-90	18
24	-78	39
27	-51	51
-27	-72	-9
21	-78	-9
-42	-69	-9
-27	-90	-3
-39	-87	-6
-9	-78	21
-27	-75	27
-30	-90	18
24	-78	39
27	-51	51
-27	-72	-9
21	-78	-9
-27	-90	-3
33	-87	-3
-9	-78	21
27	-51	51
-30	-87	9
-9	-69	6
9	-75	30
15	-63	12
9	-63	15
-27	-75	39
45	-78	-12
-33	-51	45
27	-63	30
6	-87	-3
-6	-87	-6
21	-78	-12
-27	-87	21
12	-93	3
-6	-99	6
-24	-72	-9
21	-90	21
-12	-81	-9
30	-69	-3
9	-96	15
-15	-96	15
30	-81	30
-24	-72	45
30	-75	21
27	-78	39
-27	-79	27
-27	-75	36
30	-54	51
-30	-69	45
-30	-66	57
-30	-54	51
21	-69	42
-42	6	36
39	-90	-6
21	-99	-6
42	-57	-15
3	-81	21
-30	-93	-3
-36	-84	-9
-45	-72	-9
-42	-66	-9
-33	-51	45
27	-63	30
-24	-72	45
30	-75	21
27	-78	39
-27	-79	27
-27	-75	36
30	-54	51
-30	-69	45
-30	-66	57
-30	-54	51
21	-69	42
-42	6	36
6	-87	-3
-6	-87	-6
21	-78	-12
-27	-87	21
12	-93	3
-6	-99	6
-24	-72	-9
21	-90	21
-12	-81	-9
30	-69	-3
9	-96	15
-15	-96	15
30	-81	30
39	-90	-6
21	-99	-6
42	-57	-15
3	-81	21
-30	-93	-3
-36	-84	-9
-45	-72	-9
-42	-66	-9
-27	-72	33
-30	-69	54
-33	-51	45
-30	-69	45
-12	-72	51
30	-63	33
27	-78	39
12	-72	45
33	-60	42
45	-57	-3
-42	6	36
-36	-24	63
-24	-21	75
-30	-33	72
-51	-30	54
-45	-36	63
0	-3	60
3	12	42
-60	-21	15
-51	-24	18
-57	-45	30
-54	-39	24
60	-36	27
57	-30	54
60	-21	21
57	-33	42
42	-42	39
45	-45	48
60	-42	39
33	-48	36
57	18	-3
48	3	6
45	6	3
60	9	15
51	18	-12
12	0	9
0	-9	12
3	-6	9
3	-15	15
3	-27	12
-12	-12	15
6	-63	-12
-18	-24	21
3	-45	6
-3	-36	6
18	-15	24
-12	-18	9
0	-51	0
3	-54	-3
27	-33	9
6	-36	6
-12	0	12
9	-54	-12
3	-75	-12
-48	0	6
-57	6	-3
42	0	57
48	3	39
54	9	39
3	-30	27
36	45	33
39	42	30
36	39	27
9	-66	48
-27	-3	-15
-39	42	27
-36	-24	63
-24	-21	75
-30	-33	72
-51	-30	54
-45	-36	63
0	-3	60
3	12	42
-60	-21	15
-51	-24	18
-57	-45	30
-54	-39	24
60	-36	27
57	-30	54
60	-21	21
57	-33	42
42	-42	39
45	-45	48
60	-42	39
33	-48	36
57	18	-3
48	3	6
45	6	3
60	9	15
51	18	-12
12	0	9
0	-9	12
3	-6	9
3	-15	15
3	-27	12
-12	-12	15
6	-63	-12
-18	-24	21
3	-45	6
-3	-36	6
18	-15	24
-12	-18	9
0	-51	0
3	-54	-3
27	-33	9
6	-36	6
-12	0	12
9	-54	-12
3	-75	-12
-48	0	6
-57	6	-3
42	0	57
48	3	39
54	9	39
3	-30	27
36	45	33
39	42	30
36	39	27
9	-66	48
-27	-3	-15
-39	42	27
-36	-24	63
-24	-21	75
-30	-33	72
-51	-30	54
-45	-36	63
0	-3	60
3	12	42
-60	-21	15
-51	-24	18
-57	-45	30
-54	-39	24
60	-36	27
57	-30	54
60	-21	21
57	-33	42
42	-42	39
45	-45	48
60	-42	39
33	-48	36
57	18	-3
48	3	6
45	6	3
60	9	15
51	18	-12
12	0	9
0	-9	12
3	-6	9
3	-15	15
3	-27	12
-12	-12	15
6	-63	-12
-18	-24	21
3	-45	6
-3	-36	6
18	-15	24
-12	-18	9
0	-51	0
3	-54	-3
27	-33	9
6	-36	6
-12	0	12
9	-54	-12
3	-75	-12
-48	0	6
-57	6	-3
42	0	57
48	3	39
54	9	39
3	-30	27
36	45	33
39	42	30
36	39	27
9	-66	48
-27	-3	-15
-39	42	27

// Notebaert K, 2011: Ratio 1.25 Below > Ratio 1 (Habituation)
// Notebaert K, 2011: Ratio 1.5 Below > Ratio 1 (Habituation)
// Notebaert K, 2011: Ratio 2 Below > Ratio 1 (Habituation)
// Notebaert K, 2011: Ratio 2 Below > Ratio 1.25 Below
// Notebaert K, 2011: Ratio 1.5 Above > Ratio 1 (Habituation)
// Notebaert K, 2011: Ratio 2 Above > Ratio 1 (Habituation)
// Notebaert K, 2011: Ratio 2 Above > Ratio 1.25 Above
// Subjects=13
-42	-50	46
-42	-50	46
-42	-50	46
-42	-50	46
-42	-50	46
-42	-50	46
-42	-50	46

// Price G R, 2011: (conjunction) Arabic digits>Scrambled digits and 
// Letters>Scrambled letters
// Price G R, 2011: (conjunction) Arabic digits>Letters and Arabic 
// digits>Scrambled digits
// Subjects=19
-37.86	-63.14	48.5
-46.53	-61.14	33.93

// Roggeman C, 2011: Different vs. Same Location Deviants
// Roggeman C, 2011: Large vs. Small Numerical Deviants
// Roggeman C, 2011: Far vs. Close Numerical Deviants
// Subjects=23
35	-84	-12
25	-98	9
-25	-97	3
39	-63	45

// Peelen M V, 2012: Action Verbs > Object Nouns
// Peelen M V, 2012: Object Nouns > Action Verbs
// Peelen M V, 2012: State Verbs > State Nouns
// Subjects=27
-53.27	-30.54	3.57
-50.97	-54.16	14.44
-59.45	-45.78	27.22
35.55	-83.65	-3.04
-26.72	-35.35	-19.75
-63.98	-25.4	2.14

// Balodis I M, 2012: Healthy Controls
// Subjects=14
-9	45	24
-51	27	-6
3	-54	54
3	-54	54
-12	45	21
-51	30	-6
-18	18	-6
3	24	-15
9	33	-3
-18	-51	9
48	-9	-9
24	-81	-9
27	-57	54
-60	0	39
-42	-60	3
-18	18	45
-6	48	48
21	60	12
-9	-27	-18
-39	-72	18
-39	-72	18
-51	21	18
-57	-42	-6
-9	-30	-15
27	48	21
-36	42	-21
-42	-72	8
-18	0	36
3	-87	-27
-45	27	-21
-15	-63	18
-45	-69	33
-27	30	51
54	-66	24
-33	-51	3
-30	-93	-27
-3	-60	30
-27	24	48
-21	-18	-18
66	-9	30
54	-69	24
-54	9	-18
-54	-9	36
24	-48	9
0	33	-15
24	-78	-9
-48	12	33
54	12	30
9	42	6
33	-57	15

// Balodis I M, 2012: Pathological Gamblers
// Subjects=14
-9	45	24
-51	27	-6
3	-54	54
3	-54	54
-12	45	21
-51	30	-6
-18	18	-6
3	24	-15
9	33	-3
-18	-51	9
48	-9	-9
24	-81	-9
27	-57	54
-60	0	39
-42	-60	3
-18	18	45
-6	48	48
21	60	12
-6	18	-21
-36	12	60
-63	-33	-15
27	-18	-33
18	-87	-45
-9	72	0
-39	-96	-9
-9	72	0
45	21	-27
6	-60	-3
-18	12	54
-30	-30	-9
54	-3	45
9	-6	12
-15	72	3
-30	-87	12
36	-78	0
12	-36	12
-63	-9	6
9	-63	0
45	-15	6
45	-36	9
-30	-21	-18
18	3	72
3	15	24
24	18	57
3	15	24

// Ritchey M, 2011: Negative, Neutral, & Positive: Control > MDD
// Ritchey M, 2011: Negative & Positive > Neutral: Control > MDD
// Ritchey M, 2011: Negative > Positive: MDD > Control
// Subjects=14
4.98	45.65	-26
29.3	-61.71	-4.58
26.83	-60.37	55.84
-22.6	-65.5	-7.81
-6.14	-83.24	8.24
21.42	-3.97	-18
21.77	16.16	13.61
-26.99	-26.61	-4.86
29.21	-29.6	-5.52
34.12	13.15	49.56
-33.86	10.23	56.61
-2.75	-0.03	36.93
-54.74	-59.18	15.65
9.54	-31.95	62.29
18.37	-57.88	71.42
-47.9	17.5	-25.67
69.6	-4.45	31.65
-2.99	40.82	26.16
52.72	27.71	-13.83
-31.04	29.03	27.81
-2.52	6.09	56.49
-46.99	3.52	42.93
-34.59	10.26	-.53
-21.8	-12.5	65.38
-5.49	-22.56	71.7
-19.48	-26.99	-9.43
-50.75	-26.69	-4.44
-47.45	-53.58	-5.2
-54.74	-59.18	15.65
65.52	-30.01	45.45
13.72	-41.79	48.62
-42.9	-75.92	8.14
-31.1	-84.16	-.21

// Samson A, 2011: Healthy Controls
// Subjects=12
20	-100	8
-8	8	56
-12	-98	-10
6	-34	46
-24	-44	-16
38	-82	32
-26	-88	30
8	14	70

// Samson A, 2011: Major depressive disorder (MDD) group
// Subjects=21
20	-100	8
-8	8	56
-12	-98	-10
6	-34	46
-24	-44	-16
38	-82	32
-26	-88	30
8	14	70
-12	34	38
26	16	40
-12	-48	16
18	-78	14
22	-74	2
-6	76	18

// Samson A, 2011: Subgroup of MDD, Responders
// Subjects=10
-26	-20	20
48	-26	14

// Samson A, 2011: Subgroup of MDD, Non-responders
// Subjects=11
-26	-20	20

// Barrett J, 2011: Own Positive > Unfamiliar Positive
// Barrett J, 2011: Own Negative > Unfamiliar Negative
// Barrett J, 2011: Own Positive > Own Negative
// Subjects=22
52.26	-56.76	-42.29
-53.6	17.62	-20.54
-63.05	-7.05	-8.33
-34.3	-4.64	-21.13
52.23	21.94	-15.43
36.04	23.47	-35.45
-9.52	-5.7	4.33
-15.05	15.45	-10.77
20.18	11.97	-17.57
27.23	-27.52	49.23
49.57	-15.21	41.25
-40.72	1.83	-19.37
17.33	-96.42	-15.14
39.52	52.72	12.25
-33.66	-47.43	44.9
65.41	-13.74	17.52
33.39	-43.25	10.33
39.36	54.35	-7.96
23.94	14.47	55.78
-2.18	72.02	17.8
-11.57	34.75	32.18
17.39	-16.68	25.01
20.7	-74.88	15.36
-22.18	19	35.86
46.11	-8.02	10.57
36.58	-33.46	12.82
23.64	8.05	13.94
49.66	-24.21	48.69
-14.96	26.25	5.05
-1.83	19.64	42.26
10.88	-67.13	-7.48
14.09	-80.32	-13.11

// Billot P E, 2011: Isoamyl Acetate, 1 - Phenyl Ethyl Alcohol, 1
// Billot P E, 2011: Isoamyl Acetate, 3 - Phenyl Ethyl Alcohol, 3
// Billot P E, 2011: Isoamyl Acetate, 6 - Phenyl Ethyl Alcohol, 6
// Subjects=17
7.51	1.46	-.93
11.96	-4.46	18.47
-10.5	-3.7	16.44
-54.46	30.76	11.82
1.02	8.23	-9.23
-25.77	15.04	-15.07
-26.85	-6	-25.56
-3.04	-49.96	-4.3
-15.1	-31.19	-35.85
9.07	11.98	66.2
11.04	37.75	55.09
-37.03	14.57	48.67
43.15	4.39	47.48
12.96	49.79	31.76
-56.49	27.54	25.5
33.04	49.8	2.53
-22.56	56.78	1.47
59.15	-52.9	20.88
-51.92	-58.34	29.3
17.21	0.18	9.1
49.23	21.86	11.38
51.37	-28.57	-7.84
55.62	-37.6	-14.94
63.1	-52.96	-21.54
15.34	-77.28	12.27
26.88	-88.24	-20.4
6.55	-83.16	-21.7
34.25	-83.85	-33.12
6.93	-6.69	58.87
-3.75	-7.81	59.08
-2.82	6.14	46.75
-66.95	-20.74	35.24
-55.37	-21.41	11.75
-51.14	-10.81	10.81
51.44	-5.88	10.33
47.23	-16.22	14.59
41.64	-2.36	-12.15
-39.59	-48	-30.81
-7.49	-86.99	-42.41
-19.42	-21.87	-38.81

// Frodl T, 2011: Subgroup of MDD, Mitrtazapine
// Subjects=11
48	-24	20
4	-10	50
12	0	48
30	-10	62

// Frodl T, 2011: Subgroup of MDD, Venlafaxine
// Subjects=13
-42	-52	-16
-4	-54	6
-8	-44	-24
6	-52	-2
8	52	38

// Zanto T P, 2011: V4 connectivity, Attend > Ignore
// Zanto T P, 2011: V5 connectivity: attend > Ignore
// Subjects=20
-38	30	8
-4	20	40
46	18	4
32	56	14
18	36	40
20	48	-10
44	20	24
38	8	58
-36	4	54
-26	52	-14
-36	-52	42
44	-50	36
36	-70	52
-22	-62	66
8	-60	46
14	-70	62
-50	-22	48
30	-28	48
-36	50	12
-22	0	60
-32	32	16
2	-2	60
58	12	24
4	14	54
-56	8	36
10	10	70
34	-42	38
-8	-66	62
-34	-38	42
-30	-48	60
-44	-42	58
56	-30	52
30	-50	58
18	-62	22

// Aybek S, 2014: (Patient > Healthy Controls) x (Escape > Severe Event)
// Aybek S, 2014: (Patient > Healthy Controls) x (Escape < Severe Event)
// Subjects=12
12	8	68
30	42	72
28	34	54
52	44	20
40	58	24
42	54	30
26	46	-4
22	44	0
28	42	2

// Yoshino A, 2013: MP x LP
// Yoshino A, 2013: (Patient > Healthy Controls) x MP x Neutral
// Yoshino A, 2013: (Patient > Healthy Controls) x LP x Sad
// Yoshino A, 2013: (Patient < Healthy Controls) x MP x Sad
// Subjects=11
8	34	24
6	20	30
-8	6	32
42	0	-4
-40	-8	-6
6	-4	12
-8	-4	14
-18	54	26
-34	24	48
-56	8	8
-16	14	8
-66	-24	34
60	-24	20
-60	-24	20
-2	12	58
50	2	44
-38	-8	62
-56	-62	6
-56	4	10
28	22	-16
50	2	-4
38	-10	-24
28	22	-16
50	2	-4
38	-10	-24
28	22	-16
50	2	-4
38	-10	-24

// Roy M, 2010: Positive vs. Neutral
// Roy M, 2010: Negative vs. Neutral
// Roy M, 2010: All Pictures
// Roy M, 2010: All pictures-positive correlation with symptomatic improvement
// Roy M, 2010: Contrast of positive pictures hits minus positive pictures 
// misses
// Roy M, 2010: Contrast of negative pictures hits minus negative pictures 
// misses
// Roy M, 2010: Contrast of neutral pictures hits minus neutral misses 
// revealed
// Subjects=20
55.53	-68.16	16.9
-43.93	-93.05	8.73
-17.57	-79.85	45.08
20.84	35.9	29.61
-14.41	51.52	-19.52
46.56	-50.91	-4.82
9.39	51.81	-17.72
33.39	-22.97	-15.21
-26.55	-98.85	14.61
-32.73	-64.91	44.98
44.78	-89.67	16.97
52.92	-53.95	-14.72
-37.5	-85.79	5.66
-41.92	-75.58	0.24
46.75	3.05	21.21
-13.56	20.66	40.67
-43.75	3.53	42.87
-18.54	-22.61	-19.96
-1.01	-11.96	1.1
20.71	-30.72	5.94
28.84	-1.69	-28.44
-18.28	52.7	16.28
-12.2	49.71	-16.02
18.44	35.19	10.67
14.8	17.31	60.68
-59.12	-72.79	8.11
55.47	-69.64	12.57
-22.18	20.83	43.04
-12.27	53.55	-20.88
50.8	-67.89	-14.42
-41.77	-89.75	9.49
-26.57	-100.12	12.5
39.9	-27.1	-13.79
-20.68	44.34	-4.14
44.74	7.48	34.25
-56.86	-2.01	30.2
57.52	-17.95	14.14
-39.81	0.64	11.72

// Voon V, 2011: Internal-Fixation vs. External-Fixation
// Voon V, 2011: External-Fixation vs. Internal-Fixation
// Voon V, 2011: External + Internal (CD) vs. External + Internal (HV)
// Voon V, 2011: External + Internal (HV) vs. External + Internal (CD)
// Subjects=11
-8	-4	74
-44	20	0
-36	-56	38
2	14	54
36	0	62
42	48	-4
-6	-56	18
6	-48	24
10	-50	10
10	-48	24
-6	-52	8
-34	22	-4
54	-46	10
-62	-50	4
20	-2	-14
-20	-20	0
-8	-4	74

// Contreras-Rodriguez O, 2014: Criminal Psychopaths
// Subjects=22
32	-86	-8
-22	-92	-8
40	-50	-24
-36	-62	-20
32	-64	46
-30	-48	42
18	-30	-4
-22	-30	-6
-6	-28	-10
12	-18	6
52	14	34
-48	6	38
-2	22	46
24	-62	12
-18	-88	12
-32	2	46
-52	20	14
-2	24	44
32	-86	-10
-20	-94	-6
40	-50	-22
-38	-62	-20
36	-60	48
-32	-52	44
18	-32	-4
-22	-30	-10
-4	-28	-20
10	-16	8
44	12	30
-48	24	24
4	20	48
12	-64	8
-32	2	46
18	-98	0
-24	-96	-6
38	-50	-22
-38	-62	-18
34	-66	52
-28	-48	42
22	-30	-4
-24	-28	-6
10	-24	-10
38	22	24
-50	18	22
-4	20	46
-18	-88	14
-28	-2	50
0	36	40
48	34	16
-44	8	14
-26	6	62
54	42	4
-16	-54	44
20	-92	14
4	-22	-2

// Contreras-Rodriguez O, 2014: Controls
// Subjects=22
32	-88	-8
-22	-94	-8
40	-54	-22
-40	-56	-26
34	-56	46
-30	-50	40
22	-4	-20
22	-30	-4
-22	-30	-2
-6	-26	-10
42	14	26
-44	20	24
-4	18	50
24	-62	12
-18	-88	12
-32	2	46
-52	20	14
-2	24	44
36	-82	-14
-20	-92	-8
40	-54	-22
-38	-62	-22
32	-54	50
-30	-56	44
20	-14	-18
20	-30	-4
-20	-30	-2
6	-30	-6
10	-14	6
42	14	28
-44	22	24
-2	18	50
12	-64	8
-32	2	46
18	-96	-2
-24	-94	-8
38	-54	-22
-38	-52	-26
34	-56	38
24	-30	-4
42	14	22
-44	18	24
-18	-88	14
-28	-2	50

// Jiang W, 2013: Lie-rest>True-Rest
// Jiang W, 2013: True>Rest
// Jiang W, 2013: Lie>True
// Subjects=10
-6	24	42
3	30	39
38	18	57
-51	-45	48
-45	-51	39
-45	12	27
39	9	42
-45	24	30
-42	51	3
-33	54	3
3	30	39
-39	9	42
-45	-51	39
-45	24	30
30	18	57
-51	-45	48
-6	24	42
-45	12	27
-42	51	3
-33	54	3
3	30	39
-39	9	42
-45	-51	39
-45	24	30
30	18	57
-51	-45	48
-6	24	42
-45	12	27
-42	51	3
-33	54	3

// Larson C L, 2013: Early Alternative Focus, Psychopaths > Nonpsychopaths
// Subjects=24
-51.34	15.66	-4.79
-51.46	38.58	-11.17
-23.71	51.52	-11.46

// Prehn K, 2013: Antisocial offenders with hypo-reactivity (EHO group)
// Subjects=11
-36	-3	51
-33	-9	45
9	42	-6
9	33	-9
-27	-84	-33
-30	-78	30
-42	-75	36
54	36	3
42	-75	-15
-18	-27	27
-24	-33	24
36	-27	-3
30	0	21
24	9	39
-21	-42	21

// Prehn K, 2013: Antisocial offenders with emotional hyper-reactivity (EHE 
// group)
// Subjects=12
-31	-29	-24
-27	-84	-33
-30	-78	30
-42	-75	36
42	-75	-15
-18	-27	27
-24	-33	24
36	-27	-3
-21	-42	21
-24	-54	15

// Prehn K, 2013: Healthy Controls
// Subjects=13
-36	-3	51
-33	-9	45
9	42	-6
9	33	-9
-31	-29	-24
54	36	3
-18	-27	27
-24	-33	24
36	-27	-3
30	0	21
24	9	39
-21	-42	21
-24	-54	15

// Pujara M, 2014: Gain x loss
// Subjects=18
-21	9	-9
-12	-66	60
-36	42	39
-39	57	15
-45	-66	6

// Reniers R L E P, 2012: Moral > Non-Moral
// Reniers R L E P, 2012: Non-Moral > Moral
// Reniers R L E P, 2012: Moral > Baseline
// Reniers R L E P, 2012: Non-Moral > Baseline
// Reniers R L E P, 2012: Baseline > Moral
// Reniers R L E P, 2012: Baseline > Non-Moral
// Subjects=24
-28.84	35.83	31.58
-3.25	53.09	8.15
-7.74	56.19	-4.41
-57.62	-37.89	48.33
-2.49	-33.13	50.28
-53.39	-42.96	39.79
-29.05	-78.39	-7.54
0.91	-65.16	-28.41
14.06	-75.78	-16.38
-7.51	63.38	15.04
-2.87	49.41	37.64
9.72	61.96	10.41
-46.8	36.21	-20.82
-46.76	28.86	-18.97
56.38	30.84	19.42
-3.07	27.13	17.43
-42.12	8.31	2.03
-50.76	8.28	2.18
-7.75	-16.08	-19.67
-54.62	-65.28	-61.07
-63.19	-57.14	-53.88
-54.35	2.38	-26.31
55.78	6.6	-33.08
-28.42	-45.23	48.56
-33.13	-88.65	9.23
36.24	-81.22	27.49
-28.94	-90.74	-1.84
-33.36	-69.59	-4.98
-42.03	-62.17	-5.56
-7.35	-86.41	-2.63
14.42	-92.74	8.83
27.15	-82.45	-8.1
5.16	-61.31	-33.35
35.54	-67.92	-25.36
9.77	-79.94	-14.77
-7.35	60.26	27.68
-7.19	49.4	37.71
14.56	42.86	46.95
14.47	49.89	41.78
9.77	63.44	14.74
-54.22	25.21	-11.76
-53.7	26.92	29.52
56.42	31.15	22.75
48.84	26.56	19.97
-2.7	25.47	45.61
-41.52	8.42	49.08
40.55	4.04	43.63
-50.39	11.08	32.15
-37.06	-11.36	55.44
-16.26	5.65	-4.87
-7.45	-9.44	5.44
-53.53	-57.18	25.52
-38.25	13.72	-32.19
-66.7	-46.67	12.37
-51.16	1.97	-30.8
-28.42	-45.23	48.56
-28.82	-84.38	8.74
-28.63	-78.57	24.97
36.24	-81.22	27.49
-29.05	-78.39	-7.54
-46.38	-66.75	-8.4
-2.99	-86.08	0.62
14.42	-92.74	8.83
27.15	-82.45	-8.1
22.33	-45.71	-39.66
5.13	-65.87	-36.26
9.77	-79.94	-14.77
5.07	54.03	-16.74
48.4	51.72	-9.41
0.91	43.14	-6.63
-2.83	7	31.75
10.33	-25.41	40.33
-20.04	-57.06	24.93
22.68	-36.52	-10.32
-46.52	-3.28	-6.83
44.18	5.45	-10.36
-37.89	-12.07	-9.47
-50.67	-18.41	3.7
-53.71	-28.98	17.13
64.9	-13.86	0.16
53.13	-60.05	0.45
60.64	-60.43	-4.12
-62.39	-21.57	16.54
-19.54	-39.08	67.97
60.97	-31.69	27.77
-11.26	-64.71	34.5
18.85	-56.92	24.26
14.97	-39.37	62.93
14.68	-67.81	34.37
5.07	54.03	-16.74
27.28	39.97	26.85
15.03	-38.96	67.37
0.95	43.46	-3.3
5.34	39.63	1.49
-7.06	-14.19	35.04
6.01	-25.42	40.41
5.9	-22.96	32.32
18.78	-54.15	19.5
5.78	-32.61	20.95
22.69	-40.78	-9.9
-46.52	-3.28	-6.83
44.28	-15.72	-7.15
44.13	-3.68	-16.18
-46.33	-22.65	4.05
56.44	-28.9	11.88
-58.14	-60.44	2.38
53.18	-59.73	3.78
60.63	-57.24	-4.44
-19.54	-39.08	67.97
-66.54	-23.63	29.14
65.39	-25.53	36.05
-11	-39.78	60.05
-6.91	-72.14	35.17
10.38	-72.08	34.87
19.25	-39.67	59.52

// Sadeh N, 2013: Fearless-dominance, Positive vs. Neutral
// Sadeh N, 2013: Implusive-Antisociality, Positive vs. Neutral
// Sadeh N, 2013: Impulsive-Antisociality, Negative vs. Neutral
// Sadeh N, 2013: Fearless-dominance x impulsive-antisociality, Negative vs. 
// Neutral
// Subjects=49
11	18	66
-65	-46	32
-45	8	-24
-59	-31	-12
-47	-63	35
-5	65	-5
-15	29	53
-27	-8	-23
-5	-80	28
41	-21	50
-20	-23	67
-1	-10	51
36	-17	7
30	19	-17
-61	-21	-10
-53	-44	3
-41	-53	42
58	-7	21
-51	-9	30
-3	35	33
-2	64	-20

// van Beilen M, 2011: Healthy Controls
// Subjects=21
-38	-34	60
-36	-20	16
14	-54	-18
38	-28	58
18	-20	2
-12	-54	-22
-8	20	42
-56	-42	38
54	42	46
62	-18	28
28	64	2
50	38	14
-10	-66	34
28	-42	-24
52	4	26
56	-46	28
52	6	-8
-48	14	-10
-10	20	40
6	14	34
-52	16	8
-28	-36	71
10	-58	2
-16	-13	-12
22	-32	-24
-8	10	60
40	10	46
-48	14	10
-6	18	40
-34	46	24
-54	12	30
-56	-26	28
-22	-70	50
-8	4	10
32	38	28
54	8	0
60	-40	36
6	-70	40
-20	-54	8
-48	-42	26
26	-76	-4
-16	-48	-26
54	4	16
-10	20	40
-8	-62	-48
16	-60	42
46	-8	50
0	8	62
6	14	32
-8	16	42
52	-42	50
-44	18	4
44	2	-4
-36	50	12
-50	-38	26
-8	-14	58
12	-8	60
52	-32	36
44	-76	-12
30	44	36
36	16	46
52	2	4
-58	-24	28
-36	-44	64
-46	-34	26
52	-2	4
-46	-40	58
26	36	24
26	24	52
-54	-38	-6
32	-32	8
52	-32	36
-2	-42	12
48	38	14
40	-10	46
56	-46	28
-10	20	10
-48	14	-10
-46	-34	28

// van Beilen M, 2011: Conversion Patients
// Subjects=9
-10	-8	52
-30	-30	54
28	-68	2
4	-20	52
38	-28	58
48	40	8
38	22	8
8	60	34
38	-6	-4
-2	-52	-44
-34	-22	52
12	-56	-20
36	-26	60
38	4	14
-22	52	-26
-8	20	42
44	40	22
54	-40	46
28	64	2
50	38	14
-10	-66	34
28	-42	-24
52	4	26
56	-46	28
52	6	-8
-48	14	-10
-10	20	40
6	14	34
-52	16	8
-12	8	70
4	8	66
-36	54	0
28	62	2
42	38	16
46	46	-2
-52	-44	48
52	-48	46
-10	-66	36
8	-66	36
-32	-74	44
-8	34	36
10	40	46
-20	-54	8
-48	-42	26
26	-76	-4
-16	-48	-26
54	4	16
-10	20	40
34	-10	60
-10	-8	64
8	-4	72
-32	-44	40
34	-40	52
10	-22	76
30	-30	48
56	-46	14
58	-34	26
-8	8	42
6	-2	44
-46	-66	4
-12	-26	38
-6	60	2
-6	-64	10
-24	-46	-8
-50	-38	26
52	0	6
12	4	68
-14	8	70
-38	-44	64
-34	-76	32
62	-42	18
-46	-34	26
-10	-4	64
56	8	0
36	40	28
-20	-82	-14
-46	-34	-28
40	-12	-12
48	38	14
40	-10	46
56	-46	28
-10	20	10
-48	14	-10
-46	-34	28

// van Beilen M, 2011: Feigners
// Subjects=13
-34	-22	52
12	-56	-20
36	-26	60
38	4	14
-22	52	-26
-56	-42	38
54	42	46
44	40	22
54	-40	46
62	-18	28
-28	-36	71
10	-58	2
-16	-13	-12
22	-32	-24
-8	10	60
40	10	46
-48	14	10
-6	18	40
-34	46	24
-54	12	30
-56	-26	28
-22	-70	50
-8	4	10
32	38	28
54	8	0
60	-40	36
6	-70	40
-12	8	70
4	8	66
-36	54	0
28	62	2
42	38	16
46	46	-2
-52	-44	48
52	-48	46
-10	-66	36
8	-66	36
-32	-74	44
-8	34	36
10	40	46
-8	-62	-48
16	-60	42
46	-8	50
0	8	62
6	14	32
-8	16	42
52	-42	50
-44	18	4
44	2	-4
-36	50	12
34	-10	60
-10	-8	64
8	-4	72
-32	-44	40
34	-40	52
10	-22	76
30	-30	48
56	-46	14
58	-34	26
-8	8	42
6	-2	44
-46	-66	4
-12	-26	38
-6	60	2
-6	-64	10
-24	-46	-8
-8	-14	58
12	-8	60
52	-32	36
44	-76	-12
30	44	36
36	16	46
52	2	4
-58	-24	28
-36	-44	64
52	0	6
12	4	68
-14	8	70
-38	-44	64
-34	-76	32
62	-42	18
52	-2	4
-46	-40	58
26	36	24
26	24	52
-54	-38	-6
32	-32	8
52	-32	36
-2	-42	12
-10	-4	64
56	8	0
36	40	28
-20	-82	-14
-46	-34	-28
40	-12	-12
48	38	14
40	-10	46
56	-46	28
-10	20	10
-48	14	-10
-46	-34	28

// Bruhl A B, 2011: Reboxetine > Placebo: Negative vs. Neutral
// Bruhl A B, 2011: Citalopram > Placebo: Negative vs. Neutral
// Bruhl A B, 2011: Reboxetine > Citalopram: Negative vs. Neutral
// Bruhl A B, 2011: Reboxetine > Citalopram: Positive vs. Neutral
// Bruhl A B, 2011: Citalopram > Reboxetine: Positive vs. Neutral
// Subjects=16
22.04	-10.6	75.75
10.96	-20.15	22.03
-5.03	-23.16	25.81
-30.74	-33.86	13.62
-69.38	-2.97	3.67
68.45	-45.1	-16.68
-53.38	-62.46	-23.87
46.32	-91.53	4.19
-40.23	-101.82	2.7
24.13	-96.75	34.99
8.1	-75.99	43.47
4.28	-82.35	-38.47
4.42	2.56	13.51
-5.37	19.45	-1.18
14.07	-27.76	5.91
-34.17	-82.4	-35.8
45.77	47.79	-10.83
59.78	42.56	2.83
68.72	-62.07	11.5
27.24	-103.22	19.89
14.24	36.62	54.03
6.92	0.75	-78.93
-1.9	51.87	46.25
42.84	27.62	17.66
7.63	47.73	33.1
-1.5	-13.2	71.78
26.54	37.9	-13.13
-56.27	-3.15	41.45
62.38	-5.36	43.62
36.8	-57.55	31.56
-27.31	-57.94	32.33
-37.13	-53.45	8.65
17.06	-10.25	-15.67
-47.84	-93.38	-11.3
13.81	22.22	-8.32
4.26	22.94	1.77
-5.35	-12.24	-11.9
-29.93	-11.33	-11.69
-21.34	-21.77	-9.8
20.48	6.34	19.7
-14.78	3.93	19.19
1.22	-16.04	7.3
-21.16	-17.69	15.5
20.52	-20.69	14.16
41.68	-56.86	-28.77
26.75	-40.14	-17.74
-27.76	-44.96	-20.05
-41.68	-64.04	-31.67
-21.33	10.18	4.25
2.39	26.72	37.16
-2.13	-72.44	-33.65
-18.13	-59.07	-24.55
-34.27	-63.63	-40.72
29.91	16.49	-1.33
-17.72	31.91	64.83
-66.27	-7.15	-9.4

// Cooney R E, 2010: Major depressive disorder
// Subjects=14
1.12	43.32	17.94
58.37	-53.17	58.83
-35.25	9.75	-0.02
-26.47	15.55	32.85
37.82	-72.32	19.41
61.06	-9.08	9.37
1.57	-51.96	38.19
-71.53	-31.59	-8.4
12.93	-30.74	-4.98
-7.17	16.35	41.48
-10.26	-72.61	19.98
28.64	27.63	-22.33
42.18	-42.92	41.42
5.13	52.75	-11.9
-26.2	-97.02	22.21
-67.28	-24.16	-9.08

// Cooney R E, 2010: Healthy Controls
// Subjects=14
37.57	-58.43	-7.41
-42.07	-70.23	53.6
-39.16	-89.67	8.36
-51.11	-9.41	15.15
57.86	-1.35	13.22
13.53	-73.87	56.62
22	-8.75	72.25
29.6	-65.69	64.67
-14.44	-92.47	25.04
1.01	62.01	11.91
10.29	-69.92	52.98
28.95	63.8	32.63

// Herwig U, 2010: Major depressive disorder
// Subjects=14
-40.48	36.18	25.7
-47.8	9.24	35.85
-49.21	22.19	-3.13
44.78	26.64	-9.05
-32.19	18.17	-15.26
1.29	38.52	38.41
2.57	13.2	55.02
-10.58	2.13	9.26
43.83	21.31	4.79
2.24	-13.2	2.59
9.63	-21.84	-13.5

// Seo Y, 2010: Positive correlation between age and sexual brain, ERO vs. HA
// Seo Y, 2010: Negative correlation between age and sexual brain, ERO vs. HA
// Seo Y, 2010: ERO vs. HA
// Seo Y, 2010: Food vs. Nature
// Subjects=21
26	-78	-16
22	-2	-22
4	4	12
44	44	12
12	12	6
24	4	52
32	18	36
-24	32	28
-24	-8	48
-26	4	62
-52	6	32
-24	30	-8
-34	18	-12
40	20	-6
-4	38	52
-38	-8	42
-2	22	22
0	40	16
6	44	20
12	0	14
-32	-56	48
-48	-70	-6
40	-76	8
50	-78	-20
-46	-70	20
68	-52	14
-4	-10	-16
22	-32	4
26	2	-14
2	-52	-36
28	-62	-48
36	-70	-12
-44	-60	-20
38	-82	-6
-26	-90	4
42	-64	-18
-22	-76	-12
-34	4	-18
-28	2	-22

// Plailly J, 2011: Familiar - Unfamiliar: Olfaction and Music
// Plailly J, 2011: Familiar - Unfamiliar: Olfaction
// Plailly J, 2011: Familiar - Unfamiliar: Music
// Plailly J, 2011: Unfamiliar - Familiar: Olfaction and Music
// Plailly J, 2011: Unfamiliar - Familiar: Olfaction
// Plailly J, 2011: Unfamiliar - Familiar: Music
// Subjects=13
-6	54	-4
-21	21	56
-6	48	39
-6	36	39
-3	39	35
-39	9	35
-51	30	0
-51	27	11
-39	-39	39
-39	-39	25
-51	-51	21
-48	-48	18
-3	-3	28
12	39	7
-36	-15	14
-3	60	60
-33	12	12
-27	6	6
-33	-3	-3
-45	-75	-75
-54	-21	-21
-51	-57	-57
-3	-39	-39
-60	-45	-45
-45	-48	-48
48	-60	-60
30	24	7
27	21	46
60	-39	32
63	-51	25
12	24	35
-48	-24	46
-27	-18	56
-39	-21	18
39	-39	32

// Reske M, 2010: Correlation analysis: BOLD signal for Rotten yeast vs. 
// Vanilla stimulation and Age
// Reske M, 2010: Rotten yeast vs. Vanilla
// Reske M, 2010: Rotten yeast vs. Ambient air
// Reske M, 2010: Vanilla vs. Ambient air
// Subjects=15
-46	18	30
-4	4	12
44	-34	10
-38	-42	10
52	-16	8
-46	-6	38
56	4	40
-12	14	46
-62	6	18
-4	58	-16
-34	32	-18
32	48	-8
-48	8	12
-28	22	8
-42	36	26
12	50	40
6	28	44
20	2	68
-12	14	44
-46	-6	38
58	6	40
64	10	26
42	-12	38
50	-4	20
-62	0	26
-54	-14	24
-2	58	-16
64	-26	-24
-64	-54	-10
-36	-80	44
54	-40	46
-26	-4	-28
-22	16	18
-10	10	4
-42	-72	32
32	62	20
-28	60	20
54	-46	32

// Burgmer M, 2011: Pain anticipation (with information on pain intensity): 
// FMS Patients > Healthy Controls
// Subjects=12
38	18	40
-24	-58	42
-6	-40	-2

// de Greck M, 2013: Somatoform Patients
// Subjects=20
32.9	58.2	-12.67
-24.75	-4.21	-30.19
-14.56	47.96	65.68
-34.35	-17.22	-32.34
-34.46	17.93	-31.94
20.11	22.2	-22.89
-37.4	37.12	9.98
-21.52	-3.94	-26.91
-37.91	84.53	-37.49
32.9	58.2	-12.67
35.79	87.89	-41.96
22.93	90.73	-45.4
-34.35	-17.22	-32.34
-14.56	47.96	65.68
-34.35	-17.22	-32.34
-34.46	17.93	-31.94
20.11	22.2	-22.89
-37.4	37.12	9.98
-21.52	-3.94	-26.91
-37.91	84.53	-37.49
32.9	58.2	-12.67
35.79	87.89	-41.96
22.93	90.73	-45.4

// de Greck M, 2013: Healthy Subjects
// Subjects=20
-46.76	-9.75	24.05
49.31	-3.6	12.4
7.88	-54.09	23.8
49.01	42.7	-8.21
-49.85	14.49	48.82
55.88	11.18	37.85
7.99	6.35	62.22
23.89	54.54	64.69
-11.94	12.24	-25.03
23.35	6.11	-24.92
17.15	-11.42	-3.31
-24.02	95.62	-33
33.7	91.73	-33.34
-29.38	91.01	-37.01
-41.02	48.13	-39.97
47.61	78.79	-36.87
49.81	53.08	-39.2
-49.97	-22.97	18.51
49.34	-3.35	15.72
7.97	9.52	61.95
55.9	11.44	41.17
-49.84	11.32	49.09
20.69	57.95	67.78
-18.31	-.49	-23.89
23.35	6.11	-24.92
-41.09	84.77	-34.12
35.8	91.32	-38.9
42.28	52.52	-45.76
-46.9	-27.67	-1.21
-2.72	10.43	60.89
4.7	7.67	52.11
-41.09	84.77	-34.12
29.41	91.54	-35.5
42.33	46.43	-41.9
30.86	-5.57	-25.14
11.19	6.37	62.18
-24.78	15.33	-25.14
21.19	10.24	-26.36
-37.89	84.79	-34.16
32.61	88.13	-38.6
-37.8	49.38	-37.89
-50.03	-20.32	11.59
4.78	6.33	62.26
23.36	8.48	-21.77
-41.09	84.77	-34.12
42.26	78.67	-37.92
32.9	58.2	-12.67
-24.75	-4.21	-30.19
-14.56	47.96	65.68
-34.35	-17.22	-32.34
-34.46	17.93	-31.94
20.11	22.2	-22.89
-37.4	37.12	9.98
-21.52	-3.94	-26.91
-37.91	84.53	-37.49
32.9	58.2	-12.67
35.79	87.89	-41.96
22.93	90.73	-45.4

// Karama S, 2011: Amusement - Neutral
// Karama S, 2011: Disgust - Neutral
// Karama S, 2011: Sexual Arousal - Neutral
// Karama S, 2011: Conjunction Analysis: Amusement - Neutral / Disgust - 
// Neutral / Sexual Arousal - Neutral
// Karama S, 2011: Amusement > Disgust and Sexual Arousal
// Karama S, 2011: Disgust > Amusement and Sexual Arousal
// Karama S, 2011: Sexual Arousal > Amusement and Disgust
// Subjects=18
-45	10	30
-44	0	40
12	2	72
44	0	54
-60	-44	2
-58	-48	8
-52	-28	-12
-52	-12	-20
54	-48	4
52	0	-24
-62	-44	26
-30	-48	62
56	-36	20
34	-42	6
38	-84	-14
4	-94	8
-52	-58	8
-6	-52	42
8	-56	50
-2	-4	-4
-22	-18	-16
-6	-38	-42
4	-4	-6
8	-36	-42
-20	-86	-27
18	-80	-42
0	-62	-26
-10	66	18
-46	8	28
14	64	20
54	22	32
-54	-44	6
-54	-18	-18
-52	-34	-6
58	-12	-22
-36	-50	62
-60	-36	20
38	-44	48
62	-38	14
-26	-88	4
-54	-48	4
-12	2	14
16	10	14
8	-32	-20
2	-62	-38
-40	12	28
-40	4	40
48	4	52
54	14	30
-62	-44	14
-62	-30	20
-28	-54	62
62	-28	38
36	-54	58
52	-68	-12
2	-78	0
-40	6	-4
-2	-54	56
4	-54	58
-16	-16	-18
-10	14	2
-4	-32	-40
14	12	4
4	-30	-32
-44	-54	-30
0	-68	-36
-6	14	52
-48	12	28
-44	4	42
40	28	-18
2	14	48
50	6	30
44	4	48
-50	-40	2
-48	-30	24
60	-30	26
44	-50	-24
-50	-54	-4
12	-18	38
-2	-4	-4
-20	-14	-18
0	-62	-36
-60	-46	2
-52	-28	-12
-54	4	-24
68	-40	-2
34	8	-40
0	-56	54
4	-92	10
-52	-44	8
64	-56	18
-36	30	4
68	-24	30
-28	-60	-10
32	-62	-8
-26	-88	6
-26	-94	24
32	-90	12
40	8	-14
0	-16	-18
0	-30	-20
-8	-6	-10
-26	-6	-16
-7	-6	-12
0	-70	-10
-4	40	-16
0	38	-16
4	38	-16
-56	-62	-12
42	-74	-10
-22	-54	68
-26	-74	52
28	-50	70
36	-54	56
-4	36	-14
-4	-38	32
-8	-78	44
-2	-76	48
4	36	-12
2	-38	32
6	-78	50
8	-70	38
-28	-60	-30

// Lee S J, 2013: FM Patients
// Subjects=23
-51	6	27
54	8	27
-36	-9	63
36	-9	63
-51	-29	51
51	-29	51
-36	-48	57
40	-36	57
-3	0	57
3	0	57
-24	-3	0
-30	-54	-27
30	-54	-27
-3	12	30
3	12	30
-54	6	29
54	6	29
-27	-15	57
27	-15	63
-45	-30	45
50	-27	45
-6	6	51
-15	-21	13
15	-21	13
-15	-71	-12
15	-71	-12
-51	6	27
54	8	27
-36	-9	63
36	-9	63
-51	-29	51
51	-29	51
-3	0	57
3	0	57
-36	-48	57
36	-48	57
-33	15	3
-24	-3	0
-30	-54	-27
30	-54	-27
-51	6	27
54	8	27
-36	-9	63
36	-9	63
-51	-29	51
51	-29	51
-36	-48	57
36	-48	57
-3	0	57
3	0	57
-24	-3	0
-30	-54	-27
30	-54	-27
-7	18	36
-54	10	32
54	10	32
-36	-9	63
36	-9	63
-45	-36	52
45	-36	52
-42	-48	57
42	-48	57
-6	0	57
-37	14	9
-18	5	3
18	5	3
-15	-16	9
15	-16	9
-27	-23	-12
-9	-18	-12
9	-18	-12
-33	-52	-24
33	-52	-24
54	8	27
-36	-48	57
-3	0	57
30	-54	-27

// Lee S J, 2013: Healthy Controls
// Subjects=24
-3	12	33
3	12	33
-54	10	32
54	10	32
-36	-9	63
36	-9	63
-45	-36	52
45	-36	52
-36	-48	57
36	-48	57
-6	0	57
6	0	57
-33	18	0
33	18	0
-21	9	0
21	9	0
-9	-16	9
9	-16	9
-30	-18	-15
-30	-18	-15
-9	-18	-12
9	-18	-12
-33	-52	-24
33	-52	-24
-3	12	30
3	12	30
-54	6	29
54	6	29
-27	-15	57
27	-15	63
-45	-30	45
50	-27	45
-6	6	51
-15	-21	13
15	-21	13
-15	-71	-12
15	-71	-12
-51	6	27
54	8	27
-36	-9	63
36	-9	63
-51	-29	51
51	-29	51
-3	0	57
3	0	57
-36	-48	57
36	-48	57
-33	15	3
-24	-3	0
-30	-54	-27
30	-54	-27
-3	12	33
3	12	33
-54	10	32
54	10	32
-36	-9	63
36	-9	63
-45	-36	52
45	-36	52
-36	-48	57
36	-48	57
-6	0	57
6	0	57
-33	18	0
33	18	0
-21	9	0
21	9	0
-9	-16	9
9	-16	9
-30	-18	-15
-30	-18	-15
-9	-18	-12
9	-18	-12
-33	-52	-24
33	-52	-24
-51	6	27
54	8	27
-36	-9	63
36	-9	63
-51	-29	51
51	-29	51
-36	-48	57
36	-48	57
-3	0	57
3	0	57
-24	-3	0
-30	-54	-27
30	-54	-27
-7	18	36
-54	10	32
54	10	32
-36	-9	63
36	-9	63
-45	-36	52
45	-36	52
-42	-48	57
42	-48	57
-6	0	57
-37	14	9
-18	5	3
18	5	3
-15	-16	9
15	-16	9
-27	-23	-12
-9	-18	-12
9	-18	-12
-33	-52	-24
33	-52	-24
-45	-36	52

// Lopez-Sola M, 2014: Healthy Controls
// Subjects=25
-52	-14	-6
-70	-30	6
48	-24	-4
74	-24	-2
22	-88	-20
0	-100	-14
46	-8	0
20	-54	-12
62	-18	2
-64	-32	12
28	-28	-4
-30	-30	-3
4	-88	-8
16	-56	-26
-44	-32	54
66	-14	22
-54	-40	22
42	0	2
-40	0	2
24	2	0
-24	-2	0
12	-20	8
-12	-22	2
-10	-22	-4
54	10	12
-56	8	14
54	10	32
-58	6	28
-4	-2	50
16	-104	-6
74	-26	-4
-68	-10	-4
20	-54	-30
16	-104	-6
74	-26	-4
-68	-10	-4
20	-54	-30
16	-104	-6
74	-26	-4
-68	-10	-4
20	-54	-30
-52	-14	-6
-70	-32	6
72	-24	0
50	-18	-10
2	-96	-12
-32	-20	6
44	-24	-10
46	-8	0
20	-56	-12
-28	-78	-2

// Lopez-Sola M, 2014: FM Patients
// Subjects=35
-52	-14	-6
-70	-30	6
48	-24	-4
74	-24	-2
22	-88	-20
0	-100	-14
46	-8	0
20	-54	-12
54	-16	4
-50	-20	10
36	-8	-14
-18	-30	-2
6	-90	-6
22	-56	-24
-44	-26	52
58	-28	20
-56	-36	22
42	0	2
-38	4	2
26	6	0
-20	-2	-2
14	-22	8
-12	-22	8
-8	-26	-4
52	10	6
-52	4	6
58	10	32
-58	6	28
-4	-2	52
2	-86	-12
62	-24	4
-54	-12	0
40	-88	-20
-6	-92	-22
-10	-92	-23
62	-24	2
-56	-16	0
16	-104	-6
74	-26	-4
-68	-10	-4
20	-54	-30
16	-104	-6
74	-26	-4
-68	-10	-4
20	-54	-30
16	-104	-6
74	-26	-4
-68	-10	-4
20	-54	-30
-52	-14	-6
-70	-32	6
72	-24	0
50	-18	-10
2	-96	-12
-32	-20	6
44	-24	-10
46	-8	0
20	-56	-12
-28	-78	-2
68	-16	-2
-70	-30	12

// Berent-Spillson A, 2012: Deep Processing vs. Shallow Processing
// Berent-Spillson A, 2012: 4-Second Delayed Match vs. 1-Second Delayed Match
// Subjects=56
-56	24	-10
38	26	4
-4	26	50
52	22	30
-54	22	20
-38	22	-40
-56	-16	-34
-34	-66	44
-2	16	52
-52	10	28
26	-74	56
-24	-74	54

// Berent-Spillson A, 2010: Post-Menopausal Women
// Subjects=55
50	32	2
6	24	42
54	20	8
-40	14	6
-26	-54	46
20	-58	52
40	-40	38
4	-28	0

// Berent-Spillson A, 2010: Subgroup of Post-Menopausal Women, Estrogen 
// Therapy
// Subjects=17
54	20	6
8	60	0
12	30	36
-40	14	12
58	-62	28
-26	-60	52
-18	-30	-14
2	-36	32
2	-28	-2
24	26	48
-30	20	42
-44	4	-16
46	-16	-2
-44	-28	12
60	-62	28
-50	-72	18
2	-20	44
54	-8	52

// Berent-Spillson A, 2010: Subgroup of Post-Menopausal Women, Estrogen Plus 
// Progestin Therapy
// Subjects=20
54	20	6
8	60	0
12	30	36
-40	14	12
58	-62	28
-26	-60	52
-18	-30	-14
2	-36	32
2	-28	-2
-12	14	62
-28	8	10
56	18	4
-44	6	-16
-42	-30	16
60	-54	38
-20	-42	4
0	-28	-4
54	-8	52

// Berent-Spillson A, 2010: Subgroup of Post-Menopausal Women, Never Treated
// Subjects=28
54	20	6
8	60	0
12	30	36
-40	14	12
58	-62	28
-26	-60	52
-18	-30	-14
2	-36	32
2	-28	-2
24	26	48
-30	20	42
-44	4	-16
46	-16	-2
-44	-28	12
60	-62	28
-50	-72	18
2	-20	44
-12	14	62
-28	8	10
56	18	4
-44	6	-16
-42	-30	16
60	-54	38
-20	-42	4
0	-28	-4

// Burgmer M, 2012: Secondary hyperalgesia: FMS > HC
// Burgmer M, 2012: Secondary hyperalgesia: FMS < HC
// Subjects=17
-44	38	-2
12	-28	72
-16	-48	68

// Loggia M L, 2014: Healthy Controls
// Subjects=14
-36	-4	48
-30	-60	-22
48	-28	16
-2	-4	68
52	-60	12
-62	-38	20
4	-28	-4
12	-18	38
34	-78	-10
-10	-8	66
16	-4	66
-10	-20	12
-52	-64	8
-4	-78	-2
-10	-68	8
56	-50	20
12	2	16
-10	2	8
18	-38	64
32	-26	14
20	-76	-40
4	-4	42
-12	-44	64
40	24	4
20	-62	10
12	-16	14
14	-22	70
42	-2	46
-16	2	0
-16	-18	70
6	-14	-10
-4	28	54
22	-52	52
-30	-46	44
-44	8	-6
26	-30	-24
-38	-22	0
-60	-36	36
-4	18	-12
-10	-58	4
20	-62	10
-10	-56	26
20	-58	-6
-18	-62	6
4	-6	68
8	-12	44
-22	-6	64
48	-28	16
40	-14	4
-6	-4	8
0	-28	-4
-16	2	4
6	-20	6
-8	18	4
6	-12	-12
16	-98	-4
-14	-98	2
10	-72	18
22	-82	16
56	-24	20
8	-72	-24
-8	-68	-4
-26	-72	34
-30	-62	-22
-8	-86	0
-54	-26	20
-18	-10	-2
-34	-24	4
6	-14	-12
-12	-18	-2
-24	-2	0
-34	2	2
6	-26	-2
38	22	14
38	8	-12
60	8	16
42	-10	4
46	20	-2
26	-2	2
-28	30	52
-20	-30	78
-4	68	4
-18	0	22
-30	-46	70
12	64	8
-10	58	38
40	-24	64
28	-48	68
-38	34	40
-16	-44	74
14	-44	74
-14	-50	74
6	-36	56
-28	2	68
-26	48	-8
-40	-90	-6
52	12	44
-42	-14	64
-62	-56	-10
24	36	32
-44	-22	-20
-8	-42	72
6	-42	56
-34	26	8
18	20	64
4	36	-2
-56	-44	50
-4	34	0
-4	32	20
-30	24	8
8	8	54
26	-46	70
2	32	46
-18	20	2
0	14	48
14	-28	76
6	44	16
-22	16	4
-16	-44	74
-14	-50	74
-60	-28	48
-46	-12	58
-50	42	-2
-36	30	48
-8	42	56
-44	18	10
-43	18	8

// Loggia M L, 2014: FM Patients
// Subjects=31
-10	-34	68
34	-88	-12
-10	-32	68
52	-42	14
30	-50	44
-36	-24	2
40	2	56
52	-34	24
-42	-68	4
-42	-2	52
6	14	30
-16	-72	-38
32	-60	-14
-10	-10	68
-60	-38	20
-30	-46	44
-8	-8	68
32	26	0
4	-28	-4
30	-78	-22
-8	-70	-2
12	0	68
16	-28	40
10	-42	66
-38	0	4
50	-8	42
-6	-84	0
6	-84	2
22	-34	-20
-2	16	52
-60	-28	32
34	-26	14
-10	8	6
8	8	8
-10	-28	-2
-10	20	-14
-18	2	-4
12	-8	16
18	2	2
-10	-58	4
20	-62	10
-10	-56	26
20	-58	-6
-18	-62	6
4	-6	68
8	-12	44
-22	-6	64
48	-28	16
40	-14	4
-6	-4	8
0	-28	-4
-16	2	4
6	-20	6
-8	18	4
6	-12	-12
52	10	42
60	6	20
46	20	-2
52	-32	28
-38	-90	-2
46	-48	42
32	22	2
-32	-64	56
18	12	9
-32	-56	46
30	-56	48
14	14	0
-32	-70	-26
22	0	0
38	-62	46
-40	-50	38
30	-64	-24
40	-14	4
6	-34	-14
-24	-2	0
-36	-24	2
-10	-20	-2
-34	18	0
-40	-38	16
-40	16	-2
-16	-2	-2
10	-14	-2
-52	6	34
-14	14	2
-8	54	-12
-2	64	30
2	58	-4
2	60	38
44	32	20
30	32	6
24	2	70
2	32	50
16	50	-14
32	-90	-4
50	-60	-18
46	-82	-2
46	-28	26
56	-44	10
2	-44	72
14	-34	74
6	-44	48
32	-50	42
22	-26	72
-22	-100	-8
-16	-44	74
-14	-50	74
-60	-28	48
-46	-12	58
-50	42	-2
-36	30	48
-8	42	56
-44	18	10
-43	18	8

// Martinsen S, 2014: FM patients + HC: Incongruent > Congruent
// Martinsen S, 2014: HC > FM: Incongruent > Congruent
// Subjects=23
-36	-52	46
30	-52	-24
6	18	42
30	22	-8
-44	-52	-18
38	-2	64
-4	-20	32
24	46	38
40	38	34
-8	-18	4
12	-70	8
22	-14	24
42	-2	-16
26	-14	-16
44	-40	24
6	-56	0
-38	-24	-8
-14	6	22

// Seo J, 2012: FM Patients
// Subjects=19
-48	15	24
51	9	21
-33	25	-6
33	26	-8
-6	20	47
6	27	42
-6	3	66
3	12	57
-18	6	-3
15	0	-3
-27	-72	54
21	-78	54
-30	-63	42
51	-45	45
-33	21	-21
-42	18	48
27	18	57
9	42	15
-6	-24	3
6	-24	0
51	-45	18
-42	-69	42
45	-45	21
-17	-39	68
18	-39	69
-9	63	2
6	57	3
-24	-3	-24
36	0	-24
-24	-7	-24
39	-12	-18
-24	-12	-27
23	-12	-31
-36	-14	2
36	0	12
-3	-48	21
9	-48	21
-33	9	-31
-33	9	-27
33	9	-27
-12	-38	72
9	-42	69
33	26	-8
-48	15	24
51	-45	45
33	26	-8
-48	15	24
51	9	21
51	-45	45
51	-45	45
51	-45	45

// Seo J, 2012: Healthy Controls
// Subjects=22
-42	9	30
30	9	57
-33	24	-6
33	26	-6
-6	24	45
9	27	45
-3	15	54
6	18	54
-15	3	0
15	3	0
-12	9	0
15	9	6
-54	-51	-15
-27	-66	45
39	-66	51
-39	-60	48
42	-45	42
-9	-78	-34
35	-63	-39
-33	21	-21
-42	18	48
27	18	57
9	42	15
-6	-24	3
6	-24	0
51	-45	18
-42	-69	42
45	-45	21
-27	-39	63
30	-36	63
-6	54	0
3	57	0
-24	1	-27
24	-4	-19
-23	-6	-24
24	-3	-21
-23	-12	-27
27	-9	-30
-37	-18	18
39	-12	15
-6	-48	33
9	-60	21
-42	12	-29
54	2	-15
-42	0	-15
58	6	-13
-6	-26	50
9	-34	55

// Bertolino A, 2010: Healthy Controls
// Subjects=37
-29	13	54
-51	15	19
40	40	15

// Bertolino A, 2010: Subgroup of Healthy Controls, GG Genotype (rs1076560)
// Subjects=26
4	-2	35
-41	31	30
33	-1	45
63	8	7
10	16	40

// Bertolino A, 2010: Subgroup of Healthy Controls, GT Genotype (rs1076560)
// Subjects=11
45	36	-14
45	-68	45
8	66	4
-38	43	-6
33	-1	45
63	8	7
10	16	40

// Brendel B, 2011: Four Syllable Categories > Baseline, Healthy Volunteers
// Subjects=20
-3	0	63
3	15	36
-60	-3	21
-63	-9	15
-57	-3	27
-45	-15	39
-48	-12	42
-51	-6	45
-54	-9	48
48	-9	39
63	-6	15
60	0	21
60	-3	24
54	3	48
-57	6	6
-36	18	6
-39	6	6
42	9	3
36	21	3
-39	-33	15
-48	6	0
60	-9	9
54	9	3
-27	-3	-6
-21	6	6
24	6	0
24	-3	6
24	0	-6
-12	18	6
15	-15	6
18	-12	3
-54	12	-3
-57	-21	3
-57	-30	6
-51	-18	0
-51	-42	18
-48	-39	15
54	-30	3
60	-6	3
66	-15	6
48	-18	6
-42	-42	-15
-30	-57	48
-21	-87	-9
-42	-78	-9
-42	-66	-12
42	-66	-15
39	-84	-6
-15	-90	-9
15	-87	-3
24	-87	-3
-18	-63	-18
-12	-63	-18
-27	-57	-27
-27	-66	-18
12	-63	-18
18	-60	-21
-30	-63	-54
15	-69	-48
33	-57	-51

// Brendel B, 2010: Motor prepareness (NCT>BL)
// Brendel B, 2010: Overall network (LCT>BL)
// Brendel B, 2010: Overall network (LCT>BL), Faster > Slower Syllable 
// Repetitions
// Subjects=16
-3	6	51
-3	-3	60
3	6	51
12	0	66
6	-18	30
-63	3	24
-54	-9	15
-51	-9	42
66	3	15
51	3	42
57	0	30
33	48	30
-57	6	9
57	12	0
48	21	-6
-42	12	0
-39	18	-6
39	24	3
-6	-24	6
-15	-12	3
-18	-9	6
18	-9	0
9	-12	6
6	-18	9
-21	6	-3
24	6	12
30	0	-9
21	3	9
-24	-12	-9
-63	-18	0
-51	-24	9
-54	6	-6
-51	-36	18
63	-21	9
51	-15	6
57	-39	24
-42	-57	-30
-15	-21	-9
-9	-21	-18
15	-18	-6
9	-21	-12
6	3	60
9	15	33
-57	-6	36
-51	-6	42
-57	-3	44
51	-6	33
60	0	18
48	0	48
51	9	6
-45	6	0
-15	-18	0
15	-18	0
-24	-15	-3
24	-12	-3
-45	-21	6
-57	-24	12
-48	-12	0
66	-21	9
51	-12	3
-21	-60	-24
15	-60	-21
-12	-24	-9
12	-21	-6
-57	-9	33
54	-6	33
60	0	21
-45	-21	6
51	-12	3
66	-21	9
63	-15	6

// Parkinson A L, 2012: Shifted Vocalization > Rest
// Parkinson A L, 2012: Unshifted Vocalization > Rest
// Parkinson A L, 2012: Shifted Vocalization > Unshifted Vocalization
// Subjects=12
60	-12	-1
66	-17	13
68	-23	3
-56	-2	-1
-61	-16	6
-56	-24	9
-66	-31	9
63	-29	3
-1	-1	65
-47	-11	43
-21	-29	62
50	-9	32
-47	-14	42
-35	-55	59
-36	34	7
43	23	11
-32	24	9
37	15	19
22	6	6
-23	8	6
-10	-18	1
61	-5	5
60	-12	-1
-61	-14	9
-61	-7	6
-59	-5	9
1	0	66
-49	-7	32
50	-10	39
15	-29	66
-52	-7	21
-33	15	-10
49	14	9
-38	5	0
41	19	6
22	3	6
-23	-4	6
63	-17	9
66	-19	13
66	-29	9
51	-28	9
-57	-29	9
-52	-28	6

// Fonzo G A, 2013: Negative Functional Activation Correlates of CM (childhood 
// maltreatment), Angry faces vs. Shapes
// Fonzo G A, 2013: Negative Functional Activation Correlates of CM, Fearful 
// faces vs. Shapes
// Fonzo G A, 2013: Positive Functional Activation Correlates of CM, Angry 
// face vs. Shapes
// Fonzo G A, 2013: Positive Functional Activation Correlates of CM, Fearful 
// face vs. Shapes
// Fonzo G A, 2013: Task-evoked activation, Angry faces vs. Shapes
// Fonzo G A, 2013: Task-evoked activation, Fearful faces vs. Shapes
// Fonzo G A, 2013: Task-evoked activation, Happy faces vs. Shapes
// Fonzo G A, 2013: Task-evoked connectivity, Angry faces vs. Shapes
// Fonzo G A, 2013: Task-evoked connectivity, Fearful faces vs. Shapes
// Subjects=33
-11.56	16.18	25.93
14.09	16.33	25.63
4.24	45.74	7.66
-2.17	45.7	7.74
-10.57	-49.46	-10.95
20.48	-65.05	-8.88
0.48	-10.42	52.56
2.62	-10.4	52.53
35.54	-69.47	1.35
-28.57	-78.57	-.5
-45.69	-41.52	12.21
-44.66	14.12	29.83
52.49	23.54	19.01
8.8	-57.83	2.91
47.22	15.47	25.32
-44.7	15.89	25.22
1.39	23.08	45.28
6.65	-57.93	1.83
47.22	15.56	26.43
45.42	-34.81	49.63
-46.55	-31.73	42.62
1.61	-32.87	51.08
2.63	-46.58	38.84
0.49	-46.6	38.87
30.18	-71.88	-1.73
-37.14	-70.08	0.01
49.18	-3.92	-5.42
-37.97	-28.08	47.79
34.74	-43.59	47.14
47.01	-3.13	-8.81
17.22	-56.86	-12.88
-14.84	-57.06	-12.49
-6.89	-28.01	59.7
10.21	-27.91	59.49
21.92	-16.2	58.38
-3.06	-60.07	-11.26
5.49	-60.02	-11.36
-14.4	-21.79	58.15
-2.93	25.89	40.63
5.62	25.94	40.53
21.51	-51.21	-8.94
-14.82	-52.48	-8.42
1.48	-7.84	44.53
-8.33	-65.93	-4.02
10.9	-65.82	-4.25
44.96	-15.4	-2.18
-52	-41.68	24.56
58.13	-41.39	32.19
11.02	-3.09	36.21
-8.21	-3.21	36.44
14.13	-68.89	-2.91
-11.52	-69.04	-2.61
-52.09	-29.42	17.96
2.64	-68.42	31.75
0.5	-68.43	31.78
5.57	-67.97	-4.01
-2.98	-68.02	-3.91
5.88	-22.99	54.67
-2.67	-23.04	54.77
14.02	-1.87	10.43
-11.62	-2.02	10.73
-13.7	31.57	32.47
32.09	-18.19	-9.6

// White S F, 2014: Positive PCL(Post-Traumatic Stress Disorder Checklist) 
// Score Association, Task trials > View trials
// White S F, 2014: Positive PCL Score Association, Negative and Positive > 
// Neutral
// Subjects=57
25.4	28.92	42.84
-.11	7.07	51.66
54.08	27.29	19.23
44.29	45.24	4.45
51.21	-41.75	35.09
28.43	13.93	13.95
-19.69	9.96	8.15
67.08	-53.22	9.1
-12.87	-94.43	20.17
-38.65	-86.09	6.38
35.16	-91.48	12.68
60.48	-58.49	-17.14
-16.49	-16.43	-3.06
15.78	-60.13	6.93
67.06	-7.27	25.32
34.83	-58.64	-16.84

// Cubillo A, 2010: ADHD Patients
// Subjects=11
-29.97	24.59	-1.32
39.55	21.2	3.74
-17.64	-1.29	62.04
8.6	-14.82	-5.15
27.8	21.13	3.88
-37.12	-24.84	20.75

// Cubillo A, 2010: Healthy Controls for Stop Task
// Subjects=14
-29.97	24.59	-1.32
39.55	21.2	3.74
-17.64	-1.29	62.04
8.6	-14.82	-5.15

// Cubillo A, 2010: Healthy Controls for Switch Task
// Subjects=13
27.8	21.13	3.88
-37.12	-24.84	20.75

// Davanger S, 2010: Continuous Meditation > All Control Tasks
// Davanger S, 2010: Continuous Meditation > Pseudoword Repetition
// Davanger S, 2010: Continuous Meditation > Physical Relaxation
// Davanger S, 2010: Continuous Meditation > Word Sequence Generation
// Davanger S, 2010: Continuous Meditation > Rest After Meditation
// Davanger S, 2010: Control Tasks > Rest After Control Tasks
// Davanger S, 2010: Word Sequence Generation > Rest After Control Tasks
// Subjects=4
-38.16	24.22	-23.14
-25.13	33.51	-16.44
-38.16	24.22	-23.14
-25.13	33.51	-16.44
-38.16	24.22	-23.14
-25.13	33.51	-16.44
-38.16	24.22	-23.14
-20.87	36.3	-21.27
-62.64	-11.43	-1.27
-53.88	-26.93	4.6
-50.22	7.97	44.79
49.92	-23.71	10.36
49.88	36.13	19
-2.7	-17.15	37.5
56.73	-42.03	32.22

// Fairhall S L, 2014: Healthy Controls Experiment 1
// Subjects=16
42	-46	-23
-42	-46	-26
48	-58	16
51	-76	-5
3	-58	34
-51	-46	13
60	-4	-26
21	-7	-17
-21	-4	-17
30	-43	-11
30	-61	-8
39	-82	19
18	-55	13
-33	-88	19
-27	-64	-8
-27	-43	-17
-15	-58	10
6	-58	40
30	-34	-17
36	-79	37
18	-55	22
-30	-85	37

// Fairhall S L, 2014: Healhty Controls Experiment 2
// Subjects=17
45	-55	19
3	-49	28
3	53	-14
24	-1	-23
45	-46	-23
42	-79	-14
-42	-82	-14
-24	-4	-20
51	-7	-26
30	-43	-11
30	-61	-8
39	-82	19
18	-55	13
-33	-88	19
-27	-64	-8
-27	-43	-17
-15	-58	10
3	-49	28
3	53	-14
-39	-79	34
-27	-32	-20
-15	-55	16
30	-31	-20
18	-52	16

// Ross L A, 2011: Fame > No fame
// Ross L A, 2011: No fame > Fame
// Subjects=11
-4.26	58.35	20.08
-2.3	59.73	-3.47
-4.43	41.15	-9.7
-3.22	6.43	-4.57
-21.43	-7.4	-16.58
-59.83	-11.26	-8.01
-39.77	20.36	-27.62
-35.29	-34.6	-23.06
5.2	47.98	-4.81
5.19	48.95	-6
-37.51	54.66	2.93
62.07	-37.13	-9.47
9.11	-68.84	39.52
4.63	24.59	50.69
42.9	57.89	37.42
0.37	-25.88	31.55
-4.76	-72.01	41.06

// de Greck M, 2010: Win > Lose
// Subjects=12
-12	10	4
14	12	2
-18	6	-4

// Allen M, 2012: Mindfulness Training
// Subjects=19
-32	-24	28
-32	-20	40
-38	-14	20
-24	44	26
-32	42	26
-12	30	32
24	24	-22
28	22	-14
36	18	-14
6	46	30
20	38	30
2	44	12
-30	26	22
-40	38	24
-28	36	20
30	16	50
24	-2	56
-12	12	48

// Allen M, 2012: Control
// Subjects=19
-30	26	22
-40	38	24
-28	36	20
30	16	50
24	-2	56
-12	12	48

// Dickenson J, 2012: Focused breath > Mindwandering
// Dickenson J, 2012: Mindwandering > Focused Breath
// Subjects=31
39	-7	22
18	26	3
42	-58	25
24	2	52
-36	-19	25
-45	5	10
12	26	40
-30	-40	-10
42	-79	31
30	-25	-5
9	38	43
36	-52	43
21	38	34
-3	50	-8
-3	50	7
-48	14	-8
-42	11	52
-6	38	-8
-39	-61	58
-6	-67	64
0	-46	61
0	8	64
-9	-46	1
-30	-64	58
-27	-73	49
51	17	-2
-33	59	7
0	-22	55
-42	-4	58
-12	-37	-2
-3	23	37
60	-13	10
3	-76	46
-3	26	43

// Farb N A S, 2012: Waitlist controls
// Subjects=16
27	-51	12
15	-12	51
-30	-42	-6
45	-24	24
-24	-51	6
-9	-24	21
-33	-6	15
-12	-60	15
-9	-48	-45
3	-81	-27
-42	-54	48
-48	15	21
45	-48	54
36	57	18
0	18	63
39	24	0

// Farb N A S, 2012: Training Group
// Subjects=20
33	-6	15
15	-21	51
-21	-18	21
-12	-54	21
27	-51	9
33	-36	-3
-30	-18	36
18	-60	-48
0	-42	-45
-3	27	51
-45	-54	51
-51	12	30
33	-57	54
57	0	-39

// Gard T, 2012: Practitioners
// Subjects=17
49.35	-17.52	11.33
46.38	-47.98	30.65
36.21	-43.91	-39.83
29.81	48.47	-.67
17.08	16.41	-1.18
-1.68	-34.81	40.13
-1.51	-36.44	60.34
-14.95	16.48	2.53
-37.44	-73.16	-39.88
-34.35	54.17	-3.76
-31.11	-31.12	-33.44
-30.55	-28.63	39.95
-53.01	-38.8	34.37
1.51	17.77	59.11
10.6	48.61	2.89
-47.29	16.63	-33.91
71.9	-32.73	19.04
58.81	-32.21	-14.31
13.99	-74.74	-23.61
-21.6	4.09	-33.16
-30.59	-58.73	22.4
-46.96	-22.81	-7.19
-46.87	-48.19	-5.06
45.89	2.87	-13.76
62.22	-3.73	23.41
42.98	12.53	28.96
17.18	-15.57	-1.84
17.08	16.41	-1.18
4.78	8.53	63.19
1.45	-12.58	38.23
-37.36	-6.38	-1.99
-24.54	49.68	19.93
-43.54	22.3	39.17
-46.75	2.48	30.83
-56.28	-19.78	32.81

// Gard T, 2012: Controls
// Subjects=17
49.35	-17.52	11.33
46.38	-47.98	30.65
36.21	-43.91	-39.83
29.81	48.47	-.67
17.08	16.41	-1.18
-1.68	-34.81	40.13
-1.51	-36.44	60.34
-14.95	16.48	2.53
-37.44	-73.16	-39.88
-34.35	54.17	-3.76
-31.11	-31.12	-33.44
-30.55	-28.63	39.95
-53.01	-38.8	34.37
1.51	17.77	59.11
10.6	48.61	2.89
-47.29	16.63	-33.91
71.9	-32.73	19.04
58.81	-32.21	-14.31
13.99	-74.74	-23.61
-21.6	4.09	-33.16
-30.59	-58.73	22.4
-46.96	-22.81	-7.19
-46.87	-48.19	-5.06
36.48	-18.11	4.84
55.62	-28.8	-11.21
43.14	4.3	46.38
43.24	-44.05	40.39
40.15	-26.41	62.37
20.95	-42.65	60.6
10.78	-18.78	-1.5
13.9	3.45	-3.4
11.26	-23.67	59.12
7.76	12.84	36.03
1.42	-26.04	29.33
-14.94	0.1	-2.79
-40.62	-3.74	-8.86
-49.8	-32.18	37.12
-46.5	-44.33	44.79

// Guleria A, 2013: Meditation > Control
// Guleria A, 2013: Control > Meditation
// Subjects=14
-41	32	38
-46	8	18
-32	4	60
-6	-52	58
-52	-50	12
-54	-24	8
-54	-44	44
-52	-16	32

// Ives-Deliperi V L, 2011: Meditation vs. Control, Activations
// Ives-Deliperi V L, 2011: Meditation vs. Control, Deactivations
// Subjects=10
11.13	-40.41	21.5
-15.08	49.16	-1.44
21.28	52.99	3.51
36.41	29.53	15.34
-37.41	13.94	-.68
27.14	-35.06	34.25
-13.4	-56.54	35.4
16.56	-60.33	38.72

// Kilpatrick L A, 2011: Mindfulness-based Stress Reduction (MBSR) 
// Participants > Controls, Auditory/Salience
// Kilpatrick L A, 2011: MBSR Participants > Controls, Medial Visual
// Kilpatrick L A, 2011: MBSR Participants > Controls, Lateral Visual
// Kilpatrick L A, 2011: MBSR Participants > Controls, Sensori-motor
// Kilpatrick L A, 2011: MBSR Participants > Controls, Executive Control
// Subjects=15
12	42	18
-50	-20	16
0	-74	18
-24	-96	20
-20	-68	4
20	-72	12
6	38	10
2	-26	32
10	-46	70
6	-42	56
0	-74	22
20	-50	6
-50	-50	32

// Lee T M C, 2012: Experts, Focused Attention Meditators (FAM)
// Subjects=11
44	-58	20
2	-12	-4
4	-66	24
-34	22	-6
-4	34	16
-26	-60	20
-10	40	42
28	-24	46
2	8	32
18	-26	-10
-40	-78	0
18	-86	30
-22	-80	10
-22	-70	8

// Lee T M C, 2012: Novices, FAM
// Subjects=11
44	-58	20
2	-12	-4
4	-66	24
-10	40	42
38	34	12
28	-24	46
50	-68	-4
40	-68	-20
18	-26	-10
-40	-78	0
18	-86	30
-22	-70	8
-22	-80	10
34	-76	8
-8	-82	10

// Lee T M C, 2012: Novices, LKM
// Subjects=11
-4	34	16
42	34	14
-34	46	18
-12	6	20
14	-4	22
-22	0	-6
28	20	30
-14	42	26
18	46	30
-10	30	48
-16	24	48

// Lee T M C, 2012: Experts, Loving-Kindness Meditators (LKM)
// Subjects=11
-4	34	16
42	34	14
-34	46	18
-12	6	20
-22	0	-6
-14	42	26
18	46	30
-10	30	48
-16	24	48

// Lutz J, 2014: Perception negative vs. Perception neutral, Mindfulness > 
// Basic
// Lutz J, 2014: Expectation negative vs. Expectation neutral, Mindfulness > 
// Basic
// Lutz J, 2014: Expectation unknown vs. Expectation neutral, Mindfulness > 
// Basic
// Subjects=22
-49.11	44.08	18.45
-41.21	10.02	59.13
-50.93	15.54	48.74
27.71	-15.99	-22
-40.47	-10.91	8.46
-51.25	18.8	8.33
-48.31	49	-14.31
-44.58	18.24	41.75
-5.98	13.15	55.12
-64.02	-43.35	-9.73
-57.36	-53.94	17.84
-60.47	-46.33	33.97
-54.49	28.3	7.57
-38.13	2.16	39.68
-2.78	13.17	55.08
-60.82	6.05	9.51
41.72	6.16	1.63
-44.87	8.55	-.92
-6.16	24.56	37.44
58.09	-36.36	28.42
-16.02	21.93	4.31

// Manna A, 2010: Monk Group
// Subjects=8
-8.51	29.97	11.36
13.89	36.28	8.34
13.81	55.23	5.64
1.76	-68.65	56.31
58.82	20.6	8.03
-9.71	72.52	11.15
-50.26	43.21	7.38
-49.04	37.1	24.61
62.3	-51.28	14.01
-43.81	9.62	-1.03
52.32	46.03	7.08
-42.55	-24.67	9.64
-42.64	-9.07	4.99
-30.26	-51.96	68.66
-27.71	54.41	26.26
-26.83	64.5	5.33
-50.23	35.81	8
26.74	46.56	16.25
55.58	33.36	8.11
-50.05	-31.49	4.72
-40.37	-30.75	13.47
-4.66	-72.12	53.33
-33.17	25.71	-.27
-2.04	43.81	24.62
58.81	23.78	7.76
13.9	34.17	8.52
17	52.88	2.45
-2.25	58.05	2.24
-56.42	-37.7	7.55
-17.55	-62.94	49.37

// Manna A, 2010: Novice Group
// Subjects=8
-23.1	-22.24	39.33
-11.64	24.12	18.58
13.71	42.14	-12.22
17	61.68	6.18
23.47	26.05	-.95

// Taylor V A, 2011: Experienced
// Subjects=12
-28.35	28.18	-15.86
-11.58	-48.5	12.74
14.56	-53.44	27.35
27	-32.15	-9.71
-5.29	-22.61	2.22
19.58	-29.97	2.53
19.65	-21.8	9.56
-28.38	-1.58	-24.12
-37.77	34.79	9.42
12.86	59.01	1.68
12.28	-47.79	18.98
15.01	54.56	-.15

// Taylor V A, 2011: Beginners
// Subjects=10
32.77	-24.97	20.86
-20.73	3.43	-16.9
20.41	7.49	-10.16
-28.35	28.18	-15.86
-11.58	-48.5	12.74
14.56	-53.44	27.35
27	-32.15	-9.71
-5.29	-22.61	2.22
19.58	-29.97	2.53
19.65	-21.8	9.56
-28.38	-1.58	-24.12
-28.38	-1.58	-24.12
29.99	-1.16	-22.91
12.86	59.01	1.68
12.28	-47.79	18.98
32.84	26.99	37.01
-26.54	29.22	41.16
13.43	-49.39	24.73
42.7	-63.87	29.02
-29.65	-69.34	31.91

// Wang D, 2011: Meditation 1 vs Control, Activations
// Wang D, 2011: Meditation 1 vs Control, Deactivations
// Wang D, 2011: Meditation 2 vs Control, Activations
// Wang D, 2011: Meditation 2 vs Control, Deactivations
// Wang D, 2011: Meditation 2 vs Meditation 1, Activations
// Wang D, 2011: Meditation 2 vs Meditation 1, Deactivations
// Wang D, 2011: Post-meditation Baseline 2 vs Pre-meditation Baseline 1, 
// Activations
// Subjects=10
0	64	18
-18	14	10
54	-68	-12
-28	-62	34
-30	10	-22
44	-4	-4
-18	-34	-6
18	-24	-22
-50	-2	-4
-24	-58	46
40	-78	2
26	-57	63
-44	-18	46
-12	16	-28
-34	12	20
-18	-32	-22
-2	-48	-32
44	16	-24
-40	-22	52
-52	-44	54
14	44	14
-14	40	-12
38	-24	48
-28	36	8
38	0	56
4	-48	64

// Xu J, 2014: Nondirective Meditation vs. Rest
// Xu J, 2014: Concentrative practicing vs. Rest
// Xu J, 2014: Nondirective meditation vs. Concentrative practicing
// Subjects=14
22	36	-21
24	-86	27
36	-83	0
30	-86	20
7	-74	-14
-56	5	17
-14	-56	55
-61	-15	14
-19	-60	47
44	-26	-27
27	-17	-6
-37	-2	-7
-20	-74	-12
38	-27	-32
8	37	10
8	6	31
-3	42	-3
-27	-2	-8
-7	10	-9
-24	-11	2
-11	15	3
23	-5	-21
-16	-15	15
22	-5	-2
25	4	-5
-13	-89	24
-36	5	49
-6	-3	61
-39	-14	41
-34	7	55
-48	-20	37
17	-74	5
-37	6	58
15	-87	19
4	11	31
-1	13	34
-21	-75	-11
7	6	53
52	-6	-22
28	-24	-32
36	-2	-20
47	-29	-19
31	2	-19

// Buhler M, 2010: Anticipatory brain activity to monetary reward, Occasional 
// smokers > Dependent smokers
// Buhler M, 2010: Anticipatory brain activity in the motivation task, All 
// smokers
// Subjects=21
20	18	-6
-6	12	-6
12	-2	16
18	26	-16
6	58	8
-10	34	6
8	6	-14
-10	-2	16
-32	4	6
26	-8	0
12	40	30
-10	64	8
-16	16	-4
20	16	-6
10	10	-6
-12	-4	14
14	-18	10
14	-12	-8
-6	-24	-6
6	-26	-6
-38	-16	62
-38	-28	46
36	-22	58
50	-22	44
34	54	8
8	40	32
10	38	24
-16	-92	-18
14	-88	-18
-12	-98	-8
6	-92	14

// Callan D E, 2010: Spaced Condition > Verbal Working Memory of Spaced 
// Condition, P<0.005
// Callan D E, 2010: Spaced Condition > Verbal Working Memory of Spaced 
// Condition, P<0.05
// Callan D E, 2010: Massed Condition > Verbal Working Memory of Massed 
// Condition
// Callan D E, 2010: Massed Condition Correlated with Behavioral Performance, 
// 10-min Recall
// Callan D E, 2010: Massed Condition Correlated with Behavioral Performance, 
// 1-day Recall
// Callan D E, 2010: Spaced Condition Correlated with Behavioral Performance, 
// 10-min Recall
// Callan D E, 2010: Spaced Condition Correlated with Behavioral Performance, 
// 1-day Recall
// Callan D E, 2010: Massed vs. Spaced Decreasing Activity Trend Relative to 
// Verbal Working Memory Conditions, P<0.005
// Callan D E, 2010: Massed vs. Spaced Decreasing Activity Trend Relative to 
// Verbal Working Memory Conditions, P<0.05
// Subjects=13
53.19	13.71	20.05
33.35	27.1	-7.84
-56.69	5.82	45.11
-4.86	28.76	46.44
-1.91	13.51	21
-33.77	-54.72	50.71
34.32	-60.86	50.16
-31.11	-95.21	-3.6
33.73	-101.36	-4.1
-53.81	9.72	17.78
-57.15	22.06	12.13
-28.22	23.69	-6.45
-40.34	13.51	57.52
-1.43	23.63	60.33
-23.94	-67.03	56.24
-24.7	-3.77	9.65
-50.58	12.92	17.41
49.98	7.31	20.73
-47.48	21.68	7.52
-43.67	6.28	49.32
40.35	-1.88	26.29
-8.02	22.78	51.57
-1.57	29.18	50.82
-50.7	-43.81	-3.87
-50.01	-45.21	50.04
-33.65	-57.08	59.9
-18.17	-.14	13.67
30.51	-32.29	11.54
-5.61	-29.36	-24
42.8	-63.59	-48.33
-47.34	12.94	17.35
-43.98	13.78	26.18
-60.28	22.88	21.07
-34.75	23.25	-10.78
-66.69	-55.38	10.99
-20.6	-63	64.75
-47.23	13.77	26.23
-47.37	22.51	16.41
-31.45	20.49	-6.08
-66.69	-55.38	10.99
-46.78	-42	49.67
-30.47	-70.66	52.23
53.17	11.37	18.04
-56.92	7.35	27.03
-28.09	21.33	2.75
-60.11	7.75	31.53
1.67	45.56	53.63
-47.69	46.37	-3.88
-37.09	-48.77	45.69
-28.06	-1.42	0.51
53.15	11.16	15.82
-60.18	10.53	26.77
-28.09	21.33	2.75
-40.47	15.87	48.32
56.62	8.58	33.94
1.67	45.56	53.63
-47.82	48.73	-13.08
-31.36	-1.85	-3.87
-1.51	29.6	55.26
-50.58	12.92	17.41
-34.63	20.89	-1.58
33.33	33.48	-8.47
-37.48	7.42	26.69
8.03	31.58	41.46

// Chapin H, 2010: Expressive > Mechanical
// Chapin H, 2010: Mechanical > Expressive
// Chapin H, 2010: Experienced > Inexperienced
// Chapin H, 2010: Inexperienced > Experienced
// Subjects=7
20.44	-42.41	-5.21
46.09	-59.86	-12.96
42.23	-33.6	51.79
50.13	30.01	-7.16
15.91	-1.17	-22
-1.29	72.34	-5.66
7.32	37.87	-11.79
-30.39	-46.72	53.73
3.34	58.54	35.59
-13.66	50.66	45.37
-60.49	-44.39	31.58
15.93	12.2	-14.2
-14	42.66	-3.02
-1.17	12.1	-13.99
-22.48	-22.55	-19.76

// Chen J L, 2012: Listening to melodies at pre-training
// Chen J L, 2012: Early > Late learning (melody training)
// Chen J L, 2012: Late > Early learning (melody training)
// Chen J L, 2012: Early > Late learning (random training)
// Chen J L, 2012: Late > Early learning (random training)
// Subjects=16
54	-10	-2
-46	-24	8
52	2	42
-48	-6	44
36	-2	52
-24	-6	48
52	-6	42
-54	4	26
-26	-4	54
2	-52	22
-4	40	-26
-40	48	-10
-26	-4	52
4	-10	70
2	0	42
26	-28	70
18	8	50
6	-30	42
46	-78	16
-26	52	-12

// Dennis N A, 2011: Younger Healthy Controls
// Subjects=12
-51.6	13.34	21.87
-27.11	-36.26	-16.22
-23.03	-38.73	48.94
-59.39	-55.1	-9.33
-22.97	-71.16	46.55
29.57	-95.77	9.99
-19.21	-89.54	-1
-23.64	52.99	19.71
-9.84	-11.83	71.83
34.29	-5.27	59.22
12.82	12.78	-10.55
33.58	-17.16	1.02
-23.45	-11.23	21.58
-3.27	10.26	-2.18
13.24	-35.54	12.15
9.84	-54.23	-3.87
-23.84	-31.68	-13.37
25.86	-31.5	-14.24
21.85	4.77	18.1
29.29	-.49	7.29

// Dennis N A, 2011: Older Healthy Controls
// Subjects=12
-43.25	34.14	2.86
-27.15	-36.57	-19.56
-24.12	30.76	-22.91
-51.48	18.63	32.55
-59.2	-44.93	7.59
-40.1	-20.14	-15.36
41.93	-12.72	-20.85
-19.45	46.55	7.95
-23.84	-31.68	-13.37
25.86	-31.5	-14.24
21.85	4.77	18.1
29.29	-.49	7.29

// Dillo W, 2010: Healthy Controls
// Subjects=15
10.36	10.94	50.18
8.35	7.71	61.74

// Dillo W, 2010: ADHD Patients
// Subjects=15
25.65	-68.75	46.6
34.42	-65.56	57.34
-2.6	8.76	50.62
55.5	11.56	31.42
33.74	-96.9	-2.3

// Escoffier N, 2012: Conjunction: Voice > Rest and Music > Rest
// Escoffier N, 2012: Voice > Music
// Escoffier N, 2012: Music > Voice
// Escoffier N, 2012: Conjunction: Emotion Tracking > Pitch Tracking (Music 
// and Voice)
// Subjects=16
-60	-23	15
60	-19	12
-54	-16	12
54	14	-24
64	-4	-7
-1	-80	37
9	-69	45
-51	-35	13
43	-13	-2
-4	57	8
11	45	0

// Fan J, 2011: All Prime and Target Events in Common
// Fan J, 2011: All Face Primes
// Fan J, 2011: Fear Prime
// Fan J, 2011: Fear Target
// Fan J, 2011: Fearful Targets Primed by Fearful Primes
// Subjects=25
-32	-56	-24
6	-82	-10
34	-48	-24
-44	-36	48
-32	-42	42
-4	2	50
42	8	30
36	2	48
34	2	62
2	-28	28
-12	-16	8
10	-14	10
-38	-4	16
-44	0	6
-34	20	6
-14	-30	-2
-8	-22	-10
32	24	2
-16	-88	-14
-38	-86	-8
-26	-92	-4
42	0	56
50	18	22
42	2	26
34	-60	-12
46	-76	-8
22	-56	-4
-16	-70	8
-12	-64	4
4	20	38
4	16	48
-8	8	38
-30	-28	60
-32	-26	52
-34	-14	64
-54	6	-10
-64	-14	-6
-54	-42	2
-12	54	-2
-20	54	6
-16	36	10
62	-22	0
66	-38	12
52	-36	6
44	16	-2
36	20	-6
46	8	2
-56	-58	18
48	-52	24
58	-56	30
50	-38	26
22	-10	20
38	-26	16
36	-14	16
12	-14	70
-2	-6	70
22	-12	70
-14	-62	24
0	-60	30
-12	-58	32
-6	-38	8
-20	-18	70
-60	-30	14
46	-6	8
44	4	2
58	0	6
-8	16	2
-10	14	12
-20	-48	-26
-32	-42	-24
42	-80	-10
-42	2	30
42	4	26
40	18	20
38	12	38
-36	-18	62
-38	-28	52
-30	-26	54
8	14	46
2	40	36
2	32	40

// Friederici A D, 2010: Correct-Intelligible > Correct-Rotated
// Friederici A D, 2010: Incorrect-Intelligible > Correct Intelligible
// Subjects=17
-58	-4	4
62	-4	-14
-54	-16	4
-60	-42	6
-62	18	16
-12	-28	2
44	-20	6

// Glahn D C, 2010: Bipolar Disorder Patients
// Subjects=15
-26.25	-31.28	-7.9
-26.23	-33.11	-3.34
20.24	-32.99	-8.06
-45.37	21.15	24.14
-49.59	16.64	20.03
-45.26	5.42	42.97
-47.66	44.45	-8.52
47.53	36.09	13.69
49.78	9.61	28.81
39.2	9.25	24.45
-5.16	20.6	43.92
-7.25	23.63	59.26
-34.43	-68.3	43.52
-36.56	-63.98	45.45
34.55	102.14	-8.52
1.41	-79.24	-2.56
24.67	-92.33	-12.9
-28.24	-76.5	-22.55
-60.03	-37.6	-2.83
-24.16	-27.2	-10.41
24.48	-32.82	-5.87
-30.69	23.31	-11.61
-51.66	10.86	29.32
-45.35	17.08	26.63
-45.28	2.65	32.06
34.82	23.86	-12.04
43.34	32.4	22.84
39.11	32.23	20.66
47.72	-2.88	31.89
-.96	22.33	37.11
-3.07	22.58	41.55
-25.99	-68.5	39.04
-32.34	-57.23	51.63
-34.46	-59.89	42.94
-55.71	-23.81	49.47
35.28	-68.25	34.22
45.73	-31.91	40.55
33.18	-81.69	21.84
1.48	-98.15	-1.27
14.21	-106.04	5.86
-45.17	-67.97	-18.6
-15.73	-7	8.13
-24.22	-3.41	-.94
18.07	-4.62	7.77
22.22	7.21	-6.38
-47.49	30.21	34.63
-11.51	18.18	39.68
-23.82	-76.34	48.44
39.22	-1.66	18.54
-22.12	3.18	3.03
24.38	1.47	2.88
-28.13	-101.31	-14.19
33.16	-100.53	-10.17
-.99	33.24	43.03
-15.44	-73.29	28.21
16.22	-64.75	25.22
-70.63	-34.02	-11.89
-32.68	-17.44	-22.13
-30.57	-17.56	-24.35
-24.02	-74.23	-20.51
20.34	-69.66	-21.09
-22	10.63	55.8
22.38	8.9	55.65

// Glahn D C, 2010: Healthy Controls
// Subjects=24
-24.15	-29.3	-10.27
-34.79	-19.69	-24.18
-32.72	-4.7	-20.78
26.58	-30.84	-8.24
28.57	-10.76	-25.17
26.44	-6.57	-25.44
-47.54	31.23	16.8
-38.98	6.49	25.1
-49.49	7.76	47.28
-51.86	38.11	-8.06
45.42	31.6	9.57
45.51	19.94	25.9
41.3	9	20.02
-7.33	28.45	34.51
-5.15	18.64	46.27
-30.2	-72.6	41.57
-28.13	-69.19	28
37.41	-63.22	47.19
35.27	-61.68	38.21
33.12	-90.16	-13.1
-17.54	-107.53	-13.83
28.93	-100.7	-12.35
37.31	-88.56	-22.11
-22.04	-29.28	-10.28
22.34	-28.91	-10.57
-34.92	20.9	-15.86
-51.66	8.63	27.25
-49.6	23.49	28.44
-26.08	-20.11	71.24
36.97	22.45	-.85
49.7	28.38	25.3
45.42	38.58	20.19
43.45	7.59	31.2
3.28	18.3	39.58
1.18	18.42	41.81
-23.85	-70.17	45.8
-36.58	-50.83	53.43
-32.36	-60.01	40.72
-53.6	-26.3	42.97
22.66	-71.48	52.28
33.16	-52.48	50.91
-34.5	-92.82	-12.52
-9.06	-106.78	-2.83
14.21	-106.04	5.86
-5.14	-31.65	-16.88
-13.57	-21.82	6.91
-22.11	-1.16	1.11
15.96	-4.63	7.78
15.92	3.64	5
-47.49	30.21	34.63
-11.51	18.18	39.68
-23.82	-76.34	48.44
39.22	-1.66	18.54
-22.12	3.18	3.03
24.38	1.47	2.88
-28.13	-101.31	-14.19
33.16	-100.53	-10.17
-.99	33.24	43.03
-15.44	-73.29	28.21
16.22	-64.75	25.22
-70.63	-34.02	-11.89
-32.68	-17.44	-22.13
-30.57	-17.56	-24.35
-24.02	-74.23	-20.51
20.34	-69.66	-21.09
-22	10.63	55.8
22.38	8.9	55.65

// Greening S G, 2011: Main Effect of Condition: OA > IR, RR, and CTL
// Greening S G, 2011: Main Effect of Condition: OA, RR, CTL > IR
// Greening S G, 2011: Interaction of Condition and Relearning Stage
// Greening S G, 2011: OA Error Feedback > IR Error Feedback
// Greening S G, 2011: Conjunction Analysis (OA, RR, IR): Error Feedback >/= 
// Correct Feedback
// Greening S G, 2011: Conjuction Analysis (OA, RR, IR): Correct Feedback > 
// Error Feedback
// Greening S G, 2011: OA Error Feedback > OA Correct Feedback
// Greening S G, 2011: OA Correct Feedback > OA Error Feedback
// Greening S G, 2011: IR Error Feedback > IR Correct Feedback
// Greening S G, 2011: IR Correct Feedback > IR Error Feedback
// Subjects=21
-32.54	-56.77	47.91
14.34	-87.61	16.5
-15.46	-75.5	38.13
-19.17	-73.08	-26.71
19.63	-70.48	17.23
37.3	65.06	6.78
-41.51	36.6	31.26
-10.56	56.08	32.61
-46.52	-66.6	32.16
-1.61	-63.78	36.99
-68.19	-42.34	3.61
33.08	59.03	11.79
-33.16	56.52	12.76
44.16	19.2	46.23
-44.64	16.49	32.98
35.22	20.58	-3.97
-34.24	21.3	-2.12
2.44	29.44	44.73
-40.11	0.43	58.81
40.16	-61.45	49.69
-33.6	-63.29	46.23
4.88	-67.38	45.02
-9.27	-79.97	7.21
3.56	-74.35	9.93
9.98	-74.23	10.96
-26.55	-87.42	-18.74
-41.58	-68.48	-20.15
39.62	-69.22	-23.25
23.84	-97.55	-2.85
4.61	-88.78	2.21
30.14	-86.57	-12.77
9.79	-13.61	10.34
-9.45	-14.79	10.66
-1.25	54.11	-7.48
32.04	59.28	15.13
-33.2	58.29	8.15
42.01	19.01	44.04
-43.51	13.84	39.88
42.71	19.65	-2.86
-38.52	21.19	-3.17
1.35	30.4	43.55
-22.9	-66.31	47.48
39.06	-65.06	44.43
25.97	-97.54	-2.88
-28.7	-84.26	-18.98
11.03	-74.39	8.74
62.1	-39.08	-7.08
-60.81	-35.58	-5.96
-1.98	-11.57	10.31
-32.08	-21.29	-16.41
35.19	58.7	7.33
-35.31	58.62	12.61
-43.94	49.97	-2.18
42.03	18.13	46.34
-44.63	15.44	33.07
34.16	20.66	-2.85
-33.17	21.31	-2.13
2.44	29.44	44.73
-37.97	0.53	59.89
43.33	-61.86	44.12
-34.67	-63.3	46.25
33.1	-40.79	-26.68
-26.53	-89.45	-17.45
-34.22	-47.71	-27.55
-9.28	-79	6.01
4.88	-67.38	45.02
26.97	-87.3	-8.21
-64.03	-32.52	-7.3
63.15	-35.9	-7.36
9.79	-13.61	10.34
-4.43	56.55	-3.18
-60.55	-29.58	30.33
64.45	-28.03	25.42
-37.3	1.88	8.47
-9.19	-53.85	28.43
60.35	-20.72	51.62

// Haase L, 2011: Male Healthy Controls
// Subjects=9
44.93	-5.8	-1.87
-38.49	25.94	3.12
16.12	-15.49	-.72
61.1	-.99	17.62
-51.08	-14.61	16.7
15.15	-67.19	-8.64
-1.19	50.31	-1.58
41.59	52.05	3.36
-4.27	9.85	-1.5
-.72	-27.2	28.33
-37.39	44.86	13.79
-4.16	-13.15	3.77
9.99	-82.86	9.46
-36.17	-12.83	10.81
51.43	-55.43	-11.16
30.85	30.53	-12.56
15.35	-50.79	24.55
51.69	-54.97	22.25
50.47	-53.18	4.27
10.09	-68.63	28.34
54.37	15.44	-17.14
35.34	-33.06	-9.51
6.47	-42.21	-15.1
31.95	-6.45	-22.85
25.99	-62.24	13.12
-22.54	-7.75	-21
32.07	-29.37	-16.47
-1.16	55.05	4.71
-16.82	-25.78	20.59
20.57	-23.52	18.86
-16.19	44.33	-8.71
38.59	-31.56	-4.09
6.78	-48.9	22.26
46.87	-8.99	-29.5
-48.96	5.04	22.84
29.38	-75.66	32.05
-50	-18.92	15.94
16.5	-58.82	30.79
-26.66	3.63	2.63
-23.05	-75.6	23.73
35.7	-68.9	22.49
22.61	-64.06	-10.11
-14.77	-35.51	4.66
51.52	-28.17	11.09
54.79	-18.66	23.63
9.78	-68.63	-12.92
28.3	-59.37	36.27
28.81	12.88	-6.59
10.08	-72.06	25.28
-23.48	9.99	2.06
19.52	-59.54	7.39
42	-63.38	10.8
22.81	-66.41	14.62
6.62	-48.33	2.14
-.8	-60.97	4.4
-.71	-50.17	20.22
-.91	-14.91	8.34
9.85	-69	-3.97
-17.01	-49.75	-14.2
42.13	-68.69	24.63
36.28	15.04	-6.86
3.35	21.21	20.88
-39.2	-78.04	7.39
-10.88	76.94	-.36
36.07	66.68	-13.42
-39.19	-47.23	20.42
-1.28	66.97	-6.32
70.61	-19.65	-4.35
67.56	-18.04	16.74
22.63	-14.42	12.49
-68.33	-29.45	-8.62
-39.29	-21.85	18.29
-2.83	-71.93	14.26
26.23	-77.28	38.91
12.66	67.57	0.16
48.69	-67.11	44.49
38.5	3.76	-1.48
35.21	-24.57	-23.6
41.57	9.01	-16.45
-46.08	44.5	-3.92
35.22	22.78	-3.04
25.68	-79.76	-34.48
-36.37	-64.36	-36.17
35.11	28.27	-14.65
41.69	-9.51	-8.21
-3.45	65.56	-10.64
4.21	52.08	7.13
-48.88	-34.86	16.15
48.65	-70.8	38.11
16.12	-15.49	-.72
-37.27	-46.1	-6.46
-45.94	42.61	12.96
-23.02	-58.8	34.58
44.27	-43.33	35.86
-58.3	-32.86	42.85
-21.53	-11.68	-30.72
-7.44	-37.01	-15.38
-4.24	-56.79	-23.79
27.56	73.57	-6.09
23.35	-12.56	-32.28
28.67	1.56	-29.06
-52.27	-7.1	3.82
22.51	33.76	16.26
-57.39	-67.4	8.94
-46.83	9.28	22.46
-.8	-60.97	4.4
25.49	-5.86	-28.4
64.19	4.43	4.86
51.69	-54.97	22.25
57.87	-41.93	-2.33
-32.99	-61.48	-13.03
51.55	-10.22	22.96
35.34	-33.06	-9.51
49.39	-31.35	11.38
32.04	-20.91	-17.18
45.37	-84.79	22.6
-12.35	-69.91	27.59
57.82	-55.65	-14.56
3.19	55.85	14.63
47.9	31.26	-18.39
-23.59	-25.18	-26.22
19.3	40.34	19.09
-67.21	-27.88	-2.07
7.53	3.84	2.22
-15.93	17.33	13.62
38.59	-31.56	-4.09
41.74	40.48	18.82
-20.46	8.13	-22.36
13.39	-85.27	33.04

// Haase L, 2011: Female Healthy Controls
// Subjects=12
-9.49	-18.56	3.17
41.84	-7.96	11.73
57.93	-1.72	22.18
38.5	13.71	3.26
-10.88	76.94	-.36
12.97	-15.97	7.16
-4.23	-17.18	-7.04
-54.3	-37.86	5.31
64.03	55.44	3.93
-35.16	0.84	8.53
12.88	-12.59	-4.27
44.85	3.2	-9.31
-2.83	-71.93	14.26
-20.43	67.71	4.99
19.29	7.25	4.02
-25.59	-49	-17.51
12.93	-3.28	6.1
63.16	0.45	8.55
19.31	-18.9	-3.82
-15.84	-34.46	4.58
19.63	-61.77	19.85
22.58	-64.32	-13.43
-10.53	-68.75	-12.68
-51.13	4.68	18.43
44.9	10.32	0.13
-38.55	35.2	-1
29.01	-47.65	-4.87
9.81	-57.28	-3.84
9.64	10.11	0.55
61.16	-10.25	21.74
-51.09	-18.04	13.64
38.45	26.4	2.2
41.69	-2.9	-5.42
-54.47	13.15	4.38
22.62	-35.37	3.1
-16.71	-63.13	19.26
28.74	54.98	1.03
50.38	13.92	18.72
41.7	16.9	2.96
57.91	-4.18	17.92
-1.1	2.93	-8.76
-42.73	32.86	10.4
41.67	46.31	11.64
45.1	1.37	22.06
-48.91	5.55	29.48
23.79	-29.93	18.24
38.59	-31.47	-2.99
35.51	-6.09	22.8
-48.96	5.04	22.84
29.38	-75.66	32.05
-50	-18.92	15.94
16.5	-58.82	30.79
-26.66	3.63	2.63
-23.05	-75.6	23.73
35.7	-68.9	22.49
22.61	-64.06	-10.11
-14.77	-35.51	4.66
51.52	-28.17	11.09
54.79	-18.66	23.63
9.78	-68.63	-12.92
28.3	-59.37	36.27
28.81	12.88	-6.59
10.08	-72.06	25.28
-23.48	9.99	2.06
19.52	-59.54	7.39
42	-63.38	10.8
22.81	-66.41	14.62
6.62	-48.33	2.14
-.8	-60.97	4.4
-.71	-50.17	20.22
-.91	-14.91	8.34
9.85	-69	-3.97
-17.01	-49.75	-14.2
42.13	-68.69	24.63
36.28	15.04	-6.86
3.35	21.21	20.88
-39.2	-78.04	7.39
-10.88	76.94	-.36
36.07	66.68	-13.42
-39.19	-47.23	20.42
-1.28	66.97	-6.32
70.61	-19.65	-4.35
67.56	-18.04	16.74
22.63	-14.42	12.49
-68.33	-29.45	-8.62
-39.29	-21.85	18.29
-2.83	-71.93	14.26
26.23	-77.28	38.91
12.66	67.57	0.16
48.69	-67.11	44.49
38.5	3.76	-1.48
35.21	-24.57	-23.6
41.57	9.01	-16.45
-46.08	44.5	-3.92
35.22	22.78	-3.04
25.68	-79.76	-34.48
-36.37	-64.36	-36.17
35.11	28.27	-14.65
41.69	-9.51	-8.21
-3.45	65.56	-10.64
4.21	52.08	7.13
-48.88	-34.86	16.15
48.65	-70.8	38.11
16.12	-15.49	-.72
-37.27	-46.1	-6.46
-45.94	42.61	12.96
-23.02	-58.8	34.58
44.27	-43.33	35.86
-58.3	-32.86	42.85
-21.53	-11.68	-30.72
-7.44	-37.01	-15.38
-4.24	-56.79	-23.79
27.56	73.57	-6.09
23.35	-12.56	-32.28
28.67	1.56	-29.06
-52.27	-7.1	3.82
22.51	33.76	16.26
-57.39	-67.4	8.94
-46.83	9.28	22.46
-.8	-60.97	4.4
25.49	-5.86	-28.4
64.19	4.43	4.86
51.69	-54.97	22.25
57.87	-41.93	-2.33
-32.99	-61.48	-13.03
51.55	-10.22	22.96
35.34	-33.06	-9.51
49.39	-31.35	11.38
32.04	-20.91	-17.18
45.37	-84.79	22.6
-12.35	-69.91	27.59
57.82	-55.65	-14.56
3.19	55.85	14.63
47.9	31.26	-18.39
-23.59	-25.18	-26.22
19.3	40.34	19.09
-67.21	-27.88	-2.07
7.53	3.84	2.22
-15.93	17.33	13.62
38.59	-31.56	-4.09
41.74	40.48	18.82
-20.46	8.13	-22.36
13.39	-85.27	33.04

// Habib R, 2010: Pathological Gamblers
// Subjects=11
-11.93	-20.48	-9.08
13.84	10.14	-15.91
35.22	24.92	-31.18
55.22	-39.83	-1.59
-56.11	-45	-4.78
-55.45	-47.66	47.02
-.56	-7.47	37.62
29.48	-97.56	2.32
-45.54	-17.8	67.43
41.79	-1.75	-29.78
28.82	-4.02	-30.45
-20.86	2.5	-26.89
62.86	-44.71	3.25
-26.72	-102.33	0.39
-64.3	-23	35.76
3.34	-51.06	-4.07
-9.94	-19.59	-22.65
10.5	-84.32	41.68
64.73	26.46	-4.94
63.23	-45.2	32.43
-18.53	-30.16	-20.34
33.8	-97.55	2.25
37.42	0.05	-33.24
7.5	-.85	-6.87
1.04	-47.75	-14.45
23.75	-50.42	70.59
48.23	38.46	-24.9
-5.7	31.24	-18.79
-1.09	-.47	-2.28
-24.51	-104.13	3.89
27.35	-103.95	2.99
-10.91	-55.52	63.85
21.58	-59.25	68.14
-26.44	-87.07	25.77
40.68	-80.37	36.29
-26.4	12.83	49.5
34.19	15.9	56.01
31.66	-101.81	2.71
-20.23	-104.43	0.49
37.42	0.05	-33.24
7.5	-.85	-6.87
-22.76	-1.06	-7.45
1.04	-47.75	-14.45
-63.69	-45.13	-5.76
-9.91	-19.39	-20.43
-32.58	-57.18	58.78
21.58	-63.61	67.45
34.11	19.63	50.04
-28.64	18.79	44.47
9.17	-64.74	-58.85
34.45	-50.04	62.53
42.81	-80.57	34.03

// Habib R, 2010: Healthy Controls
// Subjects=11
-11.93	-20.48	-9.08
-.7	58.24	40.09
-56.52	-2.09	-28.07
7.83	-94.66	0.16
27.77	-0.08	57.7
-17.42	-24.08	67.57
51.38	23.95	49.32
42.6	39.35	42.34
-17.82	-80.66	24.99
-34.79	-18.17	62.8
29.66	23.04	40.81
55.47	-60.92	13.94
-37.39	-59.77	19.89
67.09	26.85	10.66
-33.08	25.49	36.04
27.32	35.92	29.49
71.26	-13.6	-8.94
-22.97	60.83	-11.33
-31.54	-87.48	-35.73
31.74	27.95	35.81
-37.74	26.28	10.27
-.84	39.66	25.12
65.19	-30.27	19.71
-55.33	-44.6	56.8
10.59	-59.57	53.79
44.95	-33.69	41.68
-34.81	-53.35	53.95
-48.94	51.71	-15.59
58.39	-62.23	-11.75
38.35	25.61	44.89
33.95	-57.08	21.77
-37.82	-71.7	-15.9
-.52	30.04	48.48
38.28	-81.08	17.35
51.75	-34.57	66.31
-26.78	-84.14	-.29
-45.84	12.76	49.84
56.52	16.57	27.55
-24.51	-104.13	3.89
27.35	-103.95	2.99
-10.91	-55.52	63.85
21.58	-59.25	68.14
-26.44	-87.07	25.77
40.68	-80.37	36.29
-26.4	12.83	49.5
34.19	15.9	56.01
27.35	-105.02	3.1
44.97	-36.78	43.11
-28.41	-44.07	49.56
-3.4	-65.79	56.89
-51.09	49.58	-15.34
38.35	25.61	44.89
48.7	44.12	12.63
-32.85	23.96	54.11
-50.58	35.88	21.86
-2.69	29.93	47.41
33.37	-67.93	-25.33
5.45	-82.08	-14.49
-39.93	-75.76	-13.22
-18.11	-101.44	-2.08
64.83	-55.93	-13.6
7.93	-30.48	20.71

// Mies G W, 2011: Positive Feedback > Negative Feedback
// Mies G W, 2011: Invalid Feedback > Valid Feedback
// Subjects=29
-52	-46	42
54	-38	36
-48	-58	48
8	42	18
12	44	18
-18	-50	36
-22	24	48
-28	22	42
-30	8	0
-56	-58	-8
-34	-16	42
58	4	12
10	-38	44

// Nakamura Y, 2011: Umami
// Nakamura Y, 2011: Salty
// Subjects=20
40	-4	15
52	-2	15

// Kucian K, 2011: Developmental dyscalculia (DD) children
// Subjects=16
-12	30	42
3	21	57
-39	21	3
39	24	42
-12	-18	36
-63	-39	57
18	-63	48
63	-54	0
-15	-3	9
-24	-33	75
-36	-84	36
30	-42	51
21	-36	75
-36	-27	15
-12	-33	-27
-45	9	30
9	18	39
39	21	45
-9	30	42
9	36	54
-33	27	27
-39	-15	45
-36	-48	48
-24	3	66
-42	15	0
-27	-18	42
-39	-66	6
-12	39	39
-36	3	39
-51	-27	12
-18	3	54
-36	-63	30
9	12	60
24	48	24
63	-66	21
-48	-45	54

// Kucian K, 2011: Healthy control children (CC)
// Subjects=16
42	-45	60
-3	18	60
-42	-63	-30
-30	-48	48
3	-18	30
-9	-75	-24
-45	3	45
33	21	21
-36	15	9
24	0	69
51	6	36
-12	-18	36
-63	-39	57
18	-63	48
63	-54	0
-15	-3	9
-24	-33	75
-36	-84	36
30	-42	51
21	-36	75
-36	-27	15
-12	-33	-27
-45	9	30
9	18	39
39	21	45
-9	30	42
9	36	54
-33	27	27
-39	-15	45
-36	-48	48
-24	3	66
-42	15	0
-27	-18	42
-39	-66	6
-12	39	39
-36	3	39
-51	-27	12
-18	3	54
-36	-63	30
9	12	60
24	48	24
63	-66	21
-48	-45	54

// Meusel L C, 2013: PRE, Recollection memory task (Recollect-encode), Healthy 
// controls > Patients (Hypoactivity)
// Meusel L C, 2013: PRE, Recollection memory task (Recollect-encode), 
// Patients > Healthy controls
// Meusel L C, 2013: POST > PRE, n-back (2-back - 0-back)
// Meusel L C, 2013: POST > PRE, Recollection memory task (Recollect-encode)
// Meusel L C, 2013: PRE, n-back (2-back - 0-back) , Healthy controls > 
// Patients (Hypoactivity)
// Subjects=13
10.55	-9.03	-26.85
-9.75	-8.1	-26.7
22.44	-17.45	-12.9
-19.09	-35.96	-.83
-37.37	-32.87	-14.26
19.58	22.31	47.37
-9.36	44.34	45.85
41.58	44.22	-1.56
32.01	31.48	-.38
-54.29	10.55	25.78
9.73	49.51	28.47
3.18	51.36	11.66
45.15	-34.29	15.02
-54.68	9.87	-24.34
38.94	-38.88	38.89
23.03	-57.49	47.33
-41.23	-26.41	42.11
32.02	-21.08	-19.4
-25.55	-36.52	-7.4
35.14	70.33	6.36

// Penades P, 2013: Healthy Control (HC)
// Subjects=15
-26	-66	52
42	38	24
-2	18	44
22	-34	72
6	46	-12
-30	-98	-5
30	-94	-4

// Penades P, 2013: Subgroup of schizophrenia patients, cognitive remediation 
// therapy (SZ-CRT)
// Subjects=17
-26	-66	52
42	38	24
-2	18	44
22	-34	72
6	46	-12
-30	-98	-5
30	-94	-4
10	-66	28
-30	-98	0
26	-98	-4
-46	-38	56
46	-42	52
30	2	60
-26	-62	52
-34	50	16
42	42	20
0	-57	16
2	38	-20
-30	-98	-4
-2	-56	36
-46	-70	28
-3	-88	0
-38	-18	60
22	-66	60
30	-2	48

// Penades P, 2013: Subgroup of patients, social skills training (SZ-SST)
// Subjects=18
10	-66	28
-30	-98	0
26	-98	-4
-46	-38	56
46	-42	52
30	2	60

// Rowland L M, 2010: Schizophrenia
// Subjects=17
48	14	16
38	10	26
50	30	10
34	30	10
20	-18	46
28	-62	36
-54	-32	-16
38	-72	50
24	12	-18
-44	-22	3
-52	2	-20
-8	-100	12
10	-6	36
-8	-54	60
30	-70	-14
56	-56	-12

// Rowland L M, 2010: Healthy Controls
// Subjects=17
50	4	40
20	-18	52
50	38	6
40	10	26
-6	4	28
32	30	4
-12	-44	-2
12	-42	-2
8	-52	12
8	-58	38
-8	-52	12
-38	-70	34
-10	-36	28
14	-88	2
34	-82	2
38	10	26
50	30	10
34	30	10
20	-18	46
28	-62	36
-54	-32	-16
26	34	-6
10	-22	44
-8	-52	58
32	-72	-16
10	-6	36
-8	-54	60
30	-70	-14
56	-56	-12

// Subramaniam K, 2014: 2-back > 0-back
// Subjects=16
48.91	41.32	28.59
-43.92	32.9	35.49
39.81	26.91	-10.17
-33.61	22.61	-6.25

// Vianin P, 2014: RECOS vs. TAU at T2
// Vianin P, 2014: T2 vs. T1 in RECOS
// Subjects=8
50	-56	44
52	8	42
-48	34	30
-32	-96	2
-2	-36	50
-20	-74	54
52	6	42
-30	-62	56
38	-64	58
36	-88	-8
-32	-94	0
60	-28	40
-6	2	74
-6	-20	76

// Bugden S, 2012: Large Ratio > Small Ratio
// Subjects=17
-29.37	-66.95	39.8
-13.96	-5.24	-16.85
14.02	-39.28	-5.4
-13.71	-46.59	-1.12
7.58	-72.58	-22.6
0.35	-79.92	7.09

// Meintjes E M, 2010: Proximity Judgment (PJ)  > Proximity Judgment Control 
// (PJCTL)
// Meintjes E M, 2010: Exact Addition (EA) > Exact Addition Control (EACTL)
// Subjects=16
43.29	-44.6	47.13
34.75	-67.71	38.01
-9.1	-68.32	34.11
-3.72	-64.6	40.42
-29.36	-65.81	40.82
4.74	-87.49	18.83
33.33	25.34	30.23
40.7	36.33	20.3
-21.29	30.33	17.05
6.68	24.8	39.5
-44.66	18.44	30.59
13.3	-66.41	29.23
13.21	-75.01	14.34
29.91	22.03	1.55
-26.74	21.52	0.01
34.51	-44.93	16.03
-18	1.62	17.19
36.82	-57.38	33.78
-33.71	-53.4	36.48
-40.16	-44.01	34.66
-29.39	-62.81	38.34
4.75	-59.86	32.12
-9.13	-63.11	32.56
28.2	-18.59	40.66
41.86	25.22	27.91
33.13	54	15.56
-18.18	51.32	13.03
-26.34	9.17	46.76
2.36	25.41	33.92
3.47	25.76	38.34
-6.33	24.96	15.1
-8.33	21.91	30.99
0.28	-3.76	28.58
-43.66	22.16	23.57
-35.03	10.92	28.87
34.18	19.77	-.54
35.21	-63.04	-39.33
4.22	-47.82	-32.45
17.16	7.32	5.16
-14.87	4.13	8.02
32.38	-41.52	19.12
22.6	-15.82	8.15

// Mussolin C, 2010: Number Comparison vs. Fixation (Developmental Dyscalculia 
// (DD) Children > Control Children))
// Mussolin C, 2010: Small Numerical Distance vs. Large Numerical Distance 
// (Control Children > DD Children)
// Mussolin C, 2010: Close Color Distance vs. Far Color Distance (Control 
// Children > DD Children)
// Subjects=15
28	-30	42
46	-32	34
-2	-20	-12
30	36	36
-18	-64	52
42	-46	54
-12	-28	46
-10	-76	-6
16	-64	0
-2	-80	30

// Park J, 2012: Letter > Number
// Park J, 2012: Number > Letter
// Subjects=20
-57	-28	28
-36	-37	-23
24	-43	58
51	-25	34
3	20	34
48	-73	-2

// Kedia G, 2014: Distance effect in the beauty conditions
// Kedia G, 2014: Distance effect in height conditions
// Kedia G, 2014: Distance effect in the women conditions
// Kedia G, 2014: Distance effect in the dog conditions
// Kedia G, 2014: Main effect of judgment: Beauty>Height comparisons
// Kedia G, 2014: Main effect of judgment: Height>Beauty comparison
// Kedia G, 2014: Main effect of judgment: Height>Control condition
// Kedia G, 2014: Main effect of target: Women>dogs
// Kedia G, 2014: Main effect of target: Dogs>Women
// Kedia G, 2014: Conjunction analyses of the beauty and height distance 
// effects
// Kedia G, 2014: Conjunction analyses of the beauty and height distance 
// effects (reaction time as a covariate)
// Kedia G, 2014: Conjunction analyses of the women and dog distance effects
// Kedia G, 2014: Conjunction analyses of the women and dog distance effects 
// (reaction time as a covariate)
// Kedia G, 2014: Distance and judgment interactions, Deactivations
// Subjects=25
49.89	44.95	21.49
4.87	31.02	47.17
-34.75	18.89	-11.47
-40.69	9.85	29.87
-33.78	-55.89	49.7
31.04	-55.66	48.58
43.22	-61.53	-14.92
-28.31	-70.04	-33.03
-5.61	-86.22	-35.18
-1.81	36.13	33.33
-40.8	28.68	24.65
55.99	22.4	-13.36
-54.23	15.32	-14.14
-40.15	-51.79	59.49
31.18	-57.92	58.88
-44.74	-68.46	-49.72
39.75	-69.8	-34.22
7.43	-72.48	-26.68
-37.6	28.38	21.26
1.62	31.01	47.23
-31.52	22.1	-11.84
-33.89	-50.13	42.41
27.93	-54.74	58.62
49.7	-61.51	-15.03
-28.31	-70.04	-33.03
-37.68	-83.84	-7.97
49.75	47.21	11.19
4.81	33.9	43.52
-50.99	15.33	-14.2
33.24	25.2	-16.61
-40.69	9.85	29.87
-36.89	-54.97	59.75
34.43	-61.1	59.14
33.03	-74.88	-53.77
-5.52	-85.6	-28.52
36.57	-52.92	-25.75
-34.72	-56.36	-24.19
27.68	9.08	52.31
-59.85	-30.77	44.3
24.77	-54.13	65.34
-14.14	-60.96	63.32
37.6	-74.78	50.36
27.68	9.08	52.31
24.77	-54.13	65.34
-17.39	-57.78	63.06
53.16	25.51	20
46.3	-43	-23.53
53.29	-62.2	11.87
-47.11	-71.81	17.89
11.43	-89.82	28.76
-56.69	-31.38	37.58
-27.95	-87	-7.83
30.48	-86.17	-2.18
1.53	33.58	40.25
-36.89	-54.97	59.75
31.18	-57.92	58.88
-41.28	-70.08	-32.81
1.53	33.58	40.25
-36.89	-54.97	59.75
31.18	-57.92	58.88
-41.28	-70.08	-32.81
56.46	32.52	25.97
4.81	33.9	43.52
-36.95	-52.09	56.11
31.14	-58.23	55.55
-34.81	-66.87	-33.24
56.46	32.52	25.97
4.77	33.59	40.19
-36.95	-52.09	56.11
31.14	-58.23	55.55
-34.81	-66.87	-33.24
4.14	51.87	-5.31
-60.04	-58.47	23.51
-17.92	-55.13	22.47

// Mier D, 2014: Healthy Controls
// Subjects=18
-63	-48	3
-54	-48	3
-48	-54	12
54	-51	12
54	36	-3
51	-3	-24
-48	-6	-21
-51	9	-33
-48	33	-3
-45	-42	-18
-15	-81	-39
24	-54	-12
-45	-51	12
-51	-45	6
-60	-39	-9
57	-48	12
36	-66	45
-30	-66	39
60	21	3
-12	51	39
45	24	30
-3	-81	42
-45	36	18
27	18	21
-36	21	21
-54	21	12
24	-54	-12
30	-63	-15
24	-57	-15
-9	15	66
9	18	63
12	-48	-36
18	-42	-33
24	-21	-27
-12	-45	-36
12	-48	-36
30	-9	45
18	-39	-30
21	-51	-39
12	-48	-36

// Mier D, 2014: Psychopaths
// Subjects=11
24	-54	-12
-45	-51	12
-51	-45	6
-60	-39	-9
57	-48	12
36	-66	45
-30	-66	39
60	21	3
-12	51	39
45	24	30
-3	-81	42
-45	36	18
27	18	21
-36	21	21
-54	21	12
24	-54	-12
30	-63	-15
24	-57	-15
-9	15	66
9	18	63
-15	-6	-24
18	-39	-30
21	-51	-39
12	-48	-36

// Bolling D Z, 2011: Healthy Controls
// Subjects=24
46.09	-11.45	7.52
10.96	-53.16	8.07
-8.25	-59.62	8.83
-11.85	45.04	0.1
-53.56	19.19	-13.98
-47.05	-7.21	-11.84
-46.81	-21.27	12.75
-43.96	-44.65	-42.2
30.64	-55.02	64.88
43.26	5.59	62.99
65.36	-47.26	-3.09
43.37	-42.77	57.01
-39.99	-69.67	46.84
-18.38	63.53	-8.07
52.16	-1.81	-33.51
36.68	16.95	45.39
-30.7	19.21	39.28
4.55	35.79	44.18
23.42	-23.93	-27.98
36.61	-13.4	24.52
20.92	-42.9	57.28
4.39	-51.57	-12.06
-8.76	-18.81	-41.42
-14.54	-78.18	17.15
-36.86	-21.04	56.11
42.8	-2.47	0.11
23.81	-46.22	14.03
33.34	-30.56	9.26
-27.6	-1.61	17.57
-34.09	-35.42	-6.28
-14.75	-44.05	4.26
-14.66	-13.45	28.45

// Bolling D Z, 2011: Autism spectrum disorder (ASD) patients
// Subjects=24
-8.37	-34.5	3.38
-56.24	-9.5	41.98
-59.72	-5.74	8.25
40.13	-43.04	53.73
36.46	34.44	23.85
36.31	26.3	1.12
39.58	50.07	19.16
23.99	14.99	62.43
17.1	59.45	18.63
-21.54	57.42	-4.17
-33.76	-48.46	31.61
-40.74	-41.2	-39.18
49.76	-39.56	56.67
62.02	-18.99	-8.76
36.35	-81.98	-36.64
43.21	-83.92	20.32
13.95	3.96	3.25
-4.81	-53.86	41.77
-14.88	-2.56	4.12
-46.61	-42.19	31.23
42.78	23.68	7.95
-37.51	21.66	-11.03
39.92	14.06	48.94
4.24	16.08	-4.35
-5.5	41.14	-9.69
-66.31	-7.58	-14.94
11.27	-20.24	62.18
42.97	-7.27	20.58
20.57	-36.73	13.27
-37.36	-26.18	-10.36
-24.39	-31.17	6.63

// DeRamus T P, 2014: Healthy Controls
// Subjects=19
-4	-68	54
66	-44	24
62	-40	40
54	-42	22
38	-92	6
-40	-48	-12
-54	22	10
38	-50	-22
-46	36	12
-6	54	30
-36	-90	2
-42	-82	-2
-12	40	50

// DeRamus T P, 2014: Autism Spectrum Disorder ASD patients
// Subjects=17
44	-64	6
62	-40	4
-4	-40	30
-10	-34	32
14	-48	34
-40	-60	36
-50	-60	44
-44	-50	46
32	18	44
26	16	54
24	-94	-10
24	-98	0

// Brieber S, 2010: Coherent Motion (CM) > Random Motion (RM)
// Brieber S, 2010: Interaction (Controls > ASD Patients x CM > RM)
// Subjects=15
-14	-34	61
16	-54	55

// Delmonte S, 2012: Reward anticipation: Monetary incentive delay> Social 
// incentive delay
// Delmonte S, 2012: Reward feedback: Monetary incentive delay (MID) > Social 
// incentive delay (SID)
// Subjects=21
44	-6	58
-36	34	-6
0	10	64
-44	34	14
42	26	-10
56	-26	-2
-50	-58	-2
-56	-24	-12
-34	-6	-23
-46	-24	48
8	-52	44
-28	-50	44
14	-28	64
-20	-66	38
24	-74	44
36	-90	6
-32	-90	12
-34	-6	-28
32	-76	-30
8	-86	-38
-34	-46	-24
-24	-82	-32
42	22	-12
10	-28	64
-54	14	32
-4	46	30
4	34	20
4	-30	34
-32	24	4
66	-24	6
54	-14	4
-40	-32	10
52	-62	-12
-32	-94	6
-16	-74	8
16	-70	10
30	-66	-4
42	-46	-16
-28	-64	-12
62	-14	30
-46	-24	44
-34	-50	56
-54	-30	38
-20	-48	46
16	12	0
-28	-34	2
42	-74	-38

// Cascio C J, 2012: Healthy Controls
// Subjects=18
-20	-3	-20
-30	3	-18
25	3	-28
23	-5	-18
8	15	-13
-33	-23	23
-30	-25	15
-35	33	-20
48	-3	3
43	5	5
40	20	8
-45	5	3
-38	13	-3
8	35	20

// Cascio C J, 2012: Autism Spectrum Disorder ASD patients
// Subjects=17
-23	-8	-15
25	-5	-18
-13	25	-8
-38	-15	23
43	-5	3
45	10	-13
40	3	-13
15	28	-13
48	-3	3
43	5	5
40	20	8
-45	5	3
-38	13	-3
8	35	20

// Carter E J, 2012: Healthy controls
// Subjects=13
-62	-6	28
56	30	4
-28	22	-6
26	20	0
40	4	58
52	16	46
4	-98	-2
-36	-2	64
-40	-14	64
2	18	50
12	10	72
42	20	32
-46	6	28
-58	24	22
40	26	20
-26	26	0
32	-24	24
-48	32	36
40	2	58
-58	-50	2
2	-98	4
12	-36	68
-38	-36	44
-34	-4	66
-22	-14	72
-58	10	34
28	22	0
30	0	6
-42	-4	14
24	2	72
-16	22	28
-10	6	10
-42	4	26
36	26	-18
-54	26	30
-30	20	-8
40	6	54
52	16	46
-64	-8	-28
2	-98	-2
-44	6	48
34	0	68
-12	26	34
10	24	38
-12	-14	14
-54	-50	52
-42	-36	38
-18	-6	44
18	-34	36
-8	-30	44
-46	48	10
-26	-30	62
44	-14	46
-50	0	2
44	2	10
-12	-12	64
16	-12	66
-6	6	6
12	32	32
-40	-44	-24
44	-46	-22
-28	-28	-6
28	-28	-6
34	16	-18
-30	18	-8
42	6	52
52	-2	-26
52	-56	10
-60	-12	-20
-50	-44	2
-62	-56	16
-52	-76	14
28	-56	-10
34	-94	14
36	-94	-2
28	-86	40
-18	-96	-4
-26	-96	20
40	4	30
2	-54	26
-4	46	16
6	30	64
8	64	6
-48	12	4
44	42	-12
-46	36	-2
-28	24	-2
42	4	58
30	48	-12
-26	-88	-4
6	-36	48
22	-84	14
18	-100	18
-14	-98	26
46	-46	0
44	44	-10
-22	-52	48
22	-16	68
-22	-2	-24
4	24	-6
-36	34	-6
-38	10	52
-60	-4	-22
22	-86	16
-14	-98	26
-12	-6	24
-32	-16	-16
-32	16	-22
-52	18	-2
44	28	4
30	14	-18
-28	20	-6
42	4	58
-64	-50	-4
-68	-42	-2
-14	4	2
-44	10	-24
-26	-88	-4
6	-36	48
32	26	42
28	-26	56
22	-84	14
18	-100	18
46	-14	0
-28	-86	-2
-40	-36	40
44	-58	-6
34	30	40
18	-18	68
32	-24	66
16	-4	62
-52	20	2
52	-2	-26
4	40	10
30	12	-18
-28	-14	-16
-28	14	-10
-30	-26	-10
-32	14	-22
-8	8	-2
-58	-14	-20
-46	8	-22
-32	34	30
-10	-90	30
2	-54	22

// Carter E J, 2012: Autism Spectrum Disorder ASD patients
// Subjects=12
-20	-2	-22
-12	24	0
40	6	34
-36	2	50
-62	-6	24
36	-72	-26
-40	-14	66
-52	14	36
0	-52	52
30	-8	70
30	-62	50
-10	14	48
-20	-4	-24
2	6	-14
14	18	42
-48	6	52
38	46	38
-62	-6	-24
20	-104	8
24	-16	-20
-38	-18	68
48	-18	62
42	6	34
2	-56	24
-32	-2	-6
-44	-20	22
30	-10	72
-30	-70	46
26	-58	48
2	0	72
-10	14	48
20	-10	-2
20	-8	-16
-16	-6	-14
-34	16	32
40	6	36
-30	20	-6
38	-52	-20
-52	10	42
-30	-10	70
-36	2	50
0	-52	52
26	24	0
38	-10	68
20	-64	60
-8	16	48
-42	20	-20
14	2	40
-6	12	38
-52	-22	40
-38	-18	16
44	2	-4
-42	52	14
-18	-38	66
-34	-22	58
26	-32	70
48	-18	46
-14	-4	44
50	-26	38
-54	-30	24
-28	-48	-12
34	20	18
-26	24	0
40	10	40
44	-56	16
-52	-58	18
46	-56	-10
-28	-92	-4
-26	-72	26
-48	-64	-18
30	-68	32
-22	-62	56
28	-54	54
-42	20	-18
-48	12	4
44	42	-12
-46	36	-2
-28	24	-2
42	4	58
30	48	-12
-26	-88	-4
6	-36	48
22	-84	14
18	-100	18
-14	-98	26
46	-46	0
44	44	-10
-22	-52	48
22	-16	68
-22	-2	-24
4	24	-6
-36	34	-6
-38	10	52
-60	-4	-22
22	-86	16
-14	-98	26
-12	-6	24
-32	-16	-16
-32	16	-22
-52	18	-2
44	28	4
30	14	-18
-28	20	-6
42	4	58
-64	-50	-4
-68	-42	-2
-14	4	2
-44	10	-24
-26	-88	-4
6	-36	48
32	26	42
28	-26	56
22	-84	14
18	-100	18
46	-14	0
-28	-86	-2
-40	-36	40
44	-58	-6
34	30	40
18	-18	68
32	-24	66
16	-4	62
-52	20	2
52	-2	-26
4	40	10
30	12	-18
-28	-14	-16
-28	14	-10
-30	-26	-10
-32	14	-22
-8	8	-2
-58	-14	-20
-46	8	-22
-32	34	30
-10	-90	30
2	-54	22

// Sabatino A, 2013: Face targets: ASD > Controls
// Sabatino A, 2013: High autism interest (HAI) targets: ASD < Controls
// Sabatino A, 2013: Group (ASD, Controls) X Target (Face, HAI) Interactions
// Subjects=15
40	8	-8
-6	52	18
-6	56	28
-26	-2	-20
-6	14	0
-48	-10	8
-58	10	14
-34	-76	24
2	6	30
62	-8	10
10	-82	-4
26	20	42
28	-66	-18
50	2	26
30	-56	-12
-16	-60	-6
22	-50	-2
0	-50	4
0	0	-4
26	-2	48

// Sato W, 2012: Healthy Controls
// Subjects=13
34	-84	8
52	-62	0
40	-60	-12
50	-36	6
54	6	-12
54	-28	28
40	-2	50
56	28	10
52	8	36
32	-10	-16
28	-8	-12
6	64	22
-14	50	18
-48	-78	0
-56	-50	10
-52	-18	0
-62	-32	20
-42	-58	-16
-46	-32	22
-26	-6	-16

// Sato W, 2012: Autism Spectrum Disorder ASD Patients
// Subjects=12
46	-78	0
52	-64	-2
48	-48	6
60	-24	38
48	-6	46
46	8	36
-52	-72	2
-58	-54	2

// Tully L M, 2014: Healthy Controls
// Subjects=24
3	-67	-35
-18	-67	-44
36	14	19
6	11	52
-6	11	46
-42	2	31
-27	-49	-50
6	-28	28
-36	-19	64
39	-88	-8
-36	17	4
-27	-7	43
42	20	-8
-39	-46	10
21	-46	46
-42	-34	-14
6	-61	-35
-21	-70	7
-15	-70	-38
21	-64	7
12	-10	13
12	-25	73
-15	14	34
48	26	-17

// Tully L M, 2014: Schizophrenia
// Subjects=23
33	20	7
-24	-61	49
-21	-49	-32
24	-52	-20
-30	-88	-11
24	-61	-47
45	-40	61
24	-64	52
48	-46	-2
-12	-16	10
-33	17	10
21	-64	4
69	-34	22
-39	-43	64
-33	-16	64
-15	14	34
48	26	-17

// Morita T, 2012: Autistic Subjects (ASD)
// Subjects=15
-24	-42	34
4	-38	32
-28	-34	28
44	40	-10
36	46	0
36	18	-8

// Morita T, 2012: Healthy Controls (HC)
// Subjects=15
38	8	-8
48	6	26
48	34	4
-40	20	-8
-4	24	28
60	-22	28
52	14	-8
10	8	-8
28	-78	32
-36	14	-6
-44	16	-12
-6	8	32
4	-28	26
-24	-78	22
46	-62	-4
8	20	32
-44	-62	-12
-26	-84	34
54	-22	42
6	-12	6
-4	-10	6
46	4	42
2	6	38
38	-84	-6
-46	-68	-4
32	16	4
-4	-12	40
-34	26	0
-14	48	32
-46	36	12
-46	18	-16
2	28	20
32	20	2
46	16	-10
48	32	12
-20	-26	-14
-10	-28	4
6	-12	10
-24	-42	34
4	-38	32
-28	-34	28
44	40	-10
36	46	0
36	18	-8

// Rahko J S, 2012: ASD vs. Controls, Happy expressions
// Rahko J S, 2012: ASD vs. Controls, Fearful expressions
// Rahko J S, 2012: Happy vs. Fear, Group differences
// Subjects=25
-40	-12	-14
24	16	-6
-42	42	24
40	48	26
-50	-68	8
-58	-36	46
50	0	12
-54	6	-28
66	-36	14
-46	-8	58
28	64	12
-50	-2	-36
36	10	-22
-58	-16	-8
-28	-18	0
66	0	20
-56	-54	-22
68	-6	22
46	52	8
54	12	12
54	14	14
-60	-42	44
-56	-8	-30
-56	-52	-24
22	6	-14
30	66	-6
6	70	-2
14	72	-2
-30	-20	2
66	-30	10
64	-28	10
64	4	24
64	6	26
2	36	32
-20	-2	54
-50	-22	58
18	-76	-4
12	-66	-16
-36	4	8
66	-10	0
62	-10	28
-48	42	0
-36	26	-6
64	-12	32
56	14	36
-42	10	8
-56	28	0
-62	-40	42
-60	-38	42
-42	-28	2
-34	22	4
-48	12	20
-48	14	22
44	6	30
68	-34	38
-62	-26	42
62	-18	48

// Schneider K, 2013: Autistic Subjects (ASD)
// Subjects=28
-45	26	4
60	20	19
-45	-4	52
57	2	46
-12	53	28
51	-19	-11
45	-31	7
15	2	13
54	-67	4
24	-79	-35

// Schneider K, 2013: Subgroup of Autistic Subjects, Males
// Subjects=15
-21	35	28
24	35	31

// Schneider K, 2013: Subgroup of Autistic Subjects, Females
// Subjects=13
-21	35	28
24	35	31
3	-28	-5

// Schneider K, 2013: Healthy Controls (CON)
// Subjects=28
-3	-13	40
54	29	-5
63	11	25
42	-1	43
-3	53	31
0	-28	-5
-18	-97	13

// Schneider K, 2013: Subgroup of Healthy Controls, Females
// Subjects=13
3	-28	-5

// Schulte-Ruther M, 2011: Autistic Patients (ASD)
// Subjects=14
0	-58	34
-6	-48	26
2	48	-16
-8	56	-14
4	62	18
-8	56	34
-16	34	52
-38	20	44
-46	36	-8
-48	22	6
50	26	-12
0	-58	34
-2	-54	34
-50	-62	34
50	-54	30
60	-36	-4
-56	-14	-18
50	6	-30
48	4	-40
-54	-30	-18
28	-80	-36
-24	-86	-42
12	62	30
50	16	46
40	26	-12
50	-50	30
0	-58	34
-6	-48	26

// Schulte-Ruther M, 2011: Control Subjects (CS)
// Subjects=14
8	56	-10
-8	58	-18
12	-50	28
0	-48	26
-16	-58	-2
54	-38	-4
-60	-60	16
2	48	-16
-8	56	-14
-2	56	8
-4	56	26
8	56	28
-4	54	-16
8	58	-6
-40	30	-14
-52	30	-4
12	-50	30
-6	-52	28
-4	-64	32
-52	-58	24
54	-36	-4
-58	-40	-6
34	-76	-36
12	62	30
50	16	46
40	26	-12
50	-50	30
-6	56	-14
8	58	-6
12	-50	30
-2	-48	28
-58	-62	14
54	-36	-4

// Han D H, 2014: Emotional word > Neutral word, ASD patients > Healthy 
// controls
// Han D H, 2014: Facial emoticons > Neutral faces, ASD patients < Healthy 
// controls
// Subjects=10
35.45	-84.68	-16.33
59.93	-40.49	-11.4
66.38	-40.02	-5.93
34.36	-87.05	-19.47

// Koldewyn K, 2011: Biological motion > Coherent motion, Healthy controls > 
// ASD patients
// Koldewyn K, 2011: Biological motion > Coherent motion, ASD patients > 
// Healthy controls
// Subjects=16
30	18	0
14	-62	50
30	34	30
-40	-58	46
4	38	16
42	-76	-4
-40	-78	-4

// Masten C L, 2011: Autism Spectrum Disorder ASD patients
// Subjects=19
6	33	-4
-48	15	4
42	30	0
57	30	12
6	12	-4
33	-87	24
-51	-24	-12
60	-3	-16
-21	-81	-20
15	-84	-16
-9	-51	48
42	0	52
-48	18	20
42	-15	12
-45	12	-8
45	36	-12
21	3	-12
36	-84	-12
51	-18	-16
57	-60	16
-36	6	-20
0	-42	4
21	-54	-12
6	-42	44
33	-81	44
27	-3	-8
0	24	20
3	0	48
-60	-18	16

// Masten C L, 2011: Healthy Controls
// Subjects=17
0	36	-16
36	18	-24
-45	15	-12
39	36	-16
54	39	8
-42	27	-12
6	3	4
-3	-99	20
42	-63	24
-63	-33	0
63	-12	-12
6	-57	-48
30	-78	-32
3	-42	40
21	3	-12
0	60	36
-18	-21	-12
24	-18	-8
-60	-30	-20
42	-15	12
-45	12	-8
45	36	-12
21	3	-12
36	-84	-12
51	-18	-16
57	-60	16
-36	6	-20
0	-42	4
21	-54	-12
6	-42	44
33	-81	44
27	-3	-8
0	24	20
3	0	48
-60	-18	16

// Pfeifer J H, 2013: Group x target interaction: Healthy Controls > ASD 
// patients for Self > Other (age covariate)
// Pfeifer J H, 2013: Healthy controls > ASD patients, Self > Other (age 
// covariate)
// Pfeifer J H, 2013: ASD patients > Healthy controls, Other > Self (age 
// covariate)
// Subjects=18
36.14	-3.08	47.51
-30.53	11.11	30.29
-33.61	6.4	57.26
-1.97	1.69	27.43
19.93	70.6	12.6
-2.17	58.82	30.18
0.97	51.33	10.7
-2.25	46.52	-15.59
23.18	48.56	14.09
48.66	17.26	16.08
29.6	23	9.14
-30.6	12.84	6.86
-30.51	11.51	36.92
36.14	-3.08	47.51
-24.31	32.21	12.16
0.93	43.4	-15.4
-11.56	16.96	19.79
-30.51	11.51	36.92
-36.78	6.37	57.28
36.14	-3.08	47.51
-24.31	32.21	12.16
45.48	17.03	12.79
-11.56	16.96	19.79
29.59	26.15	8.93
23.19	45.41	14.3
29.61	40.38	34.59
-2.18	58.62	26.87

// Watanabe T, 2012: Autism Spectrum Disorder ASD patients
// Subjects=15
-26	-4	-18
60	4	0
2	34	8
0	30	52
54	28	22
38	42	-4
-38	16	-8
-26	-6	-20
56	2	0

// Watanabe T, 2012: Healthy Controls
// Subjects=17
32	24	2
-26	22	-2
50	28	22
-54	18	20
-4	20	50
40	-54	56
-30	-64	48
-44	-44	52
2	34	8
0	30	52
54	28	22
38	42	-4
-38	16	-8
-26	-6	-20
56	2	0

// Daly E, 2014: Healthy Controls
// Subjects=14
66.14	28.88	-9.48
51.13	56.8	-4.96
24.64	58.95	25.28
70.63	10.27	10.99
-33.33	67.92	-4.92
-56.85	43.58	-14.88
-64.15	21.21	-.65
-37.18	-8.98	19.42
58.74	-3.32	-12.27
-63.75	-60.32	18.45
-60.56	-69.28	12.47
5.65	-93.52	-4.1
-5.96	-108.5	9.56
-48.78	-88.67	8.39
-32.79	-101.15	-3.01
-29.82	9.67	12.19
-41.48	-90.51	-16.07
5.24	52.72	1.49
32.14	42.71	20.98
43.92	47.43	26.02
35.49	3.6	24.22
-3.1	47.15	26.58
13.03	19.76	28.7
-13.6	11.65	36.37
24.56	17.51	-1.36
20.4	23.09	16.07
-13.68	7.54	24.45
-25.5	10.12	17.68

// Daly E, 2014: Autistic Subjects
// Subjects=14
8.28	19.25	-32.54
46.95	17.13	-8.27
20.5	36.18	33.93
9.04	18.33	65.66
5.88	-17.53	56.44
58.86	2.28	5.1
15.87	16.01	-20.09
-64.21	23.87	-7.56
-22.64	39.55	-14.93
-10.27	13.04	54.06
51	26.91	-33.67
20.08	-17.58	-41.86
-45.17	26.33	-32.52
-18.41	2.8	-36.43
1.06	1	-6.39
5.72	-11.5	38.09
8.84	11.78	36.1
-6.22	23.87	28.57
43.8	17.63	-1.59
-29.86	22.36	11.13
8.59	1.56	0.16
32.07	9.1	-.74
-3.14	6.14	5.49
58.51	43.75	-22.91
43.97	47.95	32.67
20.84	6.77	66.5
20.78	10.57	60.6
-60.76	23.11	23.69
-37.7	66.95	-17.06
-33.33	67.92	-4.92
-10.85	6.96	-24.6
-25	-8.86	75.03
62.85	15.86	-26.19
1.22	23.49	22.94
-3.02	23.89	28.53
-33.04	13.88	11.88
-10.78	24.19	-8.2
-10.64	1.44	0.39
-29.88	13.39	5.19

// Diehl J J, 2014: Typically developing (TD) vs Reading difficulty (RD) by 
// task (figures vs lexical decision)
// Subjects=10
-26	-86	-38
54	-69	30
-51	0	44
54	-72	-34
-6	-6	58
-60	-44	40
10	8	-16
34	-66	-9
-42	-84	-12
34	-6	44
30	-84	18
-38	-68	9
-40	-22	-12
-30	20	7
62	-26	-13
26	-98	4
2	41	38
4	58	30
-32	32	16
66	-36	10
-22	-52	46
12	20	62
48	-2	-24
36	2	22
-48	36	-6
46	34	34
30	22	54
-36	-12	-20
34	16	4
62	24	0
12	8	70
30	-8	-4
64	18	14
62	-26	47
-58	26	2
46	38	-16
-30	-4	10
34	16	-36
-34	18	60
24	-24	74
-64	-57	-6
62	4	-16

// Hale T S, 2014: Healthy Controls
// Subjects=21
-10	2	50
-40	-12	66
-44	-2	28
-24	-12	50
-38	-36	38
-36	-94	-4
-10	2	50
-40	-12	66
-44	-2	28
-24	-12	50
-38	-36	38
-36	-94	-4
-12	2	46
-40	-12	66
-46	-2	26
-24	-12	50
-36	-36	36
-32	-92	-4
-18	54	40
-6	28	-12
4	26	-14
0	42	8
-14	38	18
2	54	-24
-10	6	-20
10	42	-16
-6	28	-12
4	26	-14
0	42	8
-26	-100	-16
-12	-80	-48
6	-86	-42
14	36	-26
22	44	38
-8	64	-2
-22	58	24
10	30	-22
8	26	-22
-34	24	44
-18	26	52
-2	52	-26
0	28	14
2	36	20
12	38	24
2	20	48
14	36	-26
-8	64	-2
-12	22	-24
10	30	-22
8	26	-22
-2	52	-26

// Hale T S, 2014: Attention Deficit Hyperactivity Disorder patients (ADHD)
// Subjects=21
-10	2	50
-40	-12	66
-24	-12	50
-38	-36	38
40	-82	-4
-4	-22	-16
0	-38	-24
26	-46	-28
-40	-12	66
-24	-12	50
-38	-36	38
-18	20	6
-40	-12	66
-24	-12	50
-36	-36	36
34	-86	-4
2	-26	-18
0	-34	-24
24	-48	-28
-32	-26	-14
32	-34	-4
-28	52	34
46	34	-8
-10	72	6
12	64	20
4	50	36
48	16	16
58	34	10
44	16	8
46	0	14
-2	48	14
8	48	14
64	-10	24
58	-10	48
46	8	-40
48	-2	-28
56	-28	-14
52	-28	-22
64	-22	-8
60	-44	6
-64	-10	6
62	-30	2
-60	-40	10
44	-34	4
-62	-58	30
62	-50	28
-28	52	34
46	34	-8
-10	72	6
12	64	20
-20	16	46
4	50	36
48	16	16
58	34	10
44	16	8
46	0	14
-2	48	14
8	48	14
62	4	14
64	-10	24
58	-10	48
46	8	-40
48	-2	-28
56	-28	-14
52	-28	-22
64	-22	-8
60	-44	6
-64	-10	6
62	-30	2
-60	-40	10
44	-34	4
-62	-58	30
62	-50	28
-6	-52	46
4	-52	48
-6	-56	66
4	-56	62
-14	56	8
-4	62	8
8	58	10
2	48	14
-16	46	-2
0	46	8
16	54	2
-14	56	10
-4	64	10
14	60	4
10	62	30
-18	48	-4
-8	36	6
2	54	-24
-10	6	-20
10	42	-16
-6	28	-12
4	26	-14
0	42	8
-26	-100	-16
-12	-80	-48
6	-86	-42
14	36	-26
-8	64	-2
-12	22	-24
10	30	-22
8	26	-22
-2	52	-26

// Hart H, 2013: Univariate analysis of STOP task, ADHD < Controls
// Hart H, 2013: Univariate analysis for STOP task, ADHD > Controls
// Subjects=30
30.79	26.67	-21.16
-37.56	26.6	-15.9
-2.34	14.33	-26.43
-44.66	-40.89	6.57
42.88	-62.08	-13.85
-51.96	-43.45	29.17
-5.79	-73.78	45.68
23.97	-58.86	29.59
-25.43	-69.29	-4.66

// Hernandez N, 2013: Healthy Controls
// Subjects=16
-50	18	12
-42	24	28
-28	34	-12
-44	4	36
16	-100	-8
32	-66	-30
-14	-92	-10
-4	14	58
-56	-48	-14
32	26	8
-24	-78	42
26	-56	-22
44	-18	44
-40	-10	54
2	-2	70
48	-52	-16
-50	-52	-16
-44	-2	46
-50	12	18
-42	36	8
50	12	16
44	-2	46
42	34	8
46	-42	30
24	-78	40
-44	-42	32
-24	-78	40

// Hernandez N, 2013: Developmental Dyslexia (DD)
// Subjects=15
-22	-92	-2
-24	-74	44
-18	-94	-18
-10	-90	-4
-18	-88	-18
-30	-68	52
-42	-44	44
18	-90	-18
22	-94	12
22	-88	0
14	-102	2
44	24	6
30	20	6
48	22	-8
-4	8	60
42	52	26
-42	-6	52
-40	30	2
-48	16	34
-64	0	14
-38	18	8
-56	14	-10
-38	48	30
-32	32	-12
28	-72	44
34	-64	50
12	-76	52
26	-56	-22
44	-18	44
-40	-10	54
2	-2	70
48	-52	-16
-50	-52	-16
-44	-2	46
-50	12	18
-42	36	8
50	12	16
44	-2	46
42	34	8
46	-42	30
24	-78	40
-44	-42	32
-24	-78	40

// Liu L, 2012: Control > Reading Disabled, All tasks
// Liu L, 2012: Semantic > Rhyming, All subjects
// Subjects=16
-58	14	20
16	-92	18
-40	34	-12
-64	-50	0
-44	-64	20
34	36	-14

// Olulade O A, 2012: Healthy Controls
// Subjects=9
-50	4	46
-46	34	12
-48	24	22
-44	-58	-26
-52	-64	-16
-38	-44	-28
-26	-102	-8
-34	-92	-10
-34	22	-6
22	-96	12
36	-92	10
10	-8	30
36	-92	10
-50	4	46
-40	10	26
-46	34	12
-42	-60	-24
-24	-94	-8
-36	-90	-10
-6	16	52
-4	26	38
10	28	40
46	32	38
48	32	24
38	24	22
38	-50	-34
12	-82	-32
42	-74	-32
-10	20	58
-14	32	50
-60	-52	4
-54	-44	34
-44	-4	0
-44	0	-12
44	-26	40
-58	-22	26
-48	32	14
-50	-74	-4
-36	-36	34
-44	-56	-26
44	28	28
38	24	24
50	-60	46
46	-60	36
-44	-58	-2
24	-96	10
36	-92	12
42	-84	4
42	-78	14
30	-44	46
28	-2	50
50	6	24
32	20	-8
-32	-66	-14
-30	-88	4
-22	-64	54
-50	8	28
-44	4	50
8	16	50
8	30	38
10	24	30
42	30	20
52	36	14
18	-78	54
28	-82	48
32	2	54
-32	-68	-12
-36	0	58
-22	-64	52
-20	-76	56
-6	-52	56
44	-86	6
-30	-90	6
42	30	22
-36	-40	48
-10	-80	-46
2	-36	66
36	-44	12
42	-84	4
40	-74	10
44	-82	12
-30	-88	4
-32	-66	-14
-48	-82	6
-38	-40	50
-36	-50	58
-38	-58	60
24	-60	58
24	-60	58
38	-40	40
-10	-28	62
-14	-24	54
-10	-24	10
-10	-24	10
-4	-30	10
-18	-106	2
26	-32	6
20	-18	10
52	-70	-8
8	52	10
-40	-52	34
56	-60	2
10	50	46

// Olulade O A, 2012: Reading disabled (RD)
// Subjects=6
-34	22	-6
-38	22	-16
-38	30	0
-34	22	-6
22	-96	12
36	-92	10
10	-8	30
36	-92	10
-10	20	58
-14	32	50
-60	-52	4
-54	-44	34
-44	-4	0
-44	0	-12
44	-26	40
-58	-22	26
-48	32	14
-50	-74	-4
-36	-36	34
-44	-56	-26
44	28	28
38	24	24
50	-60	46
46	-60	36
-44	-58	-2
-28	-96	-12
-42	0	32
-50	0	46
-46	6	16
24	-96	10
36	-92	12
-32	-90	-2
-48	-80	-8
-48	-72	-12
40	-82	4
22	-64	60
50	-70	-8
36	-42	46
56	-40	54
52	-30	52
18	-78	54
28	-82	48
32	2	54
-32	-68	-12
-36	0	58
-22	-64	52
-20	-76	56
-6	-52	56
44	-86	6
-30	-90	6
42	30	22
-36	-40	48
-10	-80	-46
2	-36	66
36	-44	12
-10	-28	62
-14	-24	54
-10	-24	10
-10	-24	10
-4	-30	10
-18	-106	2
26	-32	6
20	-18	10
40	-82	4
52	-70	-8
38	-72	8
-32	-90	-2
-48	-80	-8
-40	-52	36
-46	-32	44
-46	-46	44
52	-70	-8
8	52	10
-40	-52	34
56	-60	2
10	50	46

// Reilhac C, 2012: Healthy Controls
// Subjects=12
-48	25	1
-44	-41	30
-40	-50	54
-22	-63	53
-50	-35	48
30	-47	32
30	-48	50
26	-71	50
38	-38	48
-63	-18	23
51	5	-9
-46	13	-6
-48	-22	-16
-48	-37	-2
-55	-49	-16
53	18	40
53	32	15
42	55	8
-51	12	40
-36	36	13
-59	16	18
36	-2	44
34	-63	-19
-38	-63	-19
24	-71	48
32	-60	49
63	-32	20
-20	-64	49
-30	-47	32
-40	-55	34
-22	-62	34
-36	-11	-21
-38	32	11
-36	47	-2
22	35	0
48	47	7
53	19	38
-26	-38	-32
-28	52	-4
-26	-84	-4
30	-93	6
-18	-50	-31
20	-77	-16
32	-81	-20
-20	-66	49
-44	7	-5
53	3	-9
-46	-66	2
-26	-80	-9
28	-91	1
-57	18	19
-40	40	18
-38	-1	50
44	11	22

// Reilhac C, 2012: Developmental Dyslexia (DD)
// Subjects=12
-46	-46	45
32	-65	51
-42	-52	54
39	-59	58
53	-37	46
44	50	-6
-42	-32	26
-28	52	-4
-26	-84	-4
30	-93	6
-18	-50	-31
20	-77	-16
32	-81	-20
-20	-66	49
-44	7	-5
53	3	-9
-46	-66	2
-26	-80	-9
28	-91	1
-57	18	19
-40	40	18
-38	-1	50
44	11	22

// Steinbrink C, 2012: Healthy Controls
// Subjects=16
-51	-21	3
54	-18	3
-45	36	0
-36	15	3
36	18	3
-48	-21	3
51	-21	3

// Steinbrink C, 2012: Developmental Dyslexia (DD)
// Subjects=17
-51	-18	0
54	-21	3
-36	18	3
42	18	3
-48	-21	0
54	-21	0

// Wimmer H, 2010: Words > Baseline: Controls > Dyslexics, p < 0.005
// Wimmer H, 2010: Words > Baseline: Dyslexic > Controls, p < 0.005
// Wimmer H, 2010: Pseudohomophones > Baseline: Controls > Dyslexics, p < 0.05
// Wimmer H, 2010: Pseudohomophones > Baseline: Dyslexics > Controls, p < 0.05
// Wimmer H, 2010: Non-words > Baseline: Controls > Dyslexics, p < 0.005
// Wimmer H, 2010: Non-words > Baseline: Controls > Dyslexics, p < 0.05
// Wimmer H, 2010: Non-words > Baseline: Dyslexics > Controls, p < 0.005
// Wimmer H, 2010: Pseudohomophones > Words: Controls > Dyslexics, p < 0.005
// Wimmer H, 2010: Pseudohomophones > Words: Dyslexics > Controls, p < 0.005
// Wimmer H, 2010: Non-words > Pseudohomophones: Controls > Dyslexics, p < 
// 0.005
// Wimmer H, 2010: Non-words > Pseudohomophones: Dyslexics > Controls, p < 
// 0.005
// Subjects=20
-45	-48	-15
-33	-33	63
-24	-3	45
-12	-3	21
-30	9	24
-6	24	21
12	-72	12
15	12	72
15	24	33
-45	-48	-15
-33	-36	63
-48	-12	51
-24	-3	42
-12	-6	18
-9	0	3
-18	6	24
-18	15	3
-12	21	36
-27	24	18
12	-72	12
15	9	72
33	27	0
27	42	21
-57	12	12
-45	-48	-15
-51	-45	54
-33	-36	63
-48	-12	51
-18	3	21
-18	12	3
-6	24	21
-15	24	33
12	-72	12
15	12	6
12	24	33
27	39	21
-45	-51	-18
-9	12	45
-21	-87	-18
-45	6	36
-48	27	33
-21	0	-9
-21	15	0

// Arnone D, 2012: Currently Depressed in Longitudinal Analysis
// Subjects=32
21	-32	-10
-25	-25	-15
21	-25	-20
-28	-91	0
32	-91	5
-42	-46	-20
42	-49	-15
-60	-56	5
60	-56	5
-21	-4	-15
28	-7	-15
-53	14	30
56	21	25
18	4	-15
-11	-77	-5
4	42	30
-11	-53	60
-21	-81	-15
18	-88	-10
-4	-74	45
56	-32	-10
35	-7	-20
49	0	-15
56	-7	30
46	-4	-10
28	-88	25
67	-42	30
-11	-81	5
32	-70	-10
-14	-53	50
18	-56	-30
11	4	65
-35	0	-25
35	-7	-20
-63	0	15
-42	4	-25
49	0	-15
-39	-7	-5
39	7	-5
28	18	-15
-21	-81	-15
18	-88	-10
-4	-74	45
-18	-88	25
-60	-21	-5
67	-42	5
14	-88	-5
-25	-84	30
32	-88	10
-42	7	45
39	-4	55
56	-32	-10
53	-70	0
35	-7	60
-11	-74	45

// Arnone D, 2012: Depressed Patients in Remission
// Subjects=24
-28	-91	0
32	-91	5
-42	-46	-20
42	-49	-15
-60	-56	5
60	-56	5
-21	-4	-15
28	-7	-15
-53	14	30
56	21	25
18	4	-15
-11	-77	-5
4	42	30
-11	-53	60
-21	-81	-15
18	-88	-10
-4	-74	45
56	-32	-10
35	-7	-20
49	0	-15
56	-7	30
46	-4	-10
28	-88	25
67	-42	30
32	-70	-10
-14	-53	50
18	-56	-30
11	4	65
-35	0	-25
35	-7	-20
-63	0	15
-42	4	-25
49	0	-15
-39	-7	-5
39	7	-5
28	18	-15
-21	-81	-15
18	-88	-10
-4	-74	45
-18	-88	25
-60	-21	-5
67	-42	5
11	-95	0
-42	-4	35

// Arnone D, 2012: Healthy Comparison
// Subjects=54
-28	-91	0
32	-91	5
-42	-46	-20
42	-49	-15
-60	-56	5
60	-56	5
-21	-4	-15
28	-7	-15
-53	14	30
56	21	25
18	4	-15
-11	-77	-5
4	42	30
-11	-53	60
-21	-81	-15
18	-88	-10
-4	-74	45
56	-32	-10
35	-7	-20
49	0	-15
56	-7	30
28	-88	25
-11	-81	5
32	-70	-10
-14	-53	50
18	-56	-30
11	4	65
14	-88	-5
-25	-84	30
32	-88	10
-42	7	45
39	-4	55
56	-32	-10
53	-70	0
35	-7	60
-11	-74	45
11	-95	0
-42	-4	35

// Aupperle R L, 2013: Increased activation for negative & positive image 
// anticipation (ANI-API) from pre to post-treatment
// Aupperle R L, 2013: Decreased activation (ANI-API) from pre to 
// post-treatment
// Aupperle R L, 2013: Increased activation for negative and positive images 
// (NI-PI) from pre to post-treatment
// Aupperle R L, 2013: Decreased activation (NI-PI) from pre to post-treatment
// Aupperle R L, 2013: Greater Activation (ANI-API) pre-treatment=better 
// treatment response
// Aupperle R L, 2013: Greater activation (NI-PI) pre-treatment = better 
// treatment response
// Aupperle R L, 2013: Greater activation (NI-PI) from pre to post-treatment= 
// better treatment response
// Aupperle R L, 2013: ANI > API, Pre-treatment
// Aupperle R L, 2013: API > ANI, Pre-treatment
// Aupperle R L, 2013: ANI > API, Post-treatment
// Aupperle R L, 2013: API > ANI, Post-treatment
// Aupperle R L, 2013: NI > PI, Pre-treatment
// Aupperle R L, 2013: PI > NI, Pre-treatment
// Aupperle R L, 2013: NI > PI, Post-treatment
// Aupperle R L, 2013: PI > NI, Post-treatment
// Subjects=14
-3.97	-37.59	18.09
28.84	-62.56	-32.61
66.32	-15.45	-4.65
-15.97	42.25	19.34
-7.47	-65.87	-30.8
31.97	60.71	6.09
37.38	5.44	-7.18
29.48	-42.77	58.29
-17.73	-52.76	29.56
20.77	-53.33	32.51
-45.74	9.54	25.77
10.8	37.46	23.89
56.97	-20.42	28.22
31.53	-64.56	37.79
-6	-78.21	15.94
9.14	-75.09	41.16
11.12	-26.27	39.27
11.03	-79.94	5.86
21.55	-55.18	-5.26
60.77	-12.16	-30.51
44.26	-9.44	47.51
29.38	-58.05	39.5
38.93	-.5	53.52
-21.8	-64.91	51.81
61.22	-54.63	12.08
-41.27	-2.72	45.7
41.67	15.59	-.28
-35.84	-39.07	43.11
11.32	-55.99	54.03
-60.47	-35.33	38.62
40.95	-77.47	7.53
59.98	-14.71	5.4
-51.1	-19.18	12.63
-15.97	34.5	15.53
1.98	65.39	0.46
-10.35	-57	15.33
-30.93	-53.44	-19.3
-56.29	-12.21	34.4
-32.57	-52.71	45.33
34.78	-55.31	47.01
-.81	-29.2	16.23
51.52	9.24	26.91
50.54	-52.49	13.14
-38.39	45.63	23.77
-41.64	-65.82	-27.06
40.03	0.91	57.85
-21.93	-69.54	33.24
-48.96	-21.37	11.67
57.85	-11.38	7.37
50.6	-12.29	37.64
-6.55	49.05	-3.65
2.28	58.61	36.71
-12.91	27.52	-6.23
-41.18	-66.56	32.1
-.7	-53.35	20.49
-44.88	28.27	6.34
51.43	21.42	19.2
47.45	-65.57	23.19
-1.9	46.33	43.37
-34.12	-44.48	-13.33
-44.66	14.12	29.83
22.42	-14.36	-14.27
-28.91	-54.62	-34.84
-39.14	11.55	51.17
-4.25	59.49	21.1
-44.04	-5.9	-36.52
0.44	25.42	61.82
-4.82	-6.76	59.01
44.34	-33.84	48.45
48.18	-3.15	4.56
24.84	-64.16	2.14
-.72	-76.58	9.05
-48.99	-7.45	12.73
15.49	-70.28	33.99
37.63	37.76	39.17
-31.91	2.43	15.05
63.25	-23.95	9.48
-20.09	-93.47	-14.96
-49.91	-37.69	20.86
8.98	-55.95	27.29
-44.44	-63.84	26.33
6.66	-29.32	13.93
-49.18	24.64	1.12
59.9	-19.97	-7.54
-59.85	-13.63	-11.16
0.82	68.76	-10.96
-53.21	21.73	32.64
-1.11	-59.74	-34.73
-46.63	-14.98	38.99
32.5	-12.85	45.71
6.76	-78.82	6.93
-19.09	-11.84	8.3
12.35	-76.13	41.21
-12.67	-69.9	-13.67
18.15	17.47	-1.28
28.87	8.02	-.61
26.31	-11.72	74.68
-17.05	13.55	6.14
-35.1	36.56	30.07

// Buchheim A, 2012: Relevant vs. Irrelvant, Group x Time Interaction
// Buchheim A, 2012: Patients > Controls, Baseline
// Subjects=16
-34.34	-15.99	-30.21
1.02	25.83	-1.78
4.51	51.91	46.17
-34.34	-12.73	-29.37
-34.34	-15.99	-30.21

// Falconer E, 2013: No-Go > Go, Improved Treatment Response
// Falconer E, 2013: No-Go > Go, Poorer Treatment Response
// Subjects=13
-18	8	4
-28	22	-20
0	62	14
8	56	26
42	-28	-4
52	-34	42
2	-22	46
-24	-4	10
-22	-10	-2
14	-30	-6
-22	-68	-26
-2	-52	-6
46	40	-2
44	10	-2
36	-14	6
-54	-62	8
-22	-50	8
10	-42	14
40	-6	-38
-4	42	-12
2	0	50
-32	-60	48
28	10	-4
36	-4	0
-56	-26	0
0	-66	58

// Fonzo G A, 2014: Generalized Anxiety Disorder (GAD)
// Subjects=21
-2.84	-54.5	19.49
-26.37	17.63	46.06
29.22	17.16	48.8
46.44	-23.26	47.53
51.32	-21.42	-11.78
-32.11	50.9	8.76
8.14	-29.43	67.45
-54.41	-26.91	-4.53
16.24	43.98	38.9
-20.38	-15.22	-21.52
-16.56	-16.52	57.73
-0.07	-31.56	-28.19
20.67	-90.63	4.41
27.97	41.59	34.5
-23.4	-85.8	-25.6
38.82	7.1	41.73
34.72	-62.51	36.46
-31.52	-52.88	43.11
-30.98	19.64	3.56
48.25	30.46	26.28
-41.42	11.14	32.28
-34.83	-1.2	51.08
-7.1	20.29	51.19
-37.35	-45.9	-17.63
34.2	21.09	2.69
-42.7	36.37	14.56
13.08	-21.45	18.77
8.9	26.73	50.46
41.74	-45.26	-16.36
54.77	-65.04	1.87
-40.24	-73.39	12.59
53.58	-51.99	-8.13
7.61	-14.05	4.83
-11.54	-4.51	19.86
12.44	-65.33	57.03
-28.39	-71.23	25.65
41.85	-67.2	-11.18
-16.57	-17.75	55.6
8.65	-70.37	-21.68
-9.37	-89.8	-9.81
-10.65	22.22	7.57
-1.99	-.74	12.75
-19.93	5.95	45.85
0.13	-49.22	-8.86
-15.76	-22.6	20.31
-12.42	-14.61	40.79
7.93	11.29	57.35

// Fonzo G A, 2014: Healthy Controls (HC)
// Subjects=12
-2.84	-54.5	19.49
-26.37	17.63	46.06
29.22	17.16	48.8
46.44	-23.26	47.53
51.32	-21.42	-11.78
-32.11	50.9	8.76
8.14	-29.43	67.45
-54.41	-26.91	-4.53
16.24	43.98	38.9
-20.38	-15.22	-21.52
-16.56	-16.52	57.73
38.82	7.1	41.73
34.72	-62.51	36.46
-31.52	-52.88	43.11
-30.98	19.64	3.56
48.25	30.46	26.28
-41.42	11.14	32.28
-34.83	-1.2	51.08
-7.1	20.29	51.19
-37.35	-45.9	-17.63
34.2	21.09	2.69
-42.7	36.37	14.56
13.08	-21.45	18.77
8.9	26.73	50.46
41.74	-45.26	-16.36
54.77	-65.04	1.87
-40.24	-73.39	12.59
53.58	-51.99	-8.13
7.61	-14.05	4.83
-11.54	-4.51	19.86
12.44	-65.33	57.03
-28.39	-71.23	25.65
41.85	-67.2	-11.18
-16.57	-17.75	55.6
8.65	-70.37	-21.68
-9.37	-89.8	-9.81
-10.65	22.22	7.57
-1.99	-.74	12.75
-19.93	5.95	45.85
0.13	-49.22	-8.86
-15.76	-22.6	20.31
-12.42	-14.61	40.79
7.93	11.29	57.35

// Godlewska B R, 2012: Group x Condition Interaction
// Subjects=17
6	-48	14

// Lopez-Sola M, 2010: MDD Patients
// Subjects=13
-42	-10	0
50	-8	4
-58	-2	42
54	0	56
-30	6	0
28	14	2
-8	-12	44
4	-46	-24
-68	-42	-8
-4	-4	-14
-46	-26	-10
40	-14	-6
-24	24	6
-4	16	-16
-62	-42	4
4	18	-18
-40	8	14
48	-10	-6
-12	8	22
12	4	22
6	-2	-16
-66	-36	0
-6	50	-10
-36	22	34
20	34	26
-46	20	-2
-44	-24	-6
44	-16	-6
4	-2	-16
-60	-42	4
2	22	-24
-30	48	14
34	26	34
2	-38	-36
0	-20	-24
4	42	-6
36	8	32
28	38	32
-46	12	0
-2	-24	-26

// Lopez-Sola M, 2010: Controls
// Subjects=20
-36	0	-8
40	34	2
-36	32	12
46	34	36
-30	-8	-6
30	6	6
6	20	36
4	-50	-18
-2	46	-14
-46	-26	-10
40	-14	-6
-24	24	6
-4	16	-16
-62	-42	4
4	18	-18
-40	8	14
48	-10	-6
-12	8	22
12	4	22
6	-2	-16
-66	-36	0
-6	50	-10
-36	22	34
20	34	26
-46	20	-2
-44	-24	-6
44	-16	-6
4	-2	-16
-60	-42	4
2	22	-24
-30	48	14
34	26	34
2	-38	-36
0	-20	-24

// Olatunji B O, 2014: Positive Correlation: Symptom Improvement & 
// Contamination Early Phase > Neutral
// Olatunji B O, 2014: Positive Correlation: Symptom Improvement & 
// Contamination Late Phase > Neutral
// Olatunji B O, 2014: Negative Correlation: Symptom Improvement & 
// Contamination Early Phase > Neutral
// Olatunji B O, 2014: Negative Correlation: Symptom Improvement & 
// Contamination Late Phase > Neutral
// Subjects=12
39.29	-9	-42.8
43.55	6.34	-37.44
-18.1	-79.68	-29.52
-44.89	-35.54	-20.64
-25.92	34.36	-26.73
24.42	16.06	-20.19
15.73	55.13	-23.37
-53.26	-58.97	-6.32
-44.53	-69.18	12.28
47.35	-64.4	10.83
5.48	2.48	12.39
-41.31	-48.13	22.75
-2.96	-17.23	19.72
-60.68	-13.35	20.05
-68.11	-12.88	26.79
-22.02	-63.88	23.85
32.54	-38.83	40.08
20.93	-78.02	43.5
44.28	-22.38	45.25
1.16	-86.97	-29.13
-22.64	-8.86	-35.41
31.89	-4.93	-30.79
46.74	10.59	-37.83
-13.77	-83.46	-23.68
-37.42	-32.33	-21
39.31	23.12	-26.53
-13.8	-50.79	-14.15
-49.18	-20.34	-16.29
-56.71	-7.69	-17.27
-30.21	26.42	-32.7
54.36	24.15	-14.52
-41.71	-3.92	-11.07
-10.35	-64.75	11.52
8.83	-24.57	20.2
-53.16	-8.56	26.26
40.01	-50.93	34.32
-13.37	-50.74	41.6
8.92	-23.62	32.38
20.94	-81.2	43.76
-6.03	-76.35	12.44
-41.33	-43.9	22.39
32.54	-38.83	40.08
-52.83	-45.8	53.91
-2.92	49.04	50.96
24.46	-57.1	-44.17
-18.28	-57.36	-43.66
43.83	-67.68	-31.24
8.38	-5.07	-30.5
70.47	-11.16	-18.44
58.94	-70.45	-13.33
8.4	64.37	0.47
13.34	-98.99	20.81
8.49	41.11	2.42
-22.23	19.54	29.12
24.48	-61.33	-43.81
5.09	67.64	-12.03
35.19	45.5	1.75
5.28	41.09	2.46
23.36	52.4	-4.27
16.47	-92.08	13.5
-44.6	-36.95	16.27
-29.89	29.76	10.51
24.81	-24.9	14.46
-22.13	-20.01	26.86
63.44	-15.38	37.76
51.65	-6.99	37.19
16.25	56.21	45.68
-41.18	-6.18	56.03

// Ruhe H G, 2012: MDD > Controls, All Faces, Study-Entry
// Ruhe H G, 2012: MDD > Controls. Negative Faces, Study-entry
// Ruhe H G, 2012: MDD > Controls, Happy Faces, Study-entry
// Ruhe H G, 2012: Controls > MDD, All Faces, Study-entry
// Ruhe H G, 2012: Controls > MDD, Negative Faces, Study-entry
// Ruhe H G, 2012: Controls > MDD, Happy Faces, Study-entry
// Ruhe H G, 2012: Study-entry > T0, All Faces, Patients
// Ruhe H G, 2012: Study-entry > T0, Negative Faces, Patients
// Ruhe H G, 2012: Study-entry > T0, Happy faces, Patients
// Ruhe H G, 2012: T0 > Study-entry, All Faces, Patients
// Ruhe H G, 2012: T0 > Study-entry, Negative Faces, Patients
// Ruhe H G, 2012: T0 > Study-entry, Happy Faces, Patients
// Ruhe H G, 2012: Study-entry > T1, All Faces, Patients
// Ruhe H G, 2012: Study-entry > T1, Happy Faces, Patients
// Ruhe H G, 2012: T1 > Study-entry, All Faces, Patients
// Ruhe H G, 2012: T1 > Study-entry, Negative Faces, Patients
// Ruhe H G, 2012: T1 > Study-entry, Happy faces, Patients
// Ruhe H G, 2012: Study-entry > T1, Non-Responders > Responders, Negative 
// Faces
// Subjects=7
-26	4	12
-28	6	15
-12	-6	-6
50	20	-6
-34	22	-6
42	16	27
48	-2	51
-54	16	0
-4	10	63
-42	-54	-21
-8	26	42
-6	-20	51
-4	10	63
50	20	-6
-34	22	-6
42	16	27
-42	-54	-21
46	-40	-24
-16	-38	-21
58	-6	-12
-12	-22	48
54	32	3
44	2	48
54	-48	12
48	-36	6
-40	-54	-18
0	-66	12
28	-36	0
-2	-66	12
-48	-46	6
-36	16	-18
-12	-18	48
2	4	33
4	36	3
28	-28	-12
-10	22	60
-44	-4	-39
-4	22	60
2	30	33
2	2	36
-24	58	30
-50	26	-3
-28	44	42
-30	22	54
32	-2	54
24	42	48
30	-28	-9
-22	-34	-27
-24	-32	-24
50	-48	18
22	-36	0
-34	30	-9
20	-36	0
36	12	-3
28	6	48
10	-12	63
-48	22	18
-28	4	51
-4	0	60
-38	2	48
28	6	48
12	-4	66
-28	4	51
-46	20	24
42	20	21
60	-20	30
-46	8	30
-26	-16	57
6	-12	30
-26	-6	51
24	-16	-18
0	26	-3

// Wagner G, 2010: Incongruent > Congruent, All Major Depressive Disorder 
// (MDD) > Controls
// Wagner G, 2010: Baseline > Week-6, Incongruent condition, All MDD
// Wagner G, 2010: Incongruent, Baseline > Week-6, Citalopram
// Wagner G, 2010: Incongruent, Baseline > Week-6, Reboxetine
// Wagner G, 2010: Incongruent, Non-remitters > Remitters, Baseline
// Wagner G, 2010: Incongruent, Non-Remitters > Remitters, Week-6
// Wagner G, 2010: Incongruent, Remitters > Non-Remitters, Week-6
// Wagner G, 2010: Negative Correlation between Symptom Improvement & Signal 
// Change, All MDD, Baseline > Week-6
// Wagner G, 2010: Group (Citalopram & Reboxetine) x Time (Baseline & Week-6) 
// Interaction
// Subjects=8
53.85	-28.39	63.42
-50.93	19.04	-8.96
51.63	-9.15	62.67
-47.69	-37.47	63.81
40.95	-59.7	62.25
8.26	-5.03	51.8
-64.64	-48.55	3.56
-50.63	-65.19	-2.88
-9.82	41.5	-.68
-50.78	-24.67	-5.76
71.4	-33.39	-2.5
48.69	-27.09	-2.73
26.67	20.1	-24.96
43.12	-50.87	64.71
-11.05	-51.14	53.33
-15.11	-56.83	73.01
53.51	-36.41	35.08
57.06	-37.41	58.65
-3.22	-49.48	-9.72
20.41	-12.17	-13.81
-18.49	-7.95	-12.45
26.67	20.1	-24.96
51.31	14.71	42.39
-43.68	8.41	49.11
12.67	24.1	64.53
16.82	12.98	48.75
-62.59	-38.43	-3.08
52.88	-20.36	-11.32
-48.59	-23.39	-3.69
25.87	-63.8	65.16
16.82	12.98	48.75
30.04	-48.56	55.74
-15.11	-56.83	73.01
57.05	-35.28	58.44
-39.07	-44.13	60.96
-3.22	-49.48	-9.72
-39.72	-53.37	8.09
-53.99	-25.53	-3.38
-22.58	-37.98	-.44
-9.11	-83.4	29.59
29.81	-71.05	33.31
-13.46	-32.19	38.05
8.02	-92.14	15.6
-42.11	-.41	0.65
48.78	-4.47	9.59
-9.64	-57.8	-6.55
-24.79	-25.22	-1.67
37.52	-6.87	-26.96
-37.92	29.29	-3.48
-12.05	-16.61	66.74
18.21	-10.26	-16.21

// Wang Y, 2012: Positive > Neutral, Major Depressive Disorder (MDD) < 
// Controls, Pre-treatment
// Wang Y, 2012: Positive > Neutral, MDD > Controls, Post-treatment
// Wang Y, 2012: Positive > Neutral, MDD < Controls, Post-treatment
// Wang Y, 2012: Negative > Neutral, MDD > Controls, Pre-treatment
// Wang Y, 2012: Negative > Neutral, MDD > Controls, Post-treatment
// Wang Y, 2012: Negative > Neutral, Post > Pre-treatment (MDD)
// Subjects=18
-9	18	3
45	-36	12
3	24	57
33	-15	21
-12	21	0
-6	39	3
48	-39	57
39	18	57
45	24	45
60	-21	-18
42	-72	36
36	-63	48
54	30	33

// Schneider M F, 2010: Attention Deficit-Hyperactivity Disorder
// Subjects=19
-20.36	-86.77	-5.74
3.56	-91.06	4.36
14.34	-94.43	2.27
23	-96.52	2.33
-24.49	-97.44	6.59
-50.7	-62.41	-7.63

// Schneider M F, 2010: Healthy Controls
// Subjects=17
42.7	29.13	47.83
5.86	49	44.25
-15.48	2.75	55.92
15.05	17.67	-4.35
62.87	-29.3	7.33
56.66	-66.67	21.22
60.07	-48.94	38.45
-26.09	-59.29	58.87
-20.36	-86.77	-5.74
3.56	-91.06	4.36
14.34	-94.43	2.27
23	-96.52	2.33
-24.49	-97.44	6.59
-50.7	-62.41	-7.63

// Sabri M, 2013: Deviant > Standard
// Sabri M, 2013: Detected deviant > Standard
// Sabri M, 2013: Undetected deviant > Standard
// Sabri M, 2013: Detected > Undetected
// Subjects=22
8.83	-16.82	24.01
2.49	17.89	46.82
-24.05	-51.86	41.82
-10.58	-10.02	3.59
48.16	-37.47	-12.63
-29.08	38.03	-20.31
12.24	-1.54	56.14
-9.76	8.36	-20.27
45.86	3.67	-17.17
-11.39	-79.81	9.45
-55.54	10.86	2.35
-40.61	-4.71	-7.67
-26.69	47.3	16.81
-42.18	-32.88	54.93
-12.53	-32.27	18.86
-49.8	-40.98	33.4
20.44	8.11	15.09
1.84	56.19	-22.18
-48.65	-76.38	29.66
12.72	57.17	3.26
-4.99	-19.48	32.19
-32.65	-41.42	39.93
20.42	-5.26	7.29
-47.93	-14.05	9.93
-9.51	-10.01	3.57
7.97	-2.63	56.28
41.04	-39.21	34.44
29.33	-5.93	52.97
48.14	-14.58	-5.63
-28.23	-64.06	49.58
-48.74	-24.6	38.7
-29.08	36.97	-20.22
51.32	-29.08	-14.49
0.11	-6.61	5.41
-7.3	-26.75	7.18
-22.29	-9.58	10.37
26.88	-2.59	13.68
-44.59	-22.51	23.98
-33.63	-50.43	47.39
-47.51	-36.08	55.26
-38	-19.53	48.19
-1.77	-54.49	19.48
-45.5	-68.16	25.59
-5.08	46.57	46.73
52.81	-66.51	24.32
3.16	47.85	7.5

// Choi S, 2014: Hedonic block, Healthy controls > Schizophrenia
// Subjects=15
-4.36	58.38	6.7
-2.22	43.07	1.27

// Dowd E C, 2012: Effect of cue, Healthy controls > Schizophrenia
// Dowd E C, 2012: Effect of receipt, Money > No money
// Dowd E C, 2012: Effect of receipt, Healthy controls > Schizophrenia
// Dowd E C, 2012: Effect of receipt, Schizophrenia > Healthy controls
// Dowd E C, 2012: Effect of cue x receipt, Unexpected > Expected reward
// Dowd E C, 2012: Effect of receipt x group, Control no money > Money - 
// Schizophrenia money > No money
// Dowd E C, 2012: Cue Money - No Money, Correlated with physical anhedonia
// Dowd E C, 2012: Receipt Money - No money, Correlated with physical 
// anhedonia
// Dowd E C, 2012: Receipt money - No money, Correlated with social anhedonia
// Subjects=20
15.88	-62.95	-50.27
2.03	51.56	0.51
-11.92	47.62	-7.92
-.63	-36.11	36.88
1.92	-31.94	-47.13
-9.76	-50.96	-44.29
12.64	-44.74	-48.41
-36.28	-66.67	-24.82
57.77	-67.16	-25.86
38.55	-69.31	-24.35
14.06	-83.92	-18.38
-48.97	-65.38	-6.94
-38.23	-89	-10.66
-25.37	-97.3	-9
13.22	-100.19	5.3
-11.55	-4.6	18.75
15.06	3.25	7.75
47.05	45.62	16.1
-43.6	7.36	24.81
1.42	-24.98	29.24
-37.92	-56.09	43.45
-11.17	-74.24	40.2
-.7	14.78	48.23
-45.54	-9.26	44.07
47.19	34.94	29.26
-34.61	-23.17	69.65
-8.93	-26.99	73.02
44.84	23.98	-2.13
-41.73	18.89	-5.17
-32	53.07	23.08
0.35	-29.39	27.39
46.26	16.67	40.84
-45.75	23.72	30.16
-40.33	8.06	33.64
48.63	-50.11	44.18
-40.01	-58.93	48.17
0.68	-68.74	55.22
55.88	-72.27	4.7
-1.19	36.05	-7.08
-53.26	3.61	18.55
-30.75	25.38	36.53
-10.29	31.44	58.1
-15.2	-9.24	-41.03
2.11	-50.84	-29.94

// Ren T, 2012: Systemic Lupus Erythematosus Patients (SLE)
// Subjects=14
-32.14	60.41	7.96
35.66	16.32	51.03
31.9	53.42	-5.57
-51.16	29.6	24.15
-31.36	-66.57	58.75
48.69	-53.91	50.08
-37.92	-48.34	47.26
-57.15	-48.46	47.49
-15.94	-6.88	3.38
32.01	24.87	-3.18
38.55	-65.97	-22.4
6.57	-78.59	-17.63
-6.04	-46.78	23.34
25.59	-14.77	-19.85
31.97	54.19	4.4
45	39.95	25.52
-32.23	62.81	-2.27
-47.98	29.36	20.79
-3.03	33.58	29.95
-37.78	-56.83	61.35
45.47	-50.76	49.85
31.99	21.44	-6.23
54.57	-.11	2.01
-18.63	-34.51	59.26
-6.6	33.13	-16.81
32.07	-27.17	-15.54

// Ren T, 2012: Healthy Controls
// Subjects=14
45.04	30.44	26.32
-35.4	54.33	-1.53
0.31	25.11	44.01
35.82	-54.5	43.58
-37.89	-54.69	47.79
33.44	-86.66	-.53
54.63	-32.35	-1.98
-38.31	-59.05	-8.71
16.07	-.6	-.86
14	-5.39	6.26
-9.5	-6.58	6.63
31.99	21.44	-6.23
-44.63	4.52	29.52
31.9	53.42	-5.57
-38.63	54.06	-4.81
0.31	25.11	44.01
39.05	-54.22	46.87
-44.35	-42.04	46.81
35.86	-24.41	61.13
-6.62	46.08	-14.55
6.77	-50.13	20.13
-9.21	-16.7	40.93
16.63	-40.9	56.05
-50.96	-24.33	28.67
61.18	-20.99	20.41
-54.56	-2.05	-13.31
-47.77	-60.74	11.61
32.11	-30.08	-11.95
-27.73	-30.44	-11.23
-19.29	-11.7	-17.36

// Sato Y, 2013: Anorexia Nervosa (AN)
// Subjects=15
-17	3	4
34	17	7
11	0	3
-34	-92	8
-7	18	44
29	-89	3
27	-50	0
-9	-40	0
48	38	-13

// Sato Y, 2013: Subgroup of AN, Restrictive (ANR)
// Subjects=9
-30	21	-1
-16	8	0
36	20	3
8	4	3
-8	23	34
-16	8	0
38	19	-1

// Sato Y, 2013: Subgroup of AN, Binge-Purge (ANBP)
// Subjects=6
-8	23	34
-16	8	0
38	19	-1
48	38	-15

// Sato Y, 2013: Healthy Controls (HC)
// Subjects=15
-35	14	-5
-17	-48	-4
-9	22	33
34	18	0
21	45	-3
27	-50	0
-9	-40	0
48	38	-13
-8	23	34
-16	8	0
38	19	-1
48	38	-15

// Simard F, 2013: Matching according to semantic minus control matching
// Simard F, 2013: Matching according to syllable rhyme minus control matching
// Simard F, 2013: Matching according to syllable onset (attack) minus control 
// matching
// Simard F, 2013: Matching according to semantic minus matching according to 
// syllable rhyme
// Simard F, 2013: Matching according to syllable rhyme minus matching 
// according to semantic
// Simard F, 2013: Matching according to semantic minus matching according to 
// syllable onset (attack)
// Simard F, 2013: Matching according to syllable onset (attack) minus 
// matching according to semantic
// Simard F, 2013: Matching according to syllable onset (attack) minus 
// matching according to syllable rhyme
// Simard F, 2013: Matching according to syllable rhyme minus matching 
// according to syllable onset (attack)
// Subjects=14
-42.98	57.66	-12.87
-7.38	41.58	23.76
11.85	41.7	23.52
-31.07	33.04	-2.02
39.6	41.52	18.76
-50.16	32.18	16.11
-54.37	32.84	25.03
39.6	41.52	18.76
-50.16	32.18	16.11
-2.86	26.57	49.5
-49.88	13.09	44.48
-.71	-32.57	27.67
-47.88	-65.2	-4.74
-26.11	-60.96	48.18
31.7	-66.1	59.1
-30.79	-73.9	-8.67
24.79	-71.28	-7.3
-39.28	-84.35	-5.46
33.44	-89.92	-1.37
-7.11	-87.36	7.8
10.03	-86.92	12.03
-5.2	-12.82	8.22
-26.52	-34.44	5.82
24.7	-28.3	-1.98
9.76	-12.73	8.04
-11.6	0.35	13.88
13.89	9.88	-2.82
-39.51	-67.03	-29.22
37.55	-78.4	-18
-26.8	59.3	6.88
-47.92	28.82	27.52
-31.07	30.75	-4.06
35.16	30.98	-7.07
-50.16	32.18	16.11
-35.05	16.21	28.43
-7.29	35.92	33.15
9.73	41.86	25.77
-2.79	20.74	56.68
12.04	28.26	42.49
-52.01	10.96	44.68
-28.3	-48.28	47.14
-23.98	-60.95	48.16
31.61	-64.84	47.85
-43.66	-65.69	-11.44
35.36	-57.1	-17.53
-7.07	-87.02	12.23
20.86	-89.71	29.98
-17.87	-61.88	8.02
12.18	-73.53	19.8
-11.37	-71.9	15.47
14.27	-89.35	7.72
-3.12	-70.53	-22.65
7.58	-81.38	-26.32
-7.34	-10.72	8.07
-22.27	-32.47	3.37
20.48	-12.32	12.34
24.7	-28.3	-1.98
13.91	-.87	-4.15
-39.71	67.17	-.32
-.94	48.48	29.79
9.76	39.91	28.16
-31.07	30.75	-4.06
35.16	30.98	-7.07
-50.16	32.18	16.11
-54.37	32.84	25.03
-.75	28.53	47.08
-49.89	10.8	42.44
-50.05	-65.55	-9.15
-34.71	-43.92	49.08
-26.12	-58.84	48.01
33.8	-62.03	56.51
-21.89	-92.25	28.45
25.17	-91.46	34.54
-20.04	-90.75	-7.38
9.98	-85.15	7.42
-15.71	-94.61	-2.64
20.62	-98.8	-4.94
-28.83	-71.37	-31.21
37.55	-78.4	-18
-22.27	-32.47	3.37
-5.2	-12.82	8.22
22.68	-29.23	13.74
-15.95	1.75	4.89
16.07	1.6	0.07
-58.92	32.19	-10.55
-60.99	34.98	-1.84
-56.56	38.83	20.09
-30.93	-40.23	-13.72
-39.66	-18.05	-28.86
-13.51	-98.32	4.33
18.14	16.25	-3.41
-42.58	5.79	18.24
52.04	-1.95	-49.11
-47.83	-69.09	0.05
20.72	-93.37	10.22
-30.96	27.55	9.59
-39.61	30.87	-1.74
-20.15	-50.23	-6.32
-43.85	-32.54	-23.14
5.7	-74.25	11.02
20.8	-96.91	19.43
7.22	73.11	-10.28
-62.48	-28.6	57.04
48.67	-32.16	56.06
-54.25	-67.01	-0.06
37.97	-36.8	52.11
-15.72	-92.5	-2.82
13.92	43.14	14.46
-7.04	-73.47	22.25
12.02	-70.84	-.5
-11.45	-63.95	8.12
20.64	-89.82	1
-17.99	-56.56	-5.81

// Essingler C, 2012: Monetary > Control
// Essingler C, 2012: Control > Monetary
// Essingler C, 2012: Famous > Non-famous
// Essingler C, 2012: Non-famous > Famous
// Essingler C, 2012: Dull > Bright
// Subjects=27
9	0	63
0	30	-15
-33	-6	54
-54	6	9
-33	-27	54
42	-6	51
33	27	-3
39	54	18
-12	-27	42
-18	3	-12
-12	-15	-3
-30	18	6
18	6	-9
-6	-21	-12
6	-15	-12
-54	-39	27
-57	-15	18
-9	-57	63
54	-42	36
-45	12	0
36	21	9
-42	-57	9
-51	9	-6
-42	-51	-36
0	-60	-33
36	-54	-33
27	-57	-24
12	-90	6
-9	-90	3
-42	-45	-18
-60	-9	-21
42	-48	-21
-3	45	-15
0	-57	24
-24	6	57
33	54	-12
-9	-69	48
-60	-45	48
15	-66	51
45	-48	60
48	-33	54
48	9	24
6	18	48
-45	-72	-3
-36	-84	12
18	-66	3
39	-86	0
27	-81	24
-15	-75	48
-12	-66	57
-39	-39	45
21	-66	48
33	-54	54
-30	-57	-33
-3	-78	-24
42	-54	-36
-33	21	3
33	21	0
-42	-60	0
36	-84	21

// Harvey P O, 2010: Positive vs Neutral pictures
// Subjects=26
7.35	38.5	-10.76
-7.83	56.63	-11.18
-3.56	38.8	-18.45
18.9	-105.82	17.89
-13.56	-109.54	14.33
-.44	-49.26	38.4
-62.33	-9.14	23.15
-11.75	-2.76	8.21
24.71	11.76	-10.65
-11.79	6.81	7.27
-5.57	12.51	-12.45
-4.81	-23.33	40.39
-64.34	-27.67	31.74
-16.06	64.07	22.96

// Jogia J, 2012: Euthymic Bipolar
// Subjects=36
-17.95	-36.74	24.01
-16.42	46.07	-8.86
-16.53	51.83	-16.16
-22.7	-44.33	-11.02
51.15	13.47	29.07
49.18	23.63	46.03
57.44	31.8	18.18
-16.41	59.25	-5.69
-3.51	36.98	-14.91
-55.02	-30.65	-.62
-65.69	-34.11	8.87
-36.93	-59.64	55.73
12.71	-75.18	47.46
-42.29	-65.21	-26.55
-16.02	-36.27	6
9.89	-14.49	7.89
11.93	-35.08	-5.8
-42.31	-74.13	-30.15
64.05	-43.87	12.11
65.77	-3.4	-14.33
46.08	58.22	-20.1
-48.35	40.77	28.06
-50.27	7.56	40.35
-33.68	24.32	-10.9
57.53	-50.69	8.41
45.1	-46.79	50.82

// Jogia J, 2012: Healthy controls
// Subjects=37
-17.95	-36.74	24.01
-16.42	46.07	-8.86
-16.53	51.83	-16.16
-22.7	-44.33	-11.02
48.8	47.08	21.3
-48.41	40.35	23.62
5.89	42.62	44.88
4.02	25.13	64.58
-46.1	8.66	28.96
55.38	14.98	22.12
-59.32	-19.61	2.85
41.95	24.59	-12.22
-48.72	46.78	0.58
8.07	29.66	43.89
72.38	-22.1	-8.11
-67.91	-19.23	7.44
45.15	-52.96	53.67
7.74	-18.75	8.34
55.62	-64.14	25.47
-40.19	-72.21	-32.62
64.05	-43.87	12.11
65.77	-3.4	-14.33
46.08	58.22	-20.1
50.99	38.58	22.1
36.39	13.98	58.4
35.33	67.31	-14.09
39.83	20.53	-9.54
-39.17	-53.68	50.7

// Carnell S, 2014: High energy-density vs. Low energy-density in Obese vs. 
// Lean for visual cues
// Carnell S, 2014: High energy-density vs. Low energy-density in Obese vs. 
// Lean for auditory cues
// Carnell S, 2014: Conjunction of visual and auditory cues (high energy 
// density vs low energy density)x(obese vs lean)
// Subjects=10
-44	-36	10
58	-34	12
-26	-6	-6
26	34	-10
-58	-50	28
-16	-40	-8
14	-30	-32
44	8	10
0	-12	-8
-32	-6	-6
28	-12	-22
-16	-32	32
58	-30	12

// Oltmanns K M, 2012: Obese > Healthy
// Oltmanns K M, 2012: Healthy > Obese
// Subjects=10
32	-52	56
-6	-32	-6
32	18	4
28	-80	2
18	-94	14
-14	-78	-2
-30	-88	28
38	-58	-20
16	2	60
-22	-16	0
12	16	36
16	-4	8
26	-6	-18
-14	4	-10
-8	-92	14
-12	-84	-16
46	-8	56
54	-36	-3

// Christodoulou J A, 2014: Typical Readers
// Subjects=12
-.18	17.23	72.15
33.34	29.22	-8.05
-52.68	-46.83	9.91
59.76	-45.81	14.62
-35.44	-79.92	-.56
40.54	-90.13	23.81
53.27	-80.9	6.99
-40.35	-51.56	-41.38
-7.81	-85.48	-38.58
-7.48	-15.17	1.53
14.06	15.1	2.65
4.86	-39.47	-52.31
-.32	16.19	61.05
53.15	31.99	20.48
37.61	35.41	-10.97
42.64	1.29	37.14
55.3	-40.27	5.18
-41.41	-19.24	51.81
40.81	-42.14	54.92
34.23	-67.01	41.8
20.79	-83.77	1.11

// Christodoulou J A, 2014: Dyslexic Readers
// Subjects=12
8.15	23.69	48.96
40.25	52.13	29.91
31.91	10.6	45.37
-37.88	14.29	-3.11
33.38	27.31	-5.62
-65.64	-46.87	10.13
52.98	-34.94	-6.51
-37.01	-25.19	56.81
-30.44	-48.56	59.01
-56.89	-17.53	25.01
51.66	-46.14	57.37
30.1	-65.57	57.42
0.84	-59.09	-32.37
-9.68	-19.85	-2.46
10.13	-19.21	26.28
8.18	23.9	51.18
53.34	13.68	31.25
37.64	35.62	-8.75
-48.42	14	17.27
-52.73	-49.37	5.68
-50.45	-20.05	20.67
-39.2	-16.68	56
-30.36	-45.81	65.46
10.14	-80.43	14.41
-22.13	-94.81	23.1
29.64	-93.13	15.33
-7.63	-29.39	-12.75

// Cliff M, 2012: Younger Participants
// Subjects=11
63.12	-18.72	-5.45
-56.53	-14.7	2.27
13.11	-89.24	-4.54
-56.57	-6.24	1.57
63.12	-18.72	-5.45
13.11	-89.24	-4.54

// Cliff M, 2012: Older Participants
// Subjects=10
58.94	-20.98	7.05
-59.74	-17.97	1.47
16.28	-89.65	-10.12
-13.64	-89.83	-9.76
-56.57	-6.24	1.57
63.12	-18.72	-5.45
13.11	-89.24	-4.54

// Congdon E, 2014: Attention Deficit Hyperactivity Disorder
// Subjects=35
64	-16	2
-42	-28	6
-10	8	-4

// Congdon E, 2014: Healthy Controls
// Subjects=62
64	-16	2
-32	20	4
12	8	4
-8	2	-6

// Cubillo A, 2014: Controls > ADHD Placebo, Successful inhibition - Go trials
// Cubillo A, 2014: ADHD Placebo > Controls, Successful inhibition - Go trials
// Cubillo A, 2014: Controls > ADHD MPX (Methylphenidate), Successful 
// inhibition - Go trials
// Cubillo A, 2014: ADHD MPX > Controls, Successful inhibition - Go trials
// Cubillo A, 2014: Controls > ADHD ATX (Atomoxetine), Successful inhibition - 
// Go trials
// Subjects=19
35.07	32.24	-18.33
-22.67	34.81	-21.22
-44.67	-54.09	0.98
39.7	-61.84	-10.49
-25.49	-74.38	-15.38
51.42	-13.79	4.3
-41.46	-61.73	-1.76
-29.98	-40.37	-29.33
-32.62	-70.74	32.35
-10.5	-54.14	-2.75
-41.5	-58.9	-6.46

// Gilger J W, 2013: (G) nonverbally gifted normal readers
// Subjects=5
0	-82	2
-38	-62	38
-40	-62	-34
-50	14	28
-4	18	46
32	-64	-48
-22	-88	-4
-4	-46	34
-52	-18	-2
18	-100	4
58	-24	-2
-4	-98	-6
-54	26	14
-38	-50	32
-24	-14	60
26	-78	10
32	-8	62
-24	-88	-2
-40	-52	42
-24	-14	60
-46	6	22
36	-82	0
48	-38	50
32	-8	60
54	26	30

// Gilger J W, 2013: (GRD) nonverbally gifted reading disorder
// Subjects=9
-32	-80	-18
-24	-64	52
-64	-32	-2
-2	18	46
-40	8	24
58	-24	-2
6	-20	60
58	0	38
-22	-88	-4
-4	-46	34
-52	-18	-2
18	-100	4
58	-24	-2
-4	-98	-6
-54	26	14
-38	-70	-16
-36	-50	62
-22	6	52
38	-82	-2
20	-74	50
28	10	50
54	10	26
-38	-50	32
-24	-14	60
26	-78	10
32	-8	62

// Chung S C, 2014: Driving only (DO) - Driving with task (DWT)
// Chung S C, 2014: DWT - DO
// Subjects=16
11	-75	50
51	8	35
64	-31	40
58	14	30
55	11	0
27	-7	65
56	-26	50
19	-26	5
17	3	65
-22	-84	30
-55	-36	45
-56	-37	30
-28	-50	40
-55	0	35
-55	10	35
-51	7	20
-22	-37	70
-12	-6	-15
31	-68	-15
14	-59	-45
-20	-48	-15
-37	-46	-40
25	-36	25
20	-1	-5
17	-29	30
39	-26	-10
5	-28	15
-5	-26	15
-23	-6	-5
-11	-34	20

// King G R, 2011: Cannabis users < Controls, 2 Hz
// King G R, 2011: Cannabis users < Controls, 4 Hz
// King G R, 2011: Cannabis users > Controls, 2 Hz
// King G R, 2011: Cannabis users > Controls, 4 Hz
// King G R, 2011: Females > Males, 2 Hz
// King G R, 2011: Females > Males, 2 Hz
// King G R, 2011: Males > Females, 2 Hz
// King G R, 2011: Males > Females, 4 Hz
// King G R, 2011: Male cannabis users < Male controls, 2 Hz
// King G R, 2011: Male cannabis users < Male controls, 4 Hz
// King G R, 2011: Male cannabis users > Male controls, 2 Hz
// King G R, 2011: Male cannabis users > Male controls, 4 Hz
// King G R, 2011: Female cannabis users < Female controls, 2 Hz
// King G R, 2011: Female cannabis users < Female controls, 4 Hz
// King G R, 2011: Female cannabis users > Female controls, 4 Hz
// Subjects=14
-12	-104	-1
6	-96	8
50	-12	64
36	-18	54
46	-24	70
-16	-108	-6
-12	-104	0
2	18	50
-62	-26	-6
-38	10	44
46	48	-6
32	-46	64
26	62	-26
10	-108	4
40	-18	44
50	-20	52
34	-20	56
0	-108	6
20	-100	-4
-18	-90	-6
-18	-90	-6
-34	-84	-10
36	-16	50
32	-6	60
-60	0	34
-12	-104	-10
-12	-108	4
-60	-14	30
36	-18	54
2	18	50
-48	14	-12
2	22	54
-54	-32	64
22	-98	-14
56	-66	8
50	-14	66
-48	4	62
26	-94	-14
-58	16	4
48	52	-2
-36	44	12
52	20	-24

// Bartolo A, 2014: Reachability task > Color discrimination and Left-right 
// discrimination tasks
// Bartolo A, 2014: Reachable > Scrambled image
// Bartolo A, 2014: Unreachable > Scrambled image
// Bartolo A, 2014: Reachable > Unreachable, p < 0.001
// Bartolo A, 2014: Reachable > Unreachable, p < 0.01
// Bartolo A, 2014: Unreachable > Reachable
// Bartolo A, 2014: Brain areas where BOLD signal was significant for an 
// increase of reaction time (parametric analysis)
// Subjects=14
14.97	-71.15	55.99
49.67	49.88	5.32
-5.45	-92.73	-24.45
8.13	-97.9	22.89
-47.89	45.98	-19.53
-50.4	15.34	31.73
4.62	37.97	29.68
43.88	-74.09	34.49
-28.45	-50.24	-39.47
-50.35	-67.47	18.64
-11.39	-56.93	25.89
23.48	-72.5	-39.27
-27.45	-16.51	45.7
4.42	-62.01	-6.37
33.85	0.23	26.19
29.87	-44.72	-41.01
-24.07	-73.49	44.56
23.48	-24.35	-29.47
4.29	-35.63	-11.22
-27.74	-59.19	14.07
17.73	-53.94	21.74
40.42	-28.68	26.7
-11.34	-56.61	29.22
53.44	-66.48	23.49
-37.14	-77.56	36.22
17.71	-55.22	19.63
-27.73	-62.38	14.38
-44.03	-5.13	19.08
-24.62	-11.97	13.83
-18.53	61.78	-1.42
-21.73	45.61	-2.01
10.84	11.9	3.02
27.64	-94.12	27.79
37.21	17.54	38.99
-8.8	35.56	-6.83
24.29	7.92	40.16
1.14	48.2	13.04
10.55	2.06	-21.78
-15.12	-17.95	-4.79
-27.78	-94.47	4.11
30.33	-32.58	-3
-2.29	-2.47	-12.15
4.65	-6.67	22.89
-40.56	-63.62	24.81
-30.62	-9.42	52.9
-37.2	-20.05	42.85
26.75	-46.03	-31.86
-21.82	-72.14	-32.93
-4.63	-86.6	41.04
-3.81	-86.34	20.83
40.71	14	58.33
49.45	-55.73	-33.53
7.85	34.58	27.72
55.37	21.47	22.6
21.2	-6.25	49.46
-34.71	-65.08	-25.57
-4.52	-71.53	52.99
-5.45	-92.73	-24.45
14.89	-62.95	51.82
36.47	18.52	-19.37
37.54	-63.19	48.09
-33.93	8.65	51.16
14.81	14.12	61
7.55	-92.37	-21.35
-33.94	-42.89	39.46
36.52	64.85	-6.02
42.85	56.08	-19.83
61.43	19.44	-10.92
20.42	-15.36	-13.5
-52.39	-33.7	35.5
-33.72	-56.54	54.25
68.61	-33.27	33.4
50.27	-72.56	27.51
-31.59	24.87	-16.59
-1.79	-19.56	23.15

// Deprez S, 2013: Dual task (DT) > Visual task (VT) & Auditory task (AT)
// Deprez S, 2013: Multitask (MT) > VTAT
// Deprez S, 2013: MT > DT
// Subjects=33
-24	-4	50
-26	-6	30
30	0	50
-10	-70	54
22	-56	42
34	-60	-36
-40	2	30
-34	-2	62
-50	22	32
-6	12	52
34	2	50
48	30	26
-8	-72	54
14	-72	54
32	-60	-36
26	-74	-50
-50	38	16
-36	-78	8
-46	-60	-12
-4	22	44

// Njiboer M, 2014: 2-Back > Baseline
// Njiboer M, 2014: Tone-counting > Baseline
// Njiboer M, 2014: Tracking > Baseline
// Njiboer M, 2014: 2-Back and Tone-counting > Baseline
// Njiboer M, 2014: 2-Back and Tracking > Baseline
// Njiboer M, 2014: Tone-counting and Tracking > Baseline
// Njiboer M, 2014: (2-Back and Tone counting) - (2-Back + Tone-counting)
// Njiboer M, 2014: (2-Back and Tracking) - (2-Back + Tracking)
// Njiboer M, 2014: (Tone-counting and Tracking) - (Tone-counting + Tracking)
// Subjects=19
-42	2	28
-30	-52	46
0	2	58
-33	20	-2
-48	-7	52
-54	2	19
54	-1	43
66	-28	10
-60	-31	10
-3	-4	61
18	-58	-23
-48	-73	-2
48	-58	-2
39	-10	52
-54	-22	43
66	-28	25
18	-55	61
-15	-19	7
-39	50	22
39	44	31
-60	-31	10
63	-28	7
-3	8	52
-33	-43	40
-33	20	4
39	20	1
0	-67	-20
-51	2	31
36	38	31
45	2	34
-48	-73	-2
0	-1	52
-12	-19	7
15	-19	7
18	-55	-23
33	-91	-8
-48	-73	-2
54	-70	-2
-45	-19	55
-45	-37	13
-48	-1	7
66	-28	10
-21	-55	61
-9	-82	1
33	-34	-2
0	-37	22
-12	-49	46
6	-79	4
48	-1	-14
30	14	-5
-36	50	22
33	56	16
-30	2	22
33	11	25
12	8	31
45	-25	49
15	-82	7

// Ohrmann P, 2010: Women > Men, Angry faces p < 0.001 uncorrected
// Ohrmann P, 2010: Women > Men, Angry faces p < 0.001 corrected
// Ohrmann P, 2010: Women > Men, Angry faces p < 0.05 corrected
// Ohrmann P, 2010: Women > Men, Angry faces p < 0.01 corrected
// Ohrmann P, 2010: Women > Men, Fearful faces p < 0.001 uncorrected
// Ohrmann P, 2010: Women > Men, Fearful faces p < 0.01 corrected
// Ohrmann P, 2010: Women > Men, Fearful faces p < 0.05 corrected
// Ohrmann P, 2010: Women > Men, Happy faces p < 0.001 uncorrected
// Ohrmann P, 2010: Women > Men, Neutral faces p < 0.001 uncorrected
// Ohrmann P, 2010: Women > Men, Neutral faces p < 0.001 corrected
// Ohrmann P, 2010: Women > Men, Neutral faces p < 0.05 corrected
// Ohrmann P, 2010: Women > Men, Neutral faces p < 0.01 corrected
// Ohrmann P, 2010: Men > Women, Angry faces
// Subjects=8
-31.14	29.01	-12.83
-53.49	37.48	2.33
-52.22	18.68	20.62
33.66	-78.89	31.16
35	42.47	-23.64
-49.94	-42.44	14.56
50.36	-20.31	2.63
-47.7	-68.77	17.86
55.75	-52.69	-3.63
-45.81	-62.53	-11.68
-15.83	-6.82	17.88
33.27	-22.53	3.02
31.09	-1.05	5.7
-24.48	-10.1	3.75
-22.36	-16.86	-1.28
3.35	-5.11	10.82
33.12	-14.21	-13.29
-43.8	38.31	12.18
-37.5	49.29	2.27
-41.53	27.55	24.21
64.19	24.15	12.13
-41.55	9.77	14.55
33.64	-67	33.51
18.31	-.62	12.5
-28.94	18.62	-9.76
5.52	30.37	29.01
-47.72	-56.88	20.21
-17.68	-104.97	14.98
37.7	-6.62	29.51
-9.55	6.1	5.57
27.07	-88.47	4.16
7.47	5.44	-4.61
-41.67	9.63	-1.05
27.07	-88.47	4.16
27.07	-88.47	4.16
7.47	5.44	-4.61
7.68	13.04	24.86
9.73	18.79	16.55
16.25	-17.46	15.05
26.92	-13.08	15.68
16.08	-4.92	-1.61
9.69	-17.9	-3.79
18.3	3.61	12.15
-33.06	-18.24	-4.39
-45.81	-60.41	-11.86
31.34	-86.33	3.93
-4.98	-97.38	1.93
-50.03	-24.72	9.73
-43.55	-49.17	9.48
-17.77	-94.91	7.44
39.47	17.09	-8.18
-33.19	-17.41	-21.18
30.9	-.74	-17.74
1.17	-38.56	-8.65
5.65	-17.64	27.46
37.47	-9.02	-1.51
-24.43	-9.59	10.4
-33.08	1.31	0.66
24.68	-14.21	1.3
-15.9	10.01	15.35
-55.38	-7.23	16.13
33.14	12.36	0.09
-13.85	-7.38	-3.29
-20.2	-47.4	-11.01
11.8	19.18	7.57
-11.26	-63.04	33.69

// Kast M, 2011: audiovisual words and nonwords: control > dyslexic
// Kast M, 2011: audiovisual words and nonwords: dyslexic > controls
// Kast M, 2011: main effect (all stimuli) controls > dyslexic
// Kast M, 2011: stimuli overall effect: nonword > word
// Subjects=12
-52	-44	36
-12	-60	46
-36	-60	30
32	80	36
18	-66	40
56	-18	-12
34	-64	44
36	-48	32
-42	16	-2
-34	4	30
-6	10	36
-14	-46	0
36	22	0
6	18	30
28	-8	42
-52	-46	34
54	-20	-12
-52	10	2
-2	4	62

// Siniatchkin M, 2012: ADHD
// Subjects=17
4	20	36
46	42	20
9	15	4
2	20	48
-38	20	2
40	20	6

// Siniatchkin M, 2012: healthy controls
// Subjects=14
2	18	34
-42	6	-2
50	18	-2
-30	52	10
28	60	10
-4	14	2
12	6	10
4	20	36
46	42	20
9	15	4

// Vasic N, 2014: Incorrect - Correct Response Inhibition, All subjects
// Vasic N, 2014: Incorrect - Correct Response Inhibition, ADHD > Controls
// Subjects=12
-30	22	-6
34	18	-16
-2	20	38
6	30	22
10	12	58
-44	22	-4

// Carmona S, 2012: Controls > ADHD for No-Go > Go
// Carmona S, 2012: Win > Control for Controls > ADHD
// Subjects=23
63.65	-16.17	-13.03
47.07	-35.06	38.42
16.65	22.68	37.71
-52.7	-5.37	17.01
-54.86	-5.38	17.05
24.98	44.45	17.48
-7.91	-68.67	-42.48
-10.07	-59.96	-41.06
-14.31	-52.76	-32.74
-33.04	-14.69	31.05
-33.31	-42.92	4.71
-48.5	19.96	12.19
-45.64	-51.37	52.82
-45.73	-43.27	47.54
-49.94	-42.46	56.49

// Desroches A S, 2010: typical readers (TR)
// Subjects=12
-63	-24	15
-63	-27	3
-54	-15	-3
66	-12	3
60	-24	12
57	-30	-3
0	12	54
-48	-63	-24
-48	-54	-18
-48	-51	-15

// Desroches A S, 2010: reading diffuculty (RD)
// Subjects=12
57	-12	-3
57	-27	6
-60	-21	9
-63	-12	-3
-66	-33	9
-6	6	42
3	24	30
-3	18	36
-48	-51	-15

// Hu W, 2010: control English speakers
// Subjects=10
-46	6	30
-56	-38	6
-48	6	32
-48	6	32
-54	-38	4

// Hu W, 2010: dyslexic English speakers
// Subjects=11
-48	6	32
-48	6	32
-54	-38	4

// Hu W, 2010: control Chinese readers
// Subjects=14
-46	6	30
-56	-38	6
-54	-38	4
-48	6	32

// Hu W, 2010: dyslexic Chinese speakers
// Subjects=11
-54	-38	4
-48	6	32
-54	-38	4

// Waldie K, 2013: Control > Dyslexic for Regular word versus Fixation
// Waldie K, 2013: Dyslexic > Control for Regular word versus Fixation
// Waldie K, 2013: Control > Dyslexic for Pseudoword versus Fixation
// Waldie K, 2013: Dyslexic > Control for Pseudoword versus Fixation
// Subjects=12
-27	-96	-6
-3	-9	18
-12	6	3
-6	21	45
-3	36	33
-3	24	36
-42	42	36
-39	33	24
51	-9	45
-3	15	57
6	6	54
33	0	12
-51	21	9
-21	60	21
-27	57	15
39	-84	9
-15	18	-12
-12	12	-5
45	-9	39
-51	-12	24
30	-21	12
36	-69	-12
-6	24	33
54	12	0

// Gradin VB, 2011: Major-depressive disorder (MDD)
// Subjects=15
8	2	-8
-6	2	16
8	-6	16
2	-24	-4

// Gradin VB, 2011: Schizophrenia (SZ)
// Subjects=14
-26	-14	-24
32	-20	-12
-26	-38	-18
28	-48	-2
32	6	4
26	-4	-10
-6	-16	-16

// Juckel G, 2012: Prodromal Schizophrenia (UHR)
// Subjects=13
9	-81	3
-12	48	-15
21	33	-18
-12	48	-15

// Juckel G, 2012: Healthy controls
// Subjects=13
-6	-57	-6
-51	-72	6
27	-93	0
63	6	18
-15	-6	12
-36	12	9
-45	-33	21
63	-60	-3
-27	-99	6
-39	-90	9
6	-69	0
-3	-21	-15
-51	-69	-6
15	-6	-15
54	30	18
-15	-9	-15
-12	48	-15
-12	-87	12
18	-6	-12
-48	-69	-6
-9	-3	6

// Koch K, 2010: Schizophrenia
// Subjects=19
-16.43	40.54	-10.56
37.93	37.8	14.56
22.7	43.51	7.53
10.29	36.67	49.88
10.12	49.66	39.63
-19.82	19	57.74
-26.63	36.25	35.98
36.27	19.64	50
-.97	-9.42	5.33
27.12	-76.07	-8.73
39.9	-50.05	-18.24
14.07	50.17	10.38
-20.42	11.24	9.22
7.24	49.68	-17.47
63.88	-37.47	0.27
39.99	-31.89	-7.71
42.38	0.49	17.06
14.07	50.17	10.38
-22.6	13.26	7.93
-26.83	51.17	23.3

// Koch K, 2010: Healthy controls
// Subjects=20
44.42	40.06	15.35
35.36	56.57	-14.15
60.15	-47.26	45.01
-16.43	40.54	-10.56
37.93	37.8	14.56
22.7	43.51	7.53
10.29	36.67	49.88
10.12	49.66	39.63
-19.82	19	57.74
-26.63	36.25	35.98
36.27	19.64	50
-.97	-9.42	5.33
27.12	-76.07	-8.73
39.9	-50.05	-18.24
14.07	50.17	10.38
-20.42	11.24	9.22
7.24	49.68	-17.47
63.88	-37.47	0.27
39.99	-31.89	-7.71
42.38	0.49	17.06
14.07	50.17	10.38
-22.6	13.26	7.93
-26.83	51.17	23.3

// Hedden T, 2010: Incongruent Shifting (IS) > Neutral non-shifting (NN)
// Hedden T, 2010: Incongruent non-shifting (IN) > Neutral shifting (NS)
// Hedden T, 2010: NS > IN
// Subjects=17
-32	2	60
-10	0	64
28	-4	56
-44	10	30
52	8	28
-12	30	28
10	30	28
-42	34	22
48	36	24
-34	22	4
34	26	2
-8	18	50
6	12	54
-28	-78	38
30	-68	42
-46	-44	46
40	-52	48
-20	-2	22
22	-8	20
-30	-56	-34
26	-62	-34
-52	12	-8
54	20	6
52	10	12
58	18	6
32	6	44
6	16	66
6	44	52
42	10	38
52	44	-12
54	24	30
28	66	20
-68	-34	26
-62	-38	20
60	-34	50
58	-60	8
64	-50	18
-60	-36	52
64	-50	18
-60	-36	52
-56	-2	2
54	-44	4
10	4	12
12	16	8
-16	8	2
-10	16	6
-16	20	-4
-22	-70	-34
-26	-56	40

// Braem S, 2013: Task-switch cost (Task-switch > Task repetition)
// Braem S, 2013: Goschke effect (Task-switch cost after incongruent trials > 
// Task-switch cost after congruent trials)
// Braem S, 2013: Modulation of the Goschke effect
// Braem S, 2013: Picture Presentation
// Subjects=35
-2	14	54
6	-26	28
-32	44	6
-46	4	40
40	54	6
-30	-72	50
22	-32	2
14	4	8
-44	20	26
46	24	22
44	2	50
-44	-30	44
64	-50	24
-2	50	-2
-4	-40	-12
56	-70	20
-16	-20	60
36	-53	46

// Corradi-Dell'Acqua C, 2014: High-functioning Autistic Males (ASD)
// Subjects=10
-48	-21	30
-60	-33	30
57	-9	39
-3	-96	0
12	-75	-3
-15	-84	0
18	18	0
-48	-69	-15
45	-63	33
-45	-66	27
-24	21	45
-6	-57	48

// Corradi-Dell'Acqua C, 2014: Controls
// Subjects=10
36	-54	-21
45	-57	27
12	-54	9
9	-69	18
-9	-48	33
-12	-54	15
6	57	-3
6	12	-3
-15	18	-3
-21	-93	6
-6	-96	-6
30	-69	-3
9	-75	-3
-3	-96	0
12	-75	-3
-15	-84	0
18	18	0
-48	-69	-15
-27	-36	-18
-15	-39	-6
-27	27	12

// De Baene W, 2011: Task-switch > Cue-repeat contrast
// Subjects=20
-8	-77	48
-32	-4	58
-4	7	58
10	-80	6
-40	35	27

// Jack A, 2014: Autistic Subjects (ASD)
// Subjects=15
60	-34	10
52	-30	16
20	-76	-14
52	-64	-12
-24	-86	14
8	-84	-10
-32	-48	52
50	-32	22
-48	-38	24
-64	-26	30
38	-6	42
22	-88	38
0	-76	4
6	-86	42
14	-74	60
-6	-62	40
-48	-74	-12
-48	-70	2
48	18	18
50	18	34
52	12	32
-20	-64	-32
-6	-64	-34
2	-58	-32
-14	-56	-24
42	-58	-28
42	-56	-52
42	-58	-46
-46	-32	40
-32	-10	62
40	-2	36
-36	-50	68
30	-54	-26
46	-62	2
20	-46	-28
-30	-90	2
-22	-102	-6
-44	-72	0
-38	-70	-10
-50	2	2
-18	-24	2
-28	-6	2
46	-28	36
40	-44	54
40	-42	42
20	-78	44
42	-64	-2
-12	-100	8
-18	-78	34
-38	-80	6
-6	50	0
-4	32	-10
-22	54	28
-44	-18	34
12	-68	-14
22	-60	28
22	-72	-48
-12	-64	-24
-6	-64	-34
4	-68	-12
-48	-10	48
-66	-16	6
-56	-68	-2
-46	-38	36
42	4	-8
46	0	6
52	-10	50
6	-62	52
-18	-56	66
16	-58	60
54	-32	32
66	-20	20
68	-16	36
-38	-2	12
-58	10	-16
-52	14	12
6	-4	38
-36	30	-4
-22	16	-2
-14	-6	-14
-12	-60	-28

// Jack A, 2014: Healthy Controls
// Subjects=15
46	-70	-6
20	-78	-16
-50	-76	-6
46	-78	-10
-18	-86	30
-34	-52	56
42	-2	54
-56	-2	42
40	12	18
16	-30	-4
-18	-30	-4
6	-28	-14
22	-88	38
0	-76	4
6	-86	42
14	-74	60
-6	-62	40
-48	-74	-12
-48	-70	2
48	18	18
50	18	34
52	12	32
-20	-64	-32
-6	-64	-34
2	-58	-32
-14	-56	-24
42	-58	-28
42	-56	-52
42	-58	-46
-46	-32	40
-8	-2	54
-44	-6	8
28	-50	-34
-48	-80	2
-50	-68	0
28	-84	32
-8	42	-8
8	40	-20
-6	56	-8
34	-30	56
30	-26	64
12	-68	-14
22	-60	28
22	-72	-48
-12	-64	-24
-6	-64	-34
4	-68	-12
-48	-10	48
-66	-16	6
-56	-68	-2
-46	-38	36
42	4	-8
46	0	6
52	-10	50
6	-62	52
-18	-56	66
16	-58	60
54	-32	32
66	-20	20
68	-16	36
-38	-2	12
-58	10	-16
-52	14	12
6	-4	38
-36	30	-4
-22	16	-2
-14	-6	-14
-12	-60	-28

// Weisberg J, 2014: People > Tools, All Participants
// Weisberg J, 2014: Tools > People, All Participants
// Weisberg J, 2014: Localizer faces > Localizer tools, All Participants
// Weisberg J, 2014: Localizer tools > Localizer faces, All Participants
// Subjects=17
22.8	-56.55	18.26
52.71	-74.06	9.34
56.93	-54.83	9.91
18.62	-90.75	16.71
-42.35	-70.86	17.97
18.28	-32.82	-4.87
49.12	-46.24	-29.75
-8.43	-32.9	-3.44
24.49	-7.38	-20.46
-43.82	-43.2	-23.36
-2.25	-1.19	-20.67
-35.72	-41.13	57.78
-29.85	-55.46	-18.03
35.43	-63.99	-10.26
-46.81	-67.31	-4.58
-43.74	31.16	16.13
-33.33	40.46	-16
-36.42	-26.4	-27.08
-60.79	6.31	12.83
-18.77	-98.64	14.46
26.98	-85.01	-6.17
48.13	-53.13	-22.47
54.65	22.75	22.39
-19.33	-8.87	-22.06
22.31	3.1	-22.43
9.04	-59.75	33.18
59.2	-67.7	22.12
45.16	6.37	31.68
-47.8	-72.09	2.53
-29.97	-32.62	-25.52
40.51	-26.03	-29.12
42.98	-63.26	-1.49
-64.85	-25.47	28.92
29.48	-48.22	56.51
-21.82	-73.97	44.76
-20.76	-48.78	53.79
-37.23	-.69	16.49
-57.46	12.02	31.27
-6.66	-62.93	76

// Scherf K S, 2010: High-functioning Autism (HFA) Group
// Subjects=10
54.44	-5.8	-16.47
-47.86	-78.15	-7
15.26	-90.2	-3.37
-3.95	-95.6	-2.7
34.59	-83.6	11.47
-23.11	-88.26	11.41
26.27	-74.73	44.28
-17.54	-77.11	44.98
-24.17	-93.72	9.65
6.89	-36.78	41.32
-9.12	-37.77	43.81
18.49	-57	12.77
-1.12	36.74	1.79
54.65	33.67	25.94
36.72	20.72	52.88
27.89	-59.17	-16.15
-24.45	-63.71	-15.17
26.06	-87.88	11.92
-22.04	-89.4	10.37
29.48	-77.89	44.5
-19.69	-80.55	41.95
29.5	-61.26	53.14
-21.75	-66.59	57.53
37.96	-40.14	50.16
-32.56	-44.88	50.25
63.45	-19.61	38.11
2.49	-5.17	37.6
46.15	35.27	33.71
-59.48	1.14	42.24
33.47	24.59	48.13

// Scherf K S, 2010: Typically-developing (TD) Controls
// Subjects=10
43.79	-43.9	-26.54
-40.55	-54.64	-20.21
53.77	-58.82	13.63
-66.18	-31.56	-8.47
-43.07	20.46	-39.86
-40.05	-59.27	43.74
0.02	63.83	21.8
-5.53	45.2	-12.26
9.89	51.23	50.63
23.84	26.65	48.07
6.59	61.18	42.02
1.38	42.72	51.44
34.05	63.47	0.26
-15.68	35.38	54.48
-17.94	41.75	40.59
-1.24	68.46	-.87
36.61	7.46	32.8
-46.61	11.59	52.37
-50.37	30.04	-11.58
-35.3	-79.75	-42.7
18.45	-88.15	-4.69
-35.3	-79.75	-42.7
18.45	-88.15	-4.69
-3.95	-91.12	0.27
33.61	-77.2	25.44
-21.96	-84.14	23.31
23.19	-64.58	65.76
-7.81	-66	64.01
67.6	-12.15	24.06
63.24	10.03	22.25
-32	15.74	8.36
-40.6	34.98	10.19
-40.6	34.98	10.19
25.8	-65.27	-12.27
-24.42	-66.63	-11.58
8.88	-84.44	2.91
34.58	-82.63	10.27
-22.04	-88.25	11.39
38.05	-44.66	60.58
-30.33	-51.58	59.71
-57.27	-27.74	40.18
64.42	-15.17	26.58
-46.71	-30.1	22.41
-45.92	34.07	12.56

// Hakun J G, 2012: Perceptual-catch > Baseline
// Hakun J G, 2012: Rule-catch > Baseline
// Hakun J G, 2012: Rule-catch switch > Repeat
// Subjects=20
42	8	34
8	-104	2
36	-58	40
60	-48	6
-26	-56	34
12	14	44
8	-24	24
-26	-26	26
30	56	16
-12	-102	2
8	-104	2
2	-26	22
34	-58	38
10	14	48
58	-48	6
-12	-102	2
-30	28	-2
28	56	16
-40	30	18
-44	8	18
-4	22	40

// Kim C, 2012: Significant areas of activation for the main effect of 
// switching
// Kim C, 2012: Significant areas of activation for the main effect of 
// conflict
// Kim C, 2012: Conjunction analysis: Common areas of activation for both 
// switching and conflict
// Subjects=16
-25	34	-2
21	32	-3
-22	-4	45
-50	-3	37
-13	-5	54
4	29	20
-16	0	40
-22	-68	7
26	-24	40
41	-42	32
-20	-67	41
19	-68	45
18	-56	59
-38	-34	-9
45	-59	-4
-33	12	19
34	2	19
-22	12	18
25	0	19
18	-66	-31
49	14	2
-32	26	6
42	9	32
39	29	36
8	9	48
-15	-12	70
-44	-1	34
6	11	41
28	-53	43
-41	-43	46
-31	-52	38
-57	-42	35
48	-48	29
26	-69	32
52	-53	6
34	10	2
-32	12	1
-8	1	10
8	3	10
-20	1	13
12	2	3
12	-8	6
-50	-3	37
-1	13	42

// Philipp A M, 2012: Stimulus-categorization switch > Stimulus-categorization 
// repeat
// Philipp A M, 2012: Response-modality switch > Response-modality repetition
// Philipp A M, 2012: Conjunction of Stimulus-categorization switch > 
// Repetition and Response modality switch > Repetition
// Philipp A M, 2012: Interaction: Stimulus-categorization vs 
// Response-modality (switch minus repetition)
// Philipp A M, 2012: Interaction: Response-modality vs 
// Stimulus-categorization (switch minus repetition)
// Subjects=23
-44	4	30
-14	-66	46
-30	-46	44
-44	-38	46
-40	-50	46
30	-56	52
-46	24	34
-58	-50	26
56	-52	30
-12	-8	32
26	-16	18
-14	-12	48

// Piguet C, 2013: Switch > Repeat
// Piguet C, 2013: Repeat > Switch
// Piguet C, 2013: DoubleSwitch > Inhibition
// Piguet C, 2013: (Switch > Repeat) > (Color > Others)
// Piguet C, 2013: (Switch > Repeat) > (Gender > Others)
// Piguet C, 2013: (Switch > Repeat) > (Emo > Others)
// Piguet C, 2013: (DoubleSwitch > Inhibition) > (Color > Others)
// Piguet C, 2013: (DoubleSwitch > Inhibition) > (Gender > Others)
// Piguet C, 2013: (Doubleswitch > Inhibition) > (Emo > Others)
// Subjects=20
-9	-72	42
-30	-51	39
-3	-27	27
-39	-51	-24
-51	-60	-15
45	39	-6
-12	54	27
6	45	36
-12	15	12
60	-24	30
-6	-72	39
-15	-45	30
-51	-21	45
-57	-18	21
36	-75	-3
-45	-60	-9
12	-93	6
33	15	48
-30	18	51
9	30	48
-12	48	30
15	15	3
24	9	-12
-6	-45	63
45	36	-6
45	12	-12
24	-3	-3
21	6	0
-45	-24	63
12	-93	6
-33	-87	15
-15	-93	6
27	12	-3
-27	9	-15
36	-6	-6
24	-33	-9
-48	-24	-9
54	-15	-6
-63	-51	-6
42	-12	36

// Reeck C, 2014: Gender > Emotion expression task
// Reeck C, 2014: Switch > Stay trial transition
// Reeck C, 2014: 3 way interaction (Task x Trial x Congruence)
// Subjects=10
48	21	21
-33	-45	39
-30	0	63
3	-66	-12
30	-30	0
30	9	54
-6	-30	21
57	36	-3
3	-24	33
-54	36	-6
-9	-87	36
42	33	36
18	-3	27
18	-90	30
12	21	3

// Rodriguez-Pujadas A, 2013: Monolinguals
// Subjects=18
-25.11	24.89	-16.71
-1.48	-25.99	46.2
-27.45	-71.25	34.31
-7.88	-70.25	43.96
-7.71	-55.82	60.46
-52.29	-29.68	44.06
-50.7	-49.23	-4.45
-52.85	-59.02	-5.69
-27.53	-79.53	26.16
-5.45	11.21	-3.36
-15.1	-4.67	-.51
14.94	-56.05	56.73
14.06	5.21	0.26
17.48	4.34	13.74

// Rodriguez-Pujadas A, 2013: Bilinguals
// Subjects=18
-20.97	18.48	52.21
-17.63	13.79	59.34
-27.83	49.56	29.08
-24.56	41.06	29.87
-34.42	48.7	20.32
-44.43	48.72	-1.93
-11.05	-17.23	60.06
-4.47	-3.31	70.9
-53	39.43	2.5
-43.68	5.12	48.32
-14.24	-10.24	66.15
-47.03	-47.17	28.9
-43.8	-57.04	26.46
-52.39	-66.54	28.66
-46.91	-74.72	32.74
-59.3	-52.25	-1.77
-4.98	28.99	37.45
-5.42	14.72	-.35
21.31	14.24	62
21.25	-63.87	41.71
21.04	-60	25.65
40.81	-69.56	48.67
53.26	-78.78	6.78
53.14	-76.42	-2.41
4.46	38.96	17.26
17.73	17.16	36
4.73	-45.48	21.12
7.51	11.26	-3.59
13.92	10.76	-9.25

// Whitmer A J, 2012: Switch trials > Repeat trials
// Whitmer A J, 2012: Switch > Repeat correlated with behavioral inhibition
// Subjects=27
-28	-70	38
-8	8	50
26	-10	46
-6	-36	20
12	-20	-10
-30	24	2
-22	-4	64
18	-10	60
30	4	-8
-24	2	-12

// Bruffaerts R, 2013: Main Effect of Task: [Property verification - Control]
// Subjects=19
-36	-43	-23
-36	-22	-23
-9	-58	10
-36	-10	-35
-30	-37	-5
-45	-55	-20
-15	-37	1
-30	-1	-23
-3	-46	25
9	-49	1
27	-16	-17
15	-28	-11
36	-37	-20
6	2	-5
-39	32	10
-30	35	-17
-45	29	-14
-9	17	49
0	17	64
-48	-73	28
39	32	-17
-9	50	46
-12	32	49

// Gruber O, 2010: Activations due to saliency per se, Session 1
// Gruber O, 2010: Activations due to saliency per se, Session 2
// Gruber O, 2010: Activations due to behavioural relevance per se, Session 2
// Gruber O, 2010: Activations due to behavioural relevance per se, Session 3
// Gruber O, 2010: Session 2 > Session 1
// Gruber O, 2010: Session 2 > Session 3
// Subjects=11
8	-52	20
36	-80	32
44	-60	16
-4	-76	28
-32	-76	32
8	-44	24
44	-72	40
48	-56	16
-32	-76	32
-40	-20	60
-36	20	-12
32	28	-12
-40	12	-12
52	16	-16
4	28	40
-60	-56	36
64	-48	28
-28	40	32
8	-12	-12
8	-28	-16
-28	16	-16
-36	12	0
36	28	-20
40	20	-4
0	28	28
-56	-52	12
-64	-48	16
-24	44	28
8	-12	-12
8	-28	-16
32	24	-16
-32	24	-4
-4	24	56
-60	-44	28
60	-48	40

// Ruge H, 2010: Switch > Repetition for effect feedback
// Ruge H, 2010: Switch > Repetition irrespective of feedback type
// Subjects=18
-30	39	30
-6	18	45
-39	-6	52
-51	-27	45
48	-27	54
-36	-63	-12
-24	-87	-9
39	-60	-9
33	-75	27
-36	48	12
-9	0	60
-15	-72	39
-6	-60	66
24	-63	57
-6	-75	-6

// Wende K, 2012: Causal Verbal Fluency (CVF) > Baseline
// Wende K, 2012: Free Association (FA) > Baseline
// Wende K, 2012: Phonological Verbal Fluency (PVF) > Baseline
// Wende K, 2012: Conjunction: CVF, FA, PVF
// Wende K, 2012: Conjunction: (FA > PVF), (CVF > PVF)
// Subjects=18
32	-60	-30
0	8	72
12	-18	-22
32	-60	-30
0	8	72
26	-64	-24
-62	-16	2
58	-28	2
2	-34	0
4	4	72
28	-64	-24
58	-28	2
-62	-16	2
2	-34	0
4	4	72
-38	14	54
-46	-66	30
26	-80	-28
-52	26	10
-54	-10	-26
64	-12	0
30	-22	30
-2	50	-14
-26	-16	28
-54	-20	2

// Braet W, 2011: Successful inhibitions, High risk (HR) > Low risk (LR), 
// p<0.05
// Braet W, 2011: Successful inhibitions, High risk (HR) > Low risk (LR), 
// p<0.001
// Braet W, 2011: Successful inhibitions, Control > ADHD
// Braet W, 2011: Commission errors, Controls > ADHD
// Braet W, 2011: Commission errros, LR > HR
// Subjects=9
3	9	45
36	39	34
-34	44	34
45	2	42
-28	-8	46
46	15	31
48	-9	60
-25	-25	70
-15	-21	37
0	-29	25
34	14	-1
-33	18	1
8	-22	8
-18	-26	6
3	0	9
-12	5	5
0	-11	-8
2	-27	-25
51	-47	32
-54	-49	23
8	-77	34
13	-38	40
50	-74	-17
50	-25	-15
11	-72	-5
-33	-61	34
30	-66	33
-58	-46	20
-50	-45	43
0	14	43
-33	41	31
31	42	37
40	39	22
45	-15	8
0	-24	29
42	10	7
-37	13	0
-12	-19	6
10	5	6
-9	4	1
3	-24	-18
-20	-40	-6
-21	-36	-21
-49	-55	-25
-58	-44	27
56	-49	34
-39	-54	36
-12	-78	32
10	-76	19
12	-78	39
-46	-77	33
-53	-26	42
57	-26	32
53	-47	12
-54	-22	13
51	-21	-22

// Maurer U, 2011: Control > Dyslexic for Word > Symbol
// Subjects=11
54	-30	-12
-60	-63	12
-63	-27	-9

// Norton E, 2014: Whole brain phonological gradient analysis (Control > 
// PHONOdef > DOUBLEdef)
// Norton E, 2014: Whole brain rapid naming gradient analysis (Control > 
// RANdef > DOUBLEdef)
// Subjects=10
-37.84	38.62	4.56
-35.77	34.71	-2.93
-41.54	-.51	45.48
-39.21	-40.81	50.55
-66.48	-25.34	33.79
-39.61	9.85	29.85
-64.28	-25.02	37.08
-57.68	-29.59	45.27
39.75	-47.9	-29.66

// Orinstein A J, 2014: Controls > ADHD-I: Target > Baseline
// Orinstein A J, 2014: Controls > ADHD-I: Novel > Baseline
// Orinstein A J, 2014: Controls > ADHD-I: Target > Novel
// Subjects=18
33	39	24
-3	3	51
3	-3	63
6	21	33
-12	27	24
0	-6	39
-42	9	-3
36	15	-12
-36	-36	51
48	-39	48
-54	0	-6
-48	-12	0
-63	-30	-3
63	-27	-3
60	-39	15
-3	-6	6
-3	-24	6
0	-75	-18
3	-78	-36
-12	-24	-15
12	-27	-12
-60	-24	6
-42	-33	9
63	-27	3
66	-18	3
-6	-3	72
0	-6	39
3	18	33
-39	6	3
45	15	-3
-42	-27	60
-66	-27	24
45	-42	45
-12	0	0
12	0	-6
-9	-24	3
0	-42	-3
21	-54	-27
3	-69	-18
-12	-24	-15
12	-24	-12

// Dickie E, 2011: Negative correlation: [Rembered - Forgotten faces] and 
// change in CAPS score
// Dickie E, 2011: Negative correlation: [Memory x Emotion Interaction] and 
// change in CAPS score
// Subjects=18
62	-6	20
28	-40	74
-22	-40	-26
32	-12	-18
46	-24	34
-2	-44	30
36	-12	8
-16	-14	72
-4	26	-8

// Peyrin C, 2011: Dyslexic
// Subjects=12
-11.39	-73.4	21.92
4.25	93.2	11.89
17.64	-87.41	8.24
-44.03	29.84	25.71
37.24	4.57	38.03
11.27	20.64	39.12
40.2	-86.14	-2.35
-24.58	-92.64	0.52
-34.38	-70.24	-.41

// Peyrin C, 2011: Typical
// Subjects=12
-37.85	-46.83	-13.88
46.45	-52.81	-13.6
31.1	-53.01	53.92
-24.02	-69.78	49.79
-37.08	-35.59	48.87
50.38	-35.59	44.02
-18.14	-86.34	-1.34
-31.1	-69.92	2.86
4.7	-70.88	13.55
-11.51	-68.81	13.62
17.64	-87.41	8.24
-40.81	30.81	24.44
53.36	10.59	32.68
37.34	21.77	49.77
18.05	17.42	61.74
1.48	28.8	35.12
26.84	-71.66	-30.45
-11.87	-75.87	-15.93
49.89	-69.94	-1.88
-44.08	-73.36	1.18
-27.79	-82.56	5.18
-14.27	-53.17	54.71

// Doyle-Thomas K A, 2013: Autism Spectrum Disorder Participants (ASD)
// Subjects=18
-28.53	28.36	47.41
-32.48	-93.49	40.95
-50.78	-85.11	27.07
-71.36	-38.68	10.03
25.53	63.67	3.68
48.45	2.93	41.97
12.99	20.47	24.18
48.43	-53.31	16.57
22.61	-35.46	1.99
38.69	-74.45	-8.3
-2.89	-17.69	27.56
19.53	-34.19	18.65
3.37	-32.4	1.96
-19.06	-35.71	2.49
-22.75	58.16	-22.07
-41.96	48.44	-22.15
-6.68	42.13	-24.25
-3.33	56.9	1.24
-25.19	19.89	61.47
38.92	-25.93	41.15
-44.37	-71.87	32.58
51.81	-77.9	28.63
-54.51	-34.54	-20.62
-32.44	-89.81	47.33
0.54	-105.41	21.49
16.56	-97.65	24.01
20.22	73.93	12.92
-16.2	6.93	-24.54
-54.34	-26.14	5.44
38.24	9.91	-32.1
-45.05	-19.65	-35.36
19.2	-7.95	-13.66
0.04	55.29	21.41
-38.41	35.51	16.81
-29.11	38.83	-23.72
25.84	34.01	32.93
-47.66	-69.49	22.38
-9.11	-48.68	40.27
-70.44	-33.61	-7.13
57.56	-5.58	-27.68
32.2	20.33	20.62
16.78	68.17	-20.01
-41.8	56.67	1.7
-32.19	67.56	4.02
35.23	64.59	14.65
-54.45	46.24	19.44
3.63	6.61	52.21
25.48	20.38	-19.45
44.7	23.67	-19.95
9.71	32.88	19.83
45.02	7.2	14.88
-44.66	27.24	34.31
-34.97	-4.94	30.2
0.31	-34.13	21.1
9.93	-14.36	28.25
54.54	-20.17	-9.69
-64.19	2.12	-13.55
-19.03	-38.62	6.08
41.64	-27.62	-22.3
-38.21	-92.09	-9.29
38.39	-8.35	-20.54

// Doyle-Thomas K A, 2013: Typically Developing Controls (TD)
// Subjects=16
-34.42	76.55	-3.4
-45.04	66.17	0.94
-71.41	-25.99	8.97
74.84	-13.45	-7.14
-60.94	-1.83	-9.91
-63.92	-62.12	-4.81
-63.66	-75.93	23.1
-38.4	45.54	22.66
32.21	53.34	34.58
51.58	2.18	31.96
45.27	-29.84	31.37
-41.78	-15.69	-25.69
35.11	-15.74	-33.26
35.11	-15.74	-33.26
-32.19	-15.89	-29.13
-38.62	49.83	-4.46
18.96	42.29	-24.56
26	25.78	50.35
-22.07	15.71	48.4
-2.74	-45.73	36.6
-31.96	-43.15	-10.12
48.64	-87.43	29.47
35.42	-45.41	-4.01
-37.9	-81.09	36.62
6.78	-102.68	1.12
-21.67	-65.74	68.61
57.82	-19.38	0.24
44.67	-9.6	-37.23
0.04	55.29	21.41
-38.41	35.51	16.81
-29.11	38.83	-23.72
25.84	34.01	32.93
-47.66	-69.49	22.38
-9.11	-48.68	40.27
-70.44	-33.61	-7.13
57.56	-5.58	-27.68
32.2	20.33	20.62
16.78	68.17	-20.01
-41.8	56.67	1.7
-32.19	67.56	4.02
35.23	64.59	14.65
-54.45	46.24	19.44
3.63	6.61	52.21
25.48	20.38	-19.45
44.7	23.67	-19.95
9.71	32.88	19.83
45.02	7.2	14.88
-44.66	27.24	34.31
-34.97	-4.94	30.2
0.31	-34.13	21.1
9.93	-14.36	28.25
54.54	-20.17	-9.69
-64.19	2.12	-13.55
-19.03	-38.62	6.08
41.64	-27.62	-22.3
-38.21	-92.09	-9.29
38.39	-8.35	-20.54

// Eyler L T, 2012: Toddlers at risk for Austism Spectrum Disorders
// Subjects=40
63.1	7.51	3.5
-69.45	19.41	4.02
-48.3	87.55	2.53
-56.61	6.45	0.5

// Eyler L T, 2012: Typically developing Toddlers
// Subjects=40
-56.61	15.25	4.22
63.02	19.86	-2
-5.24	69.06	34.81

// Greimel E, 2012: Controls
// Subjects=13
58	22	28
50	44	18
-6	14	38
0	6	56
46	10	32
-54	-18	22
34	-88	-10
-32	-92	0
-38	32	22
48	44	22
-46	30	32
40	-70	-18
-32	-92	0
32	-90	-10
58	22	28
50	44	18
2	24	36
-8	8	40
-2	4	58
52	12	38
40	-70	-16
-40	-74	-14
32	-90	-10
32	52	30
-34	48	18
40	-70	-16
-40	-74	-14
-22	-64	32
34	-88	-10
32	52	30
-34	48	18
40	-70	-16
-40	-74	-14
-22	-64	32
34	-88	-10

// Greimel E, 2012: Autistic Spectrum Disorder patients (ASD)
// Subjects=13
-52	24	34
-30	-8	68
-48	-18	20
-40	-22	64
-40	-76	-14
40	-72	-16
42	-86	-4
48	38	28
30	54	28
-32	-6	66
42	16	-2
-32	22	6
2	24	40
16	18	62
-38	-24	66
54	-42	38
-38	-24	66
46	-54	30
34	-80	-16
-40	-78	-14
36	26	-14
-58	12	22
48	16	-4
-40	-22	64
-62	-20	38
18	-4	-20
42	-72	-16
-40	-74	-14
44	-86	-6
8	-70	12
-4	-72	8
48	38	30
2	20	40
-4	14	40
2	16	50
-38	-24	66
-60	-20	38
-56	-22	50
42	-72	-16
-40	-76	-14
44	-86	-6
48	38	30
2	20	40
-4	14	40
2	16	50
-38	-24	66
-60	-20	38
-56	-22	50
42	-72	-16
-40	-76	-14
44	-86	-6

// Hummel T, 2013: All odors - Baseline, All subjects
// Hummel T, 2013: Ambroxan stimulation, Sensitive > Insensitive
// Subjects=10
-36	2	-35
-27	8	10
39	-25	46
-39	-13	16
-24	-4	-23
21	-25	37
-33	-7	13
30	-4	-14
-24	26	7
33	-7	10
-3	-1	37
-36	17	10
-24	-10	-11

// Ishitobi M, 2011: Healthy Controls
// Subjects=24
20	-2	-2
-2	-8	-1
52	18	28
-3	4	30
4	16	54
44	-4	-2
-4	-5	-2
42	-8	-1
-3	-8	-1
38	-5	44
-3	-5	44
40	8	30
-3	12	28
2	24	56
48	-5	-1
-4	-6	-8
32	-8	-8
-3	-8	-1
30	-6	46
-3	-5	50
54	20	44
-4	26	20
2	16	60
44	-4	-2
-4	-6	-1
42	-8	-1
-4	-8	-1
32	-6	46
-3	-5	42
20	-10	-24
-32	-8	-20
-6	-52	14

// Ishitobi M, 2011: Autism Spectrum Disorder (ASD)
// Subjects=9
-3	8	32
2	22	42
42	-5	-2
-4	-3	-2
34	-9	4
-4	-7	-1
32	-6	34
-2	-6	38
48	24	32
-2	50	6
40	-6	-2
-4	-5	-1
32	-8	4
-4	-7	-1
28	-6	44
18	6	-1
-2	4	-2
56	28	30
-5	26	26
-4	8	60
46	-5	-2
-4	-5	-2
36	-8	6
-4	-7	-1
20	-10	-24
-32	-8	-20
-6	-52	14

// Liu L, 2013: Typically-developing controls (TD)
// Subjects=14
-38	8	28
-34	30	-10
-36	8	26
-36	32	-8

// Liu L, 2013: Reading disability (RD)
// Subjects=14
-36	8	26
-36	32	-8

// Rudie J D, 2012: Children with Autistic Spectrum Disorders (ASD)
// Subjects=23
14	-4	-18
-18	-10	-16
28	-16	-18
-24	-12	-26
30	-6	-8
-20	2	-8
22	-12	6
-16	0	-8
6	6	-6
-6	6	-6
8	-30	2
-24	-26	2
-4	-10	2
22	-32	-20
-20	-14	-26
30	10	-16
-38	2	-18
0	18	-8
4	68	-6
-2	40	-20
44	38	-18
-46	22	-10
28	12	-36
-24	4	-40
38	-44	-16
62	-4	-14
-62	-18	-18
48	-18	-28
-44	-26	-22
8	-86	-4
-28	-42	-8
24	-44	-14
-32	-88	-14
-26	-54	-26
-12	-62	42
8	-40	44
64	-36	32
-62	-50	34
58	-52	46
-44	-54	56
32	-46	54
42	-72	38
-38	-76	48
20	56	22
32	60	6
50	20	36
54	-20	24
40	-44	-6
50	-68	4
-32	-78	2
-6	-92	22
-10	32	26
18	8	62
28	22	38
-32	28	44
10	26	22
56	14	16
50	8	4
50	6	40
-40	0	30
50	30	-6
50	32	26
-42	40	20
36	14	6
-32	22	2
-2	16	50
16	4	62
10	18	32
44	-42	44
30	-56	44
30	-68	36
32	-62	46
48	-32	2
64	-48	-6
30	52	-10
16	2	14
22	10	-8
12	12	-8
6	-18	10
-6	-66	14
-4	-40	34
-44	-60	34
-24	-26	-26
-50	-12	-22
-14	-58	-18
20	-58	-28
-62	-32	42
-30	-48	54
-14	-62	46
0	30	4
-4	60	14
6	54	-4
30	24	-16
22	36	40
4	28	2
36	46	-4
20	10	-2
12	14	-6

// Rudie J D, 2012: Typically Developing Controls
// Subjects=25
30	-8	-16
-16	-10	-16
26	-14	-18
-20	-18	-18
30	-14	-8
-32	-12	-10
22	-10	-6
-16	-8	-8
6	8	-4
-8	10	-4
24	-30	0
-22	-34	-2
4	-6	-4
18	-16	-22
-16	-14	-24
34	8	-16
-38	0	-14
4	60	-14
0	34	-18
38	26	-14
-44	20	-18
54	10	-34
-32	26	-34
28	4	-38
-34	-50	-12
66	-12	-22
48	-46	-26
-48	-44	-26
26	-48	-12
-16	-70	-10
40	-68	-10
-32	-78	2
8	-98	0
-14	-98	16
-4	-52	-18
0	-52	56
6	-34	46
66	-34	42
-48	-52	36
44	-46	38
-42	-56	56
44	-48	58
-24	-46	46
50	-70	36
-40	-84	32
-2	32	36
18	8	58
-18	10	62
20	60	0
-22	64	-4
34	24	38
-38	34	36
10	34	16
36	4	36
-50	0	36
40	-44	-6
50	-68	4
-32	-78	2
-6	-92	22
-10	32	26
18	8	62
28	22	38
-32	28	44
10	26	22
58	16	14
-56	10	18
50	4	42
-52	4	42
46	44	-4
-44	40	18
38	40	28
-26	-2	54
38	20	-2
-32	22	2
4	14	50
10	18	30
64	-32	30
-50	-42	52
26	-52	50
-30	-48	42
34	-80	24
-36	-88	20
16	-78	54
-22	-60	46
54	-44	10
48	-24	-6
44	-50	-10
16	42	-18
18	0	14
20	2	8
-18	-2	6
-4	-54	10
-2	-48	32
-42	-64	32
-22	-26	-26
-56	-14	-18
-32	24	52
-42	20	-36
-20	-52	-30
-2	32	-4
-24	60	4
0	60	-2
-62	-32	42
-30	-48	54
-14	-62	46
0	30	4
-4	60	14
6	54	-4
30	24	-16
22	36	40
4	28	2
36	46	-4
20	10	-2
12	14	-6

// Lehn H, 2012: Odors > Rest
// Lehn H, 2012: Objects > Rest
// Lehn H, 2012: Odors > Objects
// Lehn H, 2012: Objects > Odors
// Subjects=19
36	-86	-12
-4	24	42
-8	-16	-12
-40	2	30
-30	26	-6
22	4	2
32	24	-8
-32	-14	-18
-36	56	8
0	-60	-36
36	26	22
26	-28	-6
-42	-52	40
-52	-34	-10
48	16	46
-20	-30	-4
24	-28	-4
-30	-8	-34
-36	6	-16
-36	6	-16
-48	46	8
32	-80	-44
14	-82	-32
-30	-36	-2
36	-26	-10
-28	-30	-22
26	-32	-18

// Sezille C, 2013: All odors > Baseline
// Subjects=11
-23	32	-9
25	39	-6
-33	8	14
-37	8	-9
18	1	-9
18	-12	-6
-43	32	4

// Wintermann G B, 2013: Patients with Panic Disorder (PD)
// Subjects=13
-50	30	16
-50	22	34
-42	6	46
-2	28	42
-10	20	46
8	-34	2
8	-28	4
10	-38	8
0	22	-8
-48	14	0
48	-10	0
52	-32	16
52	-30	24
-4	-42	54
48	-26	34

// Wintermann G B, 2013: Healthy Controls
// Subjects=13
0	6	16
-6	-6	22
6	-4	20
18	16	18
-6	-6	22
10	-36	0
4	-6	-12
-44	42	12
-42	46	24
60	-42	-10
64	-42	-14
-24	-52	10
-26	-60	10
8	-34	2
8	-28	4
10	-38	8
0	22	-8
32	-46	10
-18	-38	16
-10	-30	22
-12	-22	24
52	-32	16
52	-30	24
-4	-42	54
48	-26	34

// Ursu S, 2014: Schizophrenia
// Subjects=20
46	28	12
36	30	-10
-38	30	4
-48	2	36
-20	-83	-13
-44	-58	-16
28	-48	-12
26	-62	-8
26	-82	-8
46	26	14
42	-4	46
48	12	20
-2	24	-16
2	18	-10
32	-10	56
-4	8	-4
-34	28	0
-38	10	-4
8	16	52
-48	6	32
-12	66	-8
-2	12	26
36	-20	-24
30	-46	-12
20	-34	-2
-30	-56	-6
28	-84	-8
42	-46	-12
28	-12	-14
-4	-16	-2
60	26	20
50	24	18
2	8	26
-46	4	34
-34	-32	-12
-30	-58	-6
-22	-86	-10
-42	-56	-12
30	-44	-14
28	-50	-12
18	-42	-4
32	-14	-28
28	-82	-8
20	-28	2
-4	-12	-2
54	34	8
-12	-6	70
52	14	38
32	6	56
34	-6	54
34	-18	44
-28	-32	-18
-30	-18	-20
-8	62	14
20	-34	-2
8	-18	0
-32	26	-2
-18	22	8
10	-38	50
-2	44	-16
-10	16	38
-14	-32	46
42	-18	-24
-24	-78	-8
42	-46	-16
32	-20	0
24	-4	-32
42	-46	-18
34	-4	48
56	6	32
6	-4	38
-36	52	0
46	34	14
54	26	-4
50	22	34
18	-14	76
26	58	2
-4	-12	78
48	-14	58
-4	26	-20
2	24	-14
-12	22	-12
16	28	-18
-10	56	30
-18	52	34
-4	34	56
6	36	34
-2	48	12
6	34	2
34	38	-10
38	28	2
-58	26	14
-30	26	-6
48	16	34
-40	-14	64
26	-30	-16
4	-50	32
26	20	-4
30	-14	0
20	-12	20
16	-14	12
6	-10	4
22	-36	4
-16	-10	0
46	-10	0
0	-12	54
-4	-12	34
-14	-42	36
-14	16	-8
28	14	-14

// Ursu S, 2014: Healthy controls
// Subjects=20
-10	62	24
-8	14	58
8	12	62
2	38	-20
-40	34	-10
-44	20	-4
58	30	6
52	26	18
48	-8	52
-46	0	36
24	2	-22
-20	-34	-4
-32	-36	-16
38	-12	-28
30	-80	-12
44	-50	-18
-20	-86	-6
18	-30	0
-46	18	22
-44	22	18
-50	14	28
-40	34	-6
-42	28	8
-54	34	-4
-42	4	28
-46	-4	44
-30	4	-18
-26	10	-18
-10	0	-6
-2	6	-6
0	54	-14
4	14	60
28	-38	-16
-36	-42	-18
40	-48	-18
28	-84	-12
24	-74	-6
28	-84	-12
28	-54	-8
32	-82	-4
30	-34	-14
-26	2	-18
-20	-42	-4
-2	-12	-2
-20	0	-12
52	34	2
46	10	26
38	28	-2
38	26	-6
2	36	-16
24	-2	-24
-8	2	-6
-26	8	-16
0	4	32
20	18	-18
-30	32	-16
-30	36	-20
38	0	48
42	18	38
34	12	30
28	28	-24
-8	44	30
6	56	8
0	54	-16
24	2	56
28	-16	-22
28	-86	-10
-44	-60	42
42	-4	42
44	-34	-24
46	-32	-18
-44	-52	-16
-18	12	-16
-20	2	-10
-10	4	-6
-36	52	0
46	34	14
54	26	-4
50	22	34
18	-14	76
26	58	2
-4	-12	78
48	-14	58
-4	26	-20
2	24	-14
-12	22	-12
16	28	-18
-10	56	30
-18	52	34
-4	34	56
6	36	34
-2	48	12
6	34	2
34	38	-10
38	28	2
-58	26	14
-30	26	-6
48	16	34
-40	-14	64
26	-30	-16
4	-50	32
26	20	-4
30	-14	0
20	-12	20
16	-14	12
6	-10	4
22	-36	4
-16	-10	0
46	-10	0
0	-12	54
-4	-12	34
-14	-42	36
-14	16	-8
28	14	-14
-34	36	32
-50	18	42
-46	28	32
-40	6	32
-8	28	50
8	4	66
26	-8	54
38	-12	56
-10	14	54
-40	-26	60
-10	32	-8
-12	46	42
-4	20	64
-50	24	34
-52	14	40
42	10	42
-26	26	-16
-46	26	36
6	34	-4
12	32	-16
32	-32	-24
36	-14	-32
16	24	-8
18	-22	-2
22	-38	4
8	-26	12
12	-16	18
36	38	-14
-4	38	48
18	34	48
-48	34	20
-30	16	52
-18	36	40
-6	14	50
-52	32	18
-14	32	26
42	2	-14
-10	54	-18
6	38	-18
12	36	4
28	12	-22
16	-2	-22
-8	18	26
-6	-14	32
-10	16	-6
-20	8	-4
-36	4	-14
-20	-4	-24
-14	-6	-14
-2	-10	8

// Chechko N, 2012: Incongruent emotional > Congruent non-emotional
// Chechko N, 2012: Incongruent > Congruent
// Chechko N, 2012: Positive BOLD response, Incongruent > Congruent
// Chechko N, 2012: Negative BOLD response, Incongruent > Congruent
// Chechko N, 2012: Incongruent non-emotional > Congruent non-emotional
// Chechko N, 2012: Positive BOLD response, Incongruent emotional > Congruent 
// emotional
// Chechko N, 2012: Negative BOLD response, Incongruent emotional > Congruent 
// emotional
// Chechko N, 2012: Areas that positively correlated with conflict-related 
// slowing during incongruent emotional trials
// Chechko N, 2012: Areas that pos. correlated with conflict-related slowing 
// during incongruent non-emotional trials
// Subjects=24
-8	12	54
4	14	50
-44	-72	-10
-32	-56	-28
-42	52	-18
8	-70	-40
34	-48	26
36	-44	-22
-38	4	-2
-48	8	0
44	-68	-10
44	-72	-10
-22	-72	60
-42	-6	62
-48	30	16
-32	-50	46
-4	26	34
6	24	30
-44	-8	6
-43	6	5
8	16	66
-2	12	54
34	32	0
34	20	-12
34	28	-12
-18	-18	10
-4	26	34
6	24	30
-44	-8	6
-43	6	5
8	16	66
-2	12	54
34	32	0
34	20	-12
34	28	-12
-18	-18	10
50	-70	40
50	-70	40
10	44	48
34	30	30
-8	10	56
-8	18	34
12	16	38
-44	-72	-8
-46	-60	-16
-46	-48	-18
-38	-62	0
34	-52	-15
34	-48	-15
-54	0	38
-60	8	32
-44	6	4
-40	24	-8
38	-48	52
46	-66	-8
42	-78	-6
38	-84	2
38	18	-14
36	32	-8
-16	0	0
-46	-34	64
12	-12	0
-30	34	24
56	32	10
-12	-8	80
-36	-4	-12
50	-40	6
48	-72	42
48	12	18
54	22	20
46	20	-18
42	18	-14
34	24	-2
-48	40	14
-36	40	12
38	-14	50
40	-4	48
-24	-18	72
-12	-8	74
48	-38	32
-60	-38	24
-56	-34	14
-62	2	20
-60	2	32
46	36	-8
44	52	6
22	-54	10
28	-64	2
28	-76	-10
-48	-12	54
-36	-10	52
-10	12	48
6	10	46
36	40	12
38	36	10
-44	6	24
54	-42	2
-44	-16	32
50	-12	40
-32	-2	-24
18	-14	8
-44	26	24
-50	-20	36

// Hart S J, 2010: Incongruent > Congruent
// Hart S J, 2010: Congruent > Incongruent
// Hart S J, 2010: Aversive stars > Neutral stars
// Hart S J, 2010: Neutral stars > Aversive stars
// Hart S J, 2010: Neutral congruent > Aversive congruent
// Hart S J, 2010: Aversive incongruent > Neutral incongruent
// Hart S J, 2010: Aversive incongruent > Neutral incongruent, Negative 
// correlation with reaction time (RT)
// Hart S J, 2010: Neutral incongruent > Aversive incongruent, Positive 
// correlation with RT
// Subjects=14
-42.31	36.83	4.18
-48.26	-39.71	47.19
2.36	-30	26.25
13.86	-7.67	10.22
13.08	-93.92	-2.73
25.82	-97	14.05
-55.87	-24.38	-11.53
20.44	-38.53	56.69
22.12	16.23	-31.42
-5.99	-44.95	41.75
53.04	-50.14	-17.07
43.59	-78.48	-30.61
-36.56	-88.07	13.81
39.03	9.6	-38.83
-34.8	28.35	36.9
4.62	-43.84	58.26
-28.27	-53.16	-3.06
59.16	14.54	-12.65
7.35	56.93	32.47
-49.51	-13.45	10.99
-56.78	-40.35	20.65
30.93	-20.71	53.19
-38.67	-88.22	11.61
-32.5	-56.62	-7.24
14.23	-83.58	45.39
9.88	-80.87	4.16
26.65	-56.53	-14.25
-31.73	30.55	3.43
-60.98	-53.4	14.91
32.95	1.09	47.25
-28.62	27.9	-23.04
-2.82	-23	72.41
24.15	39.5	-30.8
-6.54	51.85	-31.47
5.35	27.37	32.29
-24.99	-70.96	15.9
-13.41	-29.42	55.16
-61.07	-33.71	9.12
0.1	-16.56	-12.39
30.89	-59.64	-14.06
-56.71	-72.95	5.12
-60.15	20.31	29.83
-28.62	31.26	-19.94
-52.57	-38.22	20.48
-7.07	-22.66	61.32
-24.44	65.75	8.75
-5.49	52.84	-32.65
5.36	26.59	36.78
-50.6	-9.53	6.29
67.92	-57.07	5.52
-49.69	10.78	-23.96
30.88	-61.1	-20.62
0.09	-17.81	-15.64

// Melcher T, 2011: Negative arousal > Neutral arousal
// Melcher T, 2011: Neutral arousal > Negative arousal
// Melcher T, 2011: Neutral incongruent > Baseline
// Melcher T, 2011: Negative incongruent > Baseline
// Melcher T, 2011: Neutral oddball > Baseline
// Melcher T, 2011: Negative oddball > Baseline
// Subjects=14
24	-4	-12
32	4	-24
-36	0	-24
-20	0	-28
28	28	-20
-36	28	-20
44	16	24
48	40	12
48	-20	40
-60	-20	32
-12	-20	48
28	-60	48
-20	-72	52
32	-84	4
52	-52	-4
-32	-96	0
-40	-68	-12
32	-56	-28
-40	-44	-32
-24	-44	-8
-44	0	40
-36	4	28
-36	24	20
-8	4	56
-20	-76	56
-44	-40	56
-24	-96	-8
28	-96	0
-40	-68	-28
-28	-100	16
-48	-68	-4
-32	4	32
-48	-44	16
-32	-96	-4
24	-100	-4
52	-56	-4

// Mulligan R, 2011: No go > Go (no go trials), Healthy Controls > ADHD
// Subjects=12
41.14	-56.93	39.27

// Veroude K, 2013: Incongruent - Neutral, All subjects
// Veroude K, 2013: Incongruent - Neutral, Young adults > Late adolescents
// Veroude K, 2013: Negative - Neutral, All Subjects
// Veroude K, 2013: Negative - Neutral, Young adults > Late adolescents
// Subjects=17
-28	-70	42
-35	-53	42
-7	-74	48
-42	25	30
-53	11	39
-42	-4	60
-32	-4	69
-35	-18	69
35	-56	45
32	-67	42
42	7	30
46	25	30
46	32	39
39	4	57
-4	11	57
32	25	3
-35	18	0
-14	28	42
-63	-39	-6
-39	18	-15
-4	-21	48
-39	-21	66
-35	-25	54
21	-56	-27
7	-67	-24
-7	-14	57
-18	28	42
-18	-60	24

// Wang S, 2013: ADHD
// Subjects=28
33	-27	-14
15	34	-9
-30	8	-11
-30	26	-1
42	12	-1
5	-50	5
-3	7	25
33	-10	36
-53	-26	-4
-30	-9	-15
30	-27	-14
24	-7	-15
-50	22	29
-42	-61	3
-45	-79	-6
-21	9	0
-9	-46	11
-12	-67	50
12	-53	-5
-18	21	21
-42	-58	6
21	-44	44
-27	-33	29
18	-77	-16
-45	10	30
-56	-32	2
-42	-62	42
48	-56	42
-6	-50	41

// Wang S, 2013: Healthy controls
// Subjects=31
33	-27	-14
15	34	-9
-30	8	-11
-30	26	-1
42	12	-1
5	-50	5
-3	7	25
33	-10	36
-53	-26	-4
-30	-9	-15
30	-27	-14
24	-7	-15
-50	22	29
-42	-61	3
-45	-79	-6
-21	9	0
-9	-46	11
-12	-67	50
12	-53	-5
-18	21	21
-42	-58	6
21	-44	44
-27	-33	29
18	-77	-16
0	-56	36

// Barros-Loscertales A, 2011: Cocaine-dependent subjects
// Subjects=16
-42	25	29
42	2	47
53	10	24
-48	12	27
45	-48	27
-15	-35	54
50	-53	41
-36	-48	38
45	17	-8
53	-39	38
53	-41	2

// Barros-Loscertales A, 2011: Healthy Controls
// Subjects=16
15	14	52
15	9	55
-45	22	32
42	-1	36
59	21	7
-45	22	29
53	-26	-1
45	-64	-2
33	-53	52
-30	-64	53
50	-42	38
-36	-45	38
-15	-11	6
15	-5	11
45	17	-8
53	-39	38
53	-41	2

// Krach S, 2011: Common neural activations in response to vicarious 
// embarrassing situations
// Subjects=32
-6	20	44
-4	14	54
-10	28	28
-32	24	0
-36	22	-16
-48	30	10
-4	-6	6
30	-68	-28
-2	-20	-22

// Mercadillo R E, 2012: Activated regions for all participants during 
// execution of Counting Stroop Task
// Subjects=8
32	-58	36
24	0	62
38	32	36
46	-38	-14
16	0	-6
40	22	6
-38	-2	26
-16	-62	44
-56	-52	10
-24	44	18

// Michl P, 2014: Normals
// Subjects=14
-27.33	-87.77	18.1
4.69	-84.66	14.13
7.58	-74.78	-23.53
-5.19	-34.74	0.02
-43.99	17.68	-20.66
-7.99	9.05	71.1
39.35	21.35	-21.92
-56.6	23.08	9.14
4.55	49	49.76
1.11	70.7	27.91
-1.69	-93.16	14.92
-11.48	-100.56	-11.12
-14.67	-92.66	-5.05
4.63	-80.95	7.13
4.59	-79.09	3.63
-24.29	-97.21	-7.9
26.74	-82.04	-36.53
-31.99	-81.88	-29.17
-56.3	-56.22	15.79
-53.34	-19.16	-.73
-62.89	-35.08	0.71
-63.06	-10.48	-11.39
58.67	5.86	-17.5
-46.93	12.65	11.02
-56.51	20.68	19.38
-46.56	1.19	55.47
-53.35	7.07	8.22
-5.19	61.91	38.75
20.48	54.67	39.07
1.17	33.97	20.95
4.66	-35.54	30.08
-21.31	-39.03	-12.82
10.89	-34.13	6.48
13.79	-7.61	-22.55
23.42	58.46	5.26
33	18.65	-14.93
36.42	-58.23	-18.56
-64	-32.17	-2.86
18.26	-5.53	3.99
-30.76	-94.5	-13.63
14.05	-84	-19.49
29.92	-55.87	-28.72
45.98	-42.32	-20.01
0.93	-17.98	-31.57
17.17	-5.79	0.68
-8.7	67.53	1.52
7.41	65.22	11.57

// Michl P, 2014: Subgroup of Normals, Females
// Subjects=7
33.69	-69.75	39.31
4.77	-44.28	40.85
52.86	-44	40.28
44.28	-77.31	23.1
1.49	-38.47	33.71
10.84	-28.04	2.62
39.8	6.17	29.53
32.97	46.91	-7.27
-32.2	57.61	-.72
-40.28	-52.95	15.33
-62.93	-32.17	-2.88

// Michl P, 2014: Subgroup of Normals, Males
// Subjects=7
53.5	-61.56	-21.82
-11.7	-35.8	-13.2
-37.42	-30.13	-20.07
-2.04	33.96	20.99
7.3	39.9	-13.07
20.41	34.18	21.83

// Roth L, 2014: pride > shame/guilt
// Roth L, 2014: pride > neutral
// Roth L, 2014: shame/guilt > neutral
// Roth L, 2014: neutral > shame/guilt
// Roth L, 2014: conjunction analysis (shame/guilt > neutral) & (pride > 
// neutral)
// Subjects=25
-18.79	23.1	61.12
-3.36	59.81	-2.35
-2.81	-33.3	32.21
32.45	-26.48	34.58
-57.67	-47.25	-19.52
-34.74	-68.38	35.52
-9.37	-8.47	23.52
-22.38	-20.38	-5.45
-9.12	0.7	59.54
-41.16	-2.66	60.19
-41.62	9.08	5.69
-18.92	-53.97	14.06
-9.17	-69	25.24
-16.04	-1.31	-7.12
-28.54	-17.85	27.87
-5.96	6.81	55.65
-19.25	54.66	14.99
-37.99	0.27	56.57
-60.9	21.66	4.85
51.3	15.73	0.72
-18.95	-51.05	10.47
-9.51	-59.4	-15.71
-19.24	5.28	-4.29
-22.26	3.88	19.28
48.54	-35.65	38.51
32.67	-63.78	47.74
-6	9.72	52.06
-12.51	-60.53	11.19
-44.81	12.49	8.78
-37.96	-2.65	60.16

// Wagner U, 2011: guilt > shame + sadness
// Wagner U, 2011: common network activations for guilt/shame/sadness (guilt > 
// neutral)
// Wagner U, 2011: common network activations for guilt/shame/sadness (shame > 
// neutral)
// Wagner U, 2011: common network activations for guilt/shame/sadness (sadness 
// > neutral)
// Wagner U, 2011: common network activations for guilt/sadness (guilt > 
// neutral)
// Wagner U, 2011: common network activations for guilt/sadness (sadness > 
// neutral)
// Wagner U, 2011: guilt > neutral
// Wagner U, 2011: sadness > neutral
// Wagner U, 2011: guilt > shame
// Wagner U, 2011: guilt > sadness
// Wagner U, 2011: sadness > guilt
// Wagner U, 2011: shame > sadness
// Wagner U, 2011: sadness > shame
// Subjects=18
36	32	-4
-10	42	34
0	-62	30
-16	58	24
-36	12	-22
-48	-60	26
-66	-14	-14
42	6	-42
-46	8	-40
2	-84	-2
0	-48	-6
0	60	16
0	-60	30
-14	54	26
-38	18	-20
-52	-62	30
-66	-16	-14
44	2	-42
-54	2	-30
10	-80	-6
-2	-48	-4
2	64	22
-4	-56	28
0	62	18
-30	16	-16
-60	-58	28
-56	-20	-14
46	2	-38
-48	-2	-28
4	-78	-4
-2	-48	2
-16	62	24
6	52	8
38	-24	24
54	-26	20
52	-46	26
56	-34	8
-34	-32	-4
-26	10	8
14	48	14
36	-24	24
56	-20	14
58	-36	20
46	-26	2
-32	-32	-8
-28	12	12
34	26	-16
0	50	34
-14	-10	68
24	14	40
-34	10	38
30	-44	-4
30	0	12
-26	46	30
-48	-4	50
18	14	24
-6	-2	68
-46	-18	38
-50	2	-14
-42	-22	-26
-26	-12	-28
36	-32	-6
38	-80	-10
46	-74	-20
-44	-70	-12
10	-6	-2
-10	44	36
22	36	44
10	38	14
38	30	-4
-38	24	4
-34	6	-24
-50	-4	-20
24	-6	-12
12	4	2
-16	12	14
-32	-10	-2
-20	-4	8
46	-56	-30
36	36	-2
34	18	58
34	-62	30
14	-100	6
-28	-56	-28
20	-16	68
34	42	16
14	38	16
12	16	44
-38	24	4
48	-26	36
30	-58	30
14	-66	50
-16	-66	52
-50	-6	-12
58	-56	-4
-52	-58	20
36	-14	-34
-34	-14	-32
-30	-30	-8
24	-56	-26
-30	-60	-28
8	-6	-2
-14	-10	-4

// Azevedo R T, 2014: Pain stimuli > Touch stimuli
// Azevedo R T, 2014: Pain NW (normal weight) > Pain Ob (all obese)
// Azevedo R T, 2014: Pain NW > Pain UnkOb (unknown obesity cause)
// Azevedo R T, 2014: Pain NW > Pain HormOb (hormonal obesity)
// Azevedo R T, 2014: Pain UnkOb > Pain HormOb
// Azevedo R T, 2014: Faces > Places
// Subjects=12
56	10	30
40	-2	-10
-58	10	28
-42	-4	7
-58	-22	22
-60	-36	46
34	-36	54
68	-22	32
44	-62	-10
52	-68	-14
-42	-52	-20
-44	-68	-8
54	-20	34
56	-22	20
-62	-14	14
-38	-2	4
40	4	-2
-44	-56	-22
50	-68	-12
-6	-92	-12
-4	-10	-4
-60	-24	22
54	-62	-8
-20	-88	-14
56	-20	32
-44	-56	-22
50	-70	-10
-8	-4	-2
46	20	8
48	24	6
46	-56	-22
48	-84	-2
-44	-80	-16

// Frank S, 2014: Entire cohort: Activation in response to all pictures
// Frank S, 2014: (Obese > Controls) x (N-back vs. Control)
// Subjects=11
24	-78	-30
33	-51	-18
30	-30	-6
21	-72	-36

// Geliebter A, 2013: Visual, Fed: (Males > Females) X (High ED > Low ED)
// Geliebter A, 2013: Visual, Fasted: (Females > Males) X (High ED > Low ED)
// Geliebter A, 2013: Audio, Fed: (Males > Females) X (High ED > Low ED)
// Geliebter A, 2013: Audio, Fasted: (Females > Males) X (High ED > Low ED)
// Subjects=14
-56	-50	-22
22	-46	14
-46	6	20
42	34	16
30	22	34
-22	-56	52
14	40	30
16	56	32
-32	-34	20
30	40	34
12	-64	44
42	-36	44
42	24	28
10	-28	46
-20	-12	70
36	-54	4
-24	-36	16
22	12	22
6	12	14
-10	16	14
-28	0	30
16	48	10
-34	38	32
16	16	40
-14	-6	54
28	-10	62
-4	22	54
-34	-2	60
8	-68	16
8	58	20
-18	-32	-6
-10	-98	2
-28	44	14
-12	56	14
6	30	22
-2	-52	54
14	48	22
-22	26	38
-8	-68	-26
38	-40	-6
-2	-34	-28

// Grabenhorst F, 2013: Health label > Taste label, Correlated with health 
// cost rating
// Grabenhorst F, 2013: Taste label > Health label, Correlated with taste 
// pleasantness rating
// Grabenhorst F, 2013: Health label > Taste label Correlated with difference 
// in health cost rating between successive foods
// Grabenhorst F, 2013: Taste label > Health label, Correlated with difference 
// in taste rating between successive foods
// Grabenhorst F, 2013: Brain activity (food choice task), Negative 
// correlation with confidence rating
// Grabenhorst F, 2013: Brain activity (food choice task), Correlations with 
// cost benefit
// Subjects=13
18	-6	-22
-40	12	12
12	-10	-22
40	10	-6
-42	8	6
0	10	24
-28	24	14
18	-4	-14
-8	44	-18
64	-4	6

// Grimm O, 2012: Food - Neutral stimuli correlated with TCI subscale, 
// self-directedness
// Grimm O, 2012: Food - Neutral stimuli correlated with TCI subscale, 
// self-transcendence
// Grimm O, 2012: Food - Neutral stimuli correlated with TCI subscale, 
// persistence
// Grimm O, 2012: Food - Neutral stimuli correlated with TCI subscale, harm 
// avoidance
// Subjects=27
24	-80	4
-22	-70	0
4	-40	-28
48	-36	46
-10	26	-16
4	-62	26
42	4	-6
28	-26	34

// Grosshans M, 2012: Main effect of task in all participants
// Subjects=21
12	-90	-2
-24	30	-14
-26	-70	46
0	-34	32

// Kishinevsky F I, 2012: Hard DD task > Easy DD task
// Kishinevsky F I, 2012: Hard DD task > Easy DD task, Correlations with rate 
// of weight gain between first and second weighing
// Subjects=24
-42	2	40
-8	24	38
-24	60	12
-22	50	10
-42	-78	30
-10	-54	28
4	-46	-8
16	-42	-12
-18	-46	-8
14	-54	8

// Kroemer N B, 2012: Food - Control (Sex/BMI covariates): Correlated with 
// plasma fasting ghrelin levels
// Kroemer N B, 2012: Food - Control: Correlated with plasma fasting ghrelin 
// levels
// Subjects=26
-32	-68	20
-48	-54	-22
14	44	38
34	-62	26
-32	4	24
-52	-18	24
-4	-14	-12
8	-12	-4
8	-4	0
8	-6	-4
-32	-84	32
48	30	30
-20	0	-8
54	12	14
-40	-60	-2
12	2	20
-6	-6	14
-24	10	58
-4	46	22
-48	26	12
14	44	38
34	-62	26
-32	4	24
-52	-18	24
48	30	30
54	12	14
-40	-60	-2
-24	10	58
-4	46	22
-48	26	12

// Miyake Y, 2010: Healthy Controls
// Subjects=11
46	-44	-20
30	-4	-8
34	0	-12
-10	40	34
-32	22	40
48	-52	34
-16	-32	8
52	24	-18
44	-16	50
52	12	30
44	-56	-22
-40	-48	-14
34	-54	40

// Miyake Y, 2010: Bulimia nervosa (BN) Patients
// Subjects=11
2	-74	-8
38	-32	34
50	26	16
36	-56	38

// Miyake Y, 2010: Binging-purging type anorexia nervosa (AN-BP) Patients
// Subjects=11
24	26	34
-42	36	32
-34	20	-8
8	-30	-6
22	-6	-20
48	-50	-20
48	8	28
46	-48	-16
34	-50	42

// Miyake Y, 2010: Restricting-type anorexia nervosa (AN-R) Patients
// Subjects=11
26	-10	-10
44	-58	-16
52	14	26
42	-60	-14
-44	-50	-14
50	-48	46

// Ocher C N, 2012: Post (Roux-en-Y gastric bypass) RYGB fasted: Low Calorie > 
// High Calorie
// Ocher C N, 2012: Pre RYGB fasted > Post RYGB fed: (High Calorie > Low 
// Calorie)
// Subjects=5
-44	-50	10
30	-4	44
-26	-10	66
-40	-76	14
8	-68	-16
36	8	-8
10	60	20
-10	-4	-4
-12	-56	58
30	-12	44
-22	28	48

// Owens T E, 2010: Lean Males
// Subjects=9
52	-2	45
52	35	10
0	68	60
-33	51	23
36	51	24
-8	52	28
-18	-19	78
22	-1	73
2	-58	2
1	-89	-6
3	-77	53

// Owens T E, 2010: Lean Females
// Subjects=10
45	21	33
-50	30	33
-10	56	29
13	47	24
53	13	4
53	23	9
-33	51	23
36	51	24
-8	52	28
-18	-19	78
22	-1	73
2	-58	2
1	-89	-6
3	-77	53

// Page K A, 2011: Complete Subject Cohort
// Subjects=14
-56	7	6
39	26	9
-29	-7	48
54	3	20
-40	11	-3
38	12	1
-22	7	2
25	5	1
3	-12	8
-8	-4	-6
55	-44	12
-44	-39	39
38	-49	43
-7	54	12
-3	44	9

// Page K A, 2011: Subgroup of Complete Subject Cohort, Lean Participants
// Subjects=9
37	8	2
29	1	-1
39	-49	44
-2	56	12
-4	45	8
-28	-20	-15
32	-18	-18
-7	-19	-14
-40	-14	-22
41	3	-29

// Page K A, 2011: Subgroup of Complete Subject Cohort, Obese Participants
// Subjects=5
-45	24	7
43	23	11
-25	-2	52
29	-3	50
1	21	26
-37	14	-5
39	17	-3
-18	-12	2
23	4	1
1	-14	8
-8	-3	-7
5	-5	-6
-10	-15	-12
-55	-4	-3
41	-24	-7
-40	-43	42
36	-49	45

// Simon J J, 2014: Food Incentive Delay (FID): Anticipation of high reward > 
// Anticipation of no reward, p<0.001
// Simon J J, 2014: FID: Anticipation of high reward > Anticipation of no 
// reward, p<0.05
// Simon J J, 2014: FID: Receipt of high reward > Receipt of no reward, 
// p<0.001
// Simon J J, 2014: FID: Receipt of high reward > Receipt of no reward, p<0.05
// Simon J J, 2014: Monetary Incentive Delay (MID): Anticipation of high 
// reward > Anticipation of no reward, p<0.001
// Simon J J, 2014: MID: Anticipation of high reward > Anticipation of no 
// reward, p<0.05
// Simon J J, 2014: MID: Receipt of high reward > Receipt of no reward
// Simon J J, 2014: (FID > MID) X (Anticipation of high reward > Anticipation 
// of no reward), p<0.001
// Simon J J, 2014: (FID > MID) X (Anticipation of high reward > Anticipation 
// of no reward), p<0.05
// Simon J J, 2014: (FID > MID) X (Receipt of high reward > Receipt of no 
// reward)
// Subjects=27
12	2	2
-6	5	2
6	-13	2
36	17	-6
-36	17	-6
24	-85	-2
-15	-91	2
-6	32	-2
42	41	-14
-39	47	-6
51	41	18
-51	35	18
-45	11	30
24	-91	-2
-21	-91	2
-51	-58	-10
30	-61	46
-27	-61	42
-9	2	-2
30	20	-2
27	-91	-2
-30	-79	-6
3	-13	-6
-9	-22	-2
-3	-31	-6
6	35	-6
45	38	18
-45	20	26
33	17	-10
3	-37	34
36	-64	42
-30	-64	42
60	-43	-2
-54	-58	-10
-3	56	6
-54	20	10
0	-49	26
-45	-58	30
66	-10	-14
-27	32	-14
21	-91	6
-15	-91	-2

// Stoeckel L E, 2013: Whole brain correlation between Difficult > Easy and 
// ln(K)
// Subjects=19
-20	18	64
4	22	66
0	-60	46
14	-62	50
-6	-30	42
10	-20	38
-44	-54	18
-42	-58	36
-22	-64	-34
-34	-60	-30

// Wang G J, 2013: Subgroup of Obese Females- NB32 Treatment Group
// Subjects=20
-12	39	39
-9	30	33
36	-27	-12
36	-27	-12
18	-45	66
42	-30	18
-12	39	39
-9	30	33
36	-27	-12
18	-45	66
42	-30	18
-12	39	39
-9	30	33
36	-27	-12
18	-45	66
42	-30	18
33	-6	-27

// Wang G J, 2013: Subgroup of Obese Females- Placebo Group
// Subjects=20
36	-27	-12
18	-45	66
42	-30	18
18	-45	66
-12	39	39
-9	30	33
33	-6	-27
-12	39	39
-9	30	33
36	-27	-12
18	-45	66
42	-30	18
-12	39	39
-9	30	33
36	-27	-12
18	-45	66
42	-30	18
33	-6	-27

// Abler B, 2011: Erotic - Neutral (videos): Placebo > Paroxetine
// Abler B, 2011: Erotic - Neutral (videos), Placebo > Bupropion
// Abler B, 2011: Erotic - Neutral (videos): Bupropion > Placebo
// Abler B, 2011: Erotic - Neutral (videos): Bupropion > Paroxetine
// Abler B, 2011: Erotic - Neutral (videos): Placebo
// Abler B, 2011: Erotic - Neutral (images): Placebo
// Subjects=18
-12	32	-6
14	46	4
14	32	32
-4	-24	-14
6	14	-6
16	34	30
16	20	34
-22	0	-10
26	-8	-12
18	-14	6
-22	-14	14
-6	-12	8
-36	40	-8
52	0	30
38	-56	30
-34	-62	-4
-22	-34	-6
42	-20	-14
36	-38	-12
-42	-56	-24
2	-74	-28
22	-48	-18
-14	32	-6
12	44	6
16	24	36
-4	-24	-14
10	12	-6
-18	12	-6
-22	0	-10
26	-6	-10
12	-14	2
-22	-14	14
-4	-10	6
-34	36	-6
56	6	34
36	-58	28
-36	-62	-6
38	-40	-12
-20	-34	-6
40	-22	-10
-42	-56	-24
-8	-70	-18
18	-50	-18
-6	36	-2
2	34	10
-4	26	24
-2	-12	34
-6	-24	-12
6	-26	-14
-14	20	-10
8	16	-4
-2	18	2
12	-4	-6
-6	-2	-12
-42	38	10
48	38	6
-52	4	24
50	6	18
-42	4	-4
44	8	-8
-34	18	10
38	26	8
-54	-30	30
58	-32	22
-44	-66	-4
50	-68	-10
-36	-16	-8
24	-68	-26
-22	-68	-24
0	38	6
4	28	18
12	2	24
-4	-8	28
0	-36	24
0	-12	-14
-10	8	-6
10	12	-4
14	0	4
-16	-4	-10
14	-4	-8
2	-6	4
12	2	24
0	-8	-12
30	-28	-6
-24	28	-16
34	22	-4
-18	28	-2
22	30	-12
-28	6	30
48	8	28
-42	-2	32
42	2	34
-36	14	-10
32	14	-12
-34	-38	34
32	-40	36
-44	-44	-14
42	-48	-16
30	-36	2
-34	-34	-2
-22	-72	-30
16	-76	-22

// Abler B, 2013: Females taking Oral Contraceptives
// Subjects=12
62	6	18
-58	8	16
48	44	6
60	-48	6
46	14	12
-46	-2	14
-40	6	12
36	4	16
10	48	30
-8	-6	34
-56	-38	30
12	46	22
-16	40	16
-14	18	32
6	8	28
16	46	36
32	42	22
-20	38	-8
-54	6	22
48	6	24
54	4	34
-38	-12	-6
38	-4	-12
36	30	6
-36	22	4
2	10	28
-4	-4	36
-44	36	12
50	42	6
58	-32	20
-60	-34	28
46	-58	-12
-40	-68	-8
8	-18	8
-8	-20	-12
-14	-8	-8
22	-2	-14
-22	-4	-16
-30	-60	-26
24	-66	-26
-6	-4	-6
18	-12	12
-4	-12	0
-46	0	28
44	6	28
48	16	24
34	18	-8
-32	20	8
2	30	-10
2	32	6
0	28	16
2	14	34
2	-10	34
6	50	12
52	40	2
-54	-24	34
58	-22	34
38	-66	-6
-50	-64	2
4	-16	14
4	2	-2
-10	6	-6
8	-20	-10
8	-4	-4
-6	-6	-2
-8	-8	-12
14	-16	-12
22	-6	-14
-24	-6	-16
-12	-76	-36
16	48	34

// Abler B, 2013: Healthy Control Females
// Subjects=12
48	44	6

// Abler B, 2013: Subgroup of Healthy Control Females, Unmedicated Follicular 
// Phase
// Subjects=12
62	6	18
-58	8	16
14	38	-2
-8	32	32
16	44	38
30	58	0
-20	40	-8
24	-20	-22
46	14	12
-46	-2	14
-40	6	12
36	4	16
10	48	30
-8	-6	34
-56	-38	30
-56	6	16
52	4	12
56	8	32
-40	-2	10
42	8	-8
30	20	8
-34	22	8
2	14	28
6	-2	34
-46	38	18
50	38	14
60	-32	20
-60	-34	28
46	-58	-12
-40	-68	-8
-6	-12	2
8	-18	8
14	4	-2
-8	4	-4
-6	-28	-14
-14	-10	-8
14	-10	-8
-26	-70	-26
-28	-62	-28
24	-66	-28
-46	0	28
42	8	22
42	12	-8
40	26	-16
36	32	4
-24	32	-12
-30	24	12
4	30	-12
-6	36	4
-6	24	22
0	12	38
-10	-46	18
4	-18	34
2	-2	32
4	50	38
-2	54	-2
-46	-70	18
-56	-22	34
48	-70	-12
-48	-64	2
-2	-6	8
4	-16	12
8	14	-6
-6	8	-6
6	-26	-18
6	-8	-6
-8	-8	-12
16	-16	-12
-24	-4	-18
-42	-56	-22
-34	-78	-38
-10	-76	-38
44	16	12
-46	-2	16
-28	26	-2
8	48	30
0	-10	0
8	-26	-10
14	-78	-3
-18	-46	-30

// Abler B, 2013: Subgroup of Healthy Control Females, Unmedicated Luteal 
// Phase
// Subjects=12
60	-48	6
14	38	-2
-8	32	32
16	44	38
30	58	0
-20	40	-8
24	-20	-22
12	46	22
-16	40	16
-14	18	32
6	8	28
16	46	36
32	42	22
-20	38	-8
-56	6	18
48	2	14
54	8	26
-36	-4	12
40	6	-10
38	22	8
-30	16	12
-4	18	30
2	4	32
-36	40	28
42	44	18
62	-30	22
-60	-36	-28
46	-58	-10
-44	-70	-8
0	-14	8
8	-22	-14
-16	-8	-8
-28	-70	-26
26	-66	-28
12	-4	-8
-54	6	26
50	12	28
38	30	8
4	34	-10
-2	38	12
-4	26	24
0	56	0
-56	-24	34
60	-20	34
44	-76	0
-52	-68	-6
-2	-14	4
8	16	-4
-8	16	-4
8	-24	-20
6	-6	-6
-8	-8	-12
-12	-18	-12
16	-18	-12
-26	-62	-34
46	-54	-34
20	-70	-26
12	34	-6
-16	38	18
-16	18	28
4	-40	16
12	44	38
32	34	24
10	52	14
-22	42	-8
-16	-82	-38
-38	-64	-36

// Barros-Loscertales A, 2010: Erotic > Neutral
// Barros-Loscertales A, 2010: Aversive > Neutral
// Barros-Loscertales A, 2010: Erotic > Neutral, Positive Correlations with 
// Sensitivity to Reward
// Barros-Loscertales A, 2010: Erotic > Neutral, Negative Correlations with 
// Sensitivity to Reward
// Barros-Loscertales A, 2010: Aversive > Neutral, Positive Correlations with 
// Sensitivity to Reward
// Barros-Loscertales A, 2010: Aversive > Neutral, Negative Correlations with 
// Sensitivity to Reward
// Subjects=45
4	10	-6
-2	48	0
2	12	-8
4	-22	4
-2	-16	2
-26	-2	-16
2	50	36
-2	54	30
48	18	24
-42	26	2
-38	-4	56
0	10	62
-32	20	-18
-12	-62	-10
0	-56	46
46	-70	0
-46	-72	8
40	-60	-22
-36	-76	-22
8	-60	4
-28	2	-18
28	-8	-14
30	-8	-16
-24	-18	-12
-2	-14	0
18	-10	18
42	16	24
-34	-4	50
-2	64	24
-2	64	24
18	-10	52
-30	28	6
4	8	64
-30	-56	54
-2	-88	4
2	-86	2
-38	-58	-22
36	-52	-24
-50	12	14
0	42	20
24	-68	22
-20	8	42
36	-14	2
50	12	38
52	30	26
-12	-88	14
40	-58	42

// Bianchi-Demicheli F, 2011: Healthy Controls
// Subjects=15
-27	3	-30
-3	-15	36
48	9	15
-45	3	27
-39	30	6
-12	51	6
33	0	42
45	-60	-6
-33	-66	-15
36	-69	-12
33	-60	60
-48	-72	-9
24	-54	36
12	12	27
12	-3	42
-24	3	-27
-57	-45	42
54	15	45
-18	105	6
18	-105	-3

// Bianchi-Demicheli F, 2011: Heterosexual females with Hypoactive Sexual 
// Desire Disorder (HSDD)
// Subjects=13
27	-66	-12
36	-48	57
-54	-27	36
45	-33	36
39	-42	51
48	6	27
-48	6	27
-39	27	6
-24	27	-18
42	30	-3
39	-84	6
-42	-72	-3
-36	-96	9
24	-54	36
12	12	27
12	-3	42
-24	3	-27
-57	-45	42
54	15	45
-18	105	6
18	-105	-3

// Borg C, 2014: Women with Vaginismus
// Subjects=20
-50	-62	-10
50	-56	-12
-60	-30	34
58	-26	36
24	-66	44
-46	2	28
50	6	26
-24	-6	46
32	-4	50
42	-4	-4
-6	0	-8
-18	-30	2
22	-30	0
2	-16	-12
-4	-24	-14
-44	-64	-12
50	-56	-12
-34	-86	-6
40	-78	2
-60	-32	36
-38	-46	46
34	-42	46
-28	-60	54
50	6	26
-44	-64	-10
50	-56	-12
-32	-88	-6
42	-80	4
56	-24	32
-26	-70	28
-24	-64	54
-40	-36	34
44	8	32
-50	4	30
-46	-54	-16
40	-48	-16
36	-86	-6
-20	-70	38
-50	4	30
46	2	28

// Borg C, 2014: Healthy Controls
// Subjects=21
-50	-62	-10
50	-56	-12
-60	-30	34
58	-26	36
24	-66	44
-46	2	28
50	6	26
-24	-6	46
32	-4	50
42	-4	-4
-6	0	-8
-18	-30	2
22	-30	0
2	-16	-12
-4	-24	-14
-52	-60	-10
48	-58	-12
38	-86	-6
0	-52	54
-60	-26	34
-22	-66	48
28	-78	26
-46	2	28
50	4	24
-28	-8	46
-4	-4	2
-16	-26	6
20	-24	4
-8	-22	-12
10	-20	-14
44	-64	-28
-52	-60	-10
50	-60	-12
-32	-88	-4
42	-88	-4
-60	-26	32
-20	-68	48
-44	-38	40
48	-36	38
40	-2	30
-48	2	30
-4	-10	4
-4	0	-2
-16	-26	6
20	-24	4
-8	-22	-12
4	-30	-24
12	-20	-14
-32	-48	-18
34	-50	-16
-44	4	22
-36	2	26
-16	-4	-12
22	-6	-16
8	-8	18
10	-8	20

// Borg C, 2014: Women with Dyspareunia
// Subjects=21
-50	-62	-10
50	-56	-12
-60	-30	34
58	-26	36
24	-66	44
-46	2	28
50	6	26
-24	-6	46
32	-4	50
42	-4	-4
-6	0	-8
-18	-30	2
22	-30	0
2	-16	-12
-4	-24	-14
-46	-64	-10
42	-64	-14
-34	-88	-4
40	-82	12
-58	-30	36
58	-24	36
-38	-38	38
34	-38	40
-28	-68	24
22	-64	46
54	6	28
-8	2	-6
-46	-66	-10
44	-66	-12
-34	-88	-4
42	-80	10
-62	-26	30
56	-26	40
-28	-68	24
20	-66	56
-38	-38	38
10	0	-6
-42	-46	-18
38	-62	-22
34	-90	0
-62	-26	28
-8	2	-6

// Borg C, 2014: Neutral Bodies > Neutral Objects
// Borg C, 2014: Sexual Penetration > Neutral Objects
// Borg C, 2014: Sexual Penetration > Core Disgust
// Borg C, 2014: Sexual Penetration > Core Disgust
// Borg C, 2014: Sexual Penetration > Neutral Bodies / Core Disgust > Neutral 
// Bodies, Conjunction
// Borg C, 2014: Sexual Penetration > Neutral Objects, Positive Correlations 
// with Subjective Disgust
// Borg C, 2014: Sexual Penetration > Neutral Objects, Positive Correlations 
// with Subjective Pleasure
// Borg C, 2014: Sexual Penetration > Neutral Objects, Positive Correlations 
// with Negative Associations
// Subjects=20
48	-74	0
44	-42	-10
48	-72	-2
44	8	28
10	-26	-14
24	-42	-42
4	8	28
16	-2	-10
36	-2	50
-18	-44	-42
-26	-2	50
-48	8	30
-24	8	-16
-8	-4	-10
50	-60	-6
50	-26	44
-48	-72	-4
-32	-50	56
-52	-28	40
-42	-16	54
46	-74	-2
28	-52	48
22	-28	2
20	-4	-12
-40	-74	-10
-8	-28	-2
26	-76	10
50	-68	-14
22	-16	-24
58	4	-12
-36	-70	48
-28	32	46
-46	-50	-14
28	-74	8
30	-52	34
-46	-50	-14
28	-76	42
8	-24	-16
28	-6	-20
-6	4	-6

// Cera N, 2012: Erotic > Dance: Controls > Patients
// Cera N, 2012: Erotic > Dance: Patients > Controls
// Subjects=17
41.69	10.21	-.94
3.48	11.67	35.06
38.44	-23.16	-19.3
3.07	54.57	-1.99
-13.92	21.51	-1.25
3.66	-37.06	38.03
-29.24	-53.52	62.09

// Basile B, 2011: Emotional faces > Neutral faces
// Basile B, 2011: Guilt > Anger and Sadness (sentences)
// Subjects=22
-48	32	0
-58	18	26
-48	18	-14
46	24	-14
36	28	-4
46	14	0
12	28	60
0	50	-2
-12	40	12
-4	-52	40

// Morey R A, 2012: Positive correlation between guilt and guilt ratings, 
// regardless of social consequence
// Morey R A, 2012: Negative correlation between guilt and guilt ratings, 
// regardless of social consequence
// Morey R A, 2012: Other > Self
// Morey R A, 2012: Interaction: Guilt x Social consequence
// Subjects=16
-50	46	-2
0	50	38
-2	48	26
-48	-38	34
-6	68	16
-46	38	-12
30	22	44
12	-12	44
6	-44	50
36	-34	52
8	-48	50
36	-34	52
-20	-68	24
50	20	18
40	-22	20
-46	38	-12
42	-62	8
24	-70	48
26	-6	36
-20	-68	24
26	-72	8
44	-62	24
6	-44	50
8	-48	50
24	14	50
-50	46	-2
-22	60	14
-44	36	-12
-54	-36	40

// Morita T, 2014: Self > Other
// Morita T, 2014: Partner > Other
// Subjects=32
34	-88	-8
46	-60	-16
24	-62	54
50	10	34
40	2	6
48	42	10
8	-32	-4
6	-22	4
-36	20	-6
-42	32	12
-36	-90	-10
-44	-62	-14
-48	-72	-16
6	-4	30
6	14	58
-22	-68	52
-20	-70	42
-8	-66	34
-48	-58	26
16	-62	32
-2	40	4
8	58	4
-6	56	20
44	20	24
34	4	42
-42	14	36
-34	8	46
38	-88	-14
44	-58	-12
28	-92	0

// Costumero V, 2013: Erotic > Neutral
// Subjects=45
42	-46	-17
54	-64	7
30	-52	55
36	-79	22
-21	-67	49
-33	-49	52
9	-79	16
-6	-49	19
54	32	7
45	2	52
36	32	-17
-3	56	1
-24	14	-20
-30	29	-20
-18	-4	-14
-36	20	-26
3	8	-8
-42	14	25
-42	-1	55
-42	-37	-20
12	-28	-5
0	14	55
63	-19	37

// Graf H, 2013: Erotic Expectancy > Neutral Expectancy, Placebo > Paroxetine
// Graf H, 2013: Erotic Expectancy > Neutral Expectancy, Placebo > Bupropion
// Graf H, 2013: Erotic Expectancy > Neutral Expectancy, Bupropion > 
// Paroxetine
// Graf H, 2013: Erotic Expectancy > Neutral Expectancy, Paroxetine > 
// Bupropion
// Graf H, 2013: Erotic Expectancy > Neutral Expectancy, Placebo
// Graf H, 2013: Erotic > Neutral, Placebo
// Subjects=18
-4	40	-6
-12	26	24
8	24	24
-10	-50	22
6	-26	-26
-8	-10	2
58	2	14
-24	46	38
28	24	38
40	50	14
-28	18	10
38	10	-6
36	-14	12
46	-28	26
-50	-36	16
56	-16	0
-50	-16	-2
14	-36	28
-12	26	24
8	26	26
-6	-46	20
4	-26	-26
-12	-12	6
-18	8	46
-24	46	38
32	26	38
36	48	10
38	14	-8
48	-24	26
-44	-38	26
-24	-40	-26
14	-46	-16
60	2	16
38	-12	12
54	-16	0
-22	6	44
34	26	36
28	52	12
44	-36	36
-22	-40	-24
16	-46	-16
-4	36	0
10	36	-2
-10	26	22
8	24	24
-8	12	36
8	16	28
-10	-26	36
16	-20	36
-10	-50	22
4	-44	14
-4	-30	-24
6	-30	-24
-16	0	4
14	6	-2
-10	-14	4
8	-16	0
-6	0	-8
6	0	-6
-24	-28	-8
-44	28	36
26	22	36
-26	50	10
38	50	10
-32	36	16
34	46	22
-30	18	4
30	18	2
-34	-2	6
38	-6	2
-32	-12	2
34	-10	8
-50	-14	0
50	-20	4
-54	-56	6
46	-56	6
-52	-36	18
48	-26	26
12	-56	8
-22	-66	-18
14	-70	-32
0	38	6
4	28	18
12	2	24
-4	-8	28
0	-36	24
0	-12	-14
-10	8	-6
10	12	-4
14	0	4
-16	-4	-10
14	-4	-8
2	-6	4
12	2	24
0	-8	-12
30	-28	-6
-24	28	-16
34	22	-4
-18	28	-2
22	30	-12
-28	6	30
48	8	28
-42	-2	32
42	2	34
-36	14	-10
32	14	-12
-34	-38	34
32	-40	36
-44	-44	-14
42	-48	-16
30	-36	2
-34	-34	-2
-22	-72	-30
16	-76	-22

// Habermeyer B, 2013: Females > Males, All Participants
// Habermeyer B, 2013: Boys and Girls > Men and Women, All Participants
// Habermeyer B, 2013: Girls > Women, Heterosexual Pedophilic Men > 
// Heterosexual Healthy Men
// Subjects=8
55.67	-34.89	-7.36
49.13	-17.55	-16.54
45.34	-40.07	36.69
45.11	-81.99	-9.98
35.68	-87.82	11.81
11	-98.86	-4.83
6.92	86.49	-43.74
-33.95	-95.49	-12.4
-20.12	-91.61	-18.46
-25.56	-91.61	-31.78
12.84	63.91	21.65
31.89	58.8	-4.9

// Habermeyer B, 2013: No-Go > Go, All Participants
// Habermeyer B, 2013: Interaction: Task x Group
// Habermeyer B, 2013: Go > No-Go, All Participants
// Subjects=7
58.07	-39.79	25.37
42.25	-47.6	49.62
35.27	22.23	3.7
38.65	43.86	35.3
26.08	-3.03	49.42
-9.58	-40.36	-17.3
-38.4	12.53	8.7
-25.08	-51.44	47.37
-22.21	-31.78	12.24
-41.46	27.26	34.27
-38.28	-38.99	2.99
-47.57	-65.29	35.41
-5.97	-32.8	38.9
-41.02	-60.54	55.01
-47.57	-65.29	35.41
-54.06	-46.29	33.89
-.17	36.6	-13.83
-5.91	-55.26	37.44
-47.57	-65.29	35.41

// Hamann S, 2014: Women
// Subjects=13
27	-1	-11
-21	-58	-8
45	-19	-14
9	-82	-2
-30	11	31
15	-97	10
51	44	19
-21	-1	-20
21	2	-20
-9	-64	31
60	-34	-5
-54	-34	40
-39	-64	7
-60	17	16
-27	2	67
27	-7	46
3	35	52
45	-58	16
18	29	61
-24	47	25
39	-52	52
57	23	4
21	2	-20
24	-25	49
24	44	4
-6	-13	10
15	11	16
18	38	-17
54	23	-5
-45	5	-6
-24	-25	49
-12	2	70
-27	41	16
24	14	52
24	-34	52
-54	-34	40
9	-73	49
-18	-40	43
-30	35	28

// Hamann S, 2014: Men
// Subjects=13
27	-1	-11
-21	-58	-8
45	-19	-14
9	-82	-2
-30	11	31
15	-97	10
51	44	19
-30	-1	-14
24	-1	-11
42	2	19
24	-1	-8
-24	-49	-11
-39	2	-29
-60	-4	-14
12	56	-5
-12	-73	-8
-51	-34	-11
-42	53	-14
15	26	49
-15	38	37
21	47	-17
51	-34	-11
42	53	-14
24	-25	49
24	44	4
-6	-13	10
15	11	16
18	38	-17
54	23	-5
-45	5	-6
-24	-25	49
-12	59	19
36	32	-17
-42	56	-11
-57	-37	-14
33	-70	1
-33	-73	-29
3	56	-11
-33	-73	40
-42	-13	40
54	23	34
-45	-13	16
-42	29	16
-12	88	-2
-6	-49	34
12	59	19

// Hamann S, 2014: Women with Complete Androgen Insensitivity Syndrome (CAIS)
// Subjects=13
-30	-1	-14
24	-1	-11
42	2	19
24	-1	-8
-24	-49	-11
-39	2	-29
-60	-4	-14
12	56	-5
-12	-73	-8
-18	5	-20
-33	29	-20
51	44	-17
-18	5	-20
12	-76	1
30	38	28
-12	59	19
36	32	-17
-42	56	-11
-57	-37	-14
33	-70	1
-33	-73	-29
3	56	-11
-33	-73	40
-42	-13	40
54	23	34
-45	-13	16
-42	29	16
-12	88	-2
-6	-49	34
12	59	19
-12	2	70
-27	41	16
24	14	52
24	-34	52
-54	-34	40
9	-73	49
-18	-40	43
-30	35	28

// Hu S H, 2011: Lesbian-Erotic > Neutral, Homosexual > Heterosexual Men
// Hu S H, 2011: Lesbian-Erotic > Neutral, Heterosexual > Homosexual Men
// Hu S H, 2011: Hetero-Erotic > Neutral, Homosexual > Heterosexual Men
// Hu S H, 2011: Hetero-Erotic > Neutral, Heterosexual > Homosexual Men
// Hu S H, 2011: Gay-Erotic > Neutral, Homosexual > Heterosexual Men
// Hu S H, 2011: Gay-Erotic > Neutral, Heterosexual > Homosexual Men
// Subjects=14
9	3	-15
-30	-60	-21
12	48	0
9	-42	9
12	-51	6
0	-21	-30
-30	-78	-6
12	-48	-6
21	-54	2
6	3	-15
0	-54	-42
33	-3	42
42	0	39
15	-21	45
39	-57	27
33	-63	33
51	-6	-18
-45	-45	-9
24	-87	-9
-12	42	0
-18	51	6
18	-51	-36
-12	0	27
15	-72	-39
3	-45	15
3	-48	69
3	-99	3
-42	-54	-39
-39	-51	-30
-24	33	-21
-33	-72	-12
-18	36	12
9	36	15
15	48	15
36	-54	-12
-6	-69	33

// Mason L, 2014: Anticipation of reward: High probabiltiy > Low probabiltiy, 
// All groups
// Mason L, 2014: Anticipation of reward: Large > Small, All participants
// Mason L, 2014: Gain > Loss, All participants
// Mason L, 2014: Probability of reward: High > Low, All participants
// Mason L, 2014: Large > Small reward, All participants
// Subjects=20
30	-66	38
46	10	32
46	40	20
32	10	60
44	12	32
44	26	0
-34	22	-2
4	32	48
-50	16	28
-10	12	-10
10	14	-8
-8	44	-2
-40	46	0
44	42	-2
52	12	20
-24	32	42
-16	32	52
62	-50	16
-40	22	-6
-4	-40	10
44	26	0
46	14	34
-34	20	-2
32	-62	44
-48	14	28

// Chen Z, 2013: (Semantically Incongruent (SI) - Congruent (CO)) late stage - 
// (SI-CO) early stage
// Chen Z, 2013: (Response Incongruent (RI) - SI) late stage - (RI-SI) early 
// stage
// Subjects=25
-8.06	21.4	48.34
-60.12	16.47	32.91
-47.72	18.85	-11.24
30.09	25.82	-9.89
-34.32	-36.98	10.86
4.46	-86.89	-8.39
-33.51	-47.33	72.38
-1.51	-96.24	29.62
33.47	-22.35	-8.55
-2.07	-51.19	-5.09
-34.68	-65.93	-23.24
33.27	-59.94	-31.72
-40.89	-37.63	4.32
-27.1	-51.12	65.93
27.43	-48.59	21.05
-37.92	-65.95	-23.19

// Poser B, 2011: Detected clusters of activation in the Vascular Space 
// Occupancy (VASO) data, Fixed Effect Analysis
// Poser B, 2011: Detected clusters of activation in the BOLD data, Fixed 
// Effect Analysis
// Poser B, 2011: Detected clusters of activation in the VASO data, Random 
// Effect Analysis
// Poser B, 2011: Detected clusters of activation in the BOLD data, Random 
// Effect Analysis
// Subjects=12
-28	-70	48
32	-66	54
-32	-14	58
38	-6	52
-32	20	6
34	24	2
-24	-98	2
30	-94	4
-34	-92	-5
24	-78	-12
-5	5	50
-12	54	32
14	48	38
-10	56	-14
10	50	-12
-50	-60	28
-10	-48	34
48	-24	54
-28	-66	52
32	-58	52
-36	-10	62
36	-8	52
-30	26	4
34	25	3
-22	-98	6
22	-84	-10
-42	-80	-10
36	-86	-2
-4	4	54
-12	42	40
22	36	40
18	64	6
-42	-84	32
48	-78	32
-20	-62	14
46	-24	58
-22	-72	52
24	-60	48
-34	-10	46
32	-8	45
-18	-96	-8
16	-92	-10
-48	-74	-14
28	-62	-20
-4	4	48
-12	8	28
18	42	40
-10	58	-10
1	-54	-10
-46	-74	38
-8	-56	34
44	-22	52
-32	-60	52
32	-60	46
-44	0	36
44	0	42
-28	22	6
40	12	6
-16	-92	-14
14	-90	-10
-32	-52	-18
38	-46	-20
-4	6	50
-14	36	54
-18	64	4
-44	-78	26
44	-80	34
-6	-62	16
52	-22	60

// Silton R L, 2010: Incongruent > Congruent
// Subjects=89
-31	19	-8
36	21	-6
-53	-56	-15
-8	-79	2
0	-16	7
11	11	7
-23	-2	9
41	35	13
-40	11	34
7	21	27
-35	-57	44
-5	-63	45
0	14	51
39	-50	48

// Caseras X, 2013: Healthy Controls
// Subjects=20
-52	-20	8
-44	28	4
-44	-14	12
-32	24	8
-44	34	-4

// Caseras X, 2013: Bipolar I
// Subjects=17
-30	28	-20
-44	-14	12
-36	-12	-10
-30	38	-16

// Caseras X, 2013: Bipolar II
// Subjects=15
-52	-20	8
-44	28	4
-44	-14	12
-32	24	8
-44	34	-4
-30	28	-20
-44	-14	12
-36	-12	-10
-30	38	-16

// Hooker C I, 2014: Low Social Anhedonia
// Subjects=15
24	-97	10
45	-70	4
36	-70	-5
45	-37	22
-21	-100	10
-15	-91	28
-30	-91	7
-33	-73	-11
-48	-73	10
-54	-64	13
-54	-43	25
-54	-46	7
33	8	10
21	-10	-11
-21	-7	-11
-24	-28	-8
-24	2	-17
3	29	4
-57	-7	-11
51	-1	52
18	-31	1
9	-25	4
27	-28	-5
-9	56	13
-9	-19	43
45	-13	-5
-54	11	-20
21	-97	16
15	-79	-14
30	-70	-8
-18	35	49
-18	-97	-2
-24	-97	10
-12	47	-2
-24	53	-5
-9	41	10
-9	14	-8
15	44	4
3	47	4
12	53	1
3	56	1
48	-67	4
48	-55	1
57	-37	19
45	-40	10
-39	-82	-5
-51	-73	7
-48	-58	7
-57	-46	10
9	-28	-2
-9	-34	4
54	-1	49
-18	-97	13
24	-4	-11
-21	-10	-14
-27	2	-20
48	-22	-2
-15	-79	-11
-39	-46	-14
30	-88	22
45	-4	10
-45	-10	1
-21	50	-2
-33	41	13
39	14	-8
-48	-1	-2
27	47	22
48	-7	4
-3	-7	37
-6	38	7

// Hooker C I, 2014: High Anhedonia
// Subjects=15
30	-91	10
48	-67	4
45	-79	4
54	-37	10
48	-28	1
54	-19	-5
-24	-94	-2
-36	-73	1
-33	-85	-8
-60	-46	19
-51	-46	10
9	-28	-2
-39	17	-29
-39	20	-20
-21	-7	-14
-27	-1	-17
-30	8	-20
-57	2	-20
-48	-13	-11
-51	11	-20
-33	-49	-20
-36	-55	-14
0	-55	31
-3	47	-14
3	47	-14
-9	-28	-2
45	-46	7
51	-67	4
57	-37	13
-36	-73	1
-54	-64	13
-60	-55	16
-51	-46	10
39	-49	-14
-18	-7	-11
-21	-94	10
-51	-19	-8
57	32	4
21	-91	13
-60	-7	-17
3	-58	25
63	-7	28
42	-16	49
45	-4	10
-45	-10	1
-21	50	-2
-33	41	13
39	14	-8
-48	-1	-2
27	47	22
48	-7	4
-3	-7	37
-6	38	7

// Wolf D H, 2014: Healthy Controls
// Subjects=37
16	6	-12
-16	4	-16
0	-60	18
0	-36	34
-16	-24	70
34	-20	58
0	42	-12
4	42	14
38	48	-8
-20	48	-16
20	30	44
-24	28	56
-18	-102	8
30	-96	-2
52	-20	12
-48	-60	52
-58	-16	2
-62	-30	-24
50	-74	32

// Wolf D H, 2014: Schizophrenia
// Subjects=41
16	6	-12
-16	4	-16
0	-60	18
0	-36	34
-16	-24	70
34	-20	58
0	42	-12
4	42	14
38	48	-8
-20	48	-16
20	30	44
-24	28	56
-18	-102	8
30	-96	-2
52	-20	12
-48	-60	52
-58	-16	2
-62	-30	-24
50	-74	32
-44	-66	16
-8	4	-6
8	4	-8
-40	-70	22
-52	8	32
44	22	24
-38	32	36

// Goswami R, 2012: Increased brain activation in response to somatosensory 
// stimulation
// Goswami R, 2012: Decreased brain activation in response to somatosensory 
// stimulation
// Goswami R, 2012: Increased brain activation during Lower-body Negative 
// Pressure (LBNP)
// Goswami R, 2012: Decreased brain activation during Lower-body Negative 
// Pressure (LBNP)
// Goswami R, 2012: Increased activation during Lower-body Negative Pressure 
// with Somatosensory Stimulation (LBNPSS)
// Goswami R, 2012: Decreased activation during Lower-body Negative Pressure 
// with Somatosensory Stimulation (LBNPSS)
// Goswami R, 2012: Increased activation during Apnea
// Goswami R, 2012: Decreased activation during Apnea
// Goswami R, 2012: Increased activation during Apnea with Somatosensory 
// Stimulation (ApneaSS)
// Goswami R, 2012: Decreased activation during Apnea with Somatosensory 
// Stimulation (ApneaSS)
// Subjects=15
-38	-20	18
-38	0	14
-4	48	-12
-12	-46	22
-8	10	62
-44	-34	46
38	-30	42
-28	-6	54
30	-8	50
-54	-20	0
54	-20	-4
8	-44	-46
12	-20	-20
32	12	14
16	40	20
28	-2	-26
-32	50	-36
44	-58	-36
0	-36	-34
-4	22	-14
8	34	-10
-2	-46	18
2	-44	18
-10	-18	0
30	-4	-22
-36	-54	-40
42	-56	-38
8	-10	-22
-30	-30	54
-40	-28	66
-4	22	-14
8	32	-10
-2	-46	18
2	-44	18
-10	-20	6
12	-20	6
34	-26	16
-38	16	-4
40	20	-6
-4	30	34
4	32	32
-20	-52	-28
-22	-78	-50
-10	-16	6
12	-16	6
-26	-10	4
28	-8	4
-2	22	56
4	22	54
-44	4	50
58	8	40
58	-24	46
42	-8	14
34	-38	-28
44	-60	-26
-22	-16	-14
28	-18	-14
-54	-2	-4
64	-2	-8
-36	-94	-2
34	-90	-4
38	20	-10
6	30	30
-16	-52	-32
-10	-16	6
10	-16	8
-28	-10	2
28	-8	4
-4	14	54
6	12	50
-42	2	50
46	2	46
58	-24	44
42	-8	14
38	-68	-26
48	-60	-32
-22	-16	-14
28	-18	-14
-52	-2	-4
-48	-72	8
42	-82	2
34	-90	-8

// Donnay G F, 2014: ScaleImprov > Control
// Donnay G F, 2014: JazzImprov > Control
// Donnay G F, 2014: Rest > ScaleImprov
// Donnay G F, 2014: Rest > JazzImprov
// Subjects=11
-44	29	8
-60	8	14
-56	-6	-2
-6	18	48
-56	-62	-10
-54	-42	2
-42	-36	40
-24	-70	48
-2	22	40
-26	-72	24
52	22	2
56	16	0
66	-46	20
6	22	58
58	-58	-10
58	-38	2
58	-36	50
20	-72	50
12	60	32
44	-72	-16
-54	34	12
-60	12	24
-56	-46	12
0	16	54
-46	-24	-2
-48	-42	58
-12	-80	50
-50	-38	28
50	24	0
50	14	4
64	-24	2
8	24	54
52	-52	-24
42	-52	18
58	-36	54
62	-26	46
42	-74	22
-46	28	36
-18	6	52
-22	-18	74
-48	-52	26
-8	-56	18
24	48	6
18	46	36
44	-10	56
50	-52	34
18	-64	26
-38	20	52
-18	58	20
-22	-18	64
-44	-60	26
-14	-54	68
40	38	32
26	-8	68
54	6	18
62	-58	26
6	-58	46

// Liu S, 2012: Improvised > Conventional
// Liu S, 2012: Conventional > Improvised
// Subjects=12
-6	57	18
-9	57	33
-15	48	42
-6	15	66
-8	18	47
-39	0	54
-48	30	3
-54	15	18
-48	-45	3
-45	-39	6
-45	-57	-24
-12	-3	21
-18	0	3
-6	-66	-3
-33	-90	0
15	-75	0
33	-84	3
27	-75	-33
39	48	9
34	29	37
35	-65	42
33	-66	48
3	-69	42
6	-39	24
36	-57	42
51	-42	42
-32	-65	40
-15	-75	45
-6	-69	39
0	-33	27
-36	-48	39

// Villarreal M, 2013: Subgroup of Healthy Musicians, Less Creative Group 
// (LCG)
// Subjects=6
-2	-4	78
-28	4	50
-50	32	30
38	0	20

// Villarreal M, 2013: Subgroup of Healthy Musicians, Higher Creative Group 
// (HCG)
// Subjects=6
-81	16	50
-50	32	30
50	26	8
52	19	0
-50	32	30
38	0	20

// de Manzano O, 2012: Improvise/Random - Notes
// de Manzano O, 2012: Random - Improvise
// Subjects=18
10	26	34
-42	26	26
54	14	10
-44	14	-2
48	16	-2
-2	8	58
-42	-66	-36
28	-68	-32
-16	52	34
-36	42	14
-34	26	46
24	22	56
36	-6	52
-34	12	14
-14	-28	38
-10	-24	68
-38	8	42
-62	2	24
-28	-12	66
-38	-14	50
2	-26	64
-20	-36	68
-40	-40	60
54	-46	36
-48	-54	30
4	-66	36
-60	-26	16
-28	-52	56
-44	-52	-20
32	-54	-18
-18	-66	-4
-14	-72	0
22	-62	-10
2	-78	6
-26	-32	-14
-28	-52	-20
-10	-60	-42
-14	-62	-56
-10	-80	-30
16	-64	-56
12	-70	-28

// Scheef L, 2012: preWalk: Pain > Heat (Activations)
// Scheef L, 2012: preWalk: Pain > Heat (Deactivations)
// Scheef L, 2012: postWalk: Pain > Heat (Activations)
// Scheef L, 2012: preRun: Pain > Heat
// Scheef L, 2012: postRun: Pain > Heat
// Scheef L, 2012: (preRun-postRun) > (preWalk-postWalk)
// Subjects=20
20.71	-11.05	9.6
53.5	8.34	42.98
-64.52	-18.07	19.59
-64.44	-26.27	23.76
60.9	-21.26	24.49
67.28	-15.48	17.09
60.38	14.22	-9.26
37.88	6.78	4.18
62.67	6.45	-.69
-56.2	5.82	-.84
-42.21	9.81	-4.84
42.33	-15.23	9.65
35.76	-15.88	3.1
10.13	17.99	33.8
11.87	-20.19	-7.27
-9.78	-16.22	-9.54
-27.06	-65.49	-18.94
-23.01	-72.98	-41.8
-7.81	-74.53	-36.3
-11.95	-48.01	-16.44
-1.14	-52.33	-17.32
1.02	-65.39	-19.42
26.95	-65.3	-19.87
31.21	-60.28	-23.81
37.61	-54.29	-28.99
10.13	17.99	33.8
12.61	12.73	57.81
8.17	21.67	50.28
-4.82	-38.74	36.31
67.28	-15.48	17.09
56.52	-19.57	19.92
40.03	8.91	3.94
62.68	4.32	-.48
55.06	8.24	-4.1
-40.06	11.95	-5.09
-56.13	4.11	3.81
-60.59	5.29	-6.32
9.83	-15.97	3.55
11.8	-16.35	-12.13
-11.68	-17.55	10.8
33.63	-20.04	4.67
18.57	-10.85	11.86
7.91	18.63	29.29
5.89	12.01	38.95
-5.07	18.48	28.41
5.24	-27.84	-19.85
-29.26	-63.58	-21.33
1.19	-76.16	-8.28
-9.67	-71.19	-11.94
-18.72	-68.81	-43.4
39.8	-85.85	-33.75
9.38	-43.42	-37.43
-9.78	-16.22	-9.54
6.18	6.54	60.78
32.12	-13.03	56.67
27.94	-32.74	64.29
-64.48	-19.99	22.02
-55.96	-13.24	13.37
63.07	-23.38	24.67
53.24	-17.66	17.55
44.52	-15.02	11.83
40.03	8.91	3.94
60.4	14.33	-8.15
60.54	6.65	1.57
25.05	-17.42	10.16
18.57	-10.85	11.86
-20.51	-6.92	-1.31
-11.83	-8.81	0.97
11.87	-20.19	-7.27
8.11	12.43	43.35
7.97	19.05	33.73
35.77	48.74	16.88
-33.42	52.54	15.44
58.79	11.88	34.7
16.81	-16.67	41.6
-27.07	-63.37	-19.15
-31.52	-56.66	-27.58
-29.54	-58	-42.05
-44.29	8.2	0.96
-51.82	1.89	2.83
-9.78	-16.22	-9.54
-3.61	-43.67	-39.42
33.59	-15.99	2.03
-35.64	-20.15	-4.23
60.9	-21.26	24.49
63.31	-33.63	41.37
-.64	16.03	36.42
5.95	12.42	43.39
7.94	18.84	31.51
37.88	6.78	4.18
37.78	21.35	-.62
18.57	-10.85	11.86
25.02	-15.5	7.73
-53.98	1.89	2.87
-46.49	7.88	-2.33
-66.68	-18.08	19.63
14.12	-14.03	1.04
-29.26	-63.58	-21.33
-7.54	-77.98	-15.79
-9.73	-58.53	-14.32
-27.39	-66.82	-44.57
56.23	2.38	2.06
56.12	10.26	-5.44
3.07	-27.95	-20.92
-11.44	-5.9	32.05
0.92	27.94	-8.49
-37.69	10.22	10.73

// Shukla S, 2011: Heat Pain > Baseline (Activation)
// Shukla S, 2011: Heat Pain > Baseline (Deactivation)
// Shukla S, 2011: Minimal Intensity Acupuncture (MI-EA) > Baseline 
// (Activation)
// Shukla S, 2011: MI-EA > Baseline (Deactivation)
// Shukla S, 2011: Optimal Intensity Electroacupuncture (OI-EA) > Baseline 
// (Deactivation)
// Shukla S, 2011: MI-EA, Heat Pain > Baseline (Activation)
// Shukla S, 2011: OI-EA, Heat Pain > Baseline (Activation)
// Shukla S, 2011: OI-EA, Heat Pain > Baseline (Deactivation)
// Subjects=10
51.76	-45.4	35.95
48.19	3.54	8.46
41.96	18.5	37.39
28.92	55.72	24.38
-22.31	-16.43	4.26
6.66	21.2	34.22
-44.74	49.45	32.45
-66.94	-50.31	24.34
2.96	55.65	-15.46
-48.38	12.05	-37.98
-67.38	-2.13	-13.15
-50.87	-82.71	16.84
51.27	12.13	-4.56
49.29	17	17.36
19.23	4.45	-4.66
-32.04	25.26	7.56
32.6	-31.54	51.73
19.83	-38.77	55.83
5.45	-1.12	7.12
-12.35	-45.79	36.72
12.96	62.99	37.34
-5.95	-71.1	25.38
16.57	-56.99	40.67
6.38	74.36	19.73
-3.39	72.76	-0.09
-5.76	-61.38	54.68
-9.52	63.49	31.98
42.42	-65.61	64.51
-9.58	32.17	12.3
-12.56	37.72	43.1
-25.22	19.64	58.14
-0.04	-21.27	-19.01
-57.11	-44.77	53.87
-71.17	-77.29	19.96
-45.13	-13.82	-42.54
-34.24	64.09	14.37
9.73	8.85	11.81
31.03	55.47	21.03
44.69	33.44	-17.42
54.8	-63.56	7.32
-59.38	-59.27	31.7
6.45	-27.06	-11.91
51.24	11.79	-8.99
61.29	-42.94	25.59
61.09	-45	-1
29.14	-100.15	-9.39
-2.69	-78.22	29.29
-19.05	30.31	30.41
-22.14	11.77	38.69
-28.38	-12.88	50.87
-38.04	-36.42	36.23

// Smith J K, 2011: Pain Block > Baseline
// Smith J K, 2011: Pain Ramp ON > Baseline
// Smith J K, 2011: Pain Ramp OFF > Baseline
// Subjects=14
10	-72	42
-8	-14	-6
-34	8	4
62	-44	36
46	14	6
-2	-58	-34
-58	-44	42
-38	-6	-16
-34	46	30
6	-28	26
-4	-22	28
6	14	34
18	-10	8
-12	-10	6
12	-10	-12
54	14	-8
52	34	-6
32	22	6
64	-46	36
-38	42	26
-24	14	-2
-54	10	-10
-58	-22	12
56	6	2
64	-28	18
38	2	-10
12	-4	12
-8	-2	8
-34	-22	2
8	-2	42
-10	-28	-4
28	-40	72
-38	0	-14
38	18	4

// Altenmuller E, 2014: Stimuli>Silence
// Altenmuller E, 2014: Old>New Pieces
// Altenmuller E, 2014: New>Old Pieces
// Altenmuller E, 2014: Recognized>Not Recognized Target Pieces
// Altenmuller E, 2014: Positive Pieces>Less Positive Pieces
// Altenmuller E, 2014: Recognized Positive>Recognized Less Positive Target 
// Pieces
// Subjects=18
1.52	7.99	56.58
42	8.01	39.39
37.42	21.28	4.87
53.6	-17.75	7.96
56.8	-15.62	7.74
-28.86	-54.11	-28.19
-6.27	-10.71	8.05
-1.03	-23.85	-10.98
44.74	63.62	1.24
30	22.89	12.63
-27.83	-57.79	-34.59
0.11	45.06	26.72
1.47	-32.13	33.18
-4.83	-61.77	35.74
32.01	48.02	7.15
-18	-10.52	11.52
-61.82	-37.19	0.88
60.85	-11.3	-19.43
-2.23	-54.81	-39.59
36.25	-62.15	-41.65
-25.32	15.27	42.9
-47.81	8.02	33.73
-2.85	-23.87	30.31
-12.4	-57.22	26.52
8.48	58.63	8.76
-55.26	-41.15	17.86
-18.01	-9.46	11.43
-9.31	-55.14	11.82
-2.03	-5.48	6.45
23.6	-18.7	-1.66
1.27	-53.99	-1.79
55.51	15.07	-8.2
60.94	-9.22	-6.23
22.37	-56.69	-38.6

// Coen S J, 2011: Positive Correlation between brain activity during 
// Anticipation and Neuroticism scores
// Coen S J, 2011: Negative Correlation between brain activity during 
// Anticipation and Neuroticism scores
// Coen S J, 2011: Positive Correlation between brain activity during Pain and 
// Neuroticism scores
// Coen S J, 2011: Negative Correlation between brain activity during Pain and 
// Neuroticism scores
// Subjects=31
24.48	18.86	-11.51
9.72	31.83	19.92
-49.9	-27.75	25.6
12.97	-18.25	5.12
44.83	9.63	-8.74
-35.29	7.21	-5.38
19.17	-2.84	-16.32
-6.4	46.19	14.44
5.63	24.97	41.73
8.48	-68.83	-43
-5.31	-6.27	-3.48
-58.71	-21.65	-4.92
-38.13	-56.03	16.68
47.36	-55.51	15.66
-11.29	-36.98	40.43
53.5	-39.64	-13.62
29.4	-65.54	39.01
7.79	-59.44	9.75
-42.19	-60.43	42.75
-31.85	33.83	35.84
-10.6	-55.26	-17.16
44.06	-24.7	15.34
26.61	-9.74	-23.63
47.48	-14.71	47.92
-47.83	-61.34	3.86
5.33	37.2	7.25
16.22	-25.38	9.03
-46.75	-20.58	21.61
21.5	-33.69	-2.6
-21.32	-26	-9.45
-10.51	-21.31	8.99
-15.47	3.46	68.31
36.36	26.81	7.76
-7.51	40.3	7.14
-31.95	-21.06	0.3

// Farmer A D, 2013: Subgroup of [Healthy Controls], Pain Cluster (PC) 1
// Subjects=12
35.29	-10.52	-6.94
-29.81	-18.85	1.2
-6.34	-14.74	-2.76
8.58	-19.48	-10.34
-13.38	-34.36	46.92
-14	-4.52	-21.37
-10.66	-55.86	-24.91
39.67	-9.38	7.41
-53.23	-21.31	12.83
13.24	-15.43	41.68
-6.09	-7.68	33.45
63.32	-31.98	15.73
59.15	-27.64	31.03
44.18	5.11	42.95
59.1	-23.75	26.24
63.42	-18.9	33.59
8.72	-70.75	-12.73
-53.07	-16.42	34.72
29.83	-13.95	-23.31
-25.61	1.27	-.53
-56.54	10.48	11.32
-48.96	2.84	21.91
41.68	44.19	11.82
32.22	35.9	29.35
18.23	44.65	19.86
35.27	25.49	4.54
17.09	25.3	3.65
55.74	4.27	17.24

// Farmer A D, 2013: Subgroup of [Healthy Controls], Pain Cluster (PC) 2
// Subjects=17
51.79	-29.74	45.79
-18.06	-55.05	-13.74
-33.61	-30.45	57.98
56.99	-19.11	31.45
56.78	-8.13	8.23
61.21	-33.94	18.15
24.46	-0.06	-22.19
5.87	-9.87	59.14
-31.63	-12.27	45.28
12.9	-10.14	-0.02
27.81	-63.29	-28.08
12.87	-14.88	-6.31
-33.18	22.28	-3.32
9.89	9.42	32.95
-30.96	-.97	-1.4
0.17	20.39	24.33
-22.25	-1.49	18.62
39.69	39.12	29
-25.61	1.27	-.53
-56.54	10.48	11.32
-48.96	2.84	21.91
41.68	44.19	11.82
32.22	35.9	29.35
18.23	44.65	19.86
35.27	25.49	4.54
17.09	25.3	3.65
55.74	4.27	17.24

// Foster N E V, 2013: Reversed > Control
// Subjects=12
44	-42	52
-4	20	56

// Groussard M, 2010: Conjuntion Musical Familiarity
// Groussard M, 2010: Musicians > Nonmusicians, p<0.001
// Groussard M, 2010: Musicians > Nonmusicians, p<0.002
// Groussard M, 2010: Musicians > Nonmusicians, p<0.02
// Subjects=20
-46	-26	58
-44	30	4
18	-52	-22
34	32	-10
-52	-18	22
54	-26	-4
-32	-66	44
-12	-14	-14
40	-26	-18
20	90	-8
-10	-52	2
-56	-6	10
42	-32	14
-12	-38	-12
-8	58	-10
8	62	-6
0	-22	56

// Angulo-Perkins A, 2014: Human vocalizations + music > Non-vocal sounds
// Angulo-Perkins A, 2014: Human vocalizations + music > Monkey vocalizations
// Angulo-Perkins A, 2014: Music > Human vocalizations
// Angulo-Perkins A, 2014: Human vocalizations > Music
// Angulo-Perkins A, 2014: Speech > Music
// Angulo-Perkins A, 2014: Music > Non-linguistic
// Angulo-Perkins A, 2014: Violin > Speech
// Angulo-Perkins A, 2014: Speech > Violin
// Angulo-Perkins A, 2014: Music > Human|musicians > Non-musicians
// Subjects=23
-64	-14	-4
62	-15	-4
54	-12	2
-54	4	-14
50	-2	-8
-48	-4	-8
-32	-32	48
-58	-8	12
58	-6	14
-52	20	-2
-8	62	24
-20	-6	-20
22	-2	-18
-64	-14	-4
56	-18	8
-52	22	-8
52	28	14
-4	40	42
-50	-4	46
20	-8	-20
22	-2	-18
-50	-6	-4
50	-4	-4
-32	-32	48
42	-12	-10
-58	-18	-8
58	-8	-10
-52	22	-4
52	30	8
-4	40	42
-50	0	44
-20	-10	-20
22	-6	-18
58	-14	4

// Benson S, 2012: Healthy Controls
// Subjects=30
34	12	8
58	14	6
-30	18	6
64	-22	38
-56	-24	22
-60	-42	38
8	18	36
8	14	48
18	-10	8
44	48	6
-50	42	10

// Benson S, 2012: Subgroup of Healthy Controls, Males
// Subjects=15
-2	22	-8
-32	42	-10
-18	-72	-44
8	18	36
-4	-26	-4
-26	34	24
-38	6	-38
38	-66	-36
12	60	4

// Benson S, 2012: Subgorup of Healthy Controls, Females
// Subjects=15
52	18	6
-66	-28	24
-22	-76	-24
10	18	52
-26	34	24
-38	6	-38
38	-66	-36
12	60	4

// Brattico E, 2011: Sad > Happy
// Brattico E, 2011: Happy > Sad, p < 0.001
// Brattico E, 2011: Happy > Sad, p < 0.05
// Brattico E, 2011: Lyrics > No lyrics, p < 0.001
// Brattico E, 2011: Lyrics > No lyrics, p < 0.05
// Brattico E, 2011: No lyrics > Lyrics, p < 0.001
// Brattico E, 2011: No lyrics > Lyrics, p < 0.05
// Brattico E, 2011: Sad with lyrics > Sad without lyrics, p < 0.001
// Brattico E, 2011: Sad with lyrics > Sad without lyrics, p < 0.05
// Brattico E, 2011: Happy with lyrics > Happy without lyrics, p < 0.001
// Brattico E, 2011: Happy with lyrics > Happy without lyrics, p < 0.05
// Brattico E, 2011: Happy without lyrics > Happy with lyrics
// Brattico E, 2011: Sad lyrics > Happy lyrics
// Subjects=15
-4	-30	0
10	16	-4
2	10	0
-64	-8	8
-66	-30	14
-52	-2	0
-26	-10	-6
-6	-82	20
-32	-58	-12
42	-26	10
-62	-8	-18
28	24	30
16	8	44
54	6	20
6	-46	-48
-4	18	24
-26	0	-22
8	60	20
30	-4	18
24	10	-22
18	-6	-22
-28	18	-14
-28	-14	-6
50	6	-22
-50	8	-18
56	-16	-2
-56	-14	-6
40	10	2
50	8	14
-22	4	64
-34	44	32
0	32	30
-46	16	8
-34	22	-16
-66	-10	6
46	14	-14
36	0	14
30	18	-18
62	-40	32
42	0	6

// Danielson A L, 2014: Transitions > Continuous
// Subjects=19
6	-70	-24
-48	-36	12
62	-36	6
46	8	24

// Gopinath K, 2012: Healthy Controls
// Subjects=14
45.27	31.69	56.32
-53.16	29.9	41.99
41.79	2.53	9.74
25.68	71.9	27.52
11.14	3.65	54.6
22.89	33.3	65.36
6.68	-11.46	24.7
54.55	53.5	20.93
53.26	29.26	-17.17
51.3	-13.93	-11.29
8.48	20.16	-6.97
21.36	-3.28	-8.5
37.67	-32.14	16.04
12.21	-34.81	38.86
5.71	-47.85	22.18
-53.16	29.9	41.99
-36.2	14.29	17.45
-31.93	-6.55	9.12
-9.42	64.6	46.38
-5.98	10.95	54.19
-36.04	11.52	36.64
-.83	-9.65	21.29
-63.94	39.81	33.48
-48.04	21.02	9.22
-32.25	-9.89	-34.09
-37.38	26.29	7.54
-17.11	17.35	0.25
-13.75	10.11	16.43
-26.64	-6.06	1.21
-31.49	56.14	-47.45
-39.26	-32.51	18.07
-22.96	-25.19	56.3
41.86	40.62	34.42
-48.9	41.82	44.29
50.25	7.09	-.78
-42.75	34.8	8
40.67	-10.14	-2.57
-35.11	0.29	15.27
7.69	61.53	46.44
-18.08	60.09	30.13
2.47	23.18	46.37
-2.81	13.97	51.67
25.03	31.2	65.52
-31.71	31.95	52.72
37.57	45.88	34.03
-45.69	40.78	44.34
16.92	0.44	-28.83
-20.57	-1.87	-41.59
29.95	-7.29	-6.03
18.73	-22.65	57.84
-32.61	-25.68	50.87
-2.75	-45.9	34.38
6.43	-18.43	-10.4
35.48	38.64	36.89
-20.01	33.62	45.76
50.23	9.12	-2.06
-67.23	30.22	19.82
37.55	-5.96	10.5
-36.22	-3.49	7.79
24.61	72.95	27.45
-16.78	61.36	60.12
12.14	22.69	53
-3.88	39.23	61.83
19.69	28.97	64.65
-21.99	28.72	65.15
-35.54	13.36	-36.01
-25.79	14.78	-18.39
-16.89	-8.94	18.07
-30.92	3.78	4.89
51.6	-41.57	16.67
-54.28	-35.49	8.45
3.54	-42.66	20.66
10.82	-45.81	-7.04
60.02	20.84	24.72
47.1	17.62	11.76
38.5	-17.1	-9.77
26.74	66.28	23.52
5.78	29.77	62.51
30.31	20.68	52.96
5.65	-11.13	29.14
38.75	47	48.42
51.27	-6.53	-11.92
21.23	8.46	-21.75
25.42	13.18	-30
9.58	22.71	-1.62
18.14	19.59	-1.46
19.32	-19.96	-3.73
21.36	-7.77	-11.47
12.52	48.51	-26.12
5.72	-45.48	25.33
-56.42	24.97	33.52
-54.39	26.07	20.02
-33	-25.3	0.66
-4.1	74.24	46.63
-8.08	14.62	60.6
-18.8	17.56	58.24
-10.4	8.33	34.39
-65.09	43.35	24.27
-41.83	-23.86	-35.04
-29.09	32.48	-23.19
-6.43	26.13	2.74
-18.22	26.77	-1.64
-19.09	-16.24	6.44
-20.23	-14.74	-1.48
-26.07	61.34	-35.68
-2.51	31.19	-42.34
31.3	46.24	53.03
-38.22	32.02	40.52
51.36	22.93	11.26
-39.45	30.3	18.38
40.68	3.15	4.12
-39.43	-5.79	5.79
12.88	69.8	28.96
-16.91	55.58	40.53
3.6	34.79	58.77
-2.64	-5.18	65.54
27.14	29.81	61.15
-26.33	27.92	55.23
6.73	1.11	35.91
-7.25	28.69	35.99
43.95	67.58	38.83
-45.75	51.18	41.23
27.64	0.84	-24.53
-25.78	3.95	-20.83
46.96	-6.99	-17.4
-48.12	-14.96	-15.64
21.15	23.1	-25.21
-26.94	32.67	-21
18.11	24.7	-4.12
-15.85	-15.88	10.83
-22.42	2.26	-1.77
48.74	47.61	-40.96
-20.7	48.43	-38
-4.59	32.92	-33.54
32.33	42.56	46.64
-31.93	34.03	24.67
56.7	31.68	13.81
-60.8	16.17	16.46
45	10.2	12.4
-42.73	42.71	14.03
22.76	54.99	56.86
-21.18	53.44	40.76
8.99	-12.99	45.99
-4.92	32.88	62.37
28.19	29.65	58.92
-41.34	19.66	46.06
7.77	21.64	39.75
-6.21	25.1	30.7
59.98	40.21	27.56
-36.23	63.41	33.41
-25.79	0.52	-23.89
44.72	-9.17	-31.69
-56.69	-7.52	-15.05
-21.54	28.81	-16.27
41.27	47.65	-39.76
-26.19	79.86	-43.92
-3.44	28.32	-24.25

// Gopinath K, 2012: Sydrome 1 (Syn 1)
// Subjects=11
41.86	40.62	34.42
-48.9	41.82	44.29
50.25	7.09	-.78
-42.75	34.8	8
40.67	-10.14	-2.57
-35.11	0.29	15.27
7.69	61.53	46.44
-18.08	60.09	30.13
2.47	23.18	46.37
-2.81	13.97	51.67
25.03	31.2	65.52
-31.71	31.95	52.72
37.57	45.88	34.03
-45.69	40.78	44.34
16.92	0.44	-28.83
-20.57	-1.87	-41.59
29.95	-7.29	-6.03
18.73	-22.65	57.84
-32.61	-25.68	50.87
-2.75	-45.9	34.38
6.43	-18.43	-10.4
31.3	46.24	53.03
-38.22	32.02	40.52
51.36	22.93	11.26
-39.45	30.3	18.38
40.68	3.15	4.12
-39.43	-5.79	5.79
12.88	69.8	28.96
-16.91	55.58	40.53
3.6	34.79	58.77
-2.64	-5.18	65.54
27.14	29.81	61.15
-26.33	27.92	55.23
6.73	1.11	35.91
-7.25	28.69	35.99
43.95	67.58	38.83
-45.75	51.18	41.23
27.64	0.84	-24.53
-25.78	3.95	-20.83
46.96	-6.99	-17.4
-48.12	-14.96	-15.64
21.15	23.1	-25.21
-26.94	32.67	-21
18.11	24.7	-4.12
-15.85	-15.88	10.83
-22.42	2.26	-1.77
48.74	47.61	-40.96
-20.7	48.43	-38
-4.59	32.92	-33.54

// Gopinath K, 2012: Syndrome 2 (Syn 2)
// Subjects=16
35.48	38.64	36.89
-20.01	33.62	45.76
50.23	9.12	-2.06
-67.23	30.22	19.82
37.55	-5.96	10.5
-36.22	-3.49	7.79
24.61	72.95	27.45
-16.78	61.36	60.12
12.14	22.69	53
-3.88	39.23	61.83
19.69	28.97	64.65
-21.99	28.72	65.15
-35.54	13.36	-36.01
-25.79	14.78	-18.39
-16.89	-8.94	18.07
-30.92	3.78	4.89
51.6	-41.57	16.67
-54.28	-35.49	8.45
3.54	-42.66	20.66
10.82	-45.81	-7.04
32.33	42.56	46.64
-31.93	34.03	24.67
56.7	31.68	13.81
-60.8	16.17	16.46
45	10.2	12.4
-42.73	42.71	14.03
22.76	54.99	56.86
-21.18	53.44	40.76
8.99	-12.99	45.99
-4.92	32.88	62.37
28.19	29.65	58.92
-41.34	19.66	46.06
7.77	21.64	39.75
-6.21	25.1	30.7
59.98	40.21	27.56
-36.23	63.41	33.41
-25.79	0.52	-23.89
44.72	-9.17	-31.69
-56.69	-7.52	-15.05
-21.54	28.81	-16.27
41.27	47.65	-39.76
-26.19	79.86	-43.92
-3.44	28.32	-24.25

// Engel A, 2012: VpresAtrain > VpresUntrain
// Engel A, 2012: VpresAtrain > VpresVtrain
// Engel A, 2012: Finger Movements > Eye Movements
// Subjects=22
-45	-1	7
-9	38	22
-21	8	-11
12	47	13
-12	26	49
-33	29	40
36	-4	10
24	-55	-23
-9	59	16
-27	-19	-5
9	20	4
-18	-43	40
21	-25	-11
-30	47	28
-18	2	61
30	-43	-2
-21	56	10
63	-22	40
30	32	-5
-63	-25	31
12	-70	46
18	2	55
6	14	49
12	20	37
-57	5	34
-48	2	19
54	11	19
-18	2	58
45	-37	37
33	-1	55
-3	-25	-2
-36	-31	49
-39	-28	49
-39	-34	34
-24	-49	61
-45	-25	13
-27	-13	61
-60	8	7
-45	2	4
-54	5	4
21	-55	-23
39	-37	43
51	-25	43
57	-16	40
57	14	34
12	-67	46
-30	32	31
48	-67	-17
39	50	22

// Herholz S C, 2012: Listen > Baseline
// Herholz S C, 2012: Imagine > Baseline
// Herholz S C, 2012: Conjuntion of (Listen > Baseline and Imagine > Baseline)
// Herholz S C, 2012: Listen > Imagine
// Herholz S C, 2012: Imagine > Listen
// Herholz S C, 2012: Previously Listened > Baseline
// Herholz S C, 2012: Previously Imagined > Baseline
// Herholz S C, 2012: Conjunction of (Previously Listened > Baseline and 
// Previously Imagined > Baseline)
// Subjects=10
-62	-16	4
46	-16	0
-58	0	44
-6	-78	10
-8	4	58
54	0	48
-46	-64	-18
-56	2	42
-2	10	58
54	-14	-10
-36	-60	58
54	0	48
56	16	-18
-16	-76	-12
-56	2	42
54	-14	-10
-52	8	-12
-8	4	58
54	0	48
52	6	-14
-8	-80	10
-40	-26	4
52	-12	2
2	-62	20
2	12	48
46	14	-4
34	-50	50
-56	-54	30
-32	44	28
-34	-54	-32
-36	16	-2
-6	-92	2
-32	20	-6
-4	32	36
46	20	20
30	20	-10
34	-70	-50
-56	-34	2
-38	-58	44
-6	-96	4
-40	8	28
-8	20	40
32	22	-4
46	20	20
-6	-92	2
-38	10	26
-8	20	40
30	20	-10
46	20	20
32	-66	-52
-38	-56	44
-2	-50	10
8	-60	0

// Kung S, 2013: Find Beat > Silence
// Kung S, 2013: Find Beat > Listen Iso
// Kung S, 2013: Tap Beat > Tap Iso
// Kung S, 2013: Listen Iso > Silence
// Kung S, 2013: Tap Iso > Silence
// Kung S, 2013: (Find Beat > Listen Iso) AND (Tap Beat > Tap Iso)
// Subjects=11
-64	-40	16
-38	-34	14
-48	-20	2
-48	-34	12
-62	-28	8
62	-34	10
62	-26	6
54	-22	6
42	-36	14
-30	22	-2
32	22	0
34	20	8
-14	10	-2
18	14	8
-46	8	20
-54	12	6
50	14	24
50	12	20
-30	-62	-50
-24	-68	-46
30	-64	-50
-28	-64	-26
-32	-58	-28
42	-58	-30
36	-64	-26
-12	-76	-34
-4	4	60
-4	16	44
4	12	52
-30	-50	40
-44	-10	-8
-52	-2	-2
-64	-10	4
-28	22	-2
34	22	-2
50	20	-4
-14	8	0
18	10	0
56	12	4
-2	22	42
4	14	48
12	32	22
54	-22	6
50	-30	8
-32	22	-2
34	22	-2
40	16	-2
54	18	-6
40	26	22
34	20	16
-42	6	26
48	8	22
54	12	6
-54	12	-6
-28	-66	-50
-32	-60	-40
30	-62	-56
-12	-2	12
8	-6	12
-64	-40	16
-52	-40	20
-40	-36	14
62	-34	12
42	-40	12
-28	-62	-50
26	-64	-50
42	-54	-32
-10	-74	-36
10	-78	-78
-40	-36	16
62	-34	12
42	-36	14
-38	-22	52
-46	-16	54
52	-2	52
-4	0	62
-26	-58	-24
24	-62	-52
12	-54	-18
6	-66	-16
-20	-8	-2
16	20	4
-30	22	-2
34	22	-2
50	18	-6

// Park M, 2014: Music >  Baseline
// Park M, 2014: Musicians > Non-musicians (Sadness)
// Park M, 2014: Musicians > Non-musicians (scary)
// Subjects=12
60	-18	10
-50	-24	2
22	4	34
44	-32	46

// Petrini K, 2011: Audio > Baseline
// Petrini K, 2011: Visual > Baseline
// Petrini K, 2011: Audiovisual > Baseline
// Subjects=16
54.56	-4.51	0.14
36.35	23.47	5.81
6.67	-80.82	-5.17
9.04	-99.27	17.54
-10.58	-16.62	0.79
-17.01	6.23	7.87
-25.51	-72.35	-16.67
-29.35	-61.32	43.79
-34.15	19.96	8.03
-31.53	-14.5	57.73
-36.83	-36.1	54.03
-43.81	5.21	-2.89
42.97	-72.14	-6.32
38.51	-43.33	-18.72
36.34	25.5	4.53
20.72	-96.63	9.37
5.54	-83.63	-13.85
-10.57	-13.19	3.85
-22.03	-93.71	9.62
-22.96	-78	33.96
-26.59	-71.39	-17.85
-41.46	-76.08	-8.36
-37.92	-34.08	52.76
-31.53	-14.5	57.73
-29.35	-61.32	43.79
-57.41	6.01	36.23
56.78	-20.19	3.66
18.35	-80.38	-14.27
35.32	-46.52	-18.41
20.71	-95.66	8.18
13.97	-11.27	-1.05
-11.64	-16.54	1.91
-18.8	-99.95	11.22
-24.21	-86.41	7.92
-30.42	-61.33	43.8
-31.54	-12.38	57.55
-41.48	-78.45	-11.51
-37.92	-38.48	50.89
-36.28	-1.89	0.97
-37.9	-26.25	57.67

// Schon D, 2010: Speech > Noise
// Schon D, 2010: Vocalise > Noise
// Schon D, 2010: Song > Noise
// Schon D, 2010: Song > Speech
// Schon D, 2010: Song > Vocalise
// Schon D, 2010: Vocalise > Speech
// Subjects=10
-57.39	-2.67	-11.19
-62.81	-14.86	-15.02
-65.98	-26.41	-12.06
53.76	10.93	-21.15
62.59	-2.89	-8.73
-57.43	-2.98	-14.52
-51.09	9.08	-23.66
-59.42	-8.33	-2.75
57.12	8.58	-12.01
45.05	9.32	-26.45
57.16	-6.41	-11.65
56.48	14.03	23.32
-47.9	-5.12	53.89
-56.11	16.33	8.2
50.53	5.6	-20.57
59.28	8.59	-12.05
53.84	-2.69	-17.56
-41.44	6.37	-30.28
-56.36	0.22	-14.85
-53.76	24.28	24.18
53.22	18.27	22.96
65.8	-20.62	-14.87
65.91	-14.37	-5.41
55.96	11.25	-17.86
15.12	-14.65	-5.63
-62.82	-9.48	-14.9
-53.12	0.23	-14.91
-56.2	-15.01	-5.51
-65.87	-35.46	-5.56
-62.74	-8.86	-8.24
-65.84	-23.14	-0.05
53.88	-17.68	-17.2
62.5	2.97	-14.91
-41.83	14.85	26.03
-47.09	8.22	35.74
-20.78	-11.12	-23.3
-42.47	33.03	-20.58
-44.28	26.9	5.83
20.72	-59.1	0.91
17.6	-53.82	11.64
6.24	-5.06	63.04
-8.89	-2.98	63.1
50.35	-1.89	48.53
-50.09	0.19	53.4
38.61	-5.26	59.15
-41.44	0.22	53.25
-41.84	6.03	23.54
-59.37	11.75	5.35

// Schulze K, 2011: Healthy Musicians
// Subjects=16
46.85	29.22	-17.09
47.41	8.73	48.19

// Schulze K, 2011: Healthy Volunteers
// Subjects=17
-.76	25.1	44.02
-.6	10.27	58.64
-45.77	30.15	30.73
-52.44	17.51	-8.28
-45.89	35.47	16.9
-33.19	27.66	-2.66
-32.65	0.3	56.5
-52.16	10.56	25.76
-51.94	-6.93	47.29
-42.13	-37.82	59.81
-35.85	-35.9	42.85
-26.17	-51.7	44.06
-7.36	-49.35	-9.88
-17.05	-50.18	-19.74
-36.21	-69.33	-17.91
37.91	-8.79	56.45
37.72	2.35	35.45
50.6	-.23	42.21
44.26	-25.9	41.09
24.7	-68.96	-18.64
18.18	-76.63	-34.65
11.7	-37.83	-27.79
-7.27	24.03	30.8
-3.81	10.25	58.68
-42.87	30.26	-9.46
-52.45	40.49	-.17
-48.71	-6.65	50.58
-39.21	-1.28	36.64
-58.52	4.44	29.69
-61.84	6.56	16.17
-48.62	-28.86	52.44
-35.86	-32.72	42.58

// Schulze K, 2011: Healthy Musicians
// Subjects=16
-52.28	9.28	9.14
-29.94	21.59	1.16
-26.17	-12.09	60.81
-26.25	3.51	56.16
-48.86	8.18	35.95
-32.85	4.85	32.7
-55.01	-35.24	53.05
-48.5	-40.78	63.48
-35.73	-47.81	53.88
-29.29	-60.72	51.55
-19.57	-62.81	64.99
-20.16	-6.39	10.08
15.17	17.57	27.74
5.78	10.05	55.24
34.15	21.71	-2.94
31.42	0.17	49.09
9.19	-24.05	68.1
34.86	-23.64	71.12
34.72	-25.19	51.18
27.93	-68.69	-15.36
-16.89	23.98	30.92
-26.76	44.33	5.9
-58.72	8.98	5.89
-29.97	24.5	-2.43
-36.3	15.46	5.09
-45.82	29.63	24.08
-46.05	50.3	2.28
-52.13	17.42	31.87
-26.28	3.26	52.84
-48.76	-7.17	43.93
-48.85	5.01	36.22
-32.87	4.59	29.38
-35.68	-47.3	60.53
-19.59	-63.07	61.67
-26.39	-70.39	8.83
-26.57	-6.43	10.16
-20.1	-71.63	-7.87
-17.04	-40.15	-13.89
-16.98	-56.01	-12.56
-23.5	-47.3	-23.25
2.59	6.86	55.55
28.33	-5.16	62.95
37.92	-11.96	56.72
60.18	2.75	38.5
2.74	-27.78	61.8
21.41	-7.17	-3.71
18.36	0.95	19.06
5.59	-84.17	-7.11
31.18	-74.76	-11.54
47.14	-68.83	-18.91

// Spada D, 2014: Melody as the upper voice minus melody as the lower voice 
// (cMcA_S - cMcA_B)
// Spada D, 2014: Melody as the lower voice minus melody as the upper voice 
// (cMcA_B - cMcA_S)
// Spada D, 2014: Correct melody minus altered melody
// Spada D, 2014: Altered melody minus correct melody
// Spada D, 2014: Correct melody/Correct accompaniment minus Altered 
// melody/Altered accompaniment (cMcA - aMaA)
// Spada D, 2014: Correct melody/Altered accompaniment minus Altered 
// melody/Correct accompaniment (cMaA - aMcA)
// Spada D, 2014: 2x2 interaction between violations in melody and violations 
// in accompaniment
// Subjects=20
14	-48	24
-12	-54	28
10	-40	16
6	-46	36
24	50	8
24	58	20
2	42	0
-24	46	16
66	-16	4
14	-42	8
20	-64	20
22	-52	8
14	-56	-4
-20	-48	4
-10	-54	8
54	34	0
-36	-20	56
-26	-18	64
-32	-22	52
8	-2	52
-10	-6	60
16	-46	8
22	-52	8
12	-48	32

// Trost W, 2014: Consonant > Dissonant
// Trost W, 2014: Visual cues during consonant > Dissonant music
// Trost W, 2014: Visual cues during dissonant > Consonant music
// Trost W, 2014: Visual cues during strong > Weak beats
// Trost W, 2014: Visual cues during strong > Weak beats in consonant music
// Trost W, 2014: Visual cues during weak > Strong beats in consonant music
// Trost W, 2014: Visual cues during strong > Weak beats in dissonant music
// Trost W, 2014: Interaction between Strong/Weak Beat in Consonant/Dissonant 
// Music
// Subjects=18
8	8	4
-6	-40	76
-28	-34	70
-26	-24	70
-8	-20	62
-22	-16	56
-10	-12	60
-40	-4	32
38	-58	46
28	-2	-32
-28	-86	20
42	-74	18
-10	16	6
14	16	6
12	-56	26
12	-56	26
56	-18	-12
46	20	20
-38	20	24
-12	16	4
14	16	8
-46	-28	-4
-42	-22	-2
-14	16	6
16	16	8
34	28	6
38	18	8
-46	-30	-4
-14	-16	-4
-52	-24	18
18	-68	42

// Vuust P, 2011: Tap Counter Meter (TapC) > Tap Main Meter (TapM)
// Vuust P, 2011: Tap > Listen
// Vuust P, 2011: Listen > Tap
// Subjects=18
-42	42	-4
12	10	38
8	22	32
34	-56	-40
0	-64	-22
22	-58	-34
-14	-8	14
-4	-10	62
-52	-8	44
-58	-22	44
-46	-22	50
-48	8	0
-38	16	-10
16	-2	10
-2	4	46
8	-46	28
22	-64	64
8	-68	44
10	-60	46
-2	-58	46
36	-84	22

// Logie R H, 2011: Mental rotation > Control
// Logie R H, 2011: High imagers > Low imagers
// Logie R H, 2011: Low imagers > High imagers
// Logie R H, 2011: Control > Mental rotation
// Subjects=10
-26	0	62
26	0	64
-40	10	-4
42	-18	20
4	-86	12
-10	-64	-4
56	-28	30
60	0	-8
60	-46	-16
26	14	-18
0	-4	66
6	-18	34
18	-42	-6
-52	-50	0
-2	-22	-16
36	-54	22
16	2	58
-20	10	44
40	-64	-36
-32	-42	46
-44	-56	-6
24	38	18
42	-6	44
-20	6	68
-6	-80	18
16	-78	22
58	-30	-8

// Manber T, 2012: Maintain > Reappraise: Healthy Controls > Generalized 
// Anxiety Disorder (GAD) and Panic Disorder (PD)
// Manber T, 2012: Maintain > Baseline: Healthy Controls (HC) > PD = GAD
// Manber T, 2012: Maintain > Baseline: HC > PD > GAD
// Manber T, 2012: Maintain > Baseline: HC = PD > GAD
// Manber T, 2012: Maintain > Baseline: HC > GAD > PD
// Manber T, 2012: Reappraise > Baseline: HC > PD = GAD
// Manber T, 2012: Reappraise > Baseline: HC > PD > GAD
// Subjects=18
-43.29	-25.65	52.11
-9.27	38.68	55.25
12	20.18	34.25
-43.37	4.3	54.06
-30.82	23.47	25.54
46.47	1.29	62.2
-43.71	22.7	16.83
67.39	14.22	7.35
50.09	3.26	-22.76
-56.45	-46.76	0.5
-4.99	-44.74	22.05
-30.84	-64.55	-11.68
-31.07	25.3	-5.83
-35.26	-44.12	-22.27
37.44	-60.94	-26.15
20.31	-61.39	-30.38
-5.29	35.62	15.31
45.74	41.99	-17.04
42.13	-34.63	38.5
24.92	-88.57	3.07
-26.66	-74.36	-28.75
67.54	-45.68	3.45
-52.04	-45.36	18.18
-51.7	-54.97	59.13
-47.87	-63.97	-2.61
-39.28	6.84	31.5
63.23	19.8	24.77
37.61	11.19	25.79
-9.25	34.45	55.6
-35.23	-52.58	-21.56
33.57	-87.49	16.27
-22.34	-78.22	-24.02

// Blair K S, 2011: Diagnosis-by-emotion interaction, (Patients > Controls: 
// Angry = Fearful > Neutral)
// Blair K S, 2011: Diagnosis main effect, Controls > Patients
// Blair K S, 2011: Emotion main effect, (Angry = Fearful > Neutral)
// Blair K S, 2011: Age main effect, Adults > Adolescents
// Subjects=14
8.33	47.22	-14.82
-28.98	-2.67	-23.58
12.17	-98.96	7.44
62.27	14.31	36.4
6.8	11.74	49.51
-17.17	0.2	-15.04
28.74	1.19	-20.11
18.29	-28.34	-1.9
49.43	-85.85	-5.24
-32.81	-91.46	-1.6
30.45	-63.59	36.6
-6.61	25.3	-21.73
-51.36	37.41	1.19
-56.35	6.99	35.03
65.39	13.47	25.28
1.37	8.57	36.46
57.11	-10.16	50.77
54.85	-82.85	5.6
-65.95	-70.88	5.98
-14.85	-52.83	-12.85

// Bruhl A B, 2011: Expectation Negative > Expectation Neutral, Social Anxiety 
// Disorder (SAD) > Healthy Controls (HC)
// Bruhl A B, 2011: Expectation Unknown > Expectation Neutral, SAD > HC
// Bruhl A B, 2011: Expectation Negative > Expectation Neutral, HC > SAD
// Bruhl A B, 2011: Expectation Unknown > Expectation Neutral, HC > SAD
// Subjects=14
7.61	40.87	26.99
-11.44	26.18	45.17
-17.74	-31.99	36.74
-53.24	-31.34	6.98
55.81	-59.75	1.42
52.24	12.16	-17.96
-52.91	-50.97	42.08
14.26	-98.32	1.78
7.58	-81.38	-26.32
-4.95	-98.18	5.34
-43.69	-81.43	-22.39
-27.55	-70.28	-3.43
4.46	-30.99	6.29
4.36	-9.04	1.1
-40.58	-36.23	-16.18
-17.94	-7.64	21.31
-18.23	-4.12	-15.78
55.84	-66.09	1.95
33.31	-70.43	-10.81
-27.57	-70.54	-6.76
-43.77	-32.82	-13.08
-40.81	47.02	-13.12
-21.53	54.25	-3.91

// Gorka S M, 2014: Group x Valence Interaction: Unpredictable (U) Conditions
// Gorka S M, 2014: Group x Valence Interaction: Predictable (P) Conditions
// Gorka S M, 2014: Main Effect of Group: U Conditions
// Gorka S M, 2014: Main Effect of Group: P Conditions
// Gorka S M, 2014: Main Effect of Valence: U Conditions
// Gorka S M, 2014: Main Effect of Valence: P Conditions
// Subjects=9
14	-16	58
-36	-2	18
34	-20	20
-16	-4	54
2	0	-18
-28	-42	42
-46	-54	-10
-8	-40	34
-20	-84	-32
-18	-80	-4
54	18	40
36	22	-18
-42	6	58
6	44	42
4	-98	6
22	-4	28
24	-50	-38

// Klumpp H, 2013: Main effect of group: Generalized Social Anxiety Disorder 
// Patients (gSAD) > Healthy Controls
// Klumpp H, 2013: Main effect of emotion: Match Faces > Match Shapes
// Klumpp H, 2013: Group X Emotion Interaction
// Subjects=27
-30	-98	-4
28	-86	4
-64	-42	32
8	-16	52
-34	-14	-12
-36	10	26
-18	32	54
16	-16	24
22	0	24
40	-2	62

// Klumpp H, 2012: Generalied Social Anxiety Disorder Patients > Healthy 
// Controls: Fearful > Happy faces, p<0.005
// Klumpp H, 2012: Generalied Social Anxiety Disorder Patients > Healthy 
// Controls: Fearful > Happy faces, p<0.05
// Subjects=26
58	10	36
-54	16	32
-40	20	-4
38	24	-4
-28	-68	52
-4	0	10
-52	-22	36
-2	24	46
24	-54	-8
48	-48	-30
-22	-12	-12
14	2	-20

// Aue T, 2013: Correlations between gaze duration and BOLD contrast, Spider 
// pictures > Bird pictures
// Subjects=17
-12	41	-2
15	32	-5
-3	-76	28
-13	18	12
0	-49	64
-45	-61	10

// Caseras X, 2010: Spider Phobics
// Subjects=14
36	-50	46
44	-66	-28
8	12	28
-16	-62	48
-4	18	24
-54	8	26
-20	4	-24
46	-2	48
14	-10	-22
62	20	12
-46	-12	52
-42	-10	38
6	12	38
-42	-14	20
-30	-2	48

// Caseras X, 2010: Blood Injection Injury (BII) Phobics
// Subjects=15
-50	12	-12
48	12	-6
-2	30	22
-2	36	18
10	34	14
-36	16	-16
-8	-72	24
-64	-52	34
-8	-78	36
52	-50	30
16	-68	30
10	-74	22
12	-78	34
-38	-58	34

// Caseras X, 2010: Healthy Controls
// Subjects=17
36	-50	46
44	-66	-28
8	12	28
-16	-62	48
-4	18	24
-54	8	26
-20	4	-24
46	-2	48
14	-10	-22
62	20	12
-46	-12	52
-42	-10	38
6	12	38
-42	-14	20
-30	-2	48
-50	12	-12
48	12	-6
-2	30	22
-2	36	18
10	34	14
-36	16	-16
-8	-72	24
-64	-52	34
-8	-78	36
52	-50	30
16	-68	30
10	-74	22
12	-78	34
-38	-58	34

// Gaebler M, 2014: Aversive pictures > Neutral pictures, Social Anxiety 
// Disorder (SAD) > Healthy Controls (HC)
// Subjects=21
-54	-39	27
-63	-48	24
-63	-30	18
-15	-18	42
-12	-30	39
57	-30	21
39	-33	21
57	-30	3

// Palm M E, 2011: Generalized Anxiety Disorder (GAD) Patients
// Subjects=15
10.73	69.1	6.32
7.51	49.52	3.83
49.89	-15.21	9.52
-37.51	-13.62	19.81
33.14	29.9	-23.8
-47.83	34.39	-17.26
-8.96	46.43	-16.87
16.91	65.77	-18.11
-15.43	69.47	-11.2
-31.37	52.79	6.41
17.32	63.36	13.5
39.73	31.82	-15.13
-50.72	31.55	9.96
4.29	49.72	6.11

// Palm M E, 2011: Healthy Controls
// Subjects=16
46.21	38.43	-13.66
-47.83	34.39	-17.26
46.09	26.55	-25.93
-47.69	25.64	-7.43
4.86	14.55	43.2
39.81	61.99	-2.43
-34.47	48.39	16.99
-8.36	24.64	25.61
46.29	12.69	-13.35
-41.13	-8.78	-8.62
36.5	-4.23	-21.6
-31.47	-9.27	-14.34
33.14	29.9	-23.8
-47.83	34.39	-17.26
-8.96	46.43	-16.87
16.91	65.77	-18.11
-15.43	69.47	-11.2
-31.37	52.79	6.41
17.32	63.36	13.5
39.73	31.82	-15.13
-50.72	31.55	9.96
4.29	49.72	6.11

// Schlund M W, 2012: Angry sentences: Major depressive disorder with comorbid 
// anxiety (MDD/GAD) > Healthy Controls (HC)
// Schlund M W, 2012: Angry sentences: HC > MDD/GAD
// Schlund M W, 2012: Happy sentences: MDD/GAD > HC
// Schlund M W, 2012: Happy sentences: HC > MDD/GAD
// Schlund M W, 2012: Sad sentences: MDD/GAD > HC
// Schlund M W, 2012: Sad sentences: HC > MDD/GAD
// Schlund M W, 2012: Angry faces: HC > MDD/GAD
// Schlund M W, 2012: Happy faces: MDD/GAD > HC
// Schlund M W, 2012: Happy faces: HC > MDD/GAD
// Schlund M W, 2012: Sad faces: HC > MDD/GAD
// Subjects=10
-16.29	-54.71	-19.07
-27.13	-34.23	-17.55
-35.33	-19.99	20.41
-39.73	-28.28	12.34
-22.84	25.73	-7.86
-48.86	-35.24	-27.16
-11.78	4.68	7.48
27.04	37.14	8.09
24.74	43.75	-1.49
-22.42	31.08	26.34
-1	-42.47	-3.73
-.91	-28.67	6.11
27.27	33.38	25.26
-2.84	29.96	36.2
-33.68	-4.16	-17.05
-11.6	-72.73	6.17
23.25	-67.23	28.56
29.66	-61.24	23.38
34	-56.66	26.21
22.7	-19.95	-5.24
29.23	-20.67	-1.92
7.64	-35.95	-3.4
-22.75	39.53	1.97
27.3	33.59	27.48
27.11	35.43	12.74
-15.63	12.56	45.98
-24.34	7.65	39.89
-9.59	3.83	9.77
-41.81	7.3	25.66
46.57	-26.79	0.63
24.8	36.51	1.46
26.97	30.03	0.95
25.14	33.58	27.52
-39.46	-28.44	33.64
38	-24.07	7.23
-31.1	35.1	23.85
-35.56	30.75	12.03
21.11	-.39	43.28
-9.4	-44.03	14.5
-14.19	50.95	-2.66
-28.56	-49.57	36.66
5.7	-83.51	4.7
14.48	-85.73	14.86
7.82	-57.56	6.58
16.48	-72.73	4.57
10.29	-23.49	37.9
35.93	18.21	23.26
-41.62	-28.45	33.68
38.43	-27.44	40.06
-31.35	28.87	3.18
-35.42	35.08	23.92
18.45	30.94	11.09
21.11	-.39	43.28

// Ziv M, 2013: Social Anxiety Disorder (SAD) patients
// Subjects=12
-35.23	28.67	10.66
1.28	23.03	30.79
-32.3	55.44	-15.04
4.92	-82.26	45.15
-50.48	28.84	-27.1
-68.32	-20.57	-3.79
-1.65	18.18	64.68
-54.24	0.15	28.88
59.79	-2.42	-14.59
-21.34	5.69	1.28
48.95	22.29	-24.34
-57.75	34.28	2.64
-68.35	-13.17	-4.41
-13.9	-13.35	-11.71
16.19	-11.46	10.09
41.56	7.79	-18.58
-57.73	-10.53	-12.56
-24.4	-71.92	-11.14
4.48	-71.49	-8.16
26.92	-79.01	-11.13
-28.84	-13.27	-9.31
-6.2	-79.21	-10.74
26.79	-53.98	-17.69
19.37	-61.08	-12.55
-1.68	17.92	61.36
-49.83	12.55	51.21
19.98	-51.48	70.28
26.85	-45.72	-7.23
-60.75	-11.92	11.01
-1.66	13.69	61.72
-57.73	27.94	3.17
-42.35	12.59	51.12

// Ziv M, 2013: Healthy Controls
// Subjects=13
-35.23	28.67	10.66
1.28	23.03	30.79
-32.3	55.44	-15.04
-1.86	-59.75	6.54
-1.62	10.78	65.3
-57.27	1.93	52.19
-68.03	-48.38	21.96
-57.64	-17.33	-4.18
-54.64	26.76	-12.38
-64.94	-34.15	12.92
44.99	-23.86	-1.47
-54.62	14.87	-14.72
67.47	7.42	15.72
-57.72	-6.04	-9.59
-24.4	-71.92	-11.14
4.48	-71.49	-8.16
26.92	-79.01	-11.13
-28.84	-13.27	-9.31
-6.2	-79.21	-10.74
26.79	-53.98	-17.69
19.37	-61.08	-12.55
-1.86	-59.75	6.54
31.59	-11.23	66.77
-1.62	18.52	69.12
-54.09	9.35	51.53
-64.82	-59.27	18.38
-46.85	25.57	26.67
27.44	-51.7	66.86
-23.83	-73.75	61.5
-57.81	27.08	-7.91
-1.8	12.23	42.88
31.47	-72.9	26.22
-67.71	-183.41	9.86
-32.14	53.81	5.17
-31.54	-91.51	25.16
-50.22	12.92	1
-24.01	-19.57	60.3
-2.02	-1	9.42
-49.68	-60.56	41.73
-39.07	-54.75	33.31
-32.03	-9.78	-5.11
-54.31	-34.69	5.04
-60.75	-11.92	11.01
-1.65	18.18	64.68

// Kattoor J, 2013: Pain > Baseline
// Kattoor J, 2013: CS+ > CS- (Early Acquisition, Anticipatory)
// Kattoor J, 2013: CS+ > CS- (Late Acquisition, Anticipatory)
// Kattoor J, 2013: CS+> CS- (Extinction)
// Kattoor J, 2013: CS- > CS+ (Extinction)
// Subjects=21
-34	0	12
-32	8	2
42	10	-6
32	8	8
-62	-34	32
-62	-24	26
62	-28	40
-50	-32	26
60	-38	48
62	-24	30
-48	0	10
-24	34	12
-38	44	32
44	50	14
4	-52	70
2	30	-2
-2	28	-2
4	-54	18
4	-90	16
-32	12	-28
50	-14	6
42	-6	-20
44	-28	-14
28	6	-12
-28	-24	6
26	8	-10
22	-70	-12
-40	-46	-24
-28	-62	-16
20	-70	-12
16	-68	-12
32	-66	-18
-18	-50	-16
-20	-76	-20
-38	-50	-26
6	-72	-10
-22	-50	-26
24	2	-22
12	24	26
26	-66	26
-18	-80	50
-26	-70	40
-48	-46	6
-28	-36	0
-22	12	10
-40	-24	22
32	6	46
-20	36	-16
-6	-58	34
26	12	46
-6	58	40
-10	48	22
4	54	46
4	42	24

// Balodis I M, 2013: Binge Eating Disorder (BED)
// Subjects=19
45	30	9
-30	-99	12
9	6	24
-18	-18	39
33	-45	9
-9	-93	33
3	0	63
39	-87	30
-12	-72	12
36	-54	-15
24	24	21
-39	-57	-9
63	-30	24
-69	-33	30
0	21	24
-6	54	12
21	3	-12
-33	-90	-9
27	-84	-12
-21	-21	54
54	36	21
-42	-6	0
-24	-57	9
-48	-75	36
15	-27	-15
-42	12	15
39	21	15
39	-12	45
3	-84	-12
-45	12	15
30	-81	-15
-18	-66	3
27	12	-3
48	-78	33
33	-96	6
15	-21	48
45	-30	18
-33	-96	6
-60	3	30
-42	-12	63
45	-51	-15
-15	-69	-6
3	-15	-21
39	-48	54
51	-30	12
-36	-54	48
12	51	-24
-63	6	21
9	-9	51
-33	-96	0
-45	-3	57
-24	-72	15
45	12	-6
33	-72	-3
-36	-84	0
-57	-48	3
-24	-51	0
6	15	36
-39	6	33
-54	-36	-6
-39	-63	54
-33	-21	57
-24	-48	18
42	15	-6
-24	6	-15
12	-78	-27
-15	-39	12
-6	-90	-30
15	-51	3
-66	-12	-12
42	-87	21
-54	-6	15
-9	-60	-24
-63	-6	-15
24	-21	33
-24	-33	9
-57	33	-6
3	51	21
42	-84	18
-30	15	-15
33	15	-9
-63	-60	27
3	-57	-36
45	27	45
-27	-78	-39
66	-54	30
9	-51	36
66	-54	30
51	-24	-12
3	-63	3
24	-24	33
-27	-57	3
-6	63	30
-39	-15	15
-27	-54	-3
-51	-78	-6
-18	-12	66
-57	9	36
21	-51	-15
54	-69	30
-12	-82	43
3	-63	24
-51	-38	21
-24	-21	66
-36	-15	15
-54	12	30
-42	-84	-6
-45	9	30
-18	-42	9
3	-66	-15
42	6	-12
-42	-84	-9
21	-42	63
3	-66	-15

// Balodis I M, 2013: Obese
// Subjects=19
-54	-36	-24
45	-6	60
-3	-69	-39
-39	-15	33
9	-72	-3
-51	-81	21
-3	-9	51
27	42	-21
-39	-18	-27
54	-12	21
-18	-51	-27
-57	-42	21
0	-72	-18
-6	0	54
-39	-15	36
21	33	-24
-42	30	12
-18	-21	42
9	-3	-3
-24	-42	21
-24	33	-27
24	45	-15
15	36	21
12	-33	-24
-48	-84	24
-33	-15	51
0	-57	21
0	-60	24
-51	-81	21
-27	-9	60
27	-9	60
-42	12	15
39	21	15
39	-12	45
3	-84	-12
-45	12	15
30	-81	-15
-18	-66	3
27	12	-3
48	-78	33
33	-96	6
15	-21	48
45	-30	18
-33	-96	6
-60	3	30
-42	-12	63
45	-51	-15
-15	-69	-6
3	-15	-21
39	-48	54
51	-30	12
-36	-54	48
12	51	-24
-63	6	21
9	-9	51
-33	-96	0
-45	-3	57
-24	-72	15
45	12	-6
33	-72	-3
-36	-84	0
-57	-48	3
-24	-51	0
6	15	36
-39	6	33
-54	-36	-6
-39	-63	54
-33	-21	57
-24	-48	18
42	15	-6
-24	6	-15
12	-78	-27
-15	-39	12
-6	-90	-30
15	-51	3
-66	-12	-12
42	-87	21
-54	-6	15
-9	-60	-24
-63	-6	-15
24	-21	33
-24	-33	9
-57	33	-6
3	51	21
42	-84	18
-30	15	-15
33	15	-9
-63	-60	27
3	-57	-36
45	27	45
-27	-78	-39
66	-54	30
9	-51	36
66	-54	30
51	-24	-12
3	-63	3
24	-24	33
-27	-57	3
-6	63	30
-39	-15	15
-27	-54	-3
-51	-78	-6
-18	-12	66
-57	9	36
21	-51	-15
54	-69	30
-12	-82	43
3	-63	24
-51	-38	21
-24	-21	66
-36	-15	15
-54	12	30
-42	-84	-6
-45	9	30
-18	-42	9
3	-66	-15
42	6	-12
-42	-84	-9
21	-42	63
3	-66	-15

// Balodis I M, 2013: Low Weight Controls
// Subjects=19
-54	-36	-24
45	-6	60
-3	-69	-39
-39	-15	33
9	-72	-3
-51	-81	21
-3	-9	51
27	42	-21
-39	-18	-27
54	-12	21
-18	-51	-27
-57	-42	21
0	-72	-18
-6	0	54
-39	-15	36
21	33	-24
-42	30	12
-18	-21	42
9	-3	-3
-24	-42	21
-24	33	-27
24	45	-15
15	36	21
12	-33	-24
-48	-84	24
-33	-15	51
0	-57	21
0	-60	24
-51	-81	21
-27	-9	60
27	-9	60
45	30	9
-30	-99	12
9	6	24
-18	-18	39
33	-45	9
-9	-93	33
3	0	63
39	-87	30
-12	-72	12
36	-54	-15
24	24	21
-39	-57	-9
63	-30	24
-69	-33	30
0	21	24
-6	54	12
21	3	-12
-33	-90	-9
27	-84	-12
-21	-21	54
54	36	21
-42	-6	0
-24	-57	9
-48	-75	36
15	-27	-15
6	15	36
-39	6	33
-54	-36	-6
-39	-63	54
-33	-21	57
-24	-48	18
42	15	-6
-24	6	-15
12	-78	-27
-15	-39	12
-6	-90	-30
15	-51	3
-66	-12	-12
42	-87	21
-54	-6	15
-9	-60	-24
-63	-6	-15
24	-21	33
-24	-33	9
-57	33	-6
3	51	21
42	-84	18
-30	15	-15
33	15	-9
-63	-60	27
3	-57	-36
45	27	45
-27	-78	-39
66	-54	30
9	-51	36
66	-54	30
51	-24	-12
3	-63	3
24	-24	33

// Kong J, 2013: Anticipation: Low cue, high pain (LC) > High cue, high pain 
// (HC)
// Kong J, 2013: Pain: LC > HC
// Subjects=48
-20	24	50
-48	-60	46
10	-82	-34
-4	36	54
-2	58	20
-20	60	8
-44	38	-10
-34	22	-2
14	64	10
26	60	6
38	16	34
-38	-72	32
-36	-68	50
-52	-66	30
34	-68	30
30	-64	56
8	-80	-34

// Longo M R, 2012: Laser Stimulation > Baseline
// Longo M R, 2012: Object > Hand
// Longo M R, 2012: Hand > Object
// Subjects=14
-46	-12	36
-58	-6	26
58	-6	24
52	-10	42
44	-12	36
-2	-2	58
-4	12	42
-64	-6	14
48	12	-6
-48	10	-6
-2	20	32
2	20	30
10	2	72
-2	-92	22
-6	-82	-10
54	-36	56
-48	-4	0
18	-30	62
-18	-30	62
12	-76	48
-14	-4	16
-46	-10	8
24	-98	6
-16	18	2
34	-12	16
46	-8	6
42	-14	14
32	-18	6
32	-24	12
40	-12	-6
-16	-74	-8
50	0	-40
8	-86	20
-30	-28	56
46	-66	-42
32	-20	48
-42	-20	24
-68	-18	-6
-18	-62	66
-26	-84	38
24	-100	6
16	-68	64
-48	-72	-4
28	-80	42
-34	-94	10
16	-102	8
-16	-78	50
-24	-102	6
44	-74	-8
48	-64	-2
8	60	-18
38	-86	28
16	12	-10
-12	22	6
-4	16	4
24	16	-6

// Moulier V, 2012: Pedophilic Male
// Subjects=1
-12	-96	-3
-9	-84	-24
0	3	36

// Perini I, 2013: All Painful > All Nonpainful
// Perini I, 2013: All Nonpainful > All Painful
// Perini I, 2013: All Press > All No-press
// Perini I, 2013: All Heat > All Cold
// Perini I, 2013: All Painful Press > All Painful No-press
// Perini I, 2013: All Nonpainful Press > All Nonpainful No-press
// Perini I, 2013: Conjunction: Painful Press and Nonpainful press
// Subjects=18
45.93	51.62	11.15
-38.51	41.08	6.31
38.48	15.65	0.87
-35.18	9.38	8.93
41.75	24.1	13.51
60.93	9.36	0.02
-51.24	9.03	5.8
6.23	49.76	-9.43
-14	46	-1.07
-24.17	13.93	53.03
29.27	9.93	51.64
-30.48	-19.15	52.53
-56.37	1.28	29.93
38.95	-15.73	49.22
47.45	-13.91	44.51
-.46	-39.86	57.27
-55.2	-14.15	36.78
-1.53	-32.21	59.99
-55.56	-9.12	-8.24
57.64	-5.86	-17.62
-43.52	-33.51	19.32
-20.82	-77.9	35.05
48.52	-69.97	21.32
27.27	-73.21	36.33
-29.79	-45	-6.64
-.69	9.33	46.46
-2.83	6.05	45.64
-37.93	-15.59	57.9
-37.85	-31.2	62.55
51.29	12.3	-2.34
-41.57	-3.6	6.75
-47.86	-22.16	15.07
0.06	-59.85	-22.47
19.24	-53.65	-26.55
-12.68	-68.93	-14.87
-12.67	-16.12	7.47
12.93	-9.88	3.3
-19.3	21.14	-5.62
19.46	-1.95	22.64
9.61	48.23	11.85
3.6	29.33	57
6.67	47.69	46.5
44.76	43.98	-4.92
58.79	12.6	0.89
3.65	-12.94	47.16
-12.31	-22.3	51.47
6.74	-7.6	33.29
-3.26	18.06	-5.54
48.22	3.79	11.79
35.88	-37.35	58.87
-37.89	-34.88	56.17
16.72	-43.3	66.28
-37.85	-51	54.17
-5.72	-63.24	58.18
-28.62	-25.22	15.1
32.28	-21.68	14.11
48.22	3.79	11.79
-25.35	-60.86	8.02
29.13	-57.37	7.1
-15.65	-83.01	9.77
19.5	-14.73	22.59
3.31	-72.52	-21.44
3.41	17.5	27.88
-35.74	-18.24	64.78
-31.4	-27.47	68.85
-54.04	-29.66	42.53
35.32	16.15	7.55
0.17	-68.6	-11.7
16.06	-66.61	-28.78
-3.04	-71.96	-13.61
-9.5	0.02	9.42
6.59	-15.75	10.56
-25.56	-13.54	0.71
25.66	5.8	-1.5
-3.34	18.35	-15.6
0.3	11.9	38.42
-50.8	-25.96	48.88
-37.87	-24.85	62.02
-44.81	-.71	3.2
4.32	-49	-20.08
16.04	-53.67	-26.52
0.14	-19.47	4.25
-15.8	-8.77	20.27
9.68	22.6	10.65
-28.82	-4.3	-3.38
0.27	14.82	34.83
-38.06	27.05	58.78
-37.85	-31.2	62.55
-48.08	8.53	-.89
0.06	-59.85	-22.47
19.24	-53.65	-26.55
-9.45	-19.27	7.69
-15.79	-18.54	17.74
-3.18	-23.95	-12.06

// Pfleiderer B, 2014: Anxiety-Sensitive Females
// Subjects=27
-7.98	62.08	-21.8
7.57	69.71	13.04
-9.27	-53.94	23.32
-2.55	-54.38	41.18
12.41	-55.57	27.6
-22.08	41.22	54.46
-20.01	49.32	49.14
-35.12	38.43	48.24
-22.92	-0.08	-19.88
-20.74	-21.76	-22.25
22.41	-4.59	-24.68
-44.86	19.25	-41.58
61.29	-6.79	-27.37
13.75	60.86	-13.08
3.05	61.65	-4.01
-2.55	-54.38	41.18
5.54	-8.12	7.33
-11.8	-2.01	4.78
-22.58	15.59	9.94
-61.13	13.69	37.68
-46.03	-17.07	29.26
53.38	3.04	32.3
25.71	-9.24	63.13
44.7	-3.78	28.64
-30.77	-51.05	32.37
20.33	48.53	-7.49
11.63	48.09	-11.78
24.52	47.51	-18.67
22.82	22.55	12.96
16.62	2.71	30.72
1.22	-8.14	7.4
24.95	15.76	9.12
1.22	-8.14	7.4
-13.93	-1.81	7.04
-48.19	-1.78	32.27
-48.63	-5.1	-3.25
-48.2	-14.95	29.09
-9.81	71.15	6.47
-13.99	58.99	14.47
13.87	-14.84	-19.04
26.77	0.1	-20.74
-20.7	-17.09	-18.23
-18.56	-4.11	-17.31
7.7	-8.12	7.29
-5.34	-4.32	2.66
-13.91	-6.07	7.46
1.49	-27.96	25.05
14.31	-42.13	10.54
10.1	-39.18	19.29
-58.94	13.91	39.86
-47.92	9.02	55.85
-13.61	11.52	34.85
-9.13	21.5	49.47
-9.34	24.3	33.51
-20.59	-1.48	-6.33
57.58	-32.84	15.61
-65.59	-31.15	17.54
61.77	-29.4	6.24
46.74	-30.96	13.37
-61.31	7.98	22.56
-56.66	6.03	47.33
-20.71	-21.55	-20.03
-56.58	0.06	52.4
-68.05	-13.68	-2.07
-65.6	-35.61	15.74
59.29	9.76	-11.04
61.73	11.84	11.12
55.13	13.11	2.14
-.23	5.97	66.54
9.78	-2.14	2.18
63.97	-31.32	8.63
52.68	41.64	-14.09
50.69	42.88	-.73
-31.37	29.83	1.96

// Pfleiderer B, 2014: Healthy Controls
// Subjects=27
-7.98	62.08	-21.8
7.57	69.71	13.04
-9.27	-53.94	23.32
-2.55	-54.38	41.18
12.41	-55.57	27.6
-22.08	41.22	54.46
-20.01	49.32	49.14
-35.12	38.43	48.24
-22.92	-0.08	-19.88
-20.74	-21.76	-22.25
22.41	-4.59	-24.68
-44.86	19.25	-41.58
61.29	-6.79	-27.37
13.75	60.86	-13.08
3.05	61.65	-4.01
-2.55	-54.38	41.18
5.54	-8.12	7.33
-11.8	-2.01	4.78
-22.58	15.59	9.94
-61.13	13.69	37.68
-46.03	-17.07	29.26
53.38	3.04	32.3
25.71	-9.24	63.13
44.7	-3.78	28.64
-30.77	-51.05	32.37
20.33	48.53	-7.49
11.63	48.09	-11.78
24.52	47.51	-18.67
22.82	22.55	12.96
16.62	2.71	30.72
1.22	-8.14	7.4
24.95	15.76	9.12
1.22	-8.14	7.4
-13.93	-1.81	7.04
-48.19	-1.78	32.27
-48.63	-5.1	-3.25
-48.2	-14.95	29.09
-9.81	71.15	6.47
-13.99	58.99	14.47
13.87	-14.84	-19.04
26.77	0.1	-20.74
-20.7	-17.09	-18.23
-18.56	-4.11	-17.31
7.7	-8.12	7.29
-5.34	-4.32	2.66
-13.91	-6.07	7.46
1.49	-27.96	25.05
14.31	-42.13	10.54
10.1	-39.18	19.29
-58.94	13.91	39.86
-47.92	9.02	55.85
-13.61	11.52	34.85
-9.13	21.5	49.47
-9.34	24.3	33.51
-67.87	-23.27	10.08
-67.9	-36.66	4.68
-63.73	-20.25	-3.74
74.66	-23.39	0.94
74.73	-33.82	4.21
72.25	-12.09	-15.83
-50.08	-4.17	52.71
1.97	4.06	68.94
36.01	-6.36	24.56
39.67	-63.83	-39.29
-14.38	-55.51	-39.19
2.89	-73.09	-44.47
-70	-31.79	10.96
-54.94	-27.9	5.83
57.05	9.13	-17.67
74.81	-17.89	13.84
74.69	-25.31	3.37
4.16	4.27	71.12
-11.39	11.95	39.25
39.93	23.49	-.87
40.07	9.22	7.27

// Ponseti J, 2012: Nude Boys < Nude Men, Pedophiles < Teleiophiles
// Ponseti J, 2012: Nude Girls < Nude Women, Pedophiles < Teleiophiles
// Subjects=11
-38	-62	-24
40	-64	-22
-12	-40	-2
-2	-6	4
22	-32	-4
-34	-76	0
14	-34	0
-38	-74	-16
46	-44	-12
38	-66	44
12	18	-8
-8	14	-8
32	-62	52
-42	-44	-10
-38	-46	-10
-2	4	28
-38	-78	0
-18	0	-12
-26	-56	46
44	-42	-14
54	-56	-8
-32	12	-10
44	24	22
-16	-8	10
28	-48	-30

// Russo A, 2012: Healthy Controls
// Subjects=16
54.63	-9.37	6.13
-54.36	-13.2	7.7
38.44	31.77	2.86
-32.1	27.92	0.65
3.55	9.01	41.97
57.9	-21.78	10.48
35.28	19.06	3.97
-38.51	1.47	-10.44
48.37	2.08	30.89
-34.88	-10.51	40.71
28.78	57.6	7.5
-25.68	47.76	8.95
35.31	19.32	7.29
-35.3	27.9	0.69
6.67	11.43	31.7
57.9	-21.78	10.48
61.37	-35.57	38.36
-57.31	-40.22	30.07
38.65	-15.56	10.18
12.97	-22.57	4.37
51.51	-41.37	5.5
-31.73	-77.02	6.1
-25.75	-68.23	-46
58.08	-.18	42.12
-47.65	-10.08	47.51
32.14	42.79	22.08
-28.72	42.94	29.46
41.65	31.79	2.82
-35.3	27.9	0.69
3.55	9.01	41.97
57.9	-21.78	10.48
57.8	40.83	21.95
-63.83	-24.92	22.17
38.66	-18.73	10.44
12.97	-22.57	4.37
48.32	-37.96	8.6
-25.04	-60.87	49.28
-1.05	29.76	7.95
53.64	-11.87	15.27
-60.71	-14.75	15.71
-5.47	-14.59	-28.43

// Russo A, 2012: Migraine Patients without Aura (MwoA)
// Subjects=16
53.47	-.38	-1.3
-44.7	-17.11	11.26
4.54	17.05	35.71
42.7	31.62	0.6
6.68	14.86	34.76
58.94	-18.86	6.87
42.89	-12.53	7.64
-40.52	7.23	9.17
43.21	-1.53	53.55
23.31	68.35	-4.49
-23.66	56.43	-2.95
40.58	31.78	2.84
-35.31	28.96	0.6
3.46	14.75	33.69
34.69	-37.59	42.18
-58.39	-40.4	27.87
14.52	-47.26	56.6
38.61	-13.7	6.67
-43.85	-.67	-10.2
12.9	-5.73	1.84
-12.72	-10.03	3.61
52.58	-40.31	5.4
51.29	-71.15	-35.49
-37.41	-70.62	-34.52
-3.31	-24.18	-28.77
54.65	-15.72	6.66
54.64	-14.74	5.46
41.65	31.79	2.82
-35.32	31.07	0.42
6.65	15.66	31.34
54.64	-14.74	5.46
56.09	-38.26	45.34
41.75	-3.45	1.32
-41.7	-1.63	-9.03
14.03	-20.45	4.18
-12.75	-16.98	-3.61
55.77	-64.58	-5.98
-54.16	-66.07	12.13
1.2	-56.87	-11.58
-12.71	-69.27	-19.3
-6.41	-37.43	-20.93
-1.05	29.76	7.95
53.64	-11.87	15.27
-60.71	-14.75	15.71
-5.47	-14.59	-28.43

// Strigo I A, 2013: Healthy Controls
// Subjects=22
35.21	31.49	-.42
-36.29	24.35	9.92
52.51	19.39	20.47
45.12	17.03	31.9
58.16	-44.39	34.67
0.36	-36.96	25.79
58.96	-38.41	1.82
52.4	-19.04	-8.65
12.89	11.7	7.07
-2.11	-30.54	-14.86
-39.65	-50.89	-40.61
28.87	-31.5	-16.26
-50.98	-10.24	31.95
43.82	8.03	-1.9
-17.97	37.09	35.41
-19.96	-35.06	24.75
-54.51	-.48	-6.75
35.11	40.33	-10.08
47.26	17.04	31.88

// Strigo I A, 2013: MDD Patients
// Subjects=31
40.59	18.75	-.53
-39.52	20.81	5.79
-38.55	28.6	-3.79
59.98	-10.31	7.26
-59.76	-3.97	3.64
4.48	-8.9	16.7
49.27	-29.29	-3.29
-56.56	-17.15	-1.98
-8.47	-33.33	-8.98
42.67	-26.9	-26.84
43.82	8.03	-1.9
-17.97	37.09	35.41
-19.96	-35.06	24.75
-54.51	-.48	-6.75
35.11	40.33	-10.08
47.26	17.04	31.88

// Poeppl T B, 2011: Pedophiles
// Subjects=9
42	16	24
52	-74	-6
4	-38	26
-44	-78	0
34	-16	-18
46	-22	48
-4	-54	24
48	-4	52
-18	-16	-18
32	-68	34
-20	-24	32
22	-94	-4
-30	-48	-16
-28	-92	4
-40	-44	-24
-40	26	-10
56	-72	4
-34	-80	20
66	-20	6
42	-26	-16
16	-32	-16
-32	50	-2
22	-56	50
24	38	-6
-18	12	-2
26	-30	10
18	8	4
0	-22	-12
4	58	-2
24	-64	-20
42	-58	0
38	-66	-20
-42	-24	10
-40	-70	-2
30	-74	22
28	-48	-20
-16	-62	2
6	-86	22
8	-42	64
2	-2	8
38	-24	28
-20	12	-2
16	10	0
64	-44	32
-38	56	6
-20	-6	16
-54	-18	44
-2	-22	24
-60	-2	-24
16	10	28
-36	0	-26
42	-42	2
26	-82	42
-30	-52	36
18	-68	10
16	-46	-30
20	-44	28
44	-40	-2
12	-42	30
-8	-16	14
22	12	26
34	-20	-16
42	-4	-24
28	-44	-24
32	12	16
48	-22	48
8	-12	36
-40	-44	22
42	8	16
46	-42	-2

// Poeppl T B, 2011: Controls
// Subjects=11
-28	6	-6
64	-46	40
46	-80	-6
-42	-82	-6
40	-42	-14
2	-2	8
38	-24	28
-20	12	-2
16	10	0
64	-44	32
44	-40	-2
12	-42	30
-8	-16	14
22	12	26
34	-20	-16
42	-4	-24
28	-44	-24
32	12	16
48	-22	48
8	-12	36
-40	-44	22
42	8	16
46	-42	-2
42	-74	-10
-44	-72	-4
-2	-62	24
30	32	-8
-30	16	32
46	18	-24
-38	8	32
20	-2	-10
-8	64	28
-40	26	-18
-2	-54	-10
-46	-8	-26

// Stoleru S, 2013: Children - Fixation, Pedophilic - Healthy Men
// Subjects=5
-36	-63	-27
42	-63	-33
36	-69	-33
27	-78	-30
-45	36	24
36	21	27
45	42	24
-33	12	36
-30	60	15
45	48	12
48	6	48
-6	45	51
42	3	42
27	48	36
-24	9	69
-24	-12	51
30	48	-12
-36	21	-6
48	18	-6
54	18	27
-6	-69	-9
27	-90	-3
-57	-63	-3
-39	-33	-21
-3	27	39
-3	-51	6
-33	21	9
39	21	0
-27	-48	39
-27	-69	36
-42	-45	24
-39	-33	-21
-3	-75	27

// Sundaram T, 2010: Erotic (Early Stage) > Rest
// Sundaram T, 2010: Erotic (Mid Stage) > Rest
// Sundaram T, 2010: Erotic (Late Stage) > Rest
// Subjects=14
34	-84	24
-36	-89	1
-36	-89	-1
-34	-57	-7
-22	-86	-4
-22	-93	1
-28	-58	-4
-2	2	-3
-2	-42	8
20	10	9
-10	0	2
10	1	13
-4	-4	4
-57	-36	20
-2	-8	-1
6	-43	-40
18	-27	-26
-38	-77	-23
2	-63	-10
-28	-80	26
-34	-87	3
-36	-82	-11
-38	-80	-11
22	-87	3
26	-83	12
-28	-20	-12
-32	-47	-6
-24	1	-17
6	17	25
-26	-71	13
30	-8	-6
-8	14	7
-18	-17	17
-4	-4	-7
-57	-34	20
-16	-18	-8
-49	-62	-31
-2	-72	-32
36	-84	24
-46	-70	-3
-34	-72	-3
32	-68	-8
-32	-72	-3
-26	-81	10
-30	-53	-6
30	-1	-15
6	26	15
22	17	-6
-24	-10	0
10	21	1
6	-17	16
-8	-6	-5
-57	-36	18
-10	-18	-11
-8	-41	-38
-18	-38	-30
-36	-51	-18
-2	-60	0

// Sylva D, 2013: Heterosexual Women
// Subjects=11
-15.92	4.29	10.25
-2.72	1.71	58.27
26.69	-42.94	-26.42
-48.63	-26.74	52.26
22.6	-66.35	-12.15
15.07	-.98	8.11
4.35	41.4	20.29
-25.65	-.22	-5.98
-18.07	-18.95	-1.16
-13.7	-16.76	13.11
-40.09	-54.24	39.97
64.2	-42.75	-13.49
3.47	-78.55	-3.1
-37.91	-21.94	58.43
-43.57	-23.02	17.32
-2.52	-27.04	71.83
-18.67	-41.54	50.93
-24.1	-67.78	28.66
30.03	-39.35	-7.8
-12.6	-48.36	3.48
-36.08	-77.82	-3.82
44.35	-19.5	55.05
25.83	-71.53	-10.63
-23.02	-87.4	22.48
5.7	-66.6	13.72
-19.09	-10.7	9.32
-28.26	-24.79	61.9
19.48	-14.99	19.27
44.84	-43.01	-28.86
16.08	-48.84	-19.12
-23.5	6.48	-2.11
28.69	72.9	-25.9
-21.98	72.39	-27.95
-5.96	91.52	-21.49
37.62	29.04	61.31
-27.22	95.43	-4.84
-8.72	97.22	-16.36
26.7	56.88	42.38
37.47	57.8	53.33
55.76	24.44	0.16
-8.84	60.39	-46.72
-24.41	70.52	16.84
48.2	28.05	47.45
7.53	66.68	0.07
-18.76	-22.51	19
42.6	28.19	14.04
-24.49	33.9	-7.97
-13.51	-20.58	7.63
5.03	83.81	15.39
45.17	-2.06	2.5
29.02	70.84	16.2
-29.73	70.69	19.56
31.55	51.77	-24.16
7.78	-10.31	0.95
55.91	17.9	17.43
34.19	52.64	-13.11
58.62	8.82	4.33
0.11	41.51	52.45
-13.34	-2.38	36.66
-16.8	51.45	-57.04
18.14	98.89	2.82
24.11	47.8	62.8
20.9	98.68	-0.09
-29.52	-14.96	12.92
-21.39	-1.17	19.92
-10.99	86.66	18.01
16.12	0.13	33.43
18.57	29.33	30.95
61.37	27.27	36.21
-13.46	51.35	43.3
18.75	44.79	60.21
-34.53	15.93	68.82
-21.01	13.69	74.43

// Sylva D, 2013: Homosexual Women
// Subjects=11
-15.92	4.29	10.25
-2.72	1.71	58.27
26.69	-42.94	-26.42
-48.63	-26.74	52.26
22.6	-66.35	-12.15
15.07	-.98	8.11
4.35	41.4	20.29
-25.65	-.22	-5.98
-18.07	-18.95	-1.16
-13.7	-16.76	13.11
-40.09	-54.24	39.97
64.2	-42.75	-13.49
3.47	-78.55	-3.1
-37.91	-21.94	58.43
-43.57	-23.02	17.32
-2.52	-27.04	71.83
-18.67	-41.54	50.93
-24.1	-67.78	28.66
30.03	-39.35	-7.8
-12.6	-48.36	3.48
-36.08	-77.82	-3.82
44.35	-19.5	55.05
25.83	-71.53	-10.63
-23.02	-87.4	22.48
5.7	-66.6	13.72
-19.09	-10.7	9.32
-28.26	-24.79	61.9
19.48	-14.99	19.27
44.84	-43.01	-28.86
16.08	-48.84	-19.12
-23.5	6.48	-2.11

// Sylva D, 2013: Heterosexual Men
// Subjects=12
3.47	-78.55	-3.1
-37.91	-21.94	58.43
-43.57	-23.02	17.32
-2.52	-27.04	71.83
-18.67	-41.54	50.93
-24.1	-67.78	28.66
30.03	-39.35	-7.8
-12.6	-48.36	3.48
-36.08	-77.82	-3.82
44.35	-19.5	55.05
25.83	-71.53	-10.63
-23.02	-87.4	22.48
5.7	-66.6	13.72
-19.09	-10.7	9.32
-28.26	-24.79	61.9
19.48	-14.99	19.27
44.84	-43.01	-28.86
16.08	-48.84	-19.12
-23.5	6.48	-2.11
28.69	72.9	-25.9
-21.98	72.39	-27.95
-5.96	91.52	-21.49
37.62	29.04	61.31
-27.22	95.43	-4.84
-8.72	97.22	-16.36
26.7	56.88	42.38
37.47	57.8	53.33
55.76	24.44	0.16
-8.84	60.39	-46.72
-24.41	70.52	16.84
48.2	28.05	47.45
7.53	66.68	0.07
-18.76	-22.51	19
42.6	28.19	14.04
-24.49	33.9	-7.97
-13.51	-20.58	7.63
5.03	83.81	15.39
45.17	-2.06	2.5
29.02	70.84	16.2
-29.73	70.69	19.56
31.55	51.77	-24.16
7.78	-10.31	0.95
55.91	17.9	17.43
34.19	52.64	-13.11
58.62	8.82	4.33
0.11	41.51	52.45
-13.34	-2.38	36.66
-16.8	51.45	-57.04
18.14	98.89	2.82
24.11	47.8	62.8
20.9	98.68	-0.09
-29.52	-14.96	12.92
-21.39	-1.17	19.92
-10.99	86.66	18.01
16.12	0.13	33.43
18.57	29.33	30.95
61.37	27.27	36.21
-13.46	51.35	43.3
18.75	44.79	60.21
-34.53	15.93	68.82
-21.01	13.69	74.43

// Sylva D, 2013: Homosexual Men
// Subjects=12
3.47	-78.55	-3.1
-37.91	-21.94	58.43
-43.57	-23.02	17.32
-2.52	-27.04	71.83
-18.67	-41.54	50.93
-24.1	-67.78	28.66
30.03	-39.35	-7.8
-12.6	-48.36	3.48
-36.08	-77.82	-3.82
44.35	-19.5	55.05
25.83	-71.53	-10.63
-23.02	-87.4	22.48
5.7	-66.6	13.72
-19.09	-10.7	9.32
-28.26	-24.79	61.9
19.48	-14.99	19.27
44.84	-43.01	-28.86
16.08	-48.84	-19.12
-23.5	6.48	-2.11

// Versace F, 2013: All Participants: Emotional > Neutral
// Versace F, 2013: Sexual desire x Picture category
// Subjects=11
-39.11	-71.64	21.35
33.6	-68.57	26.95
-59.46	-30.46	32.63
57.04	-33.91	32.69
-1.11	42.36	5.77
48.36	3.05	29.69
14.2	-92.32	-3.18
41.08	-57.53	31.51
4.23	38	3.85
28.8	39.11	2.36
50.55	20.12	43.85
-28.55	-31.13	21.18

// Wehrum S, 2013: Sexual - Neutral, Men and Women (Conjunction)
// Wehrum S, 2013: Sexual - Positive, Men and Women (Conjunction)
// Wehrum S, 2013: Sexual - Negative, Men and Women (Conjunction)
// Wehrum S, 2013: Sexual - Neutral / Sexual - Positive / Sexual - Negative 
// (Conjunction), Men and Women (Conjunction)
// Wehrum S, 2013: Sexual - Positive, Men - Women
// Wehrum S, 2013: Sexual - Negative, Men - Women
// Subjects=48
48	-67	-8
51	8	28
-6	47	1
15	-52	-50
-51	5	28
-27	-4	49
-6	-28	-11
54	41	7
-33	-16	-8
48	-67	-5
-12	-73	-41
39	-1	46
0	38	4
-30	-4	49
-51	5	31
27	17	-17
-6	2	-5
6	-31	-5
-15	-52	-47
0	23	25
3	-58	31
48	-70	-2
30	-52	58
-51	-73	4
0	38	-5
0	-28	28
-27	-4	49
30	-49	61
-51	-70	1
51	-73	4
-3	38	1
-24	-4	49
27	-7	49
45	-40	-23
-18	-100	4
18	-100	16
18	-31	13
-18	-100	4
-12	26	4

// Woodard T L, 2013: Women with Hypoactive Sexual Desire Disorder (HSDD)
// Subjects=10
10	-23	9
10	46	12
27	-61	-24
51	-60	1
45	-64	-14
1	-19	6
-18	-13	21
-23	-71	-23
1	-81	-12
-25	-53	-25
0	-75	44
0	-60	42
-42	-52	-23
-1	21	24
-3	44	17
-27	2	-10
-37	-85	6
14	-11	2
-57	-33	22
-36	-69	-1
-50	-5	37
-53	9	26
-49	4	20
-15	-46	37
-14	-39	-3
-48	-72	8
-44	-42	34
6	45	28
-18	-71	39

// Woodard T L, 2013: Healthy Controls
// Subjects=6
14	-70	-8
34	1	-2
38	-1	10
48	-33	34
17	-11	5
49	-31	17
43	-8	8
-3	-64	2
1	-67	-4
-12	-37	-5
-36	-1	0
-34	-29	-8
-55	-37	21
-48	-3	41
14	-11	2
-57	-33	22
-36	-69	-1
-50	-5	37
-53	9	26
-49	4	20
-15	-46	37
-14	-39	-3
-48	-72	8
-44	-42	34
6	45	28
-18	-71	39

// Cai W, 2011: Not-Stop Task (NST) > Stop-signal Task (SST)
// Cai W, 2011: Color > Motion
// Cai W, 2011: Motion > Color
// Cai W, 2011: SST: All Stop > Go
// Cai W, 2011: SST: Stop > Go, Successful trials
// Cai W, 2011: NST: Not Stop > Go
// Cai W, 2011: SST: Successful Stop > Unsuccessful Stop
// Cai W, 2011: SST Unsuccessful Stop > NST Not Stop
// Cai W, 2011: Conjunction: (SST Stop - SST Go) and (NST Not Stop - NST Go)
// Subjects=23
-60	-51	-3
-33	-66	-18
48	-63	-3
-48	69	0
-27	-90	-12
-39	-63	-9
-33	-90	9
45	-66	-15
45	-54	-18
33	-84	-9
-30	18	-15
-51	39	12
-45	12	-30
-12	27	27
9	33	24
6	45	3
-24	39	36
-27	42	21
-27	51	30
18	-3	-21
-24	-15	-33
-3	-24	-3
-18	-9	-21
9	-63	6
18	-57	9
-51	39	12
48	45	3
-42	12	-9
36	12	-6
51	15	3
-48	9	27
48	8	30
33	42	30
-36	-69	-9
39	-72	12
-30	-90	-12
-15	-60	-39
24	-3	60
21	6	55
24	9	48
33	21	51
33	39	39
12	54	36
48	9	30
12	33	48
27	6	51
-51	39	12
-48	39	0
57	21	6
51	39	0
9	-6	6
-3	-24	-3
9	-9	51
9	0	42
-45	-69	-6
-27	-84	-12
-39	-78	-12
-21	-6	48
-51	3	27
-42	-3	42
-48	-6	36
-30	-3	63
-12	-3	69
33	-84	-6
42	-63	-15
48	9	33
45	-54	-18
39	18	18
48	27	12
21	-6	69
21	3	63
30	-57	45
-6	-30	-12
-21	-27	-6
-33	24	6
3	30	3
-48	6	-21
-12	-72	6
24	42	18
30	36	21
-48	-42	12
-21	-3	-3
-27	-15	-18
-15	6	-15
33	-6	24
39	-15	21
30	-21	-3
-9	-54	15
0	-60	21
15	-45	21
-48	-75	18
12	-30	63
21	-18	66
-33	-39	24
-36	-48	9
-24	-48	30
12	-9	51
51	-51	12
21	12	0
-15	30	48
-24	30	48
21	15	27
51	-3	15
12	9	-15
-6	-57	42
-12	-48	0
39	9	-24
33	27	0
33	18	6
-24	-69	24
-18	-69	39
-12	-75	51
0	0	54
-6	12	42
9	9	48
30	-3	51
18	-3	69
33	42	24
-54	-30	24
-60	-24	33
-57	-42	15
-21	-72	6
-27	39	21
-24	-3	45
-39	12	0
-54	12	-6
-48	0	-6
-39	-54	-21
-33	-57	-15
-30	27	-3
9	12	3
-30	-78	-12
-30	-87	-15
-42	-69	-6
33	-84	-9
42	-66	-15
45	-54	-18
-21	-60	45
48	9	30
-51	6	27

// Ghahremani D G, 2012: Stop > Go
// Ghahremani D G, 2012: Negative Correlation of Stop Signal Reaction Time and 
// Successful Stop > Go
// Subjects=18
36	20	-10
48	10	16
46	4	42
-32	18	-6
4	14	48
32	50	22
-34	46	22
64	-34	8
-62	-42	16
-16	-100	0
32	50	22
4	58	32
18	62	16
2	40	6
-40	46	6
-20	54	-12
20	14	-2
12	10	10
10	-4	8
-50	-60	40
-50	-72	18
8	-84	-30

// Jimura K, 2014: Stop > Go, Negative Correlation w/ Stop Signal Reaction 
// Time (SSRT) (Runs 3-12)
// Jimura K, 2014: Stop > Go, Negative Correlation w/ SSRT (Runs 8-12)
// Jimura K, 2014: Stop > Go, Negative Correlation w/ SSRT (Runs3-7 > Runs 
// 8-12)
// Subjects=46
10	-64	-24
-2	-84	6
-12	-66	-46
-12	-64	-46

// Bhasin A, 2012: 8 Weeks: Fist clenching/extension > Rest, Right hemispheric 
// stroke
// Bhasin A, 2012: 24 Weeks: Fist clenching/extension > Rest at 24 weeks, 
// Right hemispheric stroke
// Bhasin A, 2012: BOLD activation: Left hemispheric stroke patients > Healthy 
// controls
// Subjects=8
2	-36	0
-22	-30	-4
2	-74	0
30	-30	20
30	-38	18
-24	-24	22
2	-82	-22
40	-46	-10
24	2	62
18	32	6
4	18	10
-8	8	38
48	18	40

// Diserens K, 2010: Passive extension-flexion movements of the affected arm > 
// Rest
// Diserens K, 2010: Passive extension-flexion movements of the unaffected arm 
// > Rest
// Subjects=8
-27.19	-25.93	60.87
-38.96	-34.89	56.18
3.73	-9.97	58.06
1.69	-28.76	63.01
5.63	-29.96	19.57
-27.19	-25.93	60.87
-38.96	-34.89	56.18
3.73	-9.97	58.06
1.69	-28.76	63.01
5.63	-29.96	19.57

// Hendrick O M, 2010: Stop > Go
// Hendrick O M, 2010: Post stop- stop success > Post go - stop success
// Subjects=60
4	-20	-4
4	-24	-20
4	-24	32
8	28	32
8	20	56
-4	40	32
12	8	8
32	24	-4
44	12	36
48	12	52
32	-92	-8
44	-80	-8
60	-44	36
-12	4	8
-28	-96	-8
-60	-48	36
-40	-64	-12
-40	16	-4
4	-100	0
12	36	60
8	48	52
16	52	32
12	64	8
36	56	-4
44	28	28
48	20	48
40	20	56
-48	-68	-36
36	-84	-32
48	-60	52
52	-48	56
60	-56	32

// Page S J, 2010: Post-testing > Pre-testing: Wrist flexion/extension of the 
// affected hand > Rest
// Subjects=8
3.92	-38.25	1.88
41.21	-9.48	-.96
-13.27	0.22	5.55
38.22	15.79	37.1
12.58	-33.75	18.13
-29	-46.17	26.34
-35.7	-29.49	-5.09
-45.54	-12.05	-26.51
37.87	41.77	1.47
51.22	-25.12	43.73
19.17	-12.1	49.7
19.2	-67.83	30.95
-16.75	3.98	-28.19
-48.74	20.93	-12.51
-.54	25.68	3.26
47.68	-18.7	3.09
12.46	-21.83	7.1
-13.19	-15.38	10.2
-35.32	-84.79	22.96
-19.91	-21.93	-32.67
21.72	4.21	-28.65
12.9	-70.01	44.59

// Spunt R P, 2012: Stop Failure > Stop Success
// Spunt R P, 2012: Stop Success > Stop Failure
// Spunt R P, 2012: Stop Failure > Rest, Positive Correlation with Frustration
// Spunt R P, 2012: Stop Success > Stop Failure, Correlation with Frustration
// Spunt R P, 2012: Stop Failure > Rest, Negative Correlation with Frustration
// Spunt R P, 2012: Stop Failure > Rest, Positive Correlation with Response 
// Latency
// Spunt R P, 2012: Stop Failure > Rest, Negative Correlation with Frustration
// Subjects=15
-12	24	30
-12	48	6
-15	51	27
15	-57	-18
-3	15	57
6	-24	-12
-33	-90	15
42	-72	-12
27	12	-6
-6	27	27
-33	-30	54
-33	-36	57
33	24	6
-36	30	-3
12	9	66
-45	-9	-9
39	45	9
-30	-36	57
3	-15	57

// Veverka T, 2012: W0 > W4: Imaginary finger movement with the impaired hand 
// > Rest
// Veverka T, 2012: W4 > W11: Imaginary finger movement with the impaired hand 
// > Rest
// Veverka T, 2012: W0 > W11: Imaginary finger movement with the impaired hand 
// > Rest
// Subjects=14
-24	-74	58
-48	-44	58
-16	-64	38
-26	18	12
-20	64	18
12	50	42
4	34	58
-24	-74	58
6	52	32
-20	64	18
22	38	-24
48	-32	62

// Veverka T, 2014: Subgroup of stroke patients, Group A
// Subjects=7
-22	-78	-8
48	-62	-14
-20	-74	22
16	-84	44
-8	-98	-2
-10	-74	16
-32	-86	-2

// Veverka T, 2014: Subgroup of stroke patients, Group B
// Subjects=7
-14	-82	44
-26	-100	-4
-12	-28	52
18	-88	-32
30	-94	-4
28	-78	-20
34	28	-6
24	42	-20
36	20	12
56	14	-12
-52	16	12
-44	22	-6
-28	42	-10
2	-76	2
-6	-102	2
-46	-56	24
-50	-46	18
-44	-64	30
-58	-54	6
36	-78	-22
24	-82	-40
-8	22	50
-4	-10	30
-8	18	48
-58	-18	-20
-48	2	-32
-66	-24	-2
-48	-2	-28

// Wilbertz T, 2014: Stop > Go
// Wilbertz T, 2014: Main Effect of Reward: Rewarded stop > Nonrewarded stop
// Wilbertz T, 2014: Main Effect of Success: Successful stop trials > 
// Unsuccessful stop trials
// Wilbertz T, 2014: Reward x Success: Successful stop > Unrewarded stop
// Wilbertz T, 2014: Stop Success (Reward) > Stop Success (Nonreward), Stop 
// Fail (Reward) > Stop Fail (Nonreward)
// Subjects=24
30	20	-14
32	20	0
50	20	4
46	-28	-4
32	52	-4
34	-56	44
56	-44	28
36	-44	-20
24	-58	4
14	-64	8
6	26	36
0	-30	28
2	16	46
24	56	28
10	-8	6
6	-26	-2
18	-34	0
6	-14	-6
16	-40	-6
10	-14	14
8	-22	10
-30	22	0
-32	16	-10
-44	6	30
-50	28	32
-46	36	28
-28	56	24
-44	52	-8
-44	48	2
-24	42	-16
-24	46	-14
-30	-4	46
-26	2	50
-28	48	16
-40	-62	-14
-32	-50	44
-36	-54	-18
18	-68	6
-54	-50	10
-62	-34	-14
-8	-72	12
-32	-58	-34
-26	-70	-30
-14	-40	-2
0	-22	-20
30	18	-12
-4	42	8
-46	48	-6
-40	38	-16
-30	16	-14
-34	14	-2
-2	-22	-18
-26	2	8
-38	-4	16
-48	2	6
-56	-20	18
-44	-24	20
-58	-20	48
-32	18	12
-44	-36	24
-62	-22	26
58	-14	20
58	-4	-6
-8	10	-10
10	12	14
6	14	-6
-8	4	16
-6	15	8
-10	-18	4
-12	-8	22
-8	40	-12
-2	50	-10
0	60	-12
-40	40	-12
-20	68	10
-28	60	2
-4	68	14
-4	14	36
-24	20	60
-26	28	54
-32	16	60
30	30	54
-22	30	-18
-22	22	-20
26	30	-20
-38	-78	40
-44	-78	30
48	-74	32
-32	-84	34
24	-58	-22
20	-66	-20
4	-46	36
-10	-54	10
10	6	-12
-12	4	-12
36	14	-8
-2	42	6
8	36	22
-32	16	-12
-34	14	-2

// Andres M, 2012: Arithmetic > Letter reading
// Andres M, 2012: Multiplicaton > Subtraction
// Andres M, 2012: Finger task > Colour task
// Andres M, 2012: Right hand > Left hand
// Andres M, 2012: Left hand > Right hand
// Subjects=18
-28	-72	42
-32	-58	42
32	-70	42
42	20	-2
48	-40	48
-60	14	0
60	-2	-2
-20	-68	62
-38	-44	50
-48	-69	-2
44	-40	52
30	-72	40
54	-60	-8
-28	-4	50
38	26	-4
26	-2	56
50	32	30
-46	4	34
-46	-22	62
42	-20	62

// Watanabe R, 2011: Third-person > First-person
// Watanabe R, 2011: First-person anatomical > Motor control
// Watanabe R, 2011: First-person specular > Motor control
// Watanabe R, 2011: Third-person anatomical > Motor control
// Watanabe R, 2011: Third-person specular > Motor control
// Subjects=15
-36	-8	64
38	-64	22
52	-56	26
52	-72	24
-22	8	46
24	-32	-14
38	-28	14
-56	-68	24
30	-52	4
-12	-64	24
46	-16	18
-54	-16	14
-48	8	12
-10	-66	20
8	-78	18
34	-20	12
-46	14	12
52	-70	30
-56	-66	36
-50	-76	22
-54	-14	18
-26	-46	6
-30	-54	-4
-12	-64	24
-52	16	8

// Bouhassira D, 2013: Healthy Controls
// Subjects=11
-54	-18	18
48	-4	32
16	-10	-4
-36	18	0
-4	36	24
0	-20	34
32	42	32
-32	32	34
-36	-74	-38
-36	-29	48
-24	-32	68
64	-34	24
-46	-40	40
-38	-24	62
-12	14	60
-14	-14	10
-38	8	16
-36	-14	2
-14	32	26
-28	52	28
52	12	10
-22	24	54
-20	-78	-20
28	-10	8
14	26	-2
28	-28	-20
-34	17	-7
0	-26	36
-48	22	16
32	50	11
-22	62	14

// Bouhassira D, 2013: Patients
// Subjects=10
60	-10	16
-54	-20	26
2	-14	48
-36	20	-12
-8	32	18
-42	32	20
-12	-68	-16
20	6	-8
-37	-38	61
52	-19	31
52	-16	16
-47	-26	19
-54	-46	52
48	-8	44
-8	-16	54
18	-20	2
-34	16	-10
38	-17	3
6	14	26
0	-28	36
-40	48	8
30	54	22
44	42	22
26	26	56
10	-68	-10
26	4	4
-34	17	-7
0	-26	36
-48	22	16
32	50	11
-22	62	14

// Hall G B C, 2010: Healthy Controls
// Subjects=6
11.83	-.28	3.63
-6.34	1.72	3.67
-60.68	-46.36	6.09
-60.92	6.08	-3.88
35.32	-12.37	-3.44
-41.56	-12.23	5.24
-38.06	7.24	50.41
-3.28	38.75	0.53
-3.93	26.57	49.51
-3.39	26.64	-18.53
37.41	58.51	18.48
-25.57	57.68	27.08
8.6	42.31	17.94
22.93	-45.4	38.51
17.37	4.01	31.08
-5.14	21.76	28.74
16.47	-1.95	50.55
-35.83	-31.32	46.92
5.5	-19.27	6.41
-4.29	-27.73	-19.54
-21.42	-17.17	-19.11
-24.47	-47.43	-10.96
-26.9	-2.11	-30.35
-50.13	-63.07	-18.28
-2.64	-73.31	37.8
11.52	14.07	-31.03
-52.37	31.4	6.17
51.6	-28.37	22.25
51.72	-52.43	27.62
45.27	-66.02	17.68
22.97	-52.63	41.34
12.22	-68.7	27.2
16.09	51.24	22.68
-37.35	48.63	21.28
27.81	16.9	4.23
10.75	13.89	8.03
7.48	23.13	3.94
61.18	-16.59	22.27
-43.6	9.64	26.85
-4.29	-26.58	-18.52
-37.38	-50.56	-22.82
-26.61	2.03	9.45

// Hall G B C, 2010: Patients
// Subjects=7
-11.84	-60.32	-41.25
27.28	-74.18	37.53
-23.96	-73.98	44.79
-25.12	-58.47	39.04
3.53	-74.7	5.5
13.98	-2.38	3.78
-5.24	-2.33	6.22
-32.65	-13.96	51.01
-31.01	3.98	-6.28
6.74	17.66	43.44
-1.3	29.39	-24.36
13.73	23.65	-17.36
10.47	48.3	-14.93
22.56	61.74	33.99
8.6	42.31	17.94
22.93	-45.4	38.51
17.37	4.01	31.08
-5.14	21.76	28.74
16.47	-1.95	50.55
-35.83	-31.32	46.92
5.5	-19.27	6.41
-4.29	-27.73	-19.54
-21.42	-17.17	-19.11
-24.47	-47.43	-10.96
-26.9	-2.11	-30.35
-50.13	-63.07	-18.28
-2.64	-73.31	37.8
11.52	14.07	-31.03
-52.37	31.4	6.17
51.6	-28.37	22.25
51.72	-52.43	27.62
45.27	-66.02	17.68
22.97	-52.63	41.34
12.22	-68.7	27.2
16.09	51.24	22.68
-37.35	48.63	21.28
27.81	16.9	4.23
10.75	13.89	8.03
7.48	23.13	3.94
61.18	-16.59	22.27
-43.6	9.64	26.85
-4.29	-26.58	-18.52
-37.38	-50.56	-22.82
-26.61	2.03	9.45

// Jensen K B, 2010: Painful > Non-painful
// Subjects=83
10	-24	-12
-24	0	-8
-28	-24	70
-40	-18	16
2	20	32
-54	0	0
56	-16	8
26	-56	-24
38	6	2
10	-4	2

// Jack A, 2011: Conjunction Analysis: IMI & OBS & EXE
// Subjects=15
-34	-40	42
38	-84	8
-58	10	22

// Langner R, 2014: Conjunction: Encoding and Recall Epochs for both 
// hands/delays
// Langner R, 2014: Left > Right-hand sequences
// Langner R, 2014: Right > Left-hand sequences
// Langner R, 2014: Delayed > Immediate recall
// Subjects=36
-1	-2	56
-44	-42	50
-54	5	33
-33	-9	62
-51	-36	21
-35	23	0
-1	15	42
-51	8	18
-30	-56	65
-15	8	-3
-39	-56	-30
-18	8	-1
-38	27	27
-17	-69	-24
-32	-60	42
-56	-54	2
-60	-15	23
-17	-12	9
47	-39	47
3	-2	54
40	-36	44
33	-60	-27
44	-45	48
51	8	21
30	-6	62
57	8	33
33	23	-1
15	-74	59
21	6	0
9	-68	48
51	-33	-3
8	14	33
20	9	6
41	30	24
60	-56	-8
5	-72	-20
18	-15	14
-33	-48	-26
45	-35	51
30	-12	60
38	-28	42
39	-28	42
30	-53	59
34	-27	50
8	-6	54
36	-26	57
45	-34	57
20	-62	68
17	-20	2
-41	-35	51
-41	-32	50
-32	-18	57
-32	-33	48
-36	-47	66
-36	-23	57
-37	-28	53
-8	-8	53
-28	-53	67
-17	-21	5
-51	-18	47
33	-50	29
-57	-15	29
-60	-15	15
-29	6	-5
-44	-23	36
-57	3	30
-51	-23	36
-36	-48	60
-11	14	32
-30	-54	65
-9	-14	69
-38	-17	51
-35	3	5
-56	2	20
-62	-3	8
3	-5	59
51	-17	39
24	5	-6
8	6	41
62	-32	17
23	5	2
41	-32	42
59	5	17
39	-12	51
62	-17	20
41	3	3

// Rusconi E, 2014: IIBT > IINT
// Rusconi E, 2014: IINT > IIBT
// Subjects=13
-25.22	-2.27	56.85
27.59	-1.74	54.55
-52.05	7.05	28.51
-55.66	-27.27	36.32
-36.45	-35.32	43.7
-17.47	-61.88	55.24
20.59	-59.86	49.7
47.08	-29.22	-2.43
-3.04	-43.55	22.76

// Zhao Y, 2011: Healthy Controls
// Subjects=14
-56.27	22.73	-3.64
46.32	29.37	-7.16
-52.83	3.47	8.3
46.57	0.63	6.88
33.08	26.19	-29.03
58.4	-12.92	-.94
-56.25	17.42	-3.11
-44.42	12.69	-8.45
-52.68	4.62	20.51
-50.84	7.66	-4.48

// Zhao Y, 2011: Subgroup of Patients, Contralateral Pain
// Subjects=8
64.89	-4.08	1.44
4.56	27.67	22.85
4.64	18.41	27.13
36.34	55.85	-21.94
-50.61	17.07	15.88

// Zhao Y, 2011: Subgroup of Patients, Ipsilateral Pain
// Subjects=6
17.71	-22.37	26.46
-59.55	19.22	-6.59
53.07	16.07	10.85
-55.99	10.67	16.6
-41.31	1.88	-20.88
36.41	31.18	-21.74
-47.37	7.2	13.44

// McKenna B S, 2014: Bipolar Disorder < Healthy Controls, Encode Interval
// McKenna B S, 2014: Bipolar Disorder > Healthy Controls, Maintenance 
// Interval
// Subjects=23
3.46	-61.09	0.62
-51.48	-47.86	17.8
-.99	52.73	68.33
-1.18	84.72	39.5
53.72	61.19	-8.04
-51.71	29.13	34.73
-56.18	69.22	0.93
-5.52	91.19	8.01

// Pomarol-Clotet E, 2012: Manic Patients
// Subjects=29
-42	16	26
44	-2	36
-26	-62	38
34	-58	38
-46	-76	-8
-24	-6	4
16	-2	6
-8	-52	26
-2	62	4
-32	-2	54
12	-72	56
22	-6	58
-2	42	-2
34	18	-36
-28	12	-24
-2	42	-2

// Pomarol-Clotet E, 2012: Healthy Controls
// Subjects=46
2	20	44
-38	60	18
0	50	-10
4	-52	26
24	-42	74
-32	-32	72
-48	-76	30
-32	-2	54
12	-72	56
22	-6	58
-2	42	-2
34	18	-36
-28	12	-24
-2	42	-2

// Wu G, 2014: 2-Back, Deactivation across all groups
// Subjects=20
0	-49	28
-3	56	22
51	-70	19

// Pereira C S, 2011: Familiar > Unfamiliar
// Pereira C S, 2011: Unfamiliar > Familiar
// Pereira C S, 2011: Like > Dislike
// Pereira C S, 2011: Dislike > Like
// Subjects=14
-20	-2	-18
-54	16	-10
4	-6	56
2	14	-8
22	-2	-18
0	0	66
12	-16	16
-10	-6	10
-2	14	-8
-16	8	-12
26	8	-4
2	12	40
-14	-8	-20
-44	22	-10
0	8	48
8	10	-8
-38	-32	62
-38	-26	16
-42	-78	-4
16	-92	20
6	-6	60
14	44	8
-2	58	-6
-2	-8	62
-28	20	48
58	10	10
-52	18	14
-22	28	50
-48	-12	-2
-60	-22	2

// Morris R W, 2012: Healthy Controls
// Subjects=15
43.94	45.24	-21.02
55.03	29.92	-1.76
-22.21	38.06	43.57
-49	0.92	-30.74
-11.88	71.77	13.17
50.51	15.28	-20.4
11.9	52.29	10.21
43.95	43.11	-20.81
43.94	45.24	-21.02
9.76	48.03	10.67
-16.02	60.03	25.61
52.85	29.71	-3.94
-13.27	18.48	63.29
-48.87	34.69	-13.91
-44.28	45.5	9.6

// Morris R W, 2012: Bipolar-I Disorder
// Subjects=13
43.94	45.24	-21.02
55.03	32.05	-1.97
28.75	25.01	-29.96
50.51	15.28	-20.4
11.9	52.29	10.21
43.95	43.11	-20.81
-53.16	26.17	-12.99
54.73	40.82	-23
7.81	51.81	28.25
-45.84	17.12	50.53
-3.17	67.96	17.88
57.11	29.31	-8.46

// Morris R W, 2012: Schizophrenia
// Subjects=12
55.03	29.92	-1.76
-22.21	38.06	43.57
-49	0.92	-30.74
-11.88	71.77	13.17
55.03	32.05	-1.97
28.75	25.01	-29.96
43.94	45.24	-21.02
9.76	48.03	10.67
-43.78	-1.14	38.85

// Duerden E G, 2013: Healthy Controls
// Subjects=20
24	38	31
21	17	49
36	17	46
-48	23	28
30	14	28
0	-28	34
30	17	-11
-15	-40	46
9	-43	61
42	-70	34
51	-49	43
54	-55	1
42	-52	-17
27	-49	-20
36	17	46
24	17	49
45	23	19
33	-73	-8
21	17	49
48	23	19
33	-73	-5

// Duerden E G, 2013: Autism Spectrum Disorder (ASD)
// Subjects=19
48	23	19
-33	26	-14
48	26	4
3	32	13
-33	5	7
48	-46	1
36	-73	-8
27	-46	-26
-36	-67	-26
-6	-49	-2
36	17	46
24	17	49
45	23	19
33	-73	-8

// Duerden E G, 2013: Subgroup of ASD, Autism Diagnostic Observation 
// Schedule-Generic (ADOS-G) Cutoff Participants
// Subjects=13
33	23	-17
-33	23	11
48	23	19
36	-73	-8
-30	-73	13
-45	-49	34
33	14	-35
3	32	10
21	17	49
48	23	19
33	-73	-5

// Fan J, 2012: Alerting, Healthy Controls (HC) > Autism Spectrum Disorders 
// (ASD)
// Fan J, 2012: Validity, HC > ASD
// Fan J, 2012: ((Moving+Engaging), HC > ASD
// Fan J, 2012: Disengaging, HC > ASD
// Fan J, 2012: Orienting, HC > ASD
// Fan J, 2012: Flanker (incongruent-congruent), HC > ASD
// Fan J, 2012: Alerting for Flanker, HC > ASD
// Fan J, 2012: Orienting for Flanker, HC > ASD
// Fan J, 2012: Validity for Flanker, HC > ASD
// Subjects=12
-38	36	28
-36	28	40
-46	16	44
6	6	2
-12	18	14
12	48	-12
12	22	-8
18	34	-14
-36	44	14
-24	46	4
-46	-52	48
22	52	26
26	44	20
0	36	26
4	34	12
-8	36	22
48	-46	48
54	-46	38
52	-54	40
8	-16	38
0	-14	38
4	-2	38
-18	-56	-26
-34	-38	-10
-38	-70	-8
-26	-40	-12
32	8	-30
32	16	-18
-38	28	38
-6	30	18
-2	34	10
10	40	8
48	-40	36
46	-46	44
56	-50	30
-26	-24	-20
-34	-38	-10
30	8	-14
32	8	-28
-2	34	24
0	28	32
2	2	36
20	50	14
-32	-60	30
-38	-68	28
-6	-74	-18
4	14	46
-6	16	40

// Nelissen N, 2011: Primary Progressive Aphasia (PPA)
// Subjects=19
45	6	-33

// Nelissen N, 2011: Alzheimer's Disease
// Subjects=15
54	9	-6
63	-21	15

// Nelissen N, 2011: Control Group
// Subjects=37
54	9	-6
63	-21	15
45	6	-33

// Wierenga C E, 2011: Probable Alzheimer's Disease
// Subjects=10
41.77	5.61	8.36
41.82	10.53	16.87
16.42	37.06	59.55
54.46	32.84	1.47
7.3	70.62	-1.15
63.22	13.11	20.87
45.92	76.8	20.19
11.72	39.27	5.89
50.16	30.36	-2.73
33.07	47.86	4.92
11.72	39.27	5.89
50.16	30.36	-2.73
54.52	7.12	-.83
16.08	35.75	15.05
37.43	22.5	7
41.51	48.99	-8.65
12.07	20.86	43.11
45.98	13.75	3.17
58.83	42.69	18.44
33.34	39.68	36.83
41.58	47.57	0.39
37.44	29.19	10.9
20.62	18.8	43.19

// Wierenga C E, 2011: Healthy Controls
// Subjects=22
50.48	18.29	33.97
46.17	17.92	29.59
28.98	60.8	35.11
41.48	75.06	-1.92
12.15	45.84	63.32
33.13	68.26	21.05
24.94	45.57	58.74
3.22	63.85	21.77
41.76	27.45	15.46
24.65	38.26	19.21
12.01	22.46	36.29
7.62	21.24	20.83
11.72	39.27	5.89
50.16	30.36	-2.73
33.07	47.86	4.92
11.72	39.27	5.89
50.16	30.36	-2.73
54.52	7.12	-.83
16.08	35.75	15.05
37.43	22.5	7
41.51	48.99	-8.65
12.07	20.86	43.11
45.98	13.75	3.17
58.83	42.69	18.44
33.34	39.68	36.83
41.58	47.57	0.39
37.44	29.19	10.9
20.62	18.8	43.19

// Frings L, 2010: Controls > Patients, Naming Task
// Frings L, 2010: Patients > Controls, Naming Task
// Subjects=6
-54	-12	39
-48	-72	0
54	-6	30
-48	-24	9
-39	-48	-18
48	-63	-15
63	-3	18
-18	-30	60
-60	3	3
33	-27	-21
-6	-57	33
63	-12	-18
-3	-66	51

// Fonzo G A, 2010: Intimate-Partner Violence with PTSD (IPV-PTSD) > Controls, 
// Fearful > Happy
// Fonzo G A, 2010: Controls > IPV-PTSD, Fearful > Happy
// Fonzo G A, 2010: IPV-PTSD > Controls, Angry > Happy
// Fonzo G A, 2010: Controls > IPV-PTSD, Angry > Happy
// Fonzo G A, 2010: IPV-PTSD > Controls, Male > Female faces
// Fonzo G A, 2010: Controls > IPV-PTSD, Males > Females faces
// Subjects=12
-2.82	-38.33	-41.19
-46.51	21.31	28.02
-45.81	-3.38	39.01
50.31	-72.4	17.26
46.69	6.76	8.99
32.04	64.8	3.85
-10.43	-49.52	48.83
-4.44	6.53	31.23
-58.91	-6.19	-11.46
-33.76	-6.38	34.88
-47.3	11.72	-9.3
-25.29	-18.74	47.64
-36.95	-44.86	-34.45
4.83	49.34	17.05
1	37.8	-13.49
44.19	-47.79	37.46
20.2	-61.98	39.04
-45.11	-61.61	23.59
-50.02	-5.46	33.1

// Ham T E, 2014: Controls for Stop Signal Task
// Subjects=25
62	-6	26
60	-4	6
46	6	-2
-34	2	6
-46	16	6
-60	-10	32
-14	6	14
-28	0	10
26	8	10
28	24	42

// Ham T E, 2014: Low-Performance Monitoring (PM)
// Subjects=18
62	-6	26
60	-4	6
46	6	-2
-34	2	6
-46	16	6
-60	-10	32
-36	-18	40
-44	16	6
-46	-16	14

// Ham T E, 2014: High-Performance Monitoring (PM)
// Subjects=30
-36	-18	40
-44	16	6
-46	-16	14
-14	6	14
-28	0	10
26	8	10
28	24	42

// Landr L, 2012: PTSD patients
// Subjects=17
-25.7	-2.6	43.4
35.6	-76	13.9
-17.8	-60.5	51.8
-31.7	21	51.4
-7.9	-45.7	36.3
63.4	-16.2	5.4
43.6	-46.8	53
35.6	20.3	-1.8
-47.5	-10.2	8.8
-9.9	57.1	34.9
-25.7	-83.3	-15.2
-41.6	20.1	-5.2
-7.9	57	33.1
-11.8	38.3	46.9
-23.7	-80.8	34.4
0	-47.6	38.3
-3.9	-49.4	42.1

// Landr L, 2012: Controls
// Subjects=17
25.7	-72.3	10.1
25.7	-72.3	10.1
-27.7	-4.7	41.7
21.8	5.9	61.4
5.9	14.7	42.5
45.5	8	24.5
3.9	28	36.4
-35.6	-60.6	50
33.6	-74.8	-39.1
-5.9	-81.8	-23.6
-47.5	-10.2	8.8
-15.8	57.1	34.9
-29.7	-82.9	-6.8
-11.8	38.3	46.9
-23.7	-80.8	34.4
0	-47.6	38.3
-3.9	-49.4	42.1

// Linnman C, 2011: PTSD > Trauma-exposed Non-combat Controls, Unconditioned 
// Stimulus
// Subjects=19
-22	0	-6
18	10	-12
-22	-4	48
-18	-38	-4

// Mazza M, 2012: PTSD > Healthy Controls
// Mazza M, 2012: Healthy Controls > PTSD
// Mazza M, 2012: Main Effect of Priming, All Subjects
// Subjects=10
49.2	-5.86	-3.03
-18.25	-14.15	-21.63
-11.46	-99.25	-7.88
-27.62	31.14	28.21
20.66	20.28	48.64
-46.81	-1.46	21.13
55.64	-5.56	0.22
43.23	-34.28	42.92
17.57	-57.67	31.79
-27.42	-30.44	30.03
-24.08	-44.46	41.2
58.96	-30.67	5.63
-47.02	-62.93	-30.59
-24.2	-88.52	8.09

// Moser D A, 2013: PTSD patients
// Subjects=11
-30	-28	-18
-28	-36	-18
-16	-24	-22
-22	-18	-26
-6	-24	38
-44	-32	22
56	-6	-18
54	2	0
-32	-22	60
-42	-16	58
-54	-20	54
-18	-12	66
-48	4	20
-56	14	12
20	-18	-12
-22	-20	-22
-14	-26	-20
-26	-20	64
-12	-18	46
-14	-20	70
6	-38	-22
-10	-46	-18
-16	-46	-26
48	26	28
-20	-12	62
-20	-10	70
50	20	-6
44	26	-14
-14	-42	44
-8	-38	52
-2	-24	38
0	-16	34
32	-14	-28
20	-20	-22
-34	-46	-24
-40	-36	-16
-24	-34	-16
56	6	0
44	-8	-22
46	-20	-14
54	-8	-22
-62	-46	6
-58	-52	0
-2	-42	48

// Sozda C N, 2011: Severe Traumatic Brain Injury (sTBI)
// Subjects=10
-2.13	-16.45	-11.58
26.77	-22.37	-8.08
33.13	19.94	1.69
-47.04	25.8	2.12
-11.6	34.41	27.75
4.14	-40.93	-39.71
-37.28	-54.99	-11.3
-47.12	5.22	-16.23
26.78	-18.94	-5.02
10.87	-7.98	14.32
-11.56	-4.68	17.65
26.73	56.33	18.78
-20.85	-63.98	36.11
24.08	-69.8	39.43
4.65	-19.16	35.4
-30.81	41.15	34.1
-43.33	-5.13	55.97
-17.7	11.31	59.87
10.97	-82.74	-2.83
-17.85	-79.22	3.9
62.09	-8.44	3.73
7.81	-55.84	15.02
-43.57	-10.96	21.89
-36.88	-77.28	30.72
17.3	21.9	28.47
17.44	-16.17	31.66
-46.75	15.68	36.42
43.21	-27.94	42.39
46.27	10.15	39.16
-27.31	-18.33	49.08
-33.51	-46.94	64.94
17.78	-19.17	75.4
20.51	18.74	28.7
-11.84	-53.72	-38.46
33.13	19.94	1.69
-50.21	22.87	5.74
14.1	18.7	28.77
-11.58	34.67	31.07

// Sozda C N, 2011: Healthy Controls
// Subjects=12
-2.13	-16.45	-11.58
26.77	-22.37	-8.08
33.13	19.94	1.69
-47.04	25.8	2.12
-11.6	34.41	27.75
4.14	-40.93	-39.71
-37.28	-54.99	-11.3
-47.12	5.22	-16.23
26.78	-18.94	-5.02
10.87	-7.98	14.32
-11.56	-4.68	17.65
26.73	56.33	18.78
-20.85	-63.98	36.11
24.08	-69.8	39.43
4.65	-19.16	35.4
-30.81	41.15	34.1
-43.33	-5.13	55.97
-17.7	11.31	59.87
10.97	-82.74	-2.83
-17.85	-79.22	3.9
62.09	-8.44	3.73
7.81	-55.84	15.02
-43.57	-10.96	21.89
-36.88	-77.28	30.72
17.3	21.9	28.47
17.44	-16.17	31.66
-46.75	15.68	36.42
43.21	-27.94	42.39
46.27	10.15	39.16
-27.31	-18.33	49.08
-33.51	-46.94	64.94
17.78	-19.17	75.4
20.51	18.74	28.7
-11.84	-53.72	-38.46
-15.03	-50.31	-35.36
-8.57	-10.15	-12.04
33.04	15.74	-11.34
-47.04	25.8	2.12
50.66	-67.76	22.22
-11.59	31.24	28.02
-4.78	-47	47.88
-11.32	14.26	56.2

// Terry D P, 2012: Mild Traumatic Brain Injury (mTBI), Athletes
// Subjects=20
-2	0	58
-44	-4	13
39	-27	60
-57	-21	18
22	-57	-23
-20	-54	-23
-44	-13	54
58	-15	19
-56	-22	39
57	11	25
-58	6	22
-8	9	55
-48	26	25
-26	-70	36
-33	-87	6
39	-87	-3
34	-64	-30
44	15	-9
-46	9	0
28	-90	7
54	8	39
-4	-60	40
-2	5	57
-33	36	27
44	-37	4
18	-49	28
-48	-3	45
-48	-46	18
-8	-67	39
-22	3	13
46	0	49
-30	-21	46

// Terry D P, 2012: Control, Athletes
// Subjects=20
-51	-22	45
48	-22	51
42	-3	12
-2	-1	54
62	11	25
51	-21	18
-30	-63	42
26	-57	40
30	-81	15
-3	-61	39
36	-82	-3
-4	0	59
-8	18	36
-46	-9	42
36	39	37
-56	-1	15
21	0	63
54	0	49
-24	-88	4
-58	-16	16

// Bogg T, 2012: Decision Period < Fixation
// Bogg T, 2012: Inflation Choice > Fixation
// Bogg T, 2012: Explosions > Fixation
// Subjects=27
-2	-86	6
8	-30	58
-12	38	-18
-32	-16	16
4	40	-22
4	-76	-4

// Chanraud S, 2013: Analysis of Variance (Group x Condition x Load)
// Subjects=15
48	47	7
-27	-70	-17
-42	-25	-43
-6	-40	37
-33	50	25
45	-19	46
18	-70	-11

// Chaunrad S, 2011: Alcoholics > Controls
// Chaunrad S, 2011: Controls > Alcoholics
// Subjects=15
42	-1	-14
-42	11	-14
45	-19	46
48	41	13
-33	50	25
-30	-67	-14
18	-70	-11

// Weiland B J, 2012: Negative Correlation with Resiliency for Entire Sample
// Weiland B J, 2012: 2-back > 0-back
// Weiland B J, 2012: 2-back < 0-back
// Subjects=34
20	-2	6
10	-14	-8
30	64	-6
26	48	-16
-46	28	28
44	26	32
30	24	-2
4	22	42
-34	20	0
30	6	54
42	-52	40
6	-62	48
-6	60	-3
14	40	46
-40	34	-14
50	-2	-26
36	-2	14
-40	-20	54
38	-30	64
-6	-46	24
-52	-64	30

// Gradin V B, 2013: Schizophrenia
// Subjects=14
-62.37	-8.29	20.83
-52.7	-8.67	16.22
-46.35	-3.09	6.59
60.71	0.24	13.41
58.61	-8.07	16.5
44.34	0.11	1.37
1.47	29.87	35.02
3.36	-22.48	3.18
-29.33	4.88	-12.41
26.97	1.55	-5.2
-57.66	-29.49	46.38
24.66	-52.11	-27.86
27.5	-80.91	19.76

// Gradin V B, 2013: Healthy Controls
// Subjects=18
-25	2.77	-12.28
-22.95	-3.58	-22.89
-35.53	-5.08	7.73
-66.74	-8.72	16.46
-22.73	-67.6	-18.8
33.49	-.35	-2.88
26.8	-2.99	-19.31
40.06	2.53	4.57
62.93	-8.05	16.43
22.68	-69.36	-17.16
-.6	20.7	40.44
5.37	-15.96	-7.58
-4.88	-91.77	20.27
7.12	46.62	-27.25
-1.23	65.24	0.19
-11.57	-52.85	12.05
-28.77	31.99	36.44
31.73	38.79	36.98
56.64	-74.43	18.62
-47.93	-76.43	37.41
14.38	29.5	30.35
-29.33	4.88	-12.41
26.97	1.55	-5.2
-57.66	-29.49	46.38
24.66	-52.11	-27.86
27.5	-80.91	19.76

// Grimm O, 2012: Food Images > Scrambled Control Images
// Subjects=23
30	-62	-12
-38	4	-12
46	16	-8
26	-42	-46
48	38	14
46	6	28
-24	-14	-20
-30	30	12
24	28	-16
0	2	28
-32	-54	-14

// Rausch F, 2014: Reasoning > Control
// Subjects=23
51	-43	46
30	-70	49
30	-76	31
36	20	-2
39	53	-5
30	26	-11
3	29	43
-30	20	-5
-42	44	-5
-21	47	-14
-45	26	31
-45	8	34
-42	2	58
63	-28	-20
-12	-4	-5
-18	17	61

// da Silva Alves F, 2013: Healthy Controls
// Subjects=12
37.98	-29.7	4.43
-.82	-46.64	9.01
41.83	17.17	-22.69
-16.37	18	-10.57
-2.49	24.9	62.47
-5.11	32.41	28.15
-15.98	29.62	21.89
-3.08	29.25	17.22
42.16	28.37	5.34
35.63	47.7	5.77

// da Silva Alves F, 2013: Schizophrenia
// Subjects=10
52.89	25.66	-1.3
35.63	47.7	5.77
39.88	14.36	-6.69
48.74	24.77	12.3
-5.29	35.42	14.41
52.91	28	0.71
37.68	18.4	-9.29
37.98	-29.7	4.43
-.82	-46.64	9.01
41.83	17.17	-22.69
-16.37	18	-10.57
-2.49	24.9	62.47
-5.11	32.41	28.15
-15.98	29.62	21.89
-3.08	29.25	17.22
42.16	28.37	5.34
35.63	47.7	5.77

// Polosan M, 2011: Incongruent (Human + Machine) > Congruent (Human + 
// Machine)
// Polosan M, 2011: Human (Incongruent + Congruent) > Machine (Incongruent + 
// Congruent)
// Polosan M, 2011: [Human (Incongruent > Congruent)] > [Machine (Incongruent 
// > Congruent)]
// Subjects=14
14.91	14.84	68.77
36.75	60.03	11.26
8.11	14.66	44.25
-40.43	6.29	49.27
52.91	21.41	-.88
17.37	35.29	11.8
36.75	31.55	5.11
40.8	-56.48	50.73
-27.08	-44.42	68.63
49.77	-68.65	-10.97
-10.95	-71.14	57.55
-1.28	-49.63	57.5
14.51	-99.77	14
-5.6	56.09	-5.56
-5.26	58.58	21.08
56.06	37.17	-4.74
-5.54	56.51	-1.12
-47.36	12.73	15.13
69.46	-25.15	16.89
36.46	-16.55	-27.1
33.7	-88.49	-4.25
-31.23	-73.08	-8.03
-28.06	-44.04	-7.59
60.14	-2.51	52.91
30.31	64.68	15.39
14.21	35.9	18.51
39.8	20.32	-11.76
-57.26	-60.83	-13.28
72.46	-49.97	-7.6
33.37	-44.97	-20.88

// Raboyeau G, 2010: Cognates > Baba, Early Learning Phase (T1)
// Raboyeau G, 2010: Non-cognates > Baba, T1
// Raboyeau G, 2010: Cognates > Baba, Consolidation Phase (T2)
// Raboyeau G, 2010: Non-cognates > Baba, (T2)
// Raboyeau G, 2010: [(Spanish Naming > Baba, T1 > T2]) masked by [(French 
// Naming > Baba, T1 > T2)]
// Raboyeau G, 2010: [(Spanish Naming > Baba, T2 > T1)] masked by [(French 
// Naming > Baba, T2 > T1)]
// Raboyeau G, 2010: Non-cognates > Cognates, T1
// Raboyeau G, 2010: Cognates > Non-cognates, T2
// Raboyeau G, 2010: Non-cognates > Cognates, T2
// Subjects=10
-48.53	-61.24	-6.67
-35.59	32.77	10.71
-52.71	12.06	19.77
-39.87	46.14	16.18
-26.21	-1.13	60.97
-7.05	20.89	42.77
-28.43	-51.93	45.86
-54.97	-71.89	-5.5
-9.21	-75.41	23.2
-31.52	39.63	-7.97
-19.87	6.57	51.13
-24.03	-66.59	49.48
-19.64	-61.7	55.64
37.58	28.62	-14.78
12.39	23.08	42.22
-52.68	-77.44	3.97
-50.42	2.06	27.45
-6.71	14.66	68.04
-13.77	30.05	26.29
-41.41	-25.82	50.22
-48.78	-69.69	-28.24
50.99	-64.31	0.91
14.48	5.03	32.77
26.69	-37.73	-34.92
-52.58	-72.35	12.43
-35.47	9.58	15.24
-27.11	46.86	0.2
-11.62	34.31	25.83
-43.6	-26.04	48.04
-19.47	-53.87	70.55
51.03	-68.35	3.55
22.87	-27.41	6.7
7.76	-53.62	2.83
13.77	-48.41	-33.65
-33.67	37.5	-7.72
-41.91	36.12	23.93
-43.93	21.85	32.1
-13.83	38.35	23.23
33.2	43.49	-16.18
-54.79	-.5	23.29
-31.15	-18.89	9.02
21.61	-9.72	81.17
9.46	-43.96	-31.77
-49.13	-2.25	-41.63
-17.83	7.88	42
-10.25	-59.08	-54.59
43.67	3.84	-50.53
54.88	-25.95	-25.36
29.6	-106.51	9.93
44.11	-27.91	-22.75
12.28	-1.77	29
50.84	26.49	7.62
27.13	55.3	18.61
38.25	9.58	34.16
30.02	-.51	64.43
43.01	-44.05	57.31
33.52	13.04	2.52
18.14	-10.78	-21.76
-33	-71.24	23.2
-50.52	-62.12	6.9
-15.8	17.9	34.25
-17.59	18.46	63.36
-24.14	-30.23	48.12

// Jurjanz L, 2011: Amnestic Mild Cognitive Impairment (aMCI) group
// Subjects=12
-9	-54	30
-9	45	15
57	-36	48
6	-60	21
-3	30	15
6	30	15
48	6	18
60	-57	-9
18	-60	-51
-39	-45	63
39	-21	51
39	-24	60
45	-24	21
57	-63	9
54	-27	24
57	-57	36
-54	-57	12
0	-63	33
30	9	-24
-27	-45	15
-36	-87	21
36	84	21
30	-39	-15
18	-75	-6
30	-3	51
30	15	63
-6	-61	35
6	-61	29
45	20	8
39	53	8

// Jurjanz L, 2011: Healthy Controls
// Subjects=12
-9	-54	30
-9	45	15
57	-36	48
6	-60	21
-3	30	15
6	30	15
48	6	18
60	-57	-9
18	-60	-51
-39	-45	63
39	-21	51
39	-24	60
45	-24	21
57	-63	9
54	-27	24
57	-57	36
-54	-57	12
0	-63	33
30	9	-24
-27	-45	15
-36	-87	21
36	84	21
30	-39	-15
18	-75	-6
30	-3	51
30	15	63
-9	45	17
-12	-51	30
-24	30	39
-30	24	-18
-51	6	12
-33	-12	51
-36	-42	45
33	-54	-51
51	-51	3
45	20	8
39	53	8

// Lenzi D, 2011: Single Domain Amnestic Mild Cognitive Impairment (sd-a-MCI)
// Subjects=15
-50	14	-18
62	-4	-8
-50	-62	-12
-38	30	-16
-8	50	44
36	30	-18
-24	-14	-16
22	-8	-20
-6	-62	14
-58	-16	0
62	-4	-8
-54	-42	0
-34	22	-6
-56	28	8
54	-36	44
54	-36	44
40	-62	48
4	18	46
56	16	8
26	22	-14
42	-2	44
38	-2	52
-28	-8	60
16	-10	72
32	-76	-20
44	-60	-18
-52	10	40
44	4	48
-44	20	30
50	26	14
-2	4	60
-34	-44	-24
34	-56	-28
-8	22	40
-26	-100	10
-38	-64	-24
40	-84	-12

// Lenzi D, 2011: Healthy Controls
// Subjects=14
-58	-20	-2
64	-6	-6
-56	-54	-16
-50	30	8
-8	56	32
-38	30	-14
-24	-14	-18
24	-8	-22
-8	-56	-2
-56	-16	2
62	-6	-8
-64	-34	-2
36	22	-8
-50	26	6
50	-34	46
-30	-56	54
-16	-66	52
48	18	-18
48	38	18
32	22	-8
42	4	32
36	0	54
-22	-6	48
4	32	46
24	-72	38
56	-54	-18
-44	6	36
54	4	44
-50	24	2
56	38	12
-6	10	56
-38	-54	-24
44	-52	-16
-16	8	42
-28	-98	12
-38	-68	-30
38	-68	-30

// Viinikainen M, 2010: Positive Linear Correlation between Negative Valence 
// and BOLD Activity
// Viinikainen M, 2010: Negative Linear Correlation between Negative Valence 
// and BOLD Activity
// Viinikainen M, 2010: Positive Linear Correlation between Positive Valence 
// and BOLD Activity
// Viinikainen M, 2010: Negative Linear Correlation between Positive Valence 
// and BOLD Activity
// Viinikainen M, 2010: Second-order Positive Correlation Across all Pictures
// Viinikainen M, 2010: Second-order Negative Correlation Across all Pictures
// Subjects=17
46.09	24.73	21.21
-31.09	25.13	-8.05
33.05	25.77	-5.49
-47.21	50.41	-9.98
23.33	54.26	-7.77
-15.18	56.94	-10.9
36.13	17.9	-24.94
20.18	-1.23	-23.15
-65.8	-38.62	37.84
-59.28	-40.72	51.33
46.1	21.55	21.48
-34.28	21.93	-7.74
45.89	29.27	-2.59
-4.92	17.47	55.86
14.19	29.51	44.59
14.09	21.88	28.51
-33.91	12.59	36.53
-46.89	20.74	19.27
-8.49	10.43	6.31
-14.74	-4.45	21.01
14.04	8.16	16.28
-33.79	-81.72	14.33
39.92	-74.94	12.91
-62.88	-38.25	0.98
4.38	-15.39	1.63
1.1	-22.78	-11.09
39.64	-48.18	-12.75
-27.71	-48.84	-15.27
-59.32	-37.81	47.74
65.71	-23.86	51.82
52.53	-4.56	13.55
49.31	28.18	24.23
-43.8	16.3	2.87
33.07	22.59	-5.23
-1.8	19.89	45.58
10.97	26.06	41.57
-59.79	26.49	12.24
-11.69	17.01	9.14
-33.78	-84.89	14.59
36.73	-78.13	13.21
33.19	-45.31	-16.26
-21.15	-60.47	-.98
43.04	3.27	33.08
14.09	-47.31	0.85
-27.72	-45.67	-15.53

// Vollstadt-Klein S, 2010: Spatial Working Memory > Control, Alcohol 
// Dependent > Heavy and Light Social Drinkers
// Vollstadt-Klein S, 2010: Positive Association between OCDS and Activations 
// During Spatial Working Memory Task in All Subjects
// Subjects=7
-12	42	26
-28	-28	-10
18	-12	-2

// Witt S T, 2010: Mild Traumatic brain injury (TBI)
// Subjects=33
39	42	18
-12	-15	3
-9	-18	-6
3	-24	-18
-63	51	24
-42	-36	63
6	18	45
-3	9	48
-48	12	9
-30	-12	69
57	-33	48
-33	-51	-36
-30	-57	-33
42	18	-12
-39	-18	66
-36	-24	69
-48	-27	27
-63	-39	24
-63	-21	18
-54	-25	48
-57	-21	45
66	-30	18
-51	-12	6
63	-12	3
63	-15	9
57	-21	-3
57	-36	9
-54	-36	9
-51	-93	12
-45	0	-3
-63	-30	6
-60	-21	12
24	-54	-30
-54	0	-9
-60	-36	15
-63	-15	0
60	-36	6
63	-12	0
57	-27	3
-60	-36	15
-63	-15	0
60	-36	6
63	-12	0
57	-27	3
33	15	-18
-15	15	-18
-24	-24	75
-48	12	9
-12	24	66
-63	-42	30
-39	-36	-27
-48	-60	-6
3	6	-15
-54	-72	-9
-15	-42	-30
-30	-39	-30
-3	-51	-21
0	-18	-6
39	-57	-42
-18	3	-27
-66	-18	27
66	-27	36
63	-30	45
24	-3	-36
12	51	6
48	21	30
18	-63	45
30	-69	60
33	24	24
-27	0	36
60	-63	24
0	27	0
27	33	45
-60	6	30
33	-51	66
33	-60	-45
63	-45	36
60	-3	18
-63	-3	18
-15	27	54
-30	24	54
-45	-15	27
-6	-6	36
45	-18	12
30	-3	-24
42	12	-21
-18	9	9
-9	-60	-48
21	-21	-24
60	-36	-15
-30	-96	15
-15	-63	21
9	-42	39
45	-72	24
-48	-60	15
-42	-45	9
39	-39	3
-30	-96	15
3	30	3
6	45	9
6	36	-9
6	-66	15
-12	-66	6
-3	-72	12

// Witt S T, 2010: Healthy controls
// Subjects=33
45	-27	18
-27	42	12
12	15	6
9	21	27
6	15	39
-6	6	39
30	21	-9
-42	0	3
39	9	-3
-6	-3	54
39	36	27
-36	-12	63
6	6	54
54	-42	45
-51	-36	36
-51	-24	51
-33	-24	48
54	-27	-3
-51	-15	3
63	-33	9
-45	-30	15
54	18	-12
-57	-30	15
-15	-18	12
15	-54	-21
-30	-57	-39
3	-69	-18
12	-57	-18
39	30	9
57	-12	-6
57	-30	0
-57	-12	-3
-63	-33	3
33	15	-18
-15	15	-18
-24	-24	75
-48	12	9
-12	24	66
-63	-42	30
-39	-36	-27
-48	-60	-6
3	6	-15
-54	-72	-9
-15	-42	-30
-30	-39	-30
-3	-51	-21
0	-18	-6
39	-57	-42
-18	3	-27
-66	-18	27
66	-27	36
63	-30	45
24	-3	-36
12	51	6
48	21	30
18	-63	45
30	-69	60
33	24	24
-27	0	36
60	-63	24
0	27	0
27	33	45
-60	6	30
33	-51	66
33	-60	-45
63	-45	36
60	-3	18
-63	-3	18
-15	27	54
-30	24	54
-45	-15	27
-6	-6	36
45	-18	12
30	-3	-24
42	12	-21
-18	9	9
-9	-60	-48
21	-21	-24
60	-36	-15
-30	-96	15
-15	-63	21
9	-42	39
45	-72	24
-48	-60	15
-42	-45	9
39	-39	3
-30	-96	15
3	30	3
6	45	9
6	36	-9
6	-66	15
-12	-66	6
-3	-72	12

// Van Hell H H, 2010: Non-users > Cannabis Users
// Van Hell H H, 2010: Cannabis Users > Non-users
// Van Hell H H, 2010: Cigarette Smokers > Cannabis Users
// Van Hell H H, 2010: Cannabis Users > Cigarette Smokers
// Van Hell H H, 2010: Non-users > Cannabis Users, Reward Outcome Activations
// Van Hell H H, 2010: Cannabis Users > Non-users, Reward Outcome Activations
// Van Hell H H, 2010: Cigarette Smokers > Cannabis Users, Reward Outcome 
// Activations
// Van Hell H H, 2010: Cannabis Users > Cigarette Smokers, Reward Outcome 
// Activations
// Subjects=13
-16	14	-10
16	13	-6
-12	8	3
12	8	3
-28	0	-3
32	23	-11
4	37	35
20	59	15
-28	52	27
-4	2	33
-20	-94	-5
-24	-93	5
-48	-68	20
40	-64	20
12	-76	24
24	-16	-24
-8	8	8
16	-4	20
-24	0	-8
-16	-8	16
48	20	-4
20	60	12
-24	56	28
-48	-68	20
-44	-28	-12
-36	-62	10
-12	-68	3
1	-62	10
20	17	30
28	33	40
33	-83	-6
36	0	-9
43	34	-14
53	-1	-13
55	-18	22
63	-30	31
62	-43	14
-51	-65	22
-55	-26	20
-27	-39	-8
-38	27	-4
-20	4	8
-8	-65	26
-14	-25	38
6	58	1
8	32	24
4	-18	29
12	4	7
19	8	-11
24	-72	30
22	-10	35
48	-6	34
48	10	32
43	78	15
-44	-40	-8
4	-60	14
28	49	-2
55	-6	-16
-55	-25	9
-24	14	8
0	59	15
1	2	34
25	0	18

// Gebauer L, 2014: Happy > Sad, ASD > Healthy Controls
// Gebauer L, 2014: (Happy & Sad) > Neutral, All Participants
// Gebauer L, 2014: Happy > Sad, All Participants
// Subjects=19
-24	34	42
-50	-2	8
-26	52	32
54	-14	6
-48	-16	4
54	-4	46
-6	42	-14
-6	-24	-6
-26	28	-14
-42	-18	54
10	0	58
-18	-10	-16
2	6	-6
46	28	-4
-36	26	2
38	34	-16
-56	-10	2
56	-12	4
-24	34	42
-8	46	0
-14	24	-10
24	2	-10
36	10	-22
-4	50	26
-52	-10	52
-58	-60	16
0	-22	42

// Kana R K, 2014: Autism Spectrum Disorder (ASD)
// Subjects=15
32	-52	42
54	38	2
22	-76	46
-30	-70	46
54	-64	12
4	-56	34
-48	-70	14
6	52	18
50	-62	18
-54	-66	16
4	-56	46
34	24	-12
-38	8	46
-32	24	-6
4	54	28
52	-30	48
27	-76	46
42	2	10
-22	-50	64
-60	-24	40
56	-26	48
-42	-4	0
46	48	-2
-4	-90	-6

// Kana R K, 2014: Healthy Controls
// Subjects=15
32	-52	42
54	38	2
22	-76	46
-30	-70	46
-60	-64	14
62	-52	16
-40	8	48
6	-54	48
40	-42	-22
46	10	44
34	20	-12
50	-62	18
-54	-66	16
4	-56	46
34	24	-12
-38	8	46
-32	24	-6
4	54	28
44	-40	62
-46	-40	54
-52	-2	2
44	2	-8
6	-24	56
56	-26	48
-42	-4	0
46	48	-2
-4	-90	-6

// Alaerts K, 2014: Emotion > Fixation, Healthy Controls > ASD
// Subjects=15
-45	-32	24
-17	-94	12

// Beacher F D C C, 2012: Asperger Syndrome (AS) > Healthy Controls, Verbal 
// Fluency
// Beacher F D C C, 2012: Males > Females, Verbal Fluency
// Beacher F D C C, 2012: Males > Females, Mental Rotation
// Beacher F D C C, 2012: Sex x Diagnosis Interaction, Mental Rotation
// Beacher F D C C, 2012: AS males > AS females >= Healthy Controls males > 
// Healthy Controls females, Verbal Fluency
// Beacher F D C C, 2012: AS males > AS females >= Healthy Controls males > 
// Healthy Controls females, Mental Rotation
// Subjects=14
-54	-62	-14
-48	22	-14
-42	-40	44
-24	-34	13
22	-16	-16
-20	-80	-22
-34	-90	16
-20	-88	-14
30	-90	16
46	-82	-4
-34	-48	50
32	-60	48
-26	-70	34
-22	-60	46
-50	-54	-18
-30	-2	56
-12	10	56
0	-88	-8

// Bird G, 2010: Other Pain - Other No Pain masked on Self Pain - Self No 
// Pain, Low Alexithymic
// Bird G, 2010: Other Pain - Other No Pain masked on Self Pain - Self No 
// Pain, High Alexithymic
// Bird G, 2010: Other Pain - Other No Pain masked on Self Pain - Self No 
// Pain, Low > High Alexithymic
// Bird G, 2010: Other Pain - Other No Pain masked on Self Pain - Self No 
// Pain, High > Low Alexithymic
// Bird G, 2010: Other Pain - Other No Pain masked on Self Pain - Self No 
// Pain, Healthy Controls > Autism
// Subjects=18
-12	12	36
-9	-30	42
-27	-18	-9
-9	6	0
57	-45	18
66	-3	-9
15	15	-3
21	-3	6
-3	27	48
0	-6	42
-57	-21	24
-12	-102	-6
57	21	0
42	3	36
54	-45	18
60	-27	-9
36	-63	-30
-21	-15	-9
-3	9	3
15	-12	-12
24	-6	0
21	-48	21
-39	24	24
24	-81	-9

// Gadgil M, 2013: Autism Spectrum Disorders (ASD)
// Subjects=16
42	-70	7
-42	-82	-5
39	2	55
-42	11	28
33	20	-5
-33	20	7
-33	44	13
48	-64	1
30	-91	-2
-36	-85	-5
-39	-79	4
30	-1	61
-33	-7	58
-42	50	4
-35	38	16
-39	23	4
15	-4	16
12	-16	10
27	-91	25
15	-91	16
45	-10	58
-51	-61	52
-39	-13	49
48	-73	-8
42	-64	-11
21	14	55
3	38	46
-3	38	37

// Gadgil M, 2013: Healthy Controls
// Subjects=15
-33	-85	-8
27	-58	52
39	20	4
-33	17	7
-54	8	40
48	11	25
-3	11	46
6	5	64
42	-82	-2
39	-55	55
33	23	1
-33	20	1
-48	11	25
39	38	25
-48	2	43
-30	47	25
9	-19	16
18	5	16
30	-91	-2
-51	20	25
45	-61	25
6	-28	52
-3	-28	52
-18	11	10
-51	26	7
6	50	43
-3	41	34
48	-73	-8
42	-64	-11
21	14	55
3	38	46
-3	38	37

// Georgescu A L, 2013: High-Functioning Autism (HFA)
// Subjects=13
66	-45	6
11	-60	23
45	-63	23
-32	-33	-18
-26	-36	-12
-38	23	48
-59	-12	-15
-47	-6	-33
-9	35	-29
24	-33	-14
32	-41	-9
-45	-66	21
56	-14	-27
51	-9	-20
-44	-65	20
0	15	-18
-2	48	-21
12	-60	21
-60	-12	-20
11	-50	60
57	-14	-18
48	-68	14
-9	33	15
5	27	18
11	38	-17
-38	-9	-6
-6	-80	38
3	-72	38

// Georgescu A L, 2013: Healthy Controls
// Subjects=13
47	-68	-2
-45	-72	2
48	2	6
41	8	3
12	-51	66
-5	-35	60
-51	-32	8
57	-41	12
47	-36	23
65	-47	15
-44	-65	20
0	15	-18
-2	48	-21
12	-60	21
-60	-12	-20
11	-50	60
57	-14	-18
48	-68	14
-9	33	15
5	30	18
-50	-62	23
-9	33	15
5	27	18
11	38	-17
-38	-9	-6

// Marsh L E, 2011: Autistic Spectrum Conditions (ASC)
// Subjects=18
44	-84	-14
32	-92	-4
36	-88	-12
-22	-102	-12
-52	-78	2
-30	-102	-8
-10	10	40
-8	0	46
-12	-4	70
-22	-74	0
-6	-90	-16
-26	-68	-4
-24	-10	38
-35	5	24
-25	-10	48
-56	-28	36
-35	-38	72
-60	-16	20
20	-50	40
30	-56	62
22	-70	54
-22	-100	-12
-36	-92	-12
-44	-86	-12
46	-84	-14
32	-94	0
34	-88	-12
-46	-10	18
-52	-24	18
-30	-26	18
18	12	34
-16	0	76
-12	-6	70
-14	-58	-12
-12	-88	-14
-6	-52	-20
-14	-102	-8
12	-102	-2
16	-88	-4
-22	-76	-12

// Marsh L E, 2011: Healthy Controls
// Subjects=19
48	-70	-2
-48	-76	-2
-44	-82	-10
-38	-48	64
-16	-50	76
-12	10	38
-24	-6	74
-6	0	44
22	-30	-2
6	-14	-12
8	-22	-16
-10	10	40
-8	0	46
-12	-4	70
-22	-74	0
-6	-90	-16
-26	-68	-4
8	60	6
-4	60	14
0	48	-6
38	-40	50
28	-64	54
22	-70	46
48	-72	-4
26	-96	-6
26	-92	-16
-44	-82	-12
-48	-76	-2
-50	-80	6
-6	-1	62
-10	10	36
-24	-6	74
64	-38	20
52	-35	24
48	-52	36
-36	-42	60
-32	-48	70
-52	-32	56
6	-22	0
6	-24	22
22	-30	-4
-46	-10	18
-52	-24	18
-30	-26	18
18	12	34
-16	0	76
-12	-6	70
-14	-58	-12
-12	-88	-14
-6	-52	-20
-16	-94	-20
0	-96	-16
-5	-92	-26
22	-88	-16
42	18	-16
34	12	4
36	-16	-20
56	-74	0
40	-62	-20
-48	-82	6
-28	-70	-8
-16	-78	-10

// Ohta H, 2012: Autism Spectrum Conditions (ASC)
// Subjects=24
16	-92	-6
-26	-28	-6
26	-26	-6
-22	-76	40
-46	36	34
-18	-76	40
-50	-46	58
-4	-62	58
30	4	56
-28	-62	40
24	-52	40
-42	16	28
-44	-72	8
-60	-2	-20
26	-18	-18
58	-4	4
48	2	-24
40	-10	12
-6	-62	24
-4	54	-4
-30	-90	2

// Ohta H, 2012: Healthy Controls
// Subjects=25
24	-102	4
-18	-76	40
-50	-46	58
-4	-62	58
-38	-52	50
32	-2	50
32	-70	36
-2	14	54
-2	-46	-18
-48	-56	-12
50	-10	12
-50	-76	30
-14	54	38
-6	-54	26
54	-14	58
-28	-102	-4
10	-16	48
-22	6	-24
16	-88	30
-40	-4	-14
-64	-26	14
-30	-90	2

// Redcay E, 2013: Autism Spectrum Disorders (ASD)
// Subjects=13
42	14	28
-20	-60	-24
-18	-90	28
-14	-74	-12
34	-74	20
-48	8	32
58	-38	18
6	-76	38
54	6	44
30	-20	44
-58	-8	18
14	-50	10
-28	-18	12
-22	-32	-16
10	30	-10
46	-42	6
6	62	18
28	8	4
32	-46	-6
30	-94	14
50	-4	14
-12	-28	64
-36	-14	14
38	54	18
-42	50	12
18	-90	26
-14	-82	4
-58	-34	24
0	20	52
8	-80	40
-56	-48	40
-50	12	-6
-20	-60	-14
-4	-54	60
-2	8	40
22	-58	-16

// Redcay E, 2013: Healthy Controls
// Subjects=13
0	-54	24
-54	-72	6
-10	-100	6
-42	-66	48
-62	-32	-8
44	-64	14
46	-42	6
2	58	32
6	-86	-12
-12	-82	16
-10	20	28
28	-52	52
28	8	8
58	-50	50
2	34	56
60	16	4
-28	48	24
-46	-48	42
-4	-42	48
64	-30	26
46	-46	14
2	-74	42
48	12	46
-48	20	0
2	8	56
50	26	-10
50	-64	12
-30	-28	-14
40	-16	12
2	-28	68
42	-80	-4
34	-10	-30
-30	-26	52
-26	-96	4
22	-34	-16
-60	-14	42
-20	-84	-4
-8	-14	54
26	-96	-8
-34	32	-16
10	-14	48
46	-42	6
6	62	18
28	8	4
32	-46	-6
30	-94	14
-10	-102	8
-2	-54	22
28	0	-22
14	-100	6
-48	-60	20
-28	0	-22
-4	-26	72
8	-88	30
8	-68	-14
14	0	6
-32	-84	16
32	-86	14
4	0	60
42	44	6
-56	-42	42
4	36	24
38	14	-4
60	14	4
-42	10	-4
-46	32	34
2	32	54
34	50	32

// Tanabe H C, 2012: (ES' + EN') - (BS' + BN'), Healthy Controls (3T) > ASD 
// (3T)
// Tanabe H C, 2012: (ES' + EN') - (BS' + BN'), Healthy Controls paired with 
// ASD (1.5T) > Healthy Controls (1.5T)
// Subjects=19
-22	-100	-6
32	-86	8
46	-62	2
-24	-86	8
-46	-68	2
58	10	26
50	24	24

// Yamada T, 2012: Autism Spectrum Condition (ASC)
// Subjects=25
-60	-32	-14
-48	-66	42
54	-54	50
-44	14	54
-42	50	-6
-52	-30	-14
-46	-70	48
56	-58	48
-20	20	62
32	26	52
32	52	-14

// Yamada T, 2012: Healthy Controls
// Subjects=26
-52	-30	-14
-58	-56	42
52	-74	32
-42	48	-8
22	60	20
24	24	62
-6	-62	34

// Caria A, 2011: Asperger Syndrome (AS)
// Subjects=8
-51	-39	27
69	-30	18
54	3	-9
-27	-72	-39
69	-33	3
45	-54	-45
-69	-36	21
63	12	21
57	30	-6
36	18	24
-39	15	21
24	9	12
18	6	15
15	57	30
33	33	51
-3	-81	-27
69	-18	-21
-3	48	45
6	-27	36
6	-48	24
-9	-51	18
-33	-33	21
3	-18	48
-3	48	-15
0	57	-6
6	-84	-6
3	-15	9
-3	63	63
-42	-42	12
51	-54	-39
69	-30	3
57	6	-9
-63	-42	15
63	-42	15
69	-27	21
54	30	15
60	15	9
36	-39	-33
45	12	54
69	-33	30
-51	15	-3
-18	-93	-21
12	-21	-9
-24	-81	51
6	21	70
21	-27	-12
36	60	12
-45	-18	0
0	15	69
27	-15	75
6	-15	60
36	-84	-27
0	-87	-33
-12	12	70
-39	6	15
-39	24	-6
39	-60	31
48	-60	-9
27	-15	75
-15	-3	63
-54	18	15
33	-87	-30
-21	3	60
21	-6	57

// Caria A, 2011: Healthy Controls
// Subjects=14
54	0	48
-6	3	75
6	9	72
-27	-60	-27
45	30	0
-51	-36	21
30	-57	-30
-24	6	9
48	-33	0
24	9	12
69	-33	24
48	-42	6
-36	12	3
-36	33	6
51	15	0
-12	-12	6
27	48	42
33	33	51
39	-27	12
33	33	0
-9	-24	-42
3	27	39
-30	18	-9
-36	-30	15
-15	-54	39
-63	-45	18
-9	42	21
-15	-9	6
-18	12	12
6	-30	-18
0	-24	42
-27	3	9
6	9	9
33	-39	-39
12	66	3
12	-6	0
54	3	48
-39	21	0
42	30	0
-54	21	-3
27	-15	75
6	-15	60
36	-84	-27
0	-87	-33
-12	12	70
-39	6	15
-39	24	-6
39	-60	31
48	-60	-9
27	-15	75
-15	-3	63
-54	18	15
33	-87	-30
-21	3	60
21	-6	57

// Damarla S R, 2010: Embedded Figures Task (EFT) - Fixation, Autism > Healthy 
// Controls
// Damarla S R, 2010: EFT - Fixation, Autism < Healthy Controls
// Subjects=13
-44	-38	64
20	-50	54
28	-40	56
-18	-56	58
26	-100	12
-8	42	38
-30	14	46
-20	-12	2
-62	-34	40
-42	-48	46

// Dichter G S, 2012: Monetary Anticipation, Healthy Controls > ASD
// Dichter G S, 2012: Monetary Anticipation, ASD > Healthy Controls
// Dichter G S, 2012: Monetary Outcome, Healthy Controls > ASD
// Dichter G S, 2012: Monetary Outcome, ASD > Healthy Controls
// Dichter G S, 2012: Object Anticipation, Healthy Controls > ASD
// Dichter G S, 2012: Object Anticipation, ASD > Healthy Controls
// Dichter G S, 2012: Object Outcome, Healthy Controls > ASD
// Dichter G S, 2012: Object Outcome, ASD > Healthy Controls
// Dichter G S, 2012: Anticipation, Group x Reward Type Interactions
// Dichter G S, 2012: Outcome, Group x Reward Type Interactions
// Subjects=15
-6	6	-4
-4	18	26
-36	-60	-26
8	-44	-28
40	20	4
-22	8	-20
-38	14	-12
40	6	-2
-8	-58	-8
14	-92	-6
44	-14	-6
-30	-16	70
30	-14	-10
38	18	-24
-50	-52	24
-20	56	30
26	-14	-26
-36	22	44
-64	-50	0
50	-20	60
-4	-60	46
-12	26	52
-58	-30	-2
66	-16	-4
-8	8	-10
48	34	-12
44	6	-10
-44	46	12
26	-10	-26
-44	28	6
0	6	62
40	-64	0
-32	-76	48
30	-66	28
-36	38	38
-64	-24	-10
-64	-50	-4
-44	-26	54
42	-24	52
-34	-4	56
30	-16	58
-14	28	58
4	20	58
-36	-52	64
-68	-36	8
-4	12	32
54	-56	20
-46	36	-2
26	40	44
-40	-64	14
-26	36	36
62	-22	-6
-4	54	8
6	54	6
-34	-34	42
44	-30	56
48	-10	56
-6	-72	30
60	-22	2
-40	16	22
-36	-84	24
-18	-80	-6
-24	-94	2
18	-52	72
-26	-52	-12
-58	-56	12
10	-44	28
-26	16	-26
6	56	-10
28	38	42
-24	62	-8
-38	-64	16
-58	-14	-14
66	-46	2
-62	-24	10
10	-66	28
6	30	36
-6	18	-14
0	2	-6
-18	22	10
-16	12	16
28	-52	-30
4	-66	-14
-32	24	-22
-2	-84	-18
12	-92	-6
-42	-40	12
-534	12	-12
-14	-8	10
8	8	-8
56	-42	38
4	-60	-20
-14	-66	-28
12	-68	22
36	28	4
50	34	-12
-28	-60	12
8	56	-14
26	38	42
-40	-22	6
-36	16	-10
42	16	-8
2	-82	-24
34	18	54
62	-52	4
8	30	40
0	42	-6
-44	8	-20
-16	-68	24
6	-80	46
60	-36	18
42	18	-20
2	-16	10

// Fan Y T, 2014: Autism Spectrum Disorder (ASD)
// Subjects=24
54	-30	58
-60	-28	46
-48	-14	8
-46	0	6
-2	-68	32
-14	52	30
10	-18	60
20	52	36
32	-26	-8
-46	-58	22
-16	-8	-12
-8	-52	20
-14	-68	6
34	-44	-14
-44	-10	26
10	-44	6
-6	-42	16
14	32	40
4	-20	18
48	-32	12
-58	-46	20
34	-22	-16
6	8	-2
4	-2	-6
-24	-30	36
16	-6	32
26	-30	26

// Fan Y T, 2014: Healthy Controls
// Subjects=21
8	-52	70
-58	-26	38
-48	-4	48
8	-20	-10
-28	8	40
-34	-48	56
-28	-42	46
-60	10	26
-14	-12	-14
-20	-6	-6
-4	-46	22
18	-82	-8
32	-28	-8
-20	-22	0
-16	8	30
-40	4	16
-2	-68	32
-14	52	30
10	-18	60
20	52	36
32	-26	-8
-46	-58	22
-16	-8	-12
-8	-52	20
-2	-76	-2
50	-8	58
-38	-16	40
30	-14	-6
-40	-24	-10
-6	-58	18
48	-32	12
-58	-50	16
6	-58	44
-26	-76	20
62	2	-12
22	10	-14
22	24	40
-6	64	26
6	44	-10
-8	48	-10
-2	22	-12
40	-22	22
-40	4	16
10	-44	6
-6	-42	16
14	32	40
4	-20	18
48	-32	12
-58	-46	20
-2	-28	-16
26	-28	24
-2	-32	2
20	-40	12
-24	-30	36
16	-6	32
26	-30	26

// Hadjikhani N, 2014: Autism Spectrum Disorders (ASD)
// Subjects=36
46	-40	6
50	-64	-2
48	-74	12
60	-38	18
30	-90	2
42	-62	-2
50	-26	-8
46	-58	6
46	-50	-22
62	-30	22
26	-2	-24
22	6	-36
54	-54	16
-52	-48	12
-46	-62	4
-38	-82	-12
-54	-52	16
-32	-94	-8
-46	-46	-24
-36	-88	-8
-52	-40	26
-38	-58	-26
-60	-34	-2
-38	34	-12
-46	10	26
-34	6	32
-44	26	-12
-48	-2	46
-38	40	4
-52	6	4
-50	34	4
-44	12	-10
58	28	-8
38	28	-18
38	32	-16
44	8	10
0	-32	-10
-40	34	20
-34	46	4
-14	24	24
-60	-46	48
-30	-42	40
-42	-64	40
30	-50	-56
-30	40	-16
24	-98	26
-54	-72	-2
-40	10	-26
-46	26	2
-24	14	8
30	-14	12
10	14	10
-10	20	4
4	32	10
-16	42	14
-22	34	-16
36	24	-18
6	0	54
-10	0	42
48	16	-28
-14	24	26
6	16	48
-18	-24	16
2	-16	0
-30	12	14
36	12	-18
-16	38	42
-34	14	32
-20	50	22
2	34	-12
-10	-52	-34
6	-36	-34
0	-62	-36
10	-56	-58
-14	-56	-46
-2	-66	-30
-32	8	-18
-30	4	-16
-34	-18	-18
-54	-16	-16
-44	10	0
-44	-12	-34
-40	8	-42

// Hadjikhani N, 2014: Healthy Controls
// Subjects=31
62	-52	12
48	-66	-4
38	-84	-20
60	-40	12
30	-90	-12
50	-64	-2
56	-24	-10
60	-58	8
42	-60	-22
64	-32	22
16	-8	-16
56	10	-24
64	-50	18
64	2	-18
-66	-42	16
-50	-50	6
-46	-78	0
-50	-50	20
-28	-92	-2
-36	-86	-4
-48	-34	22
56	-50	-38
-48	-16	-14
-58	2	-20
-34	6	-24
-22	0	28
-40	30	-16
-56	26	6
-42	22	-12
-52	30	0
-32	6	-18
-14	54	28
-8	62	34
58	28	-4
22	14	-26
48	32	-10
40	-6	-14
2	50	28
0	52	-18
8	52	10
0	-32	-6
-40	34	20
-34	46	4
-14	24	24
-60	-46	48
-30	-42	40
-42	-64	40
30	-50	-56
-30	40	-16
24	-98	26
-54	-72	-2
-40	10	-26

// Kana R K, 2012: Pun > Fixation, Autism > Healthy Controls
// Subjects=16
28	-40	-2
56	-30	30
30	32	50
-56	-38	38

// Lee T M C, 2013: Main Effect of Familiarity, Familiar > Unfamiliar
// Lee T M C, 2013: Main effect of Cue, Lie > Truth
// Subjects=13
-6	-54	18
-52	22	2
-54	-54	36

// Wu D, 2011: Bad Lie (BL) > Bad Truth (BT)
// Wu D, 2011: Bad Lie (BL) > Good Lie (GL)
// Wu D, 2011: GL > BL
// Subjects=20
9	-87	-6
-36	-45	63
30	-72	39
-36	-60	45
39	-51	54
-48	-42	54
36	-54	45
42	-60	48
-39	39	36
-51	-45	42
-6	-93	6
6	-78	18
-6	90	15
6	-87	12
18	54	24
-21	57	24

// Aoki Y, 2014: Social - Belief, Healthy Controls > ASD
// Aoki Y, 2014: Belief - Control, Healthy Controls > ASD
// Aoki Y, 2014: Social - Belief, Oxytocin > Placebo, ASD
// Subjects=17
48	20	-14
56	-64	36
0	18	20
4	-86	40
60	0	-22
60	18	-2
46	24	-18

// Kleinhans N M, 2011: Autism Spectrum Disorders (ASD)
// Subjects=28
44	-76	-14
-38	-50	-20
34	-46	-24
50	-24	50
-46	26	4
26	28	48
46	36	-16

// Kleinhans N M, 2011: Healthy Controls
// Subjects=25
38	-48	-22
-36	-48	-22
34	-62	42
2	-72	-34
34	-46	-24
50	-24	50
-42	-74	-10
36	-46	-18
38	-78	0
-46	26	4
26	28	48
46	36	-16

// Mizuno A, 2011: Autism
// Subjects=15
-34	-56	-32
-34	6	64
34	4	66
-2	-36	24
40	60	2
56	32	28
-20	60	0
4	-54	-26
36	26	-4
32	34	24
14	16	20
34	50	16
-10	12	24
-54	-18	22
44	-18	60
44	-44	60
22	-86	38
-6	-36	28
58	-48	-8
38	10	36

// Mizuno A, 2011: Healthy Controls
// Subjects=15
-26	-62	42
50	34	36
12	22	38
20	30	6
40	60	-2
36	4	62
30	0	-12
34	58	26
24	-12	40
44	-18	60
44	-44	60
22	-86	38
-6	-36	28
58	-48	-8
38	10	36

// Murphy C M, 2014: Autism Spectrum Disorder (ASD)
// Subjects=46
30.85	-.19	-24.48
-33.33	30.6	-19.63
-25.43	27.35	34.08
20.39	-13.26	0.16
0.93	-24.58	-34.36
-26.03	28.76	-44.1
-40.89	13.24	-37.05
-28.93	-3.21	-16.85
28.27	-29.97	44.96
-5.97	-30.69	38.72
8.95	-22.14	37.83
27.41	62.17	-29.67
-45.04	51.91	-4.56
-52.26	21.59	17.03
-1.91	-49.35	3.44
20.3	-47.21	-25.99
8.58	66.26	24.85
8.17	78.43	-24.12
-44.29	-8.43	68.52
4.94	-16.16	74.18
-25.93	1.27	-41.79
66.26	9.22	-2.26
54.66	-33.15	1.43
-47.64	-59.37	29.34
-13.2	-73.14	54.63
50.62	-18.72	37.07
35.7	-90.91	13.18
-20.92	-95.48	14.22
-9.82	-20.84	-40.12
8.43	-56.14	-44.06
-37.07	-27.59	26.55
8.35	-8.67	-35.78
40.43	9.38	-25.39
-33.33	30.6	-19.63
-45.04	51.91	-4.56
20.39	-13.26	0.16
20.3	-47.21	-25.99

// Murphy C M, 2014: Healthy Controls
// Subjects=44
30.85	-.19	-24.48
-33.33	30.6	-19.63
-25.43	27.35	34.08
20.39	-13.26	0.16
0.93	-24.58	-34.36
-26.03	28.76	-44.1
-40.89	13.24	-37.05
-28.93	-3.21	-16.85
28.27	-29.97	44.96
-5.97	-30.69	38.72
8.95	-22.14	37.83
20.3	-47.21	-25.99
27.41	62.17	-29.67
-45.04	51.91	-4.56
-52.26	21.59	17.03
-1.91	-49.35	3.44
8.58	66.26	24.85
8.17	78.43	-24.12
-44.29	-8.43	68.52
4.94	-16.16	74.18
-25.93	1.27	-41.79
66.26	9.22	-2.26
54.66	-33.15	1.43
-47.64	-59.37	29.34
-13.2	-73.14	54.63
50.62	-18.72	37.07
35.7	-90.91	13.18
-20.92	-95.48	14.22
-9.82	-20.84	-40.12
8.43	-56.14	-44.06
-37.07	-27.59	26.55
8.35	-8.67	-35.78
40.43	9.38	-25.39
-33.33	30.6	-19.63
-45.04	51.91	-4.56
20.39	-13.26	0.16
20.3	-47.21	-25.99

// Poulin-Lord M P, 2014: Autistics
// Subjects=23
-34	-84	-10
-30	-88	-2
-18	-62	-52
-28	-58	-52
-14	-72	-48
-18	28	-4
28	-86	-8
22	-64	-52
14	-76	-46
42	46	32
36	38	28
2	-56	-34
-40	-86	-4
-30	-84	4
-44	-76	14
44	-74	0
54	-72	10
58	-62	4
44	-74	0
54	-72	10
-30	-84	4
-38	-86	6
-46	-76	14
-32	-84	18
-20	-76	20
-2	-86	18
-20	-70	-6
-22	-74	50
-32	-28	38
-18	28	-4
38	-92	10
14	-94	14
26	-78	22
30	-88	24
18	-72	-8
20	-78	-16
28	-70	52
26	34	52
6	-20	70
-24	-68	-8

// Poulin-Lord M P, 2014: Healthy Controls
// Subjects=22
-36	-86	-8
-28	-86	4
-26	-62	-52
-20	-70	-50
-42	42	32
-34	54	32
28	-86	-8
30	-60	-52
20	-72	-48
52	40	12
42	40	8
38	48	34
-40	-86	-4
-30	-84	4
-44	-76	14
44	-74	0
54	-72	10
58	-62	4
44	-74	0
54	-72	10
-30	-84	4
-38	-86	6
-46	-76	14
-32	-84	18
-20	-76	20
-2	-86	18
-20	-70	-6
-22	-74	50
-32	-28	38
-18	28	-4
38	-92	10
14	-94	14
26	-78	22
30	-88	24
18	-72	-8
20	-78	-16
28	-70	52
26	34	52
6	-20	70
-24	-68	-8

// Samson F, 2012: Autism Spectrum-Speech Onset Delay (AS-SOD)
// Subjects=13
-66	-16	8
-60	-2	2
-52	-32	16
-40	-22	56
-30	-26	68
-30	-14	68
0	6	48
-10	-76	20
-22	-94	4
68	-14	10
64	-2	2
2	-2	56
32	52	22
42	46	16
26	38	14
6	-76	24
18	-76	18
-34	-26	64
-50	-22	56
-54	-22	26
-4	-12	48
0	24	42
-42	38	4
-40	48	10
-10	-26	48
-10	18	36
-22	-36	-40
-12	-16	12
60	8	-10
68	-16	22
52	-22	52
56	-32	26
6	-8	64
22	-10	72
48	42	14
44	46	22
36	44	30
52	8	42
30	-16	66
52	6	26
16	-56	-16
4	-60	-8
12	-68	-16
22	-12	16
-30	-24	16
-32	-30	22
60	-18	6
56	-12	-2
46	-14	-2
60	-14	6
-56	2	-10
-36	-46	58
-54	-30	36
-34	-20	62
-6	-10	54
-54	2	22
-42	32	14
-42	36	22
-34	42	18
-8	-24	46
-22	-54	-18
-16	-4	10
-18	2	4
-22	-20	-16
64	-22	-4
60	8	-10
64	-14	22
48	-24	42
34	-50	50
56	-32	26
32	-4	66
28	-14	62
4	-6	64
62	12	8
36	38	14
36	40	28
28	42	22
14	-98	10
24	-66	-20
22	-56	-16
24	-18	14
16	-12	6

// Samson F, 2012: Autism Spectrum-No Speech Onset Delay (AS-NoSOD)
// Subjects=14
-62	-18	16
-60	2	-2
-46	-28	50
-34	-46	56
-36	-20	62
-4	-6	56
0	-4	60
-38	-4	14
-48	-4	2
62	-16	20
62	10	6
26	-60	-20
22	-52	-20
24	-56	-20
-40	-32	8
-32	-30	68
-50	-22	52
-16	-28	54
-50	-22	26
-18	-12	70
-46	4	30
-56	6	38
-42	-16	20
-2	-8	42
-12	-4	42
-38	-40	-32
-42	-52	-30
-48	-60	-30
56	-18	52
44	-30	24
46	42	16
6	14	30
4	24	38
34	-42	-24
-56	-22	4
-52	6	2
-68	-34	4
-64	-14	16
-58	-2	20
-18	-64	54
-32	-46	52
-42	-42	30
-32	-34	20
-54	18	0
-62	6	10
-38	36	24
-6	-14	58
-2	6	66
-24	-12	56
-30	-16	66
-28	-10	42
-16	-28	4
60	-22	-1
56	-6	-8
48	-26	42
58	-14	24
34	-42	46
62	12	10
64	10	14
58	18	-2
6	-4	62
32	-8	62
38	-2	54
26	-66	-18
28	-28	14
60	-14	6
-56	2	-10
-36	-46	58
-54	-30	36
-34	-20	62
-6	-10	54
-54	2	22
-42	32	14
-42	36	22
-34	42	18
-8	-24	46
-22	-54	-18
-16	-4	10
-18	2	4
-22	-20	-16
64	-22	-4
60	8	-10
64	-14	22
48	-24	42
34	-50	50
56	-32	26
32	-4	66
28	-14	62
4	-6	64
62	12	8
36	38	14
36	40	28
28	42	22
14	-98	10
24	-66	-20
22	-56	-16
24	-18	14
16	-12	6

// Samson F, 2012: Healthy Controls
// Subjects=13
-58	-6	2
-50	-36	16
-54	-22	22
-40	-22	60
-56	4	34
-4	4	56
58	4	-4
64	-20	20
18	50	-12
28	-50	-24
18	-54	-18
-34	-26	64
-50	-22	56
-54	-22	26
-4	-12	48
0	24	42
-42	38	4
-40	48	10
-10	-26	48
-10	18	36
-22	-36	-40
-12	-16	12
60	8	-10
68	-16	22
52	-22	52
56	-32	26
6	-8	64
22	-10	72
48	42	14
44	46	22
36	44	30
52	8	42
30	-16	66
52	6	26
16	-56	-16
4	-60	-8
12	-68	-16
22	-12	16
-30	-24	16
-32	-30	22
60	-18	6
56	-12	-2
46	-14	-2
-40	-32	8
-32	-30	68
-50	-22	52
-16	-28	54
-50	-22	26
-18	-12	70
-46	4	30
-56	6	38
-42	-16	20
-2	-8	42
-12	-4	42
-38	-40	-32
-42	-52	-30
-48	-60	-30
56	-18	52
44	-30	24
46	42	16
6	14	30
4	24	38
34	-42	-24
-56	-22	4
-52	6	2
-68	-34	4
-64	-14	16
-58	-2	20
-18	-64	54
-32	-46	52
-42	-42	30
-32	-34	20
-54	18	0
-62	6	10
-38	36	24
-6	-14	58
-2	6	66
-24	-12	56
-30	-16	66
-28	-10	42
-16	-28	4
60	-22	-1
56	-6	-8
48	-26	42
58	-14	24
34	-42	46
62	12	10
64	10	14
58	18	-2
6	-4	62
32	-8	62
38	-2	54
26	-66	-18
28	-28	14

// Zurcher N R, 2013: Autism Spectrum Disorder (ASD)
// Subjects=22
30	-42	-26
40	-34	-20
36	40	32
26	-86	-8
2	24	28
-2	-22	2
14	-58	30
30	30	-6
-10	8	10
6	-36	-8
14	-42	32
48	-6	-16
-58	-8	-2
18	-66	64
-16	-70	54
24	-4	66
-26	-6	64
20	-46	68
-24	-52	66
60	-32	46
-56	-26	28
54	20	14
40	48	30
-62	-60	10
42	16	-4
-42	10	-6
6	18	38
-6	2	38
66	-16	28
-12	-40	50
24	-22	-12
-34	-18	-14
70	-36	4
68	-8	0
66	-30	28
38	8	-24
-52	14	-18
8	-38	46
10	-18	8
8	-30	-8
42	-60	-16
38	-36	-20
-42	-32	-22
30	-88	-8
8	-54	-2
16	-82	36
-40	-82	10
-36	-58	-40

// Zurcher N R, 2013: Healthy Controls
// Subjects=22
58	-64	-16
-54	-62	-12
14	-54	52
-18	-72	54
24	-10	48
-26	-10	50
9	-52	55
-10	-52	54
-40	-78	12
42	-76	18
66	-10	0
-58	-10	-2
-26	-54	62
30	-46	64
42	-60	-16
-42	60	-20
-62	-42	14
66	-32	18
24	-61	22
-18	-74	24
60	-32	44
-56	-32	44
-8	0	42
8	18	38
38	-12	-6
-42	-2	2
20	-32	-6
-56	2	6
48	-6	-16
-58	-8	-2
18	-66	64
-16	-70	54
24	-4	66
-26	-6	64
20	-46	68
-24	-52	66
60	-32	46
-56	-26	28
54	20	14
40	48	30
-62	-60	10
42	16	-4
-42	10	-6
6	18	38
-6	2	38
66	-16	28
-12	-40	50
24	-22	-12
-34	-18	-14
70	-36	4
68	-8	0
66	-30	28
38	8	-24
-52	14	-18
8	-38	46
10	-18	8
8	-30	-8
42	-60	-16
38	-36	-20
-42	-32	-22
30	-88	-8
8	-54	-2
16	-82	36
-40	-82	10
-36	-58	-40

// Zurcher N R, 2013: Autism Spectrum Disorders (ASD)
// Subjects=16
-24	-4	-24
12	-30	6
-10	-30	6
-6	-32	-2
4	44	-2
-2	44	-2
-30	-14	-18
2	36	-16
-6	36	-16
2	22	-8
-8	30	-22
-32	28	-18
4	-46	34
-2	-46	34
-6	-52	16
6	-52	18
50	-14	-20
-58	-4	-34
-60	-36	0
54	-58	16
-52	-52	20
40	-12	6
-40	-10	-2
28	-12	-32
-32	-38	-12
16	-34	76
-20	-44	66
34	-92	22
-32	-92	26
36	-82	-16
-36	-84	-12
34	-54	-18
-28	-62	-14
38	-92	12
-38	-86	-8
54	-60	-14
26	-70	46
-32	-46	42
26	4	64
50	2	28
-42	-4	40
48	8	20
-52	22	20
54	36	8
-50	32	20
30	26	-6
-26	24	-4
4	18	48
-2	14	46
48	30	32
-50	32	20
40	-64	-26
-28	-64	-36
38	-92	12
-36	-94	8
50	-70	-14
-40	-90	-10
30	-44	-20
-32	-54	-14
40	-86	18
-40	-90	16
58	-54	-16
-56	-42	-28
24	-76	40
-22	-84	38
34	6	60
52	6	36
-38	-2	36
36	24	8
-46	12	10
52	28	4
-48	24	-2
32	18	-2
-38	18	0
10	26	44
-8	34	36
-40	0	48
18	-24	2
-12	-16	2
-14	10	-4
50	-46	-40
36	-60	-44
-6	-74	-34
-8	-70	-28
36	-62	-52
-10	-72	-46
-22	-68	-58
8	10	12
-18	20	4
-14	-28	14
54	16	-6
36	18	0
-32	22	-4
16	2	-4
10	18	38
-4	22	42
46	-4	60
-44	-10	64
40	32	30
38	2	60
8	0	70
-20	14	68
8	6	68
18	-24	14
2	-46	-6
0	-48	-22
20	-66	-52
-20	-64	-25
-2	-68	-42
26	-68	-52
-28	-68	-56
2	-56	-32
-24	-40	-46
-32	-52	-30

// Zurcher N R, 2013: Healthy Controls
// Subjects=18
4	36	-16
-4	36	-16
6	12	-10
0	8	-10
-28	32	-20
2	-30	36
-6	-32	40
10	-56	26
-2	-58	36
62	4	-26
-64	-14	-24
68	-28	2
-66	-32	2
52	-2	-16
-56	-2	-12
60	-62	24
-62	-60	26
36	-14	12
-40	-18	0
30	-16	-28
-32	-30	-18
46	-26	64
-20	-46	70
22	-82	-42
36	-92	-4
-34	-90	8
42	-82	-4
-34	-82	-14
30	-52	-16
-30	-58	-18
40	-82	4
-38	-80	-2
54	-60	-12
-48	-54	-20
30	-44	46
-32	-44	42
34	-2	54
54	8	8
-44	-2	32
56	14	4
-34	10	26
-40	26	22
36	18	-6
-40	18	0
4	20	54
-2	16	52
48	28	30
-46	34	30
10	-14	6
-14	-20	8
18	0	-4
40	-56	-36
-42	-66	-34
-6	-76	-44
18	-50	-52
-4	-60	-40
-30	-2	-20
28	-6	-16
22	-10	-24
-24	-12	-20
2	46	-16
-4	38	-24
2	30	-18
-2	30	-18
-28	30	-18
4	-26	40
-2	-52	24
0	-58	22
0	-58	22
64	-10	-28
-62	-16	-18
62	0	-24
-64	-8	-26
48	-62	28
-40	-74	36
38	-20	4
-38	-6	-12
18	-8	-28
-24	-16	-28
22	-42	62
-64	-16	16
12	-26	44
-4	-24	58
18	4	22
-14	-2	18
26	-82	-46
34	-92	-6
-16	-92	0
34	-88	0
-44	-80	-6
30	-60	-10
-30	-62	-20
38	-86	12
-46	-82	-6
56	-30	-22
-44	-62	-22
26	-76	38
-28	-46	42
28	4	62
44	0	38
-50	2	38
52	16	2
-50	20	34
54	24	20
38	20	0
-32	16	2
12	26	26
-10	22	30
-48	30	22
8	-16	12
18	-12	-2
-14	-4	-6
-30	-74	-28
-4	-76	-34
-34	-64	-24
-6	-74	-46
28	-70	-60
8	10	12
-18	20	4
-14	-28	14
54	16	-6
36	18	0
-32	22	-4
16	2	-4
10	18	38
-4	22	42
46	-4	60
-44	-10	64
40	32	30
38	2	60
8	0	70
-20	14	68
8	6	68
18	-24	14
2	-46	-6
0	-48	-22
20	-66	-52
-20	-64	-25
-2	-68	-42
26	-68	-52
-28	-68	-56
2	-56	-32
-24	-40	-46
-32	-52	-30

// Abe N, 2014: Dishonest + Honest > Control
// Abe N, 2014: (Honest/harmful + honest/helpful) > (dishonest/harmful + 
// dishonest/helpful)
// Abe N, 2014: (Dishonest/harmful + honest/harmful) > (dishonest/helpful + 
// honest/helpful)
// Abe N, 2014: (Dishonest/helpful + honest/helpful) > (dishonest/harmful + 
// honest/harmful)
// Abe N, 2014: Dishonest/harmful > honest/harmful
// Abe N, 2014: Honest/harmful > dishonest/harmful
// Subjects=25
52	10	-28
18	8	70
6	-4	48
32	-56	-2
6	-60	0
-34	46	30
-24	-20	76
-2	-24	26
-2	-76	30
-22	-78	-36
40	0	4
60	-26	30
-40	0	8
-48	-16	48
-64	-32	20
42	24	54
14	-102	4
-28	-38	-16
-38	-82	36
14	0	60
32	-40	44
-38	-48	54
10	52	20
10	40	48
54	-56	24
40	0	4
62	-22	32
-48	-16	48
-24	-40	68

// Abe N, 2014: Subgroup of Normals, Honest
// Subjects=13
-24	-66	-10
-30	-32	-22
-4	-52	-24

// Abe N, 2014: Subgroup of Normals, Dishonest
// Subjects=8
46	22	4
-4	32	0
-14	-16	-14
42	34	32
-8	20	38
16	14	38
-32	26	-12
-40	52	10
-6	34	14
-38	6	0
-6	30	36
-38	36	12

// Abe N, 2014: Subgroup of Normals, Ambiguous
// Subjects=7
-26	-50	44
-36	-10	52
62	12	24
-52	-28	38
-8	20	38
16	14	38
-32	26	-12
-40	52	10
-6	34	14
-38	6	0
-6	30	36
-38	36	12

// Cui Q, 2014: Subgroup of Normals, MUD (Assigned Murderer) group
// Subjects=16
-60	-45	36
45	21	3
57	-45	33
15	6	0
33	27	-6
15	9	3
42	0	54
6	21	60
-60	15	3
-12	6	3
57	-42	33
51	30	39
-57	-51	33
-27	-81	-27
-48	39	-15
66	-27	-3
36	57	-9
39	-63	57
-63	-48	-9
9	48	42
21	57	15
-12	54	36
54	-54	33
63	-21	-9
-48	-54	27
-33	21	42
48	33	39
39	51	-9
48	6	-42
-48	36	-9
-48	-30	-6

// Cui Q, 2014: Subgroup of Normals, INC (Assigned Innocent) group
// Subjects=16
33	27	-6
15	9	3
42	0	54
6	21	60
-60	15	3
-12	6	3
57	-42	33
9	48	42
21	57	15
-12	54	36
54	-54	33
63	-21	-9
-48	-54	27
-33	21	42
48	33	39
39	51	-9
48	6	-42
-48	36	-9
-48	-30	-6

// Ding X P, 2012: Identity concealment > Control
// Ding X P, 2012: Identity faking > Control
// Subjects=12
-38	26	-6
54	24	2
38	8	-10
-46	30	-14
-34	18	-8
56	14	2
50	12	12
22	58	32
-4	-86	2
18	2	18
30	52	16
26	50	24
-22	-88	0
-14	-86	0
6	-14	8
16	24	16

// Hayashi A, 2014: Harmful/ Dishonest > Harmful/ Honest
// Hayashi A, 2014: Harmful/ Honest > Harmful Dishonest
// Hayashi A, 2014: Helpful/ Dishonest > Helpful/ Honest
// Hayashi A, 2014: Helpful/ Honest > Helpful Dishonest
// Subjects=37
6	35	-8
27	20	52
3	-58	34
45	-64	25
-9	-55	10
-39	-76	37
36	-73	-8
9	-85	-5
-54	-16	52
63	-25	37
42	-61	10
-9	-28	46
57	26	25
54	26	1
30	11	-8
48	-25	-5
18	-88	4
-6	59	34
-48	29	7
-30	17	-14
-39	11	25
-57	2	-14
-63	-19	-5
-33	-88	-8

// Ito A, 2012: Execution: (Certain/Lie + Uncertain/Lie) > (Certain/Truth + 
// Uncertain/Truth)
// Ito A, 2012: Execution: (Uncertain/Truth + Uncertain/Lie) > (Certain/Truth 
// + Certain/Lie)
// Ito A, 2012: Preparation: (Certain/Truth cue + Certain/Lie cue) > Uncertain 
// cue
// Subjects=16
-33	56	19
-9	17	58
-51	-46	37
42	17	4
21	-19	-8
12	-91	25
42	14	28
-39	47	1
-9	20	37
-18	5	70
-12	-70	-26
15	11	70

// Ito A, 2011: Main effect of 'Lie' (Neutral/Lie+Negative/Lie) > 
// (Neutral/Truth+Negative/Truth)
// Ito A, 2011: Main effect of 'Negative' (Negative/Lie+Negative/Truth) > 
// (Neutral/Lie+Neutral/Truth)
// Ito A, 2011: Main effect of 'Neutral' (Neutral/Lie+Neutral/Truth)  > 
// (Negative/Lie+Negative/Truth)
// Ito A, 2011: Neutral/Lie > Neutral/Truth
// Ito A, 2011: Negative/Lie > Negative/Truth
// Ito A, 2011: Conjunction analysis: Neutral/Lie > Neutral/Truth + 
// Negative/Lie > Negative/Truth
// Subjects=32
-42	26	30
-8	10	56
-58	-38	2
-42	-44	44
-30	-58	-32
38	28	34
40	14	0
48	-28	-6
42	-42	38
-44	28	10
-6	-26	-10
-52	-62	0
46	4	26
4	-2	36
66	-28	34
24	-56	54
-56	-62	38
38	54	-4
52	-60	48
-46	50	-10
-50	18	10
-10	12	60
-20	4	10
-58	-36	0
-46	-42	42
48	24	34
48	-46	48
-36	28	30
-28	18	6
-6	6	58
-8	-66	50
34	32	32
40	14	0
50	-36	-2
42	-42	38
-40	26	30
-10	10	60
-42	-44	44
38	28	34
48	-44	46

// Kireev M, 2013: Deceptive Claim (DecClm) > Catch
// Kireev M, 2013: Honest Claim (HonClm) > Catch
// Kireev M, 2013: (Conjunction) DecClm > Catch + HonClm > Catch
// Kireev M, 2013: DecClm > HonClm
// Kireev M, 2013: rCBF: DecClm > Catch
// Kireev M, 2013: Catch > DecClm
// Subjects=36
-45	-1	49
-51	14	22
-54	17	4
9	8	7
-33	20	1
48	20	40
42	23	28
33	23	-5
45	8	52
39	2	52
6	29	46
3	32	43
-3	17	61
3	41	22
-42	-46	37
-33	-61	52
-30	-70	28
-33	-58	40
42	-55	46
36	-49	40
33	-70	28
54	-52	34
-39	53	-2
-39	47	1
-48	41	-8
-45	41	-2
-45	50	-8
3	35	43
3	26	52
12	14	58
-36	61	52
-39	-68	46
-42	-49	40
-51	14	22
-39	-1	40
-45	5	34
-36	23	22
45	23	34
48	20	40
42	-2	39
39	-52	43
-6	8	1
-6	-10	-2
-36	20	1
3	23	55
6	38	40
-42	-1	52
-45	5	34
-45	17	22
-39	-58	49
-45	-49	46
45	20	37
42	2	34
45	11	49
39	-52	46
54	-52	34
-9	5	1
-9	-13	4
-33	23	-2
-48	14	7
42	20	10
33	23	-2
-39	53	1
15	-10	19
9	-13	16
-6	-22	1
-33	-67	28
-39	-37	37
-45	-46	34
-36	-55	34
-9	8	-5
-12	11	16
-27	13	-3
0	-64	-8
12	-61	-11
-36	-1	58
-33	8	52
-27	-4	64
36	5	55
33	-4	58
45	-4	49
42	-43	34
39	-49	49
54	-40	37
38	54	8
50	-46	40
-2	32	26
8	40	32
-40	12	26
-40	-64	46
-8	-74	22
-54	-26	26
54	-14	-4

// Lee T M C, 2010: True: Positive > Negative
// Lee T M C, 2010: True: Negative > Positive
// Lee T M C, 2010: Lie > True
// Lee T M C, 2010: True > Lie
// Lee T M C, 2010: Positive: Lie > True
// Lee T M C, 2010: Negative: Lie > True
// Lee T M C, 2010: Lie: Positive > Negative
// Lee T M C, 2010: Lie: Negative > Positive
// Lee T M C, 2010: Conjunction Analysis (Lie > True, Positive + Negative)
// Subjects=14
18	44	32
-16	38	26
-10	-46	36
34	36	10
34	-48	-12
-30	-18	10
32	0	64
6	48	34
54	22	26
32	26	-2
8	14	24
10	30	36
-36	6	44
-10	6	50
-38	-40	48
-4	-70	44
18	-38	0
50	-70	8
6	-10	20
54	24	0
44	-54	48
24	-56	4
46	-48	12
-2	56	34
-42	32	16
-36	26	38
-16	-4	44
-30	30	4
-38	10	44
-40	-46	50
-22	-42	-2
18	-26	8
46	4	-4
58	-48	42
-16	4	52
56	10	18
22	-46	66
18	-78	10
36	-70	34
46	-18	38
-42	30	14
34	24	-4
50	42	18
-2	-16	28
18	-16	74
50	-46	40
-20	-64	2
8	-62	46
-48	-52	24
-20	-64	28
16	-68	8
-22	-30	0
-14	8	14
6	-6	16
36	2	60
16	-42	-8
54	-38	0
-14	56	30
-8	34	48
-32	24	-10
-22	-44	0
46	44	20
-32	22	8
-12	-44	10
32	-40	-20
-22	-20	0
-28	-62	-2
-10	-86	4
44	6	16
-20	-72	34
-18	-26	24
-32	44	24
16	-76	-2
-40	-68	12
44	30	32
-4	-16	20
-46	-50	28
6	-46	10
-18	-26	-10
32	-52	10
50	-70	14
10	-16	16
-14	56	30
-32	24	-10
-38	-56	26
-6	34	48

// Liu J, 2012: Falsification card > BL
// Liu J, 2012: Non-Falsification card > BL
// Liu J, 2012: Falsification > Non-Falsification
// Liu J, 2012: MT > Non-Falsification
// Subjects=14
-50.54	29.6	23.6
-44.12	22.62	17.46
-1.37	7.68	61.91
14.78	10.61	57.98
-47.26	6.97	22.42
-37.06	-48.56	47.91
37.35	-46.04	36.31
-24.08	-64.78	45.94
-7.72	-70.17	56.28
44.1	-50.53	56.81
31.04	-48.01	50.06
-12	-2.4	-10.87
20.55	-14.43	-3.51
23.83	8.85	4.22
30.2	14.64	-3.19
30.89	13.24	50.73
-33.96	9.51	48.84
-30.74	-7.06	43.7
-30.83	5.39	39.11
-37.06	-48.56	47.91
40.85	-47.35	56.55
-20.66	-66.71	59.52
-7.72	-70.17	56.28
40.53	-43.15	32.61
47.2	-25.3	50.9
-53.7	30.22	30.32
-40.79	23.26	24.06
-44.13	48.77	21.6
-27.25	-70.86	49.95
-50.01	-51.8	48.45
-43.63	-48.14	41.26
39.67	-85.73	-43.84
42.93	-69.14	-38.82
52.47	-66.09	-52.73
-40.81	26.45	23.75
-44.12	45.58	21.91
8.27	7.09	55.08
-8.31	37.07	32.23
-4.9	28.44	43.11
-27.32	-64.79	45.99
-17.43	-73.39	56.76
-33.89	-52.36	41.51
42.92	-65.95	-39.13
29.9	-73	-44.94
20.29	-68.91	-35.09
4.29	-90.36	-22.61
-5.63	-62.3	-31.94
-2.27	-58.17	-22.32

// Marchewka A, 2012: Normals
// Subjects=29
-33	24	0
-3	18	51
48	21	-3
39	18	-3
30	-63	-27
-24	-102	0
6	-57	-12
36	51	9
-60	-39	-3
51	-36	-3
33	-6	63
-54	-51	27
-60	-54	18
-3	-72	-27
9	-72	-36
9	6	15
15	-15	0
-39	27	0
-33	21	-9
48	21	0
33	15	36
6	12	57
-3	18	51
-15	-96	-3
30	-63	-27
-30	-63	-30
3	-63	-15
-36	21	-9
-30	24	3
-33	-54	-33
-15	-6	21
-12	-6	9
15	-9	21
21	-3	36
-6	-63	54
6	-60	60
15	-48	72
36	33	0
39	18	-6
-9	15	50
9	9	63
-3	-54	36
3	-51	27
0	57	21
12	48	12
60	-9	-21
-54	-63	27
57	-63	30
57	-54	18
-57	0	-18

// Marchewka A, 2012: Subgroup of Normals, Females
// Subjects=15
-33	24	0
33	30	0
15	-9	21
-9	21	60
-3	18	51
-12	-3	12
-15	3	18
3	-60	-9
48	27	27
-3	-75	-27
-15	-72	-33
9	12	66
-3	18	60
-39	27	-3
-30	18	-12
-12	-96	-6
48	27	30
-3	27	45
6	21	39
-39	12	24
9	9	63
-6	12	51
-36	39	18
-51	15	3
39	33	0
39	18	-3
6	-5	-12
-21	-9	27
30	39	21
-27	-3	66
-36	-3	66
-3	-2	12
-12	-7	9
36	33	0
27	24	-3
-36	24	-12

// Marchewka A, 2012: Subgroup of Normals, Males
// Subjects=14
3	12	60
-39	27	0
33	-57	-33
-18	-96	0
39	18	-3
-57	-39	-6
-39	-45	-3
15	-12	15
21	-15	27
-54	-48	27
-6	-69	48
6	-75	57
-15	-6	21
-30	-6	24
-3	-12	15
3	-18	12
-36	21	3
-42	12	9
0	12	57
-3	30	33
-9	21	42
42	18	0
-36	0	51
33	-54	-33
-45	18	36
-45	6	24
-27	-99	-3

// McPherson B, 2012: Tones: Feigned > Correct
// McPherson B, 2012: Tones: Feigned > Incorrect
// McPherson B, 2012: Words: Feigned > Correct
// McPherson B, 2012: Words: Random > Correct
// McPherson B, 2012: Words: Feigned > Incorrect
// Subjects=15
0	39	33
51	-45	42
-42	21	36
-54	-54	48
-57	-36	-6
-36	-72	-39
30	-75	-42
-42	45	-15
36	36	39
-36	-72	-42
39	21	-15
54	-45	39
-36	18	39
-51	-54	45
-42	21	-12
-63	-33	-9
-51	-48	54
42	36	27
48	-48	36
-39	-78	-33
-36	27	42
24	57	27
54	-48	45
24	15	57
54	15	6
-36	-81	-27
18	60	24
36	36	42
-51	-51	51
51	-48	42
-42	15	48

// Vartanian O, 2012: Mismatched > Matched
// Vartanian O, 2012: Lying > Truthful
// Vartanian O, 2012: Matched: Lying > Truthful
// Vartanian O, 2012: Mismatched: Lying > Truthful
// Subjects=15
20	16	36
-28	10	20
-36	0	46
-12	16	46
42	-44	38
18	-56	40
-8	0	4
10	-76	-30
36	52	12
48	30	24
32	28	6
-58	12	26
-44	-34	-14
-34	-58	42
38	-48	34
-20	-4	22
10	-14	-10
2	-54	-30
24	-70	-42
14	-38	-50
-30	0	46
40	-42	46
4	18	48
0	-8	8
4	-80	-26

// Cascio C J, 2012: Autism Spectrum Disorders (ASD)
// Subjects=13
-22	-38	62
-12	-4	72
-48	-14	14
-18	-36	64
-32	-34	62
-24	-20	74
-36	-14	16
50	-30	24
36	-36	56
56	-10	42
-36	-8	58
-44	-26	54
24	-58	62
-4	0	50
12	50	-2
38	48	20
34	-2	46
60	-22	2
0	-46	-46
34	-34	48
36	46	22
28	42	32
26	58	16
-26	-2	62
50	2	24
6	-50	52
28	6	4
-16	-26	58
-6	-48	62
-2	2	48
32	-36	58
-46	-30	52
-32	-10	54
12	-38	52
8	30	44
-2	2	48
-34	30	34
2	16	48
36	50	22
-14	24	-2
-20	-28	4
-38	-36	22
-2	-28	-14
-14	-68	14
-20	-26	6

// Cascio C J, 2012: Healthy Controls
// Subjects=14
-34	-36	66
-54	-26	16
-44	-38	54
-38	-46	52
-54	-46	48
-46	44	0
-46	12	24
-36	46	-4
-44	-62	8
-34	-44	62
34	-48	44
-38	-40	50
-46	-56	52
44	48	-4
36	58	0
30	58	-8
48	40	-10
-54	-66	6
64	-22	16
-34	-34	70
-44	-4	56
-34	-42	54
56	20	16
-52	-72	10
36	-36	56
56	-10	42
-36	-8	58
-44	-26	54
24	-58	62
-4	0	50
12	50	-2
38	48	20
34	-2	46
60	-22	2
0	-46	-46
34	-34	48
36	46	22
28	42	32
26	58	16
-26	-2	62
50	2	24
6	-50	52
28	6	4
-16	-26	58
-6	-48	62
-2	2	48
32	-36	58
-46	-30	52
-32	-10	54
12	-38	52
8	30	44
-2	2	48
-34	30	34
2	16	48
36	50	22
-14	24	-2
-20	-28	4
-38	-36	22
-2	-28	-14
-14	-68	14
-20	-26	6

// Schneider K, 2013: Autism Spectrum Disorder (ASD)
// Subjects=28
3	53	25
-24	29	40
30	29	46
-3	-55	37
-45	-61	25
-54	-4	-35
60	-55	28
-3	-55	34
-9	50	19
-24	29	40
-42	-61	25
-57	-7	-29
3	53	25
-27	29	43
30	29	43
60	-19	-14
-45	-61	25
60	-55	28
-3	-55	37
30	-82	-35
-24	-82	-32
-3	-52	28
6	41	-8
9	-61	22
-12	-61	13
-3	29	-8
0	41	4
-18	-58	22
12	-67	31
45	-46	31
-15	-13	-20
-39	35	10
-24	-4	-23
-39	5	4
-9	-25	25
12	-67	31
-15	-61	10
9	35	-8
6	41	-8
9	-61	22
45	-46	34
45	11	34

// Schneider K, 2013: Subgroup of ASD, Non-Medicated
// Subjects=23
-39	38	10
-18	-55	22
42	-40	28
-15	-13	-20
-39	35	10
54	8	7
6	41	-8
6	-61	19
12	62	19
-3	29	10

// Schneider K, 2013: Healthy Controls
// Subjects=28
-3	-55	34
-48	-64	22
48	-58	22
0	50	22
-3	-55	34
-48	-64	25
-6	50	25
-3	56	5
-27	29	25
27	-79	-35
3	50	22
-48	-64	22
60	-49	28
-3	-55	34
0	-58	28
-57	-43	31
51	35	-5
12	-73	-2
57	-25	-14
-21	-79	-22
6	41	-8
9	-61	22
-12	-61	13
-3	29	-8
0	41	4
-18	-58	22
12	-67	31
45	-46	31
-15	-13	-20
-39	35	10
-24	-4	-23
-39	5	4
-9	-25	25
12	-67	31
-15	-61	10
9	35	-8
-39	38	10
6	41	-8
9	-61	22
45	-46	34
-18	-55	22
42	-40	28
-15	-13	-20
-39	35	10
54	8	7
6	41	-8
6	-61	19
12	62	19
45	11	34
-3	29	10

// Scheibel R S, 2012: Mild Traumatic Brain Injury (TBI) in Blast-Exposed 
// Veterans
// Subjects=15
-6	-68	32
28	-38	-14
-58	-42	12
8	-80	22
-26	-52	-26
18	20	46
-38	-26	40
-28	-58	56
24	-78	-24
56	-28	6
0	38	20
-50	-26	4
24	-30	66
20	-66	46
-26	-52	-26
38	-32	4
18	20	46
-50	-28	4
-4	-86	-8
6	-66	36
-14	-34	-4

// Scheibel R S, 2012: Control Veterans, no Traumatic Brain Injury (TBI)
// Subjects=15
8	-80	22
-26	-52	-26
18	20	46
-38	-26	40
-28	-58	56
24	-78	-24
56	-28	6
0	38	20
-50	-26	4
24	-30	66
20	-66	46
-26	-52	-26
38	-32	4
18	20	46
-50	-28	4
-4	-86	-8
6	-66	36
-14	-34	-4

// Liu Z, 2014: Controls
// Subjects=12
-6	-24	54
12	12	48
54	-9	54
-3	18	0
34	-15	16
39	-54	6
-27	-63	57
-39	-51	30
45	39	21
-24	-24	75
0	-99	0
-3	-60	-6
-42	36	0
6	54	30
-39	-39	-30
-24	-15	-30
-57	-20	-24
-39	33	-15

// Liu Z, 2014: Patients with Mild Cognitive Impairment (MCI)
// Subjects=12
21	-33	36
21	-57	45
-6	-24	54
12	12	48
54	-9	54
-3	18	0
34	-15	16
39	-54	6
-27	-63	57
-39	-51	30
45	39	21
-24	-24	75
0	-99	0
-3	-60	-6
-42	36	0
6	54	30
-39	-39	-30
-24	-15	-30
-57	-20	-24
-39	33	-15

// Berlingeri M, 2010: Picture Naming Task, Elderly Normals < Younger Normals
// Berlingeri M, 2010: Picture Naming Task, Elderly Normals > Younger Normals
// Berlingeri M, 2010: Sentence Judgement Task, Elderly Normals < Younger 
// Normals
// Berlingeri M, 2010: Sentence Judgement Task, Elderly Normals > Younger 
// Normals
// Berlingeri M, 2010: Picture Recognition Task, Elderly Normals < Younger 
// Normals
// Berlingeri M, 2010: Picture Recognition Task, Elderly Normals > Younger 
// Normals
// Berlingeri M, 2010: Sentence Recognition Tak, Elderly Normals < Younger 
// Normals
// Berlingeri M, 2010: Sentence Recognition Tak, Elderly Normals > Younger 
// Normals
// Berlingeri M, 2010: Main Effect of Picture Naming Task
// Berlingeri M, 2010: Main Effect of Sentence Judgement Task
// Berlingeri M, 2010: Main Effect of Picture Recognition Task
// Berlingeri M, 2010: Picture Naming Task > Picture Recognition Task
// Berlingeri M, 2010: Sentence Judgement Task > Sentence Recognition Task
// Berlingeri M, 2010: Picture Recognition Task > Picture Naming Task
// Berlingeri M, 2010: Sentence Recognition Task > Sentence Judgement Task
// Subjects=24
-52	-2	46
-44	-64	-4
-38	-50	-16
-34	-52	-16
-32	-86	6
-30	-86	12
-28	-48	-26
-26	-62	-18
28	-58	-12
30	-68	-10
20	-56	4
32	-84	-6
34	-84	4
36	-84	18
6	-72	12
26	-44	-22
28	-50	-18
-40	44	20
-14	-84	38
-48	42	-14
-50	36	-12
-52	22	-12
-62	-30	10
-16	-40	-10
-44	-80	28
-50	-76	16
-22	-86	42
66	-24	12
22	-34	-10
26	-28	-14
-40	-46	-14
-44	-64	-2
-30	-64	-6
-24	-50	-16
-22	-62	4
-46	-80	0
-44	-84	0
34	-52	52
38	-44	-22
40	-46	-18
16	-52	4
20	-54	4
8	-72	16
34	-42	-24
24	-42	-20
-42	44	16
-42	36	24
-40	20	44
-38	20	38
-38	10	44
36	26	46
42	6	48
-40	-60	42
-42	-56	42
48	-66	44
50	-58	44
-38	28	-8
-38	-52	56
32	24	-6
46	24	-16
40	24	28
44	36	34
44	-52	50
38	-56	46
-40	-6	52
-48	-76	28
-38	-82	36
-28	-86	40
-50	22	26
-4	12	50
-44	6	32
-50	-6	48
-38	26	-24
-14	-34	-8
-10	-42	-2
-44	-54	-22
-44	-72	-14
-42	-86	-2
-10	-78	8
32	-92	16
12	-80	12
22	-90	34
36	-42	-24
26	-52	-18
-46	24	-12
-50	20	18
-2	20	48
-62	-20	-6
-20	-22	-16
-8	-36	-4
-4	-16	10
60	-22	-8
62	-10	-10
4	-76	-14
-48	18	36
-48	26	32
-44	8	34
-34	22	-4
-42	-58	-20
50	36	20
42	42	32
2	24	48
36	22	-6
-44	-72	-14
34	-90	12
-50	-6	50
-10	-38	-10
54	-4	-24
-34	20	-6
-26	-78	-14
-22	-68	-12
-30	-66	-18
50	36	22
2	26	48
28	-76	44
34	-70	38
14	-38	-10
-44	46	-6
-34	-72	54

// Bayerl M, 2010: 2-back vs 0-back, ADHD < Healthy Controls
// Subjects=30
52	-72	24

// Cubillo A, 2012: Attention Deficit Hyperactivity Disorder (ADHD)
// Subjects=11
-49.23	19.73	-7.39
-41.2	-14.01	51.11
44.05	11.48	29.03
46.98	49.25	7.99
1.4	12.17	41.73
12.69	23.9	-14.02
8.71	-30.17	2.82
1.51	-18.5	44.3
13.22	-68.32	18.24
-18.25	-16.35	-22.56
20.16	-12.4	-30.02
55.81	-41.09	8.77
-52.1	-44.91	10.33
51.75	-34.49	39.49
-44.38	-34.63	46.18
-5.84	-78.7	37.17
20.9	-69.57	42.79
39.92	-76.08	11.89
-41.3	-76.57	12.86
-25.49	-66.72	-12.68
32.11	-50.94	-20.24
46.85	32.57	-15.14
1.16	38.29	21.7
47.27	8.33	29.26
47.21	-13.13	13.22
-13.92	-3.75	-11.4
-10.29	-31.14	33.23
-44.73	-17.37	7.94
-32.55	-54.65	47.73
-52.16	-54.31	-1.14
40.07	-78.85	31.08
13.15	-88.81	1
-32.81	-84.86	1.2
-33.09	-60.31	-25.39
-29.71	7.44	24.64
63.2	-1.41	12.05
13.13	-31.94	20.76
-44.38	-34.63	46.18
51.81	-38.29	45.39
-5.89	-74.9	31.28
5.51	-70.77	-12.69
-25.49	-66.72	-12.68
39.47	57.67	7.37
27.5	50.97	-23.16

// Cubillo A, 2012: Healthy Controls
// Subjects=15
-36.87	-17.79	56.95
-52.23	-10.01	7.41
51.7	-18.62	38.16
5.82	-13.73	50.55
-22.42	-6.55	-5.49
-10.56	-9.76	6.91
24.93	-19.3	31.84
-10.26	-39.6	33.94
27.82	-34.68	-15.98
-18.18	-23.32	-16.4
28.21	-75.63	18.68
66.11	0.02	-24.9
-56.76	-4.95	-23.07
-37.05	-81.2	7.63
8.6	-39.02	-15.39
35.28	46.44	13.94
-3.14	-18.06	-4.75
27.71	-7.19	-18.28
5.53	39.26	33.84
5.79	-6.33	49.93
63.1	-38.7	-16.04
13.41	-78.5	38.05
-17.98	-61.93	-6.47
-29.71	7.44	24.64
63.2	-1.41	12.05
13.13	-31.94	20.76
-44.38	-34.63	46.18
51.81	-38.29	45.39
-5.89	-74.9	31.28
5.51	-70.77	-12.69
-25.49	-66.72	-12.68
39.47	57.67	7.37
27.5	50.97	-23.16

// Cubillo A, 2011: Attention Deficit Hyperactivity Disorder (ADHD)
// Subjects=11
-30.06	60.97	1.2
-44.94	52.93	8.74
-49.34	23.02	-19.93
-37.33	-19.32	-4.25
46.8	6.79	-31.94
55.66	-26.17	-4.74
-60.97	4.43	-11.54
5.89	-45.96	46.56
-13.75	-50.28	-7.5
43.92	-66.73	-19.05
27.7	-40.28	-33.35
-25.56	-87.13	-28.81
47.31	12.01	35.64
-3.36	15.89	-19.86
1.32	20.2	35.49
-3.17	-34.87	-15.6
-49.5	30.11	-38.36
40.04	-46.19	40.61
27.68	-36.05	-33.7

// Cubillo A, 2011: Healthy Controls
// Subjects=15
-30.06	60.97	1.2
-44.94	52.93	8.74

// Dibbets P, 2010: Switch > NonSwitch
// Dibbets P, 2010: Switch > Baseline, ADHD > Healthy Controls
// Dibbets P, 2010: Switch > Baseline, Healthy Controls > ADHD
// Subjects=14
15.45	22.68	66.34
-21.94	-56.5	36.61
-26.8	27.44	-6.06
42.06	-57.32	20.33
24.66	36.14	19.38
16.5	-53.27	33.67
21.71	-85.42	2.85
-36	-8.92	33.9
-29.58	-38.46	22.92
25.65	7.83	-2.79
22.93	-26.66	46.97
-9.13	2.73	58.26
4.42	-10.56	9.03
-28.92	12.28	-9.23
-35.93	-27.95	35.49

// Karch S, 2010: Attention-Deficit/Hyperactivity Disorder (ADHD)
// Subjects=8
0.39	25.96	55.09
-46.77	15.42	33.09
-47.56	-42.14	45.74
1.14	45.78	22.19
5.19	64.27	-.6
18.45	49.16	50.7
-42.42	25.02	46.74
-7	14.8	62.8
10.05	22.13	59.76
-48.76	13.61	51.11
-37.36	44.06	17.2

// Karch S, 2010: Healthy Controls
// Subjects=8
2.52	25.89	53.95
-45.64	22.72	44.74
55.89	21.21	43.7
-44.28	-55.61	50.17
54	-45.42	49.3
1.14	45.78	22.19
5.19	64.27	-.6
18.45	49.16	50.7
-42.42	25.02	46.74
-7	14.8	62.8
10.05	22.13	59.76
-48.76	13.61	51.11
-37.36	44.06	17.2

// Valera E M, 2010: Attention-Deficit/Hyperactivity Disorder (ADHD)
// Subjects=21
-45	30	0
-51	36	3
-51	18	30
-48	45	-6
-42	-3	48
-48	6	54
-54	-18	27
-45	-15	33
-48	-6	36
-63	-42	30
-66	-30	33
-54	-42	0
-57	-54	6
-51	9	-12
-51	-39	24
-45	12	9
30	-69	-18
18	-57	-15
36	-24	69
21	-27	54
15	-30	66
51	-9	42
54	-36	24
39	-33	18
-6	-42	-24
-15	-48	-36
-60	15	3
-54	-18	27
-48	12	6
-36	-27	0
-51	-39	24
-24	-15	12
-27	-3	-6
-30	-21	0
-30	-15	-9
6	-54	-27
6	-48	-21
48	27	0
39	27	-9
42	33	-3
24	-3	-12
-36	-21	51
-42	-21	63
-33	-21	72
-27	-48	3
-48	0	0
-39	-33	9
-45	-27	6
-54	-24	12
-33	-39	24
-39	-33	18
-18	-39	9
15	-51	-21
6	-63	-15
30	36	15
21	48	18
66	-39	39
57	-51	51
36	-42	3
69	-21	3
21	-39	12
-6	-3	63
-9	-24	51
-27	-24	75
-36	-21	51
-42	-21	63
-60	0	9
-60	0	27
-12	-15	78
-3	9	21
-54	-15	48
-57	-15	18
-12	-21	24
-39	-21	18
-45	3	0
-30	-9	9
-6	-12	21
15	-51	-18
6	-63	-15
6	-54	-6
30	36	15
9	-15	51
12	24	45
57	6	45
45	0	60
66	-3	12
63	6	12
6	3	66
21	51	18
66	-42	36
63	-42	45
57	-51	51
33	-45	3
6	0	18
24	-45	12
21	-36	18
45	9	-3
36	21	6

// Valera E M, 2010: Healthy Controls
// Subjects=19
-45	30	0
-51	36	3
-51	18	30
-48	45	-6
-42	-3	48
-48	6	54
-54	-18	27
-45	-15	33
-48	-6	36
-63	-42	30
-66	-30	33
-54	-42	0
-57	-54	6
-51	9	-12
-51	-39	24
-45	12	9
30	-69	-18
18	-57	-15
36	-24	69
21	-27	54
15	-30	66
51	-9	42
54	-36	24
39	-33	18
-6	-42	-24
-15	-48	-36
-60	15	3
-54	-18	27
-48	12	6
-36	-27	0
-51	-39	24
-24	-15	12
-27	-3	-6
-30	-21	0
-30	-15	-9
6	-54	-27
6	-48	-21
48	27	0
39	27	-9
42	33	-3
24	-3	-12
-63	6	18
-6	0	63
-45	24	42
-33	-27	72
-39	-21	54
-51	-9	12
-48	-45	60
-57	-51	48
-60	-39	48
-51	-15	0
-63	-30	15
-60	-21	9
-36	3	3
-30	21	9
-39	-27	3
-42	3	-3
-48	9	3
-51	-39	24
-27	-18	3
-27	-12	-3
-15	-18	0
18	-54	-18
12	-63	-48
54	15	3
45	27	0
42	42	30
48	45	-6
54	3	48
60	-54	42
60	-39	51
54	-33	21
60	-27	15
63	-15	0
51	-9	-3
48	6	0
69	-30	6
48	-24	9
42	-36	21
-63	6	18
-6	0	63
-12	-27	63
-18	-21	78
-36	-12	63
-33	-27	72
-39	-21	54
-51	-15	45
-51	-9	12
-24	45	27
-9	-15	45
-15	-9	-24
-54	-21	21
-27	21	9
-42	3	-3
-45	6	6
-48	9	3
-51	-39	24
-27	-15	6
-30	-6	-3
-15	-18	3
15	-54	-18
12	-66	-51
6	-66	-36
63	6	21
42	24	-6
45	48	-3
42	45	-6
54	3	45
39	42	30
63	3	9
60	-3	45
57	-6	42
27	54	30
15	54	30
60	-54	42
57	-39	51
54	-54	51
48	-36	27
48	6	0

// Maier S J, 2014: IF-Test: CS+ > CS-, Healthy Controls > ADHD
// Maier S J, 2014: UF-Test: CS+ > CS-, ADHD > Healthy Controls
// Subjects=13
-51	0	-6
-45	-7	-26
57	-7	-29

// Wilbertz G, 2013: Attention-Deficit Hyperactivity Disorder (ADHD)
// Subjects=12
-42	14	-20
12	38	-17

// Wilbertz G, 2013: Healthy Controls
// Subjects=12
-6	50	31
-9	-97	19
48	-70	1
12	38	-17

// Vieira J B, 2014: Subgroup of Normals, High Psychopathy
// Subjects=26
3.12	46.28	0.94
3.45	37.64	40.69

// Vieira J B, 2014: Subgroup of Normals, Low Psychopathy
// Subjects=35
39.22	-46.97	71.91
17.26	-44.38	-2.77
-51.11	20.26	27.16
-2.87	51.75	58.54
48.74	-69.86	50.3
-2.87	51.75	58.54

// Cope L M, 2014: Psychopaths
// Subjects=137
15	30	57
-39	21	48
45	30	0
-15	39	12
-6	33	21
-6	-12	36
9	-33	33
18	-48	39
15	0	0
-18	-3	6
-9	-3	66
-39	36	27
30	42	42
-57	9	30
-48	12	27
-42	3	42
45	-6	24
3	-21	36
-39	-60	42
-51	-42	36
-48	-39	45
48	-51	12
54	-36	-6
-6	3	6
-18	15	6
39	-12	45
-39	-9	3
15	-102	12
-21	-12	-9
18	-33	-21
-24	-39	-24
-12	-12	63
15	-18	69
15	24	57
-12	21	54
-18	48	18
18	36	48
-6	27	57
-18	15	45
-30	18	51
27	36	39
-39	9	36
-39	15	24
-36	-3	48
45	36	3
-27	-21	63
-24	-21	72
-60	-30	45
15	-42	72
27	-27	-18
27	-39	-6
-30	0	-27
-18	39	12
-9	9	36
-3	27	18
-6	-12	39
9	-12	36
12	-42	39
3	-45	33
-39	-57	42
42	-36	30
54	-57	12
45	0	-3
54	-63	3
-39	-33	9
-39	-12	6
-39	-3	0
-9	-93	12
-3	-93	0
-21	-15	-9
-15	-3	0
-33	-15	-12
12	12	6
9	3	6
36	-21	3
36	-3	3
-36	-21	0
51	-24	51
36	-18	63
60	0	-3
-57	-6	3
45	-9	9
-27	-39	-9
-33	-6	-33
-24	-3	-36
-27	-15	-6
21	-30	9
-24	-36	-21
-30	-51	-30
18	-33	-18
18	-78	21
21	-6	-6
21	51	3
21	42	3
45	12	-27
-57	-54	6
-54	-45	0
-36	9	-42
-42	0	-42
36	-12	-27
-21	-21	18
12	39	36
-27	42	-9
-45	21	-3
6	12	15
-3	-33	-21
-12	-3	66
-6	-15	63
-36	-3	48
-30	-36	66
-36	-27	45
-42	-24	33
39	-9	45
-15	33	18
-9	6	39
-9	-12	39
12	-42	42
0	-45	45
6	-69	51
-45	-36	-12
-39	-30	-21
-54	-36	-12
-33	-33	9
-39	-30	3
-60	-27	33
3	-84	21
-15	-54	-6
-9	-69	0
-33	-21	0
-18	-18	-9
-24	-51	-18
-30	-12	21
-39	21	-21
-39	18	-6
-42	33	-6
48	36	3
57	27	15
42	18	-12
3	57	9
-9	24	54
15	30	48
3	45	18
-42	9	39
30	18	36
-45	21	30
-45	30	18
-3	27	27
-21	42	12
9	-9	33
6	-45	30
-6	-51	9
9	-51	12
27	-3	-24
24	-27	-21
18	-9	-21
21	-33	-6
45	-36	9
-51	-48	30
27	-84	27
27	-87	18
15	18	18
12	12	9
15	-15	24
0	-12	3
18	-27	3
-33	-6	3
12	-33	-18

// Cope L M, 2014: Subgroup of Psychopaths, Negative Urinalysis
// Subjects=115
15	27	57
-24	48	18
30	45	36
27	54	24
39	30	48
-42	33	30
-36	12	36
-42	6	42
21	33	48
-42	33	-3
30	-21	48
-15	39	12
-9	36	21
3	-21	36
-6	-12	36
9	-33	30
3	-51	30
18	-48	39
48	-51	9
48	-39	0
54	-39	-9
51	-18	-18
-63	-36	-12
-60	-24	-18
-51	-33	-12
-42	-48	36
-39	-39	30
-48	-39	45
-39	-60	39
15	0	0
-3	3	6
-21	-3	3

// Harenski C L, 2014: Incarcerated
// Subjects=157
33	0	-18
6	27	18
-57	-45	9
42	-57	-24
-57	-45	9
33	0	-18
6	27	18
-57	-45	9
42	-57	-24
-57	-45	9
60	-54	15
30	-90	-12
-39	-69	-12
-33	-30	-21
60	-30	18
-21	-54	-12

// Kielar A, 2011: Main effect of verb stems, covert production
// Kielar A, 2011: Main effect of past tense verbs, covert production
// Kielar A, 2011: Main effect of present tense verbs, covert production
// Kielar A, 2011: (Past tense verbs + Present tense verbs) > Baseline, covert 
// production
// Kielar A, 2011: Past tense verbs > Verb stems, covert production
// Kielar A, 2011: Present tense verbs > Verb stems, covert production
// Kielar A, 2011: Past tense verbs > Present tense verbs, covert production
// Kielar A, 2011: Main effect of verb stems, overt production
// Kielar A, 2011: Main effect of past tense verbs, overt production
// Kielar A, 2011: Main effect of present tense verbs, overt production
// Kielar A, 2011: (Past tense verbs + Present tense verbs) > Verb stems, 
// overt production
// Kielar A, 2011: Past tense verbs > Verb stems, overt production
// Kielar A, 2011: Present tense verbs > Verb stems, overt production
// Kielar A, 2011: Past tense verbs > Present tense verbs, overt production
// Kielar A, 2011: Present tense verbs > Past tense verbs, overt production
// Subjects=13
33	-70	22
-42	-4	46
-51	2	37
-3	8	52
30	-70	25
-27	-70	31
-21	-55	46
-27	-73	22
-6	5	52
6	-1	58
-48	-1	46
-51	2	34
-27	-70	31
-21	-52	43
30	-70	28
-42	-4	52
-9	8	52
-21	-55	43
-27	-70	34
-42	-4	52
-21	-55	43
-27	-70	34
-39	-4	55
-21	-55	43
-27	-73	34
-24	2	34
-9	-70	22
-51	-10	31
-54	-7	22
-33	-25	10
0	5	55
54	-7	40
57	-7	19
-18	-28	58
18	-25	58
21	2	1
33	8	4
-12	-19	4
15	-16	4
-51	-10	31
54	-7	40
-54	7	22
0	5	55
-6	20	25
18	-28	58
-21	-28	55
-3	-76	34
12	-67	10
-51	-10	31
-54	-7	22
-45	-16	37
0	5	55
54	-7	40
51	-4	49
57	-7	19
-18	-28	58
18	-28	58
12	-67	10
33	-70	25
-51	2	25
0	8	55
-6	11	40
6	17	37
-39	-4	55
51	-4	49
-33	23	1
-33	14	7
-12	-4	1
-24	-58	43
-18	-58	49
-51	5	19
-45	5	13
-51	2	31
0	8	55
6	17	34
-39	-4	55
45	2	52
51	-4	49
-33	14	7
-33	23	1
-12	-4	7
-21	-61	46
-6	11	40
3	8	55
-42	-7	49
-51	2	25
-24	-58	43
-18	-58	49
-9	26	55
21	32	46
30	26	43
24	23	37
-15	47	31
-21	26	34
-30	26	37
-15	50	13
15	44	16
15	-43	13
0	-19	13
-15	-28	49
21	-43	49
30	-58	31

// Meffert H, 2013: Main effect of hand interaction type (Love and Pain > 
// Baseline) during Experience
// Meffert H, 2013: Experience: Love > Pain
// Meffert H, 2013: Experience: Pain > Love
// Meffert H, 2013: Main effect of movie type (Love and Pain > Baseline) 
// during Observation
// Meffert H, 2013: Observation: Love > Pain
// Meffert H, 2013: Observation: Pain > Love
// Subjects=18
-45	-21	51
51	-18	48
-3	57	-3
-6	6	48
-21	-51	-27
24	-51	-30
3	-51	21
-33	-69	42
-3	-33	57
-24	-3	3
24	3	0
-39	48	-3
51	-51	-9
-36	27	39
18	-27	57
-3	-39	-12
51	12	-24
57	9	30
6	6	-3
51	36	9
6	33	39
33	24	48
-24	0	-15
-45	-21	51
51	-18	48
24	-51	-30
-21	-51	-27
-6	6	48
-9	45	-3
57	9	30
24	3	0
-30	42	27
51	-60	0
-18	9	3
3	6	-3
-60	-36	9
66	-24	3
54	-51	42
-48	-51	42
6	33	39
42	-33	57
-57	-48	18
45	-66	-9
30	3	57
-33	-39	57
-24	-12	60
18	-90	0
-45	21	21
-6	30	54
-6	57	12
3	-75	-3
-21	-90	-3
12	-27	42
-3	54	30
27	-84	6
-33	24	-18
60	-48	-12
9	-30	-3
18	-57	21
3	60	-3
-36	-78	-6
-33	-39	54
-24	-12	60
21	21	60
24	24	51
-3	-3	-6
3	-78	0
-57	-48	27
-51	18	0
3	-33	-6
-33	24	-18

// Oh T, 2011: Main effect of phonological complexity
// Oh T, 2011: Regular > Irregular
// Oh T, 2011: Irregular > Regular
// Subjects=19
-11.38	16.92	49.29
-49.08	-11.65	-.3
8.04	-53.52	44.94
-46.94	36.77	20.15
54.64	29.26	24.08
-32.12	26.6	-2.58
36.26	25.79	-5.53
-57.68	21.85	7.03
-8.44	10.94	12.95
-50.22	-16.74	-11.01
-33.64	-53.77	45.44
14.81	54.46	-4.34
23.66	47.83	32.91
39.74	35.23	33.78
14.19	22.9	41.8
42.43	0.28	-46.96
4.71	-15.22	45.11
-24.62	-23.7	-20.76
10.64	-36.7	-26.76
-18.28	-47.41	-38.91
7.02	-42.01	56.25
-24.45	-48.31	-8.66
4.41	-51.31	-8.74
61.36	-51.06	30.74
59.09	-52.44	13.03
15.32	-53.33	19.19
-49.8	-65.19	23.16

// Pliatsikas C, 2014: Regular morphology > Irregular morphology
// Pliatsikas C, 2014: Irregular morphology > Regular morphology
// Pliatsikas C, 2014: Regular morphology > Regular unrelated
// Pliatsikas C, 2014: Irregular morphology > Irregular unrelated
// Subjects=17
46	-70	8
48	2	46
16	0	16
8	2	50
34	-52	58
-46	-70	2
-38	-72	-44
-50	8	-4
-22	8	24
-40	6	26
14	20	32
12	-80	-10
40	-78	6
46	6	22
-40	24	16
-40	-70	2
8	-8	8
14	-84	-10

// Slioussar N, 2014: Real verbs (RV) + IV) > Nonce verbs (RNV + INV)
// Slioussar N, 2014: Nonce verbs (RNV + INV) > Real verbs (RV + IV)
// Slioussar N, 2014: Regular verbs (RV) > Irregular verbs (IV)
// Slioussar N, 2014: Irregular verbs (IV) > Regular verbs (RV)
// Slioussar N, 2014: Real nouns (RN + IN) > Nonce nouns (RNN + INN)
// Slioussar N, 2014: Nonce nouns (INN + RNN) > Real nouns (RN + IN)
// Slioussar N, 2014: Parametric contrast (RV > B) < (IV > B) < (RNV > B) < 
// (INV > B)
// Slioussar N, 2014: Parametric contrast (RN > B) < (IN > B) < (RNN > B) < 
// (INN > B)
// Slioussar N, 2014: Conjunction of (Regular verbs > Irregular verbs) AND (RV 
// > B) < (IV > B) < (RNV > B) < (INV > B)
// Subjects=21
-51	-64	28
-30	29	49
-9	-49	37
51	-58	22
-30	-52	46
-45	5	31
27	-64	46
42	-37	40
39	-61	-29
-6	11	52
51	-61	25
-45	5	31
-45	23	34
-45	50	1
-30	-52	43
-30	23	-2
33	-64	-29
-6	11	52
-6	-52	31
-48	-64	25
51	-58	25
-45	5	31
-33	17	4
-42	29	22
-39	-49	46
-27	-67	46
-6	11	52
27	-67	46
-12	-73	7
45	-34	49
30	-64	-26
48	29	25
48	5	28
-45	5	31
-48	20	31
-30	-52	43
-24	-61	43
-6	11	52
9	20	43
27	-64	46
30	-55	55
42	-37	40
36	-61	-29
-30	23	-2
45	35	22
-24	-4	55
-48	8	31
-33	17	4
-39	-49	46
-27	-67	46
-6	11	52
27	-67	46
33	-61	49
48	29	25
45	-34	49
48	5	28
-12	-73	7
-9	-1	-1
30	-61	29
-45	5	31
-48	8	16
-30	-52	43
-30	23	-2
-6	11	52
33	-64	-29
51	-61	25

// Wright P, 2011: Words > Baseline (MuR)
// Wright P, 2011: Main effect of task
// Wright P, 2011: Main effect of Complexity
// Wright P, 2011: Task x Complexity interaction
// Subjects=14
-60	-3	-6
-60	-30	3
-63	-18	-3
63	-18	-3
60	-6	-3
54	-27	3
-36	-51	48
-45	-51	48
-42	-57	-3
-48	-57	-12
-39	-45	-15
-36	33	-12
-48	27	-6
39	-54	48
45	-45	54
51	-39	51
66	-36	6
69	-30	-9
54	-42	15
-54	12	9
51	-27	9
60	-18	12
42	-15	6
-48	-36	18
-54	-33	-9
-51	-33	9

// Dresler T, 2012: Panic Disorder
// Subjects=20
-40	24	-18
-36	10	42
56	28	0
-48	-54	22
-2	-38	30
-42	-60	52
-2	-64	34
56	26	16
44	-38	0
60	-36	-10
-40	24	-18

// Dresler T, 2012: Healthy Controls
// Subjects=23
-46	30	-6
-40	24	-18

// Heath S, 2012: Healthy Controls
// Subjects=18
9	-42	6
-39	-69	-9
-30	-9	42
30	-42	69
57	-12	45

// Heath S, 2012: Aphasia Patient P02
// Subjects=1
-45	12	-39
42	33	12
42	-36	60
36	6	-39
9	18	30
-60	-33	51
-45	33	-9
12	72	21
-18	-81	-3
21	60	-9
39	-3	-45
-48	-45	48
-27	-60	57
42	42	-9
39	-21	-15
48	-33	39
30	-33	42
15	-36	33
3	9	54
-66	-30	0
-21	-24	-12
-57	-9	48
48	3	57
-60	-27	48
-36	3	-9
-57	-3	33
-42	3	42
-27	-78	3

// Heath S, 2012: Aphasia Patient P03
// Subjects=1
39	27	21
36	6	-24
57	0	-12
0	-18	-45
-27	-63	-39
-9	-18	51

// Heath S, 2012: Aphasia Patient P05
// Subjects=1
21	51	27
-6	39	30
-3	-3	54
60	-6	-24
36	-72	42
27	-75	12
51	-48	54
24	51	27
-42	27	-9
-15	51	30
-3	-66	57
36	-72	42
24	-75	9
12	-69	24
60	-57	30
39	-54	-3
39	-78	-18

// Heath S, 2012: Aphasia Patient P06
// Subjects=1
-45	27	21
45	36	12
21	-96	0
42	-66	-18
-54	-69	18
-42	-6	57
15	-39	75
30	-66	36
-36	-90	6
45	6	27
60	-39	39
-18	-57	30
-21	18	33
15	-54	30
-30	-3	6
30	21	-12
42	-54	-3
30	-51	42
-51	36	6
-54	-72	18
33	21	-9
60	-12	15
-42	27	21
36	-75	-27
-12	-87	3
-15	-72	-21
-21	-63	30
18	-45	-36
-21	18	30
18	-30	60
-12	66	12

// Heath S, 2012: Aphasia Patient P07
// Subjects=1
-36	51	0
36	21	-27
54	6	-30
-21	-27	24
27	-21	66
-12	-18	72
-57	-48	-6
-33	45	-12
39	-42	-48
39	33	12
39	48	30
-18	36	15
57	-51	-9
45	9	15
18	42	21
-6	-93	33
-48	-45	-3
51	18	24
39	36	12
57	-39	0
3	-87	30
45	-6	-33
36	21	-27
57	-6	6
-36	-3	-36
24	-87	0

// Heath S, 2012: Aphasia Patient P08
// Subjects=1
63	-36	27
57	18	-3
-3	33	-9
33	-66	12
-36	-48	18
-18	30	12
18	-21	-36
-21	-3	12
-48	30	-12
-3	30	-9
57	21	-3
-39	9	33
45	15	27
24	-84	-6
33	-60	51
-21	9	3
-39	3	48
57	-30	-6
-24	-63	-12
69	-42	9
-27	57	18
-39	-36	12
12	63	6
39	48	30
33	-66	12
-12	-27	-42
-33	42	39

// Rochon E, 2010: Treated Aphasia (ATr1)
// Subjects=1
-48	20	8
-36	-76	24
-8	-12	64
-8	-76	36
-12	-48	-16
12	-64	52
56	8	0
4	-60	20
-44	-76	-24
-28	60	20
-64	-48	40
-56	-20	-20
24	44	12
44	-48	-32
28	36	-12
12	-96	-4

// Rochon E, 2010: Treated Aphasia (ATr2)
// Subjects=1
-16	20	8
-8	72	8
-52	-12	-32
-56	36	8
-64	4	16
-60	-68	32
-48	-40	56
-44	60	0
-36	20	-28
44	-40	56
24	64	8
64	-8	28
24	20	52
-48	4	-24
-20	0	-28
-44	-4	20
-52	-28	12
-48	-20	-16
-24	-72	40
-24	56	-20
-8	16	40
-56	-32	48
16	0	-4
40	0	0
20	0	-28

// Rochon E, 2010: Aphasia Untreated (AUn1)
// Subjects=1
-44	-72	16
-4	-16	4
64	-4	0
4	-44	40
52	-76	20
44	-72	12
60	-32	32
52	-28	-20
20	-88	32
0	12	-8
-44	36	-12
-28	-68	44
-28	44	24
-56	16	-8
24	-72	56
0	52	16

// Rochon E, 2010: Aphasia Untreated (AUn2)
// Subjects=1
-40	20	4
-12	-44	32
-36	48	8
-36	-76	32
-48	-84	8
-36	48	8
-24	68	12
36	-84	40
48	-8	56
4	40	40
28	44	40
20	-12	16
16	28	24
44	24	4
40	44	28
28	48	-4
0	-60	24

// Rochon E, 2010: Healthy Controls
// Subjects=10
-48	20	-4
-64	-28	16
-8	-88	16
-48	8	16
52	16	-8
8	-92	-4
60	-32	8
60	-40	40
0	-84	24
-52	-80	-8
-12	-68	48
48	-80	-12
32	36	8

// Sandberg C, 2014: Aphasia Patient 1 (AP1)
// Subjects=1
-3	-21	42
-3	39	45
-24	45	45
-48	30	33
-45	30	-3
-51	27	3
-36	-15	21
0	21	54
-36	-15	57
6	63	18
30	9	66
33	57	21
48	39	-12
45	39	24
57	18	0
45	18	-3
24	-24	66
-39	24	-21
-66	-27	-3
-42	-63	-9
-33	-48	69
-51	-54	48
-60	-51	30
-48	-54	30
-15	-93	24
-21	-93	15
-48	-66	-12
-12	-93	-3
-12	-66	36
-9	-93	24
-21	-66	3
-12	-78	-15
63	-48	18
54	-42	-3
24	-90	21
48	-78	3
42	-81	-12
15	-93	6
18	-90	15
9	-90	-9
-3	-36	36
-12	63	18
-24	21	54
-42	6	57
-45	21	-9
-45	30	15
-39	51	-9
-30	24	-3
-30	6	0
-9	6	-6
0	21	54
-39	-9	60
3	-3	39
9	60	24
15	33	54
45	42	27
39	39	-18
45	24	12
54	18	0
45	9	-6
54	-15	3
6	-27	66
39	-27	63
-33	-27	45
-42	18	-15
-45	-15	-6
-60	-45	0
-54	-57	-12
-42	-48	-24
-33	-51	69
-48	-57	57
-60	-48	33
-57	-57	24
-3	-51	24
-15	-93	24
-9	-93	3
-9	-54	27
3	-81	0
-9	-84	-24
24	-30	63
66	-48	21
51	-9	6
51	-39	0
39	-24	-15
69	-39	24
27	-93	15
15	-93	6
15	-87	21
-3	-36	39
-6	45	42
-18	27	42
-42	6	57
-45	33	-15
-42	21	21
-45	48	-6
-27	24	0
45	24	15
9	12	3
36	-27	63
-54	-57	21
-54	-39	-15
-54	-30	48
-57	-48	30
-54	-63	30
54	-6	6
6	-87	12
0	30	27
-12	63	21
-12	18	51
-42	6	57
-24	27	-15
-45	39	6
-54	15	12
-36	54	-3
-30	21	-3
-15	6	6
-3	15	48
-39	6	45
12	12	45
9	60	27
33	54	12
45	42	24
57	24	15
45	18	-3
45	-3	12
30	-9	12
12	6	6
33	0	51
-48	-39	57
-48	-18	0
-60	-48	3
-48	-39	-21
-33	-9	-27
-30	-66	42
-48	-45	30
-3	-33	33
-24	-69	33
-27	-75	39
-24	-27	-18
57	-36	51
-12	33	54
-24	42	18
-42	36	-12
-45	39	6
-30	21	-3
-57	0	36
57	24	15
45	18	-3
33	-15	66
-48	21	-12
-57	-45	0
-48	-39	-18
-42	-51	-12
-30	-66	45
-57	-57	24
-24	-72	30
-48	-60	-18
21	-3	6

// Sandberg C, 2014: Aphasia Patient 2 (AP2)
// Subjects=1
0	-12	39
-9	57	36
6	48	18
3	-27	30
24	51	33
-51	-63	21
-3	-57	30
63	-51	0
9	-57	39
-9	39	21
-3	-45	36
-3	51	30
-12	57	27
-27	36	48
-42	27	-18
-57	24	15
-39	3	24
-60	3	6
0	21	57
-42	9	48
9	42	51
15	6	75
48	27	-15
48	42	0
51	18	12
36	27	-6
-54	-6	45
-54	6	-12
-63	-42	15
-54	-42	-9
-48	-48	-9
-33	-66	57
-36	-78	42
-45	-63	51
0	-48	30
-18	-93	24
-39	-78	36
-3	-69	18
27	-90	24
30	-90	15
12	-99	3
-3	54	30
-12	57	27
-27	24	45
-45	45	-6
-57	21	15
0	21	57
-33	9	30
3	33	45
45	42	0
39	18	30
39	24	-6
-54	-3	42
-54	-42	-9
-51	-51	-9
-33	-66	57
-33	-72	51
-45	-63	51
-3	-45	33
-39	-78	36
-3	-69	18
-9	-60	15
45	-36	-21
9	-39	24
27	-90	24
-6	27	30
0	-6	36
0	69	9
-24	21	54
-27	9	57
-42	27	-18
-57	18	12
-36	6	6
-48	3	9
-30	-9	6
-3	-3	75
-42	9	48
3	33	24
3	-33	30
6	60	3
39	39	6
45	21	-12
48	42	0
36	27	-6
30	-9	6
9	9	9
6	-15	78
54	6	45
9	-30	63
-21	-36	75
-51	9	-15
-66	-39	15
-63	-42	-9
-51	-57	-18
-21	-57	66
-42	-60	51
-63	-24	27
-45	-72	30
-3	-45	33
-21	-69	33
-39	-78	36
-24	-87	-9
-6	-63	15
-3	-54	12
0	-72	30
-21	-21	-27
-6	-84	-9
-3	-63	-6
15	-51	72
51	-36	6
57	-66	0
51	-72	-6
27	-63	-15
9	-21	12
24	-75	51
42	-33	48
51	-30	42
45	-63	30
33	-72	42
42	-81	3
48	-75	-12
12	-63	12
9	-66	66
21	-87	39
15	-96	-9
3	-48	0
-12	-6	48
-3	48	42
-12	72	6
-24	21	48
-39	30	-15
-57	24	15
-39	6	21
-27	33	-18
-60	0	9
0	9	66
-42	9	48
9	-39	33
6	57	30
18	66	21
36	45	3
42	36	-12
45	45	0
60	18	36
36	24	-3
15	-6	18
-54	-6	45
-54	9	-6
-60	0	0
-60	-42	-12
-51	-48	-9
-21	-81	48
-36	-72	48
-39	-63	48
-3	-45	33
-33	-81	36
-3	-66	18
-6	-69	36
-3	-84	24
-12	-84	-6
-3	-63	-6
63	-27	-3
30	-72	-15
45	-54	48
45	-66	30
33	-75	42
27	-93	3
30	-87	-6
27	-69	3
12	-66	36
9	-93	15
15	-99	-9
-3	-51	6

// Sandberg C, 2014: Aphasia Patient 3 (AP3)
// Subjects=1
-6	30	57
-15	33	51
-42	12	45
-51	33	-3
-27	21	-3
-33	3	36
12	30	24
9	18	45
6	45	45
21	66	3
36	45	21
33	30	-6
48	18	-18
33	18	3
9	15	6
-60	-39	-3
-57	-51	-9
-36	-78	45
-45	-60	42
-45	-75	36
-27	-78	-9
-3	-54	45
66	-45	0
45	-54	-9
3	-21	3
54	-48	48
54	-42	39
54	-60	24
24	-96	6
36	-93	-3
6	-90	0
15	-66	39
18	-99	9
-3	45	18
-3	-12	39
-6	33	45
-15	33	51
-27	21	51
-39	39	-3
-30	21	-3
-6	-12	75
-33	3	36
12	30	24
6	-12	33
12	54	30
21	66	3
51	18	48
48	45	-3
48	18	18
33	24	-18
15	9	-6
9	6	6
-63	-33	12
-63	-39	-3
-6	-51	21
-3	-84	45
-24	-99	9
0	-69	45
-21	-24	-21
-12	-36	-18
45	-12	-9
66	-45	0
60	-21	-18
18	-24	-12
54	-51	48
60	-45	36
39	-57	42
6	-87	0
15	-66	39
12	-102	9
0	-42	-18
-12	48	3
-6	-36	45
-12	48	12
-24	45	42
-30	36	48
9	42	0
6	-51	33
9	66	12
21	45	36
33	33	39
39	-15	-3
48	-27	18
6	18	66
27	-21	75
6	-27	75
-51	-69	18
-18	-48	72
-9	-48	27
-18	-78	27
-36	-75	24
-54	-69	-3
-3	-90	15
-3	-69	36
-24	-48	-6
-3	-48	-15
54	-15	30
60	0	-9
66	-51	9
48	-66	-3
33	-33	-3
15	-57	57
48	-33	48
66	-21	21
48	-63	33
21	-66	45
30	-63	6
12	-54	42
3	-78	39
15	-66	-9
-3	45	18
-3	27	57
-15	33	54
-27	21	54
-39	42	-3
-51	33	0
-30	21	-3
-6	-9	75
12	54	30
24	63	6
45	51	0
42	42	-6
51	42	0
9	12	0
3	21	57
-60	-48	0
-27	-69	-12
-57	-57	30
-42	-78	30
0	-63	51
-18	-27	-18
-15	-51	0
-3	-48	-15
66	-15	-6
54	-66	21
60	-45	-12
57	-51	42
63	-45	39
-6	33	54
-39	24	-3
-33	30	0
-27	28	-6
-3	12	60
-51	-3	30
6	42	12
30	6	54
42	30	-9
51	24	21
57	21	12
45	3	0
6	15	57
57	3	48
-54	-63	9
54	-36	6
57	-45	42
-3	12	27
-3	-9	36
-3	30	57
-12	57	27
-27	45	15
-42	42	-6
-45	33	0
-27	21	-3
-30	-12	3
-33	3	36
6	-21	33
15	54	30
24	15	42
33	6	54
27	33	-18
48	18	18
63	21	27
48	12	-9
12	15	12
9	-15	75
57	3	48
-60	3	18
-66	-21	9
-60	-48	-3
-51	-54	-15
-36	-66	-12
-33	-78	45
-3	-39	30
-27	-69	27
-45	-75	-9
-3	-69	42
27	-27	60
72	-30	-3
48	-54	-12
39	-60	-12
9	-6	6
30	-78	51
54	-48	45
57	-27	39
39	-57	39
33	-93	9
27	-96	-3
18	-102	0
3	-54	48
21	-99	9
27	-87	-6
-36	33	-9
57	-3	9
60	6	33
-54	-72	18
-9	-51	30
-9	-99	12
-39	-75	21
-9	-63	15
-6	-57	15
54	-12	9
51	-69	0
12	-75	21
-3	45	18
0	-12	36
-3	30	57
-12	51	30
-33	57	6
-39	39	-3
-45	33	0
-36	0	-6
-9	3	0
-3	15	63
-45	6	36
12	30	24
6	48	45
24	66	6
33	9	57
45	48	-3
48	18	18
39	15	33
36	21	-3
21	18	-6
9	6	6
60	9	30
-54	-18	21
-51	-33	21
-63	-48	-3
-45	-36	-21
-36	-24	-21
-36	-78	42
-51	-66	24
-3	-39	30
-12	-60	15
-3	-72	42
-12	-39	0
51	-15	6
45	-57	15
66	-42	-9
36	-42	-15
54	-51	42
57	-45	33
39	-57	39
42	-84	-3
3	-60	18
3	-54	45
12	-45	0

// Sandberg C, 2014: Neurologically Healthy Older Adult 1 (NHOA1)
// Subjects=1
-9	45	45
-12	45	36
-51	21	0
-51	-60	15
-51	-12	-27
-51	-69	24
-12	60	24
-54	21	0
-51	-66	21
-54	-3	-36
-33	-39	-21
-45	-72	27
-3	-51	24
-6	-57	15
3	33	33
-21	27	39
-27	18	45
-48	42	-9
-45	6	27
-33	21	-9
0	12	45
3	21	39
30	24	-12
-51	-45	-6
-42	-57	45
0	30	33
-21	27	39
-30	18	48
-45	42	-12
33	18	-21
-51	-42	18
-54	-42	-6
-45	-69	36
15	-78	-39
0	27	36
-15	48	30
-21	30	39
-54	24	-3
-54	33	0
-66	-36	-6
-60	-9	-30
-45	-69	33
12	-78	-39

// Sandberg C, 2014: Neurologically Healthy Older Adult 2 (NHOA2)
// Subjects=1
-12	60	30
-15	54	42
-33	33	51
-36	30	-12
-48	27	9
-51	-66	18
-42	-72	45
-3	-45	30
-42	-72	27
-27	27	57
-36	33	-9
-45	30	9
-51	-66	15
-39	-72	27
-36	12	63
-48	33	-3
-36	33	25
-6	24	66
-51	-66	15

// Sandberg C, 2014: Neurologically Healthy Older Adult 3 (NHOA3)
// Subjects=1
-24	-54	48
-54	27	-3
-54	-66	6
-45	-69	18
-51	27	0
-3	18	48
48	30	18
-66	-39	15
-51	-30	0
-39	-57	-12
-18	-90	-21
-3	39	39
-51	18	27
-27	24	-6
0	21	51
-39	3	57
33	48	18
48	30	18
54	18	36
33	24	0
-66	-39	15
-54	-36	-6
-39	-57	-12
57	-30	-21
30	-72	27
9	-87	30
-45	-69	12

// Allin M P G, 2010: Bipolar Disorder
// Subjects=18
1.48	-47.36	28.88
1.48	-47.36	28.88
1.47	-56.33	22.94
1.56	-55.39	35.13
-41.77	24	-7.83
-44.79	13.81	12.02
-41.52	6.86	18.14
1.48	-47.36	28.88
1.47	-56.33	22.94
-2.71	-58.59	35.45
-44.62	3.55	30.72
-41.52	6.86	18.14
1.68	-73.91	43.37
1.68	-73.91	43.37
-6.62	55.94	-10.91
-17.84	-48.42	16.93

// Allin M P G, 2010: Relatives of Bipolar Disorder
// Subjects=19
8.92	-59.89	17.58
-2.73	-51.19	34.83
-3.4	63.87	-4.92
0.84	60.21	-11.36
-41.52	6.86	18.14
5.53	-25.53	8.05
-44.71	2.61	18.53
-6.62	55.94	-10.91
-17.84	-48.42	16.93
8.95	-56.29	22.85
-6.62	55.94	-10.91

// Allin M P G, 2010: Healthy Controls
// Subjects=19
5.71	-47.85	22.18
8.89	-52.49	16.96
5.6	-44.56	9.64
-2.77	-42.73	34.12
-2.7	-46.44	41.12
1.48	-47.36	28.88
5.72	-52.08	22.54
-2.71	-58.59	35.45
-44.62	3.55	30.72
5.53	-25.53	8.05
-44.71	2.61	18.53
1.68	-73.91	43.37
1.68	-73.91	43.37
8.95	-56.29	22.85
-6.62	55.94	-10.91

// Barbour T, 2012: Positive > Control, All Participants
// Subjects=19
-6	-36	-16
4	60	36
30	52	-14

// Dannon P N, 2011: Alternation learning task > Control
// Dannon P N, 2011: Parametric modulation by number of alternations
// Dannon P N, 2011: Parametric modulation by South Oaks Gambling Screen 
// (SOGS)
// Subjects=10
42	-66	48
54	-54	36
21	-72	57
36	54	-6
45	33	27
-3	27	42
-54	-57	45
-30	-66	50
-48	-42	39
-42	51	0
-48	42	-9
-21	54	27
-33	18	57
-42	30	36
-36	12	30
9	72	6
-18	-81	6
9	-78	21
42	-60	45
54	-27	45
45	-39	48
48	39	15
42	33	15
39	51	12
-27	-69	51
-36	-60	45
-54	-27	42
-39	-51	42
-12	-75	48
-15	-87	39
-21	-69	51
-36	24	6
-48	51	6
-42	57	-6

// Power Y, 2012: Pathological Gamblers > Healthy Controls, High-risk > 
// Low-risk
// Power Y, 2012: Healthy Controls > Pathological Gamblers, High-risk > 
// Low-risk
// Subjects=13
16	14	10
36	38	-18
18	-2	-26
8	20	2
2	48	44
-14	-18	-3
46	-80	-18
20	-92	-18

// Whalley H C, 2012: Genotype x Group Interaction
// Whalley H C, 2012: Main Effect of Genotype
// Subjects=18
-44	-10	30
12	-14	62

// Worhunsky P D, 2014: Avg. Regional Brain Activity: Winning outcome > 
// Baseline
// Worhunsky P D, 2014: Avg. Regional Brain Activity: Final-reel spin 
// (matched) > Final-reel spin (unmatched)
// Worhunsky P D, 2014: Avg. Regional Brain Activity: Final-reel spin 
// (matched) < Final-reel spin (unmatched)
// Worhunsky P D, 2014: Avg. Regional Brain Activity: Non-sequential miss > 
// Full-loss
// Worhunsky P D, 2014: Avg. Regional Brain Activity: Sequential-miss > 
// Second-reel matched stop
// Worhunsky P D, 2014: Regional Group Differences: Final-reel spin (matched) 
// > Final-reel spin (unmatched)
// Worhunsky P D, 2014: Regional Group Differences: Non-sequential miss > 
// Full-loss
// Worhunsky P D, 2014: Regional Group Differences: Sequential-miss > 
// Second-reel matched stop
// Subjects=24
27	-70	-11
3	-34	31
-48	11	28
45	14	28
-30	23	-17
-21	-1	-26
15	5	-17
9	35	22
-3	11	49
42	-82	4
-42	-76	-5
30	-76	28
18	-76	-26
39	26	10
-30	29	1
6	-19	1
0	5	64
-54	-43	28
-9	-79	-2
-39	-43	34
51	-43	58
30	-79	-8
-9	-100	7
30	-79	-8
-9	-100	7
12	-73	-47
6	26	55
27	-22	4
-54	-52	-38
36	29	-11
45	-49	7
-33	-25	-14
21	-46	43
9	11	-2
-42	29	1
-18	-58	46
-60	-46	37
-30	-43	40
-39	-79	7
-63	-7	4
-27	-55	-23
60	-22	-11
-15	38	-5
-9	47	28
48	-10	-29
-36	-79	4
21	-85	-11
15	-58	-47
51	-49	55
39	44	-14
51	41	22
18	-73	61
24	8	-11
48	23	-2

// Burke M J, 2014: Symptomatic stimulation > Asymptomatic stimulation
// Subjects=10
59.15	-36.44	27.3
43.91	-18.5	-.79
32.26	24.27	30.33
19.12	73.58	8.5
10.72	8.08	1.82
16.15	-1.94	9.29
3.1	49.36	-.44
43.24	-56.11	35.83
-37.09	20.57	43.7
-46.49	-60.79	38.37

// Ponseti J, 2014: Preferred faces > Non-preferred faces, All Subjects
// Subjects=24
10	-76	8
-10	-78	12
42	-66	-6
-40	-64	-10
34	-50	-20
-40	-56	-18
-22	-12	18
-20	6	16
-44	44	8

// Schlumpf Y R, 2013: Dissociative Identity Disorder (DID) > Controls: 
// Neutral > Scrambled, EP (Emotional Parts)
// Subjects=13
-12	-26	-18
40	32	32
-28	32	48
-26	-54	-6

// Vandewalle G, 2013: Blue light > Darkness
// Vandewalle G, 2013: Darkness > Rest
// Vandewalle G, 2013: Darkness < Rest
// Subjects=3
28	52	6
58	38	0
54	44	14
-56	30	14
-12	60	-2
10	54	18
-12	50	30
18	40	36
18	54	0
16	38	50
-18	56	16
8	-74	58
10	-82	-4
-18	-98	-4
32	-80	-22
10	38	10
-10	-20	12
-48	46	14
-38	10	30
48	26	30
-38	0	52
36	2	56
8	14	50
-6	16	50
-60	-30	4
52	-38	8
-32	-42	42
40	-34	38
34	-44	46
-16	-66	60
16	-68	50
-24	-98	-8
20	-98	-12
-46	-80	4
-44	-78	-8
-46	-60	-14
-32	28	0
-26	-2	8
26	-6	4
-12	-16	4
14	-14	4
24	-66	-50
-32	-52	-56
10	-74	-40
-12	52	6
6	56	8
-6	44	8
44	42	8
-30	-34	-12
28	34	-14
-52	-74	30
46	-70	28
4	-54	36
-4	-40	34
6	-32	40
6	-50	16
-10	-56	16
-26	-20	14
-28	-34	-16

// Barke A, 2012: Chronic Low Back Pain Patients (CLBP), Low fear-avoidance
// Subjects=15
30.04	-33.72	-3.81
-7.08	-25.58	36.08
-53.22	-64.09	-3.66
52.55	-63.71	-8.25
-8.12	-25.33	39.41
-56.11	-38.85	47.79
33.81	-45.48	64.04
-43.26	-37.46	50.87
-59.48	-29.58	30.32

// Barke A, 2012: Chronic Low Back Pain Patients (CLBP), High fear-avoidance
// Subjects=15
-57.37	-32.11	24.93
-65.84	-32.45	35.1
72.94	-32.98	15.7
-23.85	-61.86	63.85
-43.26	-37.46	50.87
-46.83	-64.31	-7.06
-49.89	-75.99	7.34
30.3	-74.99	13.03
-24.22	-95.38	1.98
-2.14	21.93	3.04
-11.59	51.04	36.39
7.61	60.68	35.36
39.75	18.86	28.47
-56.62	37.09	11.32
-36.98	-2.52	47.87
48.97	28.01	-19.25
-40.73	24.81	-11.26
43.08	0.36	36.67
-49.77	-2.26	52.45
4.71	-54.83	28.36
27.23	-40.72	43.64
-1.76	-19.2	35.48
1.2	17.86	18.96
42.73	16.56	-1.49
-40.5	4.15	10.55
-43.75	-32.57	-9.76
17.41	-16.43	28.34
17.22	-5.28	7.33
-5.21	-15.19	5.07
33.18	-15.73	-5.36
-18.13	-3.09	-2.48
69.78	-45.69	16.81
-43.54	-40.28	14.31
52.62	-62.94	1.72
-36.99	-55.34	25.53
42.77	-42.33	-19.97
-40.53	-55.52	-17.9
-62.76	-23.77	23.18
65.59	-38.26	30.73
-56.27	-42.76	24.7
4.9	-72.58	46.57
1.61	-56.99	41.96
-53.12	-69.66	6.85
4.63	-88.61	4.43
-4.96	-95.01	5.07
7.92	-84.39	17.42
13.91	-19.53	-11.51
-5.28	-25.73	-7.42
39.47	-33.44	-28.48
-40.6	-43.09	-22.29
46.1	-77.3	-18.19
-8.43	-74.62	-20.02
-7.08	-25.58	36.08
-53.22	-64.09	-3.66
52.55	-63.71	-8.25
-8.12	-25.33	39.41
-56.11	-38.85	47.79
33.81	-45.48	64.04
-43.26	-37.46	50.87
-59.48	-29.58	30.32

// Barke A, 2012: Pain-free Spider Phobics
// Subjects=15
7.91	14.38	55.97
-27.72	49.92	23.29
23.32	28.91	-19.03
-30.57	-9.09	45
55.42	21.87	-16.58
-37.42	32.46	4.79
49.57	-2.01	46.83
-43.47	-3.33	37.97
4.46	24.99	28.36
1.36	9.62	36.37
-2.05	37.13	20.72
4.59	-29.71	22.91
45.9	-29.97	-25.5
-38.51	-30.39	-23.38
36.28	19.44	-5
-34.21	16.1	-.56
39.55	-3	-6.5
-30.98	16.38	2.72
7.64	-14.86	8.24
-24.47	-22.16	-.81
68.47	-2.06	3.12
-34.4	10.79	-28
49.32	-63.99	-11.54
-40.39	-67.18	-3.55
24.08	-23.59	58.97
-17.6	-27.27	56.41
46.55	-44.06	53.74
-56.29	-32.99	27.23
14.4	-60.6	35.42
-17.7	-57.88	32.22
20.61	-89.02	-2.41
-17.95	-73.65	-6.61
8.03	-93.13	28.18
-24.17	-68.46	19.79
7.33	-31.23	-38.33
-2.22	-27.26	-27.41
7.54	-58.66	-21.54
-21.44	-37.15	-29.7
20.42	-74.45	-20.36
-27.61	-80.82	-15.93
-37.41	29.29	5.06
4.58	-33.14	19.85
11.06	-25.73	32.53
1.36	9.62	36.37
39.5	16.29	-4.77
39.52	-3.26	-9.82
1.2	-8.55	7.79
-30.88	-22.2	-.74
-20.81	-27.29	56.45
-5.25	-25.48	-4.1
-5.45	-27.53	-30.69
-11.74	-52.69	-25.16
-7.08	-25.58	36.08
-53.22	-64.09	-3.66
52.55	-63.71	-8.25
-8.12	-25.33	39.41
-56.11	-38.85	47.79
33.81	-45.48	64.04
-53.22	-64.09	-3.66
-62.65	-32.51	33.95
-7.08	-25.58	36.08

// Barke A, 2012: Pain-free Controls
// Subjects=15
23.74	-55.71	1.45
-40.38	-60.58	-.75
-20.74	-52.93	55.25
23.66	-74.17	-17.08
-37.41	29.29	5.06
4.58	-33.14	19.85
11.06	-25.73	32.53
1.36	9.62	36.37
39.5	16.29	-4.77
39.52	-3.26	-9.82
1.2	-8.55	7.79
-30.88	-22.2	-.74
-20.81	-27.29	56.45
-5.25	-25.48	-4.1
-5.45	-27.53	-30.69
-11.74	-52.69	-25.16
-7.08	-25.58	36.08
-53.22	-64.09	-3.66
52.55	-63.71	-8.25
-8.12	-25.33	39.41
-56.11	-38.85	47.79
33.81	-45.48	64.04
-53.22	-64.09	-3.66
-62.65	-32.51	33.95
-7.08	-25.58	36.08

// Lloyd D M, 2014: Chronic Low Back Pain Patients with High Levels of Illness 
// Behavior (WS-H)
// Subjects=11
52	14	-12
-54	10	-20
44	22	-16
-44	22	-8
40	16	-12
10	-2	-18
30	-2	-8
-52	0	-2
-4	-56	-18
6	-52	-20
-54	-20	28
26	-4	-14
46	20	-18
42	14	-16
52	4	-14

// Lloyd D M, 2014: Chronic Low Back Pain Patients with Low Levels of Illness 
// Behavior (WS-L)
// Subjects=13
48	14	0
-48	30	8
36	22	-4
-38	4	2
50	14	-6
-46	18	22
-14	8	0
30	6	-2
26	-4	-14
46	20	-18
42	14	-16
52	4	-14

// Seminowicz D A, 2011: All Subjects: MSIT > Control
// Seminowicz D A, 2011: All Subjects: MSIT < Control
// Subjects=16
-42	-82	-10
40	-84	-2
-32	-58	54
30	-54	48
-44	6	32
52	12	28
-26	22	6
28	28	4
-8	16	46
0	-42	40
-48	-78	32
60	-62	26
-2	60	8
-24	32	42

// Shimo K, 2011: Low Back Pain
// Subjects=11
-48.7	-36.23	-14.74
-60.57	-46.05	-15.81
-33.04	13.79	37.19
32.16	-18.15	59.41
-48.14	27.02	41.75
-32.74	19.27	61.3
-41.51	23.83	53.15
-24.69	-24.5	6.1
27.08	-27.17	-2.36
-28.9	-31.33	13.57
42.19	-35.93	-5.11
31.57	-25.91	10.89
38.1	-17.81	16.7
-6.49	-50.42	72.23
20.74	-64.41	1.43
-5.22	-75.66	-2.61
-37.68	-44.41	0.45
35.77	-55.2	-4.22
31.32	-43.08	-12.06
44.45	-35.2	2.62
-32.81	-74.25	36.94
-39.23	-80.35	41.01
-43.56	-71.64	42.46
-63.71	-36.51	-5.49
-9.18	-39.07	33.05
-2.59	-40.45	40.92
-25.04	-32.62	-23.34
25.22	-32.54	20.62
22.81	-22.41	2.85
-3.17	-16.33	0.45
12.74	-15.88	61.76
-11.08	-22.86	57.26
-52.59	5.24	27.17
22.87	-30.71	5.91
9.88	-91.12	-8.06
-5.11	13.81	24.39
44.22	-7.42	-10.21

// Shimo K, 2011: Healthy Controls
// Subjects=11
-48.7	-36.23	-14.74
-60.57	-46.05	-15.81
-33.04	13.79	37.19
32.16	-18.15	59.41
-48.14	27.02	41.75
-32.74	19.27	61.3
-41.51	23.83	53.15
-24.69	-24.5	6.1
27.08	-27.17	-2.36
-28.9	-31.33	13.57
42.19	-35.93	-5.11
31.57	-25.91	10.89
38.1	-17.81	16.7
-6.49	-50.42	72.23
20.74	-64.41	1.43
-5.22	-75.66	-2.61
-37.68	-44.41	0.45
35.77	-55.2	-4.22
31.32	-43.08	-12.06
44.45	-35.2	2.62
-32.81	-74.25	36.94
-39.23	-80.35	41.01
-43.56	-71.64	42.46
-63.71	-36.51	-5.49
-9.18	-39.07	33.05
-2.59	-40.45	40.92
-25.04	-32.62	-23.34
25.22	-32.54	20.62

// Suda M, 2014: Anorexia Nervosa (AN)
// Subjects=20
24.34	64.67	-10.89
25.15	-66.45	41.36
29.4	-65.54	39.01
0.66	-54.66	58.5
28.18	-72.63	16.2
33.26	-44.62	-7.4

// Suda M, 2014: Healthy Controls (HC)
// Subjects=24
24.34	64.67	-10.89
25.15	-66.45	41.36
40.52	59.7	6.07

// Balodis I M, 2014: Post-treatment > Pre-treatment, A1Win
// Balodis I M, 2014: Post-treatment < Pre-treatment, A1Win
// Balodis I M, 2014: Post-treatment > Pre-treatment, A1Loss
// Balodis I M, 2014: Post-treatment < Pre-treatment, A1Loss
// Balodis I M, 2014: Post-treatment > Pre-treatment, A2Win
// Balodis I M, 2014: Post-treatment > Pre-treatment, A2Loss
// Balodis I M, 2014: Post-treatment < Pre-treatment, A2Loss
// Balodis I M, 2014: Post-treatment > Pre-treatment, OCWin
// Balodis I M, 2014: Post-treatment < Pre-treatment, OCWin
// Balodis I M, 2014: Post-treatment > Pre-treatment, OCLoss
// Balodis I M, 2014: Post-treatment < Pre-treatment, OCLoss
// Subjects=19
39	-27	42
-27	-3	45
-42	30	-12
-9	66	27
-57	-72	-6
24	-15	60
30	-63	21
-24	-51	42
-9	66	27
-9	66	27
45	42	-12
-39	42	0
21	18	-6
-21	-51	-33
30	-63	45
-36	-45	48
-27	-99	3
-27	-60	39
9	-33	6
-42	42	0
6	42	15
-63	-9	0
-48	-48	57
-33	-12	69
63	-39	9
9	-6	39
-3	45	24
51	-27	60
-54	3	-9
-51	-21	42
24	-3	39
-24	-3	33

// Balodis I M, 2013: Binge Eating Disorder (BED)
// Subjects=11
36	15	0
-33	-42	-9
-57	-72	12
27	-87	-39
6	-87	-39
33	57	-18
-42	-87	9
-72	-36	6
45	-87	15
60	-63	-12
75	-18	15
-30	36	9
-33	-84	31
51	-23	5
33	0	-39
-51	12	-39
-3	24	-15
-18	-45	-6
-21	-90	-30
-30	-24	-15
18	60	30
54	-63	-39

// Balodis I M, 2013: Obesity
// Subjects=13
36	15	0
-33	-42	-9
-57	-72	12
27	-87	-39
6	-87	-39
33	57	-18
-42	-87	9
-72	-36	6
45	-87	15
60	-63	-12
75	-18	15
-30	36	9
-24	12	39
-51	45	6
0	15	45
-12	-87	-18
0	-27	36
18	-78	12
-60	-66	-12
57	-57	30
-24	-75	54
-24	30	-21
54	-54	-18
-9	-24	-36
-3	-36	48
15	21	39
-57	15	24
27	21	24
60	-6	21

// Balodis I M, 2013: Lean Comparison (LC)
// Subjects=11
36	15	0
-33	-42	-9
-57	-72	12
27	-87	-39
6	-87	-39
-33	-84	31
51	-23	5
-24	12	39
-51	45	6
0	15	45
-12	-87	-18
0	-27	36
27	36	-15
48	42	6
24	6	57
54	-30	48
18	21	3
-18	72	0
27	-69	-15

// Capek C M, 2010: Main effect of group: Deaf > Hearing
// Capek C M, 2010: Main effect of group: Hearing > Deaf
// Capek C M, 2010: Main effect of condition: Speechreading > Signs
// Capek C M, 2010: Main effect of condition: Signs > Speechreading
// Capek C M, 2010: Group x Condition
// Subjects=13
47.6	-26.03	-2.82
-57.08	-17.92	9.36
-45.16	-65.71	2.68
56.1	-15.03	-11.9
-57.14	-13.97	5.61
-49.15	-2.01	41.27
-49.48	-65.73	2.76
47.69	-61.44	-2.68
63.96	-29.19	8.42
-61.4	-29.94	7.27

// Corina D P, 2013: Deaf
// Subjects=21
1	10	26
10	39	8
-2	-36	-43
-53	21	26
-67	-36	0
-13	43	4
34	-94	8

// Corina D P, 2013: Subgroup of Deaf, Proficient Readers
// Subjects=11
1	10	26
10	39	8
-2	-36	-43
-53	21	26
-67	-36	0
-13	43	4
34	-94	8
-10	10	44
-60	-15	11
-60	-40	29
62	-26	26
-38	-54	-21
-49	-36	0
37	-44	-25
26	-69	15
-20	28	40
16	36	51
-38	-44	-21
62	-11	-7
8	10	23
-67	-40	0
66	-33	-3
8	-94	15
-31	36	-7
-53	21	15
34	-94	8

// Corina D P, 2013: Subgroup of Deaf, Less proficient Readers
// Subjects=10
1	10	26
10	39	8
-2	-36	-43
-53	21	26
-67	-36	0
-13	43	4
34	-94	8
-10	10	44
-60	-15	11
-60	-40	29
62	-26	26
-38	-54	-21
-49	-36	0
37	-44	-25
26	-69	15
12	39	11
48	21	18
-53	21	26
12	-29	15
30	-33	-28
-38	-90	-3

// Emmorey K, 2013: Deaf
// Subjects=14
-.71	26.76	51.69
6.71	26.2	43.84
-48.93	14.1	29.88
-46.08	44.5	-3.92
-52.4	37.66	4.53
-41.66	30.66	9.45
-56.68	22.23	-1.94
-41.37	2.85	35.2
-48.78	-.82	43.4
-26.84	33.7	-7.7
-26.73	22.75	2.14
3.44	4.64	26.73
-27.02	19.67	-37.75
-60.74	-52.42	-3.44
-34.27	-16.45	-22.37
-34.22	-31.25	-21.13
-45.88	-50.1	-16.07
-56.46	-36.99	3.03
-60.84	-57.85	-18.59
-45.84	39.24	24.39
-41.8	44.52	-3.98
-52.43	37.4	1.2
-38.41	27.77	13
-53.26	21.22	25.99
-49.31	13.41	-20.24
-34.22	26.93	1.87
-45.75	6.11	22.71
-33.79	-.48	46.54
-48.78	-.82	43.4
6.71	26.2	43.84
14.29	16.27	52.39
6.92	12.94	65.03
-.75	22.99	44.2
-.85	32.96	35.56
-.65	11.95	52.93
51.53	10.47	29.03
43.84	51.06	17.91
36.45	51.96	30.19
40.77	32.61	27.3
51.68	12.01	48.98
48.23	21.48	20.34
40.57	19.64	-2.84
-38.55	-24.22	-26.13
-41.13	-45.19	47.03
-30.41	-55.7	47.79
33.68	-55.66	42.59
48.63	-44.65	45.96
-.85	32.96	35.56
-48.8	3.41	43.05
62.97	14.94	-10.51
-37.93	-45.17	46.99
44.32	-45.02	41.58
-38.71	32.43	-23.07
-53.34	28.02	17.61
-45.84	39.24	24.39
43.93	36.6	23.58
43.72	45.38	-.57
48.47	4.25	45.2
51.33	16.07	5.15
51.51	10.21	25.71
-.61	9.12	57.63
14.28	19.45	52.13
-48.77	3.66	46.37
-33.7	-41.26	42.16
-37.86	-47.74	55.02
36.9	-52.12	46.72
29.39	-67.91	35.86
41.08	-41.07	37.94

// Emmorey K, 2013: Hearing Controls
// Subjects=14
-3.94	34.14	51.1
6.77	19.14	48.89
36.3	19.61	-2.78
-45.67	10.23	34.63
-52.54	36.2	-14.31
-38.57	37.14	-3.39
-49.13	35.1	12.51
-50.25	26.84	2.07
-53.26	21.22	25.99
-31.02	34.61	4.54
-31.03	22.38	-2.24
-41.77	-13.32	-22.54
-45.85	-42.1	-8.93
-53.24	-41.2	3.34
51.45	32.67	27.17
-.69	15.93	49.25
6.79	15.97	49.16
-48.94	9.61	26.91
-53.52	44.8	0.6
-26.73	30.41	4.84
-38.5	19.16	-1.89
-53.35	-53.31	-15.71
-56.11	-33.39	49.56
48.77	-58.6	58.28
-33.67	-48.66	42.78
-.85	32.96	35.56
-48.8	3.41	43.05
62.97	14.94	-10.51
-37.93	-45.17	46.99
44.32	-45.02	41.58
-49.26	37.08	-3.27
-3.91	34.48	55.54
-33.76	16.33	57.4

// Filbey F M, 2012: High-calorie > Control
// Filbey F M, 2012: Positive Correlation between Binge Eating Scale (BES) and 
// High-calorie > Control
// Filbey F M, 2012: Positive Correlation between Sugar content of 
// High-calorie cues & High-calorie > Control
// Subjects=26
-16	-78	-2
2	-82	8
2	-86	6
-24	-70	-14
24	-76	-10
-10	-94	16
2	-10	58
6	10	52
4	-24	58
-40	6	26
4	24	50
-4	10	38
-16	6	-18
22	20	-18
-20	-4	-18
-38	6	16
16	-4	24
20	16	-16
-18	22	-8
10	-30	20
12	4	16
42	-72	-8
38	-74	-4
32	-64	-14
40	-76	18
52	-60	14
54	-54	0
12	-44	34
8	-42	34
8	-36	36
-16	-42	32
2	-44	34
-30	-14	-10
0	-30	30
48	-16	-6
-32	-26	4
-28	-18	-10
8	24	12
10	-6	-4
20	10	10
0	-64	44
12	6	8
6	-16	-10
-36	-4	-2
-32	-6	-4
-18	-6	56
14	-32	46
12	-24	42
2	-2	36
22	-36	66
-8	-48	62
-6	-34	48

// Hu Z, 2011: Word signing > Baseline
// Hu Z, 2011: Picture signing > Baseline
// Hu Z, 2011: Word signing & Picture signing > Baseline
// Hu Z, 2011: Word signing > Picture signing
// Hu Z, 2011: Picture signing > Word signing
// Subjects=12
-46	6	31
-36	44	20
-18	-5	62
-5	2	64
-41	-14	53
-5	18	36
-31	15	5
-44	-57	-7
-45	-58	-4
-44	-52	-19
-53	-31	47
-35	-61	51
-54	-30	49
-46	-34	29
-36	-81	-13
-38	-81	-9
-29	-44	-26
2	15	44
2	-6	63
30	-21	66
2	15	44
40	11	4
40	-43	-22
40	-57	-18
25	-93	-9
23	-56	-24
-40	5	28
-29	-2	57
-18	-2	61
-7	7	48
-46	7	37
-7	15	40
-32	21	2
-44	-53	-9
-44	-56	-3
-32	-43	-17
-31	-53	49
-22	-66	35
-46	-29	55
-40	-70	-10
-31	-78	20
-9	-82	40
-5	-86	34
-40	-50	-23
2	7	55
42	-56	-12
38	-62	-17
38	-80	-3
26	-87	0
22	-59	35
19	-54	-16
-42	7	28
-29	-3	56
-5	16	43
-7	9	48
-46	7	35
-7	15	40
-44	-53	-7
-47	-55	-4
-42	-43	-18
-38	-39	33
-44	-29	53
-38	-73	-12
-28	-65	34
-38	-71	-21
0	4	56
40	-44	-22
38	-42	-22
25	-89	-6
19	-54	-20
-51	15	23
-41	-47	41
32	-70	-31
42	-55	-9
43	-71	11
-36	-48	-19
29	-62	-14
43	-57	-13
-42	-73	4
45	-75	5
-21	-92	15
-29	-40	-23
29	-31	-21

// Husain F T, 2012: Deaf
// Subjects=14
-50	-32	2
-64	-40	2
-50	-40	-6
-42	12	50
-26	-2	61
48	-14	-14
62	-8	-18
6	54	-12
-56	-62	-10
-46	-30	28
-60	-30	38
-52	-46	30
-42	-4	6
-58	2	16
36	-58	-38
36	-80	14
30	-50	-6
-24	-58	68
-2	-78	42
-4	-54	52
-30	-62	-8
-26	-50	-6
-28	-56	4
-28	-10	66
-42	-12	54
-16	-16	70
-42	-82	-18
-46	-82	-2
-48	-78	10
-58	-64	14
-60	-56	28
-54	-68	30
-2	-56	48

// Husain F T, 2012: Hearing Controls
// Subjects=16
-50	-32	2
-64	-40	2
-50	-40	-6
-42	12	50
-26	-2	61
48	-14	-14
62	-8	-18
6	54	-12
-56	-62	-10
-46	-30	28
-60	-30	38
-52	-46	30
-42	-4	6
-58	2	16
36	-58	-38
36	-80	14
30	-50	-6
-24	-58	68
-2	-78	42
-4	-54	52
-30	-62	-8
-26	-50	-6
-28	-56	4
-28	-10	66
-42	-12	54
-16	-16	70
-42	-82	-18
-46	-82	-2
-48	-78	10
-96	-4	26
-100	-2	16
-88	8	12
34	-70	-22
48	-72	-12
46	-56	-22
-42	-76	-18
-50	-72	-16
-38	-62	-22
-24	-50	42
-34	-34	34
-16	-80	50
52	0	22
50	2	34
38	4	16
-42	2	20
-34	-4	30
-32	-14	34
50	-48	52
44	-42	36
56	-36	46

// Lock J, 2011: Anorexia Nervosa (AN)
// Subjects=14
61	-51	34
48	-60	47
50	-64	50
44	50	20
40	51	16
48	10	18
0	18	42
4	4	-7
50	30	15

// Lock J, 2011: Binge Eaters
// Subjects=13
46	10	36
34	26	2
24	14	-8
16	12	0
4	36	26
4	24	49
46	-56	45
56	-34	-4
8	-71	48
44	-58	49
-10	-18	64
10	-18	64
8	28	15
50	-55	-2
4	4	-7
50	30	15
4	4	-7
50	30	15

// Lock J, 2011: Healthy Controls (HC)
// Subjects=13
42	15	-6
42	15	-2
48	13	-7
67	-41	4
66	-38	-4
24	48	36
42	49	12
-10	-18	64
10	-18	64
8	28	15
50	-55	-2
4	4	-7
50	30	15

// Sharma H A, 2011: Chronic Low Back Pain
// Subjects=6
-8.99	-27.68	64.15
6.55	28.89	23.54
12.99	-8.14	12.08
15.04	14.08	10.19
41.74	4.21	4.02

// Archila-Suerte P, 2013: Subgroup of Bilingual Children, Younger Group
// Subjects=16
-50	-22	10
62	-6	0
18	-4	-18
-38	16	48
32	30	50
-52	-34	-6
36	-80	-4

// Archila-Suerte P, 2013: Subgroup of Bilingual Children, Older Group
// Subjects=22
18	-4	-18
-38	16	48
32	30	50
-52	-34	-6
-18	-62	52
28	-54	50
4	-56	54
34	0	50
20	2	32
-22	-22	-38
2	-44	-4
-4	-70	-10
-46	-66	-6
-34	-6	56
-58	-22	8
60	-12	6
54	-4	46
34	-60	54
56	-38	50
-42	-44	42
-36	10	30
44	20	30
6	-30	70
-24	-64	52

// Archila-Suerte P, 2013: Bilingual Adults
// Subjects=19
-18	-62	52
28	-54	50
4	-56	54
34	0	50
20	2	32
-22	-22	-38
2	-44	-4
-4	-70	-10
-46	-66	-6
-34	-6	56
36	-80	-4

// Chu W C, 2012: Subgroup of IBS, Sham Acupuncture
// Subjects=15
-50.55	-78.8	0.71
-1.32	-14.97	60.79
-43.51	-58.15	48.97
-27.31	-77.86	43.92
33.73	-71.81	1.95
-47.39	19.11	14.5
1.19	28.85	12.71
-50.84	-61.22	-17.83
50.21	12.37	40.4
37.47	-77.95	39.47
46.65	29.64	18.58
16.88	-60.28	-45.97
-48.04	-12.02	-42.92
-22.04	-63.92	-48.31
13.77	-16.63	-26.71
-28.37	-82.46	-39.65
49.8	42.1	13.93
56.45	-35.39	11.4
36.67	50.69	3.22
62.93	20.43	22.58
-37.12	-55.56	41.88

// Chu W C, 2012: Subgroup of IBS, True Acupuncture
// Subjects=15
20.44	57.01	2.87
59.2	13.49	-17.01
-63.7	-30.99	-3.8
14.67	-72.27	32.57
-7.85	-48.14	50.74
53.69	-25.28	50.79
59.48	-13.98	-.85
33.57	25.46	9.13
-53.69	-5.82	23.8
69.38	-2.81	14.68
31.1	-73.84	49.26
43.89	3.71	51.45
-8.52	48.59	17.65
-30.56	-41.84	50.5
-63.98	-3.52	-19.96
-12.06	59.47	-3.54
50.49	-47.94	49.72
-28.33	-36.24	-27.41
-1.82	-64.62	11.92
69.32	0.07	11.04
31.07	-77.35	46.24
56.24	-13.99	-.8
-66.68	-55.28	12.1
14.88	-24.8	58.12
37.55	-31.41	55.03

// Colorado R A, 2012: Right: Multiple Sclerosis (MS) > Healthy Controls (HC)
// Colorado R A, 2012: Left: MS > HC
// Colorado R A, 2012: 2-Back: MS > HC
// Subjects=23
8	-41	57
18	-21	59
-4	-27	67
16	47	33
20	55	19
2	11	29
28	17	19
44	-5	-17
24	21	13
40	23	31
20	43	11
36	45	7

// Ernst A, 2012: After rehab > Before rehab
// Ernst A, 2012: Before rehab > After rehab
// Subjects=4
14.72	-95.98	31.55
-37.61	-77.8	-.73
-36.93	-74.94	52.76
-63.4	-54.96	15.38
-50.65	-21.5	5.13
63.54	-1.69	-18.95
56.67	17.27	-45.36
31.08	70.05	-7.56
14.23	-12.14	9.82
-35.56	-32.71	-.74
-35.92	-57.3	-34.16
9.59	-78	-28.41
-16.44	-74.46	-35.04
-16.21	-83.64	-18.45
18.25	51.27	-1.01
37.8	32.41	2.77
57.65	9.23	29.38
3.37	24.61	13.09
-.56	34.09	45.84
44.32	-8.82	-2.23
22.51	22.39	-11.67
12.02	13.79	11.77

// Marsh R, 2011: Congruent > Incongruent, Healthy Controls (HC) > Bulimia 
// Nervosa (BN)
// Marsh R, 2011: Congruent > Incongruent, BN > HC (deactivations)
// Marsh R, 2011: Postcongruent interference, HC > BN
// Marsh R, 2011: Postcongruent interference, BN > HC (deactivations)
// Marsh R, 2011: Postincongruent interference, HC > BN
// Subjects=18
30	-16	8
25	-23	-14
54	20	16
7	53	8
20	54	38
-52	22	8
23	35	52
-19	50	39
14	-52	36
54	20	16
20	52	38
-54	21	16
26	18	67
26	-16	8

// Rocca M A, 2012: Healthy Controls (HC)
// Subjects=18
-16	-72	42
24	-66	50
18	-70	44
36	42	22
-28	-48	40
-22	-86	18

// Rocca M A, 2012: Benign Multiple Sclerosis
// Subjects=17
-26	-72	-18
-16	-70	42
24	-86	52
-36	34	30
48	2	22
-58	-16	-12
60	-14	-18
-34	14	56

// Rocca M A, 2012: Relapsing-remitting (RR) Multiple Sclerosis
// Subjects=17
-16	-72	42
24	-66	50
18	-70	44
36	42	22
-28	-48	40
-22	-86	18
-20	-80	-10
-16	-34	38
-16	-70	40
-30	30	28
24	44	22
-22	-82	28
20	-86	16
60	2	-10
-62	-16	-12
-34	6	58
-26	-72	-18
-16	-70	42
24	-86	52
-36	34	30
48	2	22
-58	-16	-12
60	-14	-18
-34	14	56

// Rocca M A, 2012: Secondary Progressive (SP) Multiple Sclerosis
// Subjects=23
-20	-80	-10
-16	-34	38
-16	-70	40
-30	30	28
24	44	22
-22	-82	28
20	-86	16
60	2	-10
-62	-16	-12
-34	6	58

// Ashworth F, 2011: Bulimia Nervosa (BN)
// Subjects=12
-32	-98	-6
50	18	26
-50	14	30
-34	-96	-6
42	36	12
-44	26	22

// Ashworth F, 2011: Healthy Controls (HC)
// Subjects=16
40	-74	-16
42	14	24
-48	46	-4
40	-84	-10
46	14	22
-40	6	28
54	-78	19

// Bohon C, 2011: Anticipatory Reward: Healthy Controls (HC) > Bulimina 
// Nervosa (BN)
// Bohon C, 2011: Consummatory Reward: HC > BN
// Subjects=13
60	-12	39
45	-9	-6
60	-15	36
-24	42	-3
-12	-27	-3

// Joos A A B, 2011: Bulimia Nervosa (BN)
// Subjects=13
15	48	24
45	12	-27
-9	-18	48

// Joos A A B, 2011: Healthy Controls (HC)
// Subjects=13
-6	45	6
-18	24	57
27	18	-12
-3	-30	33
48	-57	36
15	48	24
45	12	-27
-9	-18	48

// Meintjes E M, 2010: Fetal Alcohol Syndrome (FAS)
// Subjects=15
43.26	-58.14	37.11
40.04	-71.45	30.46
-4.89	-57.97	29.85
29.82	25.49	-8.78
11.84	40.47	21.4
8.74	39.36	34.91
-11.55	31.67	33.56
-13.75	16.71	19.22
-20.99	16.95	50.51
-24.21	-9.56	38.27
-52.2	-45.93	-2.96
16.25	-78.9	-8.79
-6	-88.07	12.31
-25.65	26.19	5.18
31.2	-27.32	10.13
-6.2	-23.14	12.44
3.2	-19.85	-14.71
5.74	-31.05	33.04
-43.25	-64.75	42.01
42.2	-59.12	38.32
10.11	-55.25	36.14
-10.25	-53.77	29.55
-44.26	-50.95	55.36
27.66	47.23	-2.77
-19.48	56.58	-15.28
-48.71	-58.32	29.26
1.07	-20.84	-13.48
1.07	-20.84	-13.48
29.44	-74	39.72
15.43	11.51	59.47
-51.02	12.4	35.63
35.73	-51.04	33.26
23.05	-36.46	57.83
18.59	-35.03	35.46
-2.89	-30.81	23.08
-7.89	-63.51	54.88
-12.48	-22.95	29.23
-13.38	-60.68	36.86
-18.59	-39.62	61.92
-27.21	-29.44	56.7
-31.57	-70.99	29.01
-32.59	-63.88	38.47
-40.2	-44.35	30.22
32.08	46.51	15.08
24.84	0.62	27.94
13	22.76	26.22
0.4	15.13	52.65
-8.32	19.88	32.28
-17.95	9.8	26.54
-41.52	26.57	25.41
-44.73	11.15	18.93
44.94	-24.38	-8.12
32.89	14.19	-31.29
20.44	-35.9	-3.52
-39.36	-32.48	4.68
29.24	-59.6	19.55
16.25	-53.64	1.36
2.6	-77.56	23.6
-13.55	-69.08	10.8
-26.45	-52.33	8.43
24.44	-32.1	-37.34
-2.12	-35.03	-17.83
-27.95	-40.33	-42.74
29.91	26.35	2.3
-32.02	7.83	2.33
-32.85	-30.36	17.81
27.81	2.64	-1.26
-13.84	-2.89	-.32
31.45	-73.07	24
32.33	31.56	41.98
32.9	16.48	-29.25
15.33	-80.71	9.22
-15.7	-69.18	9.72
4.37	-57.2	-16.05
32.99	-33.1	-37.36
-21.48	-28.77	-31.52
-24.54	-47.05	-19.91
0.91	-17.01	-32.76
0.91	-17.01	-32.76
-9.67	-51.16	-33.12

// Meintjes E M, 2010: Healthy Controls (HC)
// Subjects=18
44.36	-44.59	47.12
34.75	-66.57	39.03
-9.1	-68.32	34.11
34.4	24.28	30.3
6.66	26.75	37.11
-45.72	16.4	31.88
29.9	21.95	0.44
-23.48	26.45	8.48
-18	0.48	16.17
5.74	-31.05	33.04
-43.25	-64.75	42.01
42.2	-59.12	38.32
10.11	-55.25	36.14
-10.25	-53.77	29.55
-44.26	-50.95	55.36
27.66	47.23	-2.77
-19.48	56.58	-15.28
-48.71	-58.32	29.26
1.07	-20.84	-13.48
1.07	-20.84	-13.48
29.44	-74	39.72
15.43	11.51	59.47
-51.02	12.4	35.63
-40.18	-44.18	32.44
-31.52	-60.53	40.4
4.75	-59.86	32.12
5.55	28.51	32.51
-4.16	20.91	17.65
-47.93	20.02	23.8
17.17	8.47	6.18
-14.86	4.21	9.13
31.45	-73.07	24
32.33	31.56	41.98
32.9	16.48	-29.25
15.33	-80.71	9.22
-15.7	-69.18	9.72
4.37	-57.2	-16.05
32.99	-33.1	-37.36
-21.48	-28.77	-31.52
-24.54	-47.05	-19.91
0.91	-17.01	-32.76
0.91	-17.01	-32.76
-9.67	-51.16	-33.12

// Mohr H M, 2011: Bulimia Nervosa (BN)
// Subjects=15
-24.43	32.13	26.97
19.64	-26.48	35.84
26.14	-48.56	38.74
-25.52	30.81	23.75
34.14	22.69	-4.13
-28.86	12.88	-1.47
13.15	15.5	42.44
-37.18	-8.98	19.42
46.55	-22.14	61.94
-37.91	-25.19	57.59
20.32	-46.96	-22.67
-25.58	2.67	3.81

// Mohr H M, 2011: Healthy Controls (HC)
// Subjects=16
-24.43	32.13	26.97
19.64	-26.48	35.84
26.14	-48.56	38.74
-25.52	30.81	23.75
-54.11	-74.36	15.06
34.14	22.69	-4.13
-28.86	12.88	-1.47
13.15	15.5	42.44
-37.18	-8.98	19.42
46.55	-22.14	61.94
-37.91	-25.19	57.59
20.32	-46.96	-22.67

// Norman A L, 2013: Heavy Prenatal Alcohol Exposure (ALC)
// Subjects=18
37.85	-23.74	42.1
19.91	99.28	-17.08
41.65	2.13	-9.19
-39.09	-15.4	46.74
37.85	-23.74	42.1
-1.1	85.32	24.48

// Norman A L, 2013: Family History of Alcohol Use Disorders (FHP)
// Subjects=18
-31.03	-2.88	-12.39
-1.17	31.82	-6.72

// Norman A L, 2013: Healthy Controls (CON)
// Subjects=17
37.85	-23.74	42.1
19.91	99.28	-17.08
41.65	2.13	-9.19
-39.09	-15.4	46.74
37.85	-23.74	42.1
-1.1	85.32	24.48
-31.03	-2.88	-12.39
-1.17	31.82	-6.72

// Spangler D L, 2012: Bulimia Nervosa (BN)
// Subjects=12
-11	-53	50
-53	1	39
3	45	-1
-51	-38	48
3	46	0

// Spangler D L, 2012: Healthy Controls (HC)
// Subjects=12
45	20	38
-47	30	37
-10	56	29
13	50	24
53	23	9
3	46	0

// Vocks S, 2010: Own Body > Fixation, All Participants
// Vocks S, 2010: Own Body > Fixation, Healthy Controls (HC) > Anorexia 
// Nervosa (AN)
// Vocks S, 2010: Own Body > Fixation, HC > Bulimia Nervosa (BN)
// Vocks S, 2010: Own Body > Fixation, BN > AN
// Vocks S, 2010: Other Body > Fixation, All Participants
// Vocks S, 2010: Other Body > Fixation, AN > HC
// Vocks S, 2010: Other Body > Fixation, HC > AN
// Vocks S, 2010: Other Body > Fixation, BN > HC
// Vocks S, 2010: Other Body > Fixation, HC > BN
// Vocks S, 2010: Other Body > Fixation, AN > BN
// Vocks S, 2010: Other Body > Fixation, Depressive > Non-depressive
// Vocks S, 2010: Other Body > Fixation, Non-depressive > Depressive
// Subjects=1
-33.99	-13.04	-43.06
-41.28	-44.55	56.55
-44.79	-6.49	-41.28
-42.77	7.79	-49.45
-31.83	-13.03	-43.1
-44.83	-4.57	-43.71
-44.93	7.78	-49.41
-41.28	-44.55	56.55
-36.73	-53.72	73.07
-49.8	-41.42	67.59
-14.29	39.28	-12.71
-61.91	-20.61	-30.63
26.65	16.7	-26.86
-4.73	37.45	59.02
-22.6	-39.25	-2.56
-25.19	18.85	-23.95
28.81	-11.78	-33.05
47.21	-55.91	44.97
26.58	27.12	-30.13
-40.69	7.17	-56.15
-46.96	-10.96	-43.04
-55.65	-6.94	-45.53
9.22	61.51	-28.76
-57.01	-51.3	8.18
-53.36	2.82	-33.09
-42.79	5.45	-51.46
-47.04	-7.12	-47.9
3.45	-55.76	3.11
-41.18	-28.42	68.4
-55.12	-40.19	-10.88
-24.77	-43.72	-4.32
57	6.58	-21.9
31.02	-2.64	-27.26
4.34	-42.52	75.75
47.29	-39.99	54.59
41.58	2.12	-45.84
-63.92	-21.7	-19.28
30.2	-62.61	66.09
12.01	-34.46	0.86
-48.15	-56.2	24.21
-36.9	-24.35	65.69
56.97	6.38	-24.12
50.64	-3.45	-14.07
20.7	-3.4	11.09
11.95	-4.26	2.36
4.33	-40.4	75.54
2.14	-31.9	74.73
3.45	-55.76	3.11
12.01	-34.46	0.86
7.67	-45.52	-2.45
-24.78	-41.59	-4.53
31.02	-2.64	-27.26
-21	-12.79	-41.06
-48.36	-46.81	9.83
-50.35	-54.29	21.81
-57.01	-51.3	8.18
-53.36	2.82	-33.09
-46.9	-6.08	-36.8
-55.12	-40.19	-10.88
-41.79	-11.09	24.12
6.24	-5.06	63.04
-0.05	-16.81	75.52
-42.01	-25.93	3.18
-23.22	-11.08	-45.68
-33.29	5.33	15.62
-26.18	-16.22	60.22
-19.63	-11.32	66.34
-63.94	-24.04	-21.29
45.91	0.01	-45.71
56.71	-6.54	-47.49
47.97	10.23	-51.24
35.78	2.83	7.97
41.79	-22.58	-34.44
53.66	-12.31	51.75
22.91	-22.75	10.72
-29.42	-26.46	-26.12
-58.88	-38.18	33.81
-15.99	-5.45	14.15
-11.69	7.54	15.04
-44.9	-7.32	-50.16
-7.4	-82.36	-5.28
-11.85	-85.54	-16.09
-31.73	-3.48	-32.84
21.65	-40.13	77.46
28.79	-22.83	-36.43
-28.97	-62.46	2.09
-20.87	-31.51	-34.73
-56.51	-56.28	46.77
-52.86	-8.75	3.9
-54.53	-9.48	42.1
-13.49	-72.89	27.51
-47.98	10.73	51.2
-54.52	-64.11	31.82
70.5	-22.16	14.34
-43.49	-40.51	53.95
25.78	-28.39	65.02
37.48	-26.85	-33.94
24.44	29.45	-28.09
30.2	-62.61	66.09
47.29	-39.99	54.59
47.42	-43.41	63.89
-35.95	-13.72	-27.27
59.3	36.11	-4.69
-61.33	-51.32	8.26
-53.33	3.03	-30.87
-42.79	5.45	-51.46
-49.15	-4.58	-43.64
-57.28	-40.2	-10.84
-61.67	-23.2	-12.45
-70.23	-31.32	-7.01
37.22	4.02	-48.2
-54.39	-52.23	44.09
-45.8	-52.61	39.5
-52.8	-8.33	8.34
-56.82	-41.13	25.1
-21.02	-15.12	-43.07
28.89	-2.44	-25.01
61.4	-29.98	-22.84
19.04	-28.15	44.94
25.88	-62.63	66.16
-32.97	3.36	40.47
-46.88	33.45	-27.27
-50.17	-11.38	44.46
10.53	-49.04	51.63
44.32	-24.12	-5.2
54.75	8.08	-28.73
-39.13	-27.11	59.27
-32.72	-23.25	54.3
-43.34	-26.3	68.23
-59.54	-23.4	-14.7
14.38	15.25	27.28

// Zhu Y, 2014: Irritable Bowel Syndrome (IBS), Moxibustion Group
// Subjects=15
-20	64	-12
-20	60	-20
6	36	30
14	22	60
26	40	-24
26	72	-8
52	50	-10
52	34	34
52	46	40
50	22	-6
-12	-14	60
10	30	-12
6	60	-6
4	-52	24

// Zhu Y, 2014: Irritable Bowel Syndrome, Placebo Group
// Subjects=13
-38	38	-16
-28	28	-20
-36	14	36
-2	-42	30
-6	-52	8
58	24	12
-24	64	-8
-22	38	46
-52	18	0
-38	34	-14
-24	40	-16
54	-2	24
-12	46	6
-20	-66	10
10	-20	34

// McNealy K, 2011: 6-year-olds
// Subjects=16
-23.02	32.03	-20.81
46.61	9.66	11.59
-67.99	-13.26	2.37
55.13	-10.91	-2.2
-50.57	-27.47	10.2
48.78	-23.07	5.83
-46.22	-27.24	12.34
40.18	-25.02	8.41
-44.48	-12.92	-18.24
-43.66	-33.04	42.01
40.39	-27.82	24.37
-17.64	-5.97	54.58
19.11	-10.1	54.36
-28.19	-32.63	68.6
21.18	-8.59	47.45
-30.9	-1.71	31.97
-26.22	-14.3	57.79
48.99	-10.56	24.76
-67.78	-9.47	19.92
44.76	-12.08	31.71
-12.08	26.52	-11.49
14.66	-13.28	43.54
15.96	32.8	-14.83
23.26	-17.92	39.37
-39.94	-2.53	0.83
31.7	-30.39	20.29
-33.4	-10.8	3.78
16.3	2.55	6.09
20.55	-6.77	-2.02
14.15	-21.48	1.78
34.07	-33.19	36.22
26.69	-53.03	-37.89
-61.53	-6.86	1.62
59.79	-30.29	19.8
-48.29	-28.76	19.25
42.41	-28.85	13.23
-24.21	-11.08	46.23
42.32	-5.45	10.92
40.24	-18.01	14.44
66.01	-21.3	0.88
66.32	-29.86	24.13
-63.7	-20.04	-1.52
55.2	-27.92	-.52
44.57	-28.84	13.2
40.3	-19.73	19.09
-54.76	-30.91	19.57
46.77	-30.75	15.59
53.17	-24.77	10.41
44.54	-20.33	12.36
-26.11	-41.96	60.52
34.15	-23.85	44.26
19.31	-45.84	62.37
-15.4	-9.8	59.4
14.85	-9.7	58.87
-17.59	-25.32	54.25
14.87	-9.49	61.09
55.57	-5.46	33.11
-19.78	-18.95	53.65
64.11	-8.38	24.29
-39.46	-9.84	37.4
27.68	-12.82	47.76
-20.04	-3.39	36.43
21.03	1.22	37.52
-22.08	-11.28	43.97
25.38	-35.76	32.14
-33.17	-19.99	20.37
40.15	-9.92	9.16
44.54	-20.33	12.36
-41.36	-40.71	51.69
36.31	-23.84	44.22
-26.14	-42.16	58.3
-15.47	0.62	56.13
12.75	-11.42	63.56
-17.62	-25.53	52.03
55.28	-12	9.11
57.71	-7.78	31.06
-34.9	-25.59	52.33
-17.85	-18.48	35.65
21.04	-.91	37.73
-19.96	-15.94	39.91
21.19	-26.02	44.69
-31.07	-9.55	17.06
40.28	-22.06	17.08
-41.43	-43.46	45.24
-34.67	-41.36	67.33
-13.08	-37.03	66.54
8.62	-38.46	73.03
63.87	-18.97	2.93
44.9	-32.94	38.25
-23.8	-43.04	71.79
-10.92	-37.03	66.5
63.85	-21.3	0.92
-41.43	-43.46	45.24
-21.64	-45.16	71.97
27.95	-39.22	63.81
8.62	-38.46	73.03
-32.5	-36.89	69.09

// McNealy K, 2011: 10-year-olds (Time 1)
// Subjects=78
-41.43	-43.46	45.24
-34.67	-41.36	67.33
-13.08	-37.03	66.54
8.62	-38.46	73.03

// McNealy K, 2011: 13-year-olds, (Time 2)
// Subjects=39
11.57	65.1	-13.47
-18.12	51.72	28.7
-15.7	38.29	45.68
-26.25	9.51	59.91
26.67	34.34	-21.88
-28.73	18.06	36.7
-24.31	21.03	45.29
-24.24	4.02	46.98
25.59	5.23	57.21
-14.45	51.21	-22.85
18.03	32.18	-21.52
-52.72	14.19	19.56
35.32	25.65	-23.41
-59.39	-9.18	-.42
57.37	-16.87	2.83
-63.61	-14.96	6.94
35.93	-37.59	11.97
-68.14	-27.48	-11.91
-35.01	-35.14	42.07
42.81	-28.07	44.53
25.73	-9.04	65.35
-54.52	-2.89	43.69
55.56	-3.33	32.9
-24.11	-23.43	51.93
34.34	-13.68	61.18
62.14	-20.12	36.69
10.25	3.52	39.71
-11.98	22.89	-4.41
7.49	23.17	-2.52
-43.98	-33.2	17.38
59.47	-8.56	-.27
-70.07	-19.23	7.48
66.11	-18.34	9.55
-52.93	-18.08	-4.14
-70.06	-21.36	7.69
53.24	-28.6	15.27
-50.65	-34.68	1.95
-54.76	-30.91	19.57
46.77	-30.75	15.59
53.17	-24.77	10.41
44.54	-20.33	12.36
-26.11	-41.96	60.52
34.15	-23.85	44.26
19.31	-45.84	62.37
-15.4	-9.8	59.4
14.85	-9.7	58.87
-17.59	-25.32	54.25
14.87	-9.49	61.09
55.57	-5.46	33.11
-19.78	-18.95	53.65
64.11	-8.38	24.29
-39.46	-9.84	37.4
27.68	-12.82	47.76
-20.04	-3.39	36.43
21.03	1.22	37.52
-22.08	-11.28	43.97
25.38	-35.76	32.14
-33.17	-19.99	20.37
40.15	-9.92	9.16
63.87	-18.97	2.93
44.9	-32.94	38.25
-23.8	-43.04	71.79
-10.92	-37.03	66.5

// McNealy K, 2011: Adults
// Subjects=27
44.54	-20.33	12.36
-41.36	-40.71	51.69
36.31	-23.84	44.22
-26.14	-42.16	58.3
-15.47	0.62	56.13
12.75	-11.42	63.56
-17.62	-25.53	52.03
55.28	-12	9.11
57.71	-7.78	31.06
-34.9	-25.59	52.33
-17.85	-18.48	35.65
21.04	-.91	37.73
-19.96	-15.94	39.91
21.19	-26.02	44.69
-31.07	-9.55	17.06
40.28	-22.06	17.08
63.85	-21.3	0.92
-41.43	-43.46	45.24
-21.64	-45.16	71.97
27.95	-39.22	63.81
8.62	-38.46	73.03
-32.5	-36.89	69.09

// McNealy K, 2011: Subgroup of 10-year-olds, second language proficient
// Subjects=53
-63.44	-35.61	15.71
50.92	-31.99	2.19
-54.8	-26.86	16.93
63.93	-27.27	5.99
-41.79	-30.86	19.35

// Pierce L J, 2014: International Adoptees (IA)
// Subjects=21
-62	-12	2
-64	-14	2
-60	-22	4
-64	-4	-4
-60	-8	0
-60	-4	-4
-60	-8	0
-66	-22	6
-64	-26	4
-62	-28	2
60	-4	0
64	-12	4
56	-32	2
64	-8	0

// Pierce L J, 2014: Bilingual
// Subjects=12
-62	-12	2
-64	-14	2
-60	-22	4

// Pierce L J, 2014: Subgroup of IA, matched IA
// Subjects=10
-64	-6	-4
-62	-10	-2
-60	-24	4
64	-2	-8

// Pierce L J, 2014: Subgroup of Bilingual, matched Bilingual
// Subjects=10
-58	-10	2
-62	-12	4
-46	-42	8
60	-6	-2

// Pierce L J, 2014: Subgroup of Monolingual, matched Monolingual
// Subjects=10
64	-16	-4
52	-38	10
48	-86	0
28	-10	-18

// Fairchild G, 2014: Healthy Controls (HC)
// Subjects=20
52	-38	6
-42	-40	-16
44	-42	-16
52	34	0
-52	-54	4
30	-26	54
40	-12	20
-16	-78	4
36	26	6
-28	-12	58
28	-12	52
-10	-102	2
10	-76	16
10	12	52
46	-58	-2
24	-82	-20
28	-70	-2
46	-26	42

// Fairchild G, 2014: Conduct Disorder (CD)
// Subjects=20
52	-38	6
-42	-40	-16
44	-42	-16
52	34	0
-52	-54	4
30	-26	54
40	-12	20
-16	-78	4
36	26	6
-28	-12	58
28	-12	52
-10	-102	2
10	-76	16
10	12	52
46	-58	-2
24	-82	-20
28	-70	-2
46	-26	42
-52	-4	-8
42	-6	-14
-32	36	42
-28	-54	-12
40	-14	-26
24	-48	-14
-22	-76	40
-40	-78	6
-10	-4	56
14	-12	-22

// Finger E C, 2011: Diagnosis-by-phase Interactions, All Participants
// Finger E C, 2011: Diagnosis-by-response type Interactions, All Participants
// Finger E C, 2011: Main Effect of Diagnosis, Healthy Controls > Conduct 
// Disorder
// Subjects=15
23	36	-13
-32	41	25
-17	46	44
-29	-4	45
50	38	11
-59	13	20
-41	-69	45
47	-58	10
44	3	-33
-50	-54	3
-2	16	13
-4	-50	-25
5	64	-8
-44	12	49
35	-41	-10
11	26	66
-8	1	68
47	2	49
37	14	66
11	27	43
-35	47	28
44	13	13
-41	14	0
-35	-72	45
-53	-33	4
44	-64	19
-20	-88	-13
32	-81	-20
20	-10	-26
-8	7	16
5	-30	8

// Kim K R, 2012: Anorexia Nervosa (AN)
// Subjects=18
-51	15	4
59	9	18
15	7	60
-3	21	40
-35	11	-4
-13	-47	42
-15	-83	8
17	-75	-20
-1	-69	-28
-7	-85	26
37	-37	-40
59	9	14
13	7	58
-7	-1	46
-7	13	34
11	-35	-26
13	-75	-16
49	-31	48
35	-73	36
1	19	42
-11	17	32
53	-63	12

// Kim K R, 2012: Bulimia Nervosa (BN)
// Subjects=20
-35	23	6
3	-75	6
5	-41	-8
41	-71	-24
-39	-67	-22
41	21	28
5	-41	-8
11	-41	66
-27	-59	42
1	19	42
-11	17	32
53	-63	12

// Kim K R, 2012: Healthy Controls (HC)
// Subjects=20
-5	-93	10
-1	-85	-6
-37	-65	-20
-45	27	26
59	9	14
13	7	58
-7	-1	46
-7	13	34
11	-35	-26
13	-75	-16
49	-31	48
35	-73	36
41	21	28
5	-41	-8
11	-41	66
-27	-59	42

// Richlan F, 2010: Words > Baseline, Healthy controls > Dyselxia
// Richlan F, 2010: Words > Baseline, Dyslexia > Healthy controls
// Richlan F, 2010: Pseudowords > Baselines, Healthy controls > Dyslexia
// Richlan F, 2010: Pseudowords > Baseline, Dyslexia > Healthy controls
// Subjects=15
22	-90	-6
36	-86	-6
-42	-46	-16
-16	-80	8
-2	4	54
-14	-20	12
-16	0	10
18	16	6
30	-56	-30
22	-90	-4
36	-84	-6
-18	-92	-8
24	-86	18
-16	-92	16
-34	-62	50
-44	-44	40
-44	-48	-18
-46	-46	4
-52	14	14
36	4	28
-48	28	-4
34	22	12
-2	24	44
10	30	26
-16	-66	40
16	2	56
-20	2	58
-58	-2	16
-48	-4	52
32	44	34
18	2	10
-18	14	12
16	18	6
-12	-6	-6
-8	-22	16
-38	-12	-24
-28	-8	-10
-20	-2	8
-28	-50	-32
10	-58	-22
32	-54	-32
14	-18	-8

// Peyrin C, 2012: Skilled Readers
// Subjects=14
-42	-59	-12
-45	-42	41
-27	-62	35
-48	16	22
-48	-59	-9
-30	-62	51
-27	-68	29
-42	-50	44
27	-68	39
-33	-78	7
-9	-75	20
9	-79	1
9	8	51

// Peyrin C, 2012: LL
// Subjects=1
-45	-50	-12
42	-53	-12
-59	-43	18
-53	-42	25
-21	-67	49
-30	-54	35
-50	13	32
45	-56	-9
-15	-79	56
-26	-72	28
-39	-45	41
18	-79	52
30	-71	42
36	45	30
33	-15	49
-53	5	42
50	-4	39
-36	-61	64
-33	18	12
36	-32	53
3	11	54
-56	-40	25
-9	-48	28
30	-12	49
33	10	29
-18	-76	52
18	-82	49
45	-56	-9
-36	-45	41
56	-43	18

// Peyrin C, 2012: FG
// Subjects=1
53	-58	9
-21	-78	46
-45	-55	58
-53	-44	51
-27	-65	39
27	-68	42
-30	-85	-2
-33	24	8
-53	5	42
-53	19	35
-45	36	18
-50	-12	55
0	14	48
0	14	48
-45	-54	-11
-21	-71	45
-27	-80	33
-53	5	42
50	-4	39
-36	-61	64
-33	18	12
36	-32	53
3	11	54
-56	-40	25
-9	-48	28
30	-12	49
33	10	29
-18	-76	52
18	-82	49
45	-56	-9
-36	-45	41
56	-43	18

// Mohammadi B, 2011: Amyotropic Lateral Sclerosis with no right hand weakness 
// (ALS-MRC-5)
// Subjects=11
-35.84	-24.81	48.61
35.79	-8.63	58.7
0.43	0.07	50.57
-52.05	-23.53	25.27
58.03	-22.7	26.16
-27.68	-10.12	3.79
-12.72	-11.09	3.7
15.1	-9.44	8.82
-26.12	-26.98	60.95
26.25	-14.52	65.99
1.52	2.45	53.7
-28.73	-12.07	6.2
-4.12	-11.67	9.23
14.05	-15.87	8.25

// Mohammadi B, 2011: Healthy Controls
// Subjects=22
-37.95	-21.22	53.91
-.61	-2.94	53.06
-54.19	-21.34	26.22
59.08	-22.87	23.94
-26.59	-13.2	5.15
-13.77	-14.18	5.09
-26.12	-26.98	60.95
26.25	-14.52	65.99
1.52	2.45	53.7
-28.73	-12.07	6.2
-4.12	-11.67	9.23
14.05	-15.87	8.25

// Pecini C, 2011: Developmental Dyslexia
// Subjects=13
-47.89	11.56	24.51
44.02	33.14	33.91
43.87	45.86	19.46
-37.93	-56.17	42.34
-1.76	9.4	47.58
-27.22	-80.06	35.3
-42.69	-70.05	-26.7

// Pecini C, 2011: Healthy Controls
// Subjects=13
-44.74	19.87	21.54
43.79	18.69	-1.68
49.02	55.98	-1.52
56.97	3.78	38.45
43.98	38.26	31.25
44.91	52.13	17.81
-33.65	-51.74	44.15
51.83	-31.51	50.39
-.74	17.61	43.53
-61.86	-34.28	-2.71
28.38	-66.18	44.65
-4.97	-78.55	11.5
10.9	-77.96	-9.92

// Elsenbrunch S, 2010: Irritable Bowel Syndrome (IBS)
// Subjects=15
18	-52	-44
-12	-54	-42
-46	4	32
-48	36	28
-64	-24	34
68	-26	32
-40	-2	-6
-4	-76	-14
44	4	8
-42	34	12
48	36	8
-50	4	28
-50	2	14
62	-56	26
-8	-66	20
30	48	14
8	24	-4
-22	-50	-38
-18	-64	-42
-20	-58	46

// Elsenbrunch S, 2010: Healthy Controls (HC)
// Subjects=12
18	-52	-44
-12	-54	-42
-46	4	32
-48	36	28
-64	-24	34
68	-26	32
-40	-2	-6
-4	-76	-14
44	4	8
-42	34	12
48	36	8
-50	4	28
-50	2	14
62	-56	26
-8	-66	20
30	48	14
8	24	-4
-22	-50	-38
-18	-64	-42
-20	-58	46
-26	-40	50
-16	-6	-2
8	-10	-14
-12	-80	6
-18	-62	44

// Georgiou-Karistianis N, 2013: Healthy Controls (HC)
// Subjects=23
56	-20	12
-54	-34	16
22	44	30
-36	-76	16
2	42	16
-6	32	36
32	-30	42
18	-58	-20
-26	-56	-20
-36	6	6
60	-2	14
-60	8	16
-16	8	-4
-14	14	-4
46	22	4
-32	22	8
-32	26	0
34	26	-4
40	46	22
24	42	-12
54	16	10
26	14	58
46	32	34
-30	0	58
32	26	0
-32	18	6
-40	-68	-26
34	-66	44
-28	-66	26
6	18	48
-30	-26	62
-32	-28	48
48	8	24
-32	-24	54
4	-60	54
-4	-60	52
42	-48	50
-34	-58	42
56	-38	40
-42	-44	44
-52	-40	18
-56	-52	10
-16	10	20
16	8	20
-18	-6	2
20	-2	2
-6	-14	0
10	0	10
28	-56	-30
-28	-58	-32
12	-26	-16
-2	-30	-20

// Georgiou-Karistianis N, 2013: Pre-Huntington's Disease (Pre-HD)
// Subjects=27
56	-20	12
-54	-34	16
22	44	30
-36	-76	16
2	42	16
-6	32	36
32	-30	42
18	-58	-20
-26	-56	-20
-36	6	6
60	-2	14
-60	8	16
-16	8	-4
-14	14	-4
40	20	4
-32	24	8
-30	28	-2
32	28	-4
42	50	18
26	42	-14
52	12	10
28	10	58
42	32	34
-32	0	62
32	26	4
-30	20	4
-38	-68	-26
32	-66	46
-28	-70	32
6	20	48
52	8	22
2	-54	46
-8	-68	54
38	-54	50
-34	-58	42
54	-40	54
-42	-42	44
30	-54	-32
-28	-58	-32

// Georgiou-Karistianis N, 2013: Symptomatic Huntington's Disease (Symp-HD)
// Subjects=17
40	20	4
-32	16	12
-30	28	-2
32	28	6
46	36	28
26	42	-18
50	12	18
24	18	58
46	32	38
-30	0	58
32	26	4
-30	26	4
-42	-68	-26
40	-58	54
-24	-64	32
6	24	48
48	4	48
8	-66	54
-4	-60	54
48	-56	52
-42	-46	50
42	-46	46
-52	-48	16
-48	-38	18
-56	-52	10
-26	-62	-36

// Georgiou-Karistianis N, 2014: Healthy Controls (HC) 1-back
// Subjects=32
-50	12	-2
-48	10	-2
42	14	4
-42	0	16
64	-14	14
-42	-1	4
38	8	6
-46	2	20
-58	-10	18
60	-16	22
-50	8	-6
-54	-16	6
52	-10	6
-54	-34	14
56	-22	12
28	-48	-10
18	-60	-8
-12	12	-4
10	18	2
-20	18	-8
18	6	-6
-22	-4	-6
16	6	-4
30	20	-2
-34	-24	54
-50	-28	56
42	14	-20
-48	-62	0
34	-78	12
28	-50	-24

// Georgiou-Karistianis N, 2014: HC 2-back
// Subjects=22
-10	-2	46
8	-4	56
18	16	-16
-42	12	0
38	12	6
-42	0	10
50	-18	20
-38	-12	-8
40	-8	-10
-4	12	42
8	16	40
-8	-2	46
10	12	34
-8	-26	44
4	-22	26
-28	-20	62
52	0	36
-66	-10	24
60	-16	24
-62	-22	30
58	-24	24
-54	-42	20
66	-42	14
-44	-46	56
-44	8	-14
44	10	-18
-54	-18	6
50	-16	10
-54	-40	16
58	-26	16
-48	-62	4
60	-44	12
-42	-56	-4
44	-54	-10
-46	-76	26
48	-68	16
-10	8	-4
10	10	-2
-16	12	-2
16	10	-2
-12	6	-2
16	8	-2
-14	-20	4
4	-16	6
-4	-62	-18
20	-62	-24
-2	-14	56
6	-12	62
52	22	10
42	22	-10
32	16	12
-60	-10	10
54	-16	18
30	14	8
-36	-18	10
-2	10	44
6	18	38
-2	0	44
10	14	34
-4	-18	46
4	-16	42
-28	-22	56
62	6	26
-42	-30	62
60	-16	22
-58	-24	32
58	-26	40
-62	-46	16
66	-42	12
-52	-20	10
48	-20	12
-58	-20	8
56	-26	14
-48	-62	2
52	-52	8
-46	-64	-14
-46	-74	26
44	-74	16
-10	14	8
14	-10	20
-18	18	-8
24	6	0
-14	6	-4
20	0	-6
-14	-8	16
8	-2	12
-14	-58	-16
30	-58	-24

// Georgiou-Karistianis N, 2014: Pre-Huntington's (Pre-HD) 1-back
// Subjects=35
-50	12	-2
-48	10	-2
42	14	4
-42	0	16
64	-14	14
-42	-1	4
38	8	6
-46	2	20
-58	-10	18
60	-16	22
-50	8	-6
-54	-16	6
52	-10	6
-54	-34	14
56	-22	12
28	-48	-10
18	-60	-8
-12	12	-4
10	18	2
-20	18	-8
18	6	-6
-22	-4	-6
16	6	-4

// Georgiou-Karistianis N, 2014: Pre-HD 2-back
// Subjects=22
-10	-2	46
8	-4	56
18	16	-16
-42	12	0
38	12	6
-42	0	10
50	-18	20
-38	-12	-8
40	-8	-10
-4	12	42
8	16	40
-8	-2	46
10	12	34
-8	-26	44
4	-22	26
-28	-20	62
52	0	36
-66	-10	24
60	-16	24
-62	-22	30
58	-24	24
-54	-42	20
66	-42	14
-44	-46	56
-44	8	-14
44	10	-18
-54	-18	6
50	-16	10
-54	-40	16
58	-26	16
-48	-62	4
60	-44	12
-42	-56	-4
44	-54	-10
-46	-76	26
48	-68	16
-10	8	-4
10	10	-2
-16	12	-2
16	10	-2
-12	6	-2
16	8	-2
-14	-20	4
4	-16	6
-4	-62	-18
20	-62	-24
-46	-64	-16
-30	-72	-24
32	-56	-26

// Georgiou-Karistianis N, 2014: Symptomatic Huntington's Disease (Symp-HD) 
// 1-back
// Subjects=23
30	20	-2
-34	-24	54
-50	-28	56
42	14	-20
-48	-62	0
34	-78	12
28	-50	-24

// Georgiou-Karistianis N, 2014: Symp-HD 2-back
// Subjects=17
-2	-14	56
6	-12	62
52	22	10
42	22	-10
32	16	12
-60	-10	10
54	-16	18
30	14	8
-36	-18	10
-2	10	44
6	18	38
-2	0	44
10	14	34
-4	-18	46
4	-16	42
-28	-22	56
62	6	26
-42	-30	62
60	-16	22
-58	-24	32
58	-26	40
-62	-46	16
66	-42	12
-52	-20	10
48	-20	12
-58	-20	8
56	-26	14
-48	-62	2
52	-52	8
-46	-64	-14
-46	-74	26
44	-74	16
-10	14	8
14	-10	20
-18	18	-8
24	6	0
-14	6	-4
20	0	-6
-14	-8	16
8	-2	12
-14	-58	-16
30	-58	-24
-46	-64	-16
-30	-72	-24
32	-56	-26

// Gray M A, 2013: Healthy Controls
// Subjects=33
24	42	-14
16	50	-16
-6	16	44
6	16	42
-22	8	60
26	8	56
-4	14	48
2	14	50
-44	4	32
48	18	2
-48	10	-4
62	-42	20
-30	-78	18
36	-74	22
-30	18	8
30	24	4
-4	14	48
4	6	56
-28	-10	54
52	14	8
-24	-70	42
14	-68	54
-44	-46	42
46	-38	46
-24	-72	40
22	-70	46
-26	-76	38
34	-76	32
-44	-84	-6
40	-74	-8
-24	-70	42
8	-70	52
-16	-12	24
14	-14	22
-20	-4	14
24	0	12
-22	-12	4
18	-6	0
-8	-16	4
14	-10	8
-34	-68	-26
32	-66	-26
-6	-74	-24
-38	26	-12
-2	20	32
6	22	30
-2	14	54
18	14	54
-2	44	34
4	56	22
-38	26	2
-48	18	-10
-38	16	0
-2	14	54
2	14	52
30	-8	52
-10	-58	32
2	-48	44
12	16	6
-30	-16	0
16	12	-4
-20	-4	2
12	4	-4
-8	-8	4
2	-12	8
-40	22	-2
-44	10	-10
-38	20	0
-44	18	10
-6	8	8
-24	12	-2
-14	4	2
18	12	-18
-14	14	-20
16	10	-18
0	22	-10
4	14	-12
-10	32	-12
12	24	-14
-18	8	-20
-4	12	-6
-12	6	-12
-38	36	-18
40	38	-16
-8	40	-18
4	44	-18
-6	28	-12
4	36	-10
-2	-12	38
2	-12	36
-12	40	42
12	34	56
-10	40	-16
4	56	22
-46	26	-10
38	22	-20
-42	-60	26
36	18	-36
-50	-66	20
60	4	-26
-38	-22	20
38	-10	14
-8	-6	50
-16	-32	62
58	-6	8
-24	-40	64
-38	-78	44
-14	-68	28
-42	-76	28
-10	-58	32
10	-56	32
-6	14	-4
12	20	-2
-16	4	-8
16	12	-4
-20	0	-6
-4	-6	4
12	-32	4

// Gray M A, 2013: Pre-Huntington's Disease (Pre-HD)
// Subjects=32
-26	48	-12
20	50	-12
-20	52	-12
16	50	-16
-6	10	46
6	16	42
-22	8	60
24	4	58
-2	12	48
2	14	50
-46	2	26
46	22	2
-48	8	-2
50	12	-4
-46	-64	-4
58	-48	-2
-32	22	0
32	24	-2
-2	12	48
10	16	44
-40	0	32
56	14	8
-24	-70	42
30	-66	50
-44	-44	42
48	-44	46
-24	-72	40
28	-80	36
-26	-66	30
32	-74	40
-46	-68	-18
38	-74	-8
-24	-72	40
8	-70	52
-16	16	6
16	0	22
-18	0	14
16	4	6
-16	-6	-6
14	4	2
-14	-10	8
20	-22	16
-28	-70	-26
28	-62	-30
-4	-74	-26
-40	22	-2
-44	10	-10
-38	20	0
-44	18	10
-6	8	8
-24	12	-2
-14	4	2
-38	36	-18
20	26	-18
-10	38	-18
4	44	-18
-12	48	-2
4	28	-16
-4	46	12
2	44	10
-10	60	2
8	62	2
-10	38	-16
6	54	14
-50	38	-10
42	34	-10
-44	20	-28
44	14	-28
-50	12	-34
42	6	-36
-38	-16	18
40	-12	14
-50	-14	12
62	-6	28
-52	-62	40
-14	-68	28
14	-96	26
-46	-74	32
34	-90	28
-2	-54	32
8	-56	32
-8	16	-4
10	18	-6
-16	10	-10
16	12	-10
-14	-34	2

// Gray M A, 2013: Symptomatic Huntington's Disease (Symp-HD)
// Subjects=20
-38	26	-12
22	40	-18
-2	10	46
4	16	42
-2	14	54
0	16	54
-2	12	48
2	14	50
-46	2	30
52	18	0
-48	8	-2
48	12	-4
-60	-62	-2
54	-54	-12
-32	20	0
36	16	6
-2	12	46
2	14	50
-52	-8	40
48	6	14
-10	-78	52
36	-60	50
-42	-42	36
48	-44	38
-12	-76	42
30	-68	44
-28	-76	32
34	-76	32
-48	-70	-18
40	-86	-2
-10	-78	52
32	-70	42
6	4	6
-26	6	2
18	6	2
-20	-4	2
16	4	-2
-10	-16	6
18	-26	10
-30	-62	-22
36	-68	-30
-6	-76	-24
-38	26	-12
-2	20	32
6	22	30
-2	14	54
18	14	54
-2	44	34
4	56	22
-38	26	2
-48	18	-10
-38	16	0
-2	14	54
2	14	52
30	-8	52
-10	-58	32
2	-48	44
12	16	6
-30	-16	0
16	12	-4
-20	-4	2
12	4	-4
-8	-8	4
2	-12	8
18	12	-18
-14	14	-20
16	10	-18
0	22	-10
4	14	-12
-10	32	-12
12	24	-14
-18	8	-20
-4	12	-6
-12	6	-12
-22	24	-24
18	24	-16
-8	44	-18
6	28	-22
-6	28	-12
8	26	-12
-8	44	10
-8	60	26
-10	34	-12
10	26	-12
-24	26	-24
38	14	-20
-42	-60	26
36	18	-36
-64	-14	-8
60	2	-20
-38	-76	40
-40	-74	28
-10	-62	26
0	-62	20
-4	12	-6
8	18	-6
-12	6	-12
14	8	-12

// Hillen R, 2013: All Conditions > Rest
// Hillen R, 2013: S, N, PWS, PW > Landolt Sentences (LS)
// Hillen R, 2013: LS > Pseudowords (PW), Pseudoword Sentences (PWS), Nouns 
// (N), Complete Sentences (S)
// Hillen R, 2013: (S and N) > (PWS and PW)
// Hillen R, 2013: (S > N) and (PWS > PW)
// Subjects=20
-32	-98	-6
34	0	66
30	-52	46
2	14	52
38	38	24
-30	-4	52
-18	-10	22
-38	-48	-20
-50	-6	50
-64	-36	4
24	-64	-50
22	-64	-24
38	-46	54
62	-18	32
24	-34	66
-46	-62	12
48	-52	8
-40	-14	-20
10	86	24
-54	2	-14
-2	10	54
52	16	-14
22	-66	56
16	-66	28
34	-2	66

// Van den Eynde F, 2013: Bulimia Nervosa
// Subjects=21
-2.74	62.48	23.85
1.28	31.66	33.74
-13.97	-89.02	3.56
8.73	-40.31	-26.55
24.03	84.18	-2.15
-22.35	83.9	-1.59
55.53	12.43	34.73
28.26	-29.69	1.78
-40.83	-38.45	47.47
39.74	-58.81	-17.99
-29.52	24.22	42.08
20.98	-33.6	53.71
4.92	-43.54	-22.55
39.59	-19.58	-21.28
-2.74	-59.63	-24.8
43.66	-70.24	-13.4
51.36	-66	-10.16
-21.55	-58.28	45.23
28.72	-53.5	51.61
16.71	-85.77	-8.11
12.65	-22.8	-9.66
4.8	48.71	-.85
12.64	-35.11	-15.99
-2.3	-55.1	33.7
54.99	-.2	-26.76
-52.75	-57.66	5.05
-21.94	-29.7	6.04
28.05	41.3	3.19
-18.29	37.39	7.73
51.38	11.55	23.81
-52.75	3.39	29.38
-48.82	-65.93	-1.66
47.53	-61.82	-6.79
-33.67	21.09	1.91
55.48	-48.06	17.73
28.19	-42.55	-11.86
-45.5	66.94	-16.52
47.13	68.34	-6.66

// Van den Eynde F, 2013: Healthy Controls
// Subjects=23
-2.46	16.56	42.41
24.66	-80.11	13.41
-18.03	7.51	28.63
-6.6	-55.74	-25.08
24.03	84.18	-2.15
-22.35	83.9	-1.59
47.5	15.16	19.88
-44.92	3.72	32.94
4.96	66.72	27.08
43.47	-6.54	-11.38
-10.45	-47.55	-22.04
39.59	-19.58	-21.28
-2.74	-59.63	-24.8
43.66	-70.24	-13.4
51.36	-66	-10.16
-21.55	-58.28	45.23
28.72	-53.5	51.61
24.17	4.37	-15.75
47.37	42.27	13.92
16.78	-89.11	-.47
32.54	-53.76	47.91
47.72	9.32	46.13
-21.8	32.66	48.65
-45.49	50.73	-22.52
-14.23	-14.31	0.75
-37.23	-49.18	11.52
-41.31	29.71	12.32
-2.87	4.21	-15.43
20.44	-18.84	-10.08
5.11	-17.24	12.04
-41.09	7.65	32.56
47.57	-65.45	-2.81
-45	-66.29	-5.35
47.56	11.81	27.52
-33.86	2.89	-29.68
43.97	-71.04	27.15
-25.92	-39.25	-15.2
-45.5	66.94	-16.52
47.13	68.34	-6.66

// Wolf R C, 2012: Healthy Controls
// Subjects=18
22.54	13.88	-10.83
44.5	40.68	22.01
-2.48	0.88	58.12
-17.41	-6.44	72.55
-2.54	0.46	53.68

// Wolf R C, 2012: Pre-Huntington's Disease far from onset (preHDfar)
// Subjects=9
31.16	11.58	-12.99
20.8	-94.61	-0.06
-15.25	-6.43	72.51
-2.54	0.46	53.68

// Wolf R C, 2012: Pre-Huntington's Disease near onset (preHDnear)
// Subjects=9
22.54	13.88	-10.83
44.5	40.68	22.01
-2.48	0.88	58.12
-17.41	-6.44	72.55
-2.54	0.46	53.68
31.16	11.58	-12.99
20.8	-94.61	-0.06
-15.25	-6.43	72.51
-2.54	0.46	53.68

// Centeno M, 2012: Healthy Controls (HC)
// Subjects=18
27	-27	-6
-30	-24	-9
48	6	48
-45	3	54
-31	-21	-10
-48	3	42
18	-6	-22
19	-15	-18
-21	0	-24
42	9	42
45	24	24
-18	-18	-15
-39	39	24
3	-9	69
57	3	15
39	39	30
-57	-3	24
54	3	3
39	39	50
3	-9	72
-36	39	21
0	3	72
-54	1	0
30	3	-24
26	-6	-21
-24	-3	-24
-27	-12	-21
-39	36	21
54	3	3
-57	5	5
3	-9	69
42	39	27

// Centeno M, 2012: Frontal Lobe Epilepsy (FLE)
// Subjects=32
-24	-18	-15
24	-27	-9
-51	0	45
-51	6	33
-51	15	-6
45	0	54
47	9	27
51	15	-9
-30	-24	-12
-48	0	45
-51	9	33
-48	24	-9
18	-3	-21
24	-21	-12
-21	0	-21
48	21	21
45	24	21
45	33	3
48	15	39
-45	0	45
-39	39	24
3	-9	69
57	3	15
39	39	30
-57	-3	24

// Centeno M, 2012: Subgroup of FLE, Right Frontal Lobe Epilepsy (RFLE)
// Subjects=13
-36	39	21
0	3	72
-54	1	0

// Centeno M, 2012: Subgroup of FLE, Left Frontal Lobe Epilepsy (LFLE)
// Subjects=19
54	3	3
39	39	50
3	-9	72

// Centeno M, 2012: Subgroup of FLE, Memory Impairment
// Subjects=7
30	3	-24
26	-6	-21
-24	-3	-24
-27	-12	-21
24	0	-24
24	-12	-21
54	30	27
39	9	42
-24	-6	-18
-24	-12	-24

// Centeno M, 2012: Subgroup of FLE, No Memory Impairment (FLENM)
// Subjects=25
24	0	-24
24	-12	-21
54	30	27
39	9	42
-24	-6	-18
-24	-12	-24
-39	36	21
54	3	3
-57	5	5
3	-9	69
42	39	27

// Stretton J, 2012: Temporal Lobe Epilepsy with Left Hippocampal Sclerosis 
// (LHS)
// Subjects=19
-26	12	66
20	14	62
-22	6	54
34	14	58
38	22	44
18	-68	68
-30	-66	64
-30	-64	62
18	-68	68
-6	-74	56
20	10	66
-22	12	68
-36	28	32
40	30	32
20	-68	66
50	-12	6
-2	56	-12
22	-12	-24
6	-46	36

// Stretton J, 2012: Temporal Lobe Epilepsy with Right Hippocampal Sclerosis 
// (RHS)
// Subjects=19
-50	-56	54
40	26	40
-44	26	32
20	-66	66
12	-104	6
-4	-64	30
-2	66	8
-46	-18	-2
-28	-20	-20

// Stretton J, 2012: Healthy Controls (HC)
// Subjects=15
20	-70	66
32	2	56
-28	-66	62
-30	6	64
18	-68	68
-30	-66	64
-30	-64	62
18	-68	68
20	-68	64
28	8	64
-30	6	64
34	24	-4
-32	30	-4
20	-68	66
20	-66	66
12	-104	14
6	-56	32
-44	-2	-18
-8	60	36
52	-8	-2
-28	-12	-22
24	-4	-22

// Virani K, 2013: Behavioral variant of Frontotemporal Dementia (bvFTD) < 
// Healthy Controls (HC), Angry
// Virani K, 2013: bvFTD > HC, Angry
// Virani K, 2013: bvFTD > HC, Disgusted
// Virani K, 2013: bvFTD > HC, Happy
// Virani K, 2013: bvFTD < HC, Fearful
// Virani K, 2013: bvFTD < HC, Sad
// Virani K, 2013: bvFTD > HC, 100% intensity
// Virani K, 2013: bvFTD > HC, 40% intensity, p<0.005 corrected
// Virani K, 2013: bvFTD > HC, 40% intensity, p<0.005 uncorrected
// Subjects=18
23	9	-22
-35	-51	-14
23	-89	8
-2	-46	26
38	-62	32
38	14	7
-35	23	4
-20	-73	-5
23	-89	11
41	-69	38
-2	-4	52
-5	-91	-17
-20	-92	11
23	-89	8
-2	7	51
-17	73	-5
44	-14	8
23	-89	8
-8	-81	44
32	49	35
41	34	34
38	-62	32
47	-65	35
2	12	46
-5	-59	26
-5	-65	35

// Zheng J, 2012: Temporal Lobe Epilepsy (TLE)
// Subjects=12
50	-76	0
50	-54	56
12	-14	12
-46	28	20
-8	4	28
-30	-2	58
2	-68	-18
42	-78	-14
-36	-78	-28
20	-36	-28
50	22	-8
12	-30	-12

// Zheng J, 2012: Healthy Controls (HC)
// Subjects=8
-38	-80	-28
48	-70	-12
24	2	-32
-36	8	-28
-2	-84	-44
-16	-30	-4
2	-68	-18
42	-78	-14
-36	-78	-28
20	-36	-28
50	22	-8
12	-30	-12

// Baumeister S, 2014: Peak activations for NoGo > Neutral, fMRI
// Baumeister S, 2014: Peak deactivations for covariation of event-related 
// potentials during NoGo trials (N2) and brain activity across all 
// conditions, Combined fMRI & EEG analysis
// Baumeister S, 2014: Peak deactivations for covariation of event-related 
// potentials during NoGo trials (P3) and brain activity across all 
// conditions, Combined fMRI & EEG analysis
// Baumeister S, 2014: Peak areas of clusters for conjunction of N2 modulation 
// at Cz and pooled channels, Combined fMRI & EEG analysis
// Baumeister S, 2014: Peak areas of clusters for conjunction of P3 modulation 
// at Cz and pooled channels, Combined fMRI & EEG analysis
// Subjects=17
33.66	17.02	-9.26
29.7	26.96	-4.71
-33.66	23.08	-4.52
9.9	15.95	47.1
31.68	45.58	17.99
-27.72	49.63	21.47
33.66	17.53	0.97
-33.66	17.53	0.97
-11.88	24.45	22.73
54.45	-43.46	24.28
45.54	-41.33	27.86
25.74	-61.64	49.14
63.36	-43.19	29.8
-63.36	-43	33.47
-57.42	-45.21	28.05
-25.74	-75.73	0.43
-33.66	25.02	-4.62
31.68	17.35	-2.55
-33.66	17.53	0.97
-57.42	-37.19	33.18
-61.38	-47.06	30
63.36	-43.19	29.8
13.86	50.65	2.99
55.44	1.93	38.59
-1.98	3.29	-11.94
13.86	58.22	-1.07
5.94	-.56	66.35
9.9	17.43	37.82
-47.52	-51.22	-14.26
53.46	-65.51	10.65
-35.64	-78.71	18.87
-43.56	-75.11	12.97
57.42	-39.77	20.41
51.48	-36.08	16.54
-63.36	-45.95	13.35
-49.5	-11.08	50.3
13.86	73.35	47.89
-15.84	-78.52	22.35
-21.78	-68.32	-6.67
-27.72	-50.96	-9.22
27.72	-78.01	-6.19
-11.88	-68.24	-5
5.94	-87.53	-2.35
23.76	-87.69	-5.7
25.74	-87.28	2.69
-45.54	-74.13	-6.38
-33.66	21.77	8.12
-41.58	18	10
5.94	-15.97	30.28
-13.86	-16.43	-21.09
15.84	58.13	-2.91
13.86	-75.48	44.31
-23.76	-66.55	-10.13
23.76	-93.59	-7.09
23.76	-91.23	1.2
23.76	-78.17	-9.54
9.9	-89.63	-5.61
-45.54	-72.36	-9.84
-41.58	-82.95	-11.52
13.86	56.11	-4.49
18.77	19.28	35.88
13.86	-75.48	44.31
-17.82	-80.64	18.77
-23.76	-66.55	-10.13
23.76	-93.59	-7.09
23.76	-91.23	1.2
27.72	-78.17	-9.54
9.9	-89.63	-5.61
-45.54	-72.36	-9.84
-41.58	-82.95	11.52
15.84	58.13	-2.91
53.46	-.1	36.85
-29.7	-21.88	67.42
5.94	-.66	64.51
-47.52	-59.05	-15.55
13.86	-75.48	44.31
23.76	-93.59	-7.09
23.76	-91.23	1.2
23.76	-78.17	-9.54
9.9	-89.63	-5.61
-41.58	-83.04	9.68
-25.74	-64.7	-11.9
1.98	1.27	-13.52
13.86	56.11	-4.49
55.44	-.19	35.01
-43.56	-13.2	46.72
-29.7	-21.88	67.42
5.94	-.66	64.51
18.77	19.28	35.88
61.38	-27.46	-5.35
-61.38	-47.98	11.61
61.38	-41.89	16.83
9.9	-17.86	-7.52
13.86	-75.48	44.31
-17.82	-80.64	18.77
-23.76	-66.55	-10.13
27.72	-78.17	-9.54
-45.54	-72.36	-9.84
-25.74	-94.94	4.75
51.48	-67.63	7.07
-41.58	-82.95	11.52
17.82	-41.19	-8.03
-43.56	23.53	4.35
-39.6	19.65	4.54
3.96	-19.93	28.63
-15.84	-20.49	17.61
-43.56	23.53	4.35
5.94	-15.97	30.28
-39.6	19.65	4.54
3.96	-19.93	28.63
-15.84	-20.49	17.61

// Dong G, 2014: Incon_Con > Con_Con (lower activated)
// Dong G, 2014: Con_Incon > Incon_Incon (higher activated)
// Subjects=30
24	-63	39
-63	-18	-6
-3	-30	36
-39	51	6
-33	18	30
33	39	39
33	-9	39
15	48	-15
48	33	18

// Grandjean J, 2012: Incongruent > neutral
// Grandjean J, 2012: Incongruent > neutral, mostly congruent (MC)
// Grandjean J, 2012: Incongruent > neutral, mostly neutral (MN)
// Grandjean J, 2012: Incongruent trials, MC > Neutral trials, MN
// Grandjean J, 2012: Incongruent trials, mostly incongruent (MI) > Neutral 
// trials, MN
// Subjects=25
-42	14	26
-54	20	34
-44	38	34
-24	4	68
-2	18	50
-34	20	2
32	22	4
30	24	-10
-24	-70	42
-32	-50	48
-8	-64	62
30	-50	44
-44	-86	-8
-48	-56	-20
-42	-68	-10
-54	-46	14
30	-64	-34
10	-76	-28
46	-52	-42
-48	-36	54
-32	-52	50
-32	-54	66
-26	-68	38
-26	-10	54
-52	16	28
-6	18	46
-34	14	-6
14	10	6
-48	-68	-6
-44	14	28
-56	20	34
-32	22	0
-26	46	16
60	6	32
-24	-70	42
-42	-88	-10
-40	-70	-12
-50	-58	-20
44	-84	-10
8	-76	-30
-26	-68	38
-50	-36	50
-36	-40	40
-32	20	-2
-48	14	28
-6	20	44
34	20	4
32	24	-10
16	10	8
-40	-88	-6
68	-42	16
-42	14	26

// Jimura K, 2014: Mirrow-Switch (MR-SW) > Mirror-Repeat (MR-RP), Pre-Training
// Jimura K, 2014: Plain-Switch (PL-SW) > Plain-Repeat (PL-RP), Pre-training
// Jimura K, 2014: MP-RP > PL-RP, Pre-training > Post-training
// Jimura K, 2014: MR-SW > MR-RP, Pre-training > Post-training
// Subjects=14
52	-32	22
4	-12	30
14	-54	62
8	-40	24
4	4	38
-54	-40	32
-20	4	-12
-8	4	8
64	-34	12
-12	-32	38
-4	-4	50
-60	-26	8
50	-16	36
6	-68	8
36	-58	52
36	-52	38
48	8	32
-12	-82	2
40	2	56
-42	-70	-8
34	-70	38
48	-54	-14
28	-58	52
-34	-62	60
-12	-78	52
38	-82	10
32	0	60
-46	6	30
-30	-52	46
-24	-68	48
-26	-84	36
12	-72	50
-40	-38	36
-32	-88	12
24	2	46
54	-72	-2
42	-44	50
36	-92	-2
-28	-82	20
-24	-66	32
46	-80	-18
-22	6	-10

// Feng X, 2014: 1-relational > 0-relational
// Feng X, 2014: 2-relational > 0-relational
// Feng X, 2014: 2-relational > 1-relational
// Subjects=20
9	12	48
-45	3	27
-6	9	60
9	27	36
-33	-48	42
48	9	27
33	24	-3
33	-51	42
48	9	27
45	33	21
9	12	48
-45	3	27
-33	-48	42
-27	-66	48
45	-42	45
-45	-69	-9
33	-87	0
18	12	6
-18	6	6
-42	39	6
-15	3	9
-45	24	21

// Floden D, 2011: Activation Clusters for Latent Variable 1 Positive 
// Saliences/ Bootstrap Ratios
// Floden D, 2011: Activation Clusters for Latent Variable 1 Negative 
// Saliences/ Bootstrap Ratios
// Floden D, 2011: Clusters indentifed in the SPM analysis
// Subjects=9
14	-.98	8.12
-37.45	47.52	6.87
-28.11	-69.38	63.41
26.72	32.04	7.44
14	16.53	14.46
-2.82	-27.92	32.88
48.29	8.96	23.62
-53.33	32.51	20.58
55.55	45.16	9.35
35.94	-66.42	54.62
9.75	3.56	12.25
44.03	13.43	26.64
60.38	-41.32	46.66
-53.3	25.19	22.31
-53.37	36.48	16.91
27.21	-60.7	33.05
10	-27.85	32.72
-57.58	33.88	24.98
52.95	-45.25	51.53
-32.63	-47.77	40.46
1.42	-19.44	32.12
-33.17	35.57	3.37
-57.12	-54.72	49.13
48.45	-61.85	16.18
-61.69	-20.5	24.01
5.74	-92.57	8.09
10.19	-28.08	57.28
23.08	-14.11	71.57
10.02	11.93	51.69
-2.96	26.69	37.22
-2.67	5.48	65.76
-49.98	13.2	32.2
-53.31	11.9	15.62
-41.74	17.74	-6.19
-46.11	20.03	-17.49
-33.13	27.2	5.18
56.1	-33.69	49.41
40.16	-53.79	52.4
40.12	-58.62	45
35.78	-51.59	39.99
43.77	22.83	-3.14

// Kirschen M P, 2010: High load > Low load
// Kirschen M P, 2010: Audtiory: High load > Low load
// Kirschen M P, 2010: Visual: High load > Low load
// Kirschen M P, 2010: Visual > Auditory
// Kirschen M P, 2010: Auditory > Visual
// Subjects=16
-62.22	-59.75	21.44
-53.44	-29.14	38.43
-24.06	-40.99	-32.62
-7.85	-62.39	47.66
-33.6	32.59	-2.76
-38.5	11.13	31.95
-68.25	35.14	-8.02
31.79	28.98	-44.97
7.98	11.5	33.36
35.88	38.63	23.48
32.36	33.24	0.54
55.38	58.77	31.24
47.87	51.51	34.32
21.83	17.3	-66.06
33.87	37.53	34.83
51.98	54.32	18.29
-52.5	-1.69	33.45
-60.36	10.24	12.24
-23.99	-62.37	-31.62
-5.75	1.72	55.85
-32.5	28.34	-2.35
-36.08	-48.22	40.02
-67.99	-24.21	0.09
20.35	-66.26	-29.75
7.99	20.32	35.85
42.31	40.46	19.82
34.49	22.1	-4
55.68	-3.56	41.88
46.04	-47.83	39.7
24.29	-67.98	-59.9
34.17	-52.12	40.33
47.86	6.55	24.21
-61.64	-4.39	-6.46
-62.52	-32.39	4.17
-63.7	-24.4	-2.21
-22.13	-58.06	-54.49
-29.65	-62.13	-51.72
-35.72	24.08	-1.88
-40.24	-58.38	-33.98
-23.89	-63.77	-23.64
-9.49	27.52	21.99
-8.28	19.74	30.58
-51.62	9.94	19.96
-48.46	6.03	12.45
-47.94	-41.46	44.04
-29.52	-7.52	-30.23
-34.53	-31.95	-4.2
59.53	-30.04	-.39
58.45	-19.09	1.91
32.47	26.42	7.93
7.85	27.99	26.13
22.16	-60.13	-56.16
57.54	4.04	19.81
52.37	-8.45	35.7
59.92	-1.94	36.05
42.28	35.79	15.8
35.92	35.64	26.01
53.72	-17.76	-29.52
6.09	8.04	53.9
44.02	-43.5	51.64
48.38	-64	50.23
-46.46	-64.08	-14.26
-33.91	-52.47	40.4
-28.53	-74.55	33.53
-40.33	1.6	56.45
-48.27	7.49	27.99
-43.6	-41.79	-40.05
42.28	-72.51	-5.98
36.34	-52.45	-43.72
37.59	-65.45	-33.49
27.87	-69.84	-34.01
43.91	-49.75	42.17
36.32	-47.86	39.87
24.32	-69.9	-57.47
46.03	-33.69	41.67
45.64	8.26	19.59
-37.7	-76.29	-7.6
-41.87	-86.11	2.41
-40.05	-75.53	-22.2
-41.99	-68.45	-3.82
-37.71	-84.05	-10.19
-24.2	-77.72	33.77
-28.46	-52.13	43.64
-15.91	-97.83	2
-40.3	-42.43	-35.56
44.42	-73.77	-8.13
35.78	-85.82	-10.15
32.08	-58.2	44.33
24.18	-97.92	10.29
35.53	-65.79	-25.58
-60.31	-22.18	9.84
-60.44	-10.04	1.92
-56.31	1.7	-10.52
-42.44	5.92	-23.5
-63.77	-6.32	-4
-41.93	-24.25	9.73
-60.26	-41.53	9.51
-63.73	-20.25	-3.74
-11.88	-56.2	-12.27
-9.66	41.58	11.63
-29.52	-4.23	-29.44
63.89	-14.4	5.84
56.39	-26.03	8.23
68.15	-18.1	0.53
54.01	-15.58	-6.21
51.83	32.35	1.42

// Lao-Kaim N P, 2014: Healthy Controls
// Subjects=31
43.75	-60.79	-38.5
39.98	-42.47	33.61
-44.44	-42.98	34.62
-21.82	-66.22	48.57
1.45	12.68	48.38
43.91	38.55	21.19
-25.22	0.89	49.68
-44.69	23.64	29.03
-29.92	49.22	14.45
28.23	5.87	54.22
-13.85	1.42	0.43
16.1	6.26	5.26
-25.69	24.61	-1.38
36.3	21.81	-1.85
8.37	60.77	-4.8
-6.07	-52.58	17.14
-10.67	58.31	20.16
12.88	58.88	25.42
-5.97	-30.6	39.83
1.44	-11.52	38.14
51.72	-15.02	43.44

// Lao-Kaim N P, 2014: Anorexia Nervosa
// Subjects=31
-53.44	-23.53	-15.98
47.51	-41.91	40.16
-33.76	-42.91	34.49
-25.04	-62.01	48.26
16.65	-65.99	48.11
28.17	9.67	48.33
-25.24	5.12	49.32
-41.51	31.06	28.38
39.69	35.78	27.05
-29.98	53.02	8.56
31.82	63.57	-11.99
1.45	12.68	48.38
-29.98	28.82	-1.68
32.01	24.96	-2.07
0.89	60.73	-4.71
-6.12	-53.09	10.49
-56.29	-16.61	32.54
-6.37	62.99	25.29
-6.22	48.07	38.81
-5.97	-30.6	39.83

// Raabe M, 2013: Load 4 > load 1
// Raabe M, 2013: Load 1 > Load 4
// Raabe M, 2013: Conjunction of load-4 and load-1 tasks
// Raabe M, 2013: MVPA: Regions that correctly predicted target target 
// quadrant
// Subjects=12
-34	22	-2
28	-4	48
-10	26	32
-8	-66	52
42	-32	48
-40	-80	10
-40	-80	10
-22	-70	56
-28	-2	64
22	-4	56
44	-48	-14
-46	-76	-4
28	-64	60
-8	-80	12
-14	-68	-16
34	-36	-24
-54	-10	38

// Rocca M A, 2014: Healthy Controls
// Subjects=52
-36	-52	46
-24	-70	46
40	-52	40
30	-66	52
-44	6	38
-34	50	22
-48	14	26
32	6	58
38	54	22
52	22	32
-34	20	2
34	24	-4
-2	18	50
-4	8	58
36	-62	-28
-36	-66	-26
-6	-52	26
4	-52	24
-50	-26	12
58	-18	12
-6	52	-6
8	60	6
-44	-74	30
56	-64	18
26	-16	-22
22	-46	-12
-38	-46	50
38	-40	44
-54	8	24
-34	46	32
-32	46	34
40	16	48
-36	22	-4
36	24	-4
28	-62	54
-4	10	58
-34	46	32
-38	-46	48
-26	-68	48
40	-42	46
-46	2	36
-50	10	16
-44	6	50
-6	8	58
36	22	-6
40	16	48
-50	6	-34
28	-64	-6
-48	-22	14
-52	-66	26
-4	-46	30
8	-56	28
-6	-34	52
-26	-34	-12
26	-18	-24
-8	-38	50
0	-42	32
-24	-36	-14
28	-64	-6

// Rocca M A, 2014: Multiple Sclerosis Patients
// Subjects=42
-46	-48	52
-28	-66	38
40	-44	40
26	-68	58
-46	4	44
-46	12	30
-34	48	18
42	4	28
46	36	28
30	14	60
42	54	10
-32	24	-2
32	24	-4
-2	16	56
-4	26	44
34	-64	-26
-4	-48	28
6	-48	28
-44	-22	10
64	-26	20
-10	52	42
2	54	30
-52	-66	14
54	-64	10
-38	-46	50
38	-40	44
-54	8	24
-34	46	32

// Rocca M A, 2014: Subgroup of Multiple Sclerosis Patients, Cognitively 
// Impaired (CI)
// Subjects=20
-44	-50	54
-20	-72	54
36	-56	58
20	-70	52
-48	6	38
-46	18	26
2	20	48
-6	2	52
-6	-48	26
8	-46	26
-58	-28	14
64	-20	16
-36	22	-4
36	24	-4
28	-62	54
-4	10	58
-34	46	32
-38	-46	48
-26	-68	48
40	-42	46
-46	2	36
-50	10	16
44	8	48
-36	4	52
-8	10	58
-8	6	60
-44	6	50
-6	8	58
36	22	-6
40	16	48
-50	6	-34
28	-64	-6
-48	-22	14
-52	-66	26
-4	-46	30
8	-56	28
-6	-34	52
-26	-34	-12
26	-18	-24
-18	-52	-4
26	-62	-6
56	6	-6
-38	-14	-4
2	-40	36
58	-32	4
-8	-38	50
0	-42	32
-24	-36	-14
28	-64	-6

// Rocca M A, 2014: Subgroup of Multiple Sclerosis Patients, Cognitively 
// Preserved (CP)
// Subjects=22
-40	-44	46
-28	-70	38
38	-46	42
20	-62	50
-44	4	42
-52	28	32
-20	16	60
42	6	34
46	38	30
32	14	60
40	22	50
-2	14	58
8	34	40
32	22	-6
-36	22	-4
-4	-46	32
-2	-58	26
-44	-22	6
62	-30	22
-12	54	44
4	58	14
40	-36	-24
-32	46	34
40	16	48
44	8	48
-36	4	52
-8	10	58
-8	6	60
-44	6	50
-6	8	58
36	22	-6
40	16	48
-18	-52	-4
26	-62	-6
56	6	-6
-38	-14	-4
2	-40	36
58	-32	4
-8	-38	50
0	-42	32
-24	-36	-14
28	-64	-6

// Rosner Z, 2012: Generate hit > Read hit
// Rosner Z, 2012: Generate > Read (high confidence interval)
// Rosner Z, 2012: Read > Generate (high confidence interval)
// Subjects=24
0	0	28
-52	14	28
50	34	16
-46	-56	-16
46	-54	-10
32	0	10
-24	-76	26
28	-76	32
-54	14	34
52	24	26
-32	-90	8
34	-92	2
-44	4	24
42	8	26
-12	-62	42
18	-58	42
-38	-42	44
28	-56	48
-46	6	2
-4	40	18
4	30	22
-42	26	-6
-42	38	-14
-48	34	6
42	16	24
-58	-60	-20
54	-56	-14
-32	18	6
-24	-76	28
32	-72	26
10	-88	-6
-44	30	26
54	10	42
-40	-74	-20
30	-80	-4
-34	-94	10
34	-92	2
-4	16	48
12	32	28
48	-28	48
56	-20	46
-48	6	26
44	8	26
-16	-70	-30
24	-64	30
-6	38	42
-4	28	48
-36	-48	46
32	-54	48
-44	-44	46
44	-36	48
-44	-56	-16
44	-58	-12
-48	-68	26
-40	-84	36
8	-68	36
-42	-68	36
-10	-68	26
8	-68	36
4	-64	48

// Witt S T, 2013: Switch > Non-switch
// Witt S T, 2013: Non-switch > Switch
// Witt S T, 2013: High complexity > Low complexity
// Witt S T, 2013: Low complexity > High complexity
// Witt S T, 2013: Modulatory effects of stimulus complexity on switch trials
// Witt S T, 2013: Modulatory effects of stimulus complexity on non-switch 
// trials
// Witt S T, 2013: Positive correlation between BOLD response and number of 
// response options
// Witt S T, 2013: Negative correlation between BOLD response and number of 
// response options
// Witt S T, 2013: Main effects of increasing number of preceding non-switch 
// trials
// Subjects=83
10	20	44
-6	20	50
-30	8	60
30	8	62
26	0	56
-44	24	26
-42	6	30
-50	36	8
44	10	30
-34	20	-4
34	22	-2
-24	-64	48
26	-72	54
-46	-58	52
-6	-74	42
32	-68	38
0	-30	32
6	-80	2
44	-82	2
-58	-52	6
-16	-22	-4
8	-12	0
4	-20	2
-14	54	14
-10	-100	20
2	24	48
-24	4	52
26	4	52
46	34	24
-42	6	28
46	10	28
-32	22	0
32	24	-4
-22	-62	54
24	-62	54
-40	-38	42
46	-32	46
-26	-86	22
30	-82	22
-36	-76	-8
42	-80	-4
-6	-94	-6
8	-84	-6
-6	4	12
8	10	10
-12	-22	14
20	-24	16
12	-6	18
-14	50	44
12	52	44
-4	52	0
-10	60	10
-40	4	14
42	-8	14
-12	-28	44
6	-26	44
-2	-46	30
-54	-66	32
-64	-36	34
-62	-28	22
62	-26	22
62	-52	32
4	-84	28
-20	-10	-20
22	-10	-20
-64	-54	10
66	-50	4
54	0	2
-28	-2	66
32	4	62
6	20	50
58	12	16
58	12	16
-34	16	4
-40	-4	10
38	18	0
-42	-18	62
-38	-8	64
44	-8	34
-32	-14	70
-46	-36	54
-42	-38	48
46	-34	48
-24	-64	60
24	-64	60
-46	-74	-10
44	-82	-6
2	-94	-2
-20	-30	4
-12	-22	8
22	-30	0
14	-12	10
22	0	12
-30	-84	-22
24	-72	-18
-4	60	12
-2	34	0
-2	-44	40
4	-22	42
-48	-72	42
50	-68	42
-60	-18	-16
52	-14	-24
-24	-18	-22
26	-16	-26
-6	6	52
8	18	46
-24	-2	20
26	2	58
-50	4	34
48	8	30
-32	22	-2
34	22	2
-24	-58	56
26	-58	50
-46	-32	40
40	-36	46
-38	-88	10
34	-84	20
-44	-74	-8
52	-62	-10
14	-92	-6
-10	8	2
10	10	0
-10	8	2
-12	-20	10
8	-14	10
8	-26	6
-10	46	50
-16	56	34
20	48	42
-40	16	48
-50	30	-6
-52	-60	48
-52	-58	36
56	-60	42
0	-90	24
-58	-44	-4
68	-40	-2
-22	-2	62
12	12	70
32	8	60
-48	4	44
54	12	20
50	38	14
40	14	16
-54	2	16
-28	20	-2
-54	-24	52
-22	-62	56
22	-66	54
28	-74	46
-44	-40	46
46	-44	56
8	-28	28
-48	-14	-4
-28	-18	-6
18	4	-8
10	8	10
-10	-24	12
12	-20	12

// Zurawska vel Grajewska B, 2011: Homogeneous > Mixed
// Zurawska vel Grajewska B, 2011: Interaction effect between block 
// homogeneity (homegenous > mixed) and compatibility ratio (70% > 30%)
// Zurawska vel Grajewska B, 2011: Incompatible > Compatible
// Subjects=18
-22	-42	-40
-4	-52	-44
46	-52	-42
4	-34	-12
-22	-14	-6
38	30	46
40	58	14
38	10	60
-32	46	16
-34	-26	-22
32	-24	-20
-10	38	16
8	38	8
10	40	28
48	42	-2
34	20	-22
-48	-48	36
58	-46	50
14	64	12
2	-18	38
-16	12	66
-50	-40	8
8	-88	2
18	50	40
18	38	16
8	-44	16
-38	24	10
-32	-14	70
-38	-2	62
-56	-18	16
22	-52	-30
-40	-34	44

// Chiong W, 2013: Healthy Controls
// Subjects=16
50	-60	26
0	-78	42
8	60	-4
-4	34	-14
56	-64	26
4	-58	24
-20	4	-12
34	-84	16
-22	-96	4
40	-2	62
36	-46	48
-34	-24	66
-32	-60	44
40	-58	46
-36	14	30
46	38	14
-26	-72	30
8	0	52
44	20	40
4	26	48
4	-42	38
18	-54	34

// Chiong W, 2013: Behavioral variant Frontotemporal Dementia (bvFTD)
// Subjects=10
4	-42	38
18	-54	34

// Alain C, 2010: 2-back > 1-back
// Alain C, 2010: Left hand response > Right hand response
// Alain C, 2010: Right hand response > Left hand response
// Subjects=28
0.38	19.28	51.19
-28.35	3.93	61.73
-43.58	7.61	28.14
-32.03	24.2	7.65
-41.2	-36.01	41.8
-40.15	-37.24	39.66
-28.96	-65.08	-46.23
5.7	20.2	48.82
38.93	6.1	56.31
38.51	23.65	8
67.42	-34.9	-8.61
37.89	-44.17	39.35
28.46	-64.26	55.64
-.69	-3.79	41.98
-39.17	24.41	52.33
-20.3	-46.23	-23.38
-20.51	-55.06	-54.97
-23.7	-29.64	-42.57
6.77	2.6	41.36
38.01	-17.71	65.01
47.57	-18.25	57.14
39.7	-6.92	11.67
19.36	-11.78	5.62
32.81	-49.12	72.16
5.88	-32.85	51.03
-37.92	-19.82	58.25
-40.05	-19.75	59.38

// Christensen A T, 2011: Main effects of voice task
// Christensen A T, 2011: Main effects of semantic task
// Christensen A T, 2011: Voice: Incongruent > Neutral words
// Christensen A T, 2011: Semantic: Incongruent > Neutral words
// Christensen A T, 2011: Voice: Congruent > Neutral words
// Christensen A T, 2011: Semantic: Congruent > Neutral words
// Subjects=26
48.25	28.34	26.46
-39.09	4.41	55.12
-34.59	-60.24	58.26
-37.9	-58.03	45.84
-35.26	19.53	2.51
30.97	20.81	-.59
4.14	39.25	-7.41
-57.53	-18.33	10.4
4.54	35.71	43.07
-51.78	-48.17	50.75
49.18	24.69	6.68
-36.32	22.95	5.58
-1.33	58.8	-15.67
-52.21	-13.1	8.78
66.41	-14.5	7.54
-37.47	13.28	-9.21
9.51	34.08	-5.92
23.47	15.05	-5.6
-49.18	23.59	1.21
42.68	34.71	-.78
-42.81	12.19	-9.06
-4.49	53.75	-11.87
12.82	15.41	0.07
18.32	26.93	24.69
5.49	52.03	33.88

// Goldin P, 2013: Mindfulness-based stress reduction (MBSR)
// Subjects=23
23.38	49.31	-2.9
27.45	-70.27	60.62
57.29	-55.55	55.69
63.6	-37.87	49.68
-21.11	-71.04	-.1
1.15	-38.73	-10.87
-9.16	-5.19	52.23
-54.02	-34.95	42.98
-28.39	-69.03	26.58

// Goldin P, 2013: Aerobic exercise (AE)
// Subjects=19
23.38	49.31	-2.9
27.45	-70.27	60.62
57.29	-55.55	55.69
63.6	-37.87	49.68
-21.11	-71.04	-.1
1.15	-38.73	-10.87

// Holzel B K, 2013: Generalized Anxiety Disorder (GAD), Mindfulness based 
// stress reduction (MBSR)
// Subjects=15
34	-45	-19
9	-49	45
-43	-75	-10

// Holzel B K, 2013: Generalized Anxiety Disorder (GAD), Stress management 
// education (SME)
// Subjects=11
55	-31	2
-57	-46	-2
-36	10	24
-50	19	12

// Holzel B K, 2013: Healthy Controls
// Subjects=26
-17	-17	-99
-38	-38	-68
14	14	-93
-40	-40	-75

// Hayashi A, 2014: Concrete > Control
// Hayashi A, 2014: Abstract > Control
// Hayashi A, 2014: Concrete > Abstract
// Hayashi A, 2014: Abstract > Concrete
// Subjects=16
-6	4	60
14	4	68
-40	36	10
56	22	22
-28	28	-6
36	32	0
-20	6	4
30	6	0
-40	-6	50
-36	-8	66
-22	-56	44
-50	-88	-14
-24	16	-8
-4	16	52
-46	20	24
56	28	20
-44	-2	48
-46	42	-12
-30	-60	48
-48	-54	-14
-26	-86	-2
38	-82	-4
-38	42	36
-24	38	50
26	4	68
-6	-64	60
-24	-34	-22
-50	-64	12
-12	-38	-16
-52	22	6
-46	-40	28

// Zhang J, 2013: PTSD > Control: Negative > Neutral
// Zhang J, 2013: PTSD < Control: Negative > Neutral
// Subjects=20
-36	-61	-11
34	-64	-10
-1	-45	5
-18	-1	-14
-20	-63	64
-28	6	-27
41	11	-28
-52	-54	31
-36	18	30
-31	37	12
41	34	3
44	2	13

// Zoccatelli G, 2010: Stroop color-word > Fixation
// Zoccatelli G, 2010: Stroop arrow-position > Fixation
// Zoccatelli G, 2010: Stroop > Fixation
// Subjects=10
1.26	8.6	23.08
6.73	16.52	42.42
46.48	-46.95	43.94
-33.69	-60.89	36
49.34	18.66	25.03
-43.57	8.84	30.26
36.2	48.25	-4.07
-27.86	54.98	6.14
39.44	25.55	-8.89
-31.04	19.04	-4.19
-59.81	-36.35	-15.95
42.8	-71.66	-27.55
-21.41	-53.26	-31.7
7.35	54.68	-.93
-4.91	7.7	53.33
11.03	-45.79	20.83
-36.83	-56.97	45.74
-34.01	24.76	28.82
26.68	22.81	-1.83
-27.85	15.63	-7.29
52.55	-37.31	2.92
-24.07	-80.64	27.51
-5.03	-85.75	0.95
-43.54	-66.69	3.14
-53.04	-29.28	33.57
26.72	-78.87	-36.79
-43.59	15.19	29.73
7.84	13.61	46
-33.66	-60.63	39.32
10.59	45.18	-.17
33.1	-75.91	-40.46

// Georgiou-Karistianis N, 2012: Friedreich Ataxia (FRDA)
// Subjects=13
35	2	53
-36	-3	52
7	6	55
-8	4	54
45	-6	55
-53	2	42
40	-19	54
-41	-15	52
53	-18	53
-45	-28	47
34	18	7
-32	17	7
63	-29	26
-52	-47	14
48	-76	1
-23	-95	3
-10	-19	8
-16	0	18
23	7	-6
-27	2	-5
17	-49	-21
-19	-49	-19
31	-52	-23
-28	-64	-22
32	-53	-49
-30	-55	-47
-38	-70	-24
9	-75	-36
-5	-77	-34
0	-75	-20
4	23	49
-4	16	50
49	9	40
-26	-1	52
7	6	52
-3	0	58
44	-9	60
-40	-14	56
36	-20	51
-32	-21	55
43	-30	52
-47	-35	58
34	23	1
-33	19	3
24	-68	57
-13	-68	62
46	-35	54
-50	-37	52
49	-68	-3
-43	-80	-1
10	-16	10
-10	-16	11
22	10	5
-24	6	5
28	-60	-22
-24	-66	-21
32	-55	-50
-30	-54	-50
-44	-64	-25
8	-75	-38
-5	-79	-36
4	23	50
-5	20	47
49	10	40
-25	-1	53
33	27	-1
-32	24	-1
23	-67	57
-12	-68	63
36	-46	51
-50	-39	51
34	-78	31
-33	-78	37
29	-61	-23
46	29	32
-27	42	32
24	58	28
-19	54	23
-43	23	-9
49	-71	12
-44	-78	6
55	-54	12
-49	15	-15
62	-44	25
1	-26	46
-1	-35	34
-32	17	-7
15	-10	21
-15	-5	19
-12	-58	-16
-29	-64	-24

// Georgiou-Karistianis N, 2012: Controls
// Subjects=14
25	-1	60
-5	12	56
40	2	58
-32	-1	52
51	24	-5
-50	22	-3
8	5	54
-5	-1	62
52	6	40
-53	4	43
51	-5	41
-57	-17	36
56	-12	45
-58	-18	38
23	-64	63
-16	-69	59
64	-35	36
-52	-39	33
44	-77	-4
-44	-79	6
13	-10	11
-14	-12	12
18	1	21
-11	-1	18
28	5	-2
-27	7	-1
33	-55	-24
-32	-58	-27
32	-47	-49
-33	-63	-47
28	-79	-22
-42	-66	-26
7	-77	-35
-5	-78	-30
0	-68	-25
5	16	52
-3	16	52
-33	1	55
54	15	21
-53	7	22
4	5	59
-4	1	58
49	10	38
-50	1	44
53	-3	43
-56	-21	31
54	-13	44
-56	-22	42
0	33	25
0	-24	33
35	22	5
-32	25	6
39	2	49
-30	-57	56
39	-40	47
-41	-40	48
44	-78	-3
-48	-76	-3
7	-12	12
-8	-19	11
11	2	14
-12	6	11
24	11	-1
-23	9	1
7	-63	-13
-9	-59	-15
32	-57	-26
-32	-57	-27
29	-67	-46
-33	-65	-48
40	-69	-25
-37	-70	-24
8	-78	-37
-9	-76	-35
0	-68	-26
4	17	53
-2	16	51
48	10	40
-49	9	37
53	14	18
-51	7	22
0	-17	33
36	21	4
-34	25	4
14	-68	58
-15	-70	59
41	-53	52
-43	-42	48
44	-79	-3
-43	-79	6
5	-21	5
-6	-15	9
11	1	14
-11	7	11
3	-62	-15
-10	-59	-16
22	-65	-25
-26	-62	-25
40	-70	-25
-38	-69	-25
10	-79	-37
-8	-77	-37
46	29	32
-27	42	32
24	58	28
-19	54	23
-43	23	-9
49	-71	12
-44	-78	6
55	-54	12
-49	15	-15
62	-44	25
1	-26	46
-1	-35	34
-32	17	-7
15	-10	21
-15	-5	19
-12	-58	-16
-29	-64	-24

// Beaton E A, 2010: Turner Syndrome
// Subjects=11
9.27	-56.21	65.22
23.36	-12.38	-30.06
-14.51	-85.49	18.88
-31.85	-79.36	-10.43
-25.27	-60.01	19.1
33.94	39.29	-23.37
-23	-82.74	27.67
26.18	-77.88	31.16
8.81	-34.6	14.35
58.1	-4.41	42.47
10.72	-54.59	-24.15
-10.14	-91.13	28.23
45.29	-76.85	15.24
41.23	-65.84	47.82
42.75	-21.64	-13.9
-30.16	25.88	-25.96
64.1	4.55	-7.42
-14.57	-94.98	6.3
4.64	-90.64	5.71
-29.99	-22.94	-24.1
36.71	21.7	51.68
13.11	-58.52	7.38
59.92	23.15	13.38
-22.81	-63.26	59.49
-38.22	-59.17	3.56
-31.52	-3.41	63.49
-30.04	-19.05	-28.89
36.71	21.7	51.68
15.19	-43.7	6.11
14.88	51.98	4.78
55.97	-2.14	44.54
68.53	-15.72	5.38
4.64	-88.52	5.53
-49.03	20.73	19.29
-16.54	-22.86	58.26
25.5	-12.37	-30.09
-8.1	-34.93	39.1
-62.02	-5.18	-11.84
30.05	-7.32	7.35
32.59	-51.43	42.25
-51.44	6.89	-21.9
64.39	-18.77	21.3
-40.61	-59.64	-29.83
55.49	21.41	-8.73
-24.6	-9.19	-11.94
26.26	-26.5	62.53
29.68	37.15	-23.14
7.45	-21.23	-19.1
2.17	31.1	11.14
-10.28	-59.58	23.35
19.22	-41.85	-25.31
24.53	-8.09	-15.94
-14.39	-20.57	60.27
-51.17	20.72	19.32
-12.69	-14.09	6.18
30.05	-7.32	7.35
-8.1	-34.93	39.1
-31.43	-26.67	65.44
-29.92	-11.16	-9.48
-42.55	-35.59	6.1
21.94	-24.75	57.98
-59.88	-5.17	-11.87
23.72	-70.23	-7.37
-19.05	-68.54	-9.25
34.46	-71.77	-.68
2.21	-60.81	-21.3
-10.57	-51.57	-10.77
13.09	-58.69	5.16

// Beaton E A, 2010: Healthy Controls
// Subjects=13
-22.82	-61.14	59.31
-18.73	-3.67	58.91
26.14	-7.98	54.29
17.03	49.88	4.94
-40.35	30.95	40.64
-17.18	45.1	1.27
-55.72	6.86	-21.85
40.35	-4.68	-42.06
-46.88	20.91	21.48
2.01	68.99	5.74
19.63	-61.68	20.95
59.92	-3.25	2.21
-8.1	-34.93	39.1
57.98	-5.61	26.96
-38.39	-21.45	-4.06
-14.59	-59.94	18.97
-22.81	-63.26	59.49
-38.22	-59.17	3.56
-31.52	-3.41	63.49
-30.04	-19.05	-28.89
36.71	21.7	51.68
15.19	-43.7	6.11
14.88	51.98	4.78
55.97	-2.14	44.54
68.53	-15.72	5.38
4.64	-88.52	5.53
-49.03	20.73	19.29
-16.54	-22.86	58.26
25.5	-12.37	-30.09
-8.1	-34.93	39.1
-62.02	-5.18	-11.84
30.05	-7.32	7.35
32.59	-51.43	42.25
-51.44	6.89	-21.9
64.39	-18.77	21.3
-40.61	-59.64	-29.83
55.49	21.41	-8.73
-24.6	-9.19	-11.94
26.26	-26.5	62.53
29.68	37.15	-23.14
7.45	-21.23	-19.1
2.17	31.1	11.14
-10.28	-59.58	23.35
19.22	-41.85	-25.31
24.53	-8.09	-15.94
-14.39	-20.57	60.27
-51.17	20.72	19.32
-12.69	-14.09	6.18
30.05	-7.32	7.35
-8.1	-34.93	39.1
-31.43	-26.67	65.44
-29.92	-11.16	-9.48
-42.55	-35.59	6.1
21.94	-24.75	57.98
-59.88	-5.17	-11.87
23.72	-70.23	-7.37
-19.05	-68.54	-9.25
34.46	-71.77	-.68
2.21	-60.81	-21.3
-10.57	-51.57	-10.77
13.09	-58.69	5.16

// Chinier E, 2014: Motor Imagery > Baseline, Cerebral Palsy (CP) Patients
// Chinier E, 2014: Unaffected hand > Affected hand, CP Patients
// Chinier E, 2014: CP with Right lesions > CP with Left lesions, Motor 
// Imagery > Baseline
// Subjects=9
3	-87	3
-21	-66	0
18	-72	0
-12	-60	3
60	-15	6
54	0	0
51	-6	-6
66	-27	18
54	6	-3
45	-33	0
48	-24	-3
51	27	-6
45	36	-12
63	-42	36
57	-42	51
-63	-12	3
-60	-24	21
-51	21	-6
-63	-27	6
-57	-36	6
-51	9	6
-57	12	3
-45	-18	3
-48	-30	3
-48	-21	6
-39	24	3
0	6	60
-6	21	45
0	-6	63
-6	3	72
-12	9	66
15	-3	66
-21	15	66
-18	12	63
6	-6	54
24	-3	57
-12	-9	21
-21	12	21
-18	9	18
-15	15	12
18	-15	-12
30	15	6
18	12	3
21	9	6
48	6	9
57	-57	30
33	-54	66
57	-51	39
45	-42	63
57	-42	36
48	-54	54
42	-57	57
57	-42	51
57	-36	51
36	-30	60
42	-51	36
21	-9	6
-21	3	6
-21	-3	9
6	-9	6
-9	-3	12
-18	12	-6
-30	3	-3
-12	-15	12
0	15	54
-6	12	57
-6	24	42
-6	30	36
-3	-48	-18
6	-51	-18
15	-57	-21
24	-69	-24
-51	12	18
-39	12	15
-39	0	9
42	6	51
48	0	54

// Cservenka A, 2012: Family History of Alcoholism (FHA)
// Subjects=19
-6.74	-62.73	64.84
32.57	12.04	64.81
29.01	-55.31	-7.57
-.76	-50.69	13.57
13.47	-86.61	43.19
-1.21	61.14	0.86
41.42	63.46	-14.33
-.66	-10.05	43.62
41.56	61.65	3.67
-33.15	52.2	12.01
13.05	32.07	36.59
57.88	18.62	23.82

// Cservenka A, 2012: Healthy Controls (HC)
// Subjects=16
35.01	70.02	-11.46
-3.55	-52.94	67.32
16.69	-89.77	43.42
41.56	61.65	3.67
-33.15	52.2	12.01
13.05	32.07	36.59
57.88	18.62	23.82

// Dinomais M, 2013: Observation > Rest
// Dinomais M, 2013: Nonparetic observation > Paretic observation
// Dinomais M, 2013: Paretic observation > Nonparetic observation
// Subjects=19
48	-72	0
-45	-69	6
18	-78	-15
30	-69	-15
24	-78	-15
-27	-75	-15
42	-48	-18
42	-57	-15
-42	-66	-12
45	-63	-15
12	-87	6
-36	-18	60
-42	-36	55
42	-24	63
42	-24	57
57	-9	51
48	-21	27
57	-15	15
54	-15	21
18	-45	69
63	-15	21
57	-15	51
66	-9	30
57	-12	36
21	-66	-51
15	-69	-45
21	-60	-45
9	-75	-42
6	-6	69
-24	36	12
-33	33	0
45	-18	57
27	-21	72
-42	-18	60

// Enzi B, 2012: Healthy Controls (HC)
// Subjects=15
-9	12	-3
12	6	-9
-18	-24	9
12	-18	12
-33	21	9
33	24	6
-42	45	18
-18	-75	6
18	-72	6
-9	9	3
12	9	0
-9	-15	0
-27	27	3
33	24	6
-51	9	30
48	3	36
-12	-78	6
21	-78	12
18	12	-9
-9	18	-6

// Enzi B, 2012: Huntington's Disease gene carriers near to symptom onset 
// (Pre-HD near)
// Subjects=15
15	9	-3
-39	51	0
-33	24	3
-60	6	18
-42	-48	39
-3	-21	33
-33	33	6
-42	36	9
9	45	6
-57	6	21
48	9	27
18	12	-9
-9	18	-6
-45	30	12

// Enzi B, 2012: Huntington's Disease gene carriers far from symptom onset 
// (Pre-HD far)
// Subjects=15
18	12	-3
-18	3	-9
18	15	-3
-18	-18	9
9	-18	0
-30	27	9
42	12	6
-45	30	12

// Pringle A, 2011: Bulimia Nervosa
// Subjects=11
-32	-92	-12
16	0	14
0	0	53
-32	-92	-12
0	-2	54
36	-96	-6
38	-62	16
30	-10	-4
38	-46	62
18	-96	16
-6	-58	26
16	18	66
-14	-96	-2

// Pringle A, 2011: Healthy Controls
// Subjects=16
-26	-96	-4
-26	-98	4
38	-62	16
30	-10	-4
38	-46	62
18	-96	16
-6	-58	26
16	18	66
-14	-96	-2

// Van de Winckel A, 2013: Cerebral Palsy
// Subjects=17
56	-28	28
34	-28	46
-36	-26	66
-30	-20	70
4	-4	48
30	-16	60
46	0	6
-50	-2	2
14	-2	-6
-58	-22	10
58	-60	0
48	-60	-6
-46	-18	-20
-50	-74	-12
12	-50	-28
0	-64	-14
12	-56	-20
-26	-50	-36
58	-36	22
58	-42	44
44	-32	62
-44	-34	56
-42	-24	60
0	-24	46
8	-22	40
-60	30	38
46	4	12
-30	-12	4
18	2	-4
-24	6	-8
46	-46	6
-64	-30	16
60	-60	-4
64	-26	16
-66	-26	18
36	-48	46
56	-24	38
38	-38	56
-36	-30	50
-30	0	48
48	-4	4
-50	-4	0
-12	0	6
34	4	-22
-22	10	-20
38	-12	-16
-18	-26	2
34	8	-14
56	10	-4
-24	-76	-26
24	-60	66
-18	-36	52
34	-24	68
20	-14	62
-18	-18	54
-2	18	-8
24	-50	-2
-44	-54	6
48	-64	-8
-44	-20	-20
-40	-36	-12
20	-92	12
-18	-84	22
-22	-90	-2
-50	-76	12
-16	-94	-6
-50	-72	-10
0	-22	-14
-10	-44	-16
-24	-82	-36
-36	-24	64
40	-10	60
-30	-20	54
2	-4	50
30	-16	60
-10	-14	56
-40	-40	-12
-2	-62	-14
4	-50	-18
-46	-18	56
28	-20	70
30	-20	72
-38	-24	64
-6	-40	-52
-8	-8	56
30	-16	60
16	-56	-20
0	-66	-12

// Van de Winckel A, 2013: Healthy Controls
// Subjects=19
60	-30	22
-44	-18	54
-38	-24	66
-4	-2	50
40	8	2
-48	2	2
18	-2	-2
-32	-4	-4
-60	-20	10
12	-54	-18
24	-52	-28
-32	-52	-34
16	-62	-46
50	-24	20
56	-36	22
-32	-32	64
-26	-40	58
-42	-18	50
-8	-4	54
-30	-14	58
-14	-20	42
-46	2	0
-50	-28	14
26	-46	-28
16	-66	-44
58	-28	22
-60	-24	14
-34	-34	68
-52	-26	26
-40	-26	52
64	-26	14
-44	-26	20
-52	-4	0
24	-50	-30
24	-60	66
-18	-36	52
34	-24	68
20	-14	62
-18	-18	54
-2	18	-8
24	-50	-2
-44	-54	6
48	-64	-8
-44	-20	-20
-40	-36	-12
20	-92	12
-18	-84	22
-22	-90	-2
-50	-76	12
-16	-94	-6
-50	-72	-10
0	-22	-14
-10	-44	-16
-24	-82	-36
-40	-22	56
10	6	48
10	16	36
-6	18	36
40	8	2
56	8	-8
8	-56	-14
20	-54	-26
2	-64	-18
-24	-56	-26
56	-40	44
-34	-20	44
-44	-16	56
2	0	60
36	-6	50
8	6	44
-8	12	38
50	6	2
-60	4	8
16	-8	16
-16	-2	12
18	-2	-2
-18	-14	-4
-32	-4	-6
6	-58	-12
2	-66	-18
-24	-56	-26
-36	-54	-34

// Van de Winckel A, 2013: Healthy Controls
// Subjects=18
-20	-62	54
-60	-18	42
-52	8	28
-6	2	48
46	6	22
-54	8	16
40	0	0
-40	-2	2
16	-26	10
-10	-20	6
10	-20	0
-54	-58	0
-54	-62	-18
6	-56	-12
-20	-72	-26
-18	-74	-46
12	-74	-42
12	-54	-52
-40	-62	-34
-58	10	12
-18	2	62
-6	2	46
-36	2	52
32	-52	-34
12	-54	-52
-16	-20	52

// Van de Winckel A, 2013: Cerebral Palsy
// Subjects=16
14	-58	56
-20	-62	54
56	-28	44
-62	-28	40
-48	-34	54
-38	-34	44
-52	2	34
28	-8	60
48	8	18
-42	-10	0
-50	-26	14
-58	-28	16
48	-64	2
-50	-56	0
52	-60	-10
-18	-68	-30
-18	-74	-44
10	-70	-46
16	-64	-46
-34	-68	-32
-58	10	12
-18	2	62
-6	2	46
-36	2	52
32	-52	-34
12	-54	-52
-16	-20	52

// Acheson A, 2014: Family History of Substance Use Disorders (FH+) > Healthy 
// Controls (FH-): Go > Baseline
// Acheson A, 2014: FH+ > FH-: NoGo > Baseline
// Subjects=32
-4	-40	48
14	-42	46
18	-48	34
18	20	-6
42	26	-12
36	30	-6
56	-28	2
68	-24	-2
64	-10	-16
-20	20	52
-14	40	44
-24	40	42
-2	-60	48
-2	-70	50
-8	-76	42
-56	-44	14
-50	-42	6
-64	-50	10
-16	8	-12
-20	16	-12
-26	26	6
-4	-40	48
14	-44	46
26	-38	48
68	-24	-2
58	-28	4
64	-10	-16
-20	20	52
-10	34	52
-10	38	44
-54	-44	14
-62	-48	10
-56	-42	4
-4	48	0
-8	40	-4
-14	20	-12

// Barnett A J, 2014: Experiment 1 Normals
// Subjects=22
-34	-66	72
18	-42	0
-10	-38	72
4	-28	56
-4	-20	64
18	-46	64
-44	-46	48
0	8	64
24	-60	62
-52	-60	60
-12	18	56
30	-2	30
36	4	50
-48	-48	12
64	-28	44
-56	-54	42
44	-52	40
8	-38	34
10	-50	14
-4	-10	40
36	36	34
-16	68	14
26	-90	28
36	10	24
-16	68	14
26	-30	22
36	48	18
-10	50	18
-38	36	22
38	-30	18
-14	48	18
14	50	12
-36	12	12
38	14	16
-62	-38	12
44	8	10
0	-14	8
-12	-78	8
26	-64	2
-40	-18	6
-52	-24	4
58	-8	2
42	-58	4
-22	8	-38
50	38	-10
-6	-38	-60
0	8	64
0	-14	8
18	-22	74
-16	-22	42
12	2	72
-4	26	58
10	-44	72
-14	-38	68
4	4	66
26	-46	64
34	8	62
-36	22	42
10	-60	52
54	-64	38
-36	-64	12
52	14	32
0	4	32
-42	-80	32
2	-20	28
-64	-56	26
-16	-8	22
14	-2	20
20	-98	22
-14	-14	16
14	-18	16
46	-32	16
32	-26	14
-36	-16	12
-42	-14	12
-54	-24	12
-26	56	10
22	62	8
-54	-20	10
70	-24	10
-66	-28	6
0	22	-2
30	-36	-4
-14	-34	-4
-6	-72	-4
12	-86	-6
-20	-2	-42
22	-32	-34
0	4	32
0	22	-2
-2	42	-18
-30	2	38
-38	-4	64
-58	14	24
-34	12	14
-54	40	4
44	20	36
44	14	26
42	14	10
48	38	8
38	-84	36
62	-48	44
-8	-78	-44
-12	22	40
-26	-94	-8

// Barnett A J, 2014: Experiment 2 Normals
// Subjects=20
-4	-24	78
-10	-10	74
-2	-12	70
-6	-56	70
-18	46	48
0	-26	46
-6	8	40
6	-86	34
28	32	28
16	-86	22
-8	-96	22
-12	-50	-2
2	28	-4
2	54	-14
-24	-10	-14
-24	-20	-14
-26	-4	-24
58	-8	-40
60	-34	48
56	0	40
66	-50	24
50	-16	18
36	-4	12
56	-32	10
56	-72	8
66	-56	2
58	-10	0
24	-40	0
26	8	-20
50	8	-20
40	-2	-20
32	2	-22
16	2	-26
-44	-18	-8
-62	-36	36
-44	-80	36
-36	-60	26
-46	-42	20
-62	-30	18
-58	-20	16
-58	-38	12
-66	-54	-4
-42	-2	-10
-54	-16	-24
36	-80	-32
22	-72	-6
-14	-78	-10
-46	-12	-44
-44	20	-34
-28	40	-16
0	-26	46
-40	20	16
-26	-64	30
-50	2	52
-2	30	-2
-28	-40	-6
32	-42	-2
32	14	-30
40	12	56
48	12	20
32	42	-4
38	38	-8
12	36	16
-32	16	-14
12	-6	4
22	14	38
22	-78	2
20	70	-2
14	46	-6
6	44	8
58	-40	38
4	28	-2
0	16	-20
0	16	-20
54	20	-6
22	28	-14
36	16	-32
34	8	60
-4	6	58
-4	22	54
4	16	54
8	20	44
-4	12	44
38	44	32
-8	12	32
46	6	30
54	16	14
36	22	6
44	16	-8
46	22	-10
-36	-96	-6
-24	36	-12
62	-42	-14
28	52	0
32	-52	36
66	-16	-20

// Cservenka A, 2014: Family History Positive (FHP)
// Subjects=19
-61.74	-25.42	15.5
-58.88	8.41	-15.25
22.62	58.02	40.99
31.82	73.51	-7.25
3.31	4.32	8.91
22.62	58.02	40.99
-49.16	45.76	12.73
22.3	-22.25	-33.68
-39.32	41.53	39.74
55.05	-67.59	37.77
3.5	35.96	46.41
-7.13	-99.68	-0.09
-7.81	55.79	-26.5
-55.06	-15.95	54.78
6.99	1.57	69.32
42.23	1.52	65.58
3.31	-16.54	0.63
29.03	-98	-22.95
-13.55	36.37	53.26
-.26	-25.74	88.43
31.82	73.51	-7.25
54.4	22.29	-11.02
-36.54	66.76	-5.9
55.1	-40.67	55.59
-49.34	24.07	-20.02
31.82	73.51	-7.25
31.83	34.08	-21.79
58.33	-53.6	53.29
3.32	0.09	9.27

// Cservenka A, 2014: Family History Negative (FHN)
// Subjects=17
-61.74	-25.42	15.5
-58.88	8.41	-15.25
22.62	58.02	40.99
31.82	73.51	-7.25
3.31	4.32	8.91
22.62	58.02	40.99
-49.16	45.76	12.73
22.3	-22.25	-33.68
-39.32	41.53	39.74
55.05	-67.59	37.77
3.5	35.96	46.41
54.26	-3.28	-38.99
-49.4	-17.11	-43.33
-16.91	57.78	41.46
38.12	6.43	-49.65
32.52	-91.73	16.63
-42.5	-91.14	-10.43
-42.18	-8.76	64.06
-32.46	-37.25	66.34
-11.03	52.34	-29.52
-.91	31.22	26.78
19.74	-104.49	17.85
7.2	-68.74	68.53

// Dager A D, 2013: Heavy Drinkers > Light Drinkers, Alcohol > Non-alcohol
// Dager A D, 2013: No Family History of Alcoholism (FHN) > Family History of 
// Alcoholism (FHP), Alcohol > Non-alcohol
// Dager A D, 2013: Heavy Drinkers > Light Drinkers, Alcohol (second image) > 
// Alcohol (first image)
// Dager A D, 2013: FHP > FHN, Alcohol (second image) > Alcohol (first image)
// Subjects=10
30	-78	12
-9	-45	9
-15	-21	42
3	54	0
-15	9	18
15	-12	3
-21	-27	-6
42	-9	48
33	27	-21
42	-3	-27
-36	-36	-21
-15	-42	-15
9	15	60
45	12	42
57	18	9
48	15	12
60	-45	36
66	-39	-6
51	-63	-21
15	15	12
-48	-78	-12
-48	-18	-15
-30	-57	-6
36	-39	-21
30	-15	-15
-45	-15	-12
51	-3	-12
39	-42	42
-9	-48	-18
39	-18	33

// Kalpakidou A K, 2014: Verbal fluency task: Hard > Easy, Very Preterm (VPT) 
// > Normals
// Kalpakidou A K, 2014: N-back task: 3-back > 1-back, Periventricular 
// haemorrhage and ventricular dilatation (PVH+VD) < Uncomplicated 
// periventricular haemorrhage (UPVH)
// Subjects=12
23.78	-28.96	17.05
-41.47	7.37	24.79

// Marvel C L, 2010: Encoding > Baseline (positive activations)
// Marvel C L, 2010: Encoding > Baseline (negative activations)
// Marvel C L, 2010: Maintenance > Baseline (positive activations)
// Marvel C L, 2010: Maintenance > Baseline (negative activations)
// Marvel C L, 2010: Retrieval > Baseline (positive activations)
// Marvel C L, 2010: Retrieval > Baseline (negative activations)
// Marvel C L, 2010: Positive Correlation between Accuracy and Maintenance > 
// Baseline
// Subjects=16
47	43	6
-7	43	32
13	35	47
47	26	-12
-29	16	-7
17	2	39
-41	0	-32
-53	-4	-8
-40	-7	23
53	-15	2
-9	-22	36
34	-23	8
-27	-24	-15
-42	-29	53
-48	-31	19
43	-32	20
-20	-33	40
58	-34	40
-24	-42	52
12	-56	-36
-53	-60	23
16	34	-21
-7	13	5
-51	8	2
-2	-5	61
-5	-21	9
-7	-37	2
45	-58	-17
40	-64	-36
-46	-70	-52
4	-72	48
-10	-74	-20
-9	-88	1
6	68	16
-9	62	30
5	57	3
-24	27	57
-21	20	-27
-18	5	8
19	4	3
60	-6	-10
56	-8	10
45	-10	46
-42	-16	40
20	-17	-13
-21	-20	-21
0	-41	38
-58	-54	-16
16	-55	66
-57	-59	-4
-11	-61	18
-50	-70	26
32	-79	8
-27	-84	16
-40	21	40
-29	20	-3
31	19	-1
4	18	53
62	11	24
-50	10	37
-53	7	17
-5	0	24
-36	-9	19
-31	-15	62
-52	-26	39
-28	-32	64
12	-56	-14
-6	-64	-40
14	-70	-46
31	24	7
-29	22	11
-40	19	23
-5	5	53
12	-57	-40
17	38	41
8	34	56
42	29	11
23	6	0
-46	-12	35
20	-15	-17
-62	-41	1
43	-50	29
-52	-53	33
43	-63	31
-42	9	35
31	22	7
-29	22	11
6	11	45
14	-58	-42

// de Greck M, 2013: Somatoform Disorder
// Subjects=15
-25.93	42.99	-25.22
24.35	27.43	-24.49
-26.62	-10.2	2.67
-55.82	-2.97	-38.86

// de Greck M, 2013: Subgroup of Somatoform Disorder, Unmedicated
// Subjects=10
-25.93	42.99	-25.22
-24.85	40.97	-23.95
24.35	27.43	-24.49
26.49	28.59	-23.5
-26.62	-10.2	2.67
-28.77	-11.44	0.57
-55.82	-2.97	-38.86
-51.57	-8.66	-44.01

// de Greck M, 2011: Somatoform Disorder
// Subjects=20
-46.71	30.37	47.45
7.81	17.75	44.54
7.19	73.91	-13.69
17	23.21	-9.56
-43.55	29.87	40.77
14.25	4.84	42.2
4.52	26.73	37.13

// de Greck M, 2011: Subgroup of Somatoform Disorder, Unmedicated
// Subjects=20
-46.73	30.11	44.13
7.81	17.75	44.54
7.19	73.91	-13.69
17	23.21	-9.56

// de Greck M, 2011: Subgroup of Somatoform Disorder, Second Scan
// Subjects=15
-43.55	29.87	40.77
14.25	4.84	42.2
4.52	26.73	37.13

// de Greck M, 2011: Normals
// Subjects=20
-11.83	-3.11	-17.05
17.03	0.49	-14.34
7.81	17.75	44.54
-4.98	17.93	48.02
14.23	30.99	50.05
-53.17	10.01	32.5
-46.71	30.37	47.45
-14.57	44.54	62.62
62.03	-1.38	-1.32
-14.98	23.79	0.8
10.63	26.86	-3.1
-5.53	32.08	-16.73
-46.71	30.37	47.45
7.81	17.75	44.54
7.19	73.91	-13.69
17	23.21	-9.56
-46.73	30.11	44.13
7.81	17.75	44.54
7.19	73.91	-13.69
17	23.21	-9.56

// Hardee J E, 2014: Family History of Alcohol Use Disorder (FH+)
// Subjects=43
44	16	-2
-40	18	-6
56	-46	26
-62	-54	32
10	-68	38
58	-26	-8
46	2	-40
-30	42	24
44	16	-2
-34	22	6
56	-44	24
-28	10	-4
-64	52	22
-70	-28	-6

// Hardee J E, 2014: No Family History of Alcohol Use Disorder (FH-)
// Subjects=30
44	16	-2
-40	18	-6
56	-46	26
-62	-54	32
10	-68	38
58	-26	-8
46	2	-40
50	22	0
-26	44	22
-40	18	-6
46	-54	36
-60	-54	30
10	-68	38
-48	-54	36
-10	8	8
-16	2	-4
64	-34	-2
46	0	-40
-58	-28	-6
32	2	-36

// Lythe K E, 2012: Rested wakefulness: N-back > Control
// Lythe K E, 2012: Rested wakefulness: 1-back < 2-back < 3-back
// Lythe K E, 2012: Rested wakefulness: 1-back > 2-back > 3-back
// Lythe K E, 2012: Sleep deprivation: N-back > Control
// Lythe K E, 2012: Sleep deprivation: 1-back < 2-back < 3-back
// Lythe K E, 2012: Sleep deprivation: 1-back > 2-back > 3-back
// Lythe K E, 2012: Rested wakefulness > Sleep deprivation: N-back > Control
// Lythe K E, 2012: Rested wakefulness: Sustained Attention > Control
// Lythe K E, 2012: Rested wakefulness: Divided Attention > Control
// Subjects=20
42	30	36
32	2	62
-30	-2	44
32	-56	38
-28	-58	44
30	2	58
36	-50	42
-2	56	6
4	-10	42
-8	-52	16
-52	-26	14
46	4	-36
26	-42	-20
-24	-34	-18
48	-18	20
-40	-20	60
-50	14	28
34	6	52
-22	0	60
46	-44	42
-30	-46	40
46	30	34
-20	0	50
42	-42	46
-30	-48	40
-4	42	50
-1	-22	38
-8	-54	24
36	-28	12
-66	-34	0
30	-18	-26
-38	-36	68
24	-92	24
40	46	-8
54	-50	42
46	-16	-2
-58	-26	6
44	6	34
0	6	54
56	-10	2
-60	-12	6
-28	-88	-6

// Nakai T, 2014: Linear-Match
// Nakai T, 2014: Quad - Simple, masked with Linear - Match
// Nakai T, 2014: Simple-Match
// Nakai T, 2014: Linear-Simple
// Subjects=20
-27	5	55
33	5	58
-45	11	25
-51	32	22
-30	26	1
-6	20	46
-45	-40	43
-33	-52	40
48	-31	46
36	-55	43
-6	-70	46
-51	-55	-11
-24	5	55
30	5	58
-45	5	37
-45	11	25
-30	23	1
-6	20	43
0	11	55
-48	-37	43
-33	-49	40
-27	-70	43
45	-31	43
39	-52	43
33	-61	34
-12	-61	52
9	-70	49
-45	11	25
-48	-37	46
-30	-70	46
39	-55	43
-3	-70	43

// Neuner I, 2010: Tourette's Syndrome
// Subjects=19
-36	2	54
-34	-18	52
-48	-28	54
-40	-34	50
56	-18	34
16	44	28
12	32	42
12	32	42
-28	-2	54
-28	-2	54
-40	46	-6
62	18	2
50	12	16
-38	6	22
-52	10	20
62	18	2
50	12	16
-38	6	22
-52	10	20
46	38	26
46	38	14
38	24	14
-40	34	14
6	8	48
-2	18	46
60	-20	26
-8	-68	46
-26	-98	10
36	-58	-20
-38	-56	-20
4	-34	24
24	-32	-6
-40	-2	6
28	-6	-16
-28	-6	-10
16	-22	22
-24	-12	10
-16	2	10
14	-28	4
54	-18	36
-52	-26	54
-52	-10	52
-42	-32	48
26	2	44
16	42	30
48	32	32
48	48	6
38	12	44
-38	48	-8
50	12	32
50	12	32
54	40	10
-4	22	44
-28	-64	46
50	-40	48
38	-58	52
-24	-100	10
36	-58	-20
-38	-58	-20
26	-30	-6
-30	-8	-12
-18	-36	4
-30	0	-24
30	0	-24
-28	-16	8
-58	12	34
56	-16	36
-50	-22	54
-34	-34	50
4	64	24
-4	26	38
-4	26	38
4	64	24
30	32	-16
-28	28	-16
-42	50	-6
-2	56	-14
-42	50	-6
54	14	16
48	12	32
-52	10	18
30	32	16
54	14	16
48	12	32
-52	10	18
-28	28	16
52	40	8
-54	24	28
-38	32	14
-46	46	12
-48	36	14
0	6	50
48	20	-22
52	-10	-12
-60	40	-10
48	-40	48
40	-44	44
-46	-44	40
-36	-48	50
30	-56	46
12	-68	40
6	-74	44
-8	-68	46
44	-80	-10
34	-58	-18
-38	-58	-20
26	-26	8
20	-28	-14
20	-40	-8
24	-4	-14
-26	-12	10
24	6	4
-30	-4	-10
-16	6	8
20	-26	2
-12	-16	2
-32	-18	52
-48	-28	54
56	-16	36
50	-24	48
30	64	18
16	42	30
18	30	34
-14	16	38
-2	26	40
46	36	30
-40	48	-6
50	12	34
-52	12	18
64	18	12
50	12	34
-52	12	18
42	34	-14
-26	28	-14
44	36	16
38	24	14
-54	24	28
10	6	48
-22	-64	52
48	-38	50
32	-58	50
-24	-82	-14
34	-56	-18
-38	-56	20
26	-30	-4
-20	-30	-2
-38	2	18
26	-4	-14
-28	-8	-12
-24	-16	0
12	-34	2
52	-26	48
58	-16	38
-34	-24	52
-48	-22	54
-6	20	42
-36	6	20
28	32	-16
54	40	8
-44	34	14
-2	0	52
50	-42	48
-34	-48	50
32	-52	46
28	-66	48
14	-34	2
-42	-80	-10
40	-50	-24
-38	-58	-20
24	-32	-6
38	2	8
26	-6	-14
-24	-14	10
6	-24	6
-34	-18	54
-50	-28	54
-38	46	-8
-50	10	20
-36	6	22
26	32	-14
-44	36	14
-58	-20	38
38	-88	0
-40	-82	-10
-38	58	-20
28	-32	-4
-28	-10	-10
-20	-36	2
-28	26	-8
26	-6	-14
-30	4	-2
-30	-14	8
-16	-22	12
-36	0	54
24	18	42
16	42	28
32	62	18
-2	66	24
28	34	42
28	54	28
-36	6	20
48	14	0
36	24	12
-64	48	16
56	-28	-12
60	-52	10
54	-14	-18
-46	-58	0
-36	-58	14
-38	-46	50
50	-44	54
-34	-38	48
36	-52	20
38	-56	32
54	-46	32
58	-40	26
66	-46	24
-62	-56	30
0	-72	48
-12	-100	16
-38	-76	32
14	-90	4
-6	-80	4
-44	-58	-20
-14	-60	28
14	-100	10
-6	-92	14
2	38	12
2	-34	50
0	-34	26
4	-48	10
24	-30	-4
-2	-4	-12
32	-4	-18
38	-12	38
-54	-8	50
28	18	42
26	2	42
-16	18	38
-12	32	40
-22	32	-14
-24	20	38
46	32	34
48	14	14
-52	16	14
-36	34	12
52	-22	-10
-58	-36	52
-34	-74	52
-48	-70	42
0	-66	38
-42	-62	6
-36	-68	6
-30	-76	6
16	-88	6
26	-30	-8
22	-2	-14
38	-10	40
54	-16	34
62	-6	40
-40	-32	16
-44	-16	18
60	-6	14
0	64	26
-12	64	30
-6	30	32
-20	32	-14
16	34	-14
-2	58	-14
10	46	-10
30	20	40
24	12	42
-36	6	20
-58	22	26
-34	32	-14
56	2	-16
-46	58	2
-54	-32	6
0	-70	40
14	-88	4
-6	28	-8
-6	46	12
24	-4	-14
28	-8	-12
-36	4	20
-28	-36	50
-18	18	40
26	28	14
20	10	42
-48	12	16
36	24	12
50	-38	-12
54	-22	-10
-44	-62	2
-52	-58	10
-38	-48	52
58	-34	26
-8	-68	48
2	-72	48
0	-66	38
-12	-100	18
-28	-76	8
16	-88	6
-4	-94	14
-2	-42	32
-22	-32	-42
6	-28	-6
-22	26	14
24	-6	-16
-18	2	-14
-24	-16	-2
-28	-40	48
22	14	44
-34	8	18
-40	32	14
-36	-62	12
-6	66	46
2	-74	50
-10	-86	40
-30	-66	20
0	-34	48
24	-30	-6
28	-8	-14
-26	-40	50
6	46	-10
-34	6	20
62	-44	2
2	-74	48
-40	-66	2
-32	66	-4
-28	-12	-10
-14	4	-14

// Neuner I, 2010: Healthy Controls
// Subjects=19
-36	0	54
24	18	42
16	42	28
32	62	18
-2	66	24
28	34	42
28	54	28
-36	6	20
48	14	0
36	24	12
-64	48	16
56	-28	-12
60	-52	10
54	-14	-18
-46	-58	0
-36	-58	14
-38	-46	50
50	-44	54
-34	-38	48
36	-52	20
38	-56	32
54	-46	32
58	-40	26
66	-46	24
-62	-56	30
0	-72	48
-12	-100	16
-38	-76	32
14	-90	4
-6	-80	4
-44	-58	-20
-14	-60	28
14	-100	10
-6	-92	14
2	38	12
2	-34	50
0	-34	26
4	-48	10
24	-30	-4
-2	-4	-12
32	-4	-18
38	-12	38
-54	-8	50
28	18	42
26	2	42
-16	18	38
-12	32	40
-22	32	-14
-24	20	38
46	32	34
48	14	14
-52	16	14
-36	34	12
52	-22	-10
-58	-36	52
-34	-74	52
-48	-70	42
0	-66	38
-42	-62	6
-36	-68	6
-30	-76	6
16	-88	6
26	-30	-8
22	-2	-14
38	-10	40
54	-16	34
62	-6	40
-40	-32	16
-44	-16	18
60	-6	14
0	64	26
-12	64	30
-6	30	32
-20	32	-14
16	34	-14
-2	58	-14
10	46	-10
30	20	40
24	12	42
-36	6	20
-58	22	26
-34	32	-14
56	2	-16
-46	58	2
-54	-32	6
0	-70	40
14	-88	4
-6	28	-8
-6	46	12
24	-4	-14
28	-8	-12
-36	4	20
-28	-36	50
-18	18	40
26	28	14
20	10	42
-48	12	16
36	24	12
50	-38	-12
54	-22	-10
-44	-62	2
-52	-58	10
-38	-48	52
58	-34	26
-8	-68	48
2	-72	48
0	-66	38
-12	-100	18
-28	-76	8
16	-88	6
-4	-94	14
-2	-42	32
-22	-32	-42
6	-28	-6
-22	26	14
24	-6	-16
-18	2	-14
-24	-16	-2
-28	-40	48
22	14	44
-34	8	18
-40	32	14
-36	-62	12
-6	66	46
2	-74	50
-10	-86	40
-30	-66	20
0	-34	48
24	-30	-6
28	-8	-14
-26	-40	50
6	46	-10
-34	6	20
62	-44	2
2	-74	48
-40	-66	2
-32	66	-4
-28	-12	-10
-14	4	-14

// Hong D S, 2014: Turner Syndrome
// Subjects=14
-31	-4	-28
-34	19	-31
-36	1	-33
34	-10	-26
42	-41	-13
28	-8	-10
33	-7	-17
43	12	-31
0	-44	24
-1	-40	10
46	-80	3
45	-71	15
40	-66	25
40	-7	-30
27	-4	-15
45	10	-26
-37	-11	-26
42	-41	-13
45	-30	-20
56	17	17

// Hong D S, 2014: Healthy Controls
// Subjects=16
21	-12	-12
10	11	8
46	-63	25
46	-33	9
46	-41	17
52	25	6
45	18	38
-56	21	7
-39	22	9
40	-46	-14
-37	18	31
-37	6	40
34	-3	-26
25	-6	-11
36	-5	-34
53	-63	17
46	-66	17
40	-86	1
7	28	29
0	27	51
7	22	54
-46	-82	-1
-46	-75	7

// Kim S, 2013: Fragile X Premutation
// Subjects=24
44	-46	48
36	-44	40
30	-70	40
24	-62	46
36	-56	48
46	4	24
54	12	22
40	14	8
56	14	36
36	18	-6
4	26	38
-2	22	44
4	18	50
-2	12	48
10	30	24
26	4	50
20	8	54
12	22	28
-40	14	2
-42	-40	40
-42	-46	42
-34	-46	50
-20	-70	8
-8	-80	14
18	-62	6
14	-68	4
-52	0	36
-50	6	34
-48	8	40
-54	-8	42
52	-38	46
54	-34	46
38	-50	46
42	-56	50
58	-40	30
34	-62	42
-44	-42	46
-44	-56	54
-28	-62	46
-40	-50	46
-36	-62	50
-28	-54	44
-36	-50	36
-22	-58	40
-32	0	44
-28	-16	48
-30	-16	54
44	24	-6
46	18	-12
32	10	-14
56	-54	42
8	-18	34
52	-44	28
52	-40	34
32	-62	58
58	-50	32
26	46	26
38	40	36
40	26	46
48	26	30
-36	-52	62
-50	-42	40
-46	-44	32

// Kim S, 2013: Healthy Controls
// Subjects=19
32	24	0
4	22	40
48	18	2
38	20	36
10	28	22
-38	16	2
-44	2	32
-52	16	16
46	-48	46
42	-54	54
34	-58	52
28	-58	46
28	-60	52
30	-62	38
58	-44	32
28	-66	46
-46	-42	48
-32	-60	50
-30	-52	48
-30	-58	58
-24	-66	42
-60	-48	38
10	-12	6
10	-26	6
20	-6	2
-10	6	-2
-18	-28	8
-34	-2	52
-42	28	28
-52	0	36
-50	6	34
-48	8	40
-54	-8	42
52	-38	46
54	-34	46
38	-50	46
42	-56	50
58	-40	30
34	-62	42
-44	-42	46
-44	-56	54
-28	-62	46
-40	-50	46
-36	-62	50
-28	-54	44
-36	-50	36
-22	-58	40

// Lee J A, 2010: Trichotillomania
// Subjects=9
-46.19	-67.53	6.24
45.57	-69.96	-1.8
-54.1	-7.76	-8.5
47.85	-67.95	8.05
-55.7	-22.22	32.18
-33.8	-39.62	51.46
-31.81	-27.79	40.17
30.28	-58.08	-11.68
-3.87	-48.5	23.81
-8.16	-29.7	29.87
-27.53	-74	27.86
-33.53	-9.61	-6.43
-39.93	-3.49	2.04
49.98	-68.15	5.79
56.41	-57.6	3.51
-46.17	-64.13	8.15
-41.66	-46.29	26.48
-54.1	-7.76	-8.5
-45.5	-5.92	-12.19
-26.47	-74.2	25.62
-33.5	-10.47	-4.1
20.37	-41.59	61.93
-24.17	-40.32	43.52
-5.92	-28.01	36.39

// Lee J A, 2010: Healthy Controls
// Subjects=10
45.54	-63.58	-2.43
28.5	-85.89	12.39
-22.13	-79.51	26.07
31.8	-79.94	18.47
-39.75	-72.18	2.11
-22.29	-86.18	12.16
-33.67	-46.34	59.96
-38.08	-41.56	53.96
45.8	13.86	33.6
-39.75	-72.18	2.11
26.35	-85.8	13.54
45.55	-65.7	-2.22
-20.12	-88.29	12.34
48.25	-24.44	48.56
53.61	-16.02	46.51
37.56	-35.66	55.45
-45.63	-31.6	57.59
-40.37	-31.55	46.29
-54.42	-21.82	47.81
30.23	-70.5	-18.3
-46.17	-64.13	8.15
-41.66	-46.29	26.48
-54.1	-7.76	-8.5
-45.5	-5.92	-12.19
-26.47	-74.2	25.62
-33.5	-10.47	-4.1
20.37	-41.59	61.93
-24.17	-40.32	43.52
-5.92	-28.01	36.39

// Moeller S J, 2014: Healthy Controls (HC) < Intermittent Explosive Disorder 
// (IED) and Cocaine Use Disorder (CUD), Error > Correct
// Moeller S J, 2014: IED > HC and CUD, Error > Correct
// Moeller S J, 2014: HC > IED and CUD, Incongruent > Congruent
// Moeller S J, 2014: HC < IED and CUD, Incongruent > Congruent
// Subjects=11
-39	47	28
-30	59	22
-6	23	37
21	-58	-44
-15	59	34
51	-34	31
-54	-46	46
45	-10	1
-27	-25	-5

// Roessner V, 2012: Healthy Controls
// Subjects=16
42.65	51.97	2.24
-36.89	-14.7	55.58
33.71	-20.11	61.91
24.12	-13.31	68.14
-50.13	0.66	7.6
-4.96	0.58	43.89
-8.06	-1.58	57.49
-43.57	-17.56	19.09
-37.32	3.91	7.19
42.77	7.05	-.69
-31.01	25.9	1.92
29.97	20.43	8.37
-24.54	3.47	0.38
20.41	4.51	9.82
-14.79	-18.16	8.78
52.61	-33.36	12.62
24.14	-32.85	63.09
59.34	-33.33	53.81
-46.69	-26.59	26.58
52.89	-30.54	49.18
24.06	-50.26	44.48
46	-42.06	-16.68
-33.92	-89.61	-5.08
26.96	-92.93	-12.2
-17.69	-97.4	16.57
17.39	-99.07	-8.23
13.96	-45.42	-16.03
55.77	-47.06	0.35
49.24	24.23	14.52
43.22	-31.11	42.65
36.9	-43.32	50.44
17.73	-59.3	52
-14.35	-13.54	68.61
17.24	37.76	27.14
-11.66	20.69	15.52

// Roessner V, 2012: Tourette Syndrome
// Subjects=19
1.44	17	49.14
-36.86	-14.44	58.9
36.74	-12.11	41.13
-1.84	9.61	36.41
4.58	-6.73	31.02
7.69	25.27	31.64
-4.86	-4.99	54.4
-40.52	10.49	10.02
45.99	10.5	2.33
39.78	-10.46	20.89
-27.79	6.37	-3.17
-18.06	17.48	15.86
17.22	14.52	15.71
-14.8	-14.99	8.51
24.08	-23.59	58.97
39.75	-76.73	-10.36
-24.26	-92.47	-1.61
20.6	-85.85	-2.68
-40.51	-68.47	-20.16
17.15	-42.23	-16.34
1.44	17	49.14
55.77	-47.06	0.35
49.24	24.23	14.52
43.22	-31.11	42.65
36.9	-43.32	50.44
17.73	-59.3	52
-14.35	-13.54	68.61
17.24	37.76	27.14
-11.66	20.69	15.52

// Carpenter-Thompson J R, 2014: Hearing Loss with Tinnitus (TIN)
// Subjects=13
-18	-58	42
12	-66	44
46	-62	22
36	-58	42
-44	-36	26
-36	42	20
-34	-68	20
6	54	4
-4	52	2
-4	38	4
-26	-68	42
4	-22	26
-32	16	26
-36	22	20
24	-20	-12
18	-62	44
-26	-68	42
8	-60	28
58	-30	4
-8	52	-2
4	40	6
-8	-54	32
-40	-44	22
-56	-16	10
-48	-22	14
-56	-4	0
-4	58	14
6	-62	28
-54	12	2
-58	-16	12
-48	-24	16
64	-10	10
56	-12	10
54	-30	4

// Carpenter-Thompson J R, 2014: Hearing Loss (HL)
// Subjects=12
-18	-58	42
12	-66	44
46	-62	22
36	-58	42
-44	-36	26
-36	42	20
-34	-68	20
6	54	4
-4	52	2
-4	38	4
8	-60	28
44	-60	22
42	30	18
-14	34	26
16	-64	44
-18	-58	40
-8	32	6
14	42	6
62	-8	12
56	-22	12
58	4	-10
48	10	-6
56	8	-20
8	54	18
8	62	16
-26	-16	-4
-52	-6	4
-54	2	-4
-54	-14	52
10	8	4

// Carpenter-Thompson J R, 2014: Normal Hearing (NH)
// Subjects=12
-18	-58	42
12	-66	44
46	-62	22
36	-58	42
-44	-36	26
-36	42	20
-34	-68	20
6	54	4
-4	52	2
-4	38	4
-26	-68	42
4	-22	26
-32	16	26
-36	22	20
24	-20	-12
18	-62	44
-26	-68	42
44	-60	22
42	30	18
-14	34	26
16	-64	44
-18	-58	40
58	2	-8
64	-10	12
66	-26	6
-54	-6	0
-50	-22	16
-8	34	6
4	38	4
18	-20	-24
4	58	20
-54	-10	-2
-56	-2	-14
58	-8	-8
62	-16	-2
64	-10	12

// Seydell-Greenwald A, 2012: Tinnitus
// Subjects=20
13.79	16.59	-12.31
13.79	17.65	-12.4

// Boiteau T W, 2014: Normals: Experiment 1
// Subjects=19
-46	-70	-40
14	-86	-16
14	-86	-18
12	-88	-21
-40	-81	-41
-41	-79	-41
24	-64	30
-17	-61	30
27	-74	42
32	-72	42
-25	-64	28
-35	-54	24

// Boiteau T W, 2014: Normals: Experiment 2
// Subjects=28
26	-100	-4
48	-86	-8
38	-66	-12
2	-106	-12
2	-104	-12
58	-72	-8
-36	-80	-20
-18	-76	-14
-34	-88	-20
-36	-70	-18
-30	-86	10
-4	-98	-4
58	-70	-4
42	-66	-16
44	-74	-14
26	-84	-16
48	-70	-14
28	-70	-14
-26	-106	-10
-22	-104	-8
-32	-96	-8
-30	-100	-10
-44	-88	-10
-36	-88	-20

// Hammer A, 2011: All Conditions> Baseline
// Subjects=10
-47.89	14.9	26.46
47.32	5.58	35.07
-53.32	-9.13	5.12
-58.57	-38.94	5.45
-0.01	40.51	9.26

// Matchin W, 2014: Long > Short
// Matchin W, 2014: Interaction: Long > Short and BA > WH
// Matchin W, 2014: BA > WH
// Matchin W, 2014: WH > BA
// Matchin W, 2014: BA-Long > BA-Short
// Matchin W, 2014: (Long > Short) > ART
// Subjects=26
-52.21	19.91	22.74
-39.4	8.9	16.83
-46.82	-3.75	19.09
-54.62	-.54	-21.24
-48.7	-63.69	28.6
53.25	9.37	-26.65
-2.76	-54.7	30.66
56.02	-63.07	27.34
-42.4	-0.07	38.8
-52.23	20.79	20.44
54.61	-27.15	-3.53
3.6	18.32	52.34
-3.92	-82.06	7.32
13.36	-85.61	28.61
-8.06	-90.57	21.46
-51.37	24.12	-5.5
-54.4	21.5	15.94
-58.6	-33.74	3.9

// McMillan C T, 2012: Undetermined (Gender-Biased and Gender-Neutral) > 
// Directly Determined (Explicit decision)
// McMillan C T, 2012: Undetermined (Gender-Biased and Gender-Neutral) > 
// Directly determined (Passive reading)
// McMillan C T, 2012: Gender Neutral > Directly Determined
// McMillan C T, 2012: Gender Biased > Directly determined
// McMillan C T, 2012: Gender Biased > Gender Neutral
// McMillan C T, 2012: Gender Neutral > Gender Biased
// McMillan C T, 2012: Indirectly determined > Directly determined
// Subjects=16
54	22	17
-54	20	8
-44	-50	14
54	-53	28
-55	28	13
-36	12	40
-48	-37	0
54	22	17
-44	16	18
-48	-44	7
-14	-95	1
-4	35	35
48	-48	21
22	-93	5
-57	-11	-18
52	25	-6
36	-91	8
-6	23	39
-40	-59	23
55	20	17
-57	20	8
-2	39	37
-46	-46	8
-38	6	44
-10	16	51
52	-50	21
-55	-1	13
-20	2	4
20	-13	56
-10	-33	48
-14	34	11
-48	30	13
50	22	21
16	-97	7
-18	-95	5
-51	33	-10
-30	-93	3
34	15	21

// Santi A, 2010: Conjunction Analysis of areas responsive to both embedding 
// position and movement type: (DMDE - SMSE) and (SMDE - SMSE) and (DMSE 
// -SMSE)
// Santi A, 2010: Conjunction Analysis of areas responsive to movement type 
// only: (DMDE - SMSE) and (DMDE - SMDE) and (DMSE - SMSE) and (DMSE -SMDE)
// Subjects=17
-42.52	14.14	29.81
52.59	25.71	33.32
-54.34	-34.95	1.72
-50.21	32.81	10.49

// Santi A, 2012: [(WHO-WHS) & (PAR-WHS) & (PRO-WHS)]
// Santi A, 2012: Wh-Object (WHO) > Wh-Subject (WHS)
// Santi A, 2012: Parasitic (PAR) > Pronoun (PRO)
// Santi A, 2012: PRO > WHO
// Subjects=14
-48.18	41.57	-.31
41.57	-.93	-21.2
26.68	53.62	11.2
27.84	1.84	2.15
23.48	-18.84	-17.25
12.68	28.22	-13.27
-23.43	1.71	4.98
-33.33	36.14	-16.75
-42.78	48.72	9.07
-50.99	7.2	37.18
-53.51	-2.3	-16.64
-57.73	9.28	-4.18
-53.46	-12.79	-14.65
31.96	36.51	-4.15
-41.34	4.25	39.54
-44.42	-40.61	37.76

// Wang C, 2013: Independent > Calculation
// Wang C, 2013: Interdependent > Calculation
// Wang C, 2013: Control > Calculation
// Wang C, 2013: Interdependent > Independent
// Wang C, 2013: Control > Independent
// Subjects=18
10	60	8
4	-48	24
-52	-4	-10
6	44	-10
4	-44	24
-68	-34	2
52	2	-24
46	-54	28
6	62	8
4	-46	24
46	-54	28
12	32	34
-24	54	12
-36	22	34
26	-44	-26
22	-60	-36
0	38	52
-24	48	30
-38	4	14
18	-90	30

// Wei W, 2014: Frequency Adverbs > Baseline
// Wei W, 2014: Quantity Pronouns/Nouns > Baseline
// Wei W, 2014: Animal Names > Baseline
// Wei W, 2014: Arabic Digits > Baseline
// Wei W, 2014: Number Words > Baseline
// Wei W, 2014: Dot Arrays > Baseline
// Subjects=20
27	-93	6
-18	-99	0
-21	-90	3
-6	15	51
-42	6	33
-27	-3	48
-45	21	27
39	3	66
30	0	51
39	-3	48
-27	-54	42
-45	-39	42
24	-96	6
18	-102	12
-21	-99	9
-42	3	30
-30	24	3
-33	0	48
30	-60	48
42	-42	45
45	3	30
33	-3	39
33	-3	48
-27	-60	45
-27	-48	39
-3	-72	45
24	-96	3
9	-75	-27
-24	-93	9
27	-60	45
21	-72	57
39	-42	42
-45	9	30
-45	21	27
-27	-3	51
-27	-63	48
27	-60	48
-15	-99	9
-24	-3	51
-45	6	27
-9	12	51
30	21	3
-30	21	3
-30	27	12
-27	-63	51
-27	-54	45
-33	-48	42
-45	6	27
-30	21	6
-45	21	27
-6	9	54
12	12	51
9	21	48
-27	-3	51
-39	0	63
-15	-99	9
15	-102	12
18	-99	0
51	9	27
60	12	39
-45	6	27
48	33	24
-6	15	51
9	18	51
36	-3	51

// Yokoyama S, 2012: All conditions > Baseline
// Subjects=15
-45	18	21
-48	24	15
-54	18	27
-33	27	-12
-57	-45	-3
-6	18	45

// Yu X, 2013: (Concrete Classifier (CCL) - Concrete Aspect (CASP)) and 
// (Abstract Classifier (ACL) - Abstract Aspect (AASP))
// Yu X, 2013: (CASP-CCL) and (AASP-ACL)
// Subjects=20
-15	-93	-9
9	-87	0
-39	12	30
-33	30	-15
27	27	-9
-6	27	45
-57	-48	12
-57	-48	12

// Dinomais M, 2013: Passive Movements > Rest
// Dinomais M, 2013: Video-guided passive movement > Nonvideo-guided passive 
// movement
// Dinomais M, 2013: Nonparetic hand movement > Paretic hand movement
// Dinomais M, 2013: Paretic hand movement > Nonparetic hand movement
// Subjects=18
39	-18	57
45	-27	60
48	-27	24
54	-18	18
-39	-18	60
-51	-30	27
-60	-21	18
27	-15	72
9	-6	60
48	3	9
51	-9	51
-18	-51	-21
21	-48	-24
18	-51	-21
15	-81	9
21	-66	-21
-18	-72	-6
6	-75	12
12	-69	-12
-3	-60	-6
18	-75	0
18	-60	-3
51	-63	3
-21	-57	-51
-9	-75	-42
-42	-66	6
24	-57	-51
15	-21	6
-18	-24	9
48	-72	-3
-45	-72	3
-45	-75	-3
-39	-75	-15
9	-87	0
39	-78	-18
-6	-90	-3
45	-57	-24
45	-72	-21
6	-75	12
24	-81	-15
21	3	66
15	21	63
6	-48	66
9	-72	51
33	-60	51
30	-51	48
39	-18	57
36	-30	69
24	-42	75
-18	-48	-24
-21	-57	-51
9	-15	51
51	-18	24
-39	-21	60
-36	-33	69
-9	-18	54
-18	-51	66
18	-48	-21
27	-33	-36
27	-57	-42
24	-45	-51
9	-63	-39
21	-57	-45
15	-60	-45
-45	-18	21
-15	-24	6

// Eck J, 2011: Migraine
// Subjects=10
16	-84	-16
-46	48	-8
50	50	-6
-4	16	54
-24	36	-16
-26	30	-14
38	-36	-18
-34	-80	-20
-44	6	30
50	10	30
-6	14	50
40	-22	30
-8	-60	56

// Eck J, 2011: Healthy Controls (HC)
// Subjects=10
-14	-88	-12
-40	26	10
-6	10	56
-56	-54	-8
8	-58	40
60	-62	16
-26	30	-14
38	-36	-18
-34	-88	-8
-44	6	30
52	4	46
-4	8	56
-48	-66	20
-6	-56	16

// Ferraro S, 2012: Medication Overuse Headache (MOH)
// Subjects=8
7	22	31
-5	22	31
37	36	33
-36	29	28
15	8	6
-19	7	3
11	49	9
-10	49	4
2	-14	-12
8	-50	36
14	46	9
8	-14	-12
8	-50	36
8	-17	-3
-11	49	3
17	49	2
8	-53	36

// Ferraro S, 2012: Detoxified Medication Overuse Headache (D-MOH)
// Subjects=8
10	24	29
-8	25	30
45	14	12
-39	41	22
16	7	9
-18	6	6
11	49	9
-10	49	4
2	-14	-12
8	-50	36
-11	49	3
17	49	2
8	-53	36
2	-14	-12

// Ferraro S, 2012: Chronic Migraine (CM)
// Subjects=8
8	23	30
-7	21	31
42	32	28
-37	19	33
7	-15	-10
-9	-15	-10
16	7	9
-15	8	9
11	49	9
-10	49	4
2	-14	-12
8	-50	36
8	-17	-3
11	49	9
-1	52	3

// Ferraro S, 2012: Healthy Controls (HC)
// Subjects=8
9	27	32
-4	27	33
33	23	10
-30	49	24
9	-14	-9
-5	-14	-10
16	10	9
-18	6	9
11	49	9
-10	49	4
2	-14	-12
8	-50	36
14	46	9
8	-14	-12
8	-50	36
2	-14	-12
11	49	9
-1	52	3

// Bhattacharyya S, 2012: Delta9-THC > Placebo: Oddball > Control
// Bhattacharyya S, 2012: Delta9-THC < Placebo: Oddball > Control
// Bhattacharyya S, 2012: CBD > Placebo: Oddball > Control
// Bhattacharyya S, 2012: CBD < Placebo: Oddball > Control
// Bhattacharyya S, 2012: Delta9-THC< Placebo <CBD: Oddball > Control
// Bhattacharyya S, 2012: Delta9-THC> Placebo >CBD: Oddball > Control
// Bhattacharyya S, 2012: Delta-9-THC, Placebo, and CBD: Oddball > Control
// Subjects=15
39.32	47.33	-16.29
43.73	45.55	1.65
12.71	69.14	6.72
31.75	55.23	-23.56
15.81	72.45	-5.86
20.27	21.72	-1.66
27.97	-1.19	18.01
47.18	-4.67	12.51
27.95	-21.16	7.42
24.83	-17.07	19.38
43.91	-26.24	-4.6
39.49	12.86	-7.83
51.4	-5.16	5.81
24.77	-13.27	13.49
-18.35	35.35	-14.63
-22.31	2.31	12.72
-22.46	29.29	3.77
-13.87	17.71	4.64
-22.18	-32.58	15.65
-29.72	-42.03	4.26
-29.77	-42.54	-2.39
-17.99	-33.5	3.41
-18.01	-42.47	-2.53
31.83	60.4	-11.73
31.88	60.91	-5.08
43.52	51.07	-23.35
43.71	52.95	1.03
55.37	27.87	-21.54
43.72	24.52	-8.86
31.8	31.53	-27.15
-13.94	24.68	-1.52
20.46	7.23	17.4
-22.37	6.03	5.72
27.87	2.1	5.47
-53.18	7.73	30.47
-33.34	55.78	-10.59
-13.8	38.2	21.88
-33.03	-38.76	-8.24
32.17	-42.6	-8.67
-29.98	-11.76	-17.23
32.25	-37.43	3.16
27.71	-7.19	-18.28
47.3	-24.34	19.73
-32.98	-1.98	13.21
-18.04	-9.81	7
12.98	-4.88	12.92
39.51	-44.01	-27.6
24.55	-68.31	-37.65
31.96	-61.29	-43.9
47.61	-45.2	52.71
55.66	-50.37	-14.98

// Bourque J, 2013: Schizophrenia
// Subjects=14
46	-60	-10
-46	-66	-7
49	-70	4
42	-74	-7
-38	-77	4
14	-98	10
7	-91	10
35	-38	-24
-42	-80	0
-42	-49	-32
-18	-7	-21
-60	-21	35
-52	-35	38
46	-56	-21
60	-35	10
-4	-91	28
7	-98	14
52	28	18
-35	-77	-21
4	-32	7
-46	-56	7
49	-42	-10
49	-56	24
35	-18	0
-60	-28	21
52	24	-4
21	-32	10
42	0	4
46	-56	21
0	-94	7
60	18	24

// Bourque J, 2013: Cannabis Use Disorder and Schizophrenia
// Subjects=14
42	-77	-14
-14	-102	7
-4	-88	38
46	24	-18
52	28	18
49	0	52
21	-21	-10
18	-70	63
-35	-18	70
63	-4	-24
10	-84	-14
0	-94	4
46	-56	-24
52	28	32
46	21	21
18	-10	-14
46	-56	-21
60	-35	10
-4	-91	28
7	-98	14
52	28	18
-35	-77	-21
4	-32	7
-46	-56	7
49	-42	-10
49	-56	24
35	-18	0
-60	-28	21
52	24	-4
21	-32	10
42	0	4
46	-56	21
0	-94	7
60	18	24

// Bourque J, 2013: Healthy Controls
// Subjects=21
46	-70	-7
42	-46	-18
-42	-52	-14
-46	-74	4
-46	-74	-7
42	35	-10
24	-7	-10
-28	-4	-14
52	21	28
42	4	32
-10	-91	-14
32	-32	7
24	-28	0
-10	-102	7
10	-94	7
42	-46	-18
32	-32	0
-18	-10	-10
18	-18	21
-21	-18	18
56	21	32
46	4	32
-24	0	-10
38	32	10

// Schwedt T J, 2014: Migraine > Healthy Controls
// Schwedt T J, 2014: Migraine < Healthy Controls
// Subjects=24
-2	-8	32
-22	2	-2
22	12	4
46	-22	26
-36	-50	-12
42	2	54
-38	-20	-10
34	12	24
12	-16	-10
64	-50	8
-14	-18	70

// Havrankova P, 2010: Active: After real rTMS > Before real rTMS
// Havrankova P, 2010: Passive: After real r-TMS > Before real r-TMS
// Subjects=11
-32	-48	60
-46	-52	42
-6	-58	62
4	-22	68
26	-36	64
46	-40	58
50	-58	40
32	18	6
-36	-56	60
40	-54	58

// Bannbers E, 2012: Premenstrual dysphoric disorder (PMDD)
// Subjects=14
62.16	-29.79	36.52
-55.58	-26.81	40.47
40.68	-22.34	48.48
-14.44	-54.42	41.39
31	-50.55	45.83
-43.76	-37.07	33.44
20.55	21.71	4.12
-44.26	-7.96	0.32

// Bannbers E, 2012: Healthy Controls (HC)
// Subjects=13
62.16	-29.79	36.52
-55.58	-26.81	40.47
40.68	-22.34	48.48
-14.44	-54.42	41.39
31	-50.55	45.83
-43.76	-37.07	33.44
20.55	21.71	4.12
-12.69	-32.34	13.4
-18.92	-22.12	-49.14

// Carrillo B, 2010: Male-to-female transsexuals
// Subjects=18
-24	-72.98	50.11
-20.66	-58	60.89
-7.75	-49.55	58.72
34.27	-30.56	52.76
40.92	-32.59	65.18
24.73	-44.55	64.39
-42.63	-23.57	39.93
7.21	62.65	-16.51
-15.35	60.21	-6.92
-12	62.11	1.8
23.77	31.4	4.23
17.4	28.91	12.43
23.9	22.55	12.95
20.26	53.43	-12.46

// Carrillo B, 2010: Control females
// Subjects=19
1.33	-36.86	10.24
-5.26	-45.36	-0.01
-42.63	-23.57	39.93
7.21	62.65	-16.51
-15.35	60.21	-6.92
-12	62.11	1.8
23.77	31.4	4.23
17.4	28.91	12.43
23.9	22.55	12.95
20.26	53.43	-12.46

// Carrillo B, 2010: Control males
// Subjects=23
1.33	-36.86	10.24
-5.26	-45.36	-0.01
-24	-72.98	50.11
-20.66	-58	60.89
-7.75	-49.55	58.72
34.27	-30.56	52.76
40.92	-32.59	65.18
24.73	-44.55	64.39

// Dickey C C, 2010: Schizotypal Personality Disorder (SPD)
// Subjects=16
56	-40	4
-52	-10	4
-18	-26	-20
-46	-6	52
-2	-4	66
56	4	28
42	-6	46
38	-20	60
-38	30	-4

// Dickey C C, 2010: Healthy Controls (HC)
// Subjects=13
64	-20	-8
-50	-26	-2
-52	-44	14
24	-74	58
-46	16	26
10	6	62
-34	26	2

// Huang J, 2013: All Participants: Happiness appearing > Mosaic
// Huang J, 2013: All Participants: Happiness disappearing > Mosaic
// Huang J, 2013: All Participants: Praise > Blame
// Huang J, 2013: All Participants: Happiness appearing > Disappearing
// Huang J, 2013: All Participants: Incongruent (Happiness appearing with 
// blame and happiness disappearing with praise) > Congruent (Happiness 
// appearing with praise and happiness disappearing with blame)
// Subjects=14
46	-70	-10
-40	-80	-12
-42	-48	-22
6	-70	8
8	-36	2
48	-72	-10
48	36	14
-44	-80	-10
28	-58	-4
34	22	16
10	-4	2
62	-20	42
42	-44	18
-16	-8	-2
-30	22	6
-20	-62	44
-26	44	36
24	-46	44
44	-48	38
26	-30	38
-22	-52	14
26	-76	-6
16	54	48
-2	-56	6
58	26	32
-22	-38	76
-8	-30	14
18	68	28
10	-2	76
-36	-76	-44
-6	16	2
-20	-88	-26
50	-78	26
24	-20	-8
-44	24	-20
-34	-86	42
-34	30	54
0	-96	12
40	20	-22
20	32	60

// Kim S, 2014: Fragile X Premutation
// Subjects=18
-54	-60	28
-54	-66	34
-42	-52	30
-42	-66	44
-36	-68	44
-50	-74	18
-40	-74	34

// Kim S, 2014: Healthy Controls
// Subjects=18
12	-56	36
-10	-58	30
-4	-82	8
14	-78	32
-12	-54	28
14	-36	28
-56	-40	42
-40	-60	30
-38	-60	22
-56	-50	34
-50	-56	16
56	-46	38
58	-58	14
50	-60	22
52	-38	26
54	-42	46
48	-68	34
52	-38	22
64	-26	40
64	-32	38
32	-60	60
28	-30	18
48	-24	52
20	-2	20
42	-40	16
16	-22	6
14	-52	38
58	-26	24
-14	-52	8
-24	-24	4
-36	-30	-16
-24	-28	-20
-40	-20	8
-60	-4	-2
-36	-58	22
-38	-26	42
-44	-16	60
-42	-26	28
-36	-50	26
-8	-38	46
-34	-8	22

// Taylor J J, 2013: Subgroup of Normals, Naloxone
// Subjects=7
17.66	38.54	35
63.4	-41.72	46.65
-24.04	-82.45	-39.72
-34.61	-85.08	-21.35
23.81	-64.59	-12.05

// Taylor J J, 2013: Subgroup of Normals, Saline
// Subjects=7
-8.57	53.7	14.9
-29.43	47.84	-12.18
22.66	45.43	5.1
-48.68	-3.28	-6.79
-1.87	-85.77	3.93
-49.61	2.21	6.13
25.59	1.94	56.42
54.18	-32.93	3.35
6.53	34.94	8.65
-7.76	-24.9	-22.16
22.93	-27	11.14
19.36	-17.39	-12.16
4.32	-76.98	-17.21
33.64	-40.76	1.12

// Jungblut M, 2012: Conjunction: Common activation for all three conditions
// Jungblut M, 2012: Regression: Effects of Complexity
// Jungblut M, 2012: Vowel changes with regular groupings and rests > Vowel 
// changes with regular groupings
// Jungblut M, 2012: Vowel changes with irregular vowel changes > Vowel 
// changes with regular groupings
// Jungblut M, 2012: Vowel changes with irregular vowel changes > Vowel 
// changes with regular groupings and rests
// Subjects=30
-.3	14.17	62.37
-59.09	1.82	25.38
-56.98	-4.01	20.31
-4.94	16.12	37.61
6.18	14.19	62.26
55.49	-.55	28.14
61.85	-3.7	17.14
14	-37.93	-13.4
23.65	6.44	-10.11
14.24	-3.32	12.31
-47.75	17.47	-14.47
-32.55	26.87	-6.69
-8.14	23.01	42.58
33.25	24.14	-16.51
32.18	20.95	-16.17
-34.73	21.23	-9.46
-46.01	11.51	36.52
36.54	21.27	-12.92
53.13	41.67	20.64
43.99	-44.77	49.52
-31.53	24.22	-12.05
-29.36	22.1	-11.88
-43.93	10.9	29.82
-37.9	57.87	3.78
-2.77	22.82	40.27
-37.09	-42.18	47.28
-24.03	-54.58	51.65
-37.89	-67.87	-20.76
36.49	24.15	-16.56
33.29	21.16	-13.97
49.95	43.24	26.14
30.95	15.89	56.07
7.75	31.63	19.05
40.81	-47.66	53.22
27.74	-51.73	44.88
46.41	-73.95	-21.59
-34.77	24.21	-11.99
-30.44	21.04	-11.75
-40.75	7.2	24.53
-8.14	23.01	42.58
33.25	24.14	-16.51
25.72	22.19	-13.94
7.87	33.62	28.93

// Kleber B, 2013: Singer
// Subjects=14
-42	-15	36
45	-9	36
-42	-15	33
48	-9	30
63	3	3
-57	-6	15
-3	-3	60
51	-6	39
-54	-6	39
-57	3	15
45	-18	3
-39	-33	15
-36	6	12
48	6	3
27	-3	-6
-24	-6	-3
21	9	3
-24	0	9
-9	3	45
12	-15	3
-42	-15	36
45	-9	36
60	0	15
-54	-3	24
-54	-6	15
66	-24	18
-3	-3	60
54	-3	48
-51	-9	48
-51	9	3
63	-27	9
-39	-36	15
48	6	3
24	-6	-6
27	-6	-6
-42	-12	33
48	-9	39
-45	12	30
48	-3	-3
-33	-45	-39
15	-39	-51
27	0	-3
-3	-15	6

// Kleber B, 2013: Nonsinger
// Subjects=12
-42	-15	36
45	-9	36
-42	-15	33
48	-9	30
63	3	3
-57	-6	15
-3	-3	60
51	-6	39
-54	-6	39
-57	3	15
45	-18	3
-39	-33	15
-36	6	12
48	6	3
27	-3	-6
-24	-6	-3
21	9	3
-24	0	9
-9	3	45
12	-15	3
-42	-15	36
45	-9	36
60	0	15
-54	-3	24
-54	-6	15
66	-24	18
-3	-3	60
54	-3	48
-51	-9	48
-51	9	3
63	-27	9
-39	-36	15
48	6	3
24	-6	-6
27	-6	-6
-15	3	-3
-15	-18	9
15	-6	-6

// Golfinopoulos E, 2011: normal speech > baseline
// Golfinopoulos E, 2011: perturbed non-speech > baseline
// Subjects=13
-6	-12	74
-56	-12	50
-62	-4	34
-58	-10	40
-56	-10	10
62	-6	46
46	-12	42
60	-6	36
66	-4	30
52	-12	58
44	6	6
48	-12	22
-4	6	46
-6	-2	46
-2	24	28
-8	4	76
10	2	48
0	-2	68
2	20	36
-46	-38	26
48	-30	22
-48	-20	10
-68	-32	10
56	8	-6
48	-20	10
68	-22	2
60	-14	4
-40	-6	8
36	4	4
-12	-54	-18
-26	-60	-22
18	-56	-18
-22	0	-6
-24	-6	8
-12	-18	8
-14	-20	-2
18	0	4
30	-12	6
24	-12	20
10	-12	10
18	-22	-2
-44	-14	62
-62	-2	36
-58	-10	42
-46	-10	22
8	-8	72
64	6	28
62	-8	36
44	-4	12
48	-10	18
4	0	52
2	-4	60
2	8	40
-64	-22	30
-46	-36	24
60	-22	26
56	-32	28
-42	-18	6
-56	-42	22
42	-24	14
44	-10	-6
58	-58	-2
-38	-4	14
46	-2	-2
-22	-58	-24
-16	-60	-52
20	-58	-24
-24	2	-4
24	0	-10
12	-12	10

// Azevedo R T, 2013: Normals
// Subjects=27
-58	-26	38
-38	-50	58
62	-18	36
34	-58	58
28	-52	52
54	-32	42
-60	8	28
62	12	16
-48	76	4
-44	-70	0
-36	-70	-20
32	-80	26
48	-70	2
24	-90	-14
32	-90	-4
-48	-76	-14
46	-70	-10
-30	20	-2
0	34	28

// Baumgartner T, 2012: Behavior DC: Outgroup > Ingroup, p<0.005
// Baumgartner T, 2012: Behavior DC: Outgroup > Ingroup, p<0.0005
// Baumgartner T, 2012: Behavior DC: Ingroup > Outgroup, p<0.005
// Baumgartner T, 2012: Behavior DC: Ingroup > Outgroup, p<0.0005
// Baumgartner T, 2012: All Behaviors: Outgroup > Ingroup, p<0.005
// Baumgartner T, 2012: All Behaviors: Outgroup > Ingroup, p<0.0005
// Baumgartner T, 2012: All Behaviors: Outgroup > Ingroup, p<0.00005
// Baumgartner T, 2012: All Behaviors: Ingroup > Outgroup, p<0.005
// Baumgartner T, 2012: All Behaviors: Ingroup > Outgroup, p<0.0005
// Baumgartner T, 2012: All Behaviors: Ingroup > Outgroup, p<0.00005
// Subjects=16
27	-6	36
33	-6	21
-24	30	3
15	-21	18
-21	-24	12
-18	-30	18
27	-12	45
-15	39	3
6	0	-9
-51	27	-3
-48	27	-18
-36	6	60
-12	30	27
-6	39	9
54	15	15
36	24	6
51	24	3
-36	18	3
6	-12	-18
6	21	18
63	-3	24
66	-3	15
60	3	-21
57	-6	-9
63	0	-6
-45	-12	-30
-33	-6	-24
6	-24	63
12	54	-15
-57	-6	27
63	-21	-3
42	-54	-15
-33	-6	-24
-57	-27	3

// Bruneau E G, 2010: Subgroup of Normals, Jewish Israeli
// Subjects=16
0	-64	36
62	-52	30
-46	-54	30
4	64	20
46	-64	42
56	0	-36
46	26	38
-40	-58	42
-52	6	-54
50	32	16
48	-58	-6
-50	-60	-12
30	-56	8
28	-94	8
-44	36	24
-22	52	14
-50	-54	48
-40	16	50
44	14	52
-6	30	40

// Bruneau E G, 2010: Subgroup of Normals, non-Israeli Arab
// Subjects=16
8	-56	30
-4	-54	20
-48	-62	24
-2	52	28
32	18	-24
-28	14	-22
8	18	70
-62	-26	-8
-2	-12	8
-4	50	-10
46	-48	-18
6	-38	-4
-36	-44	-2
8	2	46
-26	-48	54
42	-70	16
-2	-54	34
-56	-52	30
46	-58	38
-52	-60	46
48	36	26
6	56	32
6	32	58

// Bruneau E G, 2012: All Participants: Physical Pain > Control
// Bruneau E G, 2012: All Participants: Emotional Pain > Control
// Bruneau E G, 2012: All Participants: All Physical Pain > All Emotional Pain
// Bruneau E G, 2012: All Participants: All Emotional Pain > All Physical Pain
// Bruneau E G, 2012: All Participants: South American Physical Pain > Control
// Bruneau E G, 2012: All Participants: South American Emotional Pain > 
// Control
// Bruneau E G, 2012: All Participants: Emotional Suffering of Conflict Group 
// > Ingroup
// Subjects=10
0	6	30
-38	-6	-10
40	8	-18
-62	-24	30
68	-26	32
-50	-66	0
-10	48	20
-2	56	-10
-8	-50	40
-56	-58	30
54	-60	30
-58	-20	-14
58	-18	-16
-2	4	34
-38	-8	-12
38	-2	16
-62	-34	38
62	-34	36
-58	-66	-6
-8	48	20
-4	54	-6
0	-56	32
-48	-62	28
50	-64	24
-62	-12	-20
58	-6	-18
-64	-30	30
66	-26	34
-58	-58	-4
-4	54	28
-2	56	-10
-2	-56	32
-54	-60	24
48	-62	24
-64	-12	-18
52	-16	-12
-26	-66	32

// Cheon B K, 2011: All Participants: Ingroup Bias in empathy [(Ingroup Pain > 
// Ingroup Neutral) > (Outgroup Pain > Outgroup Neutral)]
// Cheon B K, 2011: All Participants: Outgroup Bias in empathy [(Outgroup Pain 
// > Outgroup Neutral) > (Ingroup Pain > Ingroup Neutral)]
// Cheon B K, 2011: Caucasian > Korean: Ingroup Bias in empathy [(Ingroup Pain 
// > Ingroup Neutral) > (Outgroup Pain > Outgroup Neutral)]
// Cheon B K, 2011: Korean > Caucasian: Ingroup Bias in empathy [(Ingroup Pain 
// > Ingroup Neutral) > (Outgroup Pain > Outgroup Neutral)]
// Subjects=13
-6	-66	18
30	-51	-6
12	-54	9
-24	-51	-6
-21	-81	18
33	-75	18
-9	60	30
42	-42	48
-36	-45	45
27	-81	30
-48	36	9
27	27	42
15	-66	3
-42	-51	42
57	-42	45
3	-24	39
-54	-63	15
-54	-54	-3

// Contreras-Huerta L S, 2013: Pain > Non-painful touch
// Contreras-Huerta L S, 2013: (Pain > touch of same race) > (Pain > touch of 
// other race)
// Subjects=20
36	28	2
-28	22	-12
-8	20	42
-10	30	26
-38	-24	56
-60	-22	28
-32	-52	46
-56	10	10
-42	-66	-10
36	-60	-28
-28	24	8

// Contreras J M, 2013: Normals
// Subjects=17
0	-61	-16
-28	15	-20
20	61	-6
4	-29	34
-16	33	-8
14	35	-12
-12	-57	-32
-20	-31	44
-16	-45	22
-18	-81	2
48	-53	34

// Contreras J M, 2013: Subgroup of Normals, n=16
// Subjects=16
38.8	-44.3	-18.5
-37.1	-47.6	-17.3
49.8	-43.4	13.9
23.4	-39.5	-7.4
-24.1	-42.9	-4.8

// Contreras J M, 2013: Subgroup of Normals, n=14
// Subjects=14
33.3	-76.7	-8.9

// Contreras J M, 2013: Subgroup of Normals, n=11
// Subjects=11
-33.1	-77	-6.55

// Contreras J M, 2013: Subgroup of Normals, n=10
// Subjects=10
-42	-63.7	-6.7

// Contreras J M, 2013: Subgroup of Normals, n=9
// Subjects=9
-49.8	-52.8	21.3

// Contreras J M, 2013: Subgroup of Normals, n=8
// Subjects=17
40.5	-66.3	-5

// Earls H A, 2013: Own-race > Other-race
// Subjects=20
58	-26	28
-58	-30	26
46	-68	2
-46	-72	4
-30	-46	44

// Ebner N C, 2013: Normals
// Subjects=62
15	51	24
-39	51	0
21	45	9
9	39	42
-36	27	36
18	12	3
-36	6	-3
60	3	-18
-54	-30	-3
-45	-69	24
-45	-75	0

// Falk E B, 2012: my candidate > opponent, p<0.005
// Falk E B, 2012: my candidate > opponent, p<0.05
// Falk E B, 2012: opponent > my candidate, p<0.005
// Falk E B, 2012: opponent > my candidate, p<0.05
// Subjects=23
-3	-24	36
-3	-30	-27
6	-24	30
63	-51	36
-63	-36	36
60	6	12
39	12	12
39	12	12

// Feng L, 2011: Chinese faces > Caucasian faces
// Subjects=30
44	26	20
6	20	46
42	10	18
44	6	26

// Fox G R, 2013: Pain-Hateful > Pain-Likeable
// Subjects=16
6.63	20.95	30.9
-10.49	27.19	30.57
-32.08	8.37	-4.4
-31.75	-11.26	30.7
19.98	-36.17	75.68
-15.27	-32.95	79.17
-41.65	31.8	10.47
28.9	45.69	18.53
-5.8	-8.03	70.28
-41.29	9.25	49.16
-60.87	-7.66	-2.73
-25.01	-57.27	54.55
-6.02	-86.13	9.92
-29.94	8.38	-4.43
28.92	6.34	5.11
-12.73	19.55	14.51
12.9	9.67	8.36
-13.04	-26.58	-45.18
-9.5	-49.36	-9.86
9.61	-50.53	-26.7

// Gilbert S J, 2012: White > Black Faces (Collapsed over Trait and Friendship 
// Judgments)
// Gilbert S J, 2012: Trait > Friendship
// Gilbert S J, 2012: Friendship > Trait
// Subjects=16
15	-91	10
-12	-82	-5
-42	-79	49
-36	-79	-20
30	-64	-20
63	-40	-14
24	-4	-38
51	17	46
-6	29	55
-3	65	22
-36	50	-17

// Hein G, 2010: high - low self pain
// Hein G, 2010: [high - low self pain] and [(high - low ingroup pain) and 
// (high - low outgroup pain)]
// Hein G, 2010: [high - low self pain] and [high - low ingroup pain]
// Hein G, 2010: [high - low self pain] and [high - low outgroup pain]
// Hein G, 2010: [high - low ingroup pain] versus [high - low outgroup pain]
// Hein G, 2010: [high - low ingroup pain]
// Hein G, 2010: [high - low outgroup pain]
// Hein G, 2010: [high - low ingroup pain] and [high - low outgroup pain]
// Subjects=16
-36	12	-9
-30	18	12
48	18	6
57	15	0
42	18	-9
33	12	12
33	-18	12
-9	45	12
-9	24	45
0	-9	45
39	-27	69
24	-42	69
27	-27	84
-12	-48	-21
15	-60	-33
9	-6	6
-6	-36	0
-51	15	-3
-51	36	3
-32	16	-9
-3	60	30
0	48	27
-6	39	24
6	-30	51
0	-18	42
-9	-39	9
3	-42	27
54	14	5
-6	-81	-15
-9	-33	0
-51	15	-3
-36	18	12
-38	17	-1
0	54	30
-6	36	27
6	-30	51
3	-21	45
6	-33	42
0	-42	30
45	18	9
-3	-66	-3
12	-36	42
0	-45	30
-6	57	30
-6	39	30
-24	9	-27
-50	-42	9
-50	-30	6
21	-93	6
-33	-78	12
-33	-66	-24
33	-42	-24
-15	-18	6
-39	12	15
-39	18	-3
-48	15	-3
-27	24	15
45	18	9
9	18	18
6	-27	39
-6	24	36
-6	-15	42
-30	18	-33
48	18	9
30	27	-9
-6	72	6
-27	6	-30
48	12	-27
21	0	-27
57	-18	-6
-55	-30	18
-18	-59	24
-48	-81	21
-12	21	3
12	-18	6
-24	63	24
36	36	0
12	-42	39
3	-42	27
-6	57	30
-12	39	21
-18	36	45
27	48	12
-51	42	6
-51	15	-3
-30	18	-12
-36	-6	-12
33	36	0
-6	51	33
-9	36	21
-3	-21	39
0	-45	30
-6	24	66
57	30	3
42	18	27
-30	18	-33
54	12	-30
57	6	-18
51	-42	12
-54	-69	21
-66	-6	-12
51	-69	3
36	-15	-24
-21	-9	-15
48	-69	-21
-6	-81	-15
-6	-27	0

// Losin E A R, 2012: Imitate Gesture: European American (EA) > Chinese Han 
// (CH)
// Losin E A R, 2012: Imitate Gesture: African American (AA) > EA
// Losin E A R, 2012: Imitate Gesture: AA > CH
// Losin E A R, 2012: View Portrait: EA > CH
// Losin E A R, 2012: View Portrait: EA > AA
// Losin E A R, 2012: View Portrait: CH > AA
// Losin E A R, 2012: View Portrait: AA > CH
// Losin E A R, 2012: Observe Gesture: EA > CH
// Losin E A R, 2012: Observe Gesture: AA >CH
// Losin E A R, 2012: [Imitate Gesture (EA > CH)] > Observe Gesture (EA > CH)]
// Losin E A R, 2012: [Imitate Gesture (AA>EA) > Observe Gesture (AA>EA)]
// Losin E A R, 2012: [Imitate Gesture (AA>EA) > View Portrait (AA>EA)]
// Losin E A R, 2012: [Imitate Gesture (AA>CH) > Observe Gesture (AA>CH)]
// Losin E A R, 2012: [Imitate Gesture (AA>CH) > View Portrait (AA>CH)]
// Subjects=20
-22	-34	48
14	-58	26
30	-34	-22
-2	-86	32
18	-72	-2
-18	-62	-6
-48	-74	-12
34	-86	30
-18	-24	0
14	-80	-42
-36	-48	-42
-6	18	46
42	42	14
-40	2	32
22	2	70
52	10	26
-46	32	22
-26	4	66
28	-56	50
54	-20	44
-48	-34	54
56	-56	-4
-44	-46	-14
-28	-72	-10
30	-72	-8
-30	-78	20
36	-72	24
-16	-52	-46
-44	2	34
24	-4	44
-20	14	56
-48	36	20
-28	52	0
38	24	46
42	0	2
54	-20	44
-24	-54	52
38	-50	42
10	-62	22
-18	-34	-6
42	-40	-22
-44	-46	-16
-58	-56	10
-30	-74	-10
32	-66	-10
-32	-74	20
-2	-90	34
36	-82	16
-16	16	6
20	-30	8
-16	-52	-46
2	-80	-26
50	38	16
62	10	22
60	-42	-12
34	-74	-12
-26	-82	-20
-8	-92	14
24	-82	28
-20	-76	44
52	14	26
54	38	8
-28	26	-6
46	0	56
8	14	44
-14	4	72
-36	10	36
-10	-50	28
58	-28	24
36	-42	-24
52	20	-16
-10	-94	4
10	-80	-32
-12	-82	40
62	-62	0
38	-84	32
10	-10	2
-28	-20	2
-20	-62	-46
0	40	-8
-2	-54	14
8	6	0
-14	0	20
24	-96	24
-12	-98	26
32	-44	-12
24	-76	-6
-20	-98	-4
42	-64	20
-10	-90	-32
28	-74	-12
26	-88	34
-28	-72	-6
-4	-84	42
22	-44	-10
2	-94	14
52	-74	12
-6	-78	24
42	46	14
40	4	32
48	-24	56
36	-52	60
-30	-60	-14
34	-84	0
-30	-80	20
44	-62	20
-34	-76	-42
46	10	32
0	20	46
-42	11	18
40	40	16
-50	6	44
18	0	68
30	-56	54
56	-20	48
-28	-54	52
-50	-26	48
36	-42	-22
66	-16	0
60	-54	10
-22	-38	-6
-32	-68	-10
36	-72	-10
-26	-78	26
30	-76	30
12	-54	-8
-14	-94	-6
-10	-12	4
-6	-74	-36
-48	30	16
-12	0	72
-6	24	46
-30	-42	38
52	-20	40
-60	-22	34
-18	-36	-4
-30	0	-20
-36	-70	-10
-30	-78	20
-26	-70	-44
30	-64	-38
-48	6	38
-22	24	52
2	46	-8
-56	22	8
-36	-88	30
-2	-48	38
40	-38	62
-24	-54	66
-50	-48	52
-50	-52	14
30	-50	-8
-32	-30	-18
26	-22	-20
-66	-26	-12
64	-48	-8
-28	-70	-10
6	-86	26
28	-70	56
-4	-72	-36
34	-72	-48

// Losin E A R, 2012: Imitate gesture: own gender > other gender
// Losin E A R, 2012: [Imitate gesture (own gender > other gender) > [Observe 
// gesture (own gender > other gender)]
// Losin E A R, 2012: [Imitate gesture (own gender > other gender) > [View 
// portrait (own gender > other gender)]
// Subjects=19
14	14	-8
18	18	-12
-8	14	-8
18	18	2
20	18	-2
16	14	-10
18	18	-12
20	16	6
16	4	-16
18	18	-10
28	20	-8
32	20	-6
14	16	-10

// Mathur V A, 2012: African American > Caucasian: Ingroup > Outgroup
// Mathur V A, 2012: Caucasian > African American: Ingroup > Outgroup
// Mathur V A, 2012: Ingroup > Outgroup
// Mathur V A, 2012: Outgroup > Ingroup
// Subjects=10
6	-11	14
0	-65	34
50	43	-5
0	54	28
0	-47	2
-33	22	-19
42	-65	-12
0	40	50
24	-79	-16
-45	46	-15
0	-13	39
-33	-47	-3
62	-34	21
-21	-57	-35
27	11	38
-21	50	9
24	34	-9
-42	-54	-33
24	-65	-22
-24	9	58
-24	2	30
36	36	26
15	-19	31
30	15	2
0	-10	39
-3	-50	47
-6	52	-3
-6	-8	9
-3	20	60
-3	25	29
0	40	50
-3	-49	8
65	-31	24
-33	-50	-3
-27	-44	49
65	-7	25
33	-44	-5
-27	-59	42
-36	-37	21
21	-48	25
27	14	38
27	-60	25

// Mathur V A, 2010: Pain > No Pain
// Mathur V A, 2010: Ingroup (Pain + No Pain) > Outgroup (Pain + No Pain)
// Mathur V A, 2010: Outgroup (Pain + No Pain) > Ingroup (Pain + No Pain)
// Mathur V A, 2010: Participant Race (AA > CA)] x [Target Race (Ingroup Pain 
// > Outgroup Pain)
// Mathur V A, 2010: Participant Race (CA > AA)] x [Target Race (Ingroup Pain 
// > Outgroup Pain)
// Mathur V A, 2010: Positive Correlation between Ingroup Pain > Outgroup Pain 
// and Behavioral Empathy
// Mathur V A, 2010: Positive Correlation between Ingroup Pain > Outgroup Pain 
// and Willingness to donate money
// Mathur V A, 2010: Positive Correlation between Ingroup Pain > Outgroup Pain 
// and Willingness to donate time
// Subjects=14
-30	-9	61
48	-33	46
-6	14	49
-50	7	27
-33	-54	-23
-6	-14	12
-48	14	-8
0	-46	8
53	7	30
39	18	2
-48	-70	3
30	-68	34
-45	36	23
-18	-80	-31
-6	37	-12
27	3	3
-3	-44	-8
-45	15	2
-15	-9	-5
0	13	24
-18	9	-3
-53	-17	9
-3	-50	47
0	58	3
30	48	25
0	-3	6
-30	55	-15
27	55	-3
-21	-12	-9
0	43	39
-3	-46	11
0	-12	42
-15	-8	17
-21	40	37
30	-47	-5
-33	-47	-5
21	-54	19
-56	-4	42
-56	-61	1
-27	-78	20
56	-12	42
56	-14	9
-18	-54	19
-42	-34	13
-48	2	50
-24	-72	-42
6	-33	35
-9	-36	38
21	-77	26
-50	-14	3
39	-28	15
18	-27	37
-12	57	30
21	62	11
30	48	31
-18	58	-8
18	2	-10
3	24	21
9	62	22
-9	57	30
-9	65	11
9	54	33
33	48	28
-9	57	33
21	65	11
18	51	36
6	62	22

// Molenberghs P, 2014: Reward > Neutral
// Molenberghs P, 2014: Reward In-group (RI) > Reward Out-group (RO)
// Molenberghs P, 2014: Shock > Neutral
// Molenberghs P, 2014: Positive Correlation between Perspective Taking Scores 
// and Shock > Neutral
// Molenberghs P, 2014: Positive Correlation between Psychopathy Scores and 
// Shock > Neutral
// Subjects=48
-27	8	1
27	5	-5
0	23	-5
-24	11	-2
27	5	-8
-3	26	-2
-3	53	28
-48	23	-8
45	29	-8
57	-25	-5
-3	56	25
-45	23	-8
48	26	-8
57	-22	-5
-6	53	31
-45	26	-5
42	32	-11
57	-25	-2

// Molenberghs P, 2014: My Team > Other Team
// Subjects=20
-9	41	25

// Morrison S, 2012: Social > non-social words, p<0.001
// Morrison S, 2012: Social > non-social words, p=0.022
// Morrison S, 2012: Social > non-social words, p=0.008
// Morrison S, 2012: Social > non-social words, p=0.005
// Morrison S, 2012: Social > non-social words, p=0.002
// Morrison S, 2012: Social > non-social words, p=0.015
// Morrison S, 2012: Social > non-social words, p=0.016
// Morrison S, 2012: My team > other team words, p=0.012
// Morrison S, 2012: My team > other team words, p=0.018
// Morrison S, 2012: My team > other team words, p=0.016
// Subjects=20
-45	-64	31
-3	-46	28
-3	44	-17
-63	-13	-14
-45	35	-5
-66	-34	1
-6	56	16
36	-64	43
-3	32	7
12	50	-5
-18	-1	52

// Baeken C, 2011: Positive > Neutral face
// Baeken C, 2011: Neutral > Positive face
// Baeken C, 2011: Negative > Neutral face
// Baeken C, 2011: Neutral > Negative face
// Baeken C, 2011: Positive > Neutral face, Before < After Intervention
// Baeken C, 2011: Negative > Neutral face, Before < After Intervention
// Baeken C, 2011: Positive > Neutral face, Interaction (Active > Sham rTMS) x 
// (Before > After Intervention)
// Baeken C, 2011: Negative > Neutral face, Interaction (Active > Sham rTMS) x 
// (Before > After Intervention)
// Baeken C, 2011: Positive > Neutral face, Before < After Intervention, 
// Active rTMS
// Baeken C, 2011: Positive > Neutral face, Before > After Intervention, Sham 
// rTMS
// Baeken C, 2011: Negative > Neutral face, Before > After Intervention, 
// Active rTMS
// Subjects=19
6	10	20
40	-82	-12
-44	-84	-10
16	-104	4
4	12	58
22	-54	54
26	-58	54
-22	-66	48
22	-54	54
26	-58	54
-22	-66	48
28	-92	-8
-42	-48	-20
4	14	58
-44	20	-20
-44	40	-14
-60	-52	30
28	-48	-6
56	32	-4
30	-40	10
6	6	22
-40	-36	56
-34	-14	28
-62	-38	26
-28	42	8
14	-28	44
-20	14	40
-28	60	-10
14	-34	26
-54	26	-8
-30	-68	60
38	-64	22
32	12	20
12	50	44
-20	10	-6
-28	60	-10
38	-64	22
-28	60	-10
-54	26	-8
14	-34	26
32	12	20

// Hayashi T, 2013: Smoking > Neutral
// Hayashi T, 2013: Smoking < Neutral
// Hayashi T, 2013: Positive correlation between Craving and Smoking > Neutral
// Hayashi T, 2013: Positive correlation between Intention and Smoking > 
// Neutral
// Hayashi T, 2013: Positive correlation between Craving and Smoking > Neutal 
// (Immediate > Delayed)
// Hayashi T, 2013: Positive correlation between Intention and Smoking > 
// Neutal (Immediate > Delayed)
// Hayashi T, 2013: Negative correlation between Craving and Smoking > Neutral 
// (Sham > Active rTMS)
// Hayashi T, 2013: Interaction rTMS x Cigarette Abailability, Smoking > 
// Neutral associated to Craving, Smokers
// Subjects=10
-26	42	34
16	44	46
-4	20	60
-2	58	12
-18	66	10
0	32	18
0	40	-8
58	-50	30
-54	-58	32
-2	14	-2
-6	-84	-8
46	-40	6
-56	-28	-10
-56	-58	34
-16	-84	-40
-58	-22	30
20	-62	60
62	-22	30
-20	-58	54
-48	-64	-8
50	-66	-14
-56	10	28
58	10	26
38	-4	12
-38	-4	10
-4	46	-22
-34	50	-6
28	30	-16
-30	36	40
-26	28	48
40	36	14
12	4	0
20	2	18
-28	-8	16
2	0	42
-20	28	52
-18	-30	78
-2	-52	14
52	-54	6
46	-44	-20
-26	-62	56
18	-60	56
-22	14	46
0	20	24
-22	68	12
-50	-66	40
6	-92	-2
-10	-92	-14
-26	2	-2
-38	32	40
-30	36	-16
0	56	-10
-6	28	-8
-16	6	-14
-50	-62	-8
46	36	20
-28	2	32
-6	-8	36
14	32	-12
-30	-38	-6
0	16	24
-4	64	-14
-18	36	48
-48	-74	38

// Kornysheva K, 2011: Synchronization > Control, Normals
// Kornysheva K, 2011: Synchronization > Control, Conjunction of [PMv MS > PMv 
// no TMS and PMv TMS > AG TMS and PMv > AG no TMS]
// Subjects=16
-52.21	11.11	19.02
-45.86	-12.6	0.86
-55.37	-21.41	11.75
47.09	-8.87	-.52
66.44	-17.5	10.02
-58.46	-33.34	22.82
50.62	7.69	48.24
50.27	20.47	7.02
-39.52	19.67	4.77
30.98	26.44	3.4
-26.73	-76.1	-37.53
63.2	5.2	14.84
2.34	-63.84	-5.43

// Luber B, 2013: Working Memory > Baseline
// Luber B, 2013: Working Memory > Baseline, Active > Sham
// Luber B, 2013: Working Memory > Baseline, Sham > Active
// Subjects=27
23.35	-78.52	34.16
-41.85	-24.69	16.5
20.75	-66.54	1.64
20.62	-66.41	-8.45
46.58	-22.32	2.43
56.14	-11.42	-7.77
60.59	-2.82	3.63
53.4	-29.59	27.69
42.71	-18.91	39.14
60.94	-34.13	24.65
27.12	-31.21	0.28
29.19	-34.06	-7.32
22.84	22.65	14.07
-62.28	-39.34	21.66
-52.57	-41.64	19.48
73.72	-23.42	12.16
73.81	-12.92	21.21
27.79	-53.54	48.42
15.03	-48.84	64.98
17.08	-35.42	59.14
15.14	-56.73	72.49
-22.43	-66.38	5.73
-13.67	-73.17	12.97
-9.55	-75.78	-3.65
7.5	-29.34	-13.02
-9.77	-31.42	-11.4
-39.72	-53.37	8.09
37.92	-40	-2.4

// van den Heuvel O A, 2013: Planning > Baseline, Sham rTMS
// van den Heuvel O A, 2013: Planning > Baseline, Active rTMS
// van den Heuvel O A, 2013: Main Effect of Task load for Planning > Baseline, 
// Sham rTMS
// van den Heuvel O A, 2013: Main Effect of Task load for Planning > Baseline, 
// Active rTMS
// van den Heuvel O A, 2013: Planning > Baseline, Sham > Active rTMS
// van den Heuvel O A, 2013: Task load Effects for Planning > Baseline, Sham > 
// Active rTMS
// Subjects=11
-20	2	-20
28	-2	66
36	30	40
-42	16	38
-36	30	28
54	34	26
-54	8	4
34	24	2
-28	20	2
-16	16	2
14	16	-2
10	-64	58
-56	-42	40
42	-40	58
-66	-32	30
62	-28	38
-44	-78	20
44	-70	16
-60	-64	-12
-40	-64	6
-22	-8	64
24	-4	68
-2	16	50
48	28	44
-40	28	32
52	36	26
-36	46	10
32	58	-2
32	26	-6
-30	22	0
-10	8	-4
10	14	-2
10	2	10
12	-66	58
40	-42	54
-66	-32	34
62	-36	36
-42	-80	36
44	-52	34
42	-74	22
-42	26	34
-20	-2	66
44	28	42
28	12	56
-2	22	42
-42	46	6
24	58	-12
52	48	-10
-54	12	8
-44	18	16
-32	24	-2
-14	6	16
-20	2	0
-16	12	2
18	20	-2
14	4	-4
10	-62	60
-62	-32	34
-58	-38	46
-42	-50	52
48	-46	48
62	-44	34
-38	-62	38
-48	-80	24
52	-66	22
-42	26	36
-24	-2	68
40	30	42
24	2	64
-24	58	6
22	54	-20
32	60	2
-54	8	16
-30	22	-4
-22	34	-22
-16	8	20
-16	8	0
14	18	4
18	18	8
0	-4	6
-4	-26	10
-6	-68	56
-66	-32	34
44	-56	34
64	-32	36
54	-50	42
-38	-64	38
-44	-80	36
44	-76	24
-38	-2	50
-46	2	32
-42	16	18
-54	16	30
26	52	20
-12	42	44
50	38	0
-8	-54	70
-4	-46	46
8	-54	56
14	-82	30
-48	-60	40
44	-52	44
-40	0	24

// Rule N O, 2010: Election Losers > Winner
// Rule N O, 2010: Japanese Target > American Target
// Rule N O, 2010: Voted > Not Voted
// Rule N O, 2010: Culture x Participant Interaction
// Subjects=14
19.14	-56.96	-41.89
-7.57	-59.24	-41.39
47.52	-35.23	44.06
29.18	29.85	47.74
24.41	-2.78	-29.76
-22.57	-7.03	-25.52
-42.87	1.74	-20.45
-30.07	10.27	-21.31
-19.08	45.37	32.49
-8.55	-36.3	-19.88

// Scheepers D, 2013: Self > Familiar
// Scheepers D, 2013: Ingroup > Outgroup
// Scheepers D, 2013: Familiar > Self
// Subjects=41
48	42	8
50	8	22
40	26	16
-50	4	32
-46	46	8
30	-62	50
54	-24	40
-42	-38	48
-24	-68	42
44	-64	-10
-34	-60	-4
46	8	40
40	-46	38
30	-78	44
-12	-64	-6
4	54	-14
54	-16	-10
6	-54	32
54	-2	-30

// Sheng F, 2014: Pain > Neutral
// Sheng F, 2014: Asian face (Pain - Neutral) > Caucasian face (Pain - 
// Neutral)
// Sheng F, 2014: (Pain - Neutral) pain judgment > (Pain - Neutral) race 
// judgment
// Sheng F, 2014: Pain judgment > Race judgment
// Sheng F, 2014: Race judgment > Pain judgment
// Subjects=21
9	36	2
-40	30	-16
-54	16	6
54	38	0
-12	-10	10
24	20	4
46	-58	-6
-28	-92	2
40	-78	18
-40	-72	-20
4	30	52
2	46	12
38	22	-10
-40	6	-12
68	-36	26
-66	-36	28
20	-50	60
0	50	22

// Wilson S J, 2011: Speech > Rest
// Wilson S J, 2011: Sing > Rest
// Subjects=26
-5.72	7.45	59.77
-53.67	6.4	28.19
-26.22	-9.95	58.48
-24.23	-72.51	32.14
-44.49	-40.34	-24.49
37.72	19.77	-6.06
-33.54	15.47	-2.18
-18.19	-3.54	11.76
-.43	-49.6	-45.61
-40.37	-51.66	-42.49
-2.26	-4.05	74.29
-57.97	-50.37	18.19

// Zarate J M, 2010: Singing > Voice perception (before training)
// Zarate J M, 2010: Melodic singing > Simple singing (before training)
// Zarate J M, 2010: Simple singing > Voice perception (before training)
// Subjects=20
-56	-8	6
-54	4	-2
-56	-24	12
-2	4	44
-4	10	40
-56	-6	26
-46	-14	40
-54	-2	46
-56	4	26
-36	6	8
-44	-16	38
-12	-24	-2
-28	-4	-4
-16	-62	-20
60	-8	6
50	-28	10
4	4	46
2	-2	56
52	-8	46
32	16	12
40	4	6
44	-16	40
18	-14	6
22	-6	8
22	-12	6
10	-62	-20
2	-56	-18
2	-60	-24
-56	-16	6
-56	-2	0
-62	-14	6
-52	-26	12
-42	-34	24
-6	-80	10
-10	-60	0
32	-70	-22
56	2	-4
66	-10	2
60	-18	4
10	-74	14
36	-76	-16
-46	-20	4
-54	-8	6
-48	-26	12
-2	8	42
-60	0	28
-36	14	10
-34	-2	8
-34	16	12
-46	-14	40
-56	-8	18
-58	-36	34
-10	-16	4
-22	-4	-4
-30	-16	4
-26	-58	-22
-14	-60	-18
0	-64	-32
0	-58	-24
48	-22	6
58	-16	4
54	-28	10
2	-2	58
4	16	32
2	-4	42
54	-8	46
60	0	34
38	4	6
38	-10	-6
34	16	12
44	-16	40
12	-14	6
22	-6	8
26	-62	-24

// de Borst A W, 2012: Imagery > Baseline
// Subjects=7
-35.22	51.82	20.99
-43.65	28.85	27.47
35.37	45.18	25.19
-42.46	1.53	31.98
48.37	5.42	32.84
-32.63	-9.39	55.08
35.73	-3.77	52.71
2.51	9.34	46.42
-32.04	18.66	4.77
37.41	21.1	2.65
-9.47	-16.19	6.32
10.83	-12.81	6.92
-16.03	11.9	-1.54
18.19	11.3	1.47
-4.2	-23.44	-5.4
7.56	-22.23	-4.52
-19.12	-25.3	-.61
20.42	-25.07	-1.08
-54.35	-20.77	6.1
58.88	-18.32	0.14
-28.82	-37.22	-16.23
29.95	-32.55	-16.18
-47.96	-55.05	-11.17
-17.56	-69.62	45.47
20.91	-66.14	45.85
-35.82	-45.5	42.54
20.91	-66.14	45.85
-2.61	-76.31	40.28
5.96	-74.94	43.41
-16.69	-66.22	20.64
18.58	-63.72	22.25
-4.96	-79.61	11.59
5.77	-80.17	17.09
-8.33	-81.25	-9.43
12	-82.02	-7.36
-24.25	-89.04	1.45
-29.48	-80.21	19.73
1.4	-76.82	5.7

// Ashkenazi S, 2012: Developmental dyscalculia (DD)
// Subjects=17
-8	38	-6
6	44	-6
2	12	-6
60	-60	18
44	-60	58
32	-74	54
2	-64	62
56	-72	4
60	-60	36
58	-62	38
60	-58	18
-50	-64	-26
-58	-60	-18
-58	-70	-2
-58	-36	-16
-62	-24	-18
50	-62	-20
52	-48	-26
56	16	40
30	26	-20
36	20	-38
36	52	10
-52	30	30
-42	36	38
-38	48	18
0	-32	38
2	-16	12
56	-72	4
58	-62	38
6	-76	44
-2	-86	42
2	-64	64
-58	-70	2
36	64	2
42	58	10
-20	66	20
-50	32	32
-38	40	4
36	20	-40
54	20	40
54	6	48
2	-34	38
44	-60	58
-58	-60	-18
-50	-64	-26
-58	-38	-16
-44	28	-18
56	-72	4
58	-62	38
6	-78	44
2	-64	64
-58	-70	2
36	64	4
42	58	10
30	52	36
-20	66	20
-50	32	32
-38	40	4
54	20	40
54	6	48
44	-60	58
-58	-60	-18
-50	-64	-26
-58	-38	-16
-44	28	-18
-58	-70	0
-42	28	-18
54	22	38

// Ashkenazi S, 2012: Typically developing (TD)
// Subjects=17
-24	-82	48
-20	-84	48
-28	-70	50
2	-68	56
-4	-66	44
36	-62	58
44	-50	58
-22	-94	-18
-22	-102	-4
-36	-92	-14
50	28	26
26	60	-4
8	32	44
54	12	44
-54	22	32
-46	52	4
-36	42	4
-28	2	60
-32	18	2
2	-10	34
-2	-30	32
4	6	30
0	-14	-8
44	-60	58
32	-74	54
2	-64	62
56	-72	4
60	-60	36
58	-62	38
60	-58	18
-50	-64	-26
-58	-60	-18
-58	-70	-2
-58	-36	-16
-62	-24	-18
50	-62	-20
52	-48	-26
56	16	40
30	26	-20
36	20	-38
36	52	10
-52	30	30
-42	36	38
-38	48	18
0	-32	38
2	-16	12
56	-72	4
58	-62	38
6	-76	44
-2	-86	42
2	-64	64
-58	-70	2
36	64	2
42	58	10
-20	66	20
-50	32	32
-38	40	4
36	20	-40
54	20	40
54	6	48
2	-34	38
44	-60	58
-58	-60	-18
-50	-64	-26
-58	-38	-16
-44	28	-18
56	-72	4
58	-62	38
6	-78	44
2	-64	64
-58	-70	2
36	64	4
42	58	10
30	52	36
-20	66	20
-50	32	32
-38	40	4
54	20	40
54	6	48
44	-60	58
-58	-60	-18
-50	-64	-26
-58	-38	-16
-44	28	-18
-58	-70	0
-42	28	-18
54	22	38

// Berteletti I, 2014: Math Learning Disability (MD)
// Subjects=20
-46	20	-10
-48	-32	-6
26	-68	46
-42	18	-22
-56	-50	6
28	-64	50
16	-70	54

// Berteletti I, 2014: Typically Developing (TD)
// Subjects=20
-46	20	-10
-48	-32	-6
26	-68	46
-42	18	-22
-56	-50	6
-48	32	2
-56	-50	6
28	-64	50

// Soohyun C, 2011: Retrievers > Counters (univariate)
// Soohyun C, 2011: Retrievers > Counters (multivariate)
// Subjects=17
-36	36	4
-24	-6	-36
-24	-16	-22
22	-14	-18
-44	38	0
-32	26	6
-62	-38	26
64	-26	38
42	-42	42

// Cho S, 2012: Positive Correlation between Retrieval Fluency and Addition > 
// Control
// Cho S, 2012: Addition > Control task
// Cho S, 2012: Positive Correlation between Retrieval Fluency and Addition > 
// Control with Accuracy and Reaction Time as Covariates
// Cho S, 2012: Positive Correlation between Accuracy and Addition > Control 
// tasks
// Cho S, 2012: Negative Correlation between Reaction Time and Addition > 
// Control tasks
// Cho S, 2012: Positive Correlation between Age and Addition > Control
// Cho S, 2012: Positive Correlation between Education and Addition > Control
// Cho S, 2012: Positive Correlation between Retrieval Fluency and Addition > 
// Control task with Age and IQ as covariates
// Subjects=86
-42	-78	18
-36	38	6
26	-42	-6
24	-86	38
34	24	46
40	-68	26
-34	24	52
12	18	-10
0	-44	-16
32	24	0
0	14	54
-30	22	2
-34	-36	36
54	32	26
-46	0	30
32	8	56
28	-94	-4
0	14	54
-30	22	2
-34	-36	36
54	32	26
-46	0	30
32	8	56
-42	-80	18
-36	38	6
28	-42	-6
24	-86	36
-40	22	52
54	-62	20
-10	44	-8
22	-86	20
24	34	-14
-64	-2	2
2	-20	58
-42	-68	38
-46	-14	62
-34	8	58
-44	-72	44
-2	-44	36
-32	4	-42
52	-64	42
28	-12	-20
60	-2	0
60	20	10
-52	-52	4
-28	26	54
22	-74	52
-22	-66	4
-48	30	36
66	-52	22
-32	-58	60
42	-34	-2
-22	-32	4
36	-32	-4
-6	22	52
-42	-78	18
-36	38	6
26	-42	-6
24	-86	38
36	24	46
-32	-64	-24
-34	24	52

// De Smedt B, 2011: Small > Large Math Problems
// De Smedt B, 2011: Large > Small Math Problems
// De Smedt B, 2011: Addition > Subtraction
// De Smedt B, 2011: Subtraction > Addition
// De Smedt B, 2011: Problem size x Operation interaction
// De Smedt B, 2011: Group x Problem size interaction
// Subjects=8
-5.46	31.62	-8.89
-56.43	-14.73	15.66
-44.05	7.13	-33.15
55.5	-3.68	-16.66
59.13	-61.87	14.94
-1.76	-12.6	38.27
52.64	-13.3	24.32
-53.08	-59.37	16.02
39.79	-13.64	21.15
-21.39	-16.83	-14.68
39.27	23.75	-32.16
-30.42	-56.93	45.66
7.7	28.7	34.7
-49.94	12.49	36.72
-27.38	13.91	53.07
-31.04	19.04	-4.19
30.44	-50.47	41.08
33.08	26.02	-2.17
-43.94	54.37	-.32
-18.23	-10.72	-18.57
-17.6	-56.85	45.51
4.46	31.59	31.15
27.17	8.15	56.27
-31.04	19.04	-4.19
40.14	-36.44	56.52
-40.67	35.36	1.24
-53.2	-63.83	-.33
-2.05	-71.67	-23.68
-46.75	9.08	33.62
-24.16	4.15	50.51
14.52	-59.32	52.04
36.31	19.7	-1.68
42.78	30.28	10.74
-34.11	-71.86	-23.3
36.34	-59.01	-28.53
37	-68.7	52.57
31.59	-59.56	47.4
32.53	-65.24	28.91

// Du F, 2013: Abacus-trained group
// Subjects=20
18	42	18
27	36	15
12	39	36
66	-33	9
66	-24	3
63	-42	0
15	18	15
18	21	-3
57	-63	27
48	-57	27
12	-3	3
18	-12	6
-24	3	69
-27	-63	42
66	-48	-3
-3	30	-6
-51	-33	-3
51	-18	-12
-3	-39	60
-42	-3	42
-6	0	57
-36	-6	36
-30	15	27

// Du F, 2013: Non-trained group
// Subjects=19
9	15	48
-6	0	57
-6	9	51
-12	-15	3
-15	6	9
15	12	12
-24	-75	30
-51	-45	54
-30	-63	48
57	15	36
54	6	39
33	-63	33
39	-54	54
33	-66	45
-33	-81	-21
-42	-60	-27
-27	-87	-18
-6	-75	45
18	42	18
27	36	15
12	39	36
66	-33	9
66	-24	3
63	-42	0
15	18	15
18	21	-3
57	-63	27
48	-57	27
12	-3	3
18	-12	6
-51	-33	-3
51	-18	-12
-3	-39	60
-42	-3	42
-6	0	57
-36	-6	36
-30	15	27

// Metcalfe A W S, 2013: Complex > Control
// Metcalfe A W S, 2013: Control > Complex
// Metcalfe A W S, 2013: Positive Correlation between Visuospatial Working 
// Memory and Complex > Control
// Metcalfe A W S, 2013: Positive Correlation between Central Executive 
// Working Memory and Complex > Control
// Metcalfe A W S, 2013: Positive Correlation between Phonological Working 
// Memory and Complex > Control
// Metcalfe A W S, 2013: Negative Correlation between Phonological Working 
// Memory and Complex > Control
// Subjects=74
16	-84	6
38	-68	-12
38	22	0
-54	-6	48
-28	22	2
-44	-44	46
-4	48	-4
2	56	18
-52	-46	32
40	42	-14
8	2	64
38	-50	32
-42	34	32
-28	-48	52
26	-50	68
-20	-82	28
16	-88	14
26	-64	-20
30	-62	38
58	-46	24
42	22	46
30	-18	-10
22	-18	60
-54	-50	34
6	-22	-6
40	-48	-26
-24	-46	54
-8	-86	-2
-22	-74	32
-20	56	2

// Mondt K, 2011: School language bilinguals
// Subjects=16
-22	-78	6
-50	-4	42
-16	-84	-18
-8	14	60
-48	10	38
-22	-78	6
-48	-4	42
28	-68	66
-14	-84	-18
-8	14	60
-48	10	38
-30	-66	54
20	12	40
-48	30	24
-10	-84	-12
-30	6	58
-10	14	56
-22	-80	60
-28	16	66
-12	-86	-18
34	-74	14

// Mondt K, 2011: Home-language bilinguals
// Subjects=8
10	-82	-14
18	12	38
30	-76	42
-46	28	24
-36	4	54
24	-84	20
-32	-4	64
4	14	24
-42	0	32
36	28	-2
12	6	34
-22	-78	6
-48	-4	42
28	-68	66
-14	-84	-18
-8	14	60
-48	10	38
-30	-66	54
20	12	40
-48	30	24
-10	-84	-12
-30	6	58
-10	14	56
-22	-80	60
-28	16	66
-12	-86	-18
34	-74	14

// Prado J, 2014: Positive Correlation between Grade and Smaller Subtraction > 
// Fixation
// Prado J, 2014: Positive Correlation between Grade and Smaller Subtraction > 
// Smaller Multiplication
// Prado J, 2014: Larger Subtraction > Smaller Subtraction
// Prado J, 2014: Larger Multiplication > Smaller Multiplication
// Prado J, 2014: Smaller Problems > Larger Problems
// Subjects=34
32	-74	38
-32	-94	2
-20	-100	6
32	-74	34
32	-84	-2
4	-52	50
-38	-46	50
2	-66	50
-30	-58	42
-40	26	26
-4	18	46
-16	-80	14
2	54	6
2	-40	42
-62	-38	34
64	-42	26

// Rosenberg-Lee M, 2011: All Children: Complex > Simple
// Rosenberg-Lee M, 2011: All Children: Simple > Complex
// Rosenberg-Lee M, 2011: 2nd Grade > 3rd Grade: Complex > Simple
// Rosenberg-Lee M, 2011: 3rd Grade > 2nd Grade: Complex > Simple
// Subjects=45
0	-36	-10
26	-94	-6
32	24	0
0	16	52
-32	20	2
-10	54	40
-6	62	8
-58	-68	8
-50	8	-20
8	-48	32
22	48	2
-48	30	34
38	-86	-8
18	-76	58
52	-70	20
2	-72	10
36	-34	-4
-10	-74	-26
-16	-86	-2

// Zvyagintsev M, 2013: Auditory > Baseline, p=0
// Zvyagintsev M, 2013: Auditory > Baseline, p=0.000001
// Zvyagintsev M, 2013: Auditory > Baseline, p=0.000024
// Zvyagintsev M, 2013: Auditory > Baseline, p=0.000041
// Zvyagintsev M, 2013: Auditory > Baseline, p=0.000161
// Zvyagintsev M, 2013: Baseline > Auditory, p<0.000009
// Zvyagintsev M, 2013: Baseline > Auditory, p<0.000067
// Zvyagintsev M, 2013: Baseline > Auditory, p<0.000004
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000004
// Zvyagintsev M, 2013: Visual > Baseline, p=0
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000126
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000008
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000007
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000005
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000017
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000036
// Zvyagintsev M, 2013: Visual > Baseline, p=0.000053
// Zvyagintsev M, 2013: Baseline > Visual, p=0.000013
// Zvyagintsev M, 2013: Baseline > Visual, p=0.000011
// Zvyagintsev M, 2013: Baseline > Visual, p=0.000212
// Zvyagintsev M, 2013: Baseline > Visual, p=0.000003
// Zvyagintsev M, 2013: Baseline > Visual, p=0.000055
// Zvyagintsev M, 2013: Baseline > Visual, p=0
// Zvyagintsev M, 2013: Baseline > Visual, p=0.000001
// Zvyagintsev M, 2013: (Auditory > Baseline) and (Visual > Baseline), p=0
// Zvyagintsev M, 2013: (Auditory > Baseline) and (Visual > Baseline), 
// p=0.000003
// Zvyagintsev M, 2013: (Auditory > Baseline) and (Visual > Baseline), 
// p=0.000001
// Zvyagintsev M, 2013: (Auditory > Baseline) and (Visual > Baseline), 
// p=0.000122
// Zvyagintsev M, 2013: (Auditory < Baseline) and (Visual < Baseline), 
// p=0.000037
// Zvyagintsev M, 2013: (Auditory < Baseline) and (Visual < Baseline), p=0
// Zvyagintsev M, 2013: (Auditory < Baseline) and (Visual < Baseline), 
// p=0.000001
// Zvyagintsev M, 2013: Auditory > Visual, p=0
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000007
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000084
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000013
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000037
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000159
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000041
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000006
// Zvyagintsev M, 2013: Auditory > Visual, p=0.000058
// Zvyagintsev M, 2013: Visual > Auditory, p=0.000004
// Zvyagintsev M, 2013: Visual > Auditory, p=0
// Zvyagintsev M, 2013: Visual > Auditory, p=0.000022
// Zvyagintsev M, 2013: Visual > Auditory, p=0.000002
// Subjects=15
51.15	33.99	-10.85
-25.67	-31.2	-21.23
-51.47	42.81	-11.53
35.27	-79.96	-37.91
22.56	-12.99	3.45
-3.43	55.87	-12.06
-41.24	-66.02	25.36
-21.83	-57.5	51.19
-41.19	-35.93	42.91
32.7	-63.52	51.07
54.48	35.3	5.73
32.03	-30.85	-21.92
-32.08	-31.24	-21.15
-48.17	40.51	-.22
41.6	-70.92	-45.44
19.02	-36.24	-49.2
35.7	-2.97	49.3
-18.79	16.5	58.33
-15.36	-56.95	57.76
-37.92	-81.35	33.3
-41.22	-69.19	25.63
54.65	-28.92	1.08
51.87	-47.55	49.51
21.62	-84.16	-8.41
22.51	-62.89	-22.47
19.94	-26.65	74.89
-22.16	-90.68	-6.25
-63.84	1.32	31.13
-5.91	0.72	59.51
54.48	35.3	5.73
-51.38	40.49	-.18
38.45	-73.6	-38.48
28.83	-30.87	-21.88
-5.58	52.43	-15.09
-9.29	-90.09	0.25
-60.62	1.51	33.3
51.87	-47.55	49.51
-60.62	1.51	33.3
51.87	-47.55	49.51
45.13	-41.15	8.9
41.52	4.1	-24.96
25.73	3.14	5.41
-18.93	-90.4	-2.96
-34.09	4.1	9.36
-71.37	-28.9	12.56
0.55	1.27	66.08
58.11	0.08	45.44
44.78	31.04	-7.19
27.02	-85.64	-.54
23.07	-20.8	67.67
16.67	-89.94	41.2
-6.32	-.22	6.06
-8.99	-93.52	38.45
-35.33	61.71	11.24
54.67	-55.07	-6.77
26.26	-57.22	50.61
29.31	-2.76	52.7
-18.6	-57.23	54.47
-28.44	-3.62	46.75
-54.29	-65.24	-4.66
35.31	-36.66	-14.78
-35.34	-25.17	-24.97

